diff --git a/files.transfemscience.org/pdfs/Anderson (1962) - Experimental stimulation of breast development in the teen-age female.pdf b/files.transfemscience.org/pdfs/Anderson (1962) - Experimental stimulation of breast development in the teen-age female.pdf new file mode 100644 index 00000000..5c1a8966 Binary files /dev/null and b/files.transfemscience.org/pdfs/Anderson (1962) - Experimental stimulation of breast development in the teen-age female.pdf differ diff --git a/files.transfemscience.org/pdfs/Angus et al. (2022) - Estimation of breast volume in transgender women using 2D photography_ validation of the BreastIdea Volume Estimator in men and transgender women (ESA-SRB-APEG-NZSE 2022, abstract no. 279).pdf b/files.transfemscience.org/pdfs/Angus et al. (2022) - Estimation of breast volume in transgender women using 2D photography_ validation of the BreastIdea Volume Estimator in men and transgender women (ESA-SRB-APEG-NZSE 2022, abstract no. 279).pdf new file mode 100644 index 00000000..55741d3d Binary files /dev/null and b/files.transfemscience.org/pdfs/Angus et al. (2022) - Estimation of breast volume in transgender women using 2D photography_ validation of the BreastIdea Volume Estimator in men and transgender women (ESA-SRB-APEG-NZSE 2022, abstract no. 279).pdf differ diff --git a/files.transfemscience.org/pdfs/Angus et al. (2023) - The effect of cyproterone and spironolactone on breast development in transgender women_ a randomised controlled trial (ESA-SRB-ENSA 2023, abstract no. 132).pdf b/files.transfemscience.org/pdfs/Angus et al. (2023) - The effect of cyproterone and spironolactone on breast development in transgender women_ a randomised controlled trial (ESA-SRB-ENSA 2023, abstract no. 132).pdf new file mode 100644 index 00000000..900d5514 Binary files /dev/null and b/files.transfemscience.org/pdfs/Angus et al. (2023) - The effect of cyproterone and spironolactone on breast development in transgender women_ a randomised controlled trial (ESA-SRB-ENSA 2023, abstract no. 132).pdf differ diff --git a/files.transfemscience.org/pdfs/Basson & Prior (1998) - Hormonal Therapy of Gender Dysphoria_ The Male-to-Female Transsexual [In Current Concepts in Transgender Identity (Denny) (pp. 298–317)].pdf b/files.transfemscience.org/pdfs/Basson & Prior (1998) - Hormonal Therapy of Gender Dysphoria_ The Male-to-Female Transsexual [In Current Concepts in Transgender Identity (Denny) (pp. 298–317)].pdf new file mode 100644 index 00000000..3264b07b Binary files /dev/null and b/files.transfemscience.org/pdfs/Basson & Prior (1998) - Hormonal Therapy of Gender Dysphoria_ The Male-to-Female Transsexual [In Current Concepts in Transgender Identity (Denny) (pp. 298–317)].pdf differ diff --git a/files.transfemscience.org/pdfs/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust [On Hormonal Therapy of the Hypoplastic Female Breast].pdf b/files.transfemscience.org/pdfs/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust [On Hormonal Therapy of the Hypoplastic Female Breast].pdf new file mode 100644 index 00000000..93c93f3f Binary files /dev/null and b/files.transfemscience.org/pdfs/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust [On Hormonal Therapy of the Hypoplastic Female Breast].pdf differ diff --git a/files.transfemscience.org/pdfs/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung [Local Hormone Treatment in Mammary Atrophy and Underdevelopment].pdf b/files.transfemscience.org/pdfs/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung [Local Hormone Treatment in Mammary Atrophy and Underdevelopment].pdf new file mode 100644 index 00000000..4a22de16 Binary files /dev/null and b/files.transfemscience.org/pdfs/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung [Local Hormone Treatment in Mammary Atrophy and Underdevelopment].pdf differ diff --git a/files.transfemscience.org/pdfs/Cox et al. (1994) - Mammary morphological and functional changes during pregnancy in women.pdf b/files.transfemscience.org/pdfs/Cox et al. (1994) - Mammary morphological and functional changes during pregnancy in women.pdf new file mode 100644 index 00000000..c9fbfb33 Binary files /dev/null and b/files.transfemscience.org/pdfs/Cox et al. (1994) - Mammary morphological and functional changes during pregnancy in women.pdf differ diff --git a/files.transfemscience.org/pdfs/Dewhurst (1982) - Breast Hypoplasia [In Pediatric and Adolescent Gynaecology (Bruni et al., 1982)].pdf b/files.transfemscience.org/pdfs/Dewhurst (1982) - Breast Hypoplasia [In Pediatric and Adolescent Gynaecology (Bruni et al., 1982)].pdf new file mode 100644 index 00000000..024fc94e Binary files /dev/null and b/files.transfemscience.org/pdfs/Dewhurst (1982) - Breast Hypoplasia [In Pediatric and Adolescent Gynaecology (Bruni et al., 1982)].pdf differ diff --git a/files.transfemscience.org/pdfs/Folley & Malpress (1948) - Hormonal Control of Mammary Growth [In The Hormones_ Physiology, Chemistry and Applications, Volume I (Pincus & Thimann)].pdf b/files.transfemscience.org/pdfs/Folley & Malpress (1948) - Hormonal Control of Mammary Growth [In The Hormones_ Physiology, Chemistry and Applications, Volume I (Pincus & Thimann)].pdf new file mode 100644 index 00000000..3ad1c02e Binary files /dev/null and b/files.transfemscience.org/pdfs/Folley & Malpress (1948) - Hormonal Control of Mammary Growth [In The Hormones_ Physiology, Chemistry and Applications, Volume I (Pincus & Thimann)].pdf differ diff --git a/files.transfemscience.org/pdfs/Folley (1950) - Lactational Physiology [In Modern Trends in Obstetrics and Gynaecology (Bowes)].pdf b/files.transfemscience.org/pdfs/Folley (1950) - Lactational Physiology [In Modern Trends in Obstetrics and Gynaecology (Bowes)].pdf new file mode 100644 index 00000000..b4432380 Binary files /dev/null and b/files.transfemscience.org/pdfs/Folley (1950) - Lactational Physiology [In Modern Trends in Obstetrics and Gynaecology (Bowes)].pdf differ diff --git a/files.transfemscience.org/pdfs/Folley (1952) - Lactation [In Marshall's Physiology of Reproduction, 3rd Edition, Volume II (Parkes)].pdf b/files.transfemscience.org/pdfs/Folley (1952) - Lactation [In Marshall's Physiology of Reproduction, 3rd Edition, Volume II (Parkes)].pdf new file mode 100644 index 00000000..ffdf287c Binary files /dev/null and b/files.transfemscience.org/pdfs/Folley (1952) - Lactation [In Marshall's Physiology of Reproduction, 3rd Edition, Volume II (Parkes)].pdf differ diff --git a/files.transfemscience.org/pdfs/Geschickter (1945) - Endocrine Physiology of the Breast [In Diseases of the Breast - Diagnosis, Pathology, Treatment, 2nd Edition (Geschickter) (pp. 42–81)] [Optimized].pdf b/files.transfemscience.org/pdfs/Geschickter (1945) - Endocrine Physiology of the Breast [In Diseases of the Breast - Diagnosis, Pathology, Treatment, 2nd Edition (Geschickter) (pp. 42–81)] [Optimized].pdf new file mode 100644 index 00000000..af14348d Binary files /dev/null and b/files.transfemscience.org/pdfs/Geschickter (1945) - Endocrine Physiology of the Breast [In Diseases of the Breast - Diagnosis, Pathology, Treatment, 2nd Edition (Geschickter) (pp. 42–81)] [Optimized].pdf differ diff --git a/files.transfemscience.org/pdfs/Göretzlehner & Lauritzen (1992) - Mammahypoplasie [Breast Hypoplasia] - Praktische Hormontherapie in der Gynäkologie, 1. Auflage [In Practical Hormone Therapy in Gynecology, 1st Edition].pdf b/files.transfemscience.org/pdfs/Göretzlehner & Lauritzen (1992) - Mammahypoplasie [Breast Hypoplasia] - Praktische Hormontherapie in der Gynäkologie, 1. Auflage [In Practical Hormone Therapy in Gynecology, 1st Edition].pdf new file mode 100644 index 00000000..d8389cc4 Binary files /dev/null and b/files.transfemscience.org/pdfs/Göretzlehner & Lauritzen (1992) - Mammahypoplasie [Breast Hypoplasia] - Praktische Hormontherapie in der Gynäkologie, 1. Auflage [In Practical Hormone Therapy in Gynecology, 1st Edition].pdf differ diff --git a/files.transfemscience.org/pdfs/Huffman, Dewhurst, & Capraro (1981) - The Breast and its Disorders in Childhood and Adolescence [In The Gynecology of Childhood and Adolescence].pdf b/files.transfemscience.org/pdfs/Huffman, Dewhurst, & Capraro (1981) - The Breast and its Disorders in Childhood and Adolescence [In The Gynecology of Childhood and Adolescence].pdf new file mode 100644 index 00000000..9e771ad6 Binary files /dev/null and b/files.transfemscience.org/pdfs/Huffman, Dewhurst, & Capraro (1981) - The Breast and its Disorders in Childhood and Adolescence [In The Gynecology of Childhood and Adolescence].pdf differ diff --git a/files.transfemscience.org/pdfs/Jacobsohn (1961) - Hormonal Regulation of Mammary Gland Growth [In Kon & Cowie - Milk_ The Mammary Gland and Its Secretion, Volume 1].pdf b/files.transfemscience.org/pdfs/Jacobsohn (1961) - Hormonal Regulation of Mammary Gland Growth [In Kon & Cowie - Milk_ The Mammary Gland and Its Secretion, Volume 1].pdf new file mode 100644 index 00000000..08ddbf3e Binary files /dev/null and b/files.transfemscience.org/pdfs/Jacobsohn (1961) - Hormonal Regulation of Mammary Gland Growth [In Kon & Cowie - Milk_ The Mammary Gland and Its Secretion, Volume 1].pdf differ diff --git a/files.transfemscience.org/pdfs/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie [In Hormonbehandlung in der Gynäkologischen Praxis, 7. Auflage].pdf b/files.transfemscience.org/pdfs/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie [In Hormonbehandlung in der Gynäkologischen Praxis, 7. Auflage].pdf new file mode 100644 index 00000000..d7a7a38a Binary files /dev/null and b/files.transfemscience.org/pdfs/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie [In Hormonbehandlung in der Gynäkologischen Praxis, 7. Auflage].pdf differ diff --git a/files.transfemscience.org/pdfs/Lauritzen (1980) - Hormonkur kann Hypoplastischer Mamma Aufhelfen [Hormone Therapy Can Help Hypoplastic Breasts].pdf b/files.transfemscience.org/pdfs/Lauritzen (1980) - Hormonkur kann Hypoplastischer Mamma Aufhelfen [Hormone Therapy Can Help Hypoplastic Breasts].pdf new file mode 100644 index 00000000..4de8b28e Binary files /dev/null and b/files.transfemscience.org/pdfs/Lauritzen (1980) - Hormonkur kann Hypoplastischer Mamma Aufhelfen [Hormone Therapy Can Help Hypoplastic Breasts].pdf differ diff --git a/files.transfemscience.org/pdfs/Lauritzen (1982) - Treatment of Mammary- and Uterus Hypoplasia by Estrogen-Progestagen Pseudopregnancy.pdf b/files.transfemscience.org/pdfs/Lauritzen (1982) - Treatment of Mammary- and Uterus Hypoplasia by Estrogen-Progestagen Pseudopregnancy.pdf new file mode 100644 index 00000000..0bcd108a --- /dev/null +++ b/files.transfemscience.org/pdfs/Lauritzen (1982) - Treatment of Mammary- and Uterus Hypoplasia by Estrogen-Progestagen Pseudopregnancy.pdf @@ -0,0 +1,3782 @@ +%PDF-1.6 +% +1 0 obj +<< +/MarkInfo << +>> +/Metadata 2 0 R +/Outlines 3 0 R +/OutputIntents [4 0 R] +/Pages 5 0 R +/StructTreeRoot 6 0 R +/Type /Catalog +/OpenAction 7 0 R +>> +endobj +8 0 obj +<< +/Author () +/CreationDate (D:20200812100728+02'00') +/Creator (GdPicture Managed PDF Plugin) +/Keywords () +/ModDate (D:20200812100752+02'00') +/Producer (Adobe Acrobat Pro DC 20 Paper Capture Plug-in) +/Subject () +/Title () +>> +endobj +2 0 obj +<< +/Length 8017 +/Subtype /XML +/Type /Metadata +>> +stream + + + + + application/pdf + + + + + + + + + + + + + + + + + + + 2020-08-12T10:07:28+02:00 + GdPicture Managed PDF Plugin + 2020-08-12T10:07:52+02:00 + 2020-08-12T10:07:52+02:00 + Adobe Acrobat Pro DC 20 Paper Capture Plug-in + + uuid: 98FAC637B447FB59A262EEEA8DF59A1D + uuid:bdddba00-ab25-44fd-a3aa-bf4bcd925598 + + + + http://ns.adobe.com/pdf/1.3/ + pdf + Adobe PDF Schema + + + + + + + internal + A name object indicating whether the document has been modified to include trapping information + Trapped + Text + + + + + + http://ns.adobe.com/xap/1.0/mm/ + xmpMM + XMP Media Management Schema + + + + + + + internal + UUID based identifier for specific incarnation of a document + InstanceID + URI + + + + + + http://www.aiim.org/pdfa/ns/id/ + pdfaid + PDF/A ID Schema + + + + + + + internal + Part of PDF/A standard + part + Integer + + + internal + Amendment of PDF/A standard + amd + Text + + + internal + Conformance level of PDF/A standard + conformance + Text + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +endstream +endobj +3 0 obj +<< +/Count 1 +/First 9 0 R +/Last 9 0 R +>> +endobj +4 0 obj +<< +/DestOutputProfile 10 0 R +/Info (sRGB IEC61966-2.1) +/OutputCondition () +/OutputConditionIdentifier (Custom) +/RegistryName () +/S /GTS_PDFA1 +/Type /OutputIntent +>> +endobj +5 0 obj +<< +/Count 3 +/Kids [11 0 R 12 0 R 13 0 R] +/Type /Pages +>> +endobj +6 0 obj +<< +/K [] +/ParentTree 14 0 R +/ParentTreeNextKey 0 +/Type /StructTreeRoot +>> +endobj +7 0 obj +<< +/Type /Action +/S /JavaScript +/JS (this.print\({bUI:true,bSilent:false,bShrinkToFit:true}\);) +>> +endobj +9 0 obj +<< +/Parent 3 0 R +/Title (Treatment of mammary-and uterus hypoplasia..) +>> +endobj +10 0 obj +<< +/Length 2574 +/Filter /FlateDecode +/N 3 +>> +stream +HyTSwoɞc [5laQIBHADED2mtFOE.c}08׎8GNg9w߽'0 ֠Jb  + 2y.-;!KZ ^i"L0- @8(r;q7Ly&Qq4j|9 +V)gB0iW8#8wթ8_٥ʨQQj@&A)/g>'Kt;\ ӥ$պFZUn(4T%)뫔0C&Zi8bxEB;Pӓ̹A om?W= +x-[0}y)7ta>jT7@tܛ`q2ʀ&6ZLĄ?_yxg)˔zçLU*uSkSeO4?׸c. R ߁-25 S>ӣVd`rn~Y&+`;A4 A9=-tl`;~p Gp| [`L`< "A YA+Cb(R,*T2B- +ꇆnQt}MA0alSx k&^>0|>_',G!"F$H:R!zFQd?r 9\A&G rQ hE]a4zBgE#H *B=0HIpp0MxJ$D1D, VĭKĻYdE"EI2EBGt4MzNr!YK ?%_&#(0J:EAiQ(()ӔWT6U@P+!~mD eԴ!hӦh/']B/ҏӿ?a0nhF!X8܌kc&5S6lIa2cKMA!E#ƒdV(kel }}Cq9 +N')].uJr + wG xR^[oƜchg`>b$*~ :Eb~,m,-ݖ,Y¬*6X[ݱF=3뭷Y~dó ti zf6~`{v.Ng#{}}jc1X6fm;'_9 r:8q:˜O:ϸ8uJqnv=MmR 4 +n3ܣkGݯz=[==<=GTB(/S,]6*-W:#7*e^YDY}UjAyT`#D="b{ų+ʯ:!kJ4Gmt}uC%K7YVfFY .=b?SƕƩȺy چ k5%4m7lqlioZlG+Zz͹mzy]?uuw|"űNwW&e֥ﺱ*|j5kyݭǯg^ykEklD_p߶7Dmo꿻1ml{Mś nLl<9O[$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! +zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km +endstream +endobj +11 0 obj +<< +/Contents [15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R] +/CropBox [0.0 0.0 391.2 537.84] +/MediaBox [0.0 0.0 391.2 537.84] +/Parent 5 0 R +/Resources 23 0 R +/Rotate 0 +/Tabs /S +/Type /Page +>> +endobj +12 0 obj +<< +/Contents 24 0 R +/CropBox [0 0 393.12 554.88] +/MediaBox [0 0 393.12 554.88] +/Parent 5 0 R +/Resources 25 0 R +/Rotate 0 +/Tabs /S +/Type /Page +>> +endobj +13 0 obj +<< +/Contents 26 0 R +/CropBox [2.64 1.92 400.08 556.8] +/MediaBox [0.0 0.0 402.96 558.72] +/Parent 5 0 R +/Resources 27 0 R +/Rotate 0 +/Tabs /S +/Type /Page +>> +endobj +14 0 obj +<< +/Nums [] +>> +endobj +15 0 obj +<< +/Length 792 +/Filter /FlateDecode +>> +stream +HMo8x] ߼Ez)EόZX#)~m -EQy8× T.zz6FOZe^G^'/Zĝd?ʂ ԂK͚ޤCYSæ,wey ,2l- P\"3\kڳMSl*MՎOɝrF@Y.ckVjE &PYp&!u3!!|>K/kCi@q&cw<ġ3$D$%&qzgΗؤ *!L]Uw}8_,3@$JraCuz}K6ap\gLj4CLIrn 5 \y/pǝ9_͈O%_⩯n$uӷe2 pݷ꟫y])F/ppB䒰Xψq_͈Pa8ύΘ9X`R9{žȞ\-ɰ&gf\:li;Ǯʠ %RA7q8oݡx 'SU3ܼ)<!AU42~4';&s8dɦ!x@.MR]&8X8"ugV;J{N`oP=^ir=nH%⌘0>i*V,C!vwqtꥣ+yDC&c]>J%/ebKfYW/ATc6EM Ek |Ojŵx?"7/Z +endstream +endobj +16 0 obj +<< +/Length 658 +/Filter /FlateDecode +>> +stream +Hn0 |]`0``ת%8 ym'R걍c4+Jl[nV|#gFcAFǺX=BL=We^P7vLe4g9-Q 6? 2N/.mJ(ӎڔrnɀXWOZc˭+ė[,ǷP$΁o}7ui$R)$ _DJB"gtJq[ZWUځV cӅp< r]q..e<?ݴ#$h1(iئj?;dt 9sq949(Vl>)[P}ʒwp2\ J)q2p0 P1s4,ε.k t%A/{ƌ.^Bir6Sej!~P mD_se3dl^n_,2 +/ޚy,3Wq'P\h0baPJ wV dxJt,gvV|0B BܜL^uvAR%+G;d!7@Rq( /!(ToQA<s-˾Eq:y^`} +endstream +endobj +17 0 obj +<< +/Length 656 +/Filter /FlateDecode +>> +stream +H=o0w!(:]gڬ4In_JH7{Ï{3KM T@C{ǻD~%Ⱥa{II"m‘:L[+}ggqS8I$yawnC2c(*u/HzzFv]Lۜ ruta_g馡nTԀvjΗ*Om)l9Cb)3#^B& TkkUYzcnƔ5.AF{dSzz:sE2nWU,҅_&l8[2)'fr?exÄ.U!͜ixK? +ھ̏&EV +0n$ +endstream +endobj +18 0 obj +<< +/Length 659 +/Filter /FlateDecode +>> +stream +HMk@[Hc/T)HJ;ѬvX̻3xǀ9~O ~U ?+ar4vZ.t6bsM+ĝ!g6!2b~e`Ʉp'%#VE22C2Mqh1B,jWN*}uҸ6t4C?u,[` ++;B`&=#ަVЖ5-: OkZZy?"yu\ip.Mo 9-0DAA)214s8hZ Z$^q*-&cArT0~_xN"ʄis)z$`R%4Xr.e#0 )yN'R58/*wJ?n~##d + ZqDr٢`#PW5):C/r8a/WK^uk ]azQJ> +stream +Hn@ EHe7P(vם@uH, _ʏxC3$%9.s|[|Q-E.Bk d".=B#Όq`^#Qr:(D@fD6X%AC#,W9M!mNV14@)e_T2Gef#.-P/P!m[X=$.`@l1ɳٮČ& Ekhr)V0rlشm'JsIZ}, *dCJ>ӆZv}P@ɥҡ59̭V[=W)2E3K ^@+.*#J|Gsu3v+ :xٗPnKMYY;+*m036bC}yM4tk}BS/jh:]<e_b~~FwݴqFȦOcpMwU@DHy]=;ԵY#3-POkAЂ陷_`R7ƓD$#ߣ"QL~Nz; RQ o +endstream +endobj +20 0 obj +<< +/Length 711 +/Filter /FlateDecode +>> +stream +HKO0Y2`,ؤI=J*Isumꢕ/>㬮MgՊʪX7W+CLAsZ`Z%uB&Sh/]7R)&'1T1RB0u`\ӌH$o8/Zph e35SA +{c#Lb.0]-j8O*8Io:!Lygt .tvL 1|3zdR +!Hۇ.V* +!ljwS"Uļi%91I`09nMc"0:׻iD4B'(t]Z,Xks.s>Ϙ+qޖgb 5dܥލkw2e[Tk9`d> +stream +Hώ@ HC.ú3窽0[վ}-K< V@b~'+BU x })6֫Vͯ/!f^186Gdۍǧ%nU!Z@ij29%5i`y=@gҰZbmO RLju3uqJ)c2 ~LBvN!P;1 +mE 6! BN(. VO/9ւw x)!&9KYpXecD՞~嬥iDgSmvm*8gʘ{? u#q&,$RQH_W?;>Bvcs=rǕ} Gćd;!Cw# n!ɰ/@#g7 CaoU ^W^V۷ea*;4F^eȠ)OHaa*ᒒӔL[(EWԇl`eLQ3}Ce@ЪyTKύH3B^r|*cZtaL48 I,iSrՔ˂jA~ߑYe⥗?ޱi;;h9],,zi΅0kXwfPʠ5PQ\NB +endstream +endobj +22 0 obj +<< +/Length 671 +/Filter /FlateDecode +>> +stream +Hn0  UEQ% (;&pyi=S"䠟H}Hfq>˅(+v˅qB{}\.ntZ:I3i0)^[p¬1{M+u8!OW#ϲȤ)fH+bzߜfQ'2·-{XBmE+Oz(?]f8ʚOPi0V.(K_– S$9;y2븄RC +! +Z'8s!I+C}8 }SMNƺ~>=z(V}*}!!kjn2k +_=^d*I})]гȖBEBn?pU)XlTp{b(aϚMmġu *3[5:m?'3T!:ZspñpzBX% eY"Iھȉ>I]Y\FS`#z8eȎTr \+hTW>lsK Q?,6-3˸lTKI'FBaGnQΌĺEt}QEqjϬ)Mdy6_d66~ЦVFKd"> +/ProcSet [/PDF /Text /ImageB /ImageC] +/XObject << +/Im0 31 0 R +>> +>> +endobj +24 0 obj +<< +/Length 4543 +/Filter /FlateDecode +>> +stream +HW]|_`_$|r@Ip/yY>IjuίO+vkZ5 صJ3]]U0JKUH!_e/!CZt†PEեж_~N8]OCB<>ϭ,T3ָy|Bz{ +ުU%P<+R<}HYƉJD2h>p|^]ͯA `ݨ,3Fqcssl~Տ-ZrhѲ5q7I]+6fcC~J(E_0mQti>!I9IT$S.Д@ [at~UNƈ!>vՇCpoOyfsc'G*(B|;1ջ^} +Ƌ)2Zh'R($JkH;mC}ª s\ X$*[e7}PT8n#s!!O2_?0+gQK-%Ma]D ӿjמ;DgB]bI4 vHYGgSKEIQ/IboNLtҰo9G @1ެJ3k*~ +xEjtEK(,T5LӶ>ji[ +5 vhg8L0]Xb,EfI|\)ssn@iI2A5Qw'owEnz3( <%S =rھS 9#;X +\h1Ds2\n7lPblI*(%ދ$/"X;&U 2mKA3:=]HNtt[2!b|vM;{Xuk#{c +qJH蛈ỴOA +:Ppt@ߨ\BF@ xvm!S +B@##?2Onzr)@j2?Q6;adp^vbzr:'ɐIOT"Lf̂%g"w"*lP6Llԁ`q'WZ݀侐_0a9S jmR-~=78g^ݺf-6< _URd SfwUac@8]h҃ahe8R7M?I:\z be^ p FהT^p,#V޲ q ItYzQy1 JГ>%y"vC9+Z3^5@^^T~JdQPzгb+P[2$+]RN<+ c3cB—$y4? *T~_E\['k(J.\- ++`w4'@J^Q7@;jW`_WI{zׇ~!&MPf<yf +)VėE wn-J̩!%O + "=:ES=˂sK:G 0i!q}>[Tp|wd yˈJ],ʠNJa&)Rܲ_٢~|bm,+`S_̾!e_ -. Dxe:iӤV۴l1`W9J᜜ +c5 V GМ4L{s#}v^D+1V>fHo&} PRӤFc#uRHTΎK!(X|Yj?a* +aQ]}&K!I%W zFLfhγaS:c[qIDkM +aM;Q`ld9P\. +2R'u`mI.)}dےB%SJcԲ~ ,LU6 ;63bIt`3t;S*&k !vD,@) +ǐEcB@Pu`RsKB +W1EY<\K[ E{[8^…F, K7}m75ZIvlp]bn)_fQ^'0PӖŋ1\9Q[ڭoGs_r[ <10Ց9A}AA [ 4] 9c/micQq]=Ji@qY]pقvu%)ᰄ .,/lUL GuF 0Z +endstream +endobj +25 0 obj +<< +/Font << +/Fh0 32 0 R +/Fh2 33 0 R +>> +/ProcSet [/PDF /Text /ImageB /ImageC] +/XObject << +/Im0 34 0 R +>> +>> +endobj +26 0 obj +<< +/Length 3955 +/Filter /FlateDecode +>> +stream +HWoFn;4].]|hKTJRvf4#r;ݝyZ'U&k+o?#kPMp-"Z pUv1SOWd}__f={ӟˮ.0 H#OO RF"[i):}g,2c\-߬R¸wۀy al!l ~so"j-Lp×ï֓/SpE.O7:)(*Sor?ϯOOLvƯ>{8=9KH}K";= §?*dTȳk~_wrY5e׭ӓW7'l!Q-p弪7HMaMMoBx.=@ʂfIjg8Iu;&!¸\4LU7[Tޥ4_m!W )vvP6pH]Z +(BQE 8l/Ԏ`.'ڻQ8J\_,2u+WBi4xcF@#)(ePCyOvD0ZͬZc3}YV˂ +D}gum0eq}a~GR{t%~.[Ֆ˘Smyi0Ӎ6֍M^^.QI@$yQH *0: + I. WeCސ +R!.XL\q l+^~;Kj\èz?MS81(&ȳ#豏mU!q[SIS׫vf'A  RGYy93p!\ćJϊSaDAoqcիSںlifgvI鵛g=rqF*4E.B`z -zIr +Dw(7,"?,e֮]=T8UsW/$+ǬԲHB dz׋cmgXU^80bHaos0~QG&yI.C Gڿ=Qn$pQo5̘($Sc†*cO\M8n5$*DIEz8*6xaHv5i>ZEͬ~,2G·RvKE;_^9}Ah6+\4`x# "ͫAHn/*gD圗3`sJx +Yx޽GKm]:hBlnvۊ!upRH{:{1uwy  BꨦGP#g Gh?ft;[ܑⶁ̐cōhJGiT`5ӷu?}vq;A-eլv "5"ҹ 'f +cD |rrbR-j}TV#(nfkEZ ]aCHJޗ$! ȸ:0A/弦x+ˮG vRPikAzŃF`nv'|納GP(e0вrzXf@P9$$'oՂM[ 7l'@ 8B9O~ܡ^x3~mZTe|QW7lI m}a#]`Hrs&+oO2M )'`0c{xW~X-%mq ocM\kCL;6 !n_sz_V 4HOBe# {~L vX(0Dj$L*OhQ8ȏ3$ﾮrK㧀OUFQDZ ?*c١=@ =KsCޯq[ΥU[C) G&M(e»_&)y+#``& k΅>C]h O+ )`Ԇ:\UI#ѹmtzF=?va/ju z'K?͡t1:)X ܼ"Du,8erlMWi/ť˵|K]kt*Sk׊ue/3`}ʀagP\X+1Z21}v9G8/ =.n9ͷ90hЍDz4ap3l9݂aI= +V`Us9YmRh{9lc}7z0-fy[8lJR$жzyc],kI`%jG<ceI9Snrk t^쇨Y:U=7b+I27U:J(#u?Kqk@1^x3xnTEGpet|Js*}jvNiabv%MIWfۇ&BO~s +ŶUrl CݦYO`+qY+Be7JaF"hʫdqrLM[n) 䋺M[BR}쮒YfG^Mry:Ak,,w/]-,-Ze"S$kOpeF'eoͫQpE<ǃ_&Kfz,،CsT2m+|.43ʽfMkcC\Z&KuoiY4QHk5Bۛxj*fe@.5ߊ9T\kI$2"s*#%8S*9kf8p֋l]n_:eeH1s~`*(>*` W}xkf-T<*U ocq_\ҵ}2QҚ6! U0WCyIV??^l] WɊ6;VN,7x{/[_UGz\%o-ౚ?u/e(fܐU@^6T'&> 0i0 +endstream +endobj +27 0 obj +<< +/Font << +/Fh0 35 0 R +/Ft0 36 0 R +>> +/ProcSet [/PDF /Text /ImageB /ImageC] +/XObject << +/Im0 37 0 R +>> +>> +endobj +28 0 obj +<< +/BaseFont /Helvetica +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +29 0 obj +<< +/BaseFont /Helvetica-Bold +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +30 0 obj +<< +/BaseFont /Helvetica-Oblique +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +31 0 obj +<< +/Length 283136 +/BitsPerComponent 8 +/ColorSpace /DeviceGray +/Filter /DCTDecode +/Height 2241 +/Subtype /Image +/Type /XObject +/Width 1630 +>> +stream +AdobedC  +"$*$ $+(( $)%%1/%).*++9+*./45554/;;;;;;;;;;;;;;;;;;;;; ^ +   m!1AQq"2a#$3BRrsb%45CSc +&'()*6789:DEFGHIJTUVWXYZdefghijtuvwxyz?!M"!"L(JU S@Qa(L&%"!HD @0M"“LB`%2 aȄiHL&D)PTQ-tRAJ"Rq(wM"e%ӉKG(A#9DO#Wh$)LD5BedO( DBh" %2a#G*$>Q2P[( ڂ!t2AHB La)2Dd@#ddrP6D@>) %);!P(>J&JCd8aJH!&De J! +@RBD/ )Gd()pwIs!xo{vh] %>PBqM"Q e1iʉS(<"aJR0! &PS2|ʔ#'FD"PvL A)J&M S#8H6O!x7DJpDB%;S;T')r$HJR! PJ%ȈO%.TF"NRyLHDJ!"pA8Ts)鄥)A&R!2!!4L$BGdS;쁺 ALl2HPwDBgnv۠(r9@DJ%"S(QLtCd&PD(w\!y/}ЄL@H )PS 8C[)x" P;D&"!B"S 섢S;%vD0e8KLn19ABD!BjM'0)D۠ @NP6Kʊe4;D&Dpe Lp8Je )) )`$L AHL&%#Iۮn^k/m>PLn&vN%)nvLL N@Ll%9D @0edd(A)#!Ht L G!-RB8A0!A0!4莨s(L)p@(&R  l8r9L#'Za>RQ'(> @KS(N% a"P6@"(; @;)HQ DJG DD' %A"SH `@2 +)t#L@( $R(;"!. D"-HLN 7H{@+& +J.Ee̕rKZ9?rR!DB  +D&6D) P L"aLn("a8i)AGeDA*@ 戄J`\|!!8G?j' R +IЂ8a"wJ 2@R.%>TAa0Nap(Ġ.7H0PD`)H&JS }R8@G DD '; S"RL!p"P +dB@ctKS$BGtȔșCL)DB!J-@2  aW .Ia"TNJ^vײ)I.Qh@; "%s *\PwDDpGdGnSL9D"\Gt4[P .)AD$DJ!2a4 GDA@R;`#tB M2eF%7HApH&7@2 wH&D("& 7M2D$Ҙ)Bs `BR钐2 D!&RI۩LJ8@ D*'t;"%>d"L() '1 +e e)DL0a&7]%D*DV4wt JɀB"e"SLnO#tDe2A"aOlTZJ!'ȔeDR$ 7GKȕ % D +IPB^䣢!(CG`JLJSDJD ʔB vA)R"a)L&R"RS q(JT("PDQ2@HHtONTFA KPL(e0&D1|cd %8Q!9Ln(DJ&Q22K a((n逗<$ '))"3Cd@!E0K(% 20% uOB"R N%R! ̤(A2RBQ)PA0eȔ"G&6Q&8Oh$R2> (#&WCGt;*.\ʉ |YaC`NP*\!0()iG)"%@Na eKrDq)D l +!0a"JLDB!( R"R )GT*P)lJhJeIa Jr ĢH!>O (R&[%1("Pv@ B4 p JPRҘ )" DD%(gd t2 "TJ +) +D$D Ne$#);P钐 t`2aA9(P &A>PJz&SqDJ"(O&WHD#AG{  +@"a p0 )(vT@B%0Ph n%>9AOvR!n!dD$(KP ]#J|4 aM!D(;'JO%2L)( lrPPR;"!>DB"wB9Bp`l 9I4D D ( ') a34& BctBH$ +D8I>PwHK;%0rB!JrBH&vN S">`#< + +"\a8D&w@G(2R+&ЄRAD\6 +i"N&Ppr9G)Ħ7@#Q a32 ;Dd#R\!tB@% Ф 0LnBs)'(D'2!!  +ܦ6D&Q +#S(N! Bh(IBa0%.(00%9D%6KJ`J + M4) F0&$7@(Bs)D'Bs((Nb)R  D!& &6DJ@Dcd;$B_&WNLDlמG{> S $L &0%2 ( h@(r8g} +9Q;)Lp)(G BiB&[$  +$Jpm +%0J"wN  pe(D' @0P + +'9@2(NRLQNRA()(R"R"7L(gdҘHLlv )NrQ(0\&pRl#paO "QP@)d!98K& GdA#P;eq +̀' )hB(ABa$&P&Q +CuRH'%#L"ne!a"7@OL&R)JL< ("2A(!\&R-&St(SJC}J@ QɄ4DpzpJNaB +(!4B +%#T# +&"%>E%"S;"!  n̠AAG)2@#pCvBS S$%H)$"PDA&2a"%9(jCtpQҎk&LJ\T +]4 +i> l&TH(DBs)9H!RaJyLAT&Q( L &@&06LQA2D Aߔ!0ADJj $R,zp)(O7dpH"ee8A!)FS +E Q ȄD숄{2PD&p(!(((L"SA0!.S#sDQ(r$Kd! !!( ;P B`$JJ(2! ("J&)3וQ%#ࢼ7"vA4NSD$O(|S (&S"j #04PI ; DJ +Nl|B! OL$L! nDN%@2%QGtS()Q@8DALG"%2$7DJ +iL#%ct;&"@@t Hr5 A ! n#(%2B(Q @K'0(@!@q;JeJP@@l0pe %2JCt K)I0%)3%S*3*(gORL И @*PP@&B|"r&2"JS&@L y& +IaQ0*$J`J +BH!t7LJ&Q $` 9$`$Brj1(;&t'DO)r wH'0) A@)H @A B Hn Je Dr6D7(@HM"P7AH4'@9A(&M CD (D샲s(@HALi@!P$# Eԉ_)SuHJJQ+z%*ʐBq)BiALl;) l M" G +R!%#O(@Q"S(!(DJDJ`B?^h&JD lACJ"Q(QGt B !!(qHAOD;DDQ@@Jh8@B鍐!dARL KD))@(A)L#D!4 RP +s)8JgeTH(t`J"O( B&J" A"!܉t\ %0%")SWB!*%"D(9D-<&a>ӔL @00PӈL$wM(L4Jz4) @L e%2% ; I2! DJ Sq)%)L O' pnBPLJ$D&DSI>ʌBs )򜨃jar%8DEQ()(&<%&(DA!PJ%"QDBH!PBe(ip 9H 2\( r B"Q0SH)NatBn-*IpQ@) ()StAD$J2JM*śtȔN DDctJ"$JV#4^bTP@ꞥ0^u@U8/s] S4?*Q+sr4Rh{0kx3T0aE.@2Q(Qʌ9I(;u̵0 +tI#^ܱm@;7(B HY_ia{?qRۦƞ>0w}MJS)L$Jdw@N "wB@!)B(HH |%8` D 'E!4D LDJ8Y훪eƇwh0uJgl^Lq%2QI ǀ 쪰oIpCdB&P6NehAG 0DJr 0/;Fʿ,fQ@tL l M"%8L $vLA0!U9 N˄ +ڻn*GNQ!;qGߒ5G{,{M/.p|Tu&.P GdW)SuJ!)HQ&R+DlUxG(DiplBaB`'0Js3&LT#&YwЯXff#I Ig*Wp,e("L +j, ]w5M +%F 2LOEksL­s  N֚D^m2i \DZ`T&KU,qI"KW Om +&o =ww%맏g[lXM:_;^*_0vN~K6;Z `wէ^kf|Uvm$궯ilvK~`*K.> mV>`]'^EkA$/-NC@jveMźHW7Rp,|?ϖv_+/eGN%L*[3a&*=1.6Z;_7J{ zؓY$l%>qñ-E羿-$ḭ,Hv^D#1Vn~䡝l-\1 Pv\h7<.v5QؙUTΞ|Ǹ.%yoj8v veQ='ex˨Nn0/j?o{&QƧ;%Nk{`7Si8t.\%HeNj{ܑ⾣Jk LppATp5!}f,ځIA Ng|vY0'_E2,"I@HOS*=ebJbdc7tj&O0z*5kw:-,:H_:S k 27#j89$8{_0ǭOZo|mBJMi 9:F-n-l)a΁%JzۂMh-4Z̛(ҢۊRunJtl˚@7Sǚ}tol٨kgcS>ph&w1_Br,6 \@zU9,ӿT Bu7<ɤAlVt? Wu J,QIv=6e7pcZAkX;G;vmiM{ʄIn]p {EL;߰_4˸57va侈ܷjGw28G|2X-_%I0BV>fڱOؾIpcȗZaƐ0d:{n#~ǕNl4S{K?59^20׶=ձ6HL_!ʸK񚾈|ٍۡ!aڌϒաAé:W#gٝKұ7$/bޅFvH6_5aJ7rCHȒw-lgpRz5 v_č\KĂEa_0˸ele߃鼊d?o%*9Ώhv!?f"v+n }i7+ac +J7"OYʑ[q_V+j y21˒Hĭ=f -A*NoҴbo`]~?45aGRz-/cy~L~-4;vhF Axh]*gzl+[hs_Ҿ}m?kI> +fڏ^7UOoTvL?XE`3qLыosq߹3󬣗;Xۗds\f^ijk%ĕیqS1Hcb4_Oq_# +v# Wбx$|B^ۇ[nû+LZ>A |ĪXҾ /T7GSgM; ݓU$ؒ|s-F}FQ\왎`uz[; KUV>曎yBf J. C&,j>yr"]cnkฎj1-*\Wbҡ "v߂p6)6CwusRΡ$ĝ؅7|,a;:N p9h I&w#f[ېl# ;75~KC5Eu#d+uxfx/\g}βYNvoCs'/1Z$6^\F*Ebsn2`n;DVo6pXצ? !H jm흥8WmyLjeǯ&_H}e{'MSYOC.s1ZՁi'|_ts"Ae1U=ͺyy)Xwv`T)jwyp<_I&m-a湈 v}BK؄7 O@}z|rg_D6Km,jB-i}ŘVTvL kcGsvY*m ۑruYjFzj o}>T ?۾睑U~}UjQO럢wԭSn}AbM.zW]L @Ɠ_&Dǯǹ^va?iE{[ /^쟢.Hqv"JN<;ڻ||ZpmRj0ΞƢ9e5{#i]g2൰m?I'FZ~!=}>:S6z+n2~+䝡1 Ӣ֧O|b^W(lBX_\~|}PVh3@`h}VӴ}mdzjG-#.8_-?kIO{6Xˉ+]*K>;-ض X>UOeU5Ҭb=qǒ۵|8 }Wo۾v y6UHW2fkn_tj?Vs9f@Av7IQpO[QRS꾠= _W;#C{ _ͿDv\T@n +:+s h쳽9fzkMJ-L7R*=6,j>=VYh |ݗOPL>kjn!!}Tii=8Ùq]۴8@;jM>ɬ@m[ΠnwX^,Jt82ZOBɧӻX[=yS&ڎr++1]O47بWvkwnyⰔ,E"hWt y/.'j/hԠØ~{*4n_C~m+kW[>]ZSx} $sUx^gKAp ,i/w}S8 ˒:6],݅Vޥ}|:/W)Q͜Dmp-o=WK߄e[wzU{vi>Ɠx6u2W{\eJ+N^\n D I  CtL(&8NR2aEGe)WDD P;(?gVa4Al6RNe0!q Jd$ R( +%J+杕3MہEoNu`odMǎ}:+y ~v/Y9G!}̴1v +{A H$WKM"Nhָim1XYgy5]꾹RZ59D/=(YOWиor]fԴA-`_679ÿuWeG`Lx/n-zo/Wa?UL~OF 5ڣf՟B["GVO>an9 >a0Tkt M$GI? 0;րGbn?}z_7|?諭r9*1L1@= }S*~-MU~}W(rEQS_[v|h O|PqT_P_#5z?~юK굽Uu+6\WeKU#ඵnE5*-h$_!)6񈀾eU,dUmE+oRA#npLpkHqپgc䵝>AN0ծlˈP@& +Tsiv!z&VSJ^`ݜiZ2$ Uţ ZKZ y/䋁uvɱ=-ٳMl;UuŰ7;J}lmJ`+`e/ y_F?vߢ4B6c?P"vuP1[T3 o1#U`q^ʟwge"njZ#wDwX/XRڠjn!Rf,m8 hz/ōJn. GD"oݏSv+佣 ցG3qBƣN4|'d WoZ7?SmϠ8?I$+E{ӻj'氹%7tF kٶ"Bdyh'Q}QH?[nOO֪x{dIE~=&O0f887'ڬvgjy{'ZZ9[Xf6+~œ̍.y{ i~.X*t2'>1 )S)Je8wQq Qa)^)t;"%"!"J +'u?UhҤI>S9Hlt)p)Bq݂dJ!Fzji,TKehKQlL +U9[(.hGz4+7SOC]dfRz}RuרjDmm[k@O1vqKI$)vVjOgWTtB ęQT׭(9!P :NJ2I9~y^[{N~c1+b󨕖hb=EimH'JYw 4f'T=_L~XhVn="@j[Hp$.1"CD+qJh4RX؀8Yאۘ*i<-5 +]Zɝ "RoLki!gIz3LU`َQ61 bm*L408 x_Gp> +2,m*BaD;< bgٝ{6+{gdb! oT,;knge%E-\qb/d]o g֕b܃Wu^K`X oPY\ߘ71Fԫ2miRGe;0E歝@&y.ί/}[S${flchCA^VZeiV֫ßP ˒2m\sHs G/G0mWm6Po h!;3.~pZ| +Y8_qDX<"Zx1 ww{NBl&'b-Sdrd, + F*Ȏ8ZF#,-oZ >0"L-&RxBKdQv4̂`x.i5KN@ХI4 B'ۿ?_-v}k9AXSǿX˴Uղ=ՍZa/ВUGK5谻%}+]\W]\vK+2 Ju=6˙^!qZC4 +#[/f'{cTkzԘ$n X0;2GWX,_hIm pUzÚ-2; M2#_:n [N Y> +*Lް4_?ӭ9ۃ3;ԋv ז8C->2J\Pm\}eӦ t;1êXSڭ-%͉[ a|;7)@{S(B4x B}\}o31NZZ6c@Ϩ_>ޕkպL92'wk hQ!agnsPΤրoH-Jwy.!u+elz~NB =&fVߴS:"@;ҩ3Fz~>Ca tLLwdLpZ%?;R':rZxj0o{mxwv+ e.Kgo 98ڭ2O9W7?H*<)D4w7<ۦi9ꄥ aHW 0ސ lSғ!N sګ-KgcѾl +vgLRrzܟ_DYю +lYBkeJ|ƊcK@psLJEvEQd/@"e*[?]+v>C \mVi> ^e'S>`JaУV+{mkQchlƆp +U>`$h Tcjp{\YQdSh>Azgm@@Cvl +s;[S1T0W Ҥ)-Lp@.z (A @)]RA*1*'uT^+ly+!9LM"QiaSBh Q BLФY(L@0eJ re(HGTB&%0PPD G )"J8G )(2R +&;!$6Ne$ p r2(%` @2L$a>S5HR2)L#TlSKA0(QA(DT I HSDgJG) ~h"T᫂:I ^ƀ .74Fe ©atncܽ2&‹R=mJ~3Qte\8P0P)r%G +.:OaS%&@& +! vJ'1.L.0N<(\ +\%dФNr@& +a2PNiD02 !ª͗/VA{6*t꾳s`-ֶS0PQAL̩B( coM[XH6 +s\~k@k ۞albP(&P6@r%(E)\&0KQ;'227NRJMp8Hn0Di΍I˵6dz e` =ǚ"L)$`$J!DB 07@E 7A0~?&Cuhį.Ṡ0S}R\JC!@BL> +A$ `# L'Q L)j) ;L%$$ +q(% F'6P R"P DA(!(ra 20R"z.AKTN rffP )!3s6MdBdBE)"glE[}V[lJo^Wy-dD*RN-@ e^@2}adoVKi1#}}ۃj4'Z8TH-<H:Z9';Pn^'U I$'[g7ָGnZwqm7QSv0. ~qX;ynM/Lrkz$urg*a.2-ݶXr~*a1Ny1\jR`@^qE/J/@LxL;PL>jֻ.;)`9' +w \ b%KTԮ>ӃIHSip) N!u'eOzUwnUweFm~-iq\.1 +VK5*VT6ȉ] aH69)F@2!rev?i?%tsK%H n=$7N#o)T" y6|R-JT ؐ<@{X QM!dBgdi 쉔#S(jD)TQ&‰2TJ0>Q|6^a9 's)nS )̠@I4pG hB6u1e[G|$eVw=<*&M>B}CUx}q,=n^5b{88]ӭ*%z9L`r~[3vrWԨۋVxc@ bII?$r`t i}:d1v)[pO9v+h*;wӖX3__^\H; ׆Ft5,b1-.60Z1a4(FQ瑲fVL{j8 +r|Bіvhkt;a|w//ŪٻPzՎIv|>n3y3#ѴQwx1ܕo-c*H-p{)Pn׸m̎98Eg;oǪvyj.F$4r}57-IN_0MDKܾq~|/LvmOͰԩeFlyn_^K`t`;ŠQd;R 6~%Hc=-[ڹFΫ{9/w> u]U>#İ{zE'j qեCnI%f;F.ѝ c;gvLk@$dO@sgRtTh&{3o{%܅Kufx@Qۛ}04#'"zhy_FxKwToC~ )7[;ܙg|Hkg{ar{iZ1ZѧIGpqR\=LOt."RI٦7BYToR fIYLR*@,'޷Y{&[[7Mi43S=^mL8 oZ\enOYJ)}ݴ]'n.z}:s_1o*Ga:5@ܭgIcS8IǸx+Oc@ rjTݢc/* vz+kkFw LݲΙN  KsJdx]86}E㋞ Ixgir@dH%\vkq$tyT7A?E +(V=̗hX՗eTHr0xUKrs^Z'}e |cCgu :X-i +qH+-p7 +̫A,"G3E.^m˶7_33ףR:ib8Zk~,...gY-tGMnY>!|󲣪ҙ|We|ߵEZp@jN< +@ s.}"h9+KmQѹlBf.0.Oi*oP,}{Aϡ[d Dr'~b \\-.N5v.k7 o#O*0 X \'I]mWL&/=W` +z, XUFTBǝ- ORgj>s청@Z=7?jw*5ƦN>>_Ln]<Ml9$2ɏ(WT}?EM@ܪq)EIa;Ly/|\6}Qg|5މoMUYdYjۉ&~]V]Nw <+sa~jS06c;Rٳq3-/8icK]en̎`+kAؗ~RvV6ɎZ@w94\9!W8O=˾V +ǖw}^|}\CќFpII5yQ mqPzR9^\id}wl46>K.B^ 1V#Zv;t:U+Bݭ ! ɘ6?U&%b8auVթDt#Na[z 2f˭hטYp9K03`Zy \#jcEKtmVzhw5I?iSfLB6VH "G0-.G"d;*{/'l|חm\O=!Ro] 3B;?b$Rrb9؀~z{*iRj1h>#pU&z؉gܾH*bƯ%J?>p_#=#߆>+oex3^ֳƂ~Aa!YR.vz/zm1vLCUi tsOhmi3Io AZcO/Ψ)LJ0GǕ%gA^ax׃S4*~,+zދ5 V {>!VvS@W}Wn洑O+'rZ +K;Rɱd?li{ϴ[0SƎUMY>"V5Wvέ.ݧ>/>}JG3X7U+{χC]l\}vPVR%q16X0iԸke6VQ _;kGQLhp+r^=!}V6R2sq&aqT= ݛػu뽖j'][:M1:D>9'/{i{ {Ն7;]B6+jh[0s[heJ>]LOPVh䒰ס5ap9+~̷XFwQ:wZ\Wd5[ӫItxxYo teߵMv~+~v1B.w`/5teq=kxq.1i2-1^›Ú~;/Ѯ{.KImq_P̶mQMT Cy39ޮYv#ǫ8W-EEZfZY`TMz["NŔK][F4 |WϳӉ]N~}{?duh}`_ɘpQ9vW*ST}WƑY~,˝V6ĕޗ55꟒֤*l=z4EZ@@;/NR[ }>i>a6v/'ŧKch >nI!HCoYnN x+罕T]L+ꁄ_+j7OEkxx9uY:O ni,iym=(T'3NT8; gM`5u<5$/gl&jQ}V+݋J5~ +Սa|9V#}v0G%o;@fHBdr[N\0=)7 is}n=c}m]Ͳ?d//RcddI\p|n_FfΘ Y xi[>{LjX.Ա6le:GEgٖ@wdLw~~6mg_ +<=+Z/7Gq/Y;IJRJ`D#irAg@ [b? +}6lm-voo>adr=a&7}mW ۦS}w{,aUeC C"IO:s"_O;r9#2-`Q}n>Ի) CR>;E2%dK v)ad(L"Q00DJ%.A +'dBŒQ*xƏբ;&ИL& 2&68B4 nhD9~}:K0Nv \W?k~.=O{[ei;x~ku.ƝnAmű~itǙQ `qh78r6e/OsZz^Vnk tهi`"f.A 8;1궸;5dZ٘|$_>ЫHdOI Meah?S]K˕2PXTխb< +:X;qÇ!afv=Q%Sƽ˵Ց 'V(h <L.ּ,{^##Zan- W1aQcUG_Yդ(5;yG}[E:]Y7~v\pYB7q{4m:M@7ʫ9L*i->+1r)+zGyi#i;' HݪuoU>? +Z曍+o;lvpVXt^*8\t'mq޵๤OYl݀V7p,-7LcÇ!aFDp};it]b\-S)z\OR|Sqp px1WoPqk_$isླྀ'g{WMB?[adr/*@/: Dpjd F +u*ze䏒\K/ sq1Lѫ `oZԐxA%_(x]޺-W7{}Kǝ沥"J{A2Z,S5_gqn8_g/n%KI> n orꅭKnW֊IQ&=zr&]\ R$mYf( :,!n77O4;|aPKs^ʄYU2yvUw_/%nQSijeWZ +vs6 Xv6mcc27Ttja?8EW6OtDyvڭYAnn>GWp,ՠ uij+`#s;ƍ¬9ikBN z}9>'Y,K1Wi1Rűl0wZ c\ 7v|0=E&[S||J2lğ|U[1 ^w-krOK8_J&9 X􁥣Dz:DBF3. +l $=!zk/td 0~jvL:4_SZ)5m|7 F7[drRܚ$l a7ح7_I#K:;i8*j2K_ $gt +Ξ?Y?8`CL3a8n"XZo\n_L\~jPϽ]hUht 1;lG뛶Th9L~Ր2sT!r Z̞Gh>Υ*m.y-sʮѪ-%Z$ҭ91gs~#2Ʀ^;Z!}3 YRm>+?;>$2_Բ~+CMt7<DhXq#޵]PYW69ܯ5Wff4I,N+]KCXUa`s[ +2ץR̒Am +vZ nKϸ>?oJwϰ&C|@ZṈʵ{4v$;vW{;f yC.+3-\Y`.%rٕZږ;y5zu7 s#vVŢ"H9.Y)-V(q+Nx;|݃ l*@0 ,aV h.;a wNa B8AJJ &ЀrJ%B.J(TIP*$_B`LS &SN4CP  `L60HA +T]\]@8Nsⴙ/)Cj"HVe("'ܦDd!DDʩu-?r]:(YyE帾,;熏伔0 PVpo 6@wA(R(%)JS)2 xIn6+אmif)Tikc;-D4 lPv@03V\~q<m2 \f Oie[iW%nk~BGDLM)@#eĤ]*M~+'V%h5K@姩vyKԩF\'r +] C85vCG~Wpl%5Zy>$~k)  DHu?BK?9zzZJ~I $HU>*$!I! +%uQ&Jmtp8uQPI<%2\|@ H~H(U.u7轢 l%2 (nɗ\HiYe[{k$ %ܴtWNk,jE:J'0SL!0P)!'SG +hJ8rP%A"SKCdL D"N!8%"7Q Y=TjRA(!#BQ &PPR!Jd$7MBxFɚQ.@vOR .JQj&S;RkT@)b(AC > .AL:<)Pe-E  +SQ))(BddDB^{.%wM@cD58Sj e'6HI6h8HU'(Yɢ߹Xa?5ܙ)ODHLnL&pa2("PL/oxMJ\y$nVvۢCG]AQ(@) vD +CdPQ7@0d2%.IDBGd78u(pP |D(4"PL &0JGdSF"M +@J| "aj)&6G";5L& +) ҈L HiB%( !7p6LH(&La!@(0N%!J8@AHRQDJ%5#L%"A p H6D p!dHD D!tB"PT;dDB8H@e=0!E͞Ll&(=2(p( A": pp20@QA5)Nv_.AHTJ(/,KY$RR!)0t#7ni "!8"z (t At# +H)"Q&7HɔDw@ (@@O"e L@0eFM.SҀ JA2(#rBf +F0PR)!t)L p PPS;%2nRr"Q2"%#h%"( +S) n2L(! RA! @2)`&7G!;"an)(@0RDJM9LHrH;Jz&0( @"wM8)Ĥ\("SAM +$L"%.6N%!gd.™HnR) ln :B;%\L6Na>(h$L'J0a$@nQ +NHDJa C!r8&GJe(%GH@D!&JA( pLHS&L`$  2 Kt\Je&wKJJ0P LA( DIM!R9BA> nH92RRdD&LJ& A(a"0 (y&L  ;!"Q@0 +șM-[ nAD$ +`a3@D LF pDnB.  +ӣܭJHHn(M4PTSQ0Q|"q&OR"R& R00S&hS"=qNRS 67HH:SrC (𤆄"aJ҄LHH%!.T!S*GtaIFa35#;(Pv@l!J&P7DJGtS(% 2|P(%d&ܠGBPvDSpBNrDR $|!(ҥ2ܧJ *'e#IR;"%0Pq)%D`BZI@2! GA(jPn"Pv@Kt +\'@nR&S%3/.R%E%AMuHcP(KR鍓B%4e0(MB) t 1A BD D wH6!(M"!Jq"!  5J=ȄD% @"aJG M!%! \ A%Q! 0C! )Rrl| 5a(N!B9@rN J%deF%2e#"Q0‘S.J@dJ9Kp)LPJ(Al A;&$D B @ A@@I2."%HlBK!%".RD쁺8Qv'eTyܭB))(t4Gژ4rS& S!|%$!!tD0.!>)Ptp'HN +R Q2L02PD% m"SJ6ATd0(rB&P6H@2(DB G(BHB! e U! )2 "PD$vDJ`$$LBDRIA(; GQ@B@`'D`$ &!3E1&S +cdn) ԦLD#D%h; DA@)OB J$d8).DL2H세pQ8NЀ0j`L&P)L&%d q̟Zd붊׵^z/&)ymQϢ51ē[{+mvp ulCuWyxCII)D SL5Y>A8@j?$TII*omQ, D(ni-ȁT–` mfF&WLu:m@mAO<!]}vo+ +WeAHL CCJeɍ ӘDD)%RH삒5O ) ϊvGL @()M !1P QGtA0PQ H@D`D HM!@J$ a &Q&Q)a"!2Q0 (!EP !ɒP&R(;l$Q##G)J)IE.R*(()(6{⭂\8B"T8AO&rBr +8NQX\hz^1Fk }wPPsAz1Lihx`)a2{xBS'Hy 'Gt CJBȀHly"0e$) 8G L!tL$ST[gdGTPP7A)j@t(!#t 8Js + #J!REI샺!PDl2wRP +e ](C|%0PJ(t @(&PL rPvQ +\ I Ze S ! W. +IA!DTIlir("*H@’9@Bh)z"wa4qV k 9m-n[|Z8hߎ|Wkfȗ9tXL"V#P]c,YN'iptz j\&6@MF-@ka+{czh6"% ct*YQ9Mg$·0JFَ.i$ɉGt>.=uB`YRw v^k.(䰰7߰R` aD.rvTG[k8̑;:sc#+MJ^Xjh]Ji.ia hIx2[չ#p┍1XmpmaX O+"%R( eH' D@ n Bd((N6N!-)$$A B(BI@QAL%@B22Q D!.8HHA%$J PBq pp: A'*$&&) ܠ@A( r l`9W6fWBa8Qiպh%9&JQ(A.R;$ + %'nZQ4߸ؙ +)G(J7G)0a0 @SD(@)P ;t e0%tjq% %JRD"Q'"SE D'H9 B +" R2e(A2J3R|6KR|AH"!!JA2>!a0RSB +D (Aa#s(@L()JCd v@9A d$6A8JQ@8AL;!J!1DJA2$BB0&S;(AIEL e0!DK.L"!$r( %ymwU)PNQdBdRL @0RJI"!BG!. & + + @#p" %$.CD"e:\'0! P!"aJ!)@ I6LBI9D#JD'0HlJq(D8MDRTF("JSR;#vԀe&Pl%d0HLA0%jv@$&;"(; BOP J:&\S I5B`'*1(AJ\&6@a4pRJL!7l0Qa@M +!sgU)@D.ɔGun#VJR'  O%1&)L@7KQ)p%0 L&SCy@22(J!1@CvNP@Js(%=2r)L a IN% M$ 46DL:RɔJs B%! e!P +9B&P6AGM ܑO x $)r\Q&R(; $QL)> OA  (>%&JCpɻA2`LD"P6@teAd"B.%"RQH÷#⭂%4P !9&SD'"6@ &JShGdHl%> HGv +Cdp +DBS5D!dbBCd%%2-$ A(Q%@H H DBe"' ) D2"CaDb%!q B`JD@@ R;)DB!A.S"d4J!(  DJgd"#A@PD : lrR%3%P8h>*BG0`n HJ@9Lȅ!8OsNa"!2a6HLD A00PA>LAt$PvA3ced'.P %ݾ&Q1Dʑ0!dJ!΄&SC@BN2A;!z a)9B"QtI $6@)Cd(-G)pe.<BԄD(*@NA@&Je2eCPRh@Jd@J|HR!E-RR!2!07H"'D8 !QB_.(.RH f>*;&hA%4p| )@1vG8I& y#a!6(>RpHeD18CB&Q'Mj"PD Lj +8D`CtL$)!@4(; +DBI2e-f~B@%(QiAe DJ@"@K @PPD)(B@P#tja!9FHɂJDr;L(@B0PLԸ@qH!"(DBGt"R6JIR!7M( +DBNa.Ą;t$RH7( K 0S(LS )ĠRt)p8J"P6DB8G((NR)A"P nQ L!0%0) vA|@"e0TyA j@3r &P6H @>PL!(9=BH#"PDa L!%KPJ@ )B (%iprjL#OJ8A(Da P A;&aDR-2Dcd +P(Ħ&6@AAD#THN!. 삗 J \T||a*G( r9DG !>a2SPq  J`JaBI(2@DJQ)8x lP0vJe(;"P7DJ&S&H&!cd靐 +P eH2Tf4H$wRe42DJrA Dr@G(@2 48 LJE҄ wHL CL!D(vFLl( DPBA +0"PL#r +`ɤ +!DnHLnwF8.JRT\L.ey,@+4Q)pre4 HSB"S!>yRD)r0a@P әLI&S;(T@t6@(%tAD)('H@(Ll@)*Ced'Nad \Pt&ILH(% g'0()(B&A +:HL;0at8A@%(&);t((p2%>P#4B\&J +@(DJt(P PPcRJdBI쀂%D)D(DJ% @ҐH\JB;R& .0(.)|x0ǎ!3% AOHD#r$ +"Qq)L7N! @@L%(8D8Gd4&R)(Q(%"!1Gt R0!!Ԝ>@"THRj J&Q7AI)A)pJ\nԸQp B; AB9KRGt!9JRЂa"N%#(-dDA0%&B )QkT!8G(AA*3*RRA)&6A(;%@BbiLJ0PJL$ )BFADR(D%.2"J?EEZh;&vL0O`B Ln@@l!%%1ABC&w  H&P +Q)((H:R&F; IdrJ&@ 5#i` HJ(v& R JM $L%rDEHnTN(CODpyNCPLM$!$ DJ r7DG) +DR0PvD$S)P7A2) ;SQKD $SPJln&HA(!" + +&AGDA2(&P .;"PJE'n'.n\^,3|2(L@1h##@2!8BAG;@PRM&(LKD@r$A@ۄ"SD <&(0! +$B7A0)D"> pR2#))PvJS(")(pG`BGd LD&CJ% B@A4!$g>LNT@#Gt*BQ%eТwA 87tJ@&T 얩%"#d"vB9C2 (pAd Q(; Rk֯. @#D\W7.o0/=2X&P6DJL@)I!3DQ !K&DJD$ B1Q BdF q)$R( $#Ȕ("PPRvNQAA%2=q)(HDA9@ S"S>S((RԂa0e GtPQiG AQʉ ( p ;RҚ %id !t;t@JS) J@OpwKpTCtJJ!2a( +D|THDB"PRJcR!;1D .Je"eEPqOP9BBd))!"S;P`J`(Eۺa );7@DG4DRG&P6@0$HLH&6D΍&P + S.RR%FP ](F\  +9RAB@Ȅ200r2 L&d„R2etJdPQ&ZTu& +@wA)%0TA(@0@(&2D DeLD&@QQJT!n2PR&S4a Ĥ7G(|nTF̢e)̄&R(&S.lPvJRW7lDxdU!Hr"%KrTJ )"edBB|TP "e$; @2Q 삀vH)L&D QqɴP#%A2%$ ;Q&; l%#SPPژt#(q@ R!DCS) +edꁺDJ%HJ%4L)8p(PxLO@0)";< HR$ +@Jh 4"etD6N;$6AH@G (0|P.\$p\eD|aKfUB&4Jct#(NR2!4ɂ GfsiyO P=Uƒ3vdvnkCF|e;RIL'Y{@<րt0gֲs@m9;FS(!VL` -F{i  s(AJ%'0@S^lOnI/p9Q16trC_0+ ;qNEiԻ*Wgv;/{*tJ-udm.2 kX87rdn!GBJ )jp {RY2ߢs%0Ll +Ur@1\l]V20ʓ!&<1AAu@3 +d. :*Đ7'cz6="Ft'R0 IIR0e0%#stJRBnHɔHӘAJPvDSܤL&7D!tJe#iJb,$&j\!Dn2AqOy0Z*V{ +ce5/5Jҫ-}zXl $RJˉb +NLiÂ'"JDRAro9/BE)J/+Pp|a}ӄa12Arɀa҄4N!0%$b qkwt- l$?kS߼+|^4qO`nRah{)՟ݴ +x)|*huw< \'4֯ kvpWOW=!mO<Ն'k]W6 ^{b.[ڔIżW6OjǘB`4ks>Ud͕0fRևG@|W*51{QgG>*}q^47nkJì\O ^;G5T#Phy PzJab+u35lVC{3'r]{hs=\.oZʔI?_}FkH>kٗ[kcJ5*3csRʛ[HH]Zae01\d:fWelևkqU} Èbhk;ٹ׵ ;Шfl +uI/lp5m(H2^WFgè˪l'zm~*0298+Ӛ3@iT[hܰ{Pr:v~V=^ԩiF}FDbJ [Vu'D׷>שl]E4\I .Wul{X3On*6rO;hS;hmsPŋTns-'TFvv/aWᡕ7pUNuTv_4״T縍`ڮ;U4=Z {_Lm8}cequ[#5<ɚ?9ԛWށW\c;cwAipI&\>#/H?Yqj>=lPv+u_2:^3C 0'*)7)Pci\}b.2miy$z5^Ƌ{Hyaf{P\J" +m+ɹҗxNdIWƭV_do̟) 8Q& ̏2=ט3wUVѫS6]ᅮL xiX7?Gx ;C4^ݎ*.&AYV4ͮ,HҾsL({-J2U T-Z:[Mr*3MnP{]hgi<gU-i ptqn+PԦi^˙ϪUsŠkZw6E-bwe4D̎:/.ẹ4T0$A!FmjX$n{xIuF<efb4NykK͌j f1k8NK2=.ԘV]t21-ktNsY]jVŅƴAd4&<9TG{Zͧ{֣ f#McY]P5hd|Wl+7♣T$AnUyOɳ=UZӱ.zxަYU܄f O8w o*ꥼwSa>A*̌i65n:OUkkT]5[#3C/n`ƙd˺lžGcMZߪދk!uEu ~jśQ7N#UCu 1P`OIVdSeZ7v!U ~[w}Kkpۦ2 tQK{ +ε!?ݡӧ:AN} y5/*2o+=uXԝXg>+ՂfxOFs]J껯3-1u= s $Nَw!ܼ7Y^hc|ףԱwOpܪ^j +{5+s'U*Pcn)T]6 [*91VZ.{Lq /cf*t0 : 7:ѻxo<ۂkw'ѩ9Sr g2ڔ<|X͵+TkU)SkV0Y"5 +och0xZFASg64Q+`Uv?޷vot(;e _."@y0Y(; I(!0>7@(L%D"9V Gn*lJvq>vH~GOZ3եHod0HG{M x a/]wl*lRT6aqy^w-i]mQ^ Rnc[벷ȴBʎlզ*c`? 2, xJܺ֬a 7/iJwFѰcqZ`ϼ/NU7߿ پm_tn|7ȵouWu_=vW+uJtC^9ڸ}\7+ƶ@]^|\GVE Z-gO,jM:?LUzvzVڐ1?bV8~p[zgwMחcJ6c5@S?bf:,cF8_G;4(d }n6 2A5_WLWlw|$rW 9P>Þ'Õ݀> G(l^[RF1KonnQKbyvZ֠P?zspqj@ G_vC0UѮ>#}ZH.#}T{[zm/<"n5F@=}^<6թ +lk⼹f^vu[Ҟ{еZD0qqY뎂EdgV<>#ٟ5Qn}6ӧ޶2B#>l/&nu,&i7)ҥj DC|/-ݭ)0As)J*j b7\zv@Tǂ +ϵ Օw.- XmjRha YoJ*ˈ&@]㘕/E5u +pSāivyµm;Kgi_ۅƧ\ + rեĬAi^k+o9o|Uu-8kcKtLJE*?S-P ayL2Gn,d[NB',Sx(& +,uiWs_Skw?%sU#FlK70ݜ7c%Jdp{[$⎭+QBj2=:)7aR-6l,hӣO`>-|Nۊ8*0[\z.#Kwળb-^=̥%ӅIRrپ4UퟌYv$wVԠgI5sF4оpiaXSBVHpO>K7R.$4lwFkkcFV[c<Dt_D/hqKDw- +`U-k[dÙ)p ] f2[UnihnU-]R}mSiFS*ZVin!^̑~@3qЊUqU\XV'Z˩>D[f}廨 j=?U0Ƃ׀Cث2Җ%uAXuF10󗥱ԍHsH>#eϳQVѪ/:Ck~52HkA +tEi Í7]XOLª\QS{wV6xaerN"{4F{T\ ^Ꮚ6=3vU.N{Aqr2F>қ=jQ=L\k-3};fe}=ڕ.<9~an0R:p3E1Cec..*(h< ㅲ웈}elq[AA\{>6}z]2:jUyvfڶ! *7ZšǮqس4'a:83LGxH훏Qؕ͠~m8iݱ4!U`9ha/X㢤>ygQʏq&%S1Nn`"}@M +`vj-ıߢl Hm ME& #/@H삔E"eAۮn@Bx`8@L&&7L!'m) 6@)9B5#9f3[wf<`R!y[cs)׮Jމ4`ʶ'۶` GfSA h#,Z+R=a8 e] Zj<=>+\wСl=#m>_~+4 \0kr6u\R0EEZH~{{ߤyrYViT^S2Z)VkQoR wv;vmcs^.+6K W0˟–C^mOK]ڍ\zx9 8MQs7q'|5eۖ\գAѸsI}6Y[n][};5}T1^24ZѢ-qA<׃:m)j:wܮ֘9UFcp0qX,=✆b:)w:iVLR}QBitF`2-lx1*4R]]s=b՚XؒUi:v݀!u&<L ੰ:-!֍u^ߗ\:W>ovgDUNka^]R'a +>KQ"G;vf&;Xr7ýDun<^AŞ)E48ݾ ]23^~-I(zo/hC+Щ޴A$%0؍˱{)iڛ - LD`=ې<˪LR kabRa{mLUOZ4_ZW4xy 0'07=WbB 9ųũ͏{ @7G+}طgn>1 F)^Sش{s6Zޥy GÀyW4ӱ,czAO1;Nĝ 2rmnҨ |mEi}n-)Uaj4۱ߢ)L'E2eFSR +gta/I *$9@nCOXИ@R@)6CRd(aHKY(sI#rmqryq;03PI 99T)'dHk)s)ʑO'eKT8Vc?qT>LKZ֘try0H)j.HP je5cjF!1 x 8PIH Q&Jq;!5'SB3T\yC] N 矴v鷒 >ĜgⓞN =[A$@rHL?Om~ |RPQ@Atw` Zqc>J@ aa>0'bN 1dH= ̶LSׂr[h|Zڝx/c\G +[SZlZ-!;) +cC@ Vڝckh7薍6y&p +@>:DңQ!{E&6]skN>%֛E!&F<.4i:ƃ؝JڇS vLRGBQ݌kI7C$x6WMcgC: >i4"cnػp8 Wc]@JvtƷ@U9[ -z*쑂Ե5ok]P<Wy{NʝImX# tӦO$ ӸmQ%ojl|P߃t\2iwa:1GޓI5 rj]TA9ޭ.mji |vUw ykj۲G47Ft!ۃsm-bt/ |õIڭ*\X8!)U`/@ێJ9K Jd/.(PqPqCv\liL#Ӊ@L 'O'!#fEϹ2Hlr%%")‘07HlJ`JdJ4 ; dJCd%!(2((! !H$6Ar5RwN!2at.RHLȔ8))J5J@A@()A0B +M'(TJn"vJPSBGbL!`Je$SH lTB%8PJzQPP0e.DD #H(9A)J!3‘$J9H@' 98JaaEd ".dvD(v\@FNB(  ȄJDi  ;T D&)0wDHϘ\=uHZ$ϒZG+/WUZY1kI> @J "9 ED ĪHUUV:D=jDl 4J Pb_`wz5O^%htDHLnd@(&FwuS ">*m: PdvOkC_> QP6HTȘH'lPQaH/.)tlԮm.%ӱvݸAs*!!Qf .խW"O^ah07Qp$ma0e(A) 0}w5l SwC +܉@u.JISvL/*'d8D(3aynp>$@R М&D#P(@)JpE6yDrB$+W(n ̀S1;t>*Ï#uõ&ܵ^yJhqplѶWnvr%<lm z:M;GW ֢5;'s ۓsz/m_ѐer>j[ +Ōk<[N)+_BLJc~ʓ%ƣ!i2q[F]ڃZ%:*- aUw.@խm$Iol(& ?j[OoZTҵ)X\/sE4Ӑ_+Ō(ѰuT82˛:Lf|$uUvQ(v7>FPIάjѪȞ~R\6lӍd<& +t뾱u7لl ;cWkU ;p lbXP~ʀ]ؓW >J#mj\CUMWuB8rOY] .Yթ5*3y@ƹr$gh6[Ji*X]_fZNKUݢפU.tw5,*0N?lVQ)G2~qwbߍ3Rq<mS\} >L^NMJrJt\םW{ +~j+SwOPkSWkHӷ mj[ۼ1y.tn70,mkސ~bWuD8I'ANl69]3z:.@ 7$}*_k=,@+l*q-':^1\::^'ܹb6Q55x+ˎ⟂>$l=煝0|Gۧwz gV]ćsƫRY5s"=ǪᜳEwJ-{} ן8|-lSh tįS}"…!ˈ%juKpj,jV tvRi+4=A xXNEpD/@ց1fzյ +nT#PfԣL@jL h݁&98Ea-@)1js]aO. TskUpZ[[S2$+ٔ+RkWwTxreHkbG3W8`V:Tf.m2Cdnca p.l;eCm>j2b?-\uhgw6 lhu*XzY?K,^q,GNe0ADw`WTڌ8> +9fSUh=Z74)d|[_3_9X1}tkGIp suei*0>osǩ9Y<7:.iAյ@փ_eWW!5CtYSqFSݬ㤫~܀ۊ\xbn_cb 5=˕3{K_w'Z7.8`jHpް]5hp"BWRhm-Odp_N!_F}ۅe@zeup[-۸@27!p,'; LFKۘ a1qf KQrW3W6w^~v+|Tm^-}[YW5Өy{ZOP:q'a;7WΕ0ds$mmK:y~0) w qֽ<<əgQ]!^+K oU M\VYm?e̅mX ?/c)ILsg\~hm]2 +ML:"2:BV6 ^˘S0֎IU-Cb'O_%mqt4ޠiOrh;O 1ꛏl.'=c{ޒxxo>*@ lHCS p7M$8/%%a!D(q!{%Hl!`"e NQ)(M#ބ) L!(!0a -~r.6T=)r{1,&]Wa6APJZTL؎8XG{uiIް}.W;SnI#䰙ؽYZ%;8c*2>,׎xu9*ʟ MgRӫ}^ 矌^ٟZ&68{^ }S$Pɼi>KWu)6zmE͔aU2-޵kJ_f,)rh2Q' of ^޸1+˅ٜFq¬ypVwyFz{ +ߔ(~,g_wg~ڨmx[\D%?E졤UN*L\^_"#s_>72gMSxxk`8pwV/k*? Cj_Tݺ{ P;0u8sa+ws +ֽQ1ei "TPj_/_jlb(R,fB*]JC{~CKǻoz*{/}7q=_ kxmn }?6Շ^Br2ڣh:.%\by^ꓩ׻Z}l}ٔ58+iۚhq$UV؞(Tm8  +el6ty(a=X/lվ\he;7YԀ #DxݥؓB}i'm+ɞ1ҟ7>[+n-o k@r(rk~ӕwh?v>G2RS؀+|ذo[6V"qql| ! $)v_L]T묏%>KݝxƕZ#cFZz1 po1 +-̏REC*=^w tQn|V֭c`@gi`ئhTmV4lsyb5oVph7/s'[PafC}:м{tHpەO3-׸د~eÿa=v!HRX <h<{b6ζ_j;ط G Gm,w%LnVݤM,4ZPv|4^VZո8wP s#6Z +c9^- +:vZQ}Jpzg cnPIyލzx#r^i6;.ݥU?P;q{\*nsTz~鰧NZGSk X9j/tv֧FeS_m;x[:\~?Ect:wWJYRG[:|Nz7hSs귞vZjaɇ譲Qk8,$iDRi\{}^<^ vx&Vx?gy2f s׭ZC[ZL2!crح\piyEkp$zvz[eV5 DG""%'*< ._܅.R JwC9^\<ßU0) ``9M.! ȔeИ}, 'F]łF[ܻh4i2YUjyeܷS r41<5'[U_1LwRuyJk~x}a£]BQ_.Tv"DGv}^іVpTO±zwU`aؿ_̹Oh0z ++wL2\R޽8DdUw:J,OixV ]׃31U= {b澋:_ȕ/fkYHcUbIΊMB@$7Y*But>s:#S/&T߃6xtf|~N]/Iװ#YZ )[*l3/x{9o1v*4kkF[6Eb/>P:;m!yJ [ V4Ւ Oju1ɦGT}:%+ˊe:׿k+} E+1A+7XP$.~u;j f7^нa)2w#>eژЧR܍t] 0+C=dژF֢@:tN*Zz U&DU0..xA\UōD)>L꽹~9lm@x'%qlc{c!Nh\2v]:Ut;9~3mkc@ҧIܱ` NX5PkZ/w%eڷXkNQi2>* QĪ^E'4gܵ ;rbz\{S"5j'eӁUj^~_`1 +OlS lb6YH;`Cn8r&vqO +p wPKvkW*` C a>YѺujU\H-;T3N}wA>mULzqW=lhR{Djo6'`*[*&*'k4#܊v n pnNOqE-9طwpGX+JZm'K ^zQ2y+MKmi +ႻRaқmMQ4`W,t1urmHD{r{5tYgW^ԥM$@kݖ)Xk 7iwuU!& : ,ľ!^k{Ro~ǁZL +8]sˉ=J皰bϷg` *2[fg{kxZzF=|նM8GMؗIL24q kkaB;]*.Bc>ulefUF;cʹ,u"cX"zcpR-kZ8 fۊU 3JLwymU%tkcR- EGګ Mh>ڏ$9u /3!UiSp:O` ݜo{ia;ls5L&ڝ;Ost0HquNކW%]LP2稙C;ۭܵ#5Xuz u{CgaW0VK},JⳚC6=:.OvhTI b3 #coEY _YzvrƀWPv@t$&Q jGd܅)JRP;.d+ɇ{N*Q*HJe1MdDa0e0HG@ =J- x4D+@C GE"!FaJP +MtLHlQiC@0a(&TC0%8S( daJ A28DKpD(R)J@NID"aPd p). RQvC&w1. eiT) :ΞQzdaGOrq6\YR*bnotn[Z<\ˌXө2˅ ♨R$:R\JO'iQ.%0.BTHAy( +!ĩ %"L](@(. BJE܅G D̙E5y`G )Ll(gt9J:7AN% !n2D҄(llR( jrvLNe$!dL@n\ MR;&D>HD#A0JdB& +I6PAHS7DGd 00J K eS;"!))2\[G;raL H*%H H (("P +ap"gPRSԂ nP! e4Gd!&)rH R%dۤvLJP܎WtIDJSfd!+I2S +BBD6LRG( +/cumZú=azgA~|B2YR,e\S!ZA!0Q:KHiHw +,pH1( .CF(vUH>{C4T%.;VdiB 8x-t'DFɁ焩S!D )f?$i;TɹyBeD C|HRGBOMQYl{{qh :Cm/iWu-[oݸUX0Ny Na1O A n7!!LǢA>D}0ls$XB)dy=E%>9)OL& +`śEyW4W]ѵvKiu3L407L7V%!x1ZVeWh3{EZtiCF=|׬R %Bi)耑a)!&d(ݒaQ  )i(*}Q--M%#L +BQp&2ܤvT9k 8N +Eu֓asvp}:TtjmTW xݸY3bh5߈ Dr Qg{AjavͫE\^ڂly䱤B#Ir 2ԴJDBzSku JkIOt:fz𯈔 %1LY|U*\6M6˵U-`CQL4rᕭS0*ZU9v n$ެ0yNb#[A0?VPi:j Qha$7tJGdS-!"S %rԂ!y*I% ˗nk\jIeN!)L"e2LS"PܷܔS 8Q*/r;kP& D&6@2PS&M8AJOr(i<Ŗh[~Idnx=|5nZIph;L)mNZ[08|J'FO1~jaͧkCj&'\0 cI~3 +J\&&ZlY+:-k; P0Y&k90g~iU( vysB])Pk˭ C~*-jҨj8 $n<xu79oxdra}~./j5jC \l7{z\d۟qGi5-+[:ЙV6H4j6⫝X'n#TZ⮷Pv`2.opNc#NTh?yKY0CD|n^IωʐnѪt .kbOػfS,5GmTE 1LRGY< /UMʎ y:X@Qĭz{mQkĕiڍѣfڴQGJyJ:^]p$45,~=y")Q1ȕT^ҥF֦ /`LG[tvͮly^I->+8UW6ƣ)o `=UkM4ۆb ֊u^ HeG +;|קo Ӷ%5 ^Ǖ&ڳC!&YzIؾv1<&H*$׬A 5rzaw*qY$WҪlUNgFl]GNNw֒79rx&IotkK{ sJg.tnjw$'{c~(ѯsY&a^Vs7mvz~s)Ծ<-[e[ZӥFC9J'.p6ks p|vWӘ޹ +'\b^dVJhD5}W8cjwT$rx_ˁ6_Tj;ԭc_-}2=wąKdY^k ; [ūX;v?aӤ7#b8`ygE{j@9*w u"haEٕyfX8R4vNsgmùozh*r=}͙^|=9Ϭ*V% UһڴʆSnA[gLޱݫoGЮvRիѥtؕj5pw˶`nlM6闾>^\c˴;T;Yq`BŎ8yU^)B09YoY)*UM_У9*8ShmSVpkltoh#y8MK$mVcX&:s o/~Us38E=ia=t!ilɏk]X8ԥMܹ$JZbjbsH8 +0Vup3w rV~WGTu~3+ߓ1zt4t.85qܜ:e?T -ay鍬jkk;}}YmgHn DyY# /*4k[SfqJօ pɓ}BUu(}*#עu*Rn,^WmͽKGO +L84 mMw;Y,-S$4Oz-*,Z4YN\ jQ>ӈ#!1 Ym-@ؓ]r`nn$]ٞ |"_ZeFT"y:1liw{Nmh0jv$. O0+7}/e~Ug` +ߪ[ho=%\dc@XK@-CTivs"a`a)R>|3nj*=@O︭^b#uVt\-*sO|)q[Ϗ.mޭd> D~:fgoSBdy^MUVTi/qӪa /1b~DzW~ yWc,oj楐sxe@OȭNT]QUcb<^|G0SêӶt el-ʚ)$VaXWU'q'^6^P.k\Un)J$h+ _;O^*k6o^ +_ SN+7#|~rЯ7iﭜ1C?jd]VʎNm.j:wT<;ϒ|eW5TR'i͵OΡ0AU0R7>$Ղv O}fǿA"-[7TwY锫aŅ࿥NRco'd'  +a+U폨[ Xn?7mՆ8yՋ%޽1\WnfC^[.y IwsRJXYoUW?R]Zt-{lw{5(|X|0 +ΡQ&Dh^Y{wZ* ٙV9y+gZmXٌ,=ihۺQ, OS Xt e=zJd&b7Ti ɓș*5W;r}ț +XK ]%t ֚^Gy-\Rqsr疶C@R*Q#+'ÃX;g90>ա 6aۯqd,&N2zˋvD8> +xJ"r@{?hn֘ ۾/FZ̕t*P o]yji}˷j/֭>5Q XHC +psN x?%.856mRe6Ӛ@$` UI̭v;s-U9 8v,~f>պoDE"m-c$-}Yn<9Uw]߬od8?^~cf{mT SyX~%V,*ғ\6q /\K4 AmaUY%n؈|tc6y5}rV]ng䰽Tm&]~Իez)3s-k0 Th8-zv95纶̘ nf7 }eWqg`5UyY7j4iot ד$w~s>ibpϱ]¿uTwxܽPD`!(A ܷ؉'#緧wG L )(>Q%L lbܦBDє2w4wuipWjcZegp)ήDexq,/nb܀cϯXbe,^%YnsF– 22[٦2JecwW=#LqWp ]p1Xe +T )ePg88HmOr[x @AqeoTK ׸84L x{0,zwSKhZ}ʲ7}V5bG +.t*B̗ٛ8IQVUsg@۬VVc 0@^&kELm- vs'w0鸅G. soo-pMG^ W1`t}]2AYmt;#֏5y<Ɲoy¤2uZw;ۖcM4\ 'D<R6|6=AVj(k +/eϕ_ +ojwu4%y/25*QHg&&۵X̸C{gڴ_OJu;!`\5wEn"W,pqq.BpL=ef]i;2/lG]H0U( #[wGkM3~dʵ.ټ2D \}[Oi w8oQu̓2Y~kVt~8m4O+kVz=:lqƵa f)ӡOr HI3l8 `cYB)>>˗ı(]=>OZc9tPX}гAcZڏ5 ɗ%פPxs˽rjwxmG{M>!bx}e#wZj *߃0~|fmpOosmU>GXe:\>w%p2j]Jถ:GsHG&=Wm-]xHumbӧM 4|n*5pۊQ|[FL,^jȏv4?[w<>XN }@RI$P. YӐjW.HNOe@50>elVsb׼z>^K i^9$7 cFm)0CXy1ZA#VoL2I;^+Pv'xk8@ t/>a"񸝞0CZOE@@$5KcOhnր08˙F|o*<9\5gl5Ǒ'Apvy*YH!GwWL..k42T1̭Uظ6W^%NZy0VZtz`:k p50ڴKrUjw^Kz40U|ׄ;l\rpF C/jUYĶ98;SmN54XYYe]ӈYkL.2ЊI$5܉]'p"U;4P4]#gWOT$S!0AH@ɄD L"a Qa S;nRARR.҆lJ + "SR; I LQ%)) *@B(@B 8D\6@D9!&BD +BiB!S)BbcqJFĴ ^,*jTpNܫ BD% A2I@* ONt @2djLL"OD&Js&@2 (F)D8L +$ tB(&PByh;R{NaĠAt&LҀR&6C5B`)@0ka(_ܳ$TH.#u6nv mS +"S9L((B`AFCdStDRs:d"~I7tA#"PbD%"|$OHS%DIu;4 CpzLL@@;Ixi2pqDQrl $A D G6A"S % a>> 8HܰI]GdRv˓.jL^{0B;%HJpp( +H')5c18ѿ O[ Lz#ǚʘ0j;qry]NU/x+naSf\d(5bpc)*^coN;]q:6֟yNIWWL$4Z@|5-ӿ yYvZ| SeIpI 5Eٹt<0w]r> BƘIڪ=_>:-!*2][zçx*O-X*TIظjÕZơ'*+T8rFaZi$}KKwU'ѩ9'`lt6'P^Kq\o]jUcpʻ͘qn蚢$]{mƧDpb4m@uJhz' ^}87̀\ڣSH#E1NˍWK*4+f) 4R_{]<+YAYPk#eX|W{Nʋ6[ˏ]WuSxpBW)\KLRDxȅUYWsON˕j{A$J@xA Fzq*/gK| ]LJرx W;I- 0 0> eR) N!ĐF+Ž"WV­*GK| և#¡_F٨ \ 2Lt4jqx!FV\D[0%D=葫D{1`< +Hے.ZfvUYU: +zssh֒%ۀHuDsӶWX$vBU*6!*u\KBl>Knΐφ+sǏEɘK,k jCN@'^=ZSf\;@jCeEi1"|ĦD!0jqPp# G5@O OR"<͵Z%t SS;"a>RAlNWܳa;%rp\M`=ztm*I'7 Q N! @t &S.Q ׸,$0 _j]܏k}S*֭y˳6Qwϼi?g +4z8 + d2 V2 +(hi1jvێc2~m^P \G.Wwft]Ǹ zLJw.4p= +e|6ptgni^,oRgYJ-O}RHp̸X5)elܻvҭo@w+Qi2&;tҩsJj6]IsS>65`Cu7kh#cu~ o(Լ]"I$UO6*@{t,ףwhisp~[uSܐ^Az/>1zNC`zyd'nЯ/hylHmw,e{kd$>h  +|ȹA"NZb˹m=4yJ`1^j Gswc]o)۵DžǴV: t9yyq>70Egnw1+^?Ӌ^W{[0z:Uy +XۛGUҴٗqKu67+=p?U~s|P.0j)<&XIpo޳I0Ę^̹WwjUգpCwDݥcqM.`'@yѿ/-\xx/Wi.uv}w1 CUkrg;@ݲr%aF0j3TdFv?P_3UjTR)q of.uB\fc嵭\_ Va)p֓7ԩyt5Ŭ`t Lņ3)_Z< U{--eR5޹d B_5 d8>]12^o&䬭J\;;NR[^ø8 + +Ɍp:Aq2cTEJUkkZH]r=>Vُ65o){uO+ÄvyN!ZuZ8-0v+Jޣ˘tIb*U۝&G0WVoNU+:%_ى-4I>8?8Ԣ^Ym@ 0]]3SfLY\H#{oHW/[LRj:uWI׸>J+aW&N})cSf^kI:ZBᴩY8@es([xxi:ǂ,NIORUIknsQym%,ݕۺGlO_ +YvL駴'Ur~{PSptR])._` +ijRn.!1vxˆZuR&u\;9PV 畮ŜiЪ t,KT}U‹x;cv2Z{\g>aLƭ$UWSeG ۪Tnۄv1[aĮTZޣVwtVG8ոma\d( BG(ܷr)(sy\l^{_r) HL S3%.SPw)򀉄,mm+oU44I+~?9#G3">AhpOj?o{mZUvd&ş~|mg5Jl,g[Y D|0!̠eZI#~}˞i8S^i,vm_'XԟZf}jvLCߧ&^Oܩoޏ^ԏW)GY+.n?UժJnxdLI즧yBZ%q3Wn~F޻꼘cUhlkG? +qO  1)`"#IWOuW:D4Zbԩ[cߴ j(z?EKف~۾W>|8PBqO1+MWvlfƟlco|깒iҤ8iW1eK<֥B%ea#B]'U_lizlلH;+AcM4uԕK5d}Q4?gTъZ[*0cϡ_38~o:g%+ۋfHu馕j늄UyeeWW.]7ßO=%} +if౼yp}孛7{c#*>ĭgPT!ԫOva@SbJagͫUͥEܳip.WX<"ΝZ.acAB.)`XvW勊MR6K 3༶m.kRU̥Dg|gZq^]䭮GͿEuqq"x=}vy[n;&:.c/,CeJUV<-୳S]χQ'1 w}Su#-;.]kWkǟ^.7l1:F:%䲝V8}:{Am@וǰ¨$!u`x,J*F7YY1DS m"G\sʘ3\Ө5A9.ژ..Iym)w̸]1?UCy^ڋP!2NʱݞMTm#ik$įi.t9bVnִ~Z$gi]V[n ǒSk3w@nk"h&8 +TG~^LXnFĕU;˫Z{^H qlVx}3VJ2êQl!Π@bfε*u*<ՐZ $h[]Ya;93Z򶠯6/_ݻݖU,7ϏUvұ{]|yU@dv4477HTQ` iiJWΩZ`Iv`X5kRBϵz rܙUb +Bj:N;BJ%MD%gd)L)/RwQ(&)*'e댮bSH(G +A BqMtDgd( OHLGTRU*꽟2+TSQ%0XC +":>^l.R2Ie3j^\KḶۣO cʔ/{tN{̸[rX>&-k$oSbyvRy?40jT9aXcX5,iq1Ϟ=&w~\R)7O'J!D買y浵WP.;6HaSjժ |2`iz3Z5#Zed1yBJ I<Ȭ +ƒC{ӻ8.DmqrkfqPG;/Uc)4`ʹj$\`Dtnk-VP>=8V + Ʀ`j>-wpR-Z᲍ZB]L'%V嬾kytPxD0q^9Ztđ* :v2yULN;p5 IcˁJqJn 4"6 +-E7ИDߪe `tE]LWeOYզ4#c9a+ '&5ϗQmvL祖Nؖ$F/.;Ou*Kx+iV76GT8Vf^mQDGkZ.e3ܭ2TfV.5*9J-/ikVuݭgQ{8*/lwuZ=7+| vD[)>SwTY_(S{7f K˗ #a*u4id*Sխ5SW!VuͽwS  +lşJAA`2 ^wH=J𳸾JeCsBP[.69 6k9WX KYn;8RU\԰K.q䪊ͮ1QBrjQ^Gqur]VcɅMեCE~.4r=K{[ 4pIuU{Ktㅗv,=&Bֿrx-h~J Xu[L3ȒBΜZ]tKìxJ`M<"HCDdrw- xvp!Qb#P3=΀!`so j$G<|}L=`<%Y嬸Zu=\B-6t"z kK^ .p[g_M3.轘P5Mw\ۈ[02WPvVuRc}%^n͘V!ˀo]cIiVު*iiދI4#GH곬WvrE=GUZ9ˊc97oSC N9F(d@yKRຘ~+Y9~)t}7^+Y>iק˽~=Univx-ή .vs-~ZiҥPqAMS$>֕0z/V ŕOJVBx `˟ү 1㼫pU[˟VqySvd +KoJd+>ڷ!_f\c4 :DYZl h䫳Zf3'MV{.j>U HZ>žM)kG)B2O +@$$ UR~RKB'.UOotwL&!ɄM4 7D&%-R %') NڈGBvNe$sAl$ 2N! P&S; DJ9CJ9A 0X{d*GP %vƆ -4p$%6THBI'Gd< ez8 a2Q`c|N (hPDSXk{ ow :A>kÃΓ%{S-I(#*S\AۙV.P$"P7G((!PRN!.;@DBm27d!3@QCvDG EБ* iݝcK=Z #^!0 DtNUm^YotL*̺wQH@@Myx;ߴ|UНdž +ʝ{M h>j!4LUeKlYVYؼ¦8Ij>IiJq@\1ԝ=Ɂz=9Ө{)n ` 5Dɀ +RSweJEqW WF\H @ l2A К +8R)&7G(n^xQmuNq fZ{ l8D;&vDGT A$p$rH^*zͳs G;bF[TtT쎧x^AN2B@ + mG5r> +d&L*miĐ%:{I^|33M':/P +.h(SHn)JhWi5 5{\!(KL!JA DBD)x7C :헔ZH+ȦN @:2p7KCD D@J&! % irZh4yrO +4n]\ 8&zmQe{no8]$@'߄iwwDnJ8D&R @8ҘTf+v j1 PwO%KGiv(peD\йڪ ]&ԥ0&)pp|]) J0 >hp=U}'~>j4m'O/*!<W|Sè>I&G̳ 6Qa fUkZ @Zw;GVX/K g}]GAge8TkO+SoU-):  \iI):#s꼔Ks^ǰ8 k[ޒ4DHY[4x֝?5scq9^8;Ch]up?QOkGw=7洭pd8H#ީk;{uk9t< wYΖIg+vhå%1WN3GoyAڀulr u?Oo=W8sHn u-do#Qh):QizGo,cI^*vj]h>o+x-mVZ76=.&9+ݎpm& T0*-X 4>*(L- r8p.xe5uU]3H&"|Ui SHqt&٬cs_4-o.Nt辘52&ɇL 1W +\s]qN9FJ4Lѩx[&cqj(hcGOzuG m^(N@?&?Tx^`&>Kۃ +.Zvp+!'S 4rO ;W;NӬ䆝?5yg}N72&GܾicV%NΪ hA/iդPڜ Yjt-_lEG@ߡ^ѼJَ$A=qZX]J =BHigl[7n_լ]loȢXrwXq]j85xYvfӧS?5ip۶/-q7? aYwwJAUls {wv_t@gqf9GG(awx~Ke-.qP qU^Vf"?}e?kh|x6jƥ_~Vu^v 5Ѩ:~j޻.Q9y-+yR-eWOUOPNn>aY2'4 ɋ+|wÈ Ɇg+LI:p#tNrO +=PvdZ |յ!Oo{EQ)HVM_׉]+v0ւI\b,M$Un|H,zkw/cfɶ9ٻuI#2@,;]w?$4\U^ inqVr;ni/Ԅz(`ق4\բ'm6s*!/~۪ÇQ|[v k85Uv9_~DVn'KܻPa༮̶>+m-.ݵO5z@hL&zyʤl&p1Vwps|BqQ-<5Hꫪg68߉5uBkTa8^XLhamHnw-OdԪ;J̵k=5rft{ +'؀FG ljc4p<PvO_BF@0%.RH/RvH)9D++;s5j[^ja90wB$pTK@@TDBEe0X)?vh!0-iopZ4;m+]a$&J)*丵-Fg mjտyf~+(Sk%D*/TR #Ty4SŨ~*sH[oЭ"{ >W{G1'[^aN{I_vjڶ5Z%Fm*u1\%X}wSª˹&Ps >ul-kW}I=fnyJ嘍PM1XvĨTMtd4meTa0fCojnF3Fcip!o;GսW: PcF; U^v.M`yl3%^Y5`lO/h&66f4VڭAT`tZCAI$xj5t=V~cciݍ@7r;p^wjCYV9M,#wUcvJō6 NyXLZb7Tw08C*۷wDs%,Jڤ1vrVpVN<,ZcK!؎h]wZ iڄq ]CjAۤ7c:qJLڕVlJ,?ili6 +wnm%`ѭ[BvwHY:5 WH#usVQeIdxUXf1E_k=a@_F"bJu_wf^G0W~am*(@#⽘wOץ5ߵ,Sew굥oE;SM鲦b~mx/V lAn<,gE -فNU~7PL1J}PA mg 3vAm(N1ۚmx!.0:/9y"@eFb;FX`VpDvi@}) }?3Y|$x.N/J` -v;644,ht* ApW%ڲ8IOd2NuQS$xhm7>S PkYJlv<OL.90ښol֐'},8j@?0]a/t9 /l+Yݝ!9q´xs0*jөS͎IIPT.7VGgh83noi42,yeY0.iii=| +`9zEIh.$L< lE `h^ʌ-k] +=wPAk`>+I5ɷ^\# ޼]z&X +$c6To Ghm+7#k_-L +ձP`)Hp>kaM1I4< > ۛS!kr0.Xj OܼO)p Lmq3a;U.iVPީ ss i6sO5I1Ugm|pZkj߻we]_Xrd%٦ +ʔN!TT=F)5pNz3V.6)uf=uueJe09h..I"O+?g;SOڼݦYzmnw+go-H$ϾVc%8El2f 1^'n Lfuj۴0-ﴪmc,{BHy̯&Hxv!v|?GU}WNDtՎmqZ-}W0>=f)UP[O| +}ovW4[ZP} +{@m H3 \ IB3%;g =JN jW4fH6=]yA* +T/cUJ$-o+w ;*2UoKhilOFW*ԮwihA$Uw֥j_SWM*?zi{ҥv&1⯰m}MF@#m,5|q-F=:ĭ8 n7N)r=xòMGi6DęE.yfĽ.DJbk7qU zvשMGHد?e۾᩾6?cV_ME\;rheW1cD[\2)iѼuuVe&TiOhmRhp] nj7AB5=> =wƨޠU}n>H)׶IP>UoaG eH +"VizckR$`o2WTfYeW8@>!k\#cۢ͘\ ƇS&=SaUvZDwoHnd6wOg,[S t=$^qS6TVax25ž]ǘ/yef;kGڕ:^@!@f>|500\ + $OB`qlco+pmjZ!mq:WmNm/ 1XޝG>e[Z楍Z$.Wh6t(6"IՅU0& A䎿b ME&#P >R.Jދ{܀o[cx9WgmTkiGf)6\Rۓ^ns#DYSpsLo]sv6V 4@j0\j)EZ!H}[Fpv~,b=9 ON Ͷ@>;Bm]<5؝JL8^J=VwS8ͳgkE=ŚԞ4:m + Rhhdrj̮y]y~Ӵ=*[T9eHk洘^ampA.q2v-N^ѧt]z^,.VF?MY +2'c@)ч{ )}QFC_,gI n`_HZ VNpi VBNaG1^؟OIDZ۾ 9X<|D5,nU$]f +8> +,Q%cDiG8tJB)BOlSWv; Q;(@ҚS}d002s(A +@JBR@B@#bi % #n|fw}%oM ` h/];}&$.հ5:  G70Q,icxll<60K|DM#nQPamy VTR`kLn Shu*b\۲wuZЪYƓDO;%z!8淰nR^HҽnZihsO Bm0ѴtUwyF}!'{pXp,נ/#PW`|pO?4 +[;,?, .qq=cmê0xuRd;ku!>ZӱouEspX{~j#YZTm!#DDGO%XL 2cz 8i"A\eQ'L|(H)]a 잡m,B;h2'[ᔭ`.Yg3V. .wZD/-u'An;nyO +vkNВGEh +2ծ"0{9h,xTu2΢ eE*M `Y^lC3p4 #],iط08N{hqgzCtUJ}!FcaNw]\ol7枇uOK!X:!>>JHih`"u-lW9f:a=(E^5` 7izg5{|핥;TZ5 7kPEiK\ ¯²ն4&J[aT^l>$u]/,zJCbANڋmZ)ZWj:S#c +xNoAǯX +mvUs]<* +8|1WtQhkG@U}fz߬\kBI5wyAg%YΒD[GS^\_,]Vz#bXc +b N/жF6)dJiSNG +llϊlSzÝ桅\(Lx̫xxT!Yk%gCP\1 wX~!i59 + \@9VVK guAGSW,_?>8#c^ed#DvP=ӵ%iᔰtZ=p0 +8dVY"@f;L334I5_ \MFz-$*Y2ҝ3@S$[Ѥ-b:GvipKs'@+\#7Mz"!j i|9W7Wq>D!O\m<1iPRUMo kq i;{!ǒ^+(4O_L-lhđ^:ɦP3y+gX}KJ/PCT.bca9+1 +fA-<$}/DsAUU,gHi$Ozj[uȈm^"f9hWiyp.NL"ube l9Z\q^gfի0] +)S~$E*mOy~'QO ubL]`T72Q>^X=*u" ^qrRpAPìQ!漘YjY\mkKм|ˌt !Hnخ)wQ! +$JQ@֞[sh}DJaH)pL #r! +@B&2e!9Bh(%ɞ=R-\% (L @jd%>R@!"%lD"QBzi;hkwk@@$Z A '! %$8L8J8JHAHBR!3E(ACD$2B4%e܂%(LL r kvWm8]J%2L"PBj )rʥ*TsAp]$PJ| B6p$xԘu +mL%BG5F!Pipxm1Lihx$P퐍0%@"SFe1C}s(%GĄL!u&RJ&J\jN`+R( +0' l( +EJAG4jA(; D#LL\6ՎPZ$ xZ12Ҹ~I=6V&6DautF:K9/6 3.iHi$o6Ls-;{oN%Z8샺 +$ D"a9 ( )&6UVJ 0gUUjMGkDx\쯩0V8ەИߕ R_cF6Y+H n;uZ1ժcFp1*x1^D),9gT;wmjsa Dir)J Myq +v@w `OUv#Q& ˋb©1/i2Ow~Sm?eD#űXYcj S ` 08MBAHh$Ʃc h@$n!)Pv0<'Bn*] +edB8)B`!*R7?4+*[5[a?n]0ox{YhVJ9szo-y^xs; oWam/]6xWdBA҂S.Ja9 JD @A`_F\@9|+ktt=C(<7T@cou_R ^P n0! JJCtL'2/u;$)% +]iWaP;Ո P; ')Ll  N%#r'{R&BUY2L{@uuų=ji]?Iu0GJP&&@`m*6'`9=⎳u&sVs}ʫsR~3y͞/BKVҊi%IΔ0Ҩ <%WMs[V ov;AAiK欲e0ԥ br,{6S]RĆ3JE j嘷)=ԿXs檆._Zƈ dDZ8#{rNhxv-Fpf#O`ETxxm +i|TpE'P{Nho,g',3Jjn +ǩl/!0h/9TZluZѻ[̯-h mAF藘jΖ]D3xU}~t?N6ZL3Wu4ǹQ?;z.MQ0W{0 1VԫR6U{GBr捕]T1iYQ4SvZ`&LAasRtc%ƙ{tLgt-h>H.+<3ƥYS%䪻LׯA阇J*4-PL]u9%@ۓ;4sNS|˽x9V40(mIuGpJhixq7Zkӏf +XJvkG~ +vi[Te#dm Uor˶ +Ԏ8H=Ԛ--QcQ wٜƟ;U=[q7ѩQBW+P(=`kZZ; ;_MŤpMeAumԶ>ߺoqPQxh(8S}Fe{zb≖*9(AT9 ѩRk7p>Z+&\׉%y1|^Oa9>|g~wѪw?l-S+2|LjTWX-{z0@H[:W: ,g ]Mח V϶7ח+aN}@?;q5u`|jlmcOYcfbwFZ]m67l7 W)ѾM`%Yv'hG[tE&k@|m7GHڠĂ'Sg x+oő-2<ɴ #ݼ} Ḳ^jtU|MLeStҪꑾJgnX@ :[I@h ;*sQ؛Ү3 #]ʘ}*:rW04[_1 n)1ۤAR}aqt^%IA?rD h l+Ô]wU* bUjhm۽vx&.:4ƒ|I`aW/pk`wSϭ{m`Hk;tXxHʏhs-%1s302ڮLngZIx4jSkӼzъcz*n-0aW_L]I+ٕyHp>axZn*]64mUM ^拋ZrmqK6T_FۍYˮqhn3T-Q0Z`vaSL@ o7+0N Xc^k.e uWyIՋ\ m˟ff+wҨ/wMY혎HP5l0Q^dn7OcLHNۯ'oA~q_E +酶f| e5_XO_ktCYRplYBݔFNydfpލvqL_W&| ܅}{eUX%USWh8j4qkD3ӪpUP,s)`p"5H^L*J}VNSU1c)vw :{.NE-&Tt:V+|=#Yyh1m;Z5)^-k ~%zn)ITx,phnM,):U\{'i&'Y:2>f\nFP7%lw0V'a-iiUF8%yT4WvSSR~d-QC :'ج zسisNIԫlJ5!ss-ңA-{]B1u|*z=jCԬU*U.kdyOEιc)P*x!ž\6ݳY 1e-e +t%I"fUWk9jHHm£yԩ\ֶNgs8}C߹tf,haeosqwYPXP$mTgPm +ŤgZ]i::`3UvYR voj9GS\VEv: Z{7kÃ&^-JjsȘEǴm{JzƠאKխA# x +Rh@ Ba 7) +tp6jw,_5eBcw˯B t򀼴{5Us5j2yN |"Fnx|r.j?R;:xXʌЭޘ[Z̕d۬BĚntNaO[F8ۻH{6Dl/t@4G9T=">>Bv_@\ +ޣ'U2Vo@LW8Z'E5m!ⵝWvۏT6ۅeE8d/uVV~BW6R@ڦ(c8Э^cXcOCGaX\qJjSmh< ㏂ cppe;Ws0<:Z6;)fGsb )O@B +%)ɅWB R  +$ Z[t%aWiNSR%9LO lDH@)( 0 &vCLnvTui6#'VXhG&WP EOUy 47 mJWO|KCG +78/ub& lXw6;7fَO:`lZc<* V= 2'ovUi1>-m-vk'm]}O/|#$}ݜsqkjmuY:ZO^ }&iQ-p `1t0-S+'N R;B_@bA{*ڀ idZv+ҸsKZ}A +4ۋԞ4ԎA?zʃ;cfuOA +. +Kt11桃g-GbN32ڑdžÞqj9^[ǎ<ʗԟKz` Bxi;L-3#O*cw8g8h?zQU /4]F}.2b ytq3 Y[>ڍ*X^_9ZAqk LA{Ɍ5`NOx^uZ+P@aLBzϸ#R{BYڭ&Z`m:DJ + = Zl~3oXܗvyJA[,ぜv1S)ZmӭHiaᙢ=vVnȪIf,4^!Dws 6k- ?MWTt9LɕWamYI4f+zv.tVV5*uSTGTl 3J3嵽6G$!uX#{@QZ%lZ} +ꀤNLB_-iS}g|a/m V/,fOU]o2@TP+I|W(UPKl'DzkW F-\qms +*TikCw>wa6c>>Šn+W׵6-v>4X]]OpוdLԷdIC4[{iB,h~BZuQ>Ի2QƝ8Sʗx*C R콞=>:j ]~ +V#UF=:C-ꉊu$#i֩Eڀ~-*Q׽roe'JM`-}\9އtVM e,~_p9?nVuL6Xd`6H/pm[|}T-0̷o03m˻@it +ǯpem&'j{/GjD6p*7}V??uJ1&mUj{W yZŻP mYʕz!`OGE@^:\*`gRuWx*2eJ7M-MHߡ>Jޔ[X&Ll$rڨsli۸Td~հt3Uy j̨vRmp]M鸦QNݴmϫ>q5ٵߍc ;ʦ̇1V8hl)X~2ȈlBi 06ȅ襱w\Rñ+_knp<_[> let4O p"O=㗋7 |i 6$VYg|_-cqk+q7xvA|+ψ é>Si?|2+m}YI|3޷=Yn,ӹ>y^LiqO5 m5NağFHi=v%SĽ5@zy҃Ԩq]2 &ѭ~ϨK0G'ESN?%GnXSNYn@6NGVXHU:h.3Tƭ4-?c/-(G[Ut]?_t{G1LmcLcky6^npwXQuj]Vvd"?ݟy[cçqI?+ٱW#gt}&!sJǃWe-#7![;+\yOݜp>]6Ni7K@t)p6Qt +CuB@m_]!!"Q+Rji[o+S@N% !0 Ӕ "PD'ALRAF˅ :hֹ.k. 'پ{zE+S66݌:Z~j@u@~i>ݮwxZ5ҍhMFcb6R0p +4Mh<7?۲k?U*@icCABSh܀*-40|`h=6jwRa!D!I xi`6vE:B8(WˡZ +;_ͱzp,)U:M]6 j48x8mNtw)+mPꆻ@`Ӹ3˶: ` h8k p9ܐ'xeML} f[vƶy%Lm\n,i\Qq JN46MG^kl"mJNiHJ :JS`~uۡok[Zlq. +h80Gڹ]㽦GR#C +@+O L"W )< +AxreE*M `u+f]7*,id&x.)rm6 ;f\596][ prehn&>1;Vv1.3#emn + yZ Bɦ'^qKp%j%z˿ ucJk keN~)g]kmЍ;{JviSE44s@N.Fsemg+:t Ɔܐ9JƝk0%FF{hi@iguh#o(N ^UZMq#uʝE#N.cc])BUi6,xo6Ch+JwEVxNƕLkgtwl TYj4hh;; j48x +;_ͱEƗ +zuUw!y!Jm1`6ܹ[jScZ2@uڽ6n8l6t."*w`w *vkZ@JҝM645])Rm mxcnqw;Ӣ~/H]hR"W+v0Ҩ%x^1m~HvZ?MYR$DASuݬ|mZ)hkG@6PeM*oUN)ĸ\mi۸OT]2;Ƈiz.<2hDK^.wQ[:M䬦7^{{vi49+^jM*[v15X*Á⼸nK iEA2azWib#MVz0 +lP ߐXᔰ[ELpG'68NeBH0e*1 +D!]&GdPvQ+Q&]nTmD~R!a04L!t(J!e`dҘLPv@t$D DnHJs)dLrB\S!DJ)JG)rHDJh;%2(p(& )%H<)(NR;"e(@r4%&E%t( )B"BpetDLH ;nDA(8D +a0FDJ&RdJct B!0! 1E"J`BI M$CdI΅rH*'e¦!wʍhD1M&& #ބ:R!9R(CwL유 TM̅ 6uu^B +%"̦YI<(AB`\p0PvDPwB9A@qX;jHmAPGHR; M("("SSS@)r #S$Ji0nr/?aw8@>Hn&ɄҀT.* uX +,nKaAuVs<0:"np9X[ڃ y.JPLPJ8:V66+w·; W h↣)4:G{Lra"NHDWbʛHcˀcMhܽ MSL0*mZ]9Vx1(;&MfQS-$ԍ]WY4 +QT$ʾ \>;tϕU!bu@u>"9 +_, O@Yy}!NAgZ؍GR 0\k,V֫m +]~pO\flBHQ` ,FӦxU3\cM^&m.)S5V}WLטQ8UƳZn*ӗUU秜qZ[Sqܫ ig-=W ɝrwiNB.*޽ yU.*k +=a!&ޭBt`9ufM36m4]m@u;.KUbǩ4ڛa٘'7=w|r9O޳ Úy*[Zl(9mVm!DS/ٯiq +߻P{H|O-NX+ް6.5fgnUmtV,)g쏊T3}kH0T=VY8pꩿh^͵8oY%݌5+czO.Z饴q=ajY{L\:Hp];rqtbIS;]aohM iV3rA>Zkin;r2hoQvLP۞%d3KFQk[m`}_%os0&5k}C h䪊{Z}KAi {2 B9{6P8X1>־xrDXZSkCgPH^摅۲txyX|G}蟊Zm7LO5 Z@#w@l,/]BZSj. qCC@Ӱ*xm']?,ш^l;2fn8ipJ 1`MM9$T4.!QmF'օuctV4ÚyY 7麽S of-%K`i/0J˙buVUOmf ۵wЪgiԴ> MCeK3I#8Yk.ѝ2-:k+Y2̈ht^*׶,]a^u"G/\RށjUN0ԕ{\aOטa%ZqE_@=2cAYuӷq7yx,隯p:7+_lH3~4tLh.?/˹Z3/.%*>gI.,U}K@yX+On*TqgTE/+\ۍR-UO*Үa SV pQ`U84ݴvsTRݳZ\I\(fPYPL58 ߁]6w  t)f0c-LaъƣϚ9PwT5&s@^8e iEC8\k(H.wམluccr@WLsmbR!ǑfL~kG%R0_ߺc_`X1}={>!Hm-)o'GsƵ=^`8cIN %9V9uJ'LNzM`i$rw\-j+{ uE3]Ap+'vMBuI2:|ʭ +ݚ-SۤePgtDQS(" ˅C(nV-fI%I9L) +M)s(rG)!CZS?Eǝ6-EKفxjwx0FCKCY|~tZfvF/oMxVC4sĭ4Ƹl tll9鏞m쩖$w^.ԩيLj=VkѤ]m_)̌e)T-p$ְfYSe:1ەv>*3+?b4[(ßOA7x-kMٰ y,>o͝Rn۬Vڛ b6՞݋X@BvcDRQ$z;F+Xz򳹲prL;06mf؏%ԛKp}WBz`xybRmKǒ0˛kkR4 nK *2$LN죊[niq|ףX6-l}IVkr(| 66t^ZԴ26> ڢ pZh:@ XK.H~owL]}'n4,euOs^{`r߼"zvkP/hf~Ceó&SeֈmwwN 6Dpm+Tn0vyl-iKc- $10gT&JΨٓ -"mvW>P;Uٵ75ϴ=JcEսVxe*:bcyw!k˿ lȨ,&TŮ-.kQk8d7uyw[89/=[{Zt4yZbJU֛?-3#{}m!J{y2vk<Ր.c`Y,G˭jQi@-xŮ(O0f|DvG*8VMkG$/%,y|-l@5 vn׵Mz@ ڍBiУ/'TX-m٭h9~[|G@˪eFv%s]r=7`ciㅋu#X+d;j"|*cA+eRz5?ESMi[>O]+ +5 lzo3W5w2V4mM"4RDKbhUٲqVigxX ւe }c# ++\.5nL}S uQ>zI*ؽܴ?ihXVJac5K\[ao4n:?zâ>l+Y8`m-vkL^jouA˿D5]׺yhKV9P}B]06N8Y>ɩ[xDQƄcuݟx[{> v?U.]a/p4uR8 "D;ϊhd\V?4;G0:/ FUp~~ +~W^?nK!w?b~jVh}LLnPuCIa7];Kw޷:E݀#uQkO^g+jT׶] ͙C,i<@q.زq[ o2bS4=)P~µ\V'Ss8Ȟ!3mblOp ׯGɔ7&j0æ?8:Na}kH3Fͯ}gvZŵ?9R\#QمRVD>mW cKx6jŶ<1 + +O-)<>Z zpjݿU+vUiZJ%rm7ۻ cu2u7m$%KjfScL8Tt +y] FCLo"Uy8M:Os$xkXcMNq$?5E1`W49ԋ~%0s}{IֶmsU읧enۑ5 72}u&1 ;b#g\**{vu( +GrA;ydC[Ը4@3 +*?Л\|5C;b6եI…7$z~cizÞM:켝&ԧN}6$m^+5Kl5-GO5q5:%Z>Ny''Lɏ5 9Nni$=)g<^`E' +, Vf;`keZQtŽC-sNj@i mb1G0Ӥ[ A>[DDh}Gi{h\⵵U>7 nx4l<ee麦XK6~|Hҳ!T1Kz&>zs WډKƿi%-e`VySh\KpxLWcAĖ9cs]ܴ[L m!GU`J!cA߆;:;ۏfw?K@@slj}G +Y$HU{9rjo=ƒѶYgkwV{ZHi`jC{F&l簁XGЫx{ ݭ~ey%z8Q^ MC|ji?wxYn:A n4^@ h` qԻN!|9QCfhe:5 h LLG+ٽZw7.;nOUގ!q*i^l׏Rt\B9YVԻ[i#ߴ6hm'p ekjJ౜1/$EauZ&ZQylKxY' "7*y:Ke2mjRxLDcުon[}KH۫\nJi I$H[\{`/Fyy֒碴˭-!A煟y %"zq!3}JVu t\t;؈J7Լq&O P2koU湢bT58jy:3n:ْ07(躦]k0I#m^ nWz@s9ܯ5_*8ޱhtsyũ;&8Đv?l›̍gf]ojZAǴj:jc~l\g>%;!3/RS!$ vHƪ?btuGDK*GdEL)(d) M@J +"pTIG"ڻD-)!۳Z@L8PRi'z 4a'0tO+bXOQj}m3XXf{,hY0j؝:-E$Zn w0v6j!J5NU04_A-sLkp sICvL.] Jkk2p]LT杆@}6#Q`!ğ9BGd^@yBB6:pL~kjjUd6OrgSZ|C@*eĤ(kQ4:|tRs˔\urKT<:$aÄ0>J@pTQAGq#l~6C܀|ˉ 4J2?<[.[w@5n\-S;%/4(>BHH@?z&yHQ)JN)L!ۥ20PDctiB!07LLS*Gb +#e$J)Hd@ @38)Bp Q 8O rgt)A(B%@2ld'|$6J! +D2A%1Q)@Be!2elct" 8H&_QS;$L6@)\?b0a)7]ГwR&|&PT;drR@)̥)'2D 7R* JxLfS"%J HJz$CtBA0Hs2d 11WtS R8c}}qf@ߟ $S'xH62xM#2wQH6TK@LS'xQ"J @ %H0,}5pJT*$ +.PLcH":Z(-(%0F)fqԺhLr"RޝӄjԂG<#LrL03/aţM6=x^nzE*:\jviq䵤@0撙&) IL0 rT~fF `*zU]M0E\VZ"M2GxcA&;J'f7f{"wە{y)A EL4ZG+ɋ_>ޥi೹áZ戟#Y|YLTCIOA<"nGEJ9K*5ָa*'cǨ44rmi)!6R-!tIe\j N]H='m6Je +,fA4զaVR % 솰0 B@xHQ +@JER(&H./ ] XpS>?U &TxN!1RPR3&S!1) K %cjdt {(_e%Yk+Cvޔݝ:8 '*վBe6ˢ]]7Y9]i=^jc.% 0{-XZ+\|lō.ΰD Zp8{.xYn9$ɎBXvp<VF azƅ ֏[e6]eVԫjl%d3%[ BȤ9ViR iVvmT(gR'#e xF5縢@sf[YٻKx1K[̦LmcZ#[^7w+I}iZ@gp13:_Xӡ+уbWөq^L镧7"CR{)RnaR?P,H[:C ;7?؍7] !h8qV\;:8[x4qkQsB 7*8k[^Npn'YRK#a=Wc{{u/fIjb}:إegoWG.={R*Ԧ]PQ{ 4t= {0¤wE[S{4zxz?Vg{֦$;b9x6)Yߤ}4MzdZDXU` uߢc80. IOs}/)t4 ^+.[_* 'iW,}2uC݀7og`7njwpv+Z{ sJ-ʂZB3kvNu)bחU̸TU ZɎ&4IpGeCebk[rJ}B=ay/7bw\i\qk+rάCSHum 7݂1Qm*UVhdq\n6$1~ %GM7}}M|һ'_QؚeG!dr/fjzZM&jDzq+ܨpѸss-u ar-ozn=^&*cuqiפCbU(V 2a+ZvTTloqmV%Km\wN;uZHy4k4蘁FoRb|O +$mËT:k_,i?,vN47һ'Hc79zw)V0]IRO*Wa cf+V1\Զѣp+(뼢Y]j.xk[rCaĬh}O6B0[fޛ[Cy l ^ק +x ec̔}G8hf[>:4;]ʗq%l*⬧oٝw0xE; {$n@Wﰪ,8isǮ j6 + a-)7dN%E4R#8JB ,q;BM>NAHR ǂgtO`LJjt9X|b1<ĭw1|8X˘Ew~{QHMޟOP=Z]"Σ[>xո%㫋ѡ]#pF5vZJN nDpU2fFɘ#pU)Wwwmဓ,y\ =cUX +6լsėtߠ输Xn3FΣGXx첷Xك%_WeiFqYZp.YЫt}q&o#a72u$CKn^wgh8akǏYD<3Fq>ʾNWMuFN=Xޓ 97B]AC^HO&W)Tmp*\q :[-N {,e~9hqizv켃d}jZ,B❭2 +b'W +4faNG֎ xตc)^)av5z8Nu~dOxo1 G*E[6L Bz}7k0 zx"@`+*UmkFGe*8W\V\{Eu|K+ZH^N˨>NgMXɂwPc5`W667/1~l8/[ S赲4[fPi7fYс +LMk(-`A(QNl۝G nzOر?R,C)R/pUF}mh6wTwx|ic?a@ݣM\ݵf??½XU4[k]ydYQa#Uΰ~:nrnfv;Eڔkヿة;'ˏ}Cc5Xtϐ[da1o=f<9)vh*ݻ+aagp+G oSİx}v +Nt:>K'VֵwWŬݧǢi)>|쬻?3aKWy?EKG&gxi\ M5lԬf%kV.YNv7t{Ze:AT/& FQXTK [[hv4o + 8v-Ej8]vZl˄ZGEl`Է1K_7WY{0}b!kaUvWz XhN3o[KT} +WivpΧ =>.,`^PNeNKH!iCp9 lFU}R?EϤ=?^O.ҫ?Q'i'y I}Ss+]~, Gz> +j.$jIU[8}ÚӸw^rp M2:S[ֵjk6ux՗v[W'wӪ<`V" $~ +]߈GT@晴cT-'EQa}+%S'LQ} +vT"o/-giBKƧ75M?.UF6Tt~`"Ui5jZR'A!n*J0(9(nD l+RS"Jl0uy/EtA3RS0%r%=P"ep(>OJ iY|{*5#dڿymqL]P2-;0t>HFVd N*D3_e*DׇGmY[Jt rmq\( +:vx/^](V8flIwpCU6x GX֝$--ٿRzԯMo%d?[YN0N89:̾1:{ƚ%usE@Xxp BLW +75۫LeR;ݾ͐dxEéSo4YO)ֵoLwyoplG1E Ȑ$UiT~/N|f m*y}ʕW#~jeZf<[tJ&N+Z7 { +e2 R{2.H/շ+GI k+ONJmՆ%@u9ߏ}}@קR}Ẩ-L۸iA`˷y~CT$9B +ŴCiQa{fR}sZЎ  $یSӘ@_2}/6P˷Y~2^N$Uwxgi}:]M<̗i}鵮֊,q^{s: +rm,=F#QϹhl[TgD}ȴH M2H Y]W٦1F l03vV}sj@ocع☈j5D9s(e]u.>`v7-^*6=8`uzt\ Z: 4֞Z,_տtwu@Wo\|,kU&YD9}eqm7PA+#ckeZ+RLan1[_k ݝ*)GdOpM1e}6)Uqt8Fg{YaOpxn7a/]mN59bU(Si*kR"@Gvǿ~WoVitzr˚ Kx>}/QvHSLR4U*^GT8}V{i5JI;īLՕyU^lx>຺ohwmf䅠 p=2%ĕ]2\%UVmpblHpq_I- G> Sp~>]>N1+}]4R h30k>Έ .S ~iNڦl[#`2 }K/hyq! ׫n4Ңw016Gܼh`" WY{.6s.x:P|q %W nRcqV c<2Nݝ@ĩ`8ooFSXBtnG +ƈyh2~Y~\3^OEy}IiT\*|Tֲv5p +<-{N#2XeejUN1i*o[Mxӗ?շ{jW}A|:ORn +ȉD$Ja_SS%)(Va xfTRS>x@C&a00B"Q L)0!-I)"e <wG p.rRqDB + @t!Ħv@t(s )HȄ8Bs;" +*(B +q)H@: `R.)!]) Rnɗ}`IJeltpqZ7 IHAU?[k*-ܓ>+paABJQL-D8Ja0TNɂXFtXdMe˹M+\*mN^ +@d&&RadL')L#t)0ePH)((P +#e&qRJ=D$\J$(;:0AkGʌB}Iz0zCVx'Z)ӄ hOnR$D/ +EG8JaD&wL)<"%.u e0!0%8JaKDBq) 6A"ʏ(q51H6@Nɹ Je>RNeDn L%28Je )2aDLݔ r0)DBH @(("N0d (%Qʈ$ + I0%@! TT[#)!d@߄9PJPh8BI@МKR&SR1 +q)I)ܢ`(tHr#v@(R#.BAɠAD#Dm%O!!N%$vGHP+l"PS*.^sj7uŽ7T=v]ۦGPO—( n8BS&9OGD;ߧEo6iȉM4G/>?Q׵k8wuvlcxG򳝠cp A\^uZQiɏxd5}. G>k_M!tSd 7#!.R4GwCgt4s̄3)P|AFo4EH<iMn+ωu*[O*z8m*S% &XBA)B4[;'J +a-!3L4M͍|ĨB)h;yw^J 4ĉFʏ.]ҭIAjlj0*-ir4-F"|$J#J +4ʥ3K̮9]ƣʷ.1{XT;2-n^GL JVL[ݲY:ޣH l +YezV4:2zyt>KCշpu7¥\ӽu|#fx+v!Li5mQe*ǽu:[ܮݤ=dS lTȕ Y{rtF/ |v[̄OI 9Bae@! G 'cb@'%24'i`Q;&9ֻF:XwTɉu +Cg8!t`p |p0CDDQ1 +mv'.]wmJ̽;{`H(1" +sIm TǢq JZx*/"@!f{Fu >n>>𯰷QNC~7QQ@!Pg۳FʥJnDZ.qI>"``ly;/F1i[$tj:k{IצHA ń:wuUƷD,_.nNstak^zL8 oµʙbvHef<"t.RC/&we-<۹A;:-; \ݡ̸r\VRp®eцUy}*ir=\s/CH$Ȟ~α}W ƩXs!V}:鸹HQaL4ޤ+ Kxw:+jcb?υtJbֵIcN-V- >SM!e\S/*:kL:/1kq^[[>Di3<مKBn Oڼ4VCX@tSVruT}WxCX\b(,c$`p:Ye^PS\`NU݊Ҹ>[n})19b޺*U$CɓCf.w4궙tZnil)S0hY~ZmHz4̐$ʍfEJI! Z*pku-*+˪[;w30 +^=>YeyQT1:&O@϶d+rEqΖz\3]0V;&~ˋ,Ɨ;I"OZ.Ť!el5Kh?ND81u{U@; uW/ +U.܏qB^ۓ&󳆹yP=mHu:d|*VVetvbZ"Y{{.麸>ӪG~4{:?Ou橸+H):^m{SIy;тk7`ڛ$/hjPL &$⬮3.%>M.Nx6ۊ^˾/[V:}"Dohya{@ Vݛsچ.1 O پ*F]MlL έF Awl{hIϊ⹀{.Ɔ2G* g.Ԩ$ȰW*]£JAQBJum[IŮsvBwg,U{3ǂٖ#RiTO=D} ̗u{T15Ul:%Ϣ5@ټlZC v'W !g{+{VҴ׍\z)h'hvJwYٶ$: jRn HYs_J }? NiX&9`L: sUC~iq^nѤktx/Uf)S.k<YuIoyPw +ªa\j xuڍ[jˈsxuKȆݚ=!.&N ɖƟ]UpkC6]`؃zInWlPӽh&DLGRG$S%;\ : ʯÞ>0 +v-sLZvqx1:1]4!u^W%;u9[ZB6.mM˃֍ N/fA̴N9ľNï-vr<މbW\π7-_ټLn/Ҙ`4v_3\t@ h=޻[<1É^C4i!ڹ Je\vNP\ ǸyCˎhE4 `2mB]uWpƒ~|-.{rwA56Qd6HjkqWXB=)0+ Gen ϊV47TN>P +DB)2GS.WJ[ދyyl'bw?m/jZU*`:gȬeeZyQvIЬokf-)} +ZoMGe[S~9PuCy靼FS;Zu^C]3-M5$H+v^(=LCu*V߶TH빙ϵSm %s"p.o OȬN.+isD;DK[+M}wp-3 +cU=G6;N + +; $ח_ZC͵ѣW@=c;dXm뾭JeMG܉e0ht|3-`Hn> 1V Lt }=ZlKXLrC*,7}:\4NǁnG-&j^7x(:JWܵԨN\Qsڀ>axMZ*:?G]v3%Ս dS*?#^-{[$a9DqO w<\ A\0mc}nx`1ݟW9 Aʙ$ťg8Ʀ*)a\XC-jws>jveJ1' .ӨXߧ S%Ov͟Z|~O_N,e 㾫Dcr|Y}KC-|ԿG}#&/?P_YcޣO{Kbxvʮʔg%2 l8n 'Qn*Ɣ|dNŵg9c$I޴M)~ +9;| tr9cմ~a Wsʭ% ۉZ:[PiC@$x6n`\湧ڞ@] +Mip#2vv6b> ynJa[У}X^޵1˩>K5EqR&Ttߵ B=́c$(X(Yd1ƁzJ1lwhM_\ݚ~)e8rf,k,]}3s~D+2қAA;T9Z݄ʀJ9k +Ãq[ۀ.y_- Zxwsںfl1>]1Z[鶋x0!dFb>¹-B&b_j wW .X{fZ'fHP=Z`ω>kO/Yfw֣F߱Uy+[ƥG9x/ѵmTK]MVJ eΚ[_J˹8a <œz *-+4SvH܎KcS{H'7+;2<ȈJM>Yޓs?zW2ԏP4C|c(?s/5G m2%%Mgk@>!F0j4~7r.SzsߘNJ߄,C|{E&ޫkNM5<(+;2\"Z-$9);guסU.)FؓN"m{-'^Uݶ5}f 'rN եx'Xe̟:{]I.-~F=wkOP嬵jڵwcr~*->EFտ5C@k\g?tVVAF~˴GVy.1R\%~ׄa NզE6$Ŕً\1Ɲvʙ +ྛcV{j - S)ήDW ŗic 꽻ÐNGۍ.rGFSiz"ߙ=J4+$RʣYVC%l}_bx6ޅrA=}%Ao.i[\i7 嬫N&y&Uk'Bph29\4=.J xp+qj]L3S_SDzūйդ3;'rKo.WMv=}R`haUI2#iyS=#O/65{Wm5/\q˒`T)ۺdžW2\ëcHkz юb=**߬ޫ>uQ"e(=V<=^kt@/b˔ƁRC\9 +Gk_ԁjp>L[RƎMdP::bl._P;--%X{~wX`4m4<]-{=m;P r%Z 1zn5i4 Wzʤ˙p`WVY'Fŝ\CT#Æ'F0*  r}qIv܎xYcGP{2' UogqiikTCf]9+uLLDQ %JBLIesq\ A.>H*M.T%>4)dDzPJN(&vC1AH@JJ@r +XHmA9\0l!=mH֒d׹t`"%2SM=<ɦ`yxfAxuT{w=N%DPAx27=ѨuSRf݂|%%?YJ;aB|$ &L(2(;$ЃPۆU;VaݚПRF4qqe(P\~*(j + P +ADFAt"vA2$NÍ`4 +UITl + $^ALn =!4r52ԝ!0! eQĠIR +4&d Bh4;%AD"q))A T)iL yg%/'{0|o;_dB@&!6NHl_R) GuApῴ>J%@0@8A.&Ѻh3BaJ!ȅA)R&))n*\p -ߢ@0HL%BN y! o Ba)dH@  C!Iu<r$n=FiQXA 5i:^\]#pzu4"~K\R'huFxjM z>2#汙_}{ˊUjM6{ MQhۆFؑSx54Q58<\@2оpt iDlWl*=w^|6؟~@Q~tzrvhsQuZ"OIFFwix#QXAppɑSK[UǬ%Z[8 nR{CORD'm]bi!tލ:FUox6u>̶ wq[wi9HU98)_;rm"zl9^gbVjE8by#{m@\W΀5R)\H +@#OR{\}I%y1:6MZi.ڣ[HpQUS$78SF%wAo;'Uͤ5D}+58JD)NX~):T;U1ovtS;+ŝU0CFQtIܖ5ayQFȕ;k]U7WbVf BW~KwJzk|%I +wv5EѻOC[)950ˏMk[alAt֚0YUvwNΤjMC_sTlJZ2j +Wƪ iP:YP;v))% dATJ. \.Hn a'V$}\D%09RSLLlQ2S.N!'! v@WoQ hfjm&:lCwVK85(;ܟE+9{s."lLs -kճp¬uS`uGb]0|^ZkEVY:H=w[|8Y}oD7ժeۙ2V̡fF6LWr-+BjT& 0%xq;CiUV0`I_Btsm^0OO%5݋VȤǜ(`I??U!c{U&74{͡;nks: T/ èTq@0N+2۹nZI-hXKӴbà F׳+F0 +ϨcSϹxwӄԪ O#/u!oE-.h +@ <;.n.e:['HJ8cr#E䶝n[;+>z;CkfJ@:C ͅ/2T-_1>*(aM7Pu0;3&<ۚ*pAguPYtO&xWY6k~|RNC7^\)9sS.&'sa+њ0eJ.Ks 85m9Tw(ٚMtԫPI.xwW ܻ JOBٺI[laaW̠`#ޭ +R8Ttiqse$Ӧ@= =ηUXo@h;^Ñh7V`ӫK}yWcŻk;NJڗ?_-tc$3fAqj! G 4qli1+݂_ue3gUp+lF^Tp\K+ҫjU!cLL/~~MzpƻC*yWP ;Ńֱ|fW c%jj32(5*br5Y2 g[ cSA:H^Fp]{2sg oY~2,R s`mmF@&ϴLE:nGV9GGuON\[b|%yԆ$3LVVtW^c:Lhs@i1-_]ײ22JVnnV^J4 y-e:M%;nJdV]{Q{ap+joե{b5A0lQō# #1)&&`X_Xђ@i}8#0[kK.Sů._[vyz*״LBh1{`V6v]Џ2"Vg&[پ]RIxBo(ִxPyg@;uXxpgOzAqǂl賸 +͕5mĹw*, V!u1-cO{ToD[[E~'S uùu#>aTq[ K\=.!lqU 8K<&3JoR>>尧=XLKYf.USfw0ه)F(eKR9RJ%;C˴ЯGc[荒Fْ%ڭqjUdhHBT^Tf5@n3H = m nuKؽ1I;<gEJ[d7d_kZ[ !4Xʄ ЛvgC@kK{ xn^ X; G(#>fko!A:b{)ܑ|d%vC谙g|Z$U!i; /`ظ>GQ{KWGcn&b-^ v"A8])+ԭJ!BaLPݷTDmD-~ g*y۟x+-Jwp쿛+y׎o)d-hD~}Wb4q~l'á[*ڋ=$nh|c{77U#L-L>s1Y>isg_~B,hΛ6i~}B ,%as*`i'pgoYV}Wyb.~ܬ{Mo/^|˾?a%iCd2?U>ϩo ]OKne̙]Z'2D,3e*dli$3+d%b{P;[~}BS܏!X\_7(ڠsdk.wZ||6ڭGRVTeB`;F[cfDu +o W&`+j\[~}BhgRYJ5BuX.;ց^QdTd|.kj1$88U)XXקiN}G}_ߙ[+ O{S`O@-ýy5309&!Ugp-E\>Q \gI6HPihgܼqRv#z{81cOU^zv?1];Z0s>kEx?Y^G㾫͜*:QJ,p*NZ 0Lvx;&nq%ómݟOs˟۵ϑZbʷ}80}56~E^\QctN,j* F񸀬{Rҗ;DsZ'-&< -nSi-Fni[cD4 {ܳM/kM# d϶MSkEG240x*7nΓyw"6 (S["% B`E!#`SN#tD]S/,%Ǽl()A2 +S(M@ p0P6AB"Siѵ*>{\tWa >Sg\/e!CY|e/jNh/O&:]m-hQo˪\Fᬍ,su4mp,mnhUj{4!ET)Nj>f >=ƨ3%ܙg%ַ #׿ɴ5kwE'ZTy_,_a»Tf3&.Ӥ+JLX) JiyN ܱ[R\>]W +n" m[flK*4SÕڎ^WXըqs+ӄ٤ ylONćQ6Ff/N)R)z-a,@YVyQWy ueX )I.2;*Es1zkNDKy]roFLGmDha N2yq2#af\}nհZhv R糚E_D;VTK;pL*× +z[ݺDyp'>Oxezmq.ȭWI1fO +`EZ>gީG,sU4^ق4)Aq;;i]zH,ێ &Kw$KmeʁgC{rȇo./(kvqwwĖTflW۳Aժ>i8ZѤl \$<,~X} CN۫ (\jjUw.*ébl4k7SO{fٵ2tQO5Z<+ u>UO;2ʑ0^; JZuR%:A,pYfvoJگm?ǒò]\]ҐZ"9rX +:{%de*fĨ& w|%y15DVdvoEj>ΣJ([a Z":!^I:t”JT~@鲶Ux,-NuU2da4Zfޯ ^jՍe!_ c: r *ؙ\﬩ k7SO?zjT Ph2tWYN(*~LȔhKy,;RVyx+݂`) $KܘBOQQSҿ0J!rz( Ɉ}?"%")) A( +Gtp >&xA IRK0u%8H@ @$ʓ DlwA(A#e0a(#eTw@ *@`BPD7v4Yh{| +og :q v[4S )E"a(& !dG*%8&R)(2!(;!ޞ !B "at(PhpiPre+ZnNCZ: A; PDB&퐆L>*\ +@O(7(JcdiLlH삤֤-9! ĠtD GIdzD! lJ!=]a \a=2_)NEDfݾʉnS +q)!&7A2(ALrnAA\E C_:g[Vt'WVA"PZJAJ@ ̠D B^|ra +Dia{=W +"WX~8 y^eG +@b<1gii lxpi@ +S@Q ('tQ: "~H;!I8 ?*XMJ.G&Bs J(D|#Ad8I4jm"586x7S&F邂e3JG#T(|s('N ` $6P]ƶ88켌ƨ{ " q#%W`NbI-~N[ɈUe{y2 eyDSk۵0A=lw]ZQqkC%$|վ ƚ_AG-;8|!zLoKh|c0綍giU=[Y1-i-+x;Ni9\qv u*.-n\)U2 V2xk=KwezVmP8>=^ChjЩMGֱYQ>Lwh zosF,zToEk$=q_L~?"@xqa nwmSհ/n _rwkn7_j]I$+Jʃnz!ڟT&Yj~m*:*|aOfR곐Ǵ:TXWc7>KA_7˖׷V¡ϴ;zoZ` 4ŜhYUf K %UWz(z辛I+ǎ2h/X wG+1v8)m~Vp_UߢWx2NLn)&wDJ )Sn$j_I(L\k/{c%XD$PBIcdII"a0S S;BrA6kAƴ گ;beB3`M<"(1`I$nIY z*;#j"kZg?NƆ@b{7-(k9+וQ5Uć0%Y^^fS-uUm[bTNֶۨʤ4\\0dǾ  c\7S8pr$.JғAuF$ Q۶)!L7L}cCaY޴sZ B220p]xm*zpOƋ* h`0wUv4Za`Ѱʯ:,p5jفZ)XЦְIcI$2c ,ik@pj0t\ӾѦ6cf|cyB1޻I 6l=V/ +/ܖ v[}[ջ3'/OkLi(]buzАƑ"G\,ÆJF'I 2o (0S%yL V 1Z1C[HsӪ8]G5YrA h.$I$d;-n4אa_vӻ}} T54n*lg3E:uԆcY 2wZ I$o&]"X=y%vT J9"yrn)P"F;~6TݥRkjڸ4I}iUZif#r"vX쑙,$y%A'%y3>cZp{]$$l|W<8H?ET47@ B=~)qE44*L߃7T)cO:/#Ս}5 N be{r [yNЫ0fb~KI v6|eQԀi|7.SvX=)dKI' `SujmOTd NB"b@+=kG4QU5_ce`-fֵeG u`y,9(V{<m}h E6<,,6PmZג:beB{ېU.KIι:H-:>+g*EgVMީAXęm3r#U`5wovwܓ? }oO/|J^4V4QMwXv1Kً =A맢gرTv*&X*?SjKOM:*vj`isn)ѱNKWU=*<݇Po1:-LJ4> ^\M:w3F\"whE[ڇ |wo ϙɶ )5O;isRw/T ||-k\]8Ic$L5P%.-Rก0wol_2ѵkNt0T b_:Mx[SmQݐ4,&DWmKrf4o_T5 I*;^YU{LVZM\2hSU 83O3xYה/-Tia$6ەqpJ﹣nnӫibuSWvY9Nb ~ɇs׼rvLiH +;fO¶k)849[DV0Jw${Ь%^X޶k^$O+\#ӈ@"Ҁ!s);dרXX$RJ +A!4MJdJ +L"%Ӻ^3;K 6'ˆX i넺ƍZ{X%[`پ׺ZѨ8D +7sp3F#KލߣWn^^-}` 9cW΅jYbXNGGU}-M'r]cJ] ygBk[^Gt+)8mK|Qzd}ޛk^NUJ0Vڣn;I Uf,~YyӋzڐF=QR*/EklAj4@#pWu*Zcsq^ wNZsT]:l[nZKO1ƭ6_o,? ^,DSM;P8e}1{Lh;(cr2\ ]"w|g9RHni$Z0֌$CNu˸\7C%h|v jSyUO^̳tE- + 6+l7;Uhm;'WvW~9XGLJ9 Aجandk@eqϊ2T*sٞadjUv L3cNRLov $|+++ mNs^;k][ZL}6AuHGq*W bƗ8n[5HW3}ӈ.q5nic6= +9o8RiwzUyYNݗv/"z}_zs'D;;o]*7A sr\̳T}fHWjé=V > ω14`eCx}y74Ѻe + Hi!8fRpvQHy;RtZ洸)f;zi<89-3H 53 J^uZD\ %zs{n+Ɍ'vT{xaV@tt͖gwc. qJs辉vIu|x+ +d7m[_!-u'W8J m.P6͢{4C7C4 Nlk ݄x-S]BG&'ن)Js;<|cnܵ9~M[n* kx_q/@1m<`gާq_RuR>+ߎV˶}qHcV81RHqd +BZ- xnNmr"WjkۓU` (iYZ<֚_v5KsX\c(9s!thos3TT0`I*pQe[ڂp@<ē/f*C+m ӎY5&dnDQK7V|ƊVQV|ɈԫXPG9ް>1\7p;=g{y^"x1:xN%r /oi m'gTGl抃I͏X*֫s1^Ul]UJ=2?kSgWŕSAh0c[u;ZXjy/ŋ+DAM?rϮ>֥ *KS4ȓ!{pkwLzCj5yl[>ٱ@0b>KzwXNXY^ڵA6#Ps.s"q5 +QukzW.<]2]~{ky}8vZ$y(yƕ +-:*R"aga3Vi4Lx !}D!Mc~90 ^IFh3p(:ZC8V7?kx4wEM,UӢ65cf|U{=Vnu'S#`=c4hU5U+/=0C"W>VbζbeX0!kZ# :ۻg h4@`lܩD!}w@)LlCu78Iۄ +'dF%w545{vA@L $DJgdBrJɔG(!9HM-0Oh;֦GԫX؁ـ4ik#[⟞`q\,2{tW=ZBm=o{|JZlI\/,i7ڃl)hk[.04kT3.wj˶U<)QvmֈpéU.\j7uK)bz{dt8i"ZDAP+Ԡ4>Jž[*# ھ +AwUڥ1X8Hp:.6VTRhkd.bUZf +Lw`4/;0B .1[ kL.M*BH O (aEϢ%Rk8{kvMw4<{vVBG1WFrl[^>ƞLP`ʦVW 4Β@+,/ 4<⽻<Am #Hiq*8vOS5t'x-OwyRy#i+ ;7z+ŻniDFܫ܇ep'C~\+kx{;- h)7_i-2HN!-q!z0XSW`{| +XnK owAsp|K֭M>=~jxvG E k^ni<:N) {aԭk1<X^oi|zՁ3AUUrs[<[7E6 v5X?,I> /a2] KF=ܞvˆ],gEI+VOse% .䁹]GuݗcMF%pYt רW=|xUrͭSԚOФ Ɔ zuզ;mwmN.yWMf5ccT7]ԫI5 Y;ZŽ>ID޾eyRF%n>ӢTuL{=6B)HOJ!XipxRpW%õ>I+oAE6T+Qmq8xkѴ:kO)cCZNiǒϽJAAHCD/%FM]24o.(|b;;#YYvpszI1A&0RpT$Ax)fbgXN֠d^,s4 +1 9#avCNq Su5ā*t6ƆMU䧃[:6ϐ^aԩ hpctWj8;:ti <|ӷetShh); *-LlEn_10!!@R;.PL/ u)χ[!IL)`)L &L%2N2Jpn% H쁺Dƒ)@Ad8o $$L DB O"JCt@;) AH"p@JS&@K(GTQ‹銄#@M JPhHlinBD"Ln)ġ pDB@B9L@KtҐL1\\J% yRABC}ӈDBQ(;"a!!`Ja <DM' (P0vM &PwJcd!Gew vH\^T!0g`V`HB P!4PwR@AtBQ)(Dp$ CQ0[*32ҿRр70\9D@@& *S(;RRLUsWz#mU0P +ȉD&vI) 'd4B R"Q +$&6HP(Bq GbJPe4 L@*@B\$L0RL@BL)S@LP +G)PDGtu)H n5EK)5 a"9R)S%>ZO&w@(%B9HLPRA0CJ`B&P!KLn7!SALl;AFr$( >HB‹.O*d7eQEZJ.ABR1`BNa("P7LH98eL9јUAkIc-U;@uIf%=F/Aq<CqqQ,ņ N [wWЮ)nwYp1Tqz֗ZںuV_408ҹcŸu_CLխ /%y{+G751V$M;[}Gǽz0\B֦5Orq:xE3^ܳ#'yc)ctzGi voBj5`̩^7Re(2 {Aj6j0~ +/J8\rװÚ\R,* BctȄ8%( Jq )L!E(J"QBrB@2t@>A@j +"R"SHoN%!)۲pHDQ(I( +\#| n% Rs( l%d ((  j@N`"%tBp +P`tADBGt +PLD@HDB!! !0(D(() DOG +1 +0;u7u<ܬHPBLn(H)7tП L'(2| gwwyr@86ΰ~XH'Vnָxt8/.KU0V1 D;s1ѭN֫E6ݮ#کB[4P l<(K`Sˬ;TF8[cA؅'*mcZ`h]iV*61[?Pb6c^$hmvjin줓dGWGص+ c4nl+{QNȏv_L[T=T?R,{U{@,v+|ך7noF,[WWz{i9P >ΈaMAyq'ȑ*;:nH ڎ!Us-@DiNB}F_V"Ѭ p˘K/qk)>$m35+wSwwJA$@㢥m{JU+1U:ê3.%A1ׯv??BV*\$"P6BQ!0S +%2tR@@ B!B(PA$D'29@$*D "PŒ”JDBD@0JG( +@D"P#܈I@B +9@)(@ AF.MХD#HLPrDB! SM D r) Hn(*$B"Q / L%.R;9r&Sj]U~Y +%"@n\& S&iSd2R"wHStX[&-]gyJh}sqrګDҤK`n@ +'X K +eǏª˹F: N&co5vm)аMޣD>Z\xzLtߢin/vH00|[3-|uQηN o/6t͖Ź J 6'XңSccOsX?~Fi)GRXUd(v7w}-uX֧^/j%9{Qx#++IM퇍^re*G$U}1{wVԬL ;L& +@DA  A("pHNe!ؙt$7LpDN!BLBDu(D#pZDB !|NwDJaiPJ Q2LPJ D G(;&&QʑDL!#d !"Ne$Pv@2!)>2t'‰2J 8C +0̅]o8?z\ +ED 7DBiBq 7FRDBG܈L@0*vZa &;`gnw+Q~ihxp |HU+/hp Ѳnu2Z|@cE^<]BX)ٲ3N Яۢ#qϚ\S +eJ;]ڈF +CppZҵ:kOX  I ZR. OL8̯5L:M ]t͔Lr@Au秆QcCD(2G5Â@JU@KJu*/lA NnJa4"D@0 ԎRsA@2zGdQ)(LJ%9@)JMT(G P #{ҘL)LJIJJ$ +F&wA0Js"(H"R)6A; M-dJ&PdJ8K*R)9Й2a)) H'2a2Rc0ZtKT'A. G'!DK;|J! +$(8J saÀD5~DD4pT@n2e0; .Sk:* J9NDJ p#Jm0xHJ[e9dBQ)0!(aKJI 6PD&DJN0!J0nԆ )B 2  G)`J@"J`%;!$*R4R7$ +apd@l&R2 +(ɄD&LI &TND@'wLlCALraR>RaD% JeJTuJ ;$ZBeDHWvDIHW2D&.p?HyHJS046Ne(&* r&7G)r%)D DJ`B9H pR"B49LB@JOJ`BNHlA *GeLRv&P6G)La"RɄ ‰q>P6@$) +@ lj N!Jp lJ APPQ2#BdB@H KH‰ +GdwBL +BS&S!&DwFF +P  d A((B8AA2 + A2 DL)J2LLlC!#ND $$&D0 +. +'u̅\.ILtݺ +% B` 7FrNadL%gd;tpDL&R"Q) J4B()&D$!. +NPHl#ޤ6B"LBH MJQ1Gdl%(AD&%?4BH(B A0! M Q0i@2!S('!$!"Q )@" +cd6@(DS(KN% a4B!p"a)pALD HJ%% ) ;"SJ%G @e$vA#D G+!%0wP;(CWz5;ʒ!6r"aJISPB +"R fJCt(PvDPQD6BZP6N&RLrNe!|(Dt 9)DܠP&I"a8R"!JL@ Q8Hn @G(A (%n$ "e4 &%"(!D +!4S)@D +$'0LM @(4BJ$dBM @t')ruA)i)QtBBɝ҄)D!'Ne-A(A)q!QJ@.|/=_ηVIBD&ctM.B ɔ((jp!L20%)iDD)%%%9RJa2%Fab $ l@G(D +5J&S(%)tAHۺ&"PL&PR&Ґ)򂃺&R)DD'0'0eE9 + Da2a Aa*#u(&B\ Kp) HQ0Q)0OD JceA%d4rR9A2SID(&RA')8J HPv'e0Ty}J.Q()D&J &G(0@ ( O@6@("Qt$%(j&PvOTBA҂! AI +#tpAN#4"Q`@$T%)(n鄎LKrD#@ +%Lx!?r pQ0HA0!AHl%S&Q("PL#r@)e 2N>Ʉ@2*\%2!9%1 +& (C$Sv Ҕ Nad gd Z)A2  t0QQ(G!0 +*.̡q"j/X(@0 +!)w@8&e9H9Op)&! LBQ&҄ `R)ݐFPa (%00"pLJD&2A2#d D)@ L0 +I'!Zc4ЙJ!~R2% )Da0% R) HHwD P6H Ї%dɑ DLn +dDDqPLI  +Ct#LJ TPe0"R \ɄJ8D H(\I0~0w޽n  +<9R&jA Kp20%e;E̵p6R{ɸkF\T2\z[nUI,VΗ8e#}-u" +.:q~ASl1C4;HߟC M*1<&Jw5h9T빅 5FZ5#sL$Vj1U"6h ߂V +! )e Rp="IALDrIR$ #J8A"H&vI3aF!2B%2A0e=(R-ID#J`B8G)D LD&J;!%JD $$&nJ +-*ID !n2Jd"QD!"Dd!(H KP @2Sp l;$L$RRH)tP$B +Gu\Ϲ@4%Ӌ\9[Q!DHQ+QrCd+"TIQ;(&wLD(;' Є&i\((iB`DBJI!@J%)  l ;  CORHG" HAja"%"gI$pOERrr`; DJcnLwL&%"vd dJ$PO-(iDCCL!怃ntre6 ;%Ғe$wM(DD$D!6A NPQGJPwDBjRtJ@S( ȘD +da9D9BNL"e)LlDJE@ " Q.) w+'(HD" @RJ8A1`J&P +gtnSD/z @9% 2pB9 L L R@ !$#h (%t%9> !H +((iG(a9IJSP4 M9#dna2e +2wAHn2!tr!)vBhdlL" 'ʈ!JrHG(;('0RRtrS"P;yAQ D!d D&L)Da1S)Ea(Bd $N#TJ..+'̠ JcdG)ӘGP7L"4i4B9LR2H08CJs*-"PdBDB +"P` D '0LajGKR;D JZP"P&Q8NPDݲ(4S(yRdDN% 5L K8 R&7OQSALe @jLnLG)iO`(BD'@*RИPL"!#Dp<@%J8G(p"%!eJ +DJCd;d +1 $LL")JPW m;GYq%")LL A B +) e(NTG(&@(R;@`ʋL(D(DlKJS 7 AQ'6G 2a)A2a!A>;') +0GpBs2;le'506D&))Qtt9D@ Љ +9I4H6wR"2 84ɠA); %9I6!9%t "e!! n2;% + ! e3PAlwHBMl"% )LTHHTTj{D(Ӕa0a0)J‘@@)#`#ސ@0L( Ԑ 0v=GDP(K)FR@ pF;OPt M*&CZL A2%"@.'tBz&Q((&rcܑ(q肉MJ) + Bm#Ȅ@d}RD?;o44 MިLJjXA +`nPUpD$ + 0R@(P +Uj6j{$B"%t q{Jຍơ=G 0!((BI%3 Q)AA 9JAH0$\74㍗@P7BG <$ҕJ'e0ߡċIڍ3{;!!q(#;* \ $PW2p+G{Z| 䕆1G1EK r!tA@B9@2))0Qr`@eJuLeD9DL(6YV|k +Ȯn +J"P7RL'!tς` Ba6G)DADOD;/./6K~Iq_7ʕ+`5K/vྦbV/}ς˗ޗoIps67+^-Jnppu+0x |Jy./x5<@Jn7cH*7^Ja7;9ۡ9^KKrG++e{۪ϫJCd7}Q.nxO2I-Zqپ^܁0k{^֘zˌz>CRaȞ>վp +*[Gpo +SH# PmVkOpr^hnωM J hAr:WXJ{āYfkމIڟmOAU޿s a9wwMp]0JEWِ + wwU` -sa.^F^Z#ghv K?Zt֊pU Tw斢t@/vg|;+ڦ1IH\F)Qt&|#!3!׎&=˴ [GS @Z7\ I泵3Iՠ[ax,Yj|C1PêګDUwR1 NY޲Iژ!v&' q˻5)w-]n> UVeZ:[ՠVxN5Kt*#eX}w4R?~݈ԫsL .@Y[w4*Y> HGEq؛1֭>_o.XƓ pc Q `$ &Y1'9I %/rNwS-RF.A'NMXz* ևaлl(鏧Sf9!|,檸!coO)1-sgzrGzED y_Iw?5[1q[Ժ3ܖRsCuS/VWju +~W7azVn^Jʓ1ƝFC2,Tmgzhx3YR0\A[Yqhprl,u] (Z¨CY'wӫ0!Ǽo_1>+g5NۓnV{oVv \<΁BsN3Dm.۞~چj6*pxpvWUaZC^-5@%vf;wVASvC,w6o-ht;-FwobԶs#7+=2i{VpyҮrq +Uޙ.7a|۴ +k4Sܑ,޵:ScI|J<~5; 'q*Ž렒wO+ː7ѭ[ {2XgTpV[Hhit6\\"w1|Uj5* prVC˦@Iag0:L͵^VOG|Lj,yV8{07Ӣj xhdܝiTTZVX)Z2!wgj/b Ŝic{$DhvB< +h;M ;e`2';N%'Uݥ;kN曋V#>vN֍ܮy_YR ;dWڥp*6^W|@Z~+mӬQ 3Gf۪ ƺ/.v­pѠ*wtOUwЛ6cV ?7GPv_r*#ۦ^o}:|֘1E!VyAGJ!Wf\OuZCHg`8[1PU\|yKJϥcP@>SKvQyY-3j+x Y]sd;p'UVmA\\Ϛǯc7 +c*a;LJ05+V.y >Gt/ސHcHR1 nΑ-*d=W>WAc؅ +R$mhR9f>kϕ(YY>kMnu6 xe:erkH$lG2S׷1ܾx~ay !}F{6_*z86vV2W/u2d@]6bG6J(Uu*իUͥM0RgkP`?ꍂKw[k1cHF*X`X`oURl&S'ܬGj'xfOWݬ]*mW6<>lQHW/6έgٵƥ:I$3_ywUk 1 \o:PQˢzo+<ΐhذ9.[]ԭirzǘÖf$']X4*i @7 &\vԘg 'm'C<@+vf'i#ZVԪ3 t,hukk +{<8!K-Dž@-)S氝^LJ|{eCۓ,/e·S* ([5Z%ngư<7kԦݸ}LYY6dޠ1SdxYNquHNJavj.s<.5a53p,06$2ԷmJ4<~ٰ9n~ wΗ.c[R;D1Q7!"cQMX,*ݏڴĭ:ƕ+ jN%M Hpm[/}ƒ8s,RǮxu9:XIZ(4@${a6ti4ThkC I^v81YaNmx[[gnLL|כ_VcKkX>kAn0Z}I0&TژE. X:e,~k=Π x,m#V`"e[YNKv7ڷxwח!5sq8@pkGn}pLq:h?d*{ewnUMi .qekE.xǼ;vϪP-HH܋Vjak^KK<ʸĶ6U#~CFÁ Ï?n,E,cd |=Uo>3R[:ty2Qt}K&>P gZ-+$5 C:PHs]zb4h G5QY^6f[eB +Mcsi6@ eK^woy3jhs3TsaQ4I1cyqJQb#Y? Zπà?]+IMof6T/5So.@ʡeEeF<[iߴ\v{ACs`7xߕkoJO˅kvVu6.ح6DڳWPw+=w7[4+&$c^ΟxǸUz*qqu:`cA!=UV Se,+VZDNܯnl# {`>˙"FK+0C3)VXGx|GjTI{)@JB +a!EJ )p +axIA\D!0S'*S)N%tɀJi&.uiwu9@_fLҦKO*Ѧ3=+\Z|UàW,zPr0O,u'Tu]GrU7YSygYK {?% + W j]cc1zN쿨*̽K]U)}#Mq$qf.=ceaQL+j=L'B ȿ7VM=QȦAq{X,+k N(xPh2Z'uTٿ/?-XOXa"Ɠ-'sj˦A,x>nB ,3vz|iU Z{ְQLTH ; uwR3ׂU^Pn+P]ҨiVo +0O}}'0'ૐjRʻI-[wwT{=xw}aB9w" ZL) $UD4uI;\^ ԓAY|Jq'Qv%X|LQy&A^b6-X#g3J-+: qQUϪbzGHVm +5Gx|5,ZԷ{)譲RUjU/w*U-30Sm7829S0cI*UuCP6 +cw>^I-|7sOIZAIy{sk\\"5kn +在p2H 5 849^;Rx^vZ[v^0Ѩ%AZgHpt[{mB+L'}GxCÙ{ZI&x%lZ \$tei8ڳrvVQדR'f umGݻPk| efk.nӱaZbz%Rzi*ș>r0lK/u)]'ޞ9hCMfÇ >*׳{j.{R 8-=Z,es@iԩLZV\ܹܟ5Pƚ]GN-h8=#H-0Fp +5u2cP"G;e8{J -AgW\-pRxA SQn*50J5+zYgDoeSY:vci ׅ0gsѺۇ_O> Lʿ-]08x^ZκLxʴ&W:pIZAkÙQIq2*uW|zх|'z>=~kqn˦UZЪOuw 1W(٢18U7:J~䍗 ha[`ǯ{\Ҩ55܃9~ %cZԬ>,zC t6s;YGESK&S='çzt.^`Ȃ6ھJAp|eS܅f!M*{/•,X _e;lPwG +[2]U:\nz;R Ɏ]m7278Ga> ͻ.o*lklm%Y=-pU hk%h#n!vӮsA{x=BG.[bUZ`꧇`niתܨ&R)*$HWJD$T %D WAdBD#$JaJe.40%J!tB$ 9@&` +et A@2!2e!(Bd +H@(tB%t#T%"aA(;%DJGe!9@[)B!2:G LJaB]IP)JCde(%|)%! r"!d"e!$()pr9K@A18N%)D l("% !!J8A0RHKP '1ؔ$L$yLBa9L A!!@!"%/*< NE9Rym7?dspG)8 @CQ&S& +!;"%HJ"B6ݦk[<"v4UCHĩa+845c|SJN%.S) (J!)D %"Le#!J&PwQ&J%~R;$7HF) +|& Or%I lRԂ!N#&. #Ll)$I )p@ S e0OJS(D PȉDOP"a(d@B|T%Gv BQQ( iM7@.D&$ D *0P&T!J ڶ {ʰ%;d%I(*DJ"A(n@"S"!eWcFxvx]5<'gA5~ ~KΖcC?EYDBYN?Q@ +Q(;$(I&JHR@0%8H$$Ln +cd" %-Pa)crJ8Q +v H2&6@"'KH@r +Mt(Ԃ !9>R(PD2JR)D(%tIM7I tL*S)J8A| lKRq%r (%"PD0N(dLLn`"JGtB() @(BW$v.@Sv«F0{Jؤ'`CdD&ȔOMBp~q~A`rqʕK-h<ߏ~ԤM-? +G}g촟&%O +ĎLqz Nn굤8IuUڶ_Joi4Ѵ6@((& + :}dPө3*MDH8D$I*@$DDB pJeJD D8@( BB2Ҁ" e%0!&& + +" D&\BQ"SAMDn%2v*2(N% DOH!08HBe a҂0HHIɡL KގPL lRR=C\ID;evBu 5輘=دM %.cdMJgOM)s)&SKD&A1 [T'Ys ?q+Kgkn>ӲUNwt\|fX~EFͮ'SVնV  {XSm'zA#ONgCx Bn*\$]8G(; u&yB2Nz$P7Q02JS &Q|Os)D&"J@e'(T@MBD;&w ;tFtD)(L HL8)9H۰l2r!&vRt4%l6I%)̥K"%>J B8@I)p'0Le0et&j L @ߔR A:;@2 Zgu)@! IGB9H`$\0KTʃJM*=xw`eHlRG*@B9O ')rLFABhqrŰ|_6?5rmQÂ1V;cTLj!GfB3%U.w{Vy-$OHd&!gyV'j[HVchPQ!"ީ(d!4rR8RBaB$"@9D 4& +$D% Dx!G)) (!(DFyCI)!4DJ`F)$B| J +N"@B +)Ġ AA I8 @A"P7F"@!tB! ! )Dl2ढ6RQnId(p~)ŒJ4"hL쀄)D%2!'/ z%D +TxDJn漶b#{u>HpdS Ӕ0Sj)@  +Ct@Ba !8{("PvOB +8DJ e #Ȕrz 鐄&;D"P9! QM2;$ +"(4QŒO) l'0R;'`B A{((;00JaJLB`%0'*:K L@2L tH (Hlʑ2'$LLF\( +DB|$ / % +%D2%ylg)LDB|&Q) ĠD2&D"R!(ĢR;% vALJa(0e.Q(]* SJe`!(G&a)P&JG("%9Hl"d H CD&&A!)ANvA0Dq((;ABQ +E) B9Hl鹲e%FQ@2H)B (s9tDIS@&Ѐa#5BDBH(R(pp:THDL B'tBE i*%D ^{=̯iTI( Ӕ@ S@9@ 22PBe )p))B|$A #%mBGd.N"P p k+A00e +@`Q e)A9D BK4J&)#SD&wAG(B%$Bcd9@O 29%OLB\&ݑ"ad0ҙ*-LrNS">)B2a"-I nt%"AJP &7DB5J;yD l&@HnRR;L$ 7bdE L:S b"nG& A Q)Ԥɻ8N! A&D9DB@Bs G#L" B Qojq2WTrNe eO'0a $L!1Ht9QD!J%"[$pJRd4HJs)BSJ&RMd;JHJP6G()B(';0#z l0IJaH$7NSp@վ;H !PR.e"aJdŽAj AGDR $JQtQLD nSD"a"e2S%0J@BnAܢ! +q)(%(L삆n&BSN!Ji Net(0eGJdDJs;) %!#[ Q'J%. +5&v_ +.DQv$ ĮX{R*I'd  R&0D "Q)̦QDJ6BGtRP7AGLDpF() 샺NP +D#pJD';ۦ +@gt(DvD)1@B&8D$B8A2D'(OLD]"6M)$ HL$Je(DJJ6L +:B!)Й(R * P))B&R; KL&DB8L DBN 9E"Q +.s)N@BTyR@-J A*.0L$%UrvQ!J & G +@ l Od"!&Q +" r@(8B +L#)L윢e !4B%(J&eB9@DadD $J9JSqG%$"!8B7L9LH58LLD8JSp)2H0` +I#dr71\&"PD#lB`BHd D%Bp0HnPvG `!d&BR&7K(;$ +NR!DB@aDlJ CN.D/%~%Y5҂%$ G +PB`r @B@)J|ctLn)Eڍ +PP67UosVIznahb Kkn'LsZ@2%xjvoz%6פT8A!DNPҐ\ /A;؈@@!(@ CD#JS;$)"Q)Ba.S #L $Q%2)  "R)E(<"e"aHD!'&7L PL'A@(&PDJa L PBQF"JpA0>R;2! rPP6DPQ(솄J|BD;%GdE AP!3 ("PJ@$ J!FAHB{j2$6O>PvO&wD7(G*PL%(&l^ޣ~?EgYeiF:3wՠ-qT V*R4\*#׃6ֲ޺AmT}U4BWh+CfTKvպ<=ԴsY{@k YUͤ BaL8d]-mUwMi,Lg'2coh4|ВYGpd|0ӮY1jz5EtSTh^1H\Q>|%% +5 J\vBAA0JDvGLee(((DJ DJ&Q8H DB@J| +s vA;tL!4L)N l*\!1 +"2r$ *$2cDBHLJgt%! D'F%0@@($ &7B\BDCLd(DA%BB@) $)pa\(J*%$ }cWLTS"R!8`B8Ne>R !9@L7HJqAX@}Ls_۳aVadx5N{O\ƚO?z|4|N?a=YDDz }ף>xZff=nmFA ڭ$:nM<ܯ= I^$T-ǂe..RnoLrE/mcûAXi::"#`x% -{do+ʒR(;LHwD8G* NҘPJ@GR !A2GG((JJ$Jq)*$J " !tADtBR$&R) "PD"PJ +Cd&(; 1"&Q@LAG BrB06ctLD pJ!.vA@2P6KR; t IPD#D‰N! !0! !(Ja"vQDRMw2HlB9O( &7L HL& "a9L숄M WͳF,hl,s@ WG;~[iM KCawW}T5ͽgר ~!aT_l?J򀰹K6-S8}sM7 2g vᴬ[@{O{~s7YD |c]gy#fc5C#q},U +LrzLv|ۧW I rxگdceʖ/FDŽDL𤆄9 &"DPDlB|L "'n29&%#T8GD\ R;$D()@02HOD%% wA#L&2$ &R>LK ;@M(L"% e4"QM %3 BD "eR$HD1@'&R)iM 4 2G(%()!8J& {)B&KRH6E=.%Gh%0%L#t D'0P!6RO|l:Q<TxR(.0)r39JQ^AA0e.Q$C"edݺI$6JS(& + M)P@(ra(2POB@LM))p(;S(>R"Js)(\p=Q(pADOKH@D.pR0!a$ HBSBQ("|)IvQ"!"A*4+U 5W!$ +m)Bs)&DJ%("PșKvG("R;&Q"R"R*J*\eS`$Ge$7t("R.a !&LRPDL I +J3)@;&d +wH쓂&NB@BP聸L D Di&wHvLȄ(A2LCtCvRA0' H S@0t 2@2LnȒQ)!9"!(Ԝ D5J0N;57ACpzJvtD Dx(Ӻ +)ZHHI %C +*p#s*%-(NP7@>M3MۦiS&A2a"PD"HȔB!t M(̡ +MHNaJKtĔR Dn(u"%F vJ!@sa 0G(JJ"a(B8@"Je5upQ!8D#ADTFC"e$ ' A`)JyAJRpBM-))Ġ (PA (;Ȅ9DJn;tHH& +a҂e"i4nO%HI!SHn@I9_ ‰0JFt+ŁNE'pLlaJR&邈7DB + +&R'G;P(J&7O atJD P +2BCD%) J8G((2g~A(vKB9LG!0%>;ۣ(BiPS rJ@ 2) *PH6ʒGt D$e8KD @HN!.P\M$%e#D'@'Q"Դ(0L샾 ӉDB&R1Z9IR;$Jh B H8 +)g"JS ԩ8^gxKN!0wAR Q;)pP6t&SAJP-KL(LPwD"B z"!S &6@Q0QaB"vDABBgtp@e;ɕ S"PSI>Eɑ +!8@ MyLG)D"%dD&A0"|҉ +A2đPD$DJ!2dBE.S^hn )zIPPQ@Jun8=GnLJ! B"P 2 UέFCG)$px)@)@bBȉABQ))Ԏd%F0^nIFMi98S"; l9AA_ (IQ!DTe>SaH3^H S)(iFG  MRKNSf-^+٧Q11;*k<ɉ\yLI5wgS\-$}g\f+x Fd!KI*3KfAaE`=ioݱH"; A*7?zk؟w] 9LrGa-Mq{a'[>x+J +S "P + G PsaE J 'GdTIYjlRfs+AlrUKtlĻ_]4|xHSQ-!HPiC\x!73WRcͨ@6-wD3LHYloo[5NTfV +nʮ UWck71+hw1ښ]"|?ҽ|F=, }GF:uՃ"`s(=i@>S-PɁڕ2`H y*Eز9V%BѮ ׯjHV(s%On҃-H]#nvap}B\I!jUm v\oMw쐺1jTƭXj55qzoä =D^$:f3nhYP^ ykm؝fS-@1tIIi5E\=d2^;P5aw+;B.#5gOk[>{|՛NXn A ߢԃ{Q*x ӦF>3VT̶][>zU7}eLO}Yڎ1kI mTh`y/MV/m;w+w ܯpwvG1Uq +MgoZv߅ə+Vo.7VwCjWmj:X(mp*0i(a߼4_̖؝vx'vcW>`XS>}V@FaJeD' 0' _ HH% +Mܮ8n{F`&Hm`L J%0P +a(;)3b> D?~lvV+6* +TZK$ج2zM[Y_e80J.v11Vc47ki})Uw}uץPQ:֘ uN+.U[\VukE{]Y,YXcc-noPݜo0JUwdl=m>pZ~RƦĭ6ݗfVRns^([{Yo^*Ѫ`>7{;DZ_`CƘhC@v䮙;ZrAIx9Ykt糿t=X+{j[\T%rf;.pkZW]Kt '>}:|"6qñ؆#R]= q>ki^fg4iHܮŮzTn*ҬCCV0;LMJU0Ir tixV9G~1Htզ.cW]\x®os~ +Z$8n)w]6Uwٟe}kmMʱ@ |e{PA<#/P9ڻ'1wT*ܯ uR΍N Z^ky$zhөAť1gFIů7JpI@i y>e|NE󰐺f\rl5X\Qkiܯ_g؅LB8ڞ$ p;7u͍zlqkGi#dzi[W3Z$DyGqmZ-[)w!$+%Fj&vL\;OīZVS4}k3d*(bìjbw..%' .]U^RKD\v5(WAw .yl^?{-U|۴u*ȫW'lu+:yg0<kg]sXt16;UmGTd^ ;x|a\gl}-}?r{^|YS[Fia'uk_]jӬK\w +Iusމ?j8•$/P+SA=e+/kM;[ܨU7T;Jnk|5DbmQJʥGpڏ?!*-g9>!vIC \Օ3,40DՍT}.A@_kIi@խ>zV_,ÅkJnѿ>K-[z{G6i})0݃@yl"EH/#+7vqdAWI̓\ݛ +f'rU67lӦTIێ遍h Ӧ=k{mۋS S$oh;Be45h⡔r]Z{h2^ .Ѹ&.mhN9Ӊ7+Ǖ-0* ]ZM`p4k֙h$N,!kD)wVw"ڵQY+ +{wwNI^ZVޣ]l530Qu +%y AamBâ gNݳnF 6 wekS4{pS4&v]uI('L;<,֫ZM:o00LBgdAZ;'Y4S,vڜ=LʸE*702`Fpb=VTwat-f#9U]-sqbj]L/6Lnb7֞mromTk^ƒ vx16ZMPI̥DJQ(-C B) P&PBCdpN ̯b%d&!2|n%St@B&%*`X\,eG"cIz1*۵kN8>lYؓ6顥G.4ǥӼ]$xBظ+b~C9{* +e~Vc2ӬZǖ8Kx=f*v74ay2 rȸQ\dq1kmiѠIF~aVe[GW޽ [v?&g޵.|dJFN1nO~V?V5WwԪg^ѦڳOS-v=oq655\7qOFYi2C ll2顿@ fK1Q?BؕCU7s!YlV͇$Y#qLTG>wT+b?!+^Aαc)QF7>Uy +gR֥^Ϊ@ٯ [Wpi$@ܷ;[8kۦ)fb*2#W˜%i3y +XMpXf&f+:eB^ؙ\Jȏ[ ?EʆJgѸ'2Jߪz !{{J>uP~.7?O<^*j'iiVtTCϒbfơ^}?|T/2&ˎ)])kbzt=Fyb&VGksCTjOX$%U,D4xz:ָ}\7vXqjg7ѰF`[1~9YAhZv!N*QZrTX#2Z}k k[bVy+DհΆJ2MAqcD`JѥCT@]ӷklOkSV +c:HuJ魪HpCp`Ud̙ԯ5+돿5i{oph=^?!ֶj "cni[bٍiSB1{_UJ6d}W %Zt)kL;GMҧXXSWl G輘{Vi},0ִ>KCܼp$!|R]|5}xF'\wU5x}"^dB)^އ q{a\2γuT{go*Xצ lC@^N̮W=$54Zg6U`?g +?k6YѿT֒J-&v\],AkQݷZ%g{0YJų$Or!is(+J.4̬\pv0 {\*G^x-vY)  ʰ(]۵TxM9Ll8@BɄӉJa&(P +d@C],U+^8 Z+FM pFS4*Ƣ}Sϝ\hQco& +bkW4o@e< H26$#zYJ;ӸJ, +zos۪sYTU 4ۯFW߇ZӡTz@^Lە2^\Qݧ*b ԟįnKZyUpzhNLƲzCcX%lzѭ +!t]:wJah^^jEҬ$$.XZx*`IV[zB^QXS 泴0+IR8bʗN3!;a: +th -x< ClIi5,VUp[@3^|т\xCl6Vzmuff@^5|eL^?6{AN޴xKiZ&]΢zi[Sc%Yܦά\jUvK2eZxq,Uk2-[R)JU})©8Y߀Gw=7zӤ<- ZTb8W<ה r4CY܍# ++`#/4jytUFeOJh<~ Bkuw3p͘ +;h,he?ǒ2,\rr~+ŌxoKkMA-U]ZɘInˌ}aG!gI/4-6S˜(Q>˔.j_5ľ ³K8]s*4@sL/E|JX<>PЅ:6o{T8U-{xsNlJqq`;< Jэe>P毬yHpLo(7sˎ?p*Wv{|X8j?j-, 8QU"v*6@=GQ-O.yoZ+KFZ0Q4oX7c9PهS)lwj֚UZЬf L%VwTƖvps0 +8mavQxꅧ`HZyDGܳWZܸnLX`n +rX㻏upZXeJ]LLɕId|B8AVΠdPT6:'L|,)RhkG@8]j d[YKˁ$Jðxu>搆Hk!P&vDD 2Es%Fe Jmi5qR +HN! BRB&9DB9"Q|$DLpG !2a giLlS.)(ȔB&PJdB 2yHrG;R邉ÈIQ)I';!-^(C)sfuiFi:-t4 ^e42 *|*ƈIeVD=VdG]=䴖l`HicFvjE{ 'ՙq%AHz|T60%E>RG(D(tp lR' )D !P6@(L)D"a"N;Gcm .JcdAD"RDTe&PL A@ߵrem չ)7Oge)"L A2a!%cu B*$wA"MO/.^]L2dU*'tM$!9!>PH )L& 0Ow#}ɂ6@pQJ pDa< H N7QKJPQ +EBE=PQRQ>0%EJG) Jd$H R *'dB! +Zz}TdJ0%=3 oDeʔJ8FJ"\LBkl!492HDB%BL!%y +we̦@/Da(& Hx3K ޺;ep;'! &;nbص<&Wf޻nڭ^;QA(M2T15:ͧ܄;HWlLF5`#L0dl9I&8T-/Yx򓃛1#ԪCcVSeE; ۪&2 Ja2 I3%&D/ wQ*))(rȯ6 +i?Ub7Hp&"N!$L2H'!dr-$D8; qt'I|+[&u:tD'oP4i̐Ɂʐ"~HpSI͞7Zw]ĩ]Y5LF{05)Q {E2R4P "mld' WQi1C +FMS'P-1VD5¨ԧE@Ѩ׫ABAB#dXBE 4tu3H&iQR-쬏h,[A[:}AAjiHI{!?`A>%x3 GPUkK<;{<}yU'ҳwP>xZA:e"~IiQy }QM¨=x=LM*ޗI'ܮOxI;qRin +A⠖G;!ިHĝheats:uAˑHAcI&Lcf]v5R:E!m0 O+z2|f VԯWyǴLDbm\%vUƦ88x> C\ +_=;WF!G }ѱ:jkO;*Wi=;Z[@ky ovawbWsL^gbtZBK=ٞ>ej.qoE^[P.`^bT ՘yE~`'-0y +lF.SDB!2!"e   +$J(!$"a?UHHD%0-)2G&%ʖDE9e2m.e%Of4ZT-V|qzW>}WҘ2[DG| ^׳5 `ǍFjڔpkgj@>0f7U:`$8>Kђ3 J/m[*l2\RgaaS&齷R]Wk*v*]:~9ɸEcpkS/(2WwC@?U}ږ=ݕծ=@^z]UOI>G+\K:s-91Գu<>9N|!O*cU +tW g6$ '0y.RA5`,(];^F>l2Nⳮi$*]fN*+26'ܸvKmZ~0Ɲ[EhlD{wE4;a+n1Nz̷O-#i Fv#kq`: '6RצjԻ-߆Vv{ KGRݔF3-Mؓ)\hh&LHr.3AyaGtc%OwY]656wuevvjTy;UÙZ`kcImߢե5͘>9Y -6xIkdUm-ؕfu0dKs}ӆ?oO0G:,mͻ).h +)ӳGOvN^?Ӌ +dN7.1|`ӫhZL/hA6ەwtkS6ؼ=6rs^@ĒT`fGڍV&wG_%Oِ;oZV3;]@c gcnV2Hd +x!dʳ7KIz/f (.,Z$ZARP +Zt@ct:) +"a"w@Rb>g!JD1iBh9r0%H #LD“%bo/k+u:*}i N,.W6ZT5 C_oܶ1:UZk>R¼Ʋ]-WW5;Gv.}6 +e:gS``~m ?.x~qvbxQ/ 72ߍhgodwuYH0|`ĭ0exL[F{,i>'d#K:<a :cu/FtlxTxf阝ͻX`yxւ!6UCNm +P*21P:O<-fSۛ:g0 j k-~z u-Äǐ]E=v&ƶ?!u? jcN vz=:<>k|Qm+^޳Lԗ42f'W}ѶcUT1%#eeom\z#e2-|g +Ԯ]ȿ\M'ā[e4ON2EUUrfPUָ# +ʸvD8K +vo@x{M͊P>0vc/5b_էpӥǍ7jzA\3#m걟WjS &K`5^~ި~} +fQ]J=DTYk#PhάQ"zDoON45:` /Ohm>dzko}uҮx$;+<75&q^r٫jЫf׾ 080-)qcVcT~hp"*8; Κ:+0O%-c*״36,$Jݏx0x{)1Jt`ŵ/ʦ{K:-x="+K>.0 *lkuG84 +/fjx} 1X4>rVs=ak]AXbh-dth\ՙRv ɔvbR$ۭ!Ywxn;s%WK/bQQ` ݽE['u)3}P.;mꗲ;iR=w]nۅ*:ݢ*,}L 8 @0'4mpԽR&:zi2Λ*7bȅu0kFmPlyZLIӦ5OHzj6ɝF'/!ceŷ%YU j,mT(7$<°H-yD4KG^~ŵlJZP;Xp:j8$m?5}wA:,vt/.-R4fXV>?U_x<7Fov{K L* Tf WWjKT9f +gs`>ôN[cP.p&ڏ\7ֳi{z G+1{+K`څ'^Lv;[w}oq[$`%T5S׷5m}Hypi{H5碤ᷘmD[H]p3ǽ]#ܣpUq{vgs]+-4m?x"\ 2-T;u˳Qo<;ϼoi"=UZjXo&klj vظSQީ[!c3wVnѿ-8|aĮ5m0gl)y R9jd  Oa 0vQrJHJPMq[ #G꽄 R; +`06@#R"Qa4 +@B" &&c8ׯ;Ǟ5H Aa{Sh#@iV61"EF ~ ՘N͎ J+b@mk^(ʱ.wȁ 觙rq6操+Dk1eb$ψqSZmUI`ot[<Izv~ˋшmqlrGUi`m@ %mZuI'ē+˙2^_|Bl0eRejƹMkN阉$>>a{j:Q,x,YHlD΀v^ϭj:nc*˔7ӪhƘ;2Ϛ +x){L2gxqJ-dǒK %(@)8G) ĥ_ +ʉDRgt3|R)D*CdD)|&D2e e#qL lwDJ&B8OBU,ZqXjoOwVtvqHl+U ]F<P$~+ܔJwO8HԒA4v@ D'Q{5'&A@(G D L ґ ay<&*q(HnaHG +1)!ܨa"R(IRuCWQ*$Jdp19L#Je(;'a!rB! nA )(D&vADcEd{GtD TX 8KsHKJ`B&PwA(suv5sCIS!2Gb\@$R=z()D=n +,xxK;wԝD؈OAA2H L#rҔp82KSF`I$0#6 +1S}A $+C&jj8h$ i&[$Or$ ''8>9KkD`^W;M"t +-cg߹ Ul6J!B&P≔)rH%06DJ%")+Ōb5bc? +eΝ:ea0@` @!)J ߄'JP:gt­9~R(!9M1r"e>P& +pA2! U vUm͖]݊͟?Z&zyba7@0L]loi h9wle'wN?ZSxFZx _SU`+/F*qOzףƭkO;KR$&%+v` հ}lN@;qm;w{Ki{W: zެݾN'Q;|3sՉ=z' |\*Zx#햍5j-.YxդLwpR)UmjIoT,RR`,z\Ԙl'Aw}r#lYz^x!R2F<өak5'@\Ycj#G%l&Ō~zwsM?\ ǨUeC^!t +nPX$XF)O+2H˕ ~{XMF ;z8xy5TpSi1]|o;dA^[`tOw}:gZ[{]0Uu1ۂFK=g{-Ȧ&>*x6t?ڂ V<1giht,&1洘n#O`Dit*ڃRtb#r}~}sP: ^ ^[hQ;S{ kZl>6R2  [@^X@2LСO:MpezU(9Z[Pa;Sb|uomR> +̔X{Mw!yqRҸ&D_\n&I$nT+tS V:X.9/ce7ToncH0 +{?}':ݦVZ;ne6YiGP;Z6*Lzo{e&D}W~+y^ݸ-t~-̒$ AmYe>1 iᔲUKzuxX,ہbދGjUIoN%z"kץeMf6L1S3s택QqfvPW]3}pג)1@;ȶ΢۷Lٝ+[ݠ=Oi\g3|Lѳ?{ N P=jo!VWg8I^{,}:!Ogs +b.2#-v;#G<'&؍œ6}`:˔q]TxH5ӵ;fw@?Xe"ڭG[\ܸIcl&YPL0z8YbXeXAt`zVmC >^,qR%YYݹ-}W ~ؽ:uCLyn8UuzH$me0G`Ri0@W-Jj}4 v@\Vxs?0l>6k}  + M<ܪ=Zj=K1}h\Um-{-,q| +wPV"~ʿ%3/_Hu.TSpXxd-_lgT qOc;,'fJB-n G+ove<4˅m8r˳ +Bv B'rn4FyR/%,S-4Pc[ZxaY|Gp}.7JY_WZTG@Ԭ;Ѽ#S)JXm] ;m`O{-(è1ʘcseJ\Z5@|5AZPZc0 ڝrl!@(8pLRՅ0O/ǺUn[RizMBK VXn LUIUXnЦi|Xj7} +[^w_]S?i쎺TaEOo5+Hm͝.-B9Ty&oTLrGAUB٧׸phq{K7 8B[ˣchEm0~k 6ҮΨM/|2J #-*Uv{Aò6[6̬V ce`.UYkCmY?)к&;_Nۢ'V>+͓jZ\:\}0BHYouAQ<6<-=z2ޥZ=BG Wa5.!^H=@'r}J,9mV]Q4P-"az{G:n,V48:ҹ,y_#5x=h鳿׿~UڕF̉vex6l4ϳ> WzkTRƪj LeGu=LFu/bM5^pDLjTpM%P9[v:7_2'.\=[~xq˜=z!dYLEf1lA]3yb;0tz`'q_ KJ+ÏepZk@6;/h.]Eĭ? 4i{}v˄K,:}Ǚ3=;zE +N>^9Vz{>5'!E5q*̭JGE7%-7~m18Yiv{I:ncY؝Zvx{:hc9uzAxϚ9ɬdzUm]y^*Z*߼h-x>c|ĿGRz9gfb=td¾ޥ[[?XiĪo-ղh%ps}W8^~ƲC@֝R +Ou{wHi hWy)¥ eڌZd8UO4s)Cv3`W-u]l@I GB%MeV-w xOݿRŮ lAߢx\xrLGJakNz޴ +(4\шS5Tcw%䱽c`1§x>heLxz֝NdǾA'n(`m'{o23\. '8-JUiUJ1iڽح +@h|־˾-ٝhmF5#Uedˊsjecc966tMM +,:ڌ IY窘s 5;A + B3M:ll 䮸[+ja=z!n1ڎSpPm:.$tkƖ"I>`u1kVB_L`69X&qwkܰ~%X>¡ŅƓ]8ZlI4 %¡vFS<}a,xo$HWh/m:M.wx v^Sn3fzGb1|=٭c6>êX\88_E"Jf>{ji,dI ־'oe+4Ty2xxj>j۽)b-(u::s0nX:΋u^̻AֶiC<#ԩӸ :@p,R58^Lc+?pږ5ӕe|sVjSIʖeue沟wMaӽɵjaek@cdgZYӤCP3Cy/MFTh,4 & r6ҭ>l2+:eI\w޽8>"!u[\Uk63m.8^ginXۤ}aU,]^L켸N?iU\.ZBL<|U ̝:|h,x{;-!xL +*ZYV4=W#fK iECﰺWeZfZ|wXqq%Oޕ&k?]&TX{oȶVNHI+YK,YRhk|N ^]Sky065isH]YRx7 iUuÍGQiw/EFႋCx^PiotZ #e\ܯhll4i{P6Jb4cYס8H<­ukY>AYh ph$䁹N. =ĎRulDy%kAg`=:鵙꾤=BI>!W\cIX"TmRG*Nh'T ?4È\2unVh1Ā H@*i洟*s?'oS?υ0@yL(|`OHqx.lfZփR&wHNɔ%2S&D#2HyPBzue ] bPz\!.C^R. ` =koai9-ezu_thL:(i D&LQ@Az H@&RԃQ"RrGuT&PMp4h(&HJS;& %J`DtJiD +A2nDe LB"S na)A@2%0vAG)Bct9"!t)Z9i5=:L!&ɔD& $P)(;%gtRPPPPv@FG(%2z( rS"R&LlD&Ccr2vKD!"%L +QPwG! )$) A(NP[%.%("RA@t"R&Pɔ(#aDK D"R@jijK$ ;uH&Qhis:?5 P7L#)Hn6LJ9H1i;dJGH9"eH)Jre9@)D"e>vm*17輟5s>h5eZni#/3xtc@!zROW)[]ݶD#QG/>#SÙ:Xuۖ6 |xq% 뚓1m?fO+B|8n\m_\?#ʵ BҥrTYC2}*9{uz2$\37V2 L+D &/K{XxEFO^WWkAh7U@F ^T4#pťsa Q7H)S -!eIY1Eu).ۤ- 2O%RJGEcrmlIh++c5{F)DU{wIH6S %(#t&ȄL% (Ln+߄]PBG(:x'ˢBPRJ8O& %mPJa S"Js]XZv [S{VI6W+psPqi׸Ω뗳5,x<N~w6-ؖ4>*q]A[H԰wݤo'0ivN\[,d82$֓R{gP#%W +el@)s@H gxWɇHs0վv9GâаjU΃%ApiW֗`Hc!xqlm_~ww V?K~k}Q6ګi`ɎUnЯ]Mtlzhpx;dsQ^0׶ /NTw6j.{$笫 ?Iiq{޼/eZP 3hC&ga|PenL%5aC6Z{(SDccge>ӿ0Pb]OB qUg]jB_H4*c|RhJYg-(dtLՎ~#Ϫ~{z:7{nna]tK:*][iq=U'9jTcץLen>}v-f 5+T>>j2bp4DXřyo鴷ic7xrF7n4C!lPݠWuKzTuUc J|y=E' gI[GAp@#~BgTWP6qMX6 ݯT[niWb8&; e:d !ٞ1[Whmzx5 {l\?x})c7s[Vٌ|GvH5Q?{.1*"Ϩds^E4vUqm%Su T6I)鉅ْ;B\:`gc/MȤX*O[יSl UkGSUtYFDq|F8èiI^<'co/jֱcZA%hWVϯ~Q@lo m^fb}%Eݬ ^֬6%p>q+kP?Yֵ){x6)R]0s#)c`#s~%y.)R*ҬbcqheUj>Tx{܆<%َet"CS5^}c$2xo5W; {>j ̌UX֎ +`|:]/M>,e Gl#x+d5á;\u #G5H^'KX;ʸ:0[DԎ}ңq# / LRj s] +33%95(oTѥ$47 +?ѺJ޻JfߥE~I_:! 5qܳ[j;5;zbW|r)_Qd4 -fV_?aVOww6690{wu_NWpi'=Uõnḙ*l3,^_5n\ʏ;T\ Vڕ2p5ιakT޶Lfc^ڵZcr-{:7e疀H+W67jԀ "z.O|az2f7SQwBi#uW$[ ҔӔDn0L&*1 +%$QL*bJoL%HJA4%0DRߔ B + Bd l%|5j4%~~6#DX׷8{O.Un]Y%ˌ E& p'w@4plreaPeVdO2cuYS1*WVajCj $ L|W1\[UޝHoBbxZC}M\ 62Riק!W*'rH|h}*U- F66ptu.`+,ɇ4jz6Nm%Xie:'KqDg&b6\$8 |&߻n'h ٥鲴wJOq g8[oRQ'p#\fiV8#y76wn?d+m͛qxK vkdj6)Pzb|&L&V/ +BԬFC\U2C I;X]ѰpcCA݀͜'ZacIX2)5$&DNf4 $؂N%g>OlX!GuninYD.VO_[aev<V$۞xzOn$wV$vʋD +]:NU3I=q{2Z.kғDH#^,3n]WvSsLi{BvCZ=_d*su KA1=쟄Smih8 :YNfZ[0i x gjĊot9 GEcmF @c㲧Z *Z#q _)VDէT{D&GVXL9ƝV8"f=W7XU*?%VM$I+%闷wu7{Z'}߻K3䲝s0<]?į ]ϥOu6z&:s%_U*s 7x!rxM|.ν D +}mc^>˚^'%wPjlլ3Mߠ^,Pҵ)誻6)X1q'1;X=c5YQhU-/WHinɧiy!C-7{>P-wb{1:wL{ (Zt"S_V6_3;s1FިFΕӀ{@9HU4[i=`tV/2/ +u]sT3|F^l޻T :xibڽ_"䬵_ ^I =fxUݛ P;)5 f`n@x,>hP'$cqzkŚp iVĀ ;7u)vT7 ճr>Ӏf[[^-{z8Yk*[Rݼo5^A\PPT29":†>reTvP6ދk>ufg7߲~>ԮFq3Zf \(! pJrl)]>r< r]Aġ9I>i&М(M$B% @@ I0q1#bk:X~ű~nk=#lDP[&A HlN3yWY80K++Z[FඝZ`5giS͟Mꅻ|~j7dC+[j -kU'i+ww_VDd#y!#xG- HG1'jp:vAi`i7`;UDzifkU=w`{5{!tfwC[`gެvmnLRp}z_uJA_,S  ժ4䓺LJ-Gi:@>'oz "aPvQ^f·޳j^<͉Q0'c8u6鱮 ˃voJi]jeZ`4eQi)BcOjHUu3Ylq[SlG_'W'4G s/jZ0~4~gcƻ*$Cf͆Xp^.0} H7X$x +i3H"W,sMe&!uKuޭBUKMy^\[2WT4;nW>&b)Q2n$anWۨp${<+ ,c^z17ih1Bs \rJc[A0WR!;q?*/m/V_p^ u:lkϜn^*̉bw^<,mxhکhVyTS,-ip;Ȁ~eXgg yP|`3.yHB>r(ʯ]^KAss/-kk5&5Zd~¹XҸ{0j4 N Ԡl{. /iEwpNJ%ĵi x4cqff9s m;C4mLhsI| +:iRݺ4*e;5Po"w]/:͏5*yW_j-M%n,EզOW9ip^պh8.w]TiooTVpOYV6Z{Uq2d/f4ifoio^~lm=Kuԑ#M-Zm.=IܴvbxREN^?Uk_lNn\KK9)qq-u* ps<"+z4\)LtD}=@ԚFv=%z2FV/vX#%USkWKe~ %_fܴql{=Z;ophsL+UZN y3ֹU*V@x|TvX#0[ն5x;弿Zñ[obEZƷlhOeVfk'աLKpږ* +nlyd\"mUdן:qgPu!'ɟ5hciVwJ֭M=?jmsyrC*\_e{qvVc}{dn%V~#FMZ : с?;GpWi(0;M̮[IHcLz|+]ٜ>hh a^ |OoSk+SoIz0LqZ!oEU}l*ś41g9h̿Nyi83Y +.RR$͎dwMw ``@[M-kZC@?|d\ ʬPv#E &O[f;b4*g@\r:Ѷ`@|yBy'K 廼zjt̆7ǰxl|#İ֋jz^b@輴r-zWtH.Ǹ+ӗgMJfZru*Dj̳7X \W(0nYUyp2~fܴdSIj2PįuUͦ ,ejw7$[p:LA08Ae.S!ߑ +<( HvQ;nّ?UrH6IJa18L98p@rHGG)̤7@2bw?$HvZgU}*BCh*vTc{ nWf+yE;*<ӋuQ-^gZM>Ed> +}ZYy + nWc@{H]ڲFkv4`idN[EpxY{"Q.X]+{PD=eypXxwrFLu^|K/֦|x?5 vaJw?jcMYk5A$_2I,ICX GsjUn3&v^| /hD%;+fY0R! d\L /ܑ}$WFFf4<Pe-cA=@b^V4K: +!aϱ+vp}AI47R$H#Zր}J5L﷜ H8GBgt At +B IJz 0y OTJ5B QLUѨ T-RITB:H ` QRJ +&PP ;69) &6LGtBGtBQ %"a 2%JR;0!LBD +"Q% 7t0‰0PT!Ir3~6DJ +gdBi&Q)dpJ!8@!cdS|<'t(Gؓid5S.8!>"K(; OWN@ R;!.‹n|HDt&S.b6Dx"!( H HR2J^iB%4#hP S +!9%dQ;!ۦ 9!P !P6C#pD#%J8LI' M@L@#܈L H6R  D%a)DJLKBD$%i2 a2JRS&.w#)r rQLDy@Hl)L HkP"p%JB,7~G(O@ ̤s a"IA!JaG }Qj"/iS'd +2ӳ`]@ ճ%(.R"W;nUw eqx>!GˮQuwN,0bv/>'թڼ#daUfJWWl`$+B &BS)P6G(SHRJ&yL\ JxVA +3,1C'c԰JB% ^z[U<'])zE@H6u~$t}1K4oȕ+_c<.!"Q!TXuu0C$O0NTjZjLs+UPA(%dxwtx-i{AM ZF>r*aHx;/N\u:/sA'o\ׄVE>榍.O]8w`j#`7'ܡVh{n $&:fQqeZ@[<sTFEO;^#\ΉQјh[mD`eIl PT8uv}Hk~<+a,zDS߫F· YlXEod#\1 ٢q*qh+S2`G+?ن!p)6 Kq43v ?ou~.u *4 kfگ55Gq۫jtl Vm׬ DL)=|:f`r~?}mZ4mKF)j֮ll)ӝ̷R$r%^ϡZ:8iO<}Rmi6#r hUm) %I٦N ޛ>5|TrPTU7.# Շfk68i=/Vh˫{Zq#~af +)Kx(;9^*fhȕŅOy*GO.Q2ſ+-)a1@%bf!ҙ\9Vئ!uJ񤺖=VS'^֬c* +4XH{GukiUŗc[LMjKO Ut#rw];rzUqg]Ϧ&>mum/n=288u0CH^ j\]z. +*{0ݚ' є񊭭S +:R;*W.݇[<ӥJuщe{[\=ө7RͣwYV.crL?U=cZ| 8;r^ea-+ᦡKL ]qL[gXx-ظ`fzkq zKAD<ʄ֓$̙S`Yfegx'KZ`GE̘}|Π2L'wնx#岝gj]{ mrUcs_ {˘O*8eѽOy$ezx/xX©;\;޽mW3 +sEŎ{$sލFz!ڏ>I$v9 ]MOZ2L7 +ʔӴhxd^}nZɁV7&y5qԙmDZ4W;.m+>̕,\`2cI\]c75+^Ȣ`L5W,h`ͣX'}8.gnN[2~괓(2eN +uI%yD˴נ3Z%ðx[{Ss&O r Nؠ6QlaߨPʊGtK3H쀘Hd"%Pr`JgeLB&A0,Nt?/ԫԮ]BOz/ЧJC Wֺ|g@q;'~=ziyzNec(Թ)i༃!m1Kv5J "lOKvҵ}`Pz.WQڦ' ?rm,ӻqn|y\RFQyicg8^ݫߧx>AmWXLR=;.Z|Ϣ執šw[BڃI+ݣK@I+iM͝N{V?j[pߠRXЏT;ܽsV͂+nANe Np:gn GN GDs.+^R_N9L.6}qTN%)hw}?T8. j#a?`h3.?x'BXb~U~ uw>hKU&c{_{GШP[4j~$-FYe3l]zzA=vhcE[:زt*]8Bd_[VQh'vz[gSɟrefT4vg{Qm\=oB3׶3̏];[ٖ>iEFq 3+g> +¬t X @w|#z;1?7+RBTq< * !XVF5չL6+g >{T3yq+Bc8[yg g +X&,ˎp>nj<载>0Pd/^w >AVʗ5@pt"-uy\ LO u}wM$[Kv1+)QG֫ś1Vm1.y&bޏmVz氐 g% ?zhYR3U6'98GrY[SX ՘Sa. B׸&s* ,@u0ZA"vFVH.m@Lt@^[~cC~~aؽIl}V樃IVmq[` B޴wDa$-U> {÷TZoJ;Uea}۔T#&7-/giaL+Eߢgk³?O +@i>֫i邏:/V1pi1+f5HcLyrrV;J֛5mk?wi;x岣o,NWф +8Bv}izc>Sp G{|ڷncgCI.aT+TUe74Ž~mpv2 Fęw;͍:'џTlV}~ kUϗD(Q;&BGt@B!dPJߍIH) +L@2TD'!B +;y"%) L&QadP7G I4XIثT}P-;TxtvLX1}!babkRg% y`'p=I[kF޵ݵiai`7iQ>S#<(q,Zw'+mK9|W:2XԨ!Hr}b-62*S.ҕ[oV J€uWp֓ ]:=j :=|ٕ$arֳ U1< E.*94`uWg]̀68hC7#}6T}b0ʔj;֏TO{(Z=i:;p:yޅK{|A/e14IeYߍa^89 #/^PtiisDyUc5jvi4z riuKG]: `A߈L}fs$7ObحhoQL|ks'y`Ɛ.-cZ ^E)*'հF޳Øb9 +agqʢqW,8.R>`5ŗ4'`N6? ]lS +5IN1i,ٻ`wV<mmo5AsLH䭮q˟A{jW i` H-YKʘc:Y*mS~x12kJW>I/w9 ɽ{Ȗ؂+u.puh0zx%!BrzzjseW7 ;h}zAd{j-yذ ʫ^ +t}6_Jpcͦ=au̸7i coe |9i4,)3xc*Z˫>_bX.NQ'oL`6mpy, f1MSn߱xq; a{iid/-ߨm3F]n:ֱ-"}X>J ˍ~uU%kot@:\DtPBv\ɗ[zv{b4ͽQ=rKqй{)Ws-RK9ܕ[qj:WR/2@v}JmW;*ɹtC`~{08an!u}.N.cXZG+ 1:&e+R;&JDRnB@J̨)At2vBaJ"S@ p()Q"Tp;AJ D76H768-p4< +$ H~jZb W{us0:(jA4='Ѫ9 Sh`;>ʇS|KD2 q JQkC8O lXQ  H1I4=BT x2Zu$`O)<[ԭSkOWPc=)6jhtLH7MB NV6<B-vַm2\;tHC@ܤ*S8 +N=@#C4b8"!&HO07Cw 0Dϊz 4 +eچ{*qOy!? xrؐ nR5jxȏT6RM'N'8J#LhfD qƕ:K^| \4ȄP{kMppA6΀x ]-د=)Fz8.wOkHYsj(M.t H#mi512#Tf>8(VC]-go¾eƕ:4^9h;=.sSD"Bkк=:s+jJ%zTmP*4 ,8j3pvE*.ՐjͶvnU+ [w)8= wx+G6GnT9f#H tXӾy:$;+J̰TpiVԫ >w~z-G +0t/.1#Ҫ P΍*: +8?Ӿ.%-k[l$w³-x.;ը-<*&"qsM-FVm)nO+FN?5pB)Htdp?Si'\\VV@ Fyj +)bEڣ|+cM${.Ѭڠ=Zx#G-iT%޸^D'\%R )S;̥D"vHC~8w OG(e@L' NP7DBCuyVa'):'eP.dA}weU)//p1' a,8l;SqZ貵@qh3Fc^lS1W8u[\0_e0>sUo][ Pdaͼ#,hwe:_^4ԩX \LS/Tִ9&F\b@עlg!ݭj08W.ui| =\^/k7lc(1U#޼W^i=ܵřQevk'u-U0m-aRLykq +l4%xRpPF%:}bOhkֵtટ.qj^.7itsaVf'*4^k;zm`Lx7eю,f>]5޵հDd+q&T@{gwe~ !m^f'=zia-ṅ0]a p콫TFP HZޫn{*fԦ"K4Hq? 5:KGg0 ikZ8xtê:; SLOhXr54%jc,m48Y-:JmVcKbLt^̹Wpj59 ËK8ĭUf3~9[mF];2C>^qb8gV{O#cU3RP|Z'Hgo&uP>j7{i/;t#*T }N?m]nWQWV5TuV܈Vk4~uhpH*|̍7u>.:Zݢ\. z:NV}gb*pN_ %,)kwdt+,m=2᥯cNDIgpLliSq:L˥:r;ZV޾mj&[lܬEmܝ.싀?ZePZ`Of }+j<8{ct=Ფ2ĩ׽j F ^_ҨX\w[bۊoJ`tCkIխ^U \;~fkșht K4u0vKzpmWZI#շhإBXmȒ9 ^ZSha?_QYgRFiy#_!Ŕ(Z>;<)̪H uʘ۱'5W1o}i5bz !ejm*HUcE &Pڴ:;Zk\tҰ”8U&È_=Q=]PsF2t8Gi57 oVgV– K MLX>2qnpK1&'V9c蔩`+ڸUm?e@D·_W\Pq!08]B˴pZTGv%>* ȶըVn^>+N2ue/<4 0+U.fŬi~J2w[4S Kv/&ukaT~fU Mc\]oʡ4lEr=vb/.hjZ֛ #~9“j޵6 'exMTƖ`wb-ct +[4j/v&ef2Z#t5>Zg,F(SDjqe +Wv? pW~:SB1ח}G8ⶬ}+2;ּj Hi +I}_gqMNۙX;n +Tii xH}w_9⸻i; BMctAs;v0߲E.®+aOK>C5Wp)Þ@0ZT>4ZO"@yN!1@ 9s- HZ]R,x$>W{ }ïm*׏Y;qLgw {WpChilgoRLx@럪E6%DW(/a{Pw;LJ!2uG)*S A#Eۨ(6Ql0|~ De`a Gjs[ddBLnm+ jt?%nk枏1§. vxuw<#pWz y6;*\ vir6ҳ`?>VoVӡWA<[Q{gZQ ݀hrKJuX]ױe-LB:^ق6udH"n\S/I5LJ*-y\\QcGrƲW\H+{0?PkH7]O.iWgڄڷ\Y>)1o/ٽp߯*=uh\>omMug?eǩY\:]m8+O.3A;媎@XkIXO]6٦4҈9mC=qWU ;ȷU}R7<=S,*r*+ ߪz`XX;.33/hKˋc}$ n&Zni'z֭FkSh$,\߂0 e-GvWc4t9uJ\V[5UaTl[K]} +L+=5uE>5 +bV># ZSXjhѤձ,Y}=):l\=8;ǚD|8qK9镧궵Fugfܵf~~^0Qٶno>q%m+VmـgƯjЂ& B]7E/|f JZچ{@- {Hz`vU$­4kvsu?Z\iiTUUh|U=|uZNtr!0;*WV[a #[Ԧ.n^,-Ø~6E06Ĝi˿eBݖ6(ڙ4z>}Z:Ŏhc9Rr= B:ͫT4qPqP쬮LT{I.lCelR9%J;[F:G h$.;*pw伽,rOOݻnźx=gQ'e*XW4*ljIlVYS}g icpؾaoCQd> +=46@*k/ v[ˏiBi?ݣN6IQ-m*SemC@`3"6 %sU35z]Uh6~UOCݘs+j}]OG,GgW[t<;OhNan D:?%tYмsa排^"N+1 D6q71N:F[m%ugUxsP|a.c+RXޢO[}_gx Y|vyt9հ5JX0gҐjUCAW 8nNA'ez2?ܼ0/B6+XyeV/e +LQ!@^nl]K̑ p80 bhi"FBaql`Uf fTax+;Um FO,g|F\@|pʔzczfPg\C|lDӥu[{o7V}qf.k+[CMG"IA:l,7x,/]hVj\iFO_j_pY%G5'_(Yi'U GE \JGbr!.QߨE'(r!M=D"a(MQ0&D'(M"MP@ (e^[V1;8Y=T1@mH^0gx| q\h{*{T+!s!qLӿ{3ՓlpPi$3Hyߕ[kڛjQ5i9ø$l3*֦iPdr`ʴ +hV-[Ilx>!`UĬ@px1qFNJ^f,Cxq'U8vh-m3`pc`xe|V;֞x-ܾݦ +w +83u459yuXѷ;rU# زT iЁ§ML[\۽fžǮ]7Kl<Vڥ&8@u<*˪-']qywVγC[L6䴀FPbI ?\aOal90W>PDkTҠ:k[j<ExW9ϢF\4BQU⋨/G$- u:W\i5z. %vpWY5f#O"S]gaHѠ..EwU6t$ivVXFޕ7sXb1k*٢\2։]t}&9i |tpjA<-v#e[ki r?Au֓>?_TX@BM&R#Tpg-T­6Gg]\2Ҭk&sİq:Wmlc@'oa06(RWezXѱX^ᤰNl +3.aTCO#q,lJo r3F Z޽6:dj3Z͸lNj@idߕ>qtF e@'ӦyO, Tv/>-[8x+}kf5V3;rlс@')|-U-jFL h {]=UupZ垎N!YdV֮zwUxf aLZOiBd+U{N.s.Wv(YsE.)BaxMԦ֝US(zDUrm;K$[ӯw[=Px qwsNM4'pV~Zu+bZ48k Mr6>Z\i˿zv9V΢ڌ_KCHM"NJ˹I95RsW`*ʌ\9Tȕa.}0}r 9FzZ>"%x0*>j50N8tKGgYj0w^D~6HW.<Y^+SH&V]\7{+TFҧY|D*ہS4ZA.\2n.Cut,FI2"O*voRy䰐>K(aN侧<^SjA˭)8TKhiSPƲJ(,'}EJ.~VRˍ!8L8ZbW;uw?rr;1Uo?I;x~Cw{{c殯}M%@\v}pDyatw4D6I>-S=oQrugw*ν4r >{>.נIT״^xkT9Usw~%yoE)C[pٳ3p4ݭHAV FA|Q[-:%èec)pNJaYEC㐼7y2u8'{^5m126]TȖvD&>Jh[ Jȹԛ1) 6(HGee(WߕQ;(D#6E^a |$Ȕp%07t 6R@8D5$DϊG}J 3ffqq^u;w{L`8{TC;2ޟ&jQH< R[%6ԃOAVVOQH<-d璀<$ &y/.@02Kj!)GQA)G5D%HD})B%"A..2R9);D  pL%#@ +DJA2J8B +ȉCwR JPSHA "gݺRS%6DJ\DPL )rzdLl&!ۄI>0%9@2(A*"uk7 +9DlBadr!.JdGtJɯߝ@.IP}>|HRD4J%Hl(0!9QR(&( r0HP +Hd@hBS() ;% ("S'dLilBrDnPA(PPwM(r@$z|)LhG D$QL)熂`I%NjM p(s\2H]i%O'0I^2'6Hv]bPJ) q{NMDN%$sn;nUyI'Yf|YƝD |կ .7m6c >6Sݏy^S)A0* 4qW>"fGXJmi`$;/6 )zE)Iy{Jeu&0pG}J4UC@>cE4@j"=d_2ƙT[|쮛zZORрR9hD@R n+qkMI*)fJAa|&NTAD9V  +6L!'D8G((7d#ߝQ'QQN!)<%ABdBi̠"SBS)@("P + RsJ +Er2UH޼-%փ6UFWmТ}7qm·k XG)4&dIjPL09Fl&JN'n*GC^F[yv lK#c|"ЧrDfP"S 'tHnvB\&*wWt+ҤDQUپ EΦ٭c@+\״(|jLq_f[R8xS=/=3{\]h=$87 H09(p)S-쥤&&;'DD&}^Hd}4Jmd𣭾p Y;˗SYGS: > +^ReM4ӪwRx:ui>]45:$B*M!A څwP||ƛ%9^caj2|5 ^jgҪS#Lkq 7;'[H |׆`ՙP^5zpx#gUX)Fxy.]oaHh ALjq7$a/LvA5Fa_u*:~ﱾ~+Z3֎s˻1 |ʹpJ b~Б!xsӻn~%Y_kcVφ.:q8N.i[:X\ڍXFgˮiR4ֵ<+Ձc4nӥ9u0x3RkyU?>ͻt"᯦kn`JXv/hd#9]msUmH 44nj2jzRFڃ 6k+2_wyVpTj?ޟnzhGu6:=n@c@- zn %) %ޑ%DH| _g쏢L# @@e>)p +'tQeJI 9c5MI.dL|UV\՝Q⛉fI=ʻ7uZ aL6_fRJInZwU=uUmJxoM:-.܍ggXm_^˴=O,nRCFل[ɄwnMSZ@pw"zh"ƥKyv2eZ6 O=L><{3tT~D X+\&^%YEAD=#x!^2e洲{c:ؽ B:*CK#B5UhvwV)֢5hVxiW1~4MG>*_ݴ\Ժ,!eb$m.S2&ʱc]U +^{̟wbqJ%&7"WǿPC!:f;}++ujy4COb$Kgl e;jnmӍF8nېv4fї7x%Un4 V8dK :؃$;NV[X앙jV{ky+Y֎$g{DDVz-q)@\neMi'xEn]J'CY;*W,ui^ޡHʲѱ.`e͈GYSuzWEVeB[6?w8yoⲙn/5..k88[aMv,.kSϽO:b]ZjtwP7 +6]JAX .0ONO-:{?b\*lsyY鲸+wS.hFcozָ,Pm:F*v|<~cٵ k pq؝iVFA q +V@#p ss"-#S}ȬCmfsaI|82:D'+]{C3]9"pkI#5ViE~bUoe^_8u婓0fiFZcó{J^Ni;$ y_ +\mE&m,-׮>@ޡNF@a`L |Q(q KƯ9~A} ծ/Zr'˘xUnwIZۓyguTni3uoaHhA-p:nyez{g0mdufi`*>D++%Sm#L< Nvrftv>eM~z-`Vl.SI[ z*BK̺dk]n/\Ӧ:;%r!AL5i--AF(bİڢRkOSBdkKXjn0TBX.ve\N7#`@鲫^٢ޝHVKhKx+#8zkbhPܽ@?.RKAQ.qd15q7ԼN! .:V8*PZt,1Ϊn-|½.=J>[,fc_A؅Qgyݤmu4բC f ٹyUQ)-M!&իw@ZZ_&@'Uhk/j@J68xݎ?jdo5% &On>8{ +]pw//j~K}_g;[jZ[L#>PRAKx^NM*A<dz77a1kz/cdtؓb޳M6+}f/ Q{{FRg=nמhl9ʙc]OPȵ^Ǝ0w^k5H ʇ1f avd0yD}]pOuqR q7votL;w׼%:oZ.'v]zTTաYCٶýi{@nlv59 "%pv׹PkmO|Xt^_xZxn(+ܴl ?5h}3]ͥ"7tʗm߲vuW4+YWe%sFUxv g1xM +\No"l9֘mgA:@K$X~_@r`|;MpeZ."bwfjfв̇{v-)jTi$ynu/IǺ ٦#N\[VpcB}cy{LTzGPc$qMX|Y-Q?m,]kuVͽQ wgK;*F"ǼUzprK Y~_뻷u(~Ș0; :M z3>J-Np{󍘲n?A"%Ye+R#!|(mX]z rc%Ϲ}qh0;- œ]<&ݾ 6"|W-4[+u~wK `<VayN:pȷW$Ry=OOx;7?^O/+R\p9ǚ9ޕG`WaƟR^>aR,KeK+cg1;&BuqkuUf|ktZZO%Kf#ݾP[U.Ow[f^: 0Imn{\ex7M=ޢX$nWUqz[/>xmo-+4;0s*4Qִ$rUOeBkXT.q W-n⣋ Y:7gjuJ @ǰI}ALI;y+`^+(pMd6Qin%vӕdʕ{壃2|Z}Z@05m*,`햹#Wu#J֣\=؍.ԩ:-A1Tܯ3.f#iMeN5{@\3Cvf ,]-M1ZuxY5=w't&\Ms8`29;}JLʿXGkf[h >gh6CJMIA Q;RyQ"PvQQ)r%C[I򀉄pNS )HNaJD(Ln(@#ceAe]ҿk\b{q:OD{gmF>LX/5gUԫ p/hpidOUnsKavBᒲJZBnW>i$nte}5AΰY 8)%xC-a?d{cj H'~VJU<^x=AVb[V'IqxWs޸:CCxj3vWէj+Sya.PYM-"eЫ#2V]~5y⭱!'[Tz8+5C Ű={ ++eGau˅K༹-\VVSubWr8W+ᗔwZ{L*//{U Rq$jJkL6Pkܴ8m-eoJ9ega\zqk)1oX[8 `P8K\#c;8}Vn$Wk\q}YX@vr6֧wY7\aW]rWA ?bQɷ8Cl+ĝ/Yd6x~Gd˔C^tâvQ_X Z,F iQ<,q8 qay1ⰽkTg"> LL^\W R6x<޳Բ͠)\KO ۆ^5$V[TA8wR̙b=IJ}d{㺫vS[be<2­!궛ܬN՗V]F$ `.<}M- p;{ܹK5$Ñ%V`>蓷6pnX=ٶmZO/VH1Cݣ.hn;VcM-HeJa ia (=Ox1̡CwzeALد-ϭzT$ 0)U1oK<eGd|^?S_%&˴q +lPQﲱl6#`m*퍊'Q%é,k49=(v}gHAI%•>WKU1ߙU.kx5$-"#x.fO osDidNۯ&+qS1RrŶuQd;~e{o|Ju4?U +(7Nb9NwyRy#iRKHiGycJV0FǍ]YLSD4Ev\7C6^ lileD^,K`qz2uQ`Ǫ]ZAxJ۴S`Ѱ1{R`wkB2a}^T@h` 8\7զ|HmhACGԀCl]wMrh @8΍hZ`nQZݗMFT-)[)kA]Ssѻ:Si>$ ]= +hfoڣEQFˍ;SMwJ2, 9%=ܕm ( J&SKA +>I) P +|$Q@z-IA2e"J"R4L"e*6cp\.LP!+D)̠ @0u0;zMcrMd%!(hF"P6\SKfH䮨ԁp2gdD"|L#' Ap!Je$vL66L5)A%F(P P)DD9DJ%0RJ!DrA0 LA;B + /pQ)JDBs;TI,>K@1J!0DB`$ +rMB@&7AQsdI"~J@ A) Dun&SҀa) JBa( Ӕ@D\lPB8J%B` p&6L6Na(;(}>e@( P2P&G( @!)LBڼxn1GܻWva%{ș@MJQ(RгH`$́-h$yXJgd<#R锸@)$6AN1OD")D RԉpaDlNQ)!tC$iA B&wQaQG)JD;x.t)a) "%dh"S;$D %0Gt4 1{vŲDZʘ;A|$J5H5G;&nvzȄ<^̄DoǢ`Oɷ q|DLE7 +SLD)="LyoUu(6$=smV"T4Vi{N̄ M q1iDOê{$8P`DH"4ljlHҀ'aQl? s'AD$*{$"V;Xծålo݈RUOEj R||02'M̍ǢUeب?7&N¼3"nXNm BWb 5kORAXk:{@'}Ty)wzɑ5 +t=>]Kd|bX^nG">k_#_5 3 +>bP--p%{n a;].^XxY`>%rj5K-TpkgcE@ g*o\D;2VmwtjTǻEP L#5S<9J8r/fQur> 01K-mWi/0zp ay0V(R`[J.k8H?H ΖVX!O aXIUvu<DV1G +t5?HHTpk 4֐C;8@^gST{H{\xst֦A_99ێΪahVxU)཰i.nj^`=\M޵:5` y3x0A|tpg +Nw fxms7=}xqY=tKDqTw]fEzy c11f`Tz0ձvoQ,uj/0.5Og{Gȃ> +άz-~')]Qu"wG{7cOUD 1Aҙ'R"P &"$Gtr"Q)I04D 쉔:&Q0<F\JȔ nSHDJ(0 FJ%Q) ޓ 8Gd rBI[t#\I@@D!4@.PD!)N' d'$g{i^$r9_]uhi9Xi:́28U:^oFW!UvqqTK>vx2Oۮ0 ?%[ei LH&xz .)h$0${Ѫ%"x~#sO0c%S=ˋjHvod uصTJ%'m6KW{W3KK@6v3#wBJ7 %0]ʳ-k1!5\㳝U)`x*ouht^DW>Fj_.ywӪwpǟTNQ7sN$`eww_ÛREZbeۈbXَ`6ޣM ka̯gժ\kOmoeɸŞF\˪2gipE_,p؃YK5Qppx`Յu|Nx;:v ^T{ḓ]-_K. \ּvt1a{s?a=Ӈ| ZA0X$qv! /~ETmsU n5n!":q?wiP1ںm~MEcd?UDl%)Almf0sյqUa[KCg䒴n!iWP7l*, RiaxK KF6uZ=.N,~\LuquV?QYfrBIaV}|jAv02.:֛sq1zfMt97k=g}W..{%Z90FЭiH +b֮EW ZWuwnJK#i eL\Tv@'V4Z6ҫ*o .­K)d%02D$d 38G) NQ2ad!>2a Je!8Jnp=@D&DBGdS"& 7Aa 4Bq+޸(L(E%/6+\cHvh]> + r 6LlP)"S"!>PwDgtL ebb>7wЬWdm~xpۋ|]6np8KRhkOI#Uǵnҡ *魪#3Zڋ74.?bfl)Ś. m:cx'h͵/Xhyғjȸ. +z>=߫h>kj T3vㅌ1 ;v]MN}JqJ(nNp0Y*ƕJswLJٵm0X,{Ɏ`u3k=2KI$݌r꺥*X#zXx]F'^M +Ke޶Eq1`_Z[~{@Uk O-nnY g }XmyM9~A`pq[:T\41'v-[fOz Idǂ-˞B'UVzp1v~jxAT0 Ŋ:jzIG;zToE孪p;NFHWl\N+//kO@[3OvI?z˷;M !2Vo='Hq /&'omcPiQA>+i~޶Eb?~M\+ϯ8<ݶʮۤ8l Xk:zwr٢_ꎑēb7F l61^@*ϴo +ma[QdT@X\ڶk 7% WنXMs@ lIM C|'`[~+ocV3JXϮkԭMǼ +mU kF'ubV0^֙hlJkqvwi0MU}Өp|dϷib- 7~kՇZ6\س iۺַm*psğ5y5hJ 5.yГ9IkxfXtZP?m,4Kj6hWn& +͖6tf=tIh^ܵuRU^d5EfӤ֮2$@8o麣j82I#mm:ժ}wGXW!fF5ӭ"Jւ@t¾Y΋:ZިӼOU'Z]e6q爞w!{30 t MxcuOn +vo8O.v&Z}$Cc)X2W`gQPa5n&f!\e%ݷ;GuJ ۼ8y/gحjصQ@6XvԽe;j[@2ۆ~09@&f8]u$z!;YdmC&7^Ϝ[}s: z5sI] +.c5eD2SQ!J"SFaI(A0jD-rPPadJSt 0 lrB% ád$7BGdDBJ?z޻e!DHDyqQ,hXV4"Q%  Ln) p)"7Bd6@G6Ur<@UAU0>2]>Lvv퍥j.{\ j]&.͍"Swǀ~ +ևҷ+*6gpt+Ֆ2{pW:5+>e޽K`W{CP^tKï6S) j"'~G*,e +޸; ݏeQ/b&wW,˓ۋm*vl: 2snUf_)]I < 3*B9v=LReG^|qGSnI8OXe]CÎq vV"U]qgX }MͯUϪH<iZ +55 |vY50g _IΛٿTsI4#W.pvm|Wkn0jE˩? ^̱iEՋJϙ{Yq7ċu0UԱֆ\=ݑTˮixu򕢱hP&7d|LϚ~m m $zᆛʌ3􏼕21sEy܂ex KqItʶUM0^|؆OhYR-!eibm]x2 Н/Y|JCH +MIt Wm{o*|ij +>A ݥ;uZr0%{ܯ\ڱL'QM66EZm/hp#ek:miJU=kC@hAp4Ni-) :>0%uq{EQ8xhm hh<h@ 7"1LihxBCtKr!B&PJn @(@@2(dplD'SA(0RA2JDB%)!0%"a8J!6N"GTH_HlDwQ!#͉U J&hNa') nP2vM)DBs +SSH2gVvp0ֲDaH$B@' tbi;^h㰅"%.Q(B`J9D%(&!8P +re!P *kiqP>;O@0 J%1EQ'M }Ɇn'z@;!D% ((PDtGdt"e! @rG!;d!9 L @8p'|$ l")L02 + p !dB +e$A0 n r%ۧ)ȄD& %B DDa*DZa>PDR *$BEDHB߷Poo9I9Ja2P&S`J C<') +i)ʉ*^2D $D +:5 HJLd۞TM +CtraE#&` H!#(@ +(@C9A@ !(Pv@ ɍE @BnQnDJAR "e."SE!(Q2@0DB"RN6B yO"#t =S;"S!%&R&6AjLBQ ĠBe"28L @B +"Rrޝ>RHRDէo B\"e7@2 +@LD&7@D'5"%8ꀜ6G((@G(G(LJ%s(2(IS;"SG~;$D#pwLɔɍ@RHB!8J!)I'(@(G(!A%N%. +9GBq*'uNMaTNP$wL$P)P6B A(Bgtr;&A)7Hn &(KL&7A; PD @ DG)&rL((LoDB!0'T9ɂ +'0|G Jp=D ܑ0"IA($uhRM@ J8G ("q4JOrAB +" 6AA@(ItHA0PD&Q@2PSr% Pa!J HPwDJ"S\'S(&A("((D PD!%"P) Q(&L ) A8LlPR  (D%!8M(Ӓ۔%ЈM"evL5tD&T\SPLLq + nJq Da2LH*1R6_ߑ +$vH‰DB. 5$D)*Cd0Dd%4 n7FtA9@B9Hp%4ȔDL &8RHI2 $$v@GdȔtDT!B4Q("QS ̡zRH;G(OE#P(2a#&9NRSJ%7L"S)ߪ DN%9B`JENJgt@0%G9@I0CPA!8DJTD""aI)LN(;"%t +0 +N0AHB5Ik3 TID) L M0Pa @RBP;#  +D"%2DNF>iDqGnS(H%$䔐Q '2a%>)jRDwI$@&p2JHCS +1(@^LnHRD # P%'2>R (& z )DZIOM";Jd$D{ & +9KR;@O((d9)  i%=PJa@ 9Ja"TN)*%x*zIԙD%&"!0%&!Ie$Bq(LG(' p2EP8A CD @ G(;R"0eJ8CJ"J$!nAPJAD"J")G(HJa(L‘*)@LJa (&He>PQ0j`(LLHL$J|A(;$ ' @3GdQ)"CPJRLhL(B. lJgd!B\ݑ0DNaD'8AJa/   +*(>*RLAL D&(n O lL"R Z֨t{L'Qu Z9=2[P~V7Ebta/] pounV=A"y+! %ɍ0UN5pWwuI{/4>x hcE'$m!4S  *ͪNLDB 9ȈF@B@%&Q %$6LЉD(xNiQ((e$|$*%3&Q" ɑ)% D!r4\vHLL7QD"SLl 8LHLK"I)QvMCu) <2%q('P\(D(QLSL$D20vL%0_ L)D(݉-xr|8H2Pcd&HnJKHD'^hLdXF:;^>ŧjPAYl#q̝w8S{#Tw{l׌PFҵ.w6bOt{Hi:[m/#o?%b.Xu2 znʽƎ JU;A pmku  %U3M ԗTw oU=>љM\PIYax*>#@:Lw}^kkF$ 6 FhmH"$4@l2QsLe8/n}겧hQFVfjdjc]z +<4{GYU&jѨLyo4©9{\ZX$ $qvWiUzՁ|֗δpʞֺ^`AmQQVâ"R8%2(vȉ@ $J e)7dЉH@K8'> +$(%"e PIQclJ +Ea#Da3II;'ESI +Ce$SH4 ! 6D9@"a2`a0!4rPwK(@G"!4; #z@"26DBa L' #L $A+ .BGeB]s=ҬN'(!29N%89BiڜPBLl) \[sL0}T;$YG6U:EvLcA%yn[bl&:H$zMSp4"!|ʍ8Jə^T{Oj8cϠ55-;AV+δ &P7Al@2@NSS 00J%6N@LlLW+_:Ϸ ĘOi64Ơ>L*lfYLz]˻ƭ#W9K}V2 ך;@^q" AZd'Z(q!RdO/}.S8G!#gd2)$ +$(;(ltQ(t@G')SD LA>"%"Ri"(! e2%("QDBCtD&D@! D'Gt(L"a D !(() %PJe-H(A TARLRT!deB`$q))%0Bze!&7:8DJ9LKpM !PP7D&Q "a8)D% '@ rgtD(A A( !> pvCD + _(GuED6RxܮhS;&L!>L@t 62 "@"4 )AJ%3@hGH;R&v@( %Ȕ ;$wM'n&vHL6Q.P&PP7DȉG(!.S( I3JatQ#T AHD$DH%t! |QD#E2wD"S%.J%>I.)JL!#"RGdȔ Bgt 2aD)P%4"P\&;& lPL%$S@(&OHDBGe yLw@߽\)!"a9B&7N%4nQtL!4'; R!%)HHJ@22eD $Dz#dp.Q(G H@ '2G(90!&DP BSM(% a( Q)nB 9CL'Q(PiD'\(!2C@) @(Q(&P7@;& +@4QKLlSG%2!S5ӺB&7@)ĠHHH jD)JJ%Dv^[7Y %JJ$i)@ e0e#T'(DJ!! !*1(NQ0 (0Ll)$"D줢&e |S%)A IܦwG)JrJNB&P DBDJ ("2!"6DB +SA0J.P&P "i $x~H(Lrtʤ$|b@ղBrXr.tdB4"2B;%0&<&vANI/R_Eڃ]{"7A ( ^ 7=4;Jr^q5=P9w!O kvvMckS2׉qq8Ku<6xOxpi;q8?5vd[jl|USLeqm;fZg"4Q +HL,%-쪛P6 G:jZb\tY/63i.NX8Vol}"S)I(RkSiD" LHJ "@B]a(d D!'D&@HD0P& +QH :VO;*qև +$ϸ-5q +me[`κ`4AyVvw*i q Hrݐ%N!(#܂<|(Al RBSJDpQTRkLv +-fcԍZYJ@'J9šc6 +)Jo}4 ʺA6e]}栏!&HxAnP}Y[mвiu$@=~ N$dO?H *1PSu1;I9aYW0kn}}ҕj\IVNa Ͻ0|sz'ݞAyBDxuDAT\'aL2}n=Q8sI*Dέ({oh> .!ZA >r^-BT+zn!L.tT5rNv[UKDs=< [wݸ;I7C:jkO;l88x\+U {@N瞊Luv*G>e{qv^ KHvwȮ,=U]WRͶk6^I {\k2MgzF +6؛;K {ٰժCZIg]=>ӈ :~kAev +ԜpGUc p]SX$;lQK^ sqU5j-l+4{D&Zǖ~iүJ$4ǹwA F&z-FTIӬ֙M!Ԍ꼴{H/1öpjqyql^OP7JGu*gu/ZΦ;yqXE㪝Crw;Boh@I㳜 nt*3fo{BA&>o%oy2{jZ+9`$0#['6i_ԭAڨO',1,MƘ]ߥ@ ^E8&I +b%I}>jƛ4)StnGEyjo]A8xY6UXaMDxjb^eVd7oVy#kD ld WVb eB6q{n-%unY^FT^TӺmZ.s=r7+s:'ԾsIi.qY>6VB$4ē ;sܲ¥:2}Z3긒l"=Xy%Lf3W}ԙ衉U.*UCq=e^]sR4?M`KMwR]FcLھA!~ `z~_mkTݵ7լYI5W[/ êT5)Vi#Wwvšjo~Wgu 5~D'LGdLrygskwA>#e닼F•B֗N$Z Beh.)iR^{{DG˪9ؕ1syQHt5GO/ToY{uSq~ OXmce76ΣPp3a8GbF+:ǺL֩>vxU#^Mk}w7iįeV]פSLH=G 0f۳^9.azW{=Gĭ`DvG]0Vcpܮqn5ƗCcU졀Ա| {ZHz=OT=Vke쏵yPc:^6+L_6i#ꪰ-..n0f-sZK :/+؅/Ep4n6sA0z501{A^ 9׬|7k4p82&gSvm@ [`T|No'IɀA^0-Z 嵻1Kn܃o+7fJQ]>v~ؾ"`qU#Zlׁ[άShA8Uapas>XZ א+kvTh}ZQ/NkҽoaVV`0^H-Cg4: I2}jk_^jA0=Vwksoin},TPSg*ٯop,f0\kevCYhFuu]M''[|vJU#A_=ڔjSd)] 5=0$Ha-cK@ m2ڋGxo>E_ۅ)6B;,zKF@6?Q8U< mLCDL*&U߻;HfȬgǪ>oEEc lvjʮmpRcDmBƞᨍ Pnt}Fz_r}}11*u!cWvP`-o{E4%'Bm]Yro0<7sȭ^C0yퟩO}xu@-6 +qL"= tްp*q*,TU)6։xW_Su#mP-qg NѬǘ`d 7LR"r % 'uaD\o.]+%&)rrr"SG((; ADNz,}Bf1%j݇!bqئuvAk]18eUkcs}RqTZ\ +/eGjx"]&yT0VvT}m\8SgWS'}V$zp\2eWl׈ UF9Rr絃Hyqse+ɔ:}?!GYӕ oY k(sax/ib6n{\ujavŨˆ>|/k!U"E6hd G?02*xG->bmZҥ]!p +Ɗt\MgB]$:rOb65C*h/x3?[R"\ۤ[eVQz` }&8s>}w]U?5LVhoUtϑYnv||H[:\Tñ۵8ٴ A?j`PRgw{W, ;^W^? z}g55:3 1n5?vM ]|g䃒*۹m}-y'Lge{:8^9γUyYLaTaƳxn7.Oč7\S[h&a~bVHx@/v{eQB=`@&w^YZstmUg#imgLS _HioDxpñ`9 A*e6v^}kWEa<鱡?z۽쏽y{L5/-\XU,P*>cV<y/O]_y]{Uu{FqN'WL7$+6hqǹs֖wp 8=ͮ+5nVkmje$Tn0w[c_~矒1bBB|8oK۔u.nҪћԩ;Sr:ju:$Q tgPy1,fW.Z_3ݷ sWf@mEVUBƲ]^si> +4dZ66+5%rGYvsQxOaOT+HrA8QAv*}]yZ &֝yU[ڵ]'o +uŕzAA %&a=̍}֍=uLD-N I(iSi47KIV՝a|ͩyXC]U F!xOR~vWβ( +W;m?^[Գpw_EȬ4oDT1/*ƗRx7&)G}S[|U\uݑ?xଐB B8GB't7޿ IHLsH{TB8G(LDd "&vR$ ="P>0DB H#,qZ֤m'Zꎂ=dʗPe /VdH~64p}v&ږ?8inV.;ʂ;#UA+cpъ3<//Jt Lϸ/fQy ^{U~ {{[h:\Ӻ= +3]RO@YjhG᭛omR#T6lը]^$I쿍t\N@sOw~8,pm澃Mk gs +N]DMZOʗg+ww*V{w5}G= ,u }N +9 +lsjp\Ug/_S7Wk>,ܾMZ9l𺶷54>`yprFwk{lcw҅598V2X'FY)X!uT'_H=Ve2VF*Tڿ>Y\>-Gk6k:/^\\:)`|\6Σi4n$Ia!I콪R $`I<w콟y{߶Y } + =""WʅԨVKw)\aWy7ܰRIڢw+WNQx:|aZOm0[GVn̴ AĐ"WK\uWe! e=M{sWoVEdo+}.0?]We贂ZL-;)hO يxny;I\l=xWற[+ʗlE[:Ĕ?Eər U ʳXc;z y voND9^,O.:p ":^I-)v}Bas'Z _D:rR,YSuOeeF0&y\]:n5IYC![8au2N 佸WKyܩ+S|pnVyB>WB(_ Dٵ^-cQ`՝FdlGf#LЪ%Kl鶃{=H,81>J28~ K{IwNJcz\ 鹶mIZ(LX(Z&2e&Kv?barދ=oEJͩQO!z'u8>=~k͆{\1*cW{o-49^ ,ibơ^x% +u-ǽ,Gaj:S VP B9C +j%"R H#D(DD"C <:nO;(rhp@0"D GN0L}ԥjH)'EҁP*DR꣨Js 9ҙq) a B5RBRIէBvLLDVo0_;= +eKosqrt'Z\+ fIԽu|JL2IH Q02%0$a(AJ ) BdJDOCe$ D % +:H; neUi6C3/Z:O+ lAE8p@B!)M)ʗ DL#t$SACd6(% p0((("Pp0jA(A2eDW +E$HD%K^܏'(1 +|@I'2a PD"RM#t DJ@'!J%8 +E4(-!Šct&PӂxK$RD R %(@lJP\%Le&Dv@0rs)DĀA#&G!(֪C[hOPwD۴kj\4CBf4zWDJG("P &B<a#pˊ6'W3^e +2uתaY= NJʙc{pn./ ljJʦ)\nFt^̿kw-paeCqM{HUT 7+N#Nx;Ba֢iv$s&*n&IcI>aw #IIQ-RUY^%J1K 18XS5-.Wծ.YۻGΉ>eµ[ `9$.WM 䭂X\\tlH0]]:ڄ F@޵\DuPp>ۃO!M 8;`A#"~J5j6Bv.7x3F%v]#U77 .qmC*0}yKmu/ `:UH굺e{N-"jӠI s۪WVt*iJC KL0Rn&7g4ULK vطBsN*½ViPrO + ۖpsp?VK`τ/Figi2] +?R%kI5qb46w\>5tVw^|?;_QsxilJVnJ̻kaYQ`ӧ_ᘝ,UjhBcytk%*7뾛"OEaVF?D: ,^F!nY// k'ގpTh66-؝[aTգMƓP=ZYzCyYl?,KۖѳP6!k.T4DOد2R=gw\~ńȸ +qywm T 7G!znwcaB8 jWI۔E -uߢW߅בֿbwIdHkVG2~s3 a5hh l%U(W}5V"I<̗H g"V•qpQGT|u~`]⡽<(WYg0j$8.}k`qa9ʀXC48Ʀ%]Ldμ<7][ӈЧp +̵-yUN!h=zܿOY<[Z07c>Y#>Z|@|]Q1 {q]5;}aOd2^\Wu6vtRĮ2-njЬ@k>jL*"Ʃ,}OUisbSW\=6gsWvِ:s'IۤocO݅Zdn)J*jܘe1u${v}AH[@&yp2ҫ31&- x/uSh}Õ7cŘz(ޜO5:nr}hwCdxpȖwԃsp&cuh]Zu q;K/pQͤu'sg,̷M֎sHxj0V1fYz`pTHf!H\9}XtIk@%]a3:S0e}U˶EeS%p{ٕ6BhtI]}Gc7𖸊pyW YÇuOC+9ٍ'[׺%O's֣Qp&9uAe,٪wy{߯*(n%RCLfDp/hj#VKm7QO}eR]QZDȧT଻AaW\h.}95o3س mjQawX\ 58V`gqݷLG+Ln$u1Sy$a[t0fP4 + +̸vMPªإ:xOqXLAFej-UZAPGQLبXZ9H9 Y +tt5u07 + ϴli择hՖO +'[[655KztX챘Ҹyri &ߜs55@޶ NWnQ֐ /Q,zӢF v 4h ٻ͵{XǒẆKh͇?VQxq~ +熎Odcq6a0G> njĨ>ݧIxTOfLXw$*/BW0ZNxi3p\ǺDʴHqB1zi.lCHcb$W C5#B`qz,fÏ^Zo 'g>p1;K2JWs\rV=7dB[km9=OzyuFmT?UDh<{ 9 yrMO j Y,Xx/3E՛46ԤKpXu;lGdXƋe g:pz*ʎJs]zx*˨Y{̞f*XU.|>'\Aw:Z<#gqz{w\{BՎ$mӕ rYu t'}4h8Ǐ+aTUw|Cx#;qӶ(Sw)b6#TZ)M;޷b'9NN|V墫pXgÅ©65Ϗ];*BAO^WG<Զkw<;rMN@ד/wto]{\4 + ˭||9@3ρ^ymW`ܠC0BDJ +$TB//oT &) L)6G( +\&wBQ*S(Q(Ja6އ?6DuYꑣ^┞c#bIUUaWn\:*nHF7U<'c\^Grf6onrU5L_Y<6k#n³ LaqIԚ:UdLSpC [7^w%Ƌi4눕{Rm<> +wgU˛5GdWmZw"~MDQ Q蹞v؎8 )ڙ贇jy +}4(OJ>Wwg~?[7Qۃa-7٥N - ccN5OjC`l>a}.!TNADmvrE +F^C@Lzہ SLNvoŀ;|6yqM+F$r[#? %U⸕ +W-\ DO`rE,V唽$8^ƪ*}Q0.66~ /]qG-APW^nkhn5ͽ/雠KqK[0oM *'^ٕ fqgGg +gNb<xIN\|:-spnh|Tdv4굜 s*+Fv֦%]=W̶7TGwmpPp,1{m7 T 1l2\YzJFdsD[[Ú״c!_c JwD=ӯi צlĩ۸pUBחh- ~ܷ(UrأY|HVzImZ m6wyX_ O\FUzaځ 4{G +9ouY%ߗGZݮ_{>*̯Te`¾ ?7UƂI-/vXieA *;>ipc l7 f]豝YTr = v6on-RiYGsyL: +NeLrP~N*ڝSg DեBR;l?&Z2k\Lz*9sH5(=Ĵr%KIjwXYŸF߂`9Euh=ϧ-練ĩWZuq{kU%"H ׻>bez?dxu `U_m2GF྆ga]ktZy gf+e΍0عvZYvuy곘mTi:Ky]h^f;V +|6LA;/Vo׫AIsz1lZރG pO**eZz&tL˒&L)̤NQ_")pJ 8AxKE횭+bj ”ȈP +A0Q  Q=S% J@(TLp5=GSa:@[Xx:ROUMG o]P \q*yi9AB̙Oiע,1j5i;jUWlu9䗓z*z6U}@wE_یBpeo3^Xn>R;:*o1ֺdDk/?5g2)9:o-z[ݏVx!shT;'a9Fjxs:Ze՞LI &VO 3_n=D?b7k +ӥ3[l*crvV \Z,w}I 'lٕ5)EzFXTVf1pF:Ps|Y˭( 2sIVЎVw=qmB7|Np0L_L5UoSrSXuqsN +h56NwO7vj2}ʘ3 &DkW \u֫yv9o `emjlg0WuŻ(> =w4*:3iLaWfܡG Z⫪ kqOu.V4NO +cAj[2,Ǘُa]VvZ7Q`ʶʹG)uWw{N>]e8\ջth_BU`c9{v*Tߩqc,rer3&ov=޴xJYr֒˜y+]#uWj>[0&}H r2ɽеw=`Dr%["EéϪwU] nVs+\FŸ'T^>>kŖrY'ta {^(\j_P+׍tqwUr>*gԚGyV.1U (}Z$tʱeM9,.jt%Z{*a^F.BlI 0JX8sh̙wpb4ͽQ,tL{i0?LN; S)` F+li2v7iU= +NL|ޓmZ)h t5Mjtu^ۧUOq]:re{M h2ݮ &mUڞB3lmȎ|k+:vioM}\gU&VVjC[7Vj48{eP:SkOc` y_K,ZQwx-gçrjN/k@.$-pAx^A۷M[&|UʍZ"m›Z x[{&04(2i(N+mx\mVih> ^;8\kS@օ&XHJcLV{5uM;W}?џTxbxvBZNڧVYG. +Ϊ .*> BD5ISk%R8@v-ZF }i8Aq(.@t) + IHlKwAy)Nqw(Y.ձxRcǝ9FLQ&xSBq;wtO Q2CH( AGQ"TJE W7P*4}WȄBLnLG 6ACQL)9@ (ntD nBHRĄ P8%=E('M("R JaB8TXIu:%0JZyn +nݷi߿HrL:PwK%DJ!Jh@GB@BFӘCrQRa8HLHNP"R;'9@HG )!6Q!! "a0 ')D" $ (JFJS(L@<$%0-M" +eBd$BCe![AL&P!2eHT`&))JQ*$BQu!ޠet"L"%0%HAeQ!D&B\mKDL PLgt}4JQ(@G(lo 8e1PN5o"lr8WsNJw A[R:\z''L?$4JNc ƧN5)L &B@4j$>;=؆'Kh}g`J@pQKwEQ"~K!v+ +ZeD S"P+˦Y0רa-taH+#SCMWFsNlAܘL[hUvkd.U<'BUN;>'0to +Dʗ߂ѵѫ L+0Lr(7G(H GٲRܱe˘KOL-޴'qjV488xD*\?u(0]QX4qBٗ+3F3>ĎQz +Uk M|b7->)d( HAi!)i%"#XQJW`6It'c[P@$u>*9c6\>wIIJ~bVkV-N;QmR)Q [QaL;i tyJ +Di(#b!ZB1DFaDJenp(&R;$TNuWֹmЀNeHlS4p)BB%>ZOD r@RebC D7S 2*M kzN.Pް +"Kj$O.5HDp}o[X~ڰ#ָ6=/i8Di +jphQꨳuWAi./I:9*` yy; - OlOuKo-iᎨ +&SlqXlix+Px[@ nѳ3NڳwfD|W{:p2%~2jQ|煗7ذ5v.;IkYRp U5mRWϸp-u1̒͸(Z I >ۅs1ö⻄<͹ZHyZS#c|==s-L1m j=+7^Tkws@VXql>vM< n9hyJ\y+DǁhfE:,$jp0f\CciU %P [8ܝo{|KM̨^ܭRvxC! +{[դ<`4;h#\ ?.eG3 $FG7YZ6\UuFks?*M4Ԫa/bU.sHd ;+WTk Lq0~+I J5Yz'G\e/{Dd!ZYX< G+11C2S,c s%X"J}WLq_鎬 <-kO3OT泘6]Ըu 0DӁb݆\55VT,q4[P^޼g*߸w:Gz?Wm[:)+!o?u.*n/[Su&5:X.0z#`|V.lVjkDmd HVS8LXcVAY)8m(pc`Vw镫:~k<:.n![npl=G|b;An7¸93[J t_K'^oyR©Wtmթzq +ōw=>3jk|tE:Zuj/Oa4̻_K~_ÙqTx<˸ Jbw15'9wkr*pn;x*ј.lqo@I ꯲qaP׸j4zU(GܔDpLI +8HHIDndV.YМP!>6HR#J%M8M +ñţ\Jx[I, W,`ы߈^cRY=e5QGT?`+w _+XwVcE: I^朖:%`TvcÙ2EZPLHyZ̷\jpܬ +N`Ī]l9Bw~˕([ŵwtǢ͵]K $: kٵTpڌ^]o!HتۚLB:v\Pnnjڗ6#[5qpEݷW!54'zBoYēxZHZZU2&@0ja H +vujI}B7q&f9U}\:[͠Yw ƽ[ˢ]JZ0Y%ҵ}Š4G֓ìW k>G/px +Z~̋]\5INh*;KP[[Kև2Cd'j~EdzBP~W'_܍mc`o)PjZ  +l(ϑ/d\ZwVޕ:I;Bf B)b<:fwX $W1Jvm(;U +[7^Sz^ӨmwocNVӪ5)vf[6^ǽiVQƀ]HL'e/ʆ}$ +Ӵ kMhnl."v-`, +Al$7u[cٽ<Fz*[Mn3M,0ظ%mAJeP+y%݅A;gOa[% 0Բ=3 5iH>3Kq6ө_p]E6x)S +uiѬ@XjB2}KPx[Ɲ0Ga7#އ˒oW:NY-31N.XT% +c cZ4`8c3xw[&ԵPxϴSӨеf负-^~Åp-0_b4Sm*43p{7X֚pJ3%_k>żyKOD,FVo+{eY{|^y5+h"p> MGm,cC_r]Z˕bqzg%s1?>"?_V~Unft>!gJjczjvI0WXO/&nne -{r\4mmXnOV>hĭ^co.V͗,%qp _%u+4 8nj߼q ?]b_iY'P?d¹b=0݃<@W,]WǶZ";<-^κBSf}lJ9A BH(;PO d(\D +#eţH DBas!"S;!4D000A Y.lN +'u⴬3&$:PQubǿJm7xX}Yk2c57ŵ3әp$yWrmFC3`'{ϤU~sÙN$RHi*v}dѭ@ax텥z7 ݥ`vQp NϧP =m,}g ٓ Q߲~f"n-IB8Zlx+J~ǻe:j5kvOqsV}Q=zx@Xl''K} xHEi2Ovd8,Sv'qFƶ'fUai,Lu͕ڳ[XvWvڶlo2:6I˒ًJ? l]ԯO𞪇-dbYytUuA$j:Gx[B/J5c꽽2n,޷z`r;׭8|>nb>6Σ^@s;Y~AGV?5Tߺ,T[Hz-~5|*5*= .QvHV?x٥.]ƣW.cRP~@;J THP@ X?U|7?Esua*W j^5wUg:Hq ]b7eR*FۈUez1>w\;Ccj[mα;_>,iw4[!0}3y\~v&j74Ě\@mSm^:F7ت32UK(ɩlOcӫTfOx.u28Arf,%؎Hmk^ <[]Qgzʌhkv*VOqo}iGhu=Od`}1a[}W+l~T=mz>f?!^jaW\Vf%i\n= ZIO%zp/l}ji$]]amJb^ezu]_ 'SI%Sp tuyWUMm hD+Ym y +.ӤZQTH_Ȟ')Ԡ%ԟ00+e, puV1XWTytHUoagCJyeIKƃSb B~ ́仫yU%Ǯi߅ۚ.^*ˊx}ß5u屃ںٞ'Đ Pu* y#bX[F`8a-[ψ0o06{Z7#f+fjLnwcro*;.~Dx->f8Xɞ9^lw$QşΥWû* ZsTyrI5R~nI b:#˔qֆՙoWi3Wcr:x+Fq'zx.Kh2d67wmOa֐s\PD~`:mkxW iazᒽ xYێ,Ya^aTbf޻$/6 +Â$|ե15FA^\'/!‹cXe,8hhqi H 1<5LvR|;&t.xG|q*G irݎ.Ԛ)ֈ@<}]:I[2hUmY\7 BP W09J;y]WEݷ-4 M<•:MƈkvpseN;ƇiOEԙ\۶ix ] ^z}+gwָOzeW i"z 'T%D0TbB E$6$?z;'b5CSv98B=ɍQlY7d{V°`y Tm[a֍Z|8$Js%&Q8a$&7HALl')I) OQJPM"a2P +(q!(  2CRsRDB"28!GBQ):|KLl l4J:qM a0@ +ADOL$QvAtL e4D(vȅї4ja ˆ`6L .x@(PB8dwQA@2@H r!B Lp)nLd %1$ +gdBD ne !1;dJ;"%2'bPBJ6D R; M%de(Iޜ'HG("$B0Gu lLS$ Q +R&vH&Q)IɎ7D20䀎R% S;/2*<(*$J( U#%cd )L!(L L P7I)Ҁ!2'h!)&(.jLe nнtKi8v:7wuGv]z\'2  ArtjNvp"L缾eWJ.$BLH&6K#Q(' qxn2q]uWpIv^\S3HA{@ r@"%DS G)) L G@0:)RlY쯘ߋⓚ +ŮiFZm@robZẗ=<׼oeq*c[LS1j=ߍՖU4iw/`&8/A# +@JzJJ4!LlF6 C׿+jmpku{A|u=0iꆶvL=@227lJBփ΂G- =桙a1"|O.%I͏粍@̄T=g."۾UWǓ.,BR58z*w a+ӝ:>i< !.\wNy"FǢ$DHi^bGw2ڬ*T wiZe]kEXT$tȑȑ+*KX9Qq]ۃ|ȔFG;)9$Jhv}Z#p2șBXU`#T/qUGGD6 9f'h#nsM౓'xnuse*BH9{oRMw&Nʝɮ{U ak#6)vmkH&zy!l΀L+ 0Ɓ4]g5Z]O{G੨vjR^Zr2xqr O` Eԩ)Tc?XǚsZw2 ? z~ZꕎemzYNi 5{,Oy-u:f5SiX t,f֯nj-.)FZ {Z1ժ,hJu>0جl9 M*X]e:.{5)ֱH ;&1O.)T̃ȎB/ycKsf\}43K:7lٜ31;-j5G>гs1ls*CX]V@:V&)tկ0SƇe`Ǧ %:vTpVi˔^l8CkEԈpX5hܵaVWsOQ$[xmק1eLN^>56f6,\̸`aH53Qa#vvԥYH5cc<8|laBgU)a5 jޛUiW,c6onݬ|%{c~i[ `OOz+ j:ces h+Ce-Ԥw9/nh_[Xz*G*%\_W{j> ; /ˣݻ\ܼy+w緉ۘk⡯}Y^1zc/c%Tf{HkG;#.o+?xi O .ۆyJyTy.{QǾy>㏚ +a%.;BE~܁1ZzUejTub \yϳ\FzU%ƃ 1T/hCY0WrݻmH Wnpf&Sjhx;¿0Bs@F@+7ZRȠuRxSrehxat ^ҳeJ'HF\a}KU'T-ATDŽ|kseI.-wI܅zUVkuoFsm5]G"y* [Rrj%tO=W ޚu,CҤegֵ.JvYٴZ]5.3 J@ƝVժ4uoFʗ+`6fL}g̨0gUs9;s޶k{JͿEbڐykݘy0_S4 bs\I=UfU~ z".aOEkVGF;K9:kR\'U>WʔBZH< yI_4+[2IVٟ Ůi m>^T.mWu=OOðxK;S;OzSR; L0ݶp=_D[aLgOLG⪻6ą;,v-%Nwj>[Ժca5Z0#ak,鵢j0nqXS qaԅ-TɁ $䪜Q Wo]d: P +u|$ $ mEiZfj2fA5tʕ3Mk̸4|cVEK?}vֶZzE{b7 m\jݭ$O{L[aPKxp+EF>@&Os/Zƚ${'x,o{OeoiNޏwV#Ib!m]wUK>EO޹sH-|>巫wHy{Pbo+Eߢ˓W7ҫS)05v=U DVwz*LFw+F7YU)Kp6jckjNkߎ7W(]u^: =cXRWi!=#oV +֌\ zSvtɨH+z{];7elp\9#䰹Zլە,gU/wb{)F[NV/vGe`JҨ+n-G1&{LH?@ӏ6w}bsӢ8~罟^z/sS˸]|Onk9s Hy/j`:2I1!h;[?jZ| ezXjR7k\[+s(l{ĒzlK\.J.Q7P'+yٍo^Liqxj+Vv@qkF,hL"EY=Yd< +UP <}VFm6b7l?8jЭS+ %bS\>Numkbgڨ@$X3gCmVp}u]]-\+EFiEXxFPB|! L&L$J̢PA(.r{K-H1a_tyDH ^P1TrM u>AVsɣЙ ƣЮcv]vr}BfJihZb9۷ǹPZ!ҭoiN6ꯩ:= +ZbzO/6Nb*:3`Ԫ;=t]ޏ}>Ol14~_C#W}tv5C^@h85[wO\)TI=%{:~#ECijA}#6[LIة wVv[uzaL1vZQvL>oFkTiMBO۵~E?o,N p\]6юe_9t +μЦm2<'[J8/a!`XJvr=_514\i$nʗ/ؽiVyIv̬ =ZA{)f:Wx+Κa.q,"P[MtSpv WNAc /FQmt! pSCm6:<.l +uj QXqAƛ˚tTnvF*m3$y'uX|*{g@| #u͘}zns0x;7} :Pb6^.VgQP0/Mj)GVtR,^_N<%eX!IL®3ByWy ڴq{q҉h䃿tj %{7Ij4 u0!qVmk@z3vua^KK=9pꔱZSsH I)><B8F'{uhds|:}r *lX !tQ]9+rǸAsW:C7w2~ղ;nz%ay]6튁~p]Vn>*96'E@JԸ>G3`,[4?K`̸m7eY'aUnmӤ*Gefw>+Ӛ1+S2}ʥs{ݎ\|0*e̹%[«x[kWSOxدF f?c1ʷ4;Ez\;Uw8N+7ѪciX>K7h%9ry6&]a !eUr<$hyp͒&< [\; zLC<5'@V9g*5wy^'Rr˯(#hu0[8 *1nÙuQ-p{b.bX-4髑Vs*5{r˱jɝVO |U=? +סu _>T9{*7 j$G[oIJಙ3%,CƸt?Or2K_Bt[ +0*LMFxImCuBT[/=Dj6SXx+g4*gnnϔ)TXK.q6xq5KPid +U.\i)SȌTX6^ۋ:`mQsxMqps˷uFnmj/w p~ n]Q Z\6XRe2"z ,ɔُ8OWu,pS?Vw-.{J\m !Ĺ#;we5-Ho%e<2ΫV6s'e!ti$u\HL`6+}"nᧁ*Fu9 $ ɂިjo<i[.,}3-!ŵKW.}I]r .u;$Ja>vIPD&Jz&PR!) +)AU D6@0! QP2)&0@)Uڠpi32Mwy |ţ.)6[(am,1o0?`tq]&d0G)b-NY؍ ?Ru6@;0xm>tI5ڥ1Thxi~gO:&>JՖm֎x֦!}<)%,PlfFeT8lD/&RZiQl4"OGh}ZMT2.N7 Mc"p<@/2ۻ'&ZM)u8]G 8lX\FY$+L_Sk `2/MmL٬D[:LtXE:Zz0⡂ѡYmo\&OU6!bB>tcuofVC]5>Z}0 p! J}[`s}= eE9?%}ov@6T$؇wȓ&>RkLƝ{o +Km'0C +.[bV'zlxxE7[*9 +T:E*Q>]DBF +C-= ܹjìRl+&N`8Uۯ>ki1 F楱p|xE&6JN:6Ot9āy^Fd񀺗(8IP˚|Ht: $u'3 4ca$ o G5 Gx%HU $_<5 HnȘL$ +8A2$ H8;Ȅ˒A)( 5-꾎$0NIU8/3 BLJrB@i y@2@"A &7MHJ!HlN! ;&J%HnaDá gtFQ a" +*(j!'ܽS()LlA(dS(PL"Q0j`"PwA8D7@t!drBDAێZeJS r%(J8@0%%NIJp(2aH#tD L7G)D'(H +gtB7dpȉ@AADr&DN!48rG(n!8K("S% e$M2D&LDD)ӄQ Ġl9LCB + +̤6A@8B! S!Dw@0D /2S +D2ąv#& +|PSN LA0L'20aJe(9GJ(2%"PvCP` C"L HLJ% )GtG)jPD#J`J\ @J@Q)B +AA;rD(OPB`$D @ D"!(LF&vH:8AD ;; J +q(! d'9H' :'0 )D02(q@&R>;lP0a 8Q JD$TTN2ss#.^ OBdB!0&7N!0eB&7MD G))&dvAD ЂA2P("RB9DNe 'A"P҂D$BDN(;#"Q`H(|$Ja(')H LPR;&RvD R )!; lJAFH8G(&H"PP}&P@(!tDG(i (S 2(;$*)&W (0T\TNFGy( tLniQ( ) @B!-hp@P HPLDB&(;e&Q.LHHma"e@;Gd$0BGtB!"p9OdLADB8G(@z|%2A9ҘNNe a (;% B=(A2 vM P2"!! #LeL!)JSa8@L5ɨ +H #d飔 ( B\%a2 +0ODW wG +*%Dj'm\ؔ#NPLJ8Ln8G D#D +8B!FI)5))%2J;!beD"edBH"<H&S +'8DJ@"a009I &tN&]Q(A)%# ()&S)rQ #'tr%d \& +9AH&BE2Q2(  Bi@RAA) 'D'R'tPLQ&B&SaT"esaIBuL !Hi'ѻJGd("2l#W %D( +.*$(*bJ. /b"J8L@ +\#"P0JrrBgtBd\ @Q!0;D(DB +&(! 8%#Ġn!%C].RP!4 LH7G jҔpB&L5lJD; @@"xRI( nG!21HȄi)8ȄJ|6R&H;(HD 4le'=JI4'hH& .S A) D&Q((r +@}А9ri%0!2wM"  TJQ(fy[ϊ̦Mt(LܦB7;Ja !3( + p rB8A(Jct 2PJHLd$6NP Fu)JCt30 *. l.Q*-%!7!>P"QD @& +a # 6G;#e.Q( L +S(2 )@02 @A A;aP*@7B|%2 R8B)D"% CdB HLdBE1D%%9% Za=)Ba.S"e2RDE&p% Q);tNuCF[NQ0S4&P)̢a8D"P|$63S N1  DB Ll|2e.B +9Q Br + @1QS!e5& PJLBDRON!l!2a) 윣e5MvI$LO@0D% +P&J&PBA0"Qq (dB"R.AG P NQ @ r ̥!HF(!r@"SJwMBS!9H +$&vCLP +L JWvD(N%s%6A|WRS;)NP !8G)L%) 4Jh !R2!E> ;Q@(ad BGd % DPQ(%%JD0%PwA vD" &TtD"%1S)B BE%p !2)S*S)JD6CG  Jq%H"!' LnD B +"S +1("PݔL$QMSDQ)@(r!DJL6P"PD 2-&@& !)jBN>KRL&9L '(JDgd6OO!8G)JctEtH&RRJPB&2! J&'lhIS!B^IۅC% e)rSBGdR;B`$ !2a"Q +2 9&S(vtJaP +  NBS)"RL쁺A>HRH'\&Ct [()J"J:8D * Bra!LBh@e(AG%Jed(dmJ!.RT&߻tJFJ CW:CgG{JEK'(OJSi=SPҁ8NPS!0)p %%d A*.>Q`J%$6RFaH; G!>Q)"xLl(3M)@r8A00eDn0!d\4e4̠$BpH`Bi Jr(jdJ"H˒D@(%2L!BH6BH% I>R(1|%q()0)ЄwD% * JHQ!4L rera I2a"I?zߝʉDB}zH)&A2RDJ&P7D0M0!"wA2aܢS!#dP9LBd$ +&Q)L&6G)LQQ%0!FQd&wNR L @C8J"PwD"PwD ;BgtJȄ# PJD 8 L!$;!@IJLlPwJ%2%  HOI.S))9 T)G) LPD#(DBG(p lJ LlRnMrLIe A3#]२̨H*{+KRꇂv]J^I `#BD"gdH"!;& S"QHB`HO5)` 솈Hl0"'$B|7@B"9HlB &)cd&QA"a)ƝK0I]nsIY +ݠ"֓4r/fcD҂ʭyq<:OqgVL FP];+cKZ zUܧuCQ ߐQ +$‰DTpCREHm! +CtO9I19L(% Q2!$&.G L ta0Q)L' ГhKA2AJeNS 1 HB&R;d\ A(; 2PJ; p)LSQ %d4S;pNPBD L0Bsb!tSJ!(9@ DB8LL.-K "Q(B!&w@"ad @AGAD PQ)Dʢ͸)4[hҲx^0$(J>A"P.RNR QP&AB + H7@((P + })D4J hGg ૿Q&[ PkiAuhs6]n'j:~nm&MtLi ;qT ,@ϭZ.o :\hdOCN VTD&LD2D/L!H%'( ]b 7M`JL'0P7QRM ('>PRLl"PS2:Q(HK8M(9D@n0 + 20SQ;D"%>wHDQD2q;n @DB9AD % HL&J&P7G*I()L9I&6MBe"a~Q)LR e'D')p̠tD'trPQ%d(D n("S%2(G)RG%B + D0Rj{MR懍.ہ CNDa!&wHl2!+r)<(wCD솸VfߢtR@)SiLBS(?zm| p +9@QR( @Na PBDJPPB@A2% S%0GdHnJN!Q!ɄPwBAL AɝLH0B)(J!1(@e QɄJ8DJ vBRP"%p@ s)j耘2R&PB!d4"P$Қe.L ID&])p%)L)r(1[ ҈MPL & |$GH KހS'GtJ;TNɵ^Ф6@0B!” ALl6E!aJa#hQ)a>P Dn!1H&Q)!JSd)L&v(G N! %BPRQ"S&P NSH@)В"& DB M)HJ +S"eD)jCDr! n(Q%Be.P eB9$APS$PQG (PB Ds@0a0P6D|JD{ИOD l A"SPvJa 8@(Bs +3O ;P7A@Be( ! eDDBiSDB9J!8 Уa) )&Q2(LLl\hDB0̨;N(*jcti1a9D @*@$Brp)Q ("R&) AȔuA(d| "TI P7@nA(L&ODQ1斔rB%q ȔL(hNaGDA9p"a &$L OB8A&PL%"t#iB +CBD$L  J|" +A0n8DBs9 7d;$B@ QDr4%Be(#Dl &$R0/H 7H:|AJ> +@ce (D 0;&6L%JdiDB +@j9P("H lD5B&逐BQ(ADɟ@(H!t("JHRpNaa$Hl}L#RL"%(% ~"!1&Ap) +:2PN!.P6NPbTRNRJ`!(=HHLJ%1%` #8Q;';!B9LK8AdD%t#!!8DB`$9G$yQz7&Wk~]S+TRL! +rACT\LjG$3耓TQo?%' !!HwDHjPo)!) PBM"J.CT~TBNL $:# @B +C8) AH:TBI +AH7PPO +a#e" &D#RQ@@B + ! ܇;ҐS)'$RHHPPX\$?4L_ +endstream +endobj +32 0 obj +<< +/BaseFont /Helvetica +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +33 0 obj +<< +/BaseFont /Helvetica-Oblique +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +34 0 obj +<< +/Length 319829 +/BitsPerComponent 8 +/ColorSpace /DeviceGray +/Filter /DCTDecode +/Height 2312 +/Subtype /Image +/Type /XObject +/Width 1638 +>> +stream +AdobedC  +"$*$ $+(( $)%%1/%).*++9+*./45554/;;;;;;;;;;;;;;;;;;;;;  f + m!1AQq"a2#Rs$3BcrSb%45C +&'()*6789:DEFGHIJTUVWXYZdefghijtuvwxyz?9HM}p=C($e7%ʋDU3Gux$ØL4'$%z&p@Ʉ(rTIR00$DJDBCQsg&g +M݄Q`]*D"Qw @np$)!Eǥ8P&Q*@O8GWO*E.Be B` DB=I O)DIGJ`y%a)YLkq. + HG"LA`B e5H7NeJNw]2%)A +X()&TC +N(.1?48H)L>> + dCd!z}DRE HS&ʈIçS$D:SQBR~j]0sa"g)BB +D 8BE)Q9P~T%Gp=B͢`a0 P &_;)B@G)&ApaDp( O!HD$S$ 7("R0U"p%H'D5 J21o&q')8 {,Ȕ $P) $ 9GJ"R )( +` S9Hc"cA#GL"% AS !=2%G %(FP1Cr D I(8Le.1:TpSDJMR,Og@A (">) Q2 8SꐆO' e"%KBDQ"TBcK@2D)L& +(QRpAHHPR8AC>JDd&[%0Rr‰ˆ(CE .Y(ܜ'( /;?b e(& a4xJf!DKs);)]0La'gR򈔜8Kr0#R.BSLeH NPDDer@)Pr +'2Jz8HA!#L"S8L +-q J0HrPDC #H "!3e9H D(%)!l0J2Z + |pS A2Ba.I9H}nJ#AL{(tc%"a0|(B" OJ9Jc %"A2  +Rh@x+)C( )B8 +Pa" : (2D8 & P3!(Bi)H)(8LG)Q2xH)H&HMr3)K>%"`SP2L( G9C)Nee6JcDcT%(R"Tb!HG%"ԈQ(J% a2%Al8Jn&IR.p2A(ŒDӄr\s&PF}3J "% eB`x(@RBE.F!8 >*q +$B`BM)%15"s NA)PD)JpBRH5)&(Lc +G"GG*DJ]2("P[ 2=1L'p pDy&JQ(Ai)SO( +C FHH; <$"a +'P"8APʃK1,F@R"N8RMp 0;_ %"~)DK @b~G% )D.Q!.TR JL @LL2RH6Q("BH}áx L D(@GL%"T$*@ +)pTHHL6 + J +~v8@(i4BB3(%P% +BF||2)r2@NR2"}"S% $'@ Da$ RpA# gMG@BaI'@P zQ0gJAҢS Q$D$= M!(0a!ɔ)*# +DD@ByQl$[>rˆ'"2@$GQpPpQ6C}gGDBq)#*`(0W)(qIS8!ʐIR J` ~I”8D!)ɔ(qqQBJNe0CH8)L&%g(>JN$ % +IG N!%8QR&%N! c H9"gR QR"HHπM& L@8DB)#܈L@H49H8)NtAPD Ϲ"TG(((9~RHB J  2A>%2 +9@J$}h2g0&PD JcԂ P9@NcK)39NQ#R03$aJ%F In@<>L$8FAl}*%D SmZ= ) J8L ` &2t2LK‘>" + -0TH )JnTD4H 0SQ"a2P쨃(dB@("PBQ(POJs S?!2#?zRB e6 A@ HJDN[>BJ0O B!)J@B!(>iH&0ϢC(F#8HeB  Ĥ r2 +"J$"PJ&pAD`$6(JH@NR=PJ:c!4NA>O*!Hp4rINa(HKBeAE6J!"%)("2)L G)0%>PIDLrAN"! +ܧ P .|DBcLc +Y&PJI@l)p3Hc(o(B +"DԜT@ `3>>)$PTHp + +%cj-ow(CGJ8LL%[ Ȃ! +$D} rP) A*1g )%LppJ&l "!( KRIJ0P(L2xDH`BP@Ja3zT(COR` DeIF!@ (D HHN@@  &PQ)q'AG8N@%Ata(9< #O@q`rJ JϹKFQQ-šQ(&2$px @t P %?iK SBI(J%B) )Bc D<g +$ R!D +hD@G) &Bs("R-LFQ#uJG O85 % e8L sԀ!)uJDC?(||A b9NfD% D02Le(L"RhB#"RH +19 +\ # 90SQ D &(!($)Sr@HR0S)rRh!( +=GޑqRS! TbzSP=S )B8@ 9=&R-d(@S8He 0d' JRH5.!!-Nc#0e.D eDc  PHH G)8A(NJ&)89"PD&\C) J` &=J>(& R%F|Ԁ8L CBPD&Z +~z9&2DJL![(0NS + B|$҈D“D| +:eD@RpvPeB:HH8HHAwI1DB` Bb}Pp%(pRDJ|I@!"eFaD]MN "*‚22-S_ $&LJ M5ДJ"} S7ޔ%>AL<J@D H"P%@L'P$)KJNAP`Q0&Q>@TtSP01| L2T7CJg)RG $&SP2gG`BNMB8I>% c@"!8N!)TDa@B Bsi $H!| +  a. +d@`#ކPD}. @Lg)$"2bPD!GH4p rHA'DSCd(( H)z%DE" +D,mDK>!dZd+Nҙ(`Bs*<&N` "Ҁ~$H(Bm LG8R!B +:aJNPJ)IDBbB e%g" LrG)Lr( $22B%%2S)4rB9A$&R Be>8C!8D)S(9@2jL{p% (r 0@rQ8J@ 'O(h "a.P0R R@1PA("8@؎TJ!j@ >pT +@FS@0 1p0!9JR9OL&R9AF(@~ԓ*%%TF%#AaHgR ra(!(qJc) +$JzT@JP"TP a )SRRD!Q9 2NpP|s)Pq') D PSDN a&JP r% 8J$ y)Bd)Q% B L"e0|)L Ġa)$r&A% 6 + Q L.H9De,@ $Sk|g(G)(ࣔ94y%>QDID& +")M(R8A)R L FAC%>iG(( KxR3 AA)BEERG<$LrJAX|EA0@q ) $BC LA aD)DE Rpa$R(9 A0L (-A&R 8La!rɟ\Ha BAlBm2a 'DN 9@e(AD"e`JHD&J!n2ԝ| ɔaED"Dg@2e6rd%O(@!.OD NRD"0 Q(R9$@(B@bJ!$SG()B$(S8A‰0!PDS&D|a(%AHA3(@T] %(HAG*%# "- # "BpdB9RQ$!W0!L a#ȔA!R1 <8BJ A@JE8@(A53Q $DaID甚Ha(ϚL DB|c(9@I);(&PSRQ$(Ġ2Q0La'NQڀQL@0}Ȕc)(@()J19LSPJ(9CD"B"Q(8GOaK4 IQN0BEЛpaz%< "=IL%2@(8IH6r)"L1% +3(kB BD&2I)"NR&>*0 +$({zKBИ2@Bg(ʑ+>BS)r2R-% +D$(Rp&D&p@0@2L| +">hI0 +I*<)(K"s B9Ϫ1u&Bq PBG8H{"(! Q"S&R%  D6Q>i*t( 4SR>ArJLa$P!Q2%< $0rdJQ"\& +G) $D`0e>QeDR +s) e3S Ϛ\'*J38OHHNP&8G("R0P$RjQ?b 2Jc甀 L#D #A0P 8AG &a(@ D%*EޢܡE.R0 rRQ +rJ +C*<("!1 򄁔` KPDD&CNL@) uIJ!2%Ep%(&T\%DMЖثЄBaHgJJ2FOؙA("LACL + %0BDB8@Ϫ&3q ( $Jg0PB8JS&RQʌ'2QAe"S %6ڀp2 t*Q))D#% ʌJrr( aJ +8K e2g02I0LTA a~(A&Q"PD! pL e>Q(锜J=ĢeBdȔR&L$ H:rL (PQ)d P0ڑ0(@("re(BfBD|0@&S "aJDJQBP3! +$EF!"e"MCMp2w(jdhBR'/ hq!N#QR< AcގQ2e>R9NJ@PLA2(3@ˆL@(O(ʈ2S#"eI" +% p2!)(!JR)Ĥ0@ )@*22&>NR)&) }QO!)ˑ2G؄` &$%2C}0J89)(@)rR@9D A ؘ2HA2>)Ž*E# &PDrG(9I%4 $PD$HA bx9DD$TNQJR%D"J+P3?T,a*@a8"a0_ e 򀈄B 4B8Hg 2R0Bs(SĠ B +PppB\G"P '2JQ(H @*"pNe1BR (@(&2<"A!ҙ)&$i aHDRP !H)>%'pe.p$J`BnS@L&P0Lc("f}()%m2RDrQS"d2N+rAKSjM2Jv6I!>SDr(D"A$d%'`"NQ(KA@(@2!Je)J!# !"!x0a p8J=H$!0& !(AA2|SR%)QR&PL$Hg"?lȎIDLBCB%(Hɷ(@ pO)' HM(RDOQ&Q@A@0DJ@dIC2>)Bd!42TKg!%3&p) +9DJG  J@$ҜG( I 0t %RDJLBR*Q~?6~ +?,YE"#Jk2ARh&8A`*DQ0 A)J|"!"aa2AtRpG J]H&%1QSJeHA!(I)ɔHJAқp>JEЉLazg)3La"a2 |PpQ2@ SH'\])!>PD& L#Q&BMRAhHN%)#?҈ЉJLH(8L Dy "e!)rL:Bd )@pNO p9Q"rL#CJ&Ra( !.BD2Pp!*1He8Jg ̣TrrA2S&RtϒrPr!#ܦXznG)HOa"cC(LPDDDG)) "'Q%kw&4*?IsKPlV΃SCL-תkByZ BDFSLDJpJ)6Osw^\\[T'فWBAK($OBD Zuupچ$>%&[Fa0%.B`BH$L8qAl'| S':yCDLMf +.m2`@eu“D/T[RjM&2C|'VI +a0OOO( 'O +F +e&S-ʉl,!\ղlwuq_iiZ kAs[F)Uy.s$V-e%M)6W EB!MG! iw-R4%G)gzy\jִe'pr_QH4 +N cI #?l.n5xx'1+l@ <'16*%0G?ZMݿֽgxh]1l'8K Ԅ(IR%!rG ‰H@/{wO$#J?H B|#*EF~JJ.RT$SRُK:s=%GƻZx- hduvlϲ?ZaOx,F7N0ڮ摣X>e|BHtO~캻Kbq%em}5a^iV46ޛ Z8hknEkf>&%+e6פe?Zh.vၕʍ_QsaCk$q]' OVv_)Sgy^Z1ZۭطlLOCEꖭC4Ɠ։S֨x-<9 8`p&}2jWXgtGUBA1W黢k a%a%ܺ#jw.nLT#0e GU 2֯ijCR -.@]N{mh3<zjߤe7\=@.QQl1M.τr7GrkpcIvk]~O]7cԙyU?TF6ןl7@֋TgwqK7n̟'hv~RE 8*;pTE*T5j>^k+rT hd{y||kn˺zjwK|քK]VSsL4>WW4*v@ё'u_q~S,L.jUԵRdVF[W~և=UݮoMtG:CaйԫP4\C`AknYebc}!c]k7qhpMBip D~*`4Naovގ=ˮKFT$q0lj[-SRvm{En-\+5M7I<䫤2uXӵzc\qxL-܃_ioEjF> ݗwhpq s@=Cȴd.zP^ !&9\fKVޱq{K\:~ +qSQ{8TX 8$NKS<ӣKǷ|zׯ7v8˛Ppj=NŅ5PN92wWXr;ִg@uz⥽'VL\|t:QMuۏT7z{(޶5'!ht.teJ:L:grJ)}LO&Jmá>oA՞M@HwrpUiOAuB}}lnkMի=IVPWkѴR!c1]&NHwwK=Znϟp;ۊ; ] FjT.\\8[Ϣ:y*}qRڍCJށ=_FgҬ{CۤRQ- kZ=/lk]wZ<>}qNgՌ;_ەiϰeqiN {V_\s^\ +mH ~ Muyu[RgAw$ $m:uU!Cz6ܫ %aN +GUٗ4麣Z= Qq$"1{GLGNGWnD1]UտҘ=E:uY4n}C)Pz|qX[ +xfO+6UjiwfjwH90e !!P"PG J eDED@ޅYc|JS 9@0B0A2m=BP $ +$ +DǪ11*X!q}|?yKF`vpY]pblj >ҡk5Ky0${۔3FJ{R*c)}RHYqg_lh5raӬ֏s-u-BuJ)R^ƀZơtRu "?k閦zHy#v65H󕗶-3Ɠ$?zTѩj$tnmRMNƶdru+?)0ė]qOf{ x?B[zmMZ%Ćde;R~測ZQͧ-k4ɟ0nB>T=J5[U@ 2QUͦ: =SBtRM-6Ra0-If\zE9`Jwc;JΛqWsKQmfo#+\V׼6! c+wZVS4)CzM΅ףXC$A^Թhiq A2y5-oIM)SiZ2nl~c5$:}lpG|Wiqʔ#j/G +N5o, +nSPm.Y[X뚷XI8XPFz|`}mlkzsj-o`?3+Ti5Wlyp#ڇm^>z!Y~*Ylp//?l׾G}a øw)2"x>KX\5}G\j9wMqu*nFv!?n!O"][Eؑ-t-˿$cDڠ *wcⴽКO=z~շt: +V ykKL鈐(j:+Y"L\X_]و[I_~Y+'n}~ 7AFxC 0y OWsR*}U)Z ʡǺWa+.d/ ~x۵65}w _Nh?Hn*`شC>7FұRpt}W}gR$z1[Sumb5XSptWFJQ->R?R♮kRO]^]Qmwxq 62 9[Ww{{S1Ji/l. ZYӬ}z~>¹ Tu&>PYj5{ʝ#KVeT9"gbʇq~<޹v83~br"~RKX*Ap*U2"3KPܺA"=Gߕv\zI0J"Վ `$:w(Igx$A]mZܷop#گo@}sT>SI2 + p> L7?&`@Zm)Ҫۚ0ZLt#YM6]T's#.wV3FVw +iة_G!]\\a`v[LSeoxeCLtU_V"ɿoV7iM?Faw.P܇A ߟܸ8>\)br.dJ.+jԯ=ޞ=֣eU؈ $=Xp?ᴠGaH e HE vR&TNTIP*5GSH8SoK`p$ pap_0!Ҁ! $ &J"9H&2H\f$j80c5jYhnakBz+Qkn^_Tx,ON';~kw=MϠRy { w{WwէJNޙs-&<_R uJ%Iq} :/ -y+`5~Qd=`w%} *ILTo*5Ru:T\oM +j+A5%j4kPV8=30GKgMϺyuJ :VL竡mkjNpd,mojV>cMpgW|෨D7R~d'C +Gjwpzg|Ӱ/cp-ѫ\V*3G5mZ="|eo[=dy|9lm]EըKD+sצ1A$9Gj4RioIeljڧziTR"wɞpwk4$6K صӭ u NJqtj3a,=շʃ'ۮiSoSz};D^wDAZm;[uX3 {3#NLܗ,guJX> e4*6T>ʼnou )6Զ{<&> iw|ݧ]+ڳXdAU׽,'D'Weil,ӢߐC[GѤ%AyKjjM(]Hi*T.GY;JZGS˚bGYzJF٭P654Jt+6A1ݛvڐ+ш@x,GnFh[P㨟gtuJgK~+klka =&Fr􊺣(z*9, |D.s*I뷤#i۶oվ -"f7lqKyp#m6pmj.5UͳMA}^VfۏEZ5.8chUtpEZ 3Z}mT{ڴ*z +/YN魣E qG> Anwt\Qa_T;nzĭۧCcPWyZKlW:Dp|wԵe +n'JӚ}$Os:o赕zdÀ +-qmHm3EdoMSY۸ + &cXߪP{YI|'~ەt.VA&-ysvn-}M* c+g4m\ʴ%dhRB@ZߪFnh;A<,P5kPt{򍝴*yc0ifG"p{ahlJM@DxfJ  V.[2֡c"hڻj:溕BI>J5{~[N 0i.0ր iG o6mkdA ?Bӿ%Pl n*\mNAty [ch ;݅i i! ~.74RX\ 2`ᣆ.[Y[;?Uk_kqNE!~0΄.aF:@ 4-9u;g\8g.ouڕZ7hDD;?j͹57\9INoN9X:~qox-̐fNem5.MG>k=8w+Ԇ_lwy^.rރr[gAJ#c]hz;e/trOCU:W- /JUjWϨVZqs=дm5[Qt[PK\#rMٷZK>m7~@W> Z4G +߶kREf|f:Ez?UǏ8Xu CWU9OmmZgtTiq'\c*_j\}(6U=88O,ӷ*k/hf +g}3P\$x9 ѵ=$}Joߪ_ghY֕MJᲞ/Q׆$2r O Cmw7npp#2vյK:&yHGL0(NW9HNel9TR"QJL90a0c > Lr DC& !؂N2y +MҎJ(#HT'#x{ yh9BF*FhuP&83PGRzGB +.&r#X|eO'DB*<SNJ`q) He( %Ha"rDeH!*]Q$pAe0e +HiRdԫ'C ,& 7(&RpCqʒ@$* +?%0%.Br@r9HHHLHLa"0) :YMT@"TF)Hc&&L!BQ(r eQTf]2%&AA2HyBE"DMTKe(9G(@‘u/. ')7"BQ"%2RT#eӕ#d$8HHLBd@(0 $D6rPrL @0QRRvQ)(DBG2H9H)(""R8N!>B@$@Na>ˆ)p<>R)&L A S鄉SIIyH53 O.t‘a<) +~(&1Q(@ea"J:e )8)D)B`J!Fe4@'@)&$Jc):zl#CJJ cDJ%j<&Qlg>!))w~%Hd)C  DK3ИIQI +2eEV= +zYfpSBH/ eSDD@y&a&L Rh [̽VͭpuIcn RsZ<48;%2B +:jmYh L$rRZۿɽzGBPOAKT\Du3]qo>KjD P%t"|AtR74 iw ]PH]"|WJBq3V{lDu%[]:NBr;RZԸa숑#%ghwBge`'ce9IRʉJSkzu2?. e1!L(G)e4y M-Hp[]>ӧT&8ȟj6;f.2> t}I +-TLHGUI.cjj5nysiӺX:^kA Wjgu?}29L#@kUjC`sT\O6D1€Z-v[*i畴щ}4I'wL>>3AYGu"}J :yGOȩH1Aq\>ڭjfOWojj2'[@\=nCb]N@;I?@̑Ph:ޛ)< 󁒦絧HG:y!F_CAQ8L @l''AQEB)vwUg1k;l7j.}C.(yf.m&=&g%;Vn3%b+sֆ܎XA#U;kR,ȉ"Kntj 8T*4@>⶛pHuWzX<=}Z[wJm@mZ.!s-5uGЪ(Pˌxw)[ܼU]V_hZMjtF$,[Fv׊4}o%r~*s]dC\5*ſ6 د߱7rB[):湭.P܍a1 >ujd< +ͨ"<ק3 Fֱk +eo{ZaCi w<[Tm:!+O_P2'vt2׀Gi7걫֛oPm黽( t~ .(]hV0FBnq`e֮a \6eOzn{z,WcWZ]Oطq5p{WT(r}m.NN im5.rS0u*YNpڍ[[ +O-89 m`kj(l6 |='jkU]U]jMZ%K&4iP7w)Us+P y*mب[N4ğUٺE[6JΨoK\00gorگ. @3bt>ս9Ò}~ +:wom뺫YNJ۪JהI~ErFqw2^@#VFaNLoz&tOHX JM/eAT\}~֟Pf7 xOL^=nO m캖 76ĐHt ?,'p~\Y{X09UmCsk]Nَ-kXH&|.gUynAa͘fMNJ}l7{3 wy}fg=TvRU $~ <O/>+Թq)w6noRaq--8\unЯUi]J_['2$n-G= .2sV6}Z[<=jXڵ_Y '+k4KJZ,%ZLqa4$sӐzgV辥0Q.2c9[ :>LI+G?{U}g cI +jSHH#Ǖf{Mm<9 { ӏ?#\fWOYI&dro5Zv蘑]THDBc(ɄGe((H(HI(P*%cB0{/g +Mr@Je8_0R8@2 +RI"PR9$)RcK"vT*5N#%YoqAk)Pa8 GJ.{wN"L`ӭ?qY= #uXtGl{9k>%.6g1;X?G #O"'ܳOW:@?̱}wJé[0N)غ}`Ma[]cN+{.k[eȳstbV.jt*XֱĶA8Y;,NʫY95>|#BkN/O=,az!wMS"-\>#UUt{.py ptX/5 +%j%2BN/jYD8LrbthZկ\q0@ v?s7꬀k)c~Z%{[2z9 }qj5Taa`q:Ό+H}x'A# \k@pvP}+x?`+x-x[Iy6?V2dywWk,kq#D)meCNl}+l=@X P<&Q֝/` ; +§kmѦWT +x=bt0 +C.3~n +}I>բM&?.LTwޱ;M0O1Tcf&$xdA['{k{FwH}y_1gj::3 [3PLHiALxa +\P?oܹ.Rx*}5g].Nڱvݻ!s*mB>gf!,^ϵi[.@PIs@lˮ>$7oB*4p+ +g/)v5)vk`2lyoȬSM$" 3sZ>zYqy~ գ +v޽44rE@> {c2Mj}:#u3>ĬIG\hYl^Y#VYQ}=۩D[{[@XӥVy6ZO#µ{9գw1ϊ{YZ+<A,y$8CH.m(ͷ\W֨~@?"UhpQM%>#V[o^ꝡY[֪m<Igx0xUnUʄ'[t-,9ap[7:WʟyXUOxYMqVԇeC#>0Uy|M\aVq]"уNJk:5;L֦!? osJͪAsL*itz+<.H\Kyp]7y'M~WR\P9WZjt\mޓs}foNsy#~NGSsς{^kz-=u-H0N]<)RWCeR wMj3mx0}sXԨ5X6$rƍmkO4*%"WM5Gas#MeVXZ*>A1%I}Vڥ& +nF2C#BaO =9ޥzVf+ӪBu0 ΡOKT:.RjSh8bi41mU.~\/t*4:ԫ=r NWpL.KW.êZ0UkdTi&:-Fd9 +ZE685ӗLs;z}۴UsVmuBP..[]n}9[Xvu}ot.)9Û&>V5e;TrNJnݹu,=5aZqjw /GO+;nmcJwU[CLZQۍ669%"J]eMV8Lhk~Oai⹭:Rۃԩ}L>M{h_eUKzD>k~>Aj7^f0D1*ƷcZ04tmͻU,:jQdqJFܮhk(c,Kv! h@ YV(RD``h4#R!A%*VjZ@eeo7Nzi=5e> J:1M2<*b[]FC/wڷmwI\ڹ?{yFejj4.-agl]=wJK>H/uCNFx%@`{[ :گ#[zߣөM[ ]=u*\TpXRƻtY/ G^ӣ 3$[{@@ 'eW-o,gvpgSMZY:}V.k\:Op4 +PJ̥H\d԰:ҖvZ'"VihmPzɖNoֻ1w/=S'#b7>ةe+?CTV2)mq=6l*ι|q%9xV躞ߣVMIf #ֺ#4ccCOpmBzugkvm[jλӪes=' +Nj5Ccui51rF0`k\dO |\ە5ԦfgtĜu]Bޞ3-{H =[udqնsSweWZV8U'\Tc! .ZǤfwItd%κMxωJ/gV;ڍa޲Fv5{LV.w]-5Hs8 뎺bKDLyֿ)j;  +t>%dzsiWA}+plVmCJd νwr ) ri͹:i6w:1m7Vhĕphռ^lYߩ +I^F ea[h`i,J.S/nzȖDWIsRl]@\˽P &Im6Юi޶qf]ˌ3[wC4* A\v][}0\dhZ=qK38Oi 5mkV7u;9 +n 4t/ɖ@8uG{?G1W:Ʒr}껝Mw@NJ{Yo3R!kn/&HG +l}_<g};XiW|Aw֍i]k=NItyV̻wkv[KGlv]CwZ]:no*uL.1+_t wP.&Hj-**W}a¥.[ hyG [Vj~xwDc9[Mˢ^m1)zH($>0A#q&Brze#LDUwӾ}0BP9Lp7qN!8Qt)0L) LR>h>h9D&8RIQ9N5HH>j]Dp9GR @)BnqQ" I#* $*A>LBj$ʐ| Dh9sHBl=<>#' Ugk6ϵkK+7Jut 8Y(a BrTyL8@)>*-%HHaBS&ORA0%(DJc +Oө@[>+nDF41["I2!xR8N%e ! (G)9I Gʊ2))54L3F223R&xK0!J| "|B8G J:HIL rTN ! #OܢLd&r=RyR&R.Je&29 uOJraDS䎤TBJ"Q J QBaeE"TTj3ZO,' e +\I_4P0pyMNe84nDBB +`2NPBe8G9D%$!LJDPDe>Qa I)Leb0S! !D6SLG?b8BA5%*SQ# L$$q +%JPB(0c9Qp%H5' Ԡ TfpO(OBg?b!F OFTȄ1FB9DQ ǚQ(qLQ[=ëdO˔QMS(i('cHa 8 ~ +c +$l#(!>Ϫ2H9*I{SRq}NͦYdr(?n;uJJ:VC5*/="L8`ymYt򛃚g#r0Q' 'AH"J! pRJaR8P8Q!F'(B% $B:|SW7DD Q9A*]0pJA>dsr)$#%)NCI\k/Q +euUYIŭg+}"PsHQkI*,[ꮧJac>j6&SR痸ID.ݸ$i]QHluϒ=E# +]!'S#+RiauU|ܢ*f@\~׻q]sXϪ 0$5bD Hӎ~drZJO}JDLy 'G"3P_X>0:1zM?FV\|P ES '4>cᔪ=K. -4"*NoJW4yRY _nikRnDCfZ5*;&H|Z>+&p 2I-VD.WTdk븯ʁ!>koT6 +0Uw7 U\֏7vzRב@l`k֧V5DYtt^HO*kvX+:C0g9;]FMZU7㵬^|%g5 }3ٯQwYu1sYD 8ySwtk |Śnׂ xRҥQ*?y+r[\V*S8DSܶYTyr~ ) R{};0Ub+]<ժOd eZ^ӾoyErٸ 9'V}[T4W#= ggyN'0BU6> %{ւIT=E'u6H>#;ڹvubd'KfmkmN:% }˦E +h4.q>KeVKxi%=+r[jǦ@]p~ElbvVTu)1 gkv֊\ +”%)8QFPAHIA($BD("TJ‰ʋ4+/p Hp_g +\r JE@$)pe6q+njE* +n-*UnZFcZW>+q.afԝA{֢Iש2k饢1'vJ:Uƽǜ Wj随+8`K'NaoԮLt4ǩk`mk:.^%oiI.kԭnc}ez& OzsnYevl2zߨeJVՎ_{uhVwP`&&Яjn[&4Z\6Ceh+\N }|>=ϧRԿ|gڛwn0 8vj݊S::11,]SR\:)ϧt[Zu>!ۃ+]ٍ`?1? o2u+p)c)jv;3WUA7 m~LIgcWhsQ8XzEk:-.^]D`8ki_KR̀L>K#zkm_OOj X7U{f}Y{3UPUi/L:3pf[shy ceޡ^ڦӻU\5X${Gj:]|ܹ㯿Om;[ 4f%bSuUkvWۊ5jX]u;>B >++j: +U & bH{,hymV}('Uc>ɷU "@$cvY*;ǒzzCs䖄ڇ5(p2ZDڕ(QqkȅYuWQՎd:1Gu];K޷5z9Z U*!q:t]%>'j5}6q: +u*,{kpzz\gg׳qBʣ:Ht)}#RVhԐOϊ4wV.DUXZ:536|ϊ}ӻ+޽PqNaSj_)\}^%il]ٵ=QqU wEP־d'J}j[)H@\mV("j Xm::i4k9PuP>+s47ʭh{JoKjt[RZ9~\"{ikI$"B] ÷΢(lOζ=YaM82+`돩J|АOcXsIfs sZ}r"1U\ZSlEzʷLV R.sUirw6Ji<Or^PmXdbqZ}cPuJ,fF1] uWPO6U]67$$h;\w/{MFVjf=(v|%"O[K*E 9zej=}*Eİbx):̐ iڲҥZt0yY;ZcE";Ϝ*G]wF{eOmk47ѴwLOL8kO%v?51? }6%[6;m I f~+?mmqrf9Ιgwwb kퟦ}.۱ֹ؜d4Pshw{ ~LJ{;/vDI-{}:iZ90$߻^P`cn&\g^޲\CC zzź죩~NKhk\[=m^0"[k.2Dd3 [*EJ<+ {-ީj;׀'fv +4)7E} jbӁ$'2-+Hn lbAĩvnno4^$s> 74Th0$3&CCk>ˈ0Z _Ruk倆kޜsޏlogI9IȘϒq辇Fhf }] j'?5R6 +M2pc%`n-KFi/q8 k)Qp^ : !va'+pSrL{?51ے[͍-vGi܁%=JMumE3 JôZ4'K3 # [sz_gw"ƭƟTS$OAv: Uqj(kDɏBɷjd6|Dx+5 aUʵ*\\yǢjVa7KKp|֢VWR n2[#][uyi>q;Na68P .25 ]^3}ARf'c]ÿo%WoHIat8gkY, |Waд=}G|+oyN鬫uRW8eǧ"|<ݷmTnch8Lk6t,*}%w.^Ji Ā|:5Jn*Sa۶-e&W=\I9䮧s~} ~[\Fy^pTp-']qeM_rۖ[Ԫf*qʧSǟO,Zuv?߹qMfQtI[c}W0j$W&-_끸y[?SƶFDa>hSO q\ghj۴ɧUGؽˆ#Kw }l GaIpޛ۰=AYѩbiUv֛Q5ݗ`5[ߖ<9^Nst]O޲r'\w\=L6I4{=Σig.XLi]Sl~CJs4 1⹺CmTmNa2VncZ4]efD8}Wl@љ,򸍂Ө^\s؞ƫyg-ŝ~+:HA+wl:tp үh3)3*׍V+vq5[PôojƬ[][Յljef}^ۉ6 goK;Mҥ*lcjToK@_0iC@Ge`>ƭh _QlOy#n~ⰻ0q#Q?hyΡM26:ttZzLәUQTPO/鑓BZo; +1xgL۬jCzl@1Y>k]mFV}v|6޶Ԩ Tz1"V&(}*އHG<}"\=s~ږzJqY!' 4 +*4dZz + Q2ZA-Yz5~qP֬8'fSӬϪEm{t;ׄӈ 7$zt.ID5'$UV캦5\-u,)1+cvtǛ5G7.5z{LG9V: &Vyqd$+w@A^e f=ԫSC^b_ +n3H}Zq& rO5!kPIo8Y,DZޘwlvz&޽JMtA±~mqϢ+YmZCjs>һ`SsQ{'xJ,l٧h3>(j/CKU?¦b}mv VgVۆO%;tRi&ZӅж]N]QܽqXʣS\ULKPŶhwz_UiU >^K3@Zni/k@-]~(]BJ]Y! ?CT4ww}S'9+`':5-fu\LpGog,>î* 8i +[xij۴+]L:N<<> /Pm7P=`cm-szSݞ]Ned^KK2Aiqݘ35}i^Wz@["mMI?eh>p4jYtLszOm6Pd'cRRVz&V&mJH=Lf Eɵ9ꇩ} +/kQhԶ]VfNF#K#D贾JKA'0hԹ.@g8W[5jfک="c{ӥd -0sʯDiԾJKzrչq,[LfIg8Vi祂Z¶yOKx"PpR t 6h#wI'[8BZGBQ/GL-̣I)D e RJT @(! e#J @SBJ:a%(@!89A +(>Q2J0TJ% +\(ʒ(H;^ mP .Htɠ o,iݴ2C2ڮAUUX9'̴N=ιJ%(@(LPL Ar AHCKH +G) 8;*%Ut%IPf&Ԙ HG(&36#" + RLSCH( &D ! e C) )( r >Bc( 9Nc + J@(L@ pG؀]Q8O Sp# D&V=mFwoDDޞTYp\:' p!8Le)(D L +>*ETH$0B4P[P%(2AG(Gs8DʓDkMFsi<8:ed +1 rCD 90AA"R)Eа,7A=OTAY>T@A20!Spv˂[Mqg tM ́l!Da>HN%%(T]]2͎PX$ZW~&H3iz-MK >Ntf: 淨vjTǑ`+`RD"S %`kuIX " c޳B'R"R&PL%>(9HG D "ED*;ШYJ9@`cL&B%+ S%DepL# &DH (ԉO1w֯WM; plj%]7֑.a8qmDҪQ$2p:@ފomQ,!܃G87Ԁ6M 0D}ֵz/[Rxǽu%YTTH.C G +<U'CS̐+\ ܹ>^kѯs޸I'ltpI񕺫UphȀ{+4Z| V\L <"TEV] rz W' WJįQ=|CSL'SeP)ĈັTUH#9SU]^So*5tުNm չ=:>1p 20kyNבIth\%eGAPcw[aUmQ=08OW?F յ.Gv{Y=2' v*psI0GX;/cgch{;iv[:{$ܺz{{ oVz]SmQLDJ".qI>济6ߚH=ܥn]Q*AskD<-!v!Ǥi.*2Js\G]-jpk$%-ePI-=?5E@ NAmM75M7t|P6M$ *wuT 4`#Hרj"A{}OOg}U%iho*pA#ZMCzXs˜9 i1o~#vQYWwH?ι .s$ཤ7 }"Oqw~_-i=^RG+_O{*pZC~k"A7Z[w[iGX #䡤]QZA>i{x=gxs[3.] /*psrkJwr]S%-'yjZK*Z5zZْx -3&YwS||Ǻ< +ַ] u uC rӷݵ'SqTl=eZcZotPѢB]P rݽq[_QfIg1VQvMch'm/uTWt3kFk {etk2EZgW}OaRzG0$lGNrU!O>\ifEY$A~K:z{u*5`~ quwL<-_X3}дMLԥU1Ϫ)UmvsG gZ&o70''v[Ӻq4~+qtTuq4I fB(װsA7k;.͓cX:i\yh-Ia &\Z5)p)H|"9\}oMƝ&Tɦs։e9mF 7Qi585.zi6 u'떞_E,զ:8.KSJR*P I" + +E Q*.*`lOdD a NaQL17(" A%(rS +pR$ލ}OPQ̧' [mC[m*TmfA/$^ [3^:Ӗݣ=5I,L/.M&àcĪݣѨY8=R%mE+iNXGJ6-J:׏}G9Q n[RvM{ yɵ2[.gt;aRP-$D̙Zm4Z\pyĭЮ4GՠlsLItmFp7nY9['W:U:sd?Wi3;4!'=5%ahUܒh%`$ V˥ԸZOK9G+fq?rԸ\@&O+'|m[~5 9=[ﯾژbKAJgV]BS3'ڷ8޸fݛfjx$O+ҩi-GKA& Ukz>-n=N\ٴb+fLx²~qJNL*2qr[-"ZPcV{:{;O<U/P[Jm;^G ,R 6J5jvyj% $H׶csGvxOrʇI0 +w÷4]ZսZ`'05i)9Uv4 +_ ʯCvm.P]ėNVNoiSeF?%3,Y[oU3YFǴM1Qh?'!j6 +t8vl&}Aֵ =A>v5 6R p zlZ^et:9񉏔-Og trFx^+hPi-`9.г 6`}Qe})XiᑏjsA-=Oh?[8 ۴V9=?%i[޾8 !k(ҵC{M92xt:enϣVyih:>i2ij]sLujN{$Ɍ nӣro*xM㌭FQ oKz`޻V00yX{ҝ +,cV]:q @Cusu Fo|50Ggn 3PaIal"=#fԴ9]Mi' }YևJ4=d48OOmwI5@= 7;i NVHt9 qpZ+ANDHe3n^Βӌ` }Uז0`ܵSp]vڅH2|J鶺uJf63{ΦjP=3[Nܴͫ)[zH>WEiߓ(2߫4acaf:Y?5sټXñaT`o=>ŕih%KbT5,h} ++XGc( :bIs16uʔȧY8 j Ukip.tz{X5?8l$q,.kR!;NKNpmF0I?bXn{*usyQFmHc fZ}{wf>.iԪSo]$ʷPSnԿI)srG,^wMp-.)<LO&+E4U>!X7V}?߼m̋@^ʚJ{6 Qe)TL:"gH]nۋz=0=}S#?{&9- +W8%'8Yvkv`Aa p=HhH1,SWDFynNԘ˙4(H෷]X0pyiGvcud1uÉWsLapݟvoD }>)Ea?.ݶP`p&0Hc2iP\&$-p";G(շt||WiLǑ[}t eB"cĕo]-N:9:^owH,qCu>fs,^ʟjigZr4IoA,~=nnlszv1̙Z+rXBΛG4a$|H WOW~BXa#]P۽>' h"G.lujX! xDNP3GOLH J +*3(9*.2rD(Ut5GNxޯ8YDB:a9F@_8!) ' 6eјRT]%"T!qf^S'/!v5]ܵvZI>/<։|rZ6~Iu;',7T4RڕkO>+?Zs+.M7O3.?f=|bm+}RJu\VSZCm5ݛi HqdNUii}4ttshhQ[~VuH=?+Ee53^KL<Siax:#rmUΖjY#.晃\>wRLώdGv5ŋYr}+W>?0Ω:Q veSEQ $m^mWO0H |Y޷MQ=>$5lo.zv֠?FujXGH6ͶZQ/q OOüA;`ֆg1VWi+ٟ g.?Ep\v?+ӫ#TNܶZOk^3-],vD +IT9\6n[;군~2%wBwãk?*jW|̧}~xCӟQl5Z)  ATݓoeon? Z3^[ݸRO5t[j6F@ϏCa62~k'ItEgaqtuwZSu:4l\b`2pޭjF~+q &P?wܴTh =HVKI}-ѹ A>ۧw2H6OFv.]J^"߭r/m.h:$QxuVڭ+bhaH2KYnөL-n}JztD] [ +,D 6OSfE pvdǴA6zmP[~mf/«s16Tt"r;Bڙ{$@l,,=X}KTLG̐OonJ;\ +<6-o-'] +g>0mWtJ +qA+}J$9uLcL>nJ֮Hc\ tv=Eu2H?ʧ麼ُ@?ܽ "V.ͅVV: + |iѣ>UHD+3uϢ5,]:o7H|gӿTљLdu.2̯o4*!lt߾K*1ޡ+I(}6}'[IVޅO^< Y+ +tA:mw'ਲNe|ZDdhjۻ5twp]2?GܺmǶֈ?4Piy% >>90o0IBh:uG8c\P R}˘MOo3kֲ=8[څ"ۢgD5rsݥ-$-?+L:=-WK񑈕vTXj8Wں]R*i>$?R]6 #+{V~лra.e5tjej6DLhgDymND׬Ƴ  yC/7_>bڏ$D`.znz6ϥM+`z(zCOqtiC>쨃f?XYq?G#]oO޷{Ņj̗wM㘜Z=LcGWTuO9+K})Tnhs:νp D hb&'>qk-Rr#y1EQ)pl'N)8 "e"P2J\DaGT*k!W党D '9R8_2P0& +Q ; Q ~('VR2B]tӂ7Ϩ[Kͭ4O=-] +~kOh-veŃ{nmD'+Θ +Pa$KOnMvmwxhE[*oZ^ 8%t/I~ WLo-:coੳ`+:Q0Fh] @ioV23'+[Wn5Ժp8U{j],چJY+.Gm.^k% COaT[]ԧLϳ6-ƷQU ߒAiԥT8{yZ;J2,ۢ)t Ǘ ̬MsdԪ}.F%Xm?KRHi&+uGV8'%gG2zfjn.f1JY5GDN=VeKUJ 7o,N`p'f .}cʽɵ,}<̬KO5P̗;s7[k[UA0?%lZc:aÞx aԵ5ĎAGvnC3r]'N0P!>XVݧիpĒ G2i] t[ZZp 9ރOCgqH}#k2-sL99n;^Ja\qWKZյ)a<t +Ze u33-3{9LZ2Ƹ_{-.Z4|99']GS4B9*{ER 5 ghG `P(иuz׈9LJg:C+~>+MOj;ʕ*4=8]M0C[ [mZCTL2>ZKlU[sX9"}W֤ê5ǧ<4:FzX>g*- +ZL>֓gasݸsy0l4]CEAO.9qNwA{L0~j?fZYL4Kq +'B۴t0Q!Gڵ׽ܸ'K?q|ͷC\5gdk4})hs`r ^VdUM0Iy|VS X۸<0K~K{d{$"RZiQ42IQZ:hޮrDVjpAΞά.pvԪ2_O < iU<z>Eǧch֎bi53oId欿 4+>JvlfM*Eg[0.xJCyah+n< 1ϒ{kD4p˳ԧ<>vmtE;2 >C0\c䷕)צm͑0# +7K3!1+%ht羭&êc$RѥUMdU|U6妓S^ TlbFzX&pܶOUj`[bJw]`;O̬CO}!8&OVE- +ޅ_L˄Wok sTRMw]@8xmN<-=}gp[՞$}m-jCZ<4:)a]NC~sQ0GOC{*۫f]Tml-opGOj}$w_9W AEU,[I OKQow]!?jƱۖ'IwgYTxJCAnI5QxAaki;6;[?ق" _wo_Ԥ?#8eS`wG8]ՙTQEƫZr@~*ǰUS֔]6+hL >G\gv qJj,vJtPs5ckx +6GH*:u==HdAJLc=: pf.5Ƈ;SIZX<|D40 Zfw xMFiK7pF<βTQoTSөS􆱢GPWĨS&PQ")$HA +*vAUe8Ne0J G)| e22#SiQ$@}0+Խdfd(8O9D4!JR%)B%J@)BD JD&PJ9DG!D!5J}&ҲNPD!8SB%B!$J@&C%DB&L'8BE83% JLB +"a'L#QM?l )H&pPB`!He16 +c "%SLA@Oa>@Q9L0R0 ! n +\(e(9HJ@p&pp 8@H"e#ʌB +eE5~ +I2ߒ, J%#OD#L"'u!Sc"zg>$ 3*5KaIBi9`J 8Z&w ʌAA(&PQ) yѲzԎ9dǪCUmXj0 %FzG>e(P +KS!pw'D K2*Z n# A3Q>h$!(iG*=^JDJ:7 1U:NKWaAM e<,-[ԢI tuJMྟu~j~u-?ح$0! "(>PBd-f袟xU:al#g L A)Jc(CD$Jp BevB.@CcgQ+1F rR)(hw#5P1y-ʦpKX8U:u:,`!, aj:=UTAad\} Dm$Ɂ+@֛Pm9gbg(HS8D E΄ɔJGrRM!IpBI)( +$UOJG%)D"a0SL &DDL ?b@dJD> % %6 4 Iq8] ֭VgWPYe*/Xkk'䝕+4j5IWVv]ݺlC{H G +0轡I''Gk|/mN>kZ;V#d%vh:85n -} ipz]?ζ]TGIq +5\]EFĆըָ ϻ !ubdUXYw}'>ݱP6<DqxX+428Jg +V=0'iE4R2ğ]v'6Q/:r <.E=FJ<oWwOY\+k eҾsxs`'yi&>K;O)jM9;Fjw͕mX'Gڷ>c-9gtha29bkuRxsp +:GN,eWt2~K_^j9=oAs_bڂ(9]>,բ8Nc [Hw.hۦZ=_~Elm^<-C8ĆWeޯB'4&ZG]eֱFڳm}A F>ku^'u?<gWKwnys!>K+IVp6k4_[AǽR5ZzS;ಭj-xx_R2I=X1;ʹ~ANUz^ܱů<l 48I<.jht  k oiKQE͟x.W(k*TDf9YIku*H_X`f9U;s[өR"]#?Gskk4wLlH>!l6ų]m=Cz {Xy%oMFr<ܷUhV7W4m3]>YnjՍ"Kz=[ %ytj[QDdڻV5:]$iLֶ_q kZ=&<8[J4{PsAlGѨQLǶZzskK^U;QO4USnWO=#fC:c~LS`x4z|V/hֹhA৤]@nh&*8Xu{IS@=*3zһ-j*: h y7$z'gG].YQܮ?s*uw:L'>W{jm+h$pr"2gYʍHmB#y`q.ʠ_}ˉXZ׬Z\ThπZ}gysqp܌|Rp;}`f\KU` y-Ե9kه5܅v(}G?3iYLǴA;VAl֍V.1Gt mvڴXYgs qǪhtn*R; LcvE6۸6$+wJ5SNJO_keJgi{ޘ+QVjUY>$ #^[7/<)YnꃻioT'=V߷mjOo*z!>,{JuA-q-a.WM18B{+/}Y0$b ~ I:=fVk2>~?]HOnj-RQ< =UwX׫iUw"A$yWmY(Lk9ϿݕqGW$z7/}F|/jM816iV cAq[ AyYnSu5p}ҳ5i}ZU+U[zV{G ӯ|צel9{i/`cT}_a0OW5wji${@;n,kUa poTvS D"~ڣuj,nG _w@э*AoHxG~\/6JT h]uԤNxw]vetE]'| wgFcm y?̰6 }hP{\<*;ѨX{^p[mRI-@⮳4Zb'˜I13nлmM68u21Xޔ5MXP$KI$-޳,oP2kCϲ'gWncdn} qd5GS\-1A~^t ϧnBP4q c7N0'H žޡpӚ>h.\*թachiE:`G, S9u]͔B xy.}˔*1<4y-貃> $\^)Fp$}oicև.wq~z;5Mb* kZF`uiW ho@ pv+i,өKjw@)vEŽv Aa[5cpk/x9 cJݿG o@D\VڲnW߫ݘRAG t]w GپN՗%1xkΥM-pZrs.ʫ{ݘ]qj .. F',3V}tM^Il O5vMޒ}گMs7>Ht"FǕ7]J닪}x}2GJ'?ύBQWۧnAvԅm&k@"8\VowL|BV4u\݃<3ڭ1v 'kG\gf/6.I{W36.[V66U8[XۖNݴ񑒹}hfQr`֛v Xݽm6h8qP +zG%v/[?5:7]%):{m1xq,]ڍOPAs  +]F6;ZEj6^SR*7rc +zou1t M u^Q V^sM'*F{Uu~iZظ+VJ-0O=# i/Vl2&T6Y1r$>+צW 0-ӭ(:}9Z.)ѥzTP|s_MrTs~aoqeoJ0:>"I\imS|pA q4n ` PW*j1Ȃ ǂ~~+SŸ51$uKMz榑^`x)N%kZS..gB:V4h]2.l^=T+.sXet,NVybٌo*~&{IuzZDpv/[A|$ݻD%"P8KD}Q(&]@DJT]} +0ߒ(Ne4#~A!0aJG*D +S*?XĝAˋ6 .q3[#%*[SiMA#ho]6Xg 1n,vƛ|e*e̜H%au]v}j7>R-ߟ1bdl"IU5֤,n[I$7#[]sNmqiH2R-G^Kt.*Thq dp}SҮNλ65OjX|< Sɴ.-華>=/"1t 4׳D6-jT6u}m;AV~zЯmeFWL- ]4U+bvRW~zZprw5sNuԈp>89Z}}P^4B[pۖ_u)-"?2aX#M449UKCm;cZ ѻթhnlcoM:uF^|8Cqv:AL` ĈrJ`=@8xrv亁vn4p ׮ I!uu{ڽy@GgSp^ 1Q'*=˫'U< k m]!áZH64]YOi z=I y3-ⷾ`dF2\E=uI$ ls5OtۉebϮW/#ni=fC'`]FנN||MfG>ط^aAϙJ+\, ƒhN>̮_ŵ_ R?װ{-?7 Nussn}J*k@pqn]OPm34齠Iɟ]$K)U|]e.;9W/ٽn1_at{ŭջZ݄5VeNjw;QwMʰ=KT o0Mj6heAZ4F֩Vf9 <~.+}.<Ok,*Rpsz$q(GwVzQvsGWkzkǡ[w&FOL{^ /W-n+ +}"prݟjvV"ck;sX{sR+d4j 1[k6զz\##VmkT/ӧIe&"\f v<;Pߤ2}נP?vgIt<kά6i~ ˘`]B*Uqze. d9[oDLO4wȴSidqm5t`qWi5JM=.,}ɪ .ڥFdhTZ2V>yWduc-#Tjn=3 'ӵp5Wp }>m\6}*:Cu8B@qc73Ut{-2xXݜOeKp}E5mrys\A +{ti{zs=#%t˚{-.r紝_E`{<5j׷5Mu@d"LxJv ՜F b5[#Wi>KMm>+Sۧu@Z3[Viذh6sNoI1ꧠn v你տú'DOWhs\^*ը- z>$g[֦%92 {JwC, OB{w֙k+tF_.pi?ZH ʞI7өKٗ25HomA4Z amN] =FN,mPe ocDޗtHwQq~05.MRCHL-M!j=H#$ +56:3S..\֟Uu7%Ǭ0coJⓨZ>P[L 14!9* X}[ 7u)jpO>Za_Ë}LɡRYM-tUuZŭzI##1Z͚Yb֞z> fԵL<!owusI]zi]Ӷ`xN9ʻBnuۓYNу.?)!% B +J#) qa BG)p)JQp} +zd,He0DN1E( Q' —<"DLZ;ݛmYu͈0V N)^~v=%tLөGKN-gwT&%GLV/uG0Z+ǎ.k0ZH(7x]2P8[ +f:a 9VS=2OdY\ꛠ 00ͫotsL;eQl[#8:St-o596KFz8d-oBR 20G]6}㮘C\0'uz}IciOO`E[ J4箷֓gvSzX0p['[c`2OVM*6 .;ds<]a(oKDeFI|Z, V]P*CAs;cLЭ齵Md WTڰzx 24H~h{QD޶X /n5ݽG T-.w-+*42O+T@P?9QPOHF R-Tղ\=q-\8Hu@~i@="Lp;vhT^I +E0@GGV՚X%Ozu&9hYM#<$~irw{%N&P?)@"{eq `:Z@{EA<}h S%y%63g :-O-kA@ +Gò ݈`c mo9m^Id5@0Cå@!h>ILq9J&i>eD!@IJQQPJc(̣HH%#p} +_ [QG4JD/!D~G9@COS0e2e0a"! '& 0'0 #L$PrɄ 2>I*"GؤrH9S(GJ:rB"SD(rD A()r}P@A0C)) e tp"zO˺%(D`%AQ{ @? +8GAr&R|%( #f +&I.#ɄA! + f.% P*]D*pP] +PQ2pJB18@(($e0e"a(@@A(9H"%DDJ8H2H‰S*$`bVrD"q ! + BxH8Ad5)FPDQ8)LL 98ςLI+R(c+ C +:0 Br@)bg "ar(.2akGG ̭cA(@)D&P 閌uj> ݲL1+P DDG m?4dr4aThѬ7:*~5VԝtHi9Vi)2᠁PLV@ x A0J:Yc*P`sY{= .A+]5ѮQHoH"&N=d +c({Q0(CD2(LHPpɻUtiw[>)2Vt<%dD"eJB軂j +@HXvVYIĐ?x p5"N% J&R"S%A)BjۊV.`~+iPtH҄ҁ$pDI&\]?N !Ēb8UjI)3qxg kFּ.h$z%J)Ne 4Q0 L%#(@1 A +@8)ˆ p%#D Ja$IHrXL޶P$T' `/$ pP!&3L"%!T} }1$̞L]"+Z2Qv/4]GMn4ڙ^!/fZZ՛vVRK$F"0jf$煓opI]vmIeJ6B zGvEQ- [ZUI\*k*9}z-V}AMX7ΫF8Vk9m@cMi8`2RH["}4]OS4Þ&Vh\OuFF^>{4waTkۢޫ[k%YZDGXc5ѵvj~Lϲ%i5\=$h]P&# Sҩ y GtEjTjbKN=ZmgVYkpJaa1URڍZesw[7TXų%w\h49Fz^ JsSrt6 ڒ)A'%jfԦ51.>E5{1H: 8VXթ4S {G{J{t:NOW.ii{ajm5zZ$2wدz/vR։o,~w㣠j˞bkZ^^]N{OQckR=LwW8{DTݼԦђǂ8fV<+kgm7=S~Un(ҳ^ֵ~"n7ZiK[ߤRqqIYJ.2>GzWG|-mw@,Ocࡸw=- _UU+SS}VţLx{u674esuu *AWɷuqLѬfɺ1U¤xAX|Ը彫H}mK],)SumrMJ~i@9j:ufHiabjioKu @1>LDd`- è3m)ClnISUZ6[en<Xw[GX̑>+] mfk>}PurOL5|Ԫ]}Vonvkl{ڴ窛;,hEP s+,qM*o1WGn 4NjJ nπqu 5ͻM,OA[:]ٴT.=Wn>uIxAnL|-iֵX@mMcT-k9 tug-5;i:<=BZ:{inVZt4C}`[M׫;Fu0 񕧴WRړX.y>0EggE1&>an-ZwasASS:{Fg=Q rh,w^ .:ʥ*cY{@f xu +%+{c[Hm +4ӫ"`x|Įshn*J2Zy +:O6TvGP_B[0A+$#Das[w?Gn1Zd.ZxMJLA\*[n]h`uLIn5/?Ohmz`o?YrF ֬aVkv I>ko5=tűiw%&V[n;:;;q]CTpSH6. ʉ HNG)%E" +' +. G)#Âc #6@@)QCNWPTmWowmA^ΫˋyCIaj e9hqH Աw,W?#k@i[p[gvɒȈyG Y}^g.gP#bT=1^gX?MֺK^m yvƀ\Ig+Ke k JU:Ŷ>.ػtn4D@aq:]1jζu=>ǂūS\ڂZ}Zї4XAK충h=>I ahnnj{|&Võ+B:C Pu@¾~ZXm +t5)Z] ST(1ͣYC@fcTnnj4prs5;zx֒ @VXuk;0`/³vBR=Tds+m-hӫuPwHRݵDF ,˟ۉ'>Q2Xz +޴ŝnK$z\]I#^ϩtSMnkIq$%GV,kSʔZ9i;A6(izе5) OZvާ 4Km\}5,rN < X;DigDHȃ4-'T2ǺH$arݥ]V8P4ǒ4!Re1x%b\mW7,Ȩ8+`zA #^1[V~<@,jSh{Ckn4ַk~}vsfmv[;Zl+Tn yE޿A$ #<[Ap<YeZGaS?3.Stٗ + Wx +JŖR(Sc)ٻ{ckowwJۚmyrT+EKR~ҲJ$Xf߽fkZ{-L ׺4Ejt@r]rT6uu>~ F29[FPi>ր -ip{8[ws>w<'?̻gT-?.&ޟ55} HdI(Կ_ftW./;.a>GBnp OP\Sk*pwϏ%>qdPw"Wu0 W/.):6{dC$A[R室mA +,+[ <$[H2Y' ʕ1긭ߤ^WkD.Ak n+:ZV]5< +T4yZԩ2zOO J殖*; wJ-8\֨ɥL{g ܢmrg@Rk5Iq[}jqKdGbjgK˸,}Q4Y|%dvaH2ϼYqq]%;fp KaJUkFKAVc;56T@#ܴ_m@-[-~ҮkuT>HMkVv+I~ȟiLh>Zi|xb0z|q b[{L2^0%m5'SjH2 ]^njU`0#I mT9+2J+ m(t֮ɱTuZBix`wZ2߯OEP\#ĜyA*3pVeE.8IZF*]q]~Ԯ,K~G0>iGuD`x`HB@!Q1FJPDRBH"RIE'p} +x[P0ADB&SC9(KAc)GJrϪ"OV֛j}_>^DcyiQ" >BgP[ٗuk+0C >+C `K9[Mn> T7f-m;rzGxy{aa'!k;9sqx֖Qasv KGkƛ>s}?hViN1 +YbQˎ@tx{:]]FH8,-)0/Fg!O4sXEKOk>xv=AYqLi] ]@c`w(֣FO|Tnu3yY=>ٯ`. nKf$`-iӯZOC 兓[t\n +̣bMp{HXݪ1֥xq2AոhﺙT,-3!iM~[JN =q:`A OikHli@3 =-XׯRij5$Nٶe=47삸{k"F}gu0OI>5SY 8K؁kӶjj@&sēnFGxcU<.K p-R]O>KwehթL:gj{36e & nVLboFv =oiLה + ZHtpVN]kJ!ԭ 5.HR+,u#7u!Gzk5rzOA.p9{Ai54t864 # ˴fڴRUX0A +nЩ߻T,45:Vj6u۵ 5(ky2 *5G3+-*Ye*/ˉ9Yk{hn{q5-=>${jD u*}|mjjD5?Tjuz5IoH5 -n$ p578EFOPh[mW%[m;KafUjUsLy'g6Ϸ40>ba6;Vk7GRaN*0s0}MkzKNVBBUL%ǘ'Fkm6Dx +wANَs&=VZRiq?[- ZS#ܹJƣj7m0 AK[Jv^(mNnεAI%ǒ`[>͔4ΐyVrP3Tc Ze$7 +˸w]B֋^/1<ݏ+p .%0BNSf }ZOqpUku[>mEcu@F.V̽ 0`t[ZKwZ۽n%dV7Z.zSV.ai5ZNWy$|.t}}zg @jjj"*$2u>Eԟ +NʌtdfWUgwMosIh逊Th A rl:Oџ\>c?o"=.u*}>ީ.o-(=6:)q!vt v W#,Vmk5,`@՘\n[*t4A畯a4pAaj:-Aqt9Ť#tiw:[VUFՔ$$ ukIo;|D4@t0x45j5z֚֮Z P5 +nA.l<-юjg. cojy0JW5pp)TڃsAo>Jm:M>aV6ݝ}CzJm4@ \x?Mc@hSyPZlq }[vZLk k7[J,h峃+ di,[VLjteF6ÀpHS \z6'Y!ŽO +43R|A*Ht4< }dG"GکcJm6QkC~HO&@p @#C1(2)~j`0'8kPcA JQ }AGK-=M|DX\O0~ zD4<.G~iuo[> ˈd.U '̴ǽ>8 8pyތfP#䉌x#(&SDr=! ൛ҭс]I,[ajo3t 2S s‡(R.=~(?"=|O9 | ˿&1Sc?)4>p't# z0 Ĥ—xJCK^G} +L$TBa!pS"^~* PZ)rӀS5 +D0DJD L@KQBQ@ +%ĘTLH&JDB%B +q)7)򓌥2)g # + B@œAABd (8@H (AdR ;  +G(HL6)L(%2QRHu&#pB"TH()̠ JQ)B:z9AI&SA5( Ȅ |?B`BLJa(0a2$QҐM)H +"  )t(pA"!E*%GuEaf qrni(NW SQGOy%QϹ2J&R-A0ReJa.Q9N! +RJE&9G +S*!Ja! &2eR&%6MĄ %BFp$i0x0vޮuv] r#ANSkdrX aj.tZ7c+7\A-:KI3QҨ*<>!is&18#|U{Gq]9[DBSHA)&P0l$ auBɭW#&des?EFX+$VuCT aֶO ] wNc"W=g 6;@;*j/IPI]m +ULaBa1p8!!֏qw6(ݝL{yaoG=\ y@2%81$$<.]TB"Ats售{OMFuNx>" y$!0AQ aŒO0 HP +e%MVmn7k+s{snvNkCڝ&gVPk0{^zE׃XJ} +*]parL7KHJS&rKe$B +E#PQ8HJ$C, x:aHA0P&!91S@%1 +1 +DJD|H 0znPZRՎz[J{m;`8[2Zn@ eZWLe`#=6z>O +M[QהM '->[sX5 9$g{QǢ:-rKa<$JnAiuNA-|aPuoWI'R֨2飧dyAXZ>qZ2C{ 7k8Y[a 9YZF7UsHѬD-1V^LК9aֵI{CVOVۚ_U|0inM{GEYO|V.+5tHt-Ww.~'P_N{iC{ O5 zu7\0&G'.fԇ{kk4  awcuW֣ *姃`ҞjLk o][rX#޺k]Et~K-,$A7MMAzG'vr7tK+:X=S +y^ۦ# ˄Q r;M߭ (:VEH*7Ks_ynI "غZgHtAJ[Z%)4PW7[VyLSKwn/d9&ya5;kРK[-F[VXRli}QXZ{aB;-D >:d*{[{2A}N y+7M{JͲUܶ[q7A`tuTyk~<-m+TwtGVg꟔JK&AD!`"ޭ [Ҭ'9I\څN X./<ոZϛBP>/-ihv~sE֔ßR=n0ց#!n/7>,We&0ީDNWiJ A$ei*GaF4Rڄ#<[V69 tG͡NNJE8e酫ܺ)w85o{y O]rUwM>|5;[Iair$:u:4PLy{Lظ+/I͡]a#OuIC~ಶMHnI* LctJ}nʶZ-*h3ꧾ*=$y 8Y_RmN%cێ鹹QsDs?Q^jIQI KbJҵۛK.5KLyۻpӍ;K`;p$:x\k4q$ 畲s{\ֶHj`ZQmz@XbS+6h56%UG_^]6 J9]9Xn똒 '5-A@ax06[+/g +irثD` 0EKD ygǕjVRTo|Y G˝\kc$-tzU{$sڮZRdA"P%(Ax`.?\VZvק[זќyl5KWGP{5:LR{Zh0@_m""l W=R/UkZK%<7QqzcMv +K9m]׼pZ`Ȑ9\^׸9gg'ܲOS}Q#-8ϽuMō:^D<V*<8\_w5wD5nk}/j43.pjD`<%sznM[;c݅[X [Բ}+:6wx l_ذRs%`H[?V*im@a8ڴerVk-MU\M*%<uںc)R׼Cwjf)ˏb_կJgSA:w\6nCCGcT^\ +^oUYݢ44qlLxXe^tdbrU޳_UfMJ!SW3wFz2濂OغM WnAm#ȎGg 7 ݶ:C:Zb#[ƋަD BoWcIkհ=U(;0Rܚjƕg{oW_kZZӞK]ۏ.<NJ䴭ZR^Ɠj:ߴjVPtffH`iz\`}3P3 +oZ4_O E3,` eo4a-rktT~vb~^6Y`0b,)s-Us{"='w@ZTkC\w&]Ĉ~Kwj\ր:-йkYLAЭK,JZ@q?-p5Yٌ@Jh̜[9o2ҥlws8=otH*ڸ/{ZN}z X(n@8XiUmTb~+ NyYu3 ں4吸ͪR9m77p{+x51XP[Uot*եy +1ذK?5IDDXKr4i0 nz:tmX:O\H#QX:j/ZI$|_i +TH{Q\&7G `zSL7kJwۏarG3Dqo!{>PiM)92HOp麞)ѦIc>_QeQc3.!ˉҚVkxvq DR ۗgDnp Aǹkw9B:35 R`RsH]gy<.qd}Sِۼ{||pOO՛n)4JڛhRiI.3 yu- R*Ѹ@p2>spz.GWfL-ըaO~m9Tи5 Ӡ^yftIm{+HɏzZG_ϻ.tpQ"?wP<{_;Jqz+`v=Laդ߸, +?y[Wk-j +]I-JZA>pJ5jY=mj`::W[mhZw{\HsK eb隦0>ҝ*4 s1+V]sW{]6۔uV%ӺC^}[\޵k\";Ch¿o!Y̬-nʍP!28!sClj:L}=򅛵]K`evxXZ(.?hs +vٰV͝~+F5_:2T!{ibI%UMaAim;ַ52q{ +NsVq9e%qݡ6϶ԙ:%MkZѡ/~+Gk;LNc|c]MM-:SOZ=]Z1.$tȕllh!:GB {+!p-{tw/C]ټ{ڗ;A,͝I4YTUoY O# ztA֘?ڕ6}[ژWicUv1]}nkDg+ڹs~y.JfH;Ra6pUWo\Z؆ s.\WȆH]~j )*%00L"PJ(9AD$D(RX:Kzdz+fPs %)D0G"QԂcA +@Ϣ]Eܘ0Wqkm˧/>ackPujԩ$afjz GiBϚ`1F5Zm4>WeX01'ȭq0c%vohy! /R~ǩR޻whEm pǕTSlю9p8cNط_aipض^Yӫ f`x]Z_ЩAaP }[ːŭ2#܎ѭ*\.<]]flk  +嶶mzuVk + pԪ{hSq.UhꖽN/H>ÁNy,<>tTVރ]䆟xǂrꋪW 0 vn wө[eרE7Tz@$ާnQDuT [Ӷ]Z wUj0ZO%g+Yi+mX)Qڬi $.p^~R{]J6d{▯oWmݻSRaܸ{'} agJ@]v^p;16kqWRqhU =!⑫eYQpWrgP擩Y`&CWYY iF''ޟV0S|<2"iq7LgqwR [Qx9>+!sHr7ue'6DwtmǜT0}[lntKթ6Aq&~2:=Ra wPuŵjl0]kvܵԟ^quzQckђZ&Thכ:mm*4\ Db@\ZRa< COW +>$s)m-VWWTwn֣_CNu]OToљn)/'At64Eeˏ&Bn6j/[Ȟg.kRڌu$Z:ލ +s1Z=@g}^wu9F&ةsUk.5mAߺe>S1[B(6 ;̭v۵twTYäs3Qjx+ҵM ŹeZBzK9Y֫Jo\Xprp F@@! ?JD$rRH($TSnV2oMyTC&B`&Ҁe(rj8CL))۔pDBQ6`}D6< J@"P (@R&ADJAħI2p#2J aRI 8JLe>SQR:#Iވ"rHaQq&QDBi +N2Ϲ2 #sꈄ۔Ҁ'ZQ$) J R&Na#e#D9LF%Q R..—* )(#S/H +ED‰ 'i!BB9e>!Da !|G$ "!\ʝ6\}kTNy[ʛlxVaErh !2H2ۗW:5Cc.ѧ\/h08ςLDD B&v"S@;\P74'6pjlysZLq*i*\4i`57jx /7&(a2 +DJ| 4D&); !-p%2!"e>(ʐl9Œp;_: {@A1ϊY;kjݕAˤ4K*A[Q"JnqiZ֜=~RcoL2*W뇐·ykUkAsNI`2Mjl{cW%#ti<&D!'Gupg_~@\5ļ739凭qX|%0!6"էڳWWvg.j 3-skJv,cV߭[2.WSUd]NC|8 4t钑[H+ߚ]&*0M@ kimaLy[*JƓ JQQl^fnjjKH GTX5-|uzƖ;wu9 nz>= 2ّT|]B޵Fsi^λX +q5\ V׷@5 g16#2k:RQ˼4y }(4yQH!lr]‘xiQ-CX\Im +" ݾϽ$t7 0zA\fU/]R޸I9au"L9=a*l' +B*0N +b.(k'Da7S!6BAY}*1M3@#@dgŒJZ]}ӧ%p,_qVj(:K@oOPJ^pe l AJ"%"!#! I&==.?lR(@pS 0QJQ0!2DADp$m;ۇxxzu=4wS}1}ꞺB]ش=#qFѩ1R_rqu|u&T=^A̮ @Ojÿe:t<gmEﲹ`qO$}b]杫ijP܊tz9t ׆@\Hp 4G< 'bioC }TzOQcM:J~޳A# >^v1e6 xwe{ +X_^ϪVu= + YV0u7sZ30WAkTz`z}\XS@sGɴܗ}qg~OQiYw%MhX`}74RC_?ہQ +yke +n[ľ dyen-̴h}^{\WӚnur`g[]@| #"TXc٘Z}{F藍k j3^hҟltuVʪi魨ZǑ0ueZ Gg=&tOm:MX~^G{߰;GҬފ 0}G[TmZ KxZ@JۛVw@p}5:J@R[< Zښ&w=#[=;ZU5Hphxus6£+}JЮ>曊_۱[:zo>+w юuYs@F!O]u$dj{\4KD2{Ph8OZ[ uZ{CZOq]anC.ZΡznU>sm-qKeQEDw Ma\~v< +_WL=jT>F 7T0<`.53{Hu2}~m䣊 \wVպڗլkQhdd>լkSkh 3].ݰfު洴G[1՟X +{f4(I NJ*j[F>Sci:ƉmO{>ym >6խ[c鷥Ǐ>aV*ypzp=iw=1rapuwԀ 9 ;TVTuN\A2q+mYuSd8$d VPҶKeYx;rڮC]:EFK)+Q1W.K +?o[vhgOwOSXWgI'pl ?VoԨcÀWt'u:voUkߓ3i #Rwl GYw{~}kj$++tW[1q쪚e7\ѹ0i-ݫ6yk09\vںYM=O&+;Yn>o]:S8+{{};Ou]NAW3^nj!HS {+l>n4oӂ_R!i6 ;׉8 FxtszSթkwɮ};v6K+ pmfDB^#r0_Dy+w[cQLOS:M6իrtz?[֦+Pӷ`dNI*ǞAOVGelGM7!q^mzڽRuG2ُ2>S- }Gk\'Ҳ2^ZMqOwjvrֶiת+ !Ă}c[@%lw.xˑ+$0\>o=FX܍ʷ=,.n +߳LDg-#5 KOX.yl9hG$Ϭ{Oh6$C5.HlZ:+ +l/WS+Oiy6zj?./_`5oD@1Ը|W5W?;gO_]wڷ?wW%[?ʆе_iMi +p`9dȘ_m[WEjQMn}c+tr`Oqڼ^02V;zOY1_LuXD@ݿz_ϦVvݭQF:+k"~kvѫ1t͗O:].AWUcnZT鸇4 16'ϭz4wM_oܹ.́?%d#K=' ]tF卦X tL{Ϻ}*7L&h .3vG+#?\߽KC:`?NYQX絁yZkwO̶dcosj^|"ƭPT }ㅏل}~fxY=}u47 O]cX7vkht?M='QAn)C;ډc-Y[S}[j? ՛wܹ]Oz Ij^)\mG4|yϚ>je7OP}ŭ +tրW7ڐgGާIx +g[mE~(֜)q?rvf4>%TvU5ZWj 5+Z]@ܸ1S#WGwV˰;{'M>?}m]Qh':XgU,'GcԯvZT* +*42v] !Oy|7%ƕJW5*to53ܰ;*x4!Tϟ&Gi[v77F>-t|糧XR Qڅ@4^<.s4bqG"F +1y[A!Qo]{D5IǢu5ksV*>K vgkRz^:ϔxӦܰ{1lXrvk]Z7|9[vުۛvN[99%`\IT䮿X([{ϼ ,.?jڮ'<BƱRpSO{4JC^} 1*uu^ eWWiZ\Rn^ <wѵ㮟>J2J46lTH.M?Vu:o'XoѮ-9u_hĞDvV׵oV1~~m&^XЏ-֩ecj:H"ZZk[B;0\ZH ! –ٴjUz[_dȏjJέ6ׯPO8Iz.+K?G+5/g][z~?swrߨjwv g(&PB&RA  D&e#*.(9I"IR!6r;˜ypVׄA(AL %!2K!0e2PqՅ}PQUSPikoPUx"^'07A:I{sOڴԶ}Ѩ޺:UnvUojm !ORӥ4;8ZK-y0[\> 9 `xy,R:Ӧ>9>\ZՕJv1\CŮWT2KIHrS?>.h-,OBVy2n L` -5,_kE5hhh:ݠU:8i\ +Uhtù1y->=J5)b@CaݲΠDI>nvn71p\|>թm]q--9mʕh[3>{K/}iolhS 23.?i]JVSLs[MHe's[ӿ Wp<2ۢ#^I>s貑nKzNDmcnj}bwME2GQ:6VLk@<+?LRo"o=רZL0%`mk4'*?*iƍf1eSڇphx'#]S?v^:w_DS͟iew$1R 4YX[RѫM\8 +!MI|8E}l^$NDKE5qzJ<+Gn͸\2tQ2|aaéwF_PYoiѕ\k܂G%kJ:ʹEjrK]O^ۚYzVm&dg[}÷i;~DŽٶix_PM/ ֮ep=_[ou^å4݀*&j O󫷞SW6cljF.VGvѴ@Z`|;fTmZ?MB\濡/-Z&#UFh\*Kwu;/S$#ʫ^m)[^iĴANU绦3XZF׼.znYX7sd[htỉdo]&jm^^HmNN'ssGAWT*ZAĕ-*֪5 'W8k4US8sd+}X +}B'6^SF5hqN2;~wR/2`7rЦ@xs\'۶&IIiG-t{M+N g6˽nkHi-&lj@"L aۺ҅:/`8¶M:'\/^GvgɕOnTnugLNx u}HS}&ཤ +Y4JAp{Zݥ^ʳ4絥\R|Mپ߽ ceferzүkpoYv5̻2 5'mSH6p.8{3o;Eurgpjm{TaOEO R.Z̸^ޚFZqadkfFbڱk> ji`SٺƆs]Dtr=\5mjp$ԴMKpE Nt&>+{6ƥ +bp?2nLө!|$JlpwH#ᕸ{;3#CMJk<[_gkNo +A]VΝzf}=1\{K,ntI!f:{\|YM@>ǯ WSGjE;[#kQh:ϑTx|VOچ4-bH SڗA7Mxq{]Y5 18H)a'g (%J%"aLq3P /%H<*]E &RHT-.䨷 ♨]ʌTBԋ.S@%$)9Q&TAy*$PL +]G)%"RL91P +RJ:JGyH9@q)ˊ B\rT%8M2 @0g(8C$"!0e (g܄8(nJ@pG I($B@ *=PTDBg>%Pi#qI2P2&BSQle l>ainחwȈj Q}0'c8hծ $+c$pHD3Na2a) +S ~ Gڂ% O0R(vRHStQ>2@(8DLDDBH"!"a2cQK taB$)iX6'w @NzWT%ژ% KSR" +DO)%)8)$p8QKRL#( K!#B9A@lsL DBa#K(  I@L(8@9DR$"e8H8P֗;) M.0) @(@ !)) gbA(L !F!( '(ġBD ApICDa0aJG"Q<&1 J!6982"! prS"9HR*-2 G)3#L/zLN8$$D `J9H @(9CDk6z:Tq"~JC ;*-> w "~JA?rO*u@> $2B B"Ja" +DE0@HKrV*<{B`'Bq_#ޤ\RhJ 8@DJSS aBQ( Je> B`$#.aFp$a0xzzwNhi|L`vj[21tPKD\vw}2ڧt΢]ePcP< lh6~kk{9Ϣڥk[[zN!I3Ժ@P\H +Q 5cNxhfS]RFYPto@ Q!(.b4Q#)ifp|P2 +5kݮ~BWsVS#^XA?jOT`dI5:r&;sOWORZcAt3'Dw+C=բ@&iV6['ɟPN.*]R..Є7HRGN=>AM @>Υ0HD :Q8>Շu깧"-#y{s$ЀP`>@Ȟk-~/!#Xw[[Uk  fm)֪zpqܵs$(¡!'EG?BBq9PkS sIh9ǼScorN4O.3>XQ "|O@:ެmz]',# 5p&F9ȁꪥqNcOp%c ZU{]AǁX{6֔wUGL vBmi?9L.*7cԏG6pޑHD|hm_$X8z= Y"FA|^Du2@ SpzicpzAoE令: d .{TzUCPhHX\Frz{>G0Yqc\ OMUJ*9 q:L?%S'˨J?%kZ g"DU^SIű='"RkԨ֟{*Omq7ͤ.7nDՃUlWT@:.Zzp<PuvSpc$I,jݽ`w"V[xi2>jvc">U NMVTkH"ATupj~*k9+-.z:<:>XXnz]Zth8s']Mv]@ڸtou 8ܾח5Ö|09ӮF_qV;B."@um{Su.Zg]>ίmNF +-/Қ4׬aXԅA +}__}0as .]"w&f bRu&5wSުԭ*^S4T4b!y+Ti,ꎰ>?):wzg%_eVh&!;?jtJEO +WQܝ6:@wFnv3{o]T rSnBp8!e%rWj϶/q)N&<]i{L9AZN\KIpn꭮涝cãVq]U{Ľ-o +ZɆCY}-q[=lji5\v7Tz.>M[NBڍ:$և:LH2A.7jݾsI%3 :JZaT s +ؾA ==X+mND#pVh'☒oM v3="~meIgD{WIލZݕc`>vqԾ߾z''vӛBkԩXlLdyi{t +Uꎨ.!=IĆ1%{NɭLmY%2A> od-H/8;EmWwORC̈+>gTUzX:ײA?re7;{Z&iog~IRGCuf)y] =KwuPyc٨ϼJZ4]mRk! aY]-Z\878&عi]\.x"L8-n.@i}Gqi6+]zu|Qe{R{ƀd`@8tv}:sQLǪͦO -oQ ?uW=.i2'[mݦjթZ35ߎ%ak[ʛ1ƝFCH21Ⲷ4$Z`2nC1TÏ1>|,лZ\|c_6 ;:eJ1\\L*H^TycZzFQR,۾:+nmdm 閲ʔQ+owZzGA>+qOPh}c\p"%iſsjS# vEQσ>'5i^.<>k\iĶ˨``Si6`3`cpZMm0I%hk]ֵ$2\ >"U<\k.ZnAU\L*;l_7N.];1'5VdצO } 3R6z"?FZ;?ODԤ`?ٞB搽s?:ʮ0n8Iqu +W:ǥY?&4j3OOZnδx9^w-_uӣIŮ{NA?%лk'LˏTNu*[Jn}yVSSk)p>%tzkRհI?jvԅ5*ǨYzԭFʹZ=sRpa> ?MeLmDKt?zV}`mVuLk4g;l_M&q,?EGhvړI vdfgcZ+,P>~僷կ鼵$fѴ}ͨ֓A>#iZ-CRǩjvk{O׮eJI>ۄ A+\v'42^Ƹ18[]uRL\G1[j{ʓ֟9\]ؒnrzH'0 \hw P=.|ʺ4xAQvhuͥ_=^<ՓCX]2K 2AF݁>ԜvKMBC̎W3ңsl۫q }PbmWdxsr +Ŭ9 gāoC@hPr("DD)%% +%E mz@2)ǚq2P &LgR8I΄JL "!)g:vٟ]1va.+Qޤq޻XӼ{'Dž.ьT'w| #ܸ{y n`/=>P%a\jNRl~wzͰ@ 2|Vg_ +>i5]&ٶq]eqېjw- yL8{^WfE]mg |eV^ⶻKN +4w$8}pWn#[wM ]vj8 h5򵚮XUua͉8+t[$ՀUlZ|]Bv;$W4{ͦwBԦ%$Wm]PN yG -n]Cjze5i>GN3Wٽ˭].֠GxTwN?U%ږmjֳɦ~jڂ$Y̶ UOiäq *r}FV?\ofgw*?Mkq3-k (=KQYC8y#(ڶvU鲥z Iv2VzQ7UZ@h6ΣS+VZVj{Jƥ6׭T8̈ǂh+YG!wo%A7wil\ڻ늓ɦ[T|NT6(Bɕּ[wܵ”y+_֫{~nwSo=32W;vjU:PG49}^`u|mRU\G8|•J٪sQ?X=׿J[r^r>6VW~-u6sb6*N"F c?k1Ių̈̀[Uj:ˬo'-SM&|y8[ч +MtBgbl)J֭V߹p/sஶڗ.d=?)Zi4{qL.[,7]6TV߹q(1ݟ;H.u{Rp8?pF8kj*y4DL-oܝ.✘${9l\۹^ƗwMV+ebvTشp9߂sSOjs}[`Jh>tTAb60>1w(I@]&OWR'"~ +ͯ^w{Ku͓rXVCnoJ3#ǁ>ar}u3S8|Vd FVV>VJu}$A].-p\&O"{D|O?='R#\'euO2勱F5k'4ϽlFxuJiN8QӍM䙏a]c[Φ VHp$1*wN4wuTpH8To>!wߜZs 9^}jM5U[ݹ@WZ]1]̼M:A l5{K=ۣȈS+&SJ#Z*/!tܷwܵ>+Y #}÷ik="p$Z_Z I4g &L Ar&yHP0PrQ8A +$*$rV% p" +c8N!"S @$r)D Las[AUowTRhr~ ۦI"`x.Z) 'etn.|qhL(Z"8+EB`eX|< Y[klTBgnvc[
0BPi깝_>}}$kS}G +R]<\y.I2=}WcLҬOW#9l.ޫWk WD]MSG}zsH23*;jwpx>[y-hwUX8}6Ф=UP͵]WffC+u:f5m> {KH~nZoZmS1[mӵۮki:MZ #MBQ-.H2$r~pqsˇOWn] IuRci@9vk's$W5{}cPS+k_qF!)= +ջ-ݚp&H[{jfph2eM`0;Go?GjUpuZϒG%ojqszb3 :juWEGqqt;#}Oim[|[o]z%]A?&T.(6폢+XI ?zͣE ]y{c=-3Z4*:wP揫vPaw[LjuwF] +{5V\rڛa| +ԉ%#9>} +ϯm]U{Y^\xd-(SBciXsF-utܨd}7^zc1rO2{ր*w?Lu>12MI(lO`{mEJ yqI {H[9šds;}1mŋ- -'iЩt9ZI Z÷ik:27]Jû@QDn}&G2tD]k>]:'>ᬦOhB8Z}FՃ˻$DFe=Ŷi9,] Lm5&j 4*8 rv{A[ݹ #rODxq}WrzZKK*3rTu.E{>~YXӱ-̀Dxi[eNU)~ܶj޷S =0#9fG}QH\gg-E>52J7VGUB>0p [KpGr۷\t&eUai\Ծk]Zdu68K\ +;8ZIhg;:r纭c˞x+&fuP eOQaUG+n©n;7uK|ҷlAuGgSmSkSsF [3{wm]Qˏ|$+Aj:渚TÜb}TڥnU:@=?bvSp  ]ot^Ed8>W.:_?${S)ͽq]^>eg.L.KZ@'o\! w @\Q3I1#Yz֓OYz@ +zf2mC'recHQw!W-t7%p+l[{Nsv3I-kf'NjVT`nj̕&09DJ@ "SpL"%) BD RHQHTSpuCHRD 3L/ (-L63%GHD{i3Wskfpjlۻ\^S3!} zM1oHC[OY' Pr0A2ICJ@ڎPJD p8 c &J  G L!*G*-tA@3CPD#bq<$rCqD""8IAcP +H0 PD y&RS )D֤ZIΐB(+ T^>+&Ֆm418V kTkm5XLcܳȜ >"PrIL@ς+}WگM>gX[JO=:-LmJ%>D eD"!!%8(q&P +g #D')D"R2%0RJ!%-}FGm=@҉A6 +6@Le)(hIxD&0DPCD[ +1)J|$[2Pܠe>9O#d2pG)8 #L >GNPDe%E(G +D$2A2eڙJ& L:-h>G(DBA0eiA!$x&pR@H1S# xHR#h3NB XJT*L0$,k=N}:Ou<8FV@(D l,Z*l׃U&5Fz{ĬHCr K%0RA0@(!.R)Q"& c B @2'> +DxASD!Bh69R<Wnj\Uk\)Հ ' >kz Ǒ 9`R4F $[5c(p P)>7o֢\K $.›d;h>78L  IOS5H0E79ZNudڏqs q"#MUM q}m9A is',I$wMMZAi;>ic3[-ҨU* +A&=[fA s)mc칤 S' +cOI{C?%7H'ހM̪̐ק_ UBjozTu1ͤ)q +Rdug?Р +c!x:CG p`.<̈.۴=kC%\ 13"=ebShUwCj8,OSuwN׵ YlRSrx[S>ಈux>kUu Y}aT.cTP(\Uc%ed,:ڽ}Vy \puݓ.ڨ~*vcWiP*qirʎM{QX@MBTƜ`OdҪaoL-G]Gu{J| )$>Jߺ{ S}JkOdgFFU`pꝠ:+[]Nm T5n0>ՅGpZ= |JԦik׆9klY۲ {#W kרú-=$ٓ./Z_Q'<,zz* ^ A26s[!>s,k-o{PS`O9LnPT5[>/\*ti;T?5scZkghMDzA1琶67p{|/o؎`i*dO+W`|yZ#O(M. =J{z%౏" YV} fgٚ zVxuV-[m[Y xXZfԝN8 IfZ4ըzZO⵷{Λk:H&!mVÇnS?FZX''FR՚jQ$x>Mq\\>!lf ?A+`6֔j)&w&pdMmmoU tq +jVX9'Ϟ%] wi89~\~\dkq+qC J($ĠAQ"PyKQN)JDBخ|}e)Ħ +hLHa3r00!0!HyJg e#W*7m踱MG7xWoڀZYHVeE{ǎekmVTj9qWA[on[TE*ԁV]QL> R\ G>-vuzPZdN{˝9}I'ZKڵ|>Kz`Q#!+P3Le+pWN|d۠:Iyy=|\Q\LX>5].~+lںsmNe2fn czgiukWmfA&c++lkִÁٽVP+_ՇUi@aC]F}+G8R/ }2]u:T->˭Cbs_A7-k*s^V޷u{8[0D,cNRMD̃Y={Zo>U}w's_Cv^9P֒ i۔ۨYs$2WGl]k@u ai[j\9 wQvpZ~SKiЪ=1 ޣ\wUE:Zc=gi.ui1+?Nu[A@ZͿ}_h7xY[lUÍ'ɐ}~n}qKHK;/#NevUk[>9ZEgyVC\I.oqhmC Q$܉zAxTGRu|;]ڕմspLj̀ޡT<'ڭ3R0{'VFuu9ēSwu` 4ِ Dzm59#[]QuKvwui2:۵=*ecrk7WjܒLy `$7LzдZހ đ[WFQy&XOYq.&d5}ޓW1%OLn})UasO[mn)uipO:]*/ ==uH޶ .I -Gef-~rnX6=}yX;oePE*U_ʬmGWl)~@T=/tۯReJo~+Kn#t+iFn*VK);8Wy>fś~h2]6@9,i6t$ 3+U5Z^ө<:̃ pb~?boc}9Ԩly a'IP)JWK09QoL[Q-sIUhU.i:"QqFyjtNp S4m$O8ro|@hzHF0d.OTK\O!v:͕K(R!x"LyZ=:ݢ>0OZ}DxRDCdf@PLJץAՈp,꾝&4ZgTmci3:yZ@`=;RN1YXYYV:$Ĭ^6'۶{ b+Npܹ[}qVɨg +uR;Uo$A O/?2۽h5*D UYYG"y8,MiU0Ԧ^@/.I#<5tdiW^A'[8y2X;)=< wOq/Ǻ,,>ʛ\!ϗaZ:xkѪo`'?>ϯ>F̺ң ,^,Q I!jv~h*U{{<a"\*۽HAihG c7ƙN0᠑=qiMR=#I#95֭Jop4K>'~m5+kM>?k΋YI9Ͽj*[z@\&~.T2̭[^]~R8؃#rQLA\OgݻoV%]6Q!k0aQWXXk # *,$H?t/TǂӬ(5:x OeUCrւ +>ॡf̦k?+(p(DJaRc(A  (eJ\R!"*<$ V vstmD᎖ +m h_\sZ|!- :L=HpӶ=/ +=뺭RˡdaaT^]|Qk{ U틆.O0K f>L=]gu^!:~~7[鷗}Sv@M9y[=wfKZnSp dXݣҡZZ@c3anٽx{]P&{6ƙckv[9Ɛ$Jޠuf?nUS"޴]OD'?~ߊ~+;;mֿzYo]{M( u:VkDD5-btAk[#J3W_k7r'I]Nr ++T wG tѪ@2Bvuu JOa"9 +;r7C4閗CAȒ3PiڽeZ}2x]f|9ۙZf#dv|:n/)1璲{TG[<9+'^ƒ}` }rۚ‘4*lj.4u?dg>+Cm709J;Z q踂iҨ%Ŧ Ja1ժ0}.e.7uwݽRyki#gښ4X{rdvvOm'~o٢!m&Ω{-OwV0?㒺vm +j8 \ðuQyofD<\r ~r=9 ӫ}˙G%j*q]ԆUm6CA oh6: SkIc'.$rٰc}D>Ø~9\ Jl0]=a| K+ݻsS*6Y}u^-fDnZ/PA=tZ:`ݒW5پۊ.$4x!'_gZg7] AA(80IK)(W>[T)La ?ET!HJA8La AVrm끯43sk]f^!tͧ}G5MD [5V8 5]iZ>kQGk^9[ YlOɗ"֩c1'9Ͻmw.~jAfFEwTIgܵfeӯu{fO%ix-] vW.1 ⫩8]U46!~+v+G{8?]N(WijT}GGLx.ZedSyvPU, mL늵+^}={]>D>ܧԫpH1cIfD$5I[kbj"SkzaܐvrDi9kI *nꜸ9?9ٕj;SsM}cLĦz=j<|h3tj_Gas$}=0׶=p0T.+hL{-eߥcqRԜs +{jֈYQ=qVP"qҺ^Da=0<B4Jz->s^&E"9̶WLg ȅ)%OUuv:- T5GZ"Boa,[oAuK"jv /y5=o߿Aτ.gAsV {`>fsgo5X{L=Y.Ϸ7?IHYޥ:Z2"#lǀZx\^ͬZj4ǧVGHguA }*1P; s,=HS(OQ93 *&4ҨA+fN$Qš2 ?N3ޖ>Zoe5> vJuR LuZ4j=Gmm] g%mƃJoz1>~RGxzsE=ZsXAYTiE!@p<=}ۍHs 1[m#BӷoLN\}JWoP=gtz%%4:[R` 8<eŻ.hoS<.uY?KOf^KǖtP`c#ej~ujOU `{n۶A,x ^WT8'ܲ}:k8<8|VO6V.8$^2P{@U өzBɁ>fVCh-i~]-yŠ:ʹ>$ϴc<3KfLPcf$ϽUhuXݙc$yj[ +P&ZA# ct4qnΙVE/XD#zLil713:_饃/Ԏd#`: $PgIxd5-澳:8'ǻXo߰8þaci[6KwyJ8.$[ƣ3=$:S{v3JFwUOlԧ8g>fgXfCLqE%0L _lK+<m}]A#|VKO{Rl:%Ns(nEgH3~ &&i-p UFәoK$ +z;i?൶;&)˄GQ&=Yco۶C̉*νkb]'ܓJ./<'8Y(r4B%0AQLK!)rQ8Q9Q9DJr+} <) S8R >P!o$L$P#B +9H)9&䠘G("TH!2 a() #BG*S)D% +\vyc]fxk%tz:Kz(00HVa Lx) +EJa8@DJDBb +P0Cp(p(S.B9@2逈%TIPP( + +WkE0G#BDQ"AlpB "!iL 4n0LSI6.AGJ@#(B>)D Ja3Du$&NQ(CrDB:gQ'( ((qr +DJe.PBDS)BR!"rpJ T\(pгa0!HG)*D/!PL& 8Hac!ȔD}4S"P( / e"&H6p9UGSHpD%VhH +BA>ipQc]IVǪ".nl:84X%9A +S)U-@uu'ܯ"?l%(Q L !@!D%HQ*RҩjZʏk\ YAHDz}i<;½UujRZ9.Nfh pTG p UwwLcpkPRK-xz"T쯩3 +ƘC% j:*M^ V-vxOF-ZkUpk<,+r[ͷQ`7*" +)D)T;5‘p# $OK~RI (\\2TsZqzeHq“y@N)\ +pª)8Rsr~ +JHOm R J~)H J$r>)j*. )4xRHa.S(BA4(0RHI#JQI"9Q)*_ +MN&!N|(ʔNP'0a)r ) \jT2OH3 鶫[荨 L$Iۚ05 =/^uG +nL݀`=VQzsGP4%T5a6xW3]؟?ZIfg˂Z2J ˕Xok;, 6v?aQo;M5K!>K/I(kp+.mZjpk$d]蟭z~kQTCFVSYI;We}Ur<+/mS.ji$ץmN}D38TVVaa"Q>@rҷ͞-yə8]M@[@uc[ĹƠ "|P(Wt2$Z6vjeF =>zOm)i8Z khHupipbVf-$1WiRs_$1+هt`OOtpd:#+Ko+})V2bHKF޶u:OYOE@Fr}[R鯪H4|n춑! FBt$8t0N@^l.i'qYAK !"(RvS% ! 2]20(2 C=( @0)Ġ4J>H"e "REPkȬA 8)rLR"W!{P%|2nW_fcz}e_*4Ox'| {NƅJeFc+ BmXڈc=ēQ'VڽRewRCKx0GvT?_:g/r~R4ha왇+mmM$ջ^хV=U aq_RuvDxǚ}i4v&i [@/l|§qn)]{*MuZbW\9UT\ho4j31${fh 0@9ej;.M"RW_ TuZo@>m&5Ԛ9L+CmۦjWtO R7gpCZZ-Ԡ,>c }}KmfD(D6FգBݗV%q\hfWTGK^ Gՙr) +Ͷޥ^]>zNI& x4(Z"Lj,+v}:I l [}itLk@s $sPnhJoyciե6.$=u:~ٷGL2ͶVFЩҽJm5$@ ݻfڕVZi@Y24}',sA>"VFkSSug8v|#%j) +`CIhw[>=#ggXA(a^VsUB'0MҽQ I-qᅩQQX2 }-D;+4BZUkK˚KpukFݓǴ*DBvSuoiY4> hߥ>hSUU*]O3~\%ΞDԫ1Wvv]J1߹t  Vo@gq&#Xubi8 Vn~*ZF yW֝Yo p>S+6Dy>{Bh=a⯴1#]J:H 5#eJ$[u'qk>ⲳk=KIᘏ䴿c.m]49Μ.@o$x /L7k qObhm` 7LZ#x3E.jwToamͽGMa I̕7^:z}c`08+iwAI%ŧfAA-glH ./T8|XAelʽ Ԫޢ\>rnZMM0 ă[atEEGv|k4u +aŭa! :`da5Cuˌ05Nֵ*n 7NJ(StgzK@`DvSSs+\T H9Vөԭkr|Ml)ʫ@ hV>ϼ4<0-t>nZ$0`O7թ_Sx -fھ/'޺ hjM%'#%s,-fIoNe|]B/r 0 + G( HHLфB%a3(Q(LI܁L &rI=S&) $20!DR)9DpG. QʑH&&_&HJ#)GP "!.S@9\eJJe Wi2LW,omn(L9,-mz,&J'[ooз oA=]x$x_T+2ҵ0i#Ђ?傟'luKKG80qmjMn)skvS4Qyk9mV檀$ ACa2D1Z/{g<8{Um{N{At;Chj7Ppx+Y$2?p~:ҝwf <|R6>̭fkچvb̑ ],ޙJ1b4-QU@"DVR.wKOyϒ"ڟJKvZbqqbWڗZG + K~h f/-=PNȥ) Y{i-鵍P@ yUVvҦAsi4!gl]e6@5&puW4)8^ǠGτ\_{~%gv&o޵NuƙBrh8uzFKWۆ8eA#ȅk-s bxY]^]a,>}&n\]4RX1d.df\1H2pu}v֥l))ґՀ< 6Nw]c{K?rvu-j7-$85mGOikCH'8-@a=Ë "ϲ*h߬h>acBεЬmKpxO*nvVi.>Ӏnhje1:YoIi6笹༷ GzYhF|5߹pvΣRȐ$$2V[6u#QGրgˎnmj s|0q;mukzK;A[]p}j`ݩS΁bwM?ȗG6ht[˽coLc! 8\jM1LC`ײjדLU_S'+YzWڅFIu 32gmT":2Aj4hIŴDA\e.\^YWIWO[D|N2XXd|^LYoeZlPi,!َ=}˖17# +;޻mu:0̓]E޿B'uRi[u5 +m=/y,MwڤD$2JyNP0 +e"@0D-LeH& &|@DnPL?$D )Bg9H3 "e T$B%"!( '$JE)Q&8Hs^ğg0O(iRG 8ێ%!B! 8Na8h4uwU8}aZxucOdǤV4n#y3W8;8LZl&KZ +ʻ kL{LJj F 3Ϛ΋^gtm=*hPϾ|VYګu:L(ѶEuTꄘtZ;i|k6t~X3zzr7J4)pddv}6WLJuWZSp|4GBmGYI^j5yP{&FָØ9ѴZZ5>NLhTX͞vS)z`ǽ[oA%hh8!s]w[R$m4=CCEܹėYuѻǃ&>K=ǪA E2 =FI9Y Wk C\FVsG +Ch, <ςY޼և0zDò 3=Rz̞W@L`x@& -vR CtG>Uv)`8WZma KƠd! |Fh3y$ˏJF~W}/d>K4;Z#Cw '$Ͽ)hto2⠗҂$D{UݫoU9:OFyicQơA>7eִc(}G+ +ƙ#'ǯ `LVϴ }3LP$BaXm9p8q1+sf:Q,p8JՖLmXcѴOyVi *8`ly?2*SmPi4 Dvw{g%hckGZcn[0k!0vmu6~egө+><}8Tt*ސ r|4ZE:b|6ຯcCh%-"}VO{{jЙykwzK(6k:N"auZGTow]yؖ6m)##>Eo xAb;F` >#>^6E7S[ @4J+ky~J3Bk?2ަ u6١ZӴ]Uد4;} E|ɽ~Wne Zw9N _e,SDmzV&P@mv:mӥP~h֌Jbzi!jm+:nϦ>\- DDchwx-1 2Eci>KYlקw4pOvo60>=;M, 2@>hi\=糂y +ۊMiPK]<YfJCZ' *2"6<~iXh4i?5}ի.EVfM *iMyT{X*u-DtW`xOV"iQLwD_VE-Z)Sop >*^ D"e.S nDBu Nc)L'2Q$r`9C$ +i N!DR)rR8L┠@ BP 9A +""R9AQQqa$,;޳S +S8GWe9P!JL{Ӕ@) A&=gB2|P?o Dx9C0ֆ8J9B™K a0L&R@8\@ eH$Le~yP9"aLa.=DB!Kz' +2s) !1 +g*AFQcI-zCJ2GQGLKK)G(4;)JHMBDJ9H!&D +mH47 Ԉ!P|(.S8 d$SLH9("TBS rS r GRp2B2r%B\$e(&a(C蒉EE#b\C +T0$ BAD! `x$ +S (HJe0R` &L%R BS"Rn2h(c92% $D$J`B L$u}) iT)NL S()NR"A')'(AIHDe0!$0e,D& (g)&|FS &8LBr2pR!7(@O#'(qNe >fO&B! +N9 RD H& $A!QPB&2 a7&THTTNP%(AJg%D2e&GR DO R>QE&#)Ԑ HK(e"t??Ow +@“D8 H'$B#.zǹ) +P G Dh(ie9D JNeؙNJ ( rDJPe"Pr00pp2pISHwjAj$D00JM)&Z9QHUia8@`q G*R0 +|~G HG)<[9(!&>@2GJPRJ$@r! NcB'!҈La&@6NP\ +bJ%!LJ +C< H" +mDJ!(@2BD#Q"RADB9GO&"R99L DDBIBP2JQ"J=ȚԝrMI*PDNRГ])'>n)%$40J%JD%"Pr1) )fPyQ"QpϹ$tr( "SH8G!! AGjp0Na"! |2HMQ2 !"2J(AP!,a 2e7&R&9DB""e D B8De a R PD&1NrE8@ +H鄥1!6n/L ĢQk9GJ\ 2PG(9A +$J\&LJNNR8P*(Q\xW’rP&>8M'6~g IR 0R"R)@A(9QL&)L$QG!( D PYSj~GiL&ҿ>:"9RH8JpJD!DJ@v$r#”Jd'(.P9DˆN.R@)L'2%CRL4La0RP`JQCp@BA(C](C(9HcH) Q( "%R&S9J8Hp4a('rS)ɅTD%HQH"<)& 0L@&P + L$DPP A(@2a" '(&PL e G Q()0J u#ґ)J\)\"e 8 J?R8Q!@Q%D2>k-($"S>TJ0!:9ҢA("PLe(L0DQ$A0L)O*D!24!-HRiJ#*)#˔KgH4@%B +DJe%P "SPrA2BD#q@nPPPLDP8#4B&J 3>2e a# LI2D$R0RH A d"e2SJDL%SeLQ%0! DRPD !LB LaB +@A +5 )uJ0QBLD%0 "BALH"nt2"SD CHDP])L#$B\$T +Q MHKlS>`JJ9AER!2zQHzEG:R>SQ'FSvxJQa) "QR"R +`Q0JdBs%0%"'BHBD8A((A))D R.Le p"Q29DJrJ D# )])5p9NBCPHnRG(H NPae>G< 7(J!" RS9L:SQ 4!#Q"R.JH#*$‰Q +Ac_}z??r)) &B|&R2<7La$% )`B &gAS'E(! c0g/TI.AS9HJHDNR-Ox0rE%HR3P)D@DJGA  !N|DA2%4P J!"!4B9@(@jrGXCa$D!Ev Ĥ'S D&2҄ &HR A H&BD|| !8H5B}2@h e8[ J +RR  Je"S9H HD%‰Q9Q)!Q|=??qYe0DpCBp 3 O`9R)AA() u.WVFJ,sA +jT`ψT+ |h]Fƽn.@L80rFoD +DAo8L40I\hmm{v*{&9[@#H"Re%N?CJ@>hiS.r&2A(8JS9@*0)7*\JSJa4L$D LApO\ $sD LL&0DppLa Q8H!B DLe'J|PT0Le!ǹ8@(9JHLJe0A0Ȕ p0 MJPxdJ8DGS( uB Bd!G ̤&L(!"aE>AtsQ :BR9D JK,dM6TLp%H O /2e <3sPDg.ҳE6KˇMGLPsH iF-gfZcWT-_G, {QCFڙ bRi]Ӭԁw.)ZE@{㏚mu).`|K"n\ʻjU8tD費HԪ̢h%5N R^M-8*}~}dָ-6iUhu:WF4ߛ>ijחu*`['UjNo\TyagS:\=/p!29YA)D"a3ȔAA@1r(&P0e1d1"e3)8S"RϚ&JL!e(H@r!.PDyJrJ'HNa(qu"PPQ2A2p $Bs +1O RJe2NaRRDM0‹p> )J@~M)LQ2(2De  uO<) (}QR/̢HQ2`~ґu&R.!4}DJE B#Q)$D +$BH':I1S(He9Jh4B 2eD'L`CL$pO"P2U6)vgkVTƟ>ũEG;.4\ 2W-j.ԅ.+oM*>KnmYY20qVlk~_dkBziUoS<#Xw8 ],C~mX~*}߭elj%;Eް_Z`Zʵu-ML}ۅr!2@"PB $DDE}& 0FPr0}$OAHA(N!(BD 8*2B` a :O2c)Jg)pAe1ԢP% e tOc 8L:Q9RPQ eJL"e0eDHQ08Bs(FaH?P@~)D(S3PHJeQ4Ba(OE +2! A)D"a!Q!"TQLe+Ђ Zf@3geh/mu{CDؚKnqqS=W@B@aBdBs)BNOk3L FO(("9NE8AQ@L) (&P +3D9&QR9%AuB!J Jr8HLrJJa )(hDBJP[8RvRJ%J!<#O% T]SJC) S)#L(9@`&THBd}%' +1) `G)B%D%`ĩ A2OP"c7RBR!"%D2 r9P%. +B˜`a1霤OO> @2RP + &"a3%O{qRiR.}BL$g>xN?@1fQ!ĜB8@O +<Q)D"S"%2! +' @  L@AD'@A9QP`D)(&L|[($Ҝ"%'a%S"RLIJ2RpD#<La"pR qP" + H1p! a SQ$%H(DeJ%qsM e"%8KF"TCNADL%"8@@HH@ +(%)JP$T&R%0u3&0}g8L&3!_H +G*!Ҥ&p!D dJ| e NQh P"P0DJ`B\a)R9Pra +$BTKc2R!.A% D AHNP! (-AQQxOprDJJe2a0aBYAO4DBG)1&rABL@0AJ8@RH.~c ACc @TQG +AE8J2D)@0Oy@ !0a0`$ +Pe'eYb?"a#( "PBR9@2/埸Ӕ &3d&5SB8)@)H(-͐SD'AQqL"aJ:0AJ@fQRI(NACBa9HNpGRa)@CPpp $@20P0$pRA2?l {)D JE%>PTe4D Be(Q"P IC( D8@q(" J0Qe)I1A( 0AHB9NJg"PpJM.P&2$2GJePQ +AF0!   +J AJn (8A@(2|Q0  aD(R(c_nܳNP0F +"!(5 !.QQJ@J:P=NRS 38DB`J0 e`G(9B(IreA2GR D'H&2 'eDD"aDNa SB"R-P Da %8L4&g eD &PrD#D]I!h@c."Q0  CQD0|%\L)D~LAt%D2%D)u" +FAL@AL"<TI˳(4&0e HL&1PJ80BEF Pp0L KH@X׿R?r(`|&4HHLgS) Q`PG  ڑ("SoH)D%>h>8B@JmCʗ)IG(Ar L9@' J22D$1HN%"Al Q̡9HAHF0e9]QCD ! T@&*E "aPAҀ4!8C():HHrAPB r\J(hsdu$J +(( "eЇ88`B"e3Aʋ 0< rS) &plb} aB!#R )tE"D +EFe.Pm>D-D)@)(&܄@2 "<ȄtW=Z:e + u L`i-DWqODḼΙԪW?X$}lvƬ~jh 4"'Hתt[ZKk{Lk.kI2*Nl 8L2a par#ݛLQ$AV`ؐ9RTCH—tG?rVWYmn?7P@E(tǂ҈( (ĩ +DʌJ&W( !1H9rNiR&ˇsKSpi +B +$CAw +]S˒u25AJvJ H 5JJvZW6!2\UPkȦIn#p)tR 6[ԤD#쌥 E'Lde"'>A)ݓaiU7tI D85v\'32yK i<{Ң8\ֳfL+;w}z%k %*ʅWŤ㓓Vχ=#L9@i&#ܢCiqd$rYɂpBk|cSB%1ޯh F1⓫'L!H uxy[j6s]BmjE#Dq2#7 G\  UOI{Anwv& O@ DBpTIL# ԦT\02P +"RH'(JGJQL|L|B)B|'`BBQ)dBNR@2c5&qHyfͩyUe.mu[CkWTVnY7odM=ڎImQB.#~\i#M!Ơ&@"}a]Svk>YtYoOt:`$jz6⸱esQ{uF?ioԁd QwwQK<17UW⍽2[yum7 [ݤӦp ZSk{t;'tJly" +Zt֫NQFt"\}NۯNg*'%څ,y;Tt6 " >0է5Bzblae_S}JOLT='[ ]{kI|,mì֩}GNH rsۧqefQEƅyNµNfV^PwA/rvE͋ {{Ì{VHjճ7U[Ut"KF y.ooշe?W{Ka e..@Z=ĥz lK%hUw.4{0-td۟򕣯H6d깽UkS0-&U.n ljUnF=*Ni.pǜ6ΆϤ׫Q"X3[OVoK-#=QsFݹlUμVXW۷lӫԣ\{w#OKyk]E}@ KcױkjlGoN'Z~]w;ksZ7..@oAo7 *:UXVюokUucϤnmOdT yOaj~vZI dx-&g4CDsϚۯsSwU g?D{i5449%WKzUӴj5ImX:K"I +ѴݷP^}7 q'WQweRӪ繄% 1.̶oA5 *Tix\we`+5,T:ctu:kq6[hꛚݎAi$[]K-{G:HlWmYQؚCR]O>ˎI?u]GUjʎc%'qY}Kw@E.-zbs^^f|V6˿o^Yɖ8_%W/h۱AMcd8ą6uAvu:9hRe\C\S{?'J;}W%IBw2ٝъZ%c靛[2GS wQOW?uT:\;'^PI>D$Ha>DQ"Ppe rJe$Q9H'LacjMdzd 8}Mlp{'R- +Dʈl)(9Sˆ0@@Vƶ~Rفwߟd&X߽=IN~J'OԟFqHS,lq>%UynRs^4 @$]A?r6|* :dq.'L~ʷv0?T8xSG=WM>5v`{frelu}nY hG5h췲cZNJcBԯ^Sim&`)4C+Iruz^X\oqL|~H7hPgjuJ8uV&#Ntr4N\4?FŧRT9E9Fޝb_4ERj:yJ&QF/ЫXr4oHll[hvV*}jgʠVp $9JnWDz=pnϩN}V PkP?(j * %5Qe(IphƦt; X0w Zk_%i Mmz 3XZv4YPD&riZ|\0:I OSm`շOEL]׿.[!A9Y4U.NE6~itu rkjIkX]X7BOQyǀ]V岴+ESDgȭU .IOKdžVlnϭu 4mC+]UҬ+~GI='w\Ұp䆸`mRVM]D$c+vr$ڑd6oѬUOcpf)ToGҬ+_Ii(Zjr敕Zuf2et\RCE۾X * Ȑ?$zدyoN/jW9R}QP}\C~D.]>Kص[V}0Wq .3rUm-Rw='MzVn263\sNт=yKSp»pi?#;]R*6#+kOtd\}ފUuV:s\|?pq^Jk}Cg@tZM+=>J`:DG@]YU} $>/U.٦?eQCӭK]n:hqr;*o'-rۃޕړI= iK>v,~}hwVb?^5ua)x#ܹ‡@h$p\ u]RBIY~+,?VFoMo#7~OWw7Vu]@#+ޣ +uB.!4GufWWOIR$x\Η5m{S!}GH-iR.q 8c uiTsP-^_TnRkTv#-1z*ᢳ |2\_e:[ql1 m7W~IZgWfֹK*/U}_,]gZ>8Z]NӴI1ϳ6 peX3g:AMO7nƷOhoxYk6P~~f[{nګLJ:"~WEym)ZՃ3/1WXZжk6ԋ*]. i_Z^mjUq7gngN{{ +YZ]?꬐$+ C?Mӯ9ӗ)in]t.@ʻqn6h,kKؕvl+V)8$| +ڠAxV>l-V`!K֎n.+kږL4h}c7&˵ҭ*qs`y&}y[#N}i) iO?\߸Nae j!l2Z5E[Uk8p[j@ɧǙJqJ% *H$ L/>TxHd G(L)ҐL La&ѪT'DL.\|j +ƏWW(wX9 [Cb.-ŭa01 Զ6G$Ä+tͻu\P!ԦJwWUh wX'#rmmM 8c˝BjwϨu + bNx3.ܼ_N}:\ϹSq_g4ZÓݛnY{o4<EmST 8svyٛ~Bzyq|U3A۵R6*K`Qѵ ӻ E֙&<{J:81,Z]5@hi'6mkn?9NA$?ζKE:--]I+ tmhp W%q_Xiӧ/>+4{{9Z͑U]|V.j.'h$ƏUqwLN9YZm+z^`nZ_ּtwUA9aK}55-F k2cm` \hc),kSu+Vk[pz? +/iZMh"A{Ȃ `x.Z)NOISthLD"8\핮fjH3*&*?{yBnmڌxeIܰ.jM5 [EnE3|e_Y6qP=;K4vmtԶ5};uCday{]pdž]Q>>#V5rM  >h-fjy$r7d*r'diVᚅ]O걜ק\8󅩯=ZL๿XK۔to 2ᒹ]#ђCjr$+ݥqupCP F3}afNUuڛ~Ys!tzfKO#gI|gbE%ZiHmLY:6Ω>Uꅗ徚ק VwjSc =8S5~Zx源-6mMvV1h +A Wթ7eJe:?gmM4&w]j\{*u,H8Gavo}Uw׮z<.Z٣X}2Gѭ]eFS0ܩ\]<@26MhQW#[F_6D̓r6ޡһ /Pd,>T\nXR _R/ =,!'gh{~mcx湄o:(-*A /EuYqFThhS[UF_[<2?<CWiwYA1lnvAptDQ;q:gYt'FcOX2xִmlz:ޝ&rJmto@̧YggtK\8 >kfGnz\2{2R>׶jU)]ۼ6,]{G=@\cd-U;GL#IV]\Q c0gtFk +̵Ð|=CMխSMw+e6ы*u{zxzz`VRӛS}ϗ\Ν5F]͗䪽_Nyi9?YlVMjF29+ucNꙶplG0Vkh56ђZ33޴m굾gS~d%վ"v ZǂovֵvJΖ +#B66bx{GGkhGCbh]4*z.欂 Ð|։A;<Ѓ]Ve<1ͩ^ :Swc]lam8Z 3ZVllΞ\ 'KhNmūC16_RAxYH:ͻZUFlh\ c:dqJ)9Q;ArǚUÛ07:2辐0|WIWMkeOaah"V>"[ӫG&xWk:-=nq#|sf1.u&v)wW[!Kt +"Zxjμe/ n,wov32=m;kVj8IvzԻ<{0JdBs)yR ! QDBB|&g  +3>D}BDeH@~*@"%&R! 0uAPpǽ.S0e J`$L +cA(A3!4ʈt %(Arta!7Q0)2gA Bq(Bap'PxHR8L@Qea 4&0rBU-.,f}Hֈh!(;(Q )0FPr20yCJD`z-mfg>+F{9cKs?DǢ.LPޖωY<$L'-GJQ2!( 0 +hʓ'GކFLDx)AyAd>BޮxRPB"%'0cA9HaBs(8CLr#@@D(EPR8HDKPnRgpTD&s$ҿ"‰AsDxLO +$ CBSI! ARq6L&TzK ="RS8Ϣ`B% +ZO$pFSDN 9"r )u"!uAP2(Na $t(!8$2'(() +ACAˆAA +l&2LĦBQ (6xK822>r2 xHl:yOΜu !- dAoQ}v47˨OL$!IAM20R%&% !=S)LTA1"TARkJj CZb:gG+,^8]f90"6p>曡#JH?rޯ*Ut8\~{*]0@&%؆r<χؕ3N+\2 s\A2<4"|OTk_sUQ{뿩¡bpxY;~K^w1Ls y_Wa=m.?%7 +[C빭QRaSHpi}&:סŽU@0HV&XUչe{Z|+:hsX i0x[塻Tl)& hwLhqI00"dq]\ q& fdGcҾT  H*5j64d@ӣUıpă.gMNE` pLI9j6tTi*u>dpU(ophȀhWeo$2#'u.)oz7̸G M|~Z2{pro5,(IkO$-ϨGҺ1J\|?%qmYVI?h5M G #VfE^~D̘&Wg[Vι}s +Ne*T`O_kk^)901>*1̞'`n%*@u=mi]Q>AW5H;Gæ33+ .+rkM6L<tn,빎- |BE՞\}}eQ_'I¸mݾfp:Ai +r8[[T= ί. c˅uQjaqVZ]ӼT׏H*n!n{B{]^1d7ԬGyY`?OjQ>@|N#%gT,p:CRpڎ괺j0f`-ˍ:F枘##nt;aۉAmtV:TseNﳢoW]@{pA*ƣHKK5NP˩Шr*=mC]ddiڥMt?.VJqA*0Jg8JP (|)TB#Q+MZ~gpJ'˄'2Ce 0'!) &擂!22.'gQs~#D}-2{=-lTmMƼM7pX{RԛFĚ = {it՝QZIï.*=!cU kX%Vx׸6VQyOúuZwEFAs@#m6F^W{O­g]Vs{lwN2?%m˚bϫlgÒeX|Vi>f2&F<7mSu{soJݍT{i'K}BWqiJc# CqǑn?ڵNpOSG`˗p-Wf}b}w@7w=;hq q%ڥj@q1Ȁc]~;˪UpG{]URN@$>o:kTiqcA}f7j]]3YݞjRqi' IgoS|թRZN-kX`=6TcQ q -橩SL}qHGmSrӫuQ‹ k Of>Y[9U׶a»>FܳNQ mɨfLTZNL~VOޝkʕVÈ|QV{_o\{FH>RT{JuJu[Eů{" ,ʝQUQՌϧ~FOE7OvuW=b!⺽ۧ_w6TGx0 A+Qқoh$83 s S~hP˚\`_f8eǗ|WbܮFnUW7!!+[t*aYUoOV|u;,*Tຐ8r?ffٕ=ky;L59l7Kt-5GqY-Ґ i{jf|Zmn:xly9z=&WG=XdwM s~B7Q6V~w?5^r2?\A?`*:WgvΦ*]R$&}/N]Fedt-NMLQԦ-lmhxi$0L-?f^ Ӻ1 {'[-S{'RuuKhXj8s1+&f6-úϟ+#hڕJ %ԧq0'൚.Zqk` aTBig_P,GK?\>ZOiNt[Z-ݵU*V|NoݽƁ!G.HWO4(kTi^%rp4v60L%e} +N! k'>5\Vzܵkk W lWj=5JwZ`wx+-v*='Ǒ.o:M2@&I>9Z*QyᵜLXZZԩ{t,yk +q6hΡc,} l'+{WR:.P3SaZn.Kpk:HOOZҙomjKYTÛ&<$r{6WrأLNv=V:j'G$t*[u.Aa5 !z)wT0.s4j}Kkwt451/ dqc]:CKY}[u}g:# iAӳZPSno[OA_L1iLsmZ]j }FLdձjxk.=G$Mi98VIykuVr~@ 'YۇaPIҭDsӘYwwl[RKL9ǹh{0t/IN'^WoCP$I̟jU-.ʽ-`a1'ͷWzZz@.ܾj:gC&9ݤk.)YɕV4Za 78I$zkvv(:V0s.8\F.7҃M1EL@pT֟EY=''vm;vR ugh+QyVMmTtTk $[~ՍFPgLF:|RqḰcVhht*.Yi.i1|0M(n1& WokK;z_LsZwn9[-ɩTsFfZ\LbmUP"H+qCTPeI#&jz=V;`o,i7X3fҷezQ.+_q`Vq qr?T4Nɮ:xl+2ҖcL[Q" \}活Pe]>:\2dXwz/}^Hal K`HQPcX$rrZz"7W.qA"| 5JJwbQ#$ j R)_ЂKRH()IA)(*%SUOkYH@L{P28A_ NT & ) QJB9He.7Sqᵁ?%v@#!q?ֱsS55= v63YLDc=sfQʦOG>wp7t"`G*OTRI[{36N|, c&kH3ㅭԾ:A -~Hړé8xij}!x{/mP5)LgBj':w{y]&N;Ec>GQ wAwIɏ:>Z.ie|<䶓cS][U{)\FFgÕ=کں- +}PՑ*cU؏^BoC65mzSنl+!7s } aA.go]G+Lj?q]Q!.+ 5^OtЫn~*G|Vxݶγ߉ay66Ds]ɤ2bt($jwPNq k3^`W3^^NHV*$ҫT.嬨--G.y隅 ?ЯG.wnVb{XrVnB=&CH9Np`ifW.X &y*.f|zAGfܳV>Ϣ,[x\VmJFz`s#coiZ4Yh%O]ʽ&—Zl\8?0Uxݖ5RF$awN0>Ҭ]R/ NJܷt_1*a[mͫjb@]DS6Z6Wiyh8c4ЧnI< +7F5{韸¨]}q@^QYPPi]L +솓}$gr-tU5bˠz+ZCH] g6/xpk2^c+[kckuar4TxVT߭JZ ˹׼:CA|ah{PjYqMF 0>kDַ95\>`,ӪI9[z*/l|I _Y= ܚ/wА:}??+_bg@$L-n~bLA; +Ԍҷh-}gVG +jYRk9dVֈ^r27}:͕z3fG+2#GjEt1i!h#{|"ĕilGS48QcCC uIn)8ҵ# ާѪ\ؿ;@<'+Wӭya{ G͋, #p,>ԏ \No#`|']Nk}/޵]6'ï + VE'@yftFkHp,]6ox-~u0d02sTi:}L25́])32#k=7h鞣+Y-zoy2 H k+;{fwLx5n}!UgU::> v6D0i;>QϺӺS<c6*WcMVpfOE.3yYZR$Rt5[jS>34O/93']ⵧNl +v?pVsgCs~*=Oqv[N uvRX@3̰6۩ZPK|kW?_p tU߬[#f>l-6Pk_NOxTSnʕ^FI]q`p B\!(L(PpQ%"eD(Je)®-$Od  +C(SDG`6M#Q)L@8%i -nkCI'i`QGz=_v']_n:u.֑ә[g#:6N}`%,vekͼ*Y{kRzzxdGnj[HtBjmzHqqkc>׽ag\iuM:c^d[%GԪ2Xo\;Aqɐteޜ ;[GIlvfp2+7VOpA [ƼJͳjwΒ"#+Ropj擪PYZwU + +dT3e{p֟X9WmM'20 V흴4>]BW1{ kJ΢aP;5_V:@o Nj +Gfh:@Ѩ6;2ssXڶz7]eπA+O Ñ IOdW-vK +wg& uU{2`ZSSns{ .vHo?-?b6QuuU՞:z#5Fޡ# 9,};Hk:Pup B{oo@]޿,MSf65O$p})lpZtCrڋn{ qh(FLyNY>W2U{lxqygvǎG-ӱH>0tfv88LgڟU;Gqmkcj8wP#@1ar[*:cD.osWh{!U~qP֭.|]Щ"Hp.h[;K3跻kkR-K-B[]P4phMKBR- +u z]iǚBF;gu=~ h -j,sVg+v~n\wp 8n>+ ΒxH;q7Qc$Zm˵isNz\DYiFO.w +IfE-i0O9Tk;rU "8m+-v<Uڈ$ѭROZ惷hM4';$Vĺ}W>+@C\4BLzLKcHZSo<眮pvqN=ze8ʶ볻Z״y2$΁Fl2zϚͩ?D8ǧ+::+;2I>MwhG j~ ;ܱ4^+s깼u训vFAcWvkE)VM}Ǣhj h\eG+O6q̨澘1VStlt:$+:Ŷ4B@V5ߣy]tǟ >6M9ҡk1ǥo"z[|OSGAF{H918-dd.SضbǞM3=mRIy2ﷅ@NRB! !P2(&QI4BD"%%H% MF3?%S' PB6z!TM1 *@Ja B:G'0!"S Hcގ-S(6Ja 4'S .aJ&SR2"A8 O%B1D$ > !(PeA(%FRD'@2L@"-Ha8L{C)cD'%#OQBDa( )Qcܙ2![ +I`y(%H JSiHS89(9HRAN1MR"a&4NJ@& B`BHMȈHS R M g@@@@Q8N%EBE#Q9Aú|~Ҷe"Sjc(M0Q css<)`="P0qSH!FPA:GA ![x$D& +Q*!s,H\%e Ģ!#S8JD"a!D$R"TI##yBù1Y[)>=8/9Ȍ J Lʔ@x1R0'DH%#Ag˄5ĴH'䫫p|=is V4` }c(V= O޲ KPOphqQuNɮMäHrLBMn{COpe.p&V5k/P@83UwLna2z̬W`ox^>*tIqk* BuV'+% 82KC-H<vI~]obzjcOpEvo]77ͤ"Dupk|@jBS;8LnժƟ"ನUmqM +U)5+mv+0˨,:RJV n b[kVV9AUf= 3ygu7u qT<&Weq6~Q֭]V"x,r޺nii$nu'D¢TxFF GYQ8"~JZrADpkGZ[ҳaw m8֪֟)+F:=?w)We:C;ҍ.NڊD(\674* +VENO[]GxV봬I+pg98\OeԽy]eul{\re+Z7N3>L=SYT\kVUk23WRY^Lr+p[_;UwV$j[NwwV?b-(=c@ƫRPPs*y*ͶiQ5-.vVBD6-yKMuJk ]5T f֭F*ceBFV6ٲinV +rKZ|? P縨ן s\jyV }o+= +6L`I<©V p5@8eFtZZ.O+tn?1P><ȬiPrIߖ/w@' |[T DBH7X"z||j@A$M;9{:a޳ UiR=+dʅJC nI;ޅJGv$9z xGLL#JVTݚf$>f4T NB{A[Pm +]4;0m1M.@əVg5(V=OI915ۦ[۶^'}{`жn,VNc?XmN[z{AM{Ui$!K/hՋ3w=y!l QV%-|VVvAP2zNՏM?#;+j`fNVMM~pz]ڥ18.yS4ڵ89kK6EUݏec蛦[?A + +`W9WK&8<䵇淶`I1X4u56eeVv5U:NKWg@$ 9k5g8}Ip10>CXiuãÇS?!uKJs`Tp8p|DnJDyNYmTZԨPg쪿m\xWGwwZDAq 3Iթjh<81څ=5wx\,֞ߟUmf=MwpJ۱k/pk 0I1}~ѭL +A|}SX+ps }b{E'5\~`i⋃w ,$QDI"PD"Q2$(0R)G $rQ8H$V%z@>PD8FQ("S8@ @ WAu{V]'纥:vTzYRlê}jwZ}FZwZDԪ+-M$}abiNjLJSz1UFm\lGW~D2Pa~gt {Z rAH< }֯Z~`70iwg1n ׶2' ]vƥC˩.OcZnnOK:Hx+%gQ1!9c$5sm+ v`:cV_`Jz7Ըs6pko9&9WKmԡwi,x`KHʋ{zϕ\h[:]lrL4tڥū\YM<#2mFƆ͵^ٽ.pI&OV۶N..ʕ,*5B;gB跺ةݵtTI#jw{2w#o˺:kku~Sf~MOz|'l?N5 =}U7]W[l|5VIԘZLV}2ZOpWLapTڂ?Gl -ms7K\AB@s7M=CFj2rMJuOI"eq0Ձ-";ʎ%ēJԶ,Oqp$4V6}zn3.hb[ I>\̵o^תI"n-+7/hp:H`p}ՠT*Q=UT9KII莩DxV $˛9asVF~5A"'2mv3uN£1ӂ= U.F{w W>iiú֒I#%NcvB{3h +sU  +pjͣ-D/8?S;Q'pdYݰm&70e`g>*U2mZ $ܱ{*qy¯dSxMQoޫ< q hйq] uC@1pOیӁ"ݞ`&&CJN݂Qn@AYN6F8uzAbv޺Z|jsAm+[mݵā.pFLof[?Qq!\hT>bi<+#Kٖ{Z>0T;;ymm>ͭBg6Z ~[]uoI՞ezjj$I|<?a+yڥ74SmIh Yҵj_G 9b9it'hMSat> n+,\ +a4k~r-1o.uXKi 4]]ѧ1זּkm0=qp''sm۪!^р~ԏhG~p{^Z|]EiS[>S?c xi5kz`hePZi5Zi8@]E>D Lvnj82E6:&=> YhvG&]L]6?G,~??zoXm>.Bj%k7 [ek)1VeZwުLҷ#K};7VwOw+{m2ӐAZM?t XgSis>Ptƭu{OuF%9Z^ڝ^fG8Xi};6QH dgQuCԪYyh`%ğ+/thV:Hֽ!xYwRҸ .h9*vM.&`Vlj4mm^M:YNyQuG ƃJ}q]tn}&=G>U2j#IwKa[?8=qS&GH\6pݵ2vⲻ3.mmAZCPFe:Rt񐭿V:{ײ=M |d-fKM7 3}io6ZeGk@'H0%tSaoQp1 I-Ge#-WehR }Mm@:48Pؖ&ʕ7rt++CHp^^u$H^ilnmu.i<=].i\Ù wV}<Ңȟ2 '>}?@x|sѸmP*dBtj*Vq~-6tNZO ]>[ԪKHFI>Nu.]KDZ=ycX]iTsG]cNx8[}RjP0&<բdʟh([&hkryq4i&Y@>*ϝ6}~)&G'ߵ+DY@~tRȏVz +/B'-͕v D y[ދE*R;@eWK:Z𣏕o빴z@A]Gik+Gte7lkZ {\և@ A}3z憛C[ګzMxVYݭR5,C^~kmt+[ӭ44Sh2 5Fz,, >_~[?qWz6lz~+Gnݔ#_:18]-ƿcF[ #}tɆ %oy^{?ɺ b@rH8 OzΈ'9\cKˍUkI*4;mK +U׸c$|-޶u?tU k@? ioo T.G=ke? :64pʊ!1g*  *3)8!)H#]r\f~z͉AIN%0` +3) b'3!4 7CJb]I9J4\jG b'jikUuQq27cm6@CzHp$Bh~SIqqꅲk5K[k)&)@rv{BR ykz~Kim-SsS@둨t\77M3жUd!0Ӷ%pHmz:5GW]̴gumx]TK OKG[R3t +Z*-2 yz4jfK%O >]uƶy,:Śu& UZGY`]avglR?SmE*mcpk]S5]&J6uML0Jơ&998˄~O@v[`Դ=M6RLO92h4\:ws<ލKYVg8YZ(5Z !syv`жվ .q|G+W}.(L&Sֶklql684jT5LOUOUzXH0XlXi}wU:e=&FzA'&NVTڋoj.`w}OT2BtjZk+C ⳃb<#X%zνkb& lʐpo<-f(i.uj-TI'~ +zCV5%el$DByiU㭝Y!!e\l:􅹧 AZb&y"7@xϚОfj=gtvu-5y}򯅮6 q5ӻ>%Y*m~FAa?zujEh<|k~#>+Km٭7{ꁐpkD4rEr=*&źe1E@$y%Ē~թt2Jmea<{Ֆlm +Bz+CxZMgfkڟŽmtiuO< m{h:L9ʆL-cf&r +kr[Ig?44)[iC|U,)R,oO⫯ҹlNk]}!ΩA.xd2-1>2Ic=#pY6ߡ6 .?-[Č͸cnP ]wg[K}ooW4"Gp֋F/٫L@2qm|P%왧P:XفQY׍o_ &4ҨyaiYliD-iƀ8WJ^{ǟOkl*]DIMZ)pªžC?5c-4RVȞ&P$OM %B2R2 +J +QBʭㅔBG( +S)*^1(!G8)rqPJc("&] t~HeB@>( n#Q`$BbR>K z%(’e3P00)LpJN`B PLH%0xN%$)x!1)D!JD&@l% a a7 @)pO<ԑ! )?a1G +[*vM 2zDV䂙|L2T H e A 5'.A!"$'2GFPH)<=JM0@HUݲզGFO +5E`*45Az + iP$m墥'0*ӂ XKE`Za΁Vm7 +MMI)I (Og)"2"PpeP +\&q=`tHH rJLAH'eDBXw&k0y șFR@2T!'|' 78O})' ) e +C O`Ieq=tm:Hm:6maea 7cKQzsGWHp4Vޫwx;Rcj40|OŸ+ CPwxOյ@xAxOm9CD.MZyA9XHX45`>cTV}$$G,-F!v~k'ㅧwhV,wGyfܴUCx ku}kw'7Ez(TFAGUJEii3㟵n6CQTSC2 ެ;Ѭ5V9=+r[jIxXvAz&b`<<[D=5Dwez(?#:Z[;l9L-n,kI h8YNCWiAs=B5lR_sp;(+UK}a­pI `.{^ZnEc:I|WgPi4T$7Zr,K"_BzJ1$dznAͧҦ tjκsffz9f̗b~Aol,[cM̫[r|8%oMA“\Z] p+#vk4/eS\'W-ٮgN(@Is[q(^Irj{ʍ1+vⷻJΛ}:bDǼ/ojxh:bg%vgEō%$|D5{e>qpP}&hT' no[U: `r*[3`Rbfy>{m1Prba]me%?FwyYZƵKEk_Z@y-MhvP[MqPI!NӏWwݑL蟕 +?Mq[2F}#hMuK?K]+wSOng:J[!> +}(I3Pۚs?he缨$@}/Sitzhp eC%?L`mˆ]iBt⡡7 Z-nK{`ko}#>`k[IpzUbHKIޔ5:CjvVmAPI<.aT'W0reާKS-kQwSK pG +PYש=-O&8^q] +Op|V|yh-9pB{U)uq=>v޿KXoE ݱ4ڰ\[ӎ}g蛆EPi;j.'V[ ipn+7>UO, nЭSʔKQ7Vf٦Ps^Y  o=MYa{]>L[kgY\Zm#cAFΣl4SԻAiqcd<ƑRi #  Չ.w n\~ IOJmwզpZ=L$˳W4^@`1֨iԤ\p^0OB]..{CF| /c^Rh<t$isy\՛el.M@=, *Хbi$pi6!pCmB=⥦wU~Z<o zk jǥsXuҵR}R1X|;tA}gZmjdA}&8n@% HuuxBʗKgզ | c]=mΣu9O_݌fk!kj襁gScS1꺺UX\)@OHL $%"a))r$e9H% !D(D(O9AS ) JDK20QWڍ&mpj49Y4 WcAOjmJ64>F9hLgVvXlPQ=>?j2-#i[oPdq<+5;mB 7tc5->FjpXX3<`.lꟕ-i\Z+Ÿ]9޻ 6ZRl p]mWuXuh1留;co_#[:ZEG'9ZεӺcET>~}jRuZ$z굽K1D-L ]/jf3[iNuƵϦ$8uvwQqZC*{G|^[kp'"u;nۋ:m6턴c;5M :ݕMz1  o~ʸufx>H$xBvw5LniKI UhVNѤ!a%j۫ФޗS2 A.SC@LJe)X\mOPdM+`N~3B>Sf]V5 U1-#=% wZH>x]NՆlۂ?|i+Lt)Ɲf wzq}cIKAqτ un[z]Ȩ׀Z21O󭍡S7|uEc%qi HhUv:>=+qmMcDzgg9VBՅ2̇cEőfp3]^m]<=˛׆H,kۚHW֨Iq$1§yk{ѹ塚I"[ݪ?V\q/NcM'2zBU ,x|QRF@[]Tz(,p=#DouI`Alriq\=< .ǀթi[JfG\ޯwgh66ִ.Ra[I0=+pS`l0 S+Zg>.ٖX8\N¦(_hڦHj}.eCZ֗d uo;oT!"; (ax֮GtP##U֕b;Ǽn~+D1c' ]kM:6xə5Jжe6UGKMߖzm6Фʝ-bzi:jjlǶfÃZ$aonZhu/n+MJ"H8Z ٬= {7?<Ƒ49?F< _eyi< =A!Jٯںu;[jTD9 2W3٥!JZ1կpQl05q somB:W4ϖ=2f5d5X@cM:+W u@1iҫЪMy<3 a]voܶQ+YL\*NXݞ +}u{POv]vbNJ5 `sWu'jLu+UfQjt;1PI$d3~4i׶Þa*wTYU}*mI$1oAmDwc _ٝGELD{Z}?Zu +Gې@16[л{CisbamlR̞3+KQ}s%GIϹnmN퍥xFxRuk:`Xi`WRl_MJVZ74eC3;GnjP5xk۾]ςn5J%+ZoFLݧR2m>_mAaܬBSςFa ((QHDJD$D$R"\n}[(@0BmC9TR 2T {әHeFSnS8J'ڑFzZk ;\1ni\:Do˶ku$8srOj- ?ۼGo[[7u٪n'xowOSƆJ)6zG,\i/ų3Ϛk*r ?r P zI{qmSYh=]<OS$0 *Qmp\Zx/5 Z 7uZFƟ^)u /}n*\$…{lU<10޲jWh%r^};7>YYpRm^ 8(l=}:oÌ:Յj,W/knW$~r921+QϟY@{'g,jnD.av [h۾7ժ:ZAǹ]i'KMaӉD!cv]S{<}9Zmlk# +RkoE% ȏF+oT4kl:$O}M:I۠t92ʆyq) 󍡯/.=-{8 ON顦|=}F4}Dsi+pܷ_Rm:Hhrr6ۢۧ].D5'$fWG_ӾNiv-~xJ[æ7q efٵ*S Q@V?Dr +k?߸.7Ax5+Yk-Q`p|Vtli2ԇSjy + N]G ČdA{wX[ocZ=.V+1ȟN֗YZ @ȅǝxk +͑M pdW*T KL\ubrU8uZ8w]0A 3SZԋIY. Len55 $/PZ^e xH[@W'ڛKQok4u[MZc+gtgj_ILrvk^)`x f4MW],V 2LxUuZ_\TuHwm+w~ps-h 8mHai0hҵe^ώI'fc[,XmnoܹN\T5GRځp&vÈ2}5) ?o_Wuk54e.Z~ZSi NFڍ FSHԻJ&~ѨuuIB+k$ֻ-hxQ!fNDv?KUzL.C\Y>Bnwc.c!2?h^{]"H33Yڿi 2Bꕝӂ|N}:wK@3]vJ!Jŕu4Kz\<$H&PSD H@ 8IABTNQ\ +XWjAHSSAO7aJ@DBG).N VjZ8$ 2E08> 6 N0{?6很?0';.?vR:{f[Ϛ$E5v\0;iOxrq$[?)i4fwy3*'@X4Cjs$q2zZI1'dZyU«2=>K}ejTdSm0=8Ӫo?:DIUjgQo[Ћ?4 Im + h h)L*o-[vP|AJ4ŽC$9+(6 d]Ga5asGY$] Eoi J&h"*կ:]\z'8[Q/ a- XEvG.m4R: ~նX;!8畏aRhkdVD$技ZDx+Mۖ[j4^q9YT4VuVJ{vܴӨAJ&hZ ̬]KBZ\|KOҨib(S H vLxʬჟ5vVYHO"d[?@-<=!j+6[,&K"1p7 +]:f&M-3ʶٖ45E K5̌4v(Sk ]S5X`D *)S]?5^cבK]WhYV=㨶~?r۲բ64x4ǒE׻;KM{r?hioJ[M-ճx-.eK-=ftEP +ARͮuL,cƇHܚ֏Y:;Gh5,ie$-Ѫi_< myaJtc^?~j &f6'g9uGw8Y\׊mGIY8X7ZۻڴyqeN맭wGՑºJ:NuF5䁓RQ>Ko۞X?5:t(զۆow *t.=y)ӴoQ9VօktzQcYvnފm o@ HcK7?.-vC)ֈ x*hXR.}6$ ]U i!`m;eysUmiNM"}AC3@- P46d6edxXE ww nYxCǑXvvӢ|Ĕ +6 {Cpzncu-[Iɠ"Hǁ)ѭuyL&M?`-a>}!fR#5 +Jw@(me:mkH џr1@t0(RV5}賴f:h@ +?l,:5wu> -r!rgN1>aWqgJ5)U6cCG 7Tt<*)XҢzM{W)D#P$#)\ (!D2 +Te(RKAQ9Xw}cP(8R)> 5XrD"Q"S@ld B0J |~H"Ry@ +`B@ @( aJg  A2 aQ2 ̠Zd$惐Q2% PDp>j=!( )9Ң]L& +M% ?jq!>Q0}ur%Xڅk>(9J%I 0 %0 3L%8@@j!  ̠"! @((OD2p2 # {r 9LDP(@n>) +CpHAG B @o O + + ?P] B(E"J!DX[/ :se.a5!)Ja0 R#*-A>2O)HHʦ z`䕇n*QI茐G+bJgXzGM,mWAa CLp0p 9@ t[i eD!`3_R 8=T\ ސ8V 7*WliUU6ed +8G) A5isRzY +Z}oQ'x>+Yn:Z1cj5L[7G`MLB{i hs +_4V=ܬ*;[i$t:DrCEH +W=pTu&ݻGП('I( (G*ݎ4s+ AQE0@!8[ #9LA("BZ\  E՛,\!81@HL(Qe j5˻Y*>jtz.a=в:-Fhe]P6'ԭLXZ[ocQOS>cIk}JUm[QZ+L>\['`ez!\so&hNeTS![M.ԛ]4˦Zy (+V(! g8-/祤^ƿG-oH-d?lSPFP +@J\  0SjœԈkdַEuQh"3$~ poȵ(Lf8[ڢ +2݄ʃ)e)pTb@*A 4JDp(@ eA"<9J +\%#:HKޔB@B\#RHʉ +pgppO_01 N0 +&rtrIHLg)N5]Ќ=19ϊ;@Цdp>K٪R3,}SpRSRz}X Ag?>}vU,-gZ3`9>Z1=>fJm.vդzZWxio_TOącm +k8 +֪v=-nI<.aݤP$ThZcׅзuNG-?X|uCB$5\~j(DRI<{>mf=L$;KVq%š랓󭅾o3컜!jvN=^I[߲WujG922 V߶pYD+CC}:Uwx1&2M:5^HoBt]fLWdpA%7%G uZ-8GoIXoo!}릵4T r5Q}kxi[-eXt\i;Z|[O${X]SѸq^0~+#Kacj=.XG' {J{CHdfAG,mqFi˺LǼ~ +{\nK/ip>9X;¿Ҵڵ@4y Qjvִm}zޡLo%m]KQju mMsK.t4[B^c@?f囿\G/?|-jRYXDRcV8&؏[T#'gnmk9 H'Kٮ]F9 p_ѴbY&2 cVmi>OL) +iw[r֩PZO+fG9y-֩N?X"p3>Ggju1WtTw"sOj5:)cCI)iQF⛨8G_<=V-~|-wjqK-x˘Mm7qh`1pߢ}!#<.[QuGSZO+=6Rnzc̀7;}onX>KT7O~7 +>sG.Ei4AyUT gS0L7U^ ;NUp~+a= .i}Jio+O\Z=BGt4wV郮cc02&٪iSGH' _}@m):n=ҝvNZ~+o_䷨20ٿ~ֺ@Y{yJLѬ<C4BAjUjkk?v˚U2퍯L^X bk5o;+GٛNk`1`eGZYFX8z~ ~Mjs^+@͎ꃞgWKiO1'NJˈ@+Tթ4c $ͳ{]\/2}[ks jS 57&y _SMęk eyiG:3DӪ ]8w隕[UZC'p[sQuZ A'Է{:@S  i hO:[T%6T OjUgYrZ|}oAi&觡ԭS걼Tݷփi$:Hd.KթjtMߛ"9 f66tH{ąnu[7TH V^mКi}J+M_sj6m5Z!WGM]>Z Vt]OSa4w[Z)wFZOn]}~|IrIZn N~mWy=zOamsWe\5.0BBB!"L"F!#GD(!(HQcܸ9ʉ% TP'0TI2)&aL'ʉi)=+0@L+@oӮ,]$xrGM@Bt&kO4. +QhʮmkAHDpLhc@?̭‹k2U\$gevb˫7p3#,!h;@O>cw6t~~@.s +:J\$&YT.P>QVl˷^Y{>Z-T֭)}zncjV +Wh hp-nk dCfa׃ʷVOjƬAw-[eeIj482VJ=(7)G<Bi5{ٿĽGjׅމɁǽl)B)ΰh?*]>TsO LϼL_]_TP FToS-xZXlj[4Stus G kShZw oFkPKw*;PkK@;=ց?⨽Q_Jf Sf~G\we"V?fwR=Ԁ|`M!VP~x]LzZ.]bs>իͦ-I%uշֵXGԽ7ZCˎZʍ# +}ضQΓ` Z},uF] ǞЫG`vwBN_iIUii}_S+QaJ+1tN LUޛz[A@ǟZ hڹ"[%[(:Cx1쫣mVY涽Y6ɵ8O$ {KO~"Tu +ԘJlBʈfh&<%hu[& Vq|yuuZmWÈUl(3追g#+4NV&b޷bcM~{))ѮkO)v:fp%@'"~KEmw0tFzJؚ\*Q̷{VpmyR-7iӀZWLc>aiu JRx}t5sꪺci╸??jۦTP% |pÇ|BwUͥ !w%߲ .~MX)Wg<cG֡QWګE8.얐mMW|qV1JEQ2lO!S[:SKX" <~Ju> '>.H@h|}yݍN)T?盧5?9I1+u?-_ZYr>VS5nml>QԵ=L,j:]7e WgΟUU6UӨd Oe-RۢH |$p81pe R&R"Q)d((!"xA*1)D`݉8[Be$r`q 1g*E a.89@ ) eBP81x[͑їPrsڋJ:' rz婣&Y3n;TWϿx]SP]VJAH[WzRVURk;3qf;S# +7n闇{~>Ͻ m=zY3)][z9pA``9 EתiLA`N{ }i[ZN^*Up!nLE-Kw{Cg#avZ}]Y=ƣHuwGL}XA(\ݨj[tFVK{O8~r;4!nx/?i!cZV1Rګ`Ȓ櫯[8QPa~ .A=VV` Gi5Z'U5}F;&:^0+Ga*Ui|+fR:u5jVKA']^~KkƉY ޗ76qjL1ídMfMG3s@׸cK(>'0t aZԵAI۶o5c^ Cq]6texZ]iX2ia FՆJRc1[өbѾ( et'TYZ!cZvl>ʭzO#vZ1ej[\ۺm 0O޳5IԭjV!ȟNӫ[XVu7$$p*4Nq"sAUub~ed_Al'bvzԯj85"VnѪ]5mUK{fjgI}VNԮGT8>*qݖ\Q˿=xIQ+y]GuZx\d,Oۇ5kPˀIOܝiOa .{0΃9,}Tz֟AK1uaR&kiq,|ap؂y-s7!kD{6N?<_ڻ0cd]BCmWao5Nҭ.)>>{H >"KhR~ZLIokM苖DJOMo?+ѦjcU]5X=v J@E``s;4b>r;OAuJ-4h {U>,^Q-w`Of-d|>嵭ÝQS$k4'WwTtvVqO+`\; ? .צo[ZsO զ7"ΥgԤꃤz#3+w[:,~CxD+ߚ;J򈚖bT{Oszu6 Lψ=mW[vY`yq]2~*qQsѨ-TGoG[Qz #+Ie7Rs\=AyvHաH4E@p$_Fjms'!sz6LYSsZHtpt*he6/_^~Uu@y}[tEuR 3$c+Nۗ/*WqT6۲ҳ^ʴayn}復ZAA$x+Q}NۭԀtǑǜڥPXyUy> +ϮrCO vU}v=ı +q}=_Q1啲VW4Jqm@DRL_PW>|y +F^q5An.VV[&d>^z\ q]0\Nʷ}ʎk^'Osi5bG$`HpJڅ^SL|I-ܱwҞ_Uq }:-=0A;nnZ-ehhuB|Ȑc}Bﮋ?Ә봍*k"ٮ='1"|CvmW_stmc:>~#uѭ^[LԦ4IaeVv6T*:A}@ZϏavlږ^z=9Ϛ\>zu+Q.%lr\M;j4^Lx.}Lp| eA!("%#'DrI*!!Q`e#%( +C(K/!ʑN0 D&B!HQiá '(M͕;uZ&``7c`\[w(#+!utMO;jw +ȑǽ^L +Jw8*t6?SkTXRq5w$ ZZ^?H~M>`~%fE,T@t0xWˆThs|-mhz`>qgBh44rz@V8<AXBkE^}#w#9>u !h.oveFҞ%fAyH,-kY݌ wc爀=˸DlBG4,[lkI ReFƕiSk=\ri#vE4>}!d@B#䫸t?:ֺ?HSm1]">JEà[@kZu)--o`hp:rק@P,e]` KO}PJuOSZ%ZC::\DnzcOhyTٍwx?52=X8M(4t؆[X|D\G"q`O0L @R'zfy?l:CjT0yYR=L%\O* tH8AKgϤJJjm!;&ho<=< +ݍ>aUDO_{C@RKs8Ǹpd{ ylƙ h>V?8<|kCK@Mǟ>I1g!0#=d&E4Y}"TQ^kB:QL\JE0My8xNe8@q'1A(2B(s$ &ZNwWژ=<&ן{TP. +AHB F!L\( D$ +' +%`܏΃ӔrS`&h%RSKP +d!Le. +C)pT!( G(A"B !(y”JGK 'h&kpP c鏊 5PDS(9@LK)pH J@)) !9&$22B0Q(pB}! %I) eJOLHM#((N%#c%@| %ڜBq)s19@AI!.rPJ +'%dL TDT!RPN2iI̤e&Ќ B +8@ <$p +%(L(X7j䏽m Ha1`Ba8A c9@1SH!A0 +G  xy'2#L"SL"a L N R(rI@@ڴn {g(D')Lk^ަʿm蚵#j7h$xrQR.qLs-Z5HqD(] +Vb*qL$%0eiɽ'Lp -B&&RTDZkm)ည; R$Vn)(Q!҄D0)u&@&^I9 [Nyk4DG- (H + 05}w>Jkr3INI@DrRi<`S[vlۧ44@&rG #iXڀG@((&9L2۳q:hwxܜ [.q L)SKNژ}ZDijԤ46 ee+U#t!LDF8ڶixہWK^@&I(R Է;ln)ؖ@V +reBJ9@k7&4?JsKp1gKTh1 i P2P[N!jwF}Y*?"|V=.%6@@ !B`D:m .F: podQ,%H9H>(>Q‰ʑ"0GNTI0q$JQ*<"!DDp?v!O2%"%"00䉕"e4l87$xvqqrOڴu4w|kڏ8uz!qJ@&<9 8`>vo@Ӛƃdѵڵ(Թ +yϔs/5R9m\iWCtnh]4MJ>Vۼu:gM$Ǩ[m +FgHkN`Li.学I1 sn}a8|JڀﭭA0{nV]T{㩇 ZݏJ]`%a:KsE< O5jDݿn:@\z߶սW% :^i%5ʵ+- +gyjAkWv7cb|UqvI,40CN +ܶA=Y?rӷfWmIπ #V(Z)tZsƎIenmMbQoi82<>jVe Ad fWUuV5KD#[ciB{^$6`znmCKosn}bIh5Զmͣ;PL@ \fڍiTQ5]8c N4jl7> 3efzK鵄ඛcr_֢@{~PPcXz^ΦTHn7m)>yǢmyaȎVP:N]GVwm=FC*JgWCZNx 5]AIBr#j٬OT0{C|?bz?42rTkZX%xF߶7 n/ɶ9 ik:{Ti!> kwHz)f~+RLklumRZފI3#t.đ=#U{iD+Sgn/]Rڍq 0`S꾎R-%d'u*-7n@d]Q&\|Z q{YZk<>>k1G$ .ZMuߖ~ծ}ڴ}:EIh>׿+geTGC0Di^Ӹ6:Ýy77hu& +hq'wԵ[OsZޥլF}%x gEq}W{z +h4 0=^ip$ u c޺ein[H74OI]^^kic|.q%s{+z;^VGFY$IY_gqoc@\H3.-Z=<=L{\\7TK?5|eV[:mNDF2ݏVe6 CDy-Ůg5V00at[[fI53̞lu_Qhc)5#5jOLC?E;_vH5 Fk:iڒIⱩ[rƞb7S2Brii~~x'Y:㫤ѷ wG+3vk'C}c@h>Pz׭㯨#ⰴMWRo[yi71 +MuWe5U]g`؆$}ꂰ5~DT&>h- ^we601XYәiNJui9`<M}jW2Poؼﴷ]R a$ȉ.LuӨ``wA >zOMGdOG+osJm}*[.Pe^0L 5- ŷE3.75f\~Nh9UҺw69COy{Ÿy'>+.l,e8?c &} t3-ι_Q4>4q>'XSoL't d#-27?$S.촿 s+k#>nEg>g 5It.L7ZЦUc8kZ IʲEpx`DΩ `t't{c\.@AVPܗ:ì4z`r5 {6  q>յ>~r#FT[^IxHX6wZs(0:=tWp4@GB r{[9 a<~K^n׏u9$@\Νsn`ni(zDI>Gu.gU0ʀFxba-#i(%DD$Q"PrP*|j"T"P )t'—(2rP[L$L00m[NܒKܒqn{GT츻 yɐ:|\ƵmK:IerYǡ²s]Sm:vOkDCmJ:#yɅ~~WuNi +.O-<;(ŵF +bѦy VshhTHOt^t#K[[]EI#pyܿRqsϢĻ}u[RH[Ǡ7pڶ=0``-CuOFhez[fj{NV`?䏵>* DtljZrSǁ&bvNGs[䫉\v>QwkIe\6^0ӒڧcZ'F#dL%kվtN] 3 |/FگU&Qgļ0ei~qZMHW?[Ieo kzB'-M徾Zچ2k1ူv=w.I*#\C +H?Ti]GOWILJp{{Vb^Sm6UC.ssm=GϷcD!ǔ)e z}=5k[OXpss9]N~i pӤM!>Sw Cl@ Uqi\>Ejf 鞯e:5*;궇Gnuzq]f9rPZ{.sdf]UfN7ٱ#O$r V`]SQi=pjmR&Auz=Kze+ݚž}Tt4rU}AʭB_Qnx{0=#[uZ\iȀ>ev[ +t J]Z-=b?֨{v3gxM +W=~4G~kc }|oXwg`"8\>cYڸr@#jBݝ7p~av=_Q3.+KܕkSGt}i>q+W2ҭfm0q&|WEڍ8+[l-y 3+[pUeO{aJ֥_;#ҷ%k[Z>KIqjxm0`|O+o/uDzLI\^ݝ}G8]G\6;ng.G +7)b.ަI\_jyeev&V~Ujc4(\}3XKAկstYT;dҷ{m 'j]:ֵn5U5b 2y]k zCq2'َ*ݟ*גӀu[9>mX*)ڕK rＮwb}9膘= SGu:O`yU4ښ^z1"<Gg–KU߆/+;^.֠H Zh6nd'ܵ +]WWlt0 E͛1+@+z l? cڃ|qُ) o@{˗^;GO!vz[? |2 + !&RHQC% +2Q +<q!J%Ѐ@%D5H($TI3@(P/OIYw/ERikDqپfVuBgߟR鎒݌2@s& [ա[uYA:m1m}Jj-i!рgd:޽sjF\4+k#0yUS]uCがvL;jw"LNnP ߕ 6QX6 +7tj +{-$Ͻd{b׵zۏLq,J^Z}[j˺|b>M4M*uHVY۷4,ǽ %v2=u:M JjU^Ųqs_UM֜yf>tJD'Ŷ56UzskKO=ww;^lli Em "7%1''Zi:k="K*hNSZ!ϒu_T\fZ'-[GYO@Pc%Cs>iT435T31~,lKz8XT\NmTCy5[mkM).{nn:h0Z0ZO$sZ.*[0Qk0dkwuҽZ^쒗+M>D2 +veZjHxcXޡ@vI-u.ПAZOkn]]y"@Y\ q̬~ m?OIw_NxKdXԷQ"Pt^PYMMCyuDnG2 >`;;i^E<5́خm5}qJ?NH,|U֞Z2 ֿ&Td5&W^M5Zs3.~njQ{\9HeGgUM>ϮZLb:}Gn݆At``;osM=IͭwNa-{C] N,_cd5ZݥJl.m7KetiԢ1>bmRkjqS3/GQ}(e*gA'x=-< ؛~+ړL\o^Ue{`Ox·OGE[Hڹ mB­Gt$+r[߾PO42cm*j)882=u>?x޻u6Tb }ioGEkZDz%̩M{?bV*6%U0JF~ J}F跨ѩZ99̶z6SUPw&FV.B:,&"}*=i5u*4EŵA1o-5mSЁr:fJ jl<N׮[}r 4$ y8w͍f\[i򶚅zՅgwE*50orgZʍA璱w~ulby<7_Y:Ӭzֹ$Z]@lpdMaj.>m Ip2H]&l ڧŇfk A*`u8u[:N 9RL{RԘ^=> }: %x.g]6nUik`r/t+ )UZ[Dc KF6./ww<*;&6toK] vѫ^פe#.8h-]Z;:@agN4@Ϛچַ,uD.E{;UĴܚ&>Fr$[^׽6qQiU7/d% +Fn۩^7e/ÓxFP=׹o}l޷[KI- +ujo)f}su}Cm7}Ic`ǀVh[ᗗQ)ϟػBQ(%)?!܃$@@E$$RJDBpy$}f<(p'S2J:%8NeR>r9 xy@1?R%@ʛ9]6{f 1 Z52vWoLĹO}L)˹GQo 8̣0'_<Rז$ AwV<א2T\KҢ 'T%nP/$b#G^G L1T‹pߐ% =)s 4.;Ġ8!HV>iu'O<$א8A$-3P!'pG'U%#PH&urPQN) R %$d!}e)ʏTt$L.$ RHޓ:L"eLV) + <P3 +Py*=R@q{ԍByJe q9LT#)rc gJfRKHL'8( ))y8QT8K>%(qMEĭ5"{,e3XOG)4J.s)pA TH&Pp@#RJ%DHuʌJA}@FS0e>"' CB\"eKeB`HipDGJTJM@o&1膙H̠uJ](rH2:pL2M0ALJ`aQ(9D9D8LAeFa>Q(9@L"aD +C  PR8@Q>@)QԂaG)W)0(Ja0Q("R%2L #B&2HJ\$DBS(ꌦ +IQt C*S 4B)p Dh(x"IMS% Gԉ66tz 晣_ +kZ=I\޷H'9=Q еz/R ,}[_uVХ-$dtMg{\N2유OPBq) +F + &Os $&AQ* xrw a3>@v&NX`ovNcn(,-Uqc>h6WX5p κ0 N' )4B}%I!@ജJm ~"zJaPL2 B` Alr[VnTΑ1@i> Bo *u:LϏހH#$cަ)P[sw_C-4oO!EpxnJ5Vxi.ηڃu|+RZw\ 1+u22Bi$SwdfPde&xN# d :yCGW d(*]/'0' wdJ2L(pQ{J]0K (% ʌ$)nGG)a8I?t/H!)MQ9MESpP2%2 +km\ƛ{ulHc[+5vP~YBP1]@.A<8\_g5 l<)T${.Ĥܭ~_mRڑ'U{M:];lu1z|O\ۍF֝,cO1+/yjgdyavqxy.h7~ufߨh:Ԫ: (I%U,7W3I`Z amM:& }k+YY>u0DoS;rGHs;O{ViR:=agozRvdN?`voVzq$ȕso=[}~-pcj=s;NרǧQ{{..du <-_V}@hΥz)72r_;>m5>=vtSBN % &xXjګEf9Z@!}kjgrG0aSnkۃu3<}_TEG6P> &jsO|]ur-X#WwM*H:dY>umu2.k"b|> -SH, f>+_k2iIZί{uUh% d[ܗ7_,!]q棨ԴjOgIA93 +Ɍ8z~-]kTxP;oM:U*;%o]r-7A{_xlwnTii{\5"E0zJW` |Çnu^*0CH$Dϒn{zd-TeH=Qեn)CZ'9Y:fuݷMpڍ%<6}c]aUѨӭD5  WPaeF2q$$I+IܷۡſM#NEJN| +;Z^fm=R,nWy:⸫omSGԮvRnG"[]8j昸u϶&V֫_u]6*$L"yX_Y{yuoQ_Tc ?xTӬWaQ}QoҺ;ܗuxJt=SPZOb\gnzN"YUK4[ߋId8i?TꃦCxCֻΫQT?bȵnip^^Ӗ?i]W+t,s1>+j4n.c:խiyCϼ~ڝ]VM8FOر(ڏmNړz:9Es*֪k=;{M еzun(8Ȍ&Cq]/gq$ǚ˟V$5MJqX-wNz1 5ftu"9 +Zŭ[e*woHFB{>j_6>M^] q,][K):F%{D9]. R]DwcA)ٵ=2kyYUnP + (SW6s1o;兩։cl6fvS"tv%s6{GS|=wM۔nMN:~m_~PNuZV[Bv@q&&Dd./ }+teX,s[չ*t,Vx8x?jlZk2{D0Wq~DTax[bHr?_.+p!i#eKR/zu1Yfpw߆:: 0LJlt½L=-w27{VӪhPd{NDQwMϪkPpzM>踵¸Tvw^\9:`>VwFޥSVs#0V6M7U4n:ҶUގ"#Lch֗8>*K۝yKOS\:]&[Km޺<}3KږnIůnG9!j4pez f q>mBJ:Mz\kFWjyiZuju)Tubխg>]V…f׬j .czEv2N',NͫJk:* !tj"z@O\擷5b泚j kXHiZ}]˻uDyޟ .KwsCKU|pQl˝%3=.2fVnAhXԿmj.y{,u*.ZPr;q@5jڴ*Ftaf.l]ݒT5fW:UԨ9^쫋UUa2BCy]. 9wI@ok}:%1`J-;VǴmrT| f~*ݝ~oqTAH^s.*?La)$.]bwWMTܾV}NꕳZ I$6RUfKv{KOD/<ۺ-/mN ?jaR3+ 09[ ,`#Tw[Oϻjzܸүjm +wjܛGiWX|-槢j'PVCl} "M~ޡs-2"qQ~5;CT>K4O)C~mLje.uAVxV?qt|[v_^5.gOԵ5ͥoAVD<2CjsIA +^K+~U?>+FWۧ˅vNAx_eG qߕ^%.[cpѿUݏ_}Y.ި K:.{j= 5lTW}Jwܸnϵi}zHjnu-uNރKM&[wՍg:I`,?vli_$3#\?_{qʎܝ?U}5in90ou7?aSmZ7*<41 Oc7O E-/pO-^.-h؆ uZ I83fi;h2#-n?OhmzbIVeo״oޫG?r]47O%+G~Cxcc$ :?[Gmj+x%$㕉Wc6w\}deUp_mޖեQ!˷x+&ֶ,ݻƽ{cLd2XcY_ ڍ{GYH^bvyukᴚ*:ZXAęwW74H2%өRs^#i IpO]2QI.ht1 +s_xޒ?s+?ghjhOWni7wѰknX{mݺڭ[浄CLf[S;epҨlsZ?N9#v^7 :ulVǨ{ԩ[ +oD5LO;wRKhwiW5n]_P{`GTkPo}O޷;Mo@6%m*eCɳoSW)vy\]S2|0龼Q;Wo\o[՟W5AJ֫j8"X܅ϴ,@8qA`5uW4yQWSqXj{53S M͑ +^߹u7ڋtk)}\SQ, z.ˢVP]j}WVd1xo[y[ԇбm@߸.VۧۼA\GjǾx]&_;+G=f8}/ZNcOQ2c`[fQqyUs0+״=z(5-nKOC&2:f;O]k_ewjfh}]qgQPU.ޣK4.d~y@ >#\ww^S"B.<g2WW}${;6MFѕuR<~?lt闏"}֩ܶt9GgU 67/dpIoٻl˸'rɁ;6^a$T`]lꔻʽ + }a#(Q21A4R) BNAq +"HpIJ!""V%qￊ(0)'0."xA&R&!H DBdr36'SnZC\0cޮZWj&GXWUaFڧ~O%n6n:j%>b.Zn9=>̒'r{oT) +4\rd?VFu8L 7{V+t!j[Zڿ=3ĭ۵4Td䟚WYW5MF pHXz➫ժD9 [mT0ۊ0`x$Ov܎[85 Ǽ«emZ-Jղ.Lǂ\?,s=JXmAN8cWE5Arj@*72e{Vژ+?{uv[mT G;o vMVAi q+OCYm[:ݯp=F5l?P3qVp8hKQVԩ&0dyy.ᦫ^Z><.Gml׆?bSH,E ^]<-տ^ڕxkGki[Jv~h#A+$g~uz DIm@NcikH"=V\VjTAB}ymuH?XJm #Ap2yQiጨ~]Y8?o%ꌵc*Ѩ&No}w5ay>kqUmu "8V%Zɢrʝ 0v߭kZvUCx Q@Ti1pRܔK*ShӒ}tUJzЈt[4m-M-{:3ɕ ն-aD-]Kaz)dw>p[j7FU=u+Ox}|>զѯ˜6C\`h7_ңI2I]%g\F__J5*OQ1sEm6څkAc%jpYBk Oٶ7VkCXAəu(>`kոB́YYۏnIǻx>"}VUC{gO궻CkBisZ𕇶k V& ώ0{O~kRڜu<'OoXOmR: rV7>bٌcQtsEjzl , CV +-]>u~p ǩ+mLr_CcuqqQ2=&frc +- .dz!s;ohաpb?XBN[hķU[h_ktzoz i=%n5.X6kEwt/]R*6 i[MWi[xs azիGY-98+;Lutƃ`B]ڵu&jk@9 s|mښ:ft_7Km* kA+dU4;wPDeC{ښ:T;FO[6_S6D\_Г}'F5]_ꏪQ˥s{j>o_psOXiIrA,-,=A|\晷R,}8bZǼNF\HZrTFޡ\<\ ][LhLӨ 9܁+3mmguۃ_}V6q,;][Riia{y#s\ZCSNǒM7e:6RۭJwveg[m׶ۯ5'3,tq>6yJ":[=YS{{3P2>ըG9}Vo$Tu*jDglw.qԥRާCGP'#[: +ID HR))?xe +1(  KƬW1Q)(&SG+2O(DM(CSnh P&B`mNTNy@P[RIAOq +} |Ij|bS(iHGCIj}PNRQ(%P1Q$   Ϲ>R'$$1(HP :PS$ e (Pee)D%2#LHPL%2)"%'IL(&PIBB ˊcd%K%x>)e*C(!L:H|Ђ&TI(A 0a)G)p$$₀aGLAQ(@2e `"SHA2gS}A%e8S8GL "%#A(PSp$aRS(9G( +A DJLa)LH (I"S 9"2 '2L.Pe (9A(.B I 9(p@&Pr $[ G$y@  J"IL((.GJQ2a$pDO DQrRH' H"Vz5lNP$LMJa0$)zBd ( \J!(%W7U;4WP@i$$픪GTsZzb`'Rq᠟ny GϕۇүS{ ><ӅeÕLTCIR4HsۯpUҪѤVty]AK']$: +AMs R4HI̓O' tq=ʺ:Nh»TwN'Eu8[ǰʏOR@lt9$Lz +e̎GRegPiۄ2TI\h:]8[/-VnTK:`9H4mO픈ʗtQ,#6Vڋ[M-ʢ .<OQ#*E2cԀѮVXÁtd$YB:I}~J$BNR>[ӓ#IypH e>ik*זn F|MJiӬfZ̑ɕ)|=Rm2DUhӫDTȜWH4@!H#TN0S ' 2<> 0rZф +u>>.PN?KP%~JE98-]1"|OiHMȒ8tz>k4+wn#ҕ#Ek4|]>A qyPب:A܀cj-zC>]B~Rʅ-GUG5o]#$LH Js +!8JA(!(()RrD9Q%D[JR!JL;#8M0a) JTN" Ne) as~Beq 1U*$uVl*\1ϡhÏ%bm]__8' #IoרjӬrxhBkVwKZb&6vR,.~5ojjU,mC $fo4jNt纞KOmPԮ]ǘWiLK"rq1ZKMu|׫wQD{Nի>m6o +}bN]~I=KgQcEUI>ٚVשKO1+/^[}Ӳ[>rvܼ/.._KYO²T۷-jRy(YַurL;"ЪB깜HOLyG, 3OݎqVJ412+[4 gV\{R4{v$zs;pճu=>'g?bkʝ<3K?foRxImRzT4mt}gG=>=>hyJu9]}"t]A#+MeZO$[V괫 RMg?C<.iY$9Xc{ndˤO[fu "G*gݟ|Ѩle'\QL{nn޻6Չ %g?wϪWQx&=w7;ḘJss$|OP@h>^1Z{ʷ{0 %uzM.T}~\{*Ua.Ol=gl{ ͭGT`y$BiwwuFỲd|W17=QYey+yNٍs ?HՅ'=ƕ= @&1gtGtQ#cP~ӛUľIw6& ;ڀ:dH +vt{IϢ I?6RzVԝRմ +UMu/$Sr g+ۚ%cs(vrI^cl-RO@O&<,Mäg^[ymH=\>`{_vI&gğjm:7 .k\$Ì|[L:E˺MOz+CHqcZ&#_^K rkGժځ2:ɩ]J=!šp!KE +iJ KOB5 ?v2O\n澭7Fw@Bwٻmk[ը+0 q 7+K7\A2т3u1wuj9 OLbVEn A-^9q|ޛlPoz<䜶OU +y qq=\q+ښ5o}U̡N@'I-⽫ah=@y}3W7FH~QWmqn\歹byZPmGS1옓'-õ*VPq}HZizI2LZ m?uP0&Nu醸%?>jݴ;&b8Yt6Ңg$ %V*:}Wu +A>BK&h$ K`0_Z{#>+{o#p rD)iN54m.32]v( kI>rVivGwCO}B}n=u:g9uZ=7Q/>ۦ0N<l.wI,|'>Gڥz.l- MI=$Q+7]4.eCV2Lͷ}>їu2z ' ܹ]LˇŬc %=oLv,{ױ'-igMLA? MW99UmCSEԋ Q0O+U6h( +=$ <iz`)NO7ݦ\_Lx>+g-m}k[Gf7nA'B శ\ӧ-h1 +:VثRcCe0KDx*5K_:⁷u7&iM2h\<g֗ԃUZXI'[-B֛ q2H oލ>6c\6ڧt07zZzU4c*x9i"Is;6̂Ay,-lVGTWgCRmJ=_Wٕ#_{dI8Thqur +Z41nMku 75.$Ou: I+_Suz/j=t8&ZU:liƍfk? Ωi1+66ꍰsz&' n6hXOdS7j_yUNM}X_%^h[Ԧ< ɏ 6m <\dŽپC y!iJ-y]W\I;G_Vڱn&Of/Ԡ0N`~;r*-! u} Gk >՝.}?yWnt:!huJ`wb_ ~^ _Zn{Bq ZǷۢZ?}JI+qڮip^.2ŽM0x]ip)j"֑b`?ḛ}fwW8[-TRR!S8[}4?FexgiDք]WS~[gZNG}Q7wIpasȒ0&>jRZ,q9X~9[n+ + 5Z->$Ϲq}v19l2TmͻCO.m˪W59+hRaǏ\I{3踮M]%>ZCn?ZTwWh}'#2۷ekq.-Ze"ܬ蚶{~* , RKʢh"<-vŽ2뗾י$y|]t:9,t|#KѪQ*2ʻhYVs-pʃhnk~b>~4|n}Jzn-~>_&U{ꚍy>9qe<+LoE[:2]Fpx\F~[4Bpծ>}< ?oFw@ܞh@$|umxRj:FB >..qsdfg=9];JNo}?e0N%oX u~ {6;=Z*$Oʥ\o-$93>^ պiVF?Xd]Mq~Sw޵Ҩ5.0mEޭuUU U\Y\YT0㒺|:2HX[nJgmFj +ZD־2q]lKCL\Ԓ`=ә +]0Z@3]2G\>w'|= M7}h{1*X{4{Z?/gS.&^{OMzl*, ǵS<صa]Sǽkwڷ_kݒjdĸ]ԭh]McDik_DZIǪ6^]w. !/[fJԚ2Z`zek{9[wf@R40jlh/1g N!Dzy5[N&+ +x9wFdM#p)jN6:P@:Ie)4gOW1"APm38b?]^]nܺwG@fvXIӟOd8H~Wj2GJp q#>~KSs٭ULH,8Vؾ_;HPgA qVxLNOuڵȱVL5w;>4PH8}cjj[q[@7ZK(]E|{?ڶ+4CYbV^:ftևg}밷cXƵ|L&2"f D J((J! J&~ԥ"Hy΅S@0)(@"BBDJ I~ ANXZ5v;8 9]~ep6īi}t8Nr<+ܶ[2Oh6ӭ> pݩ}{BtQy[ǡ3^h3, +ڵV}&4Lq+I:}E}:okj4GwMA9>+}]^˘ -&jhT]Bc޶څ5*N=خVJ6ZCeRF`}VүnZPton>{H?{PoRIdITkܶ[o\k4h.oyM'2y`->-ZZX-Q ~J";zۍZO]J^ZqVu֝P4T˩ªּ^j)0wNs-sK7ϳ h  ;Ke.d,kmT._5  Ozm덦. ECkcu^ޥթ tP-;Dmq5K6+~ +v޲:/>H_}ց'3%vΓQ4kMIFVF2)ꮏ[)Af[Row.S ov4ywyZ|s-ڎpU :䴎9P5=X}Zm~dWKL(֟ O'ni]U\m4Q3̑{mڅƸ)T*3|W9vA}w<؜ ^Z6TLj+oY܁KPzj# +ih:~F 1 h CE..–ڍKn)Okn6z [ +g{DyqVMP.$֦l-5+CˀU_PNb+6zO'݌-jjU\ + ̟5TwQZmǶʬZ[|;cq%%:`d|̌UPٷz9-Hz^$ Y^Ϊˆj3 'Ud+*^KkuJ:DB{kF:-mKI28ϹCrkh.O-p-C=U 8n=anfOi{ǒi56r\nsO`yX:˷mWpgx <åXQc-t%kluM>tdjJ^~ݛquFG9FgNz^8-L.Rgױ>g^K%T?ˍVj5"kamY< +Z9BE2Ρ1JjGB>sm>@EANAYAtA6ufײ氨::[#ITFTpwxfGލgm;Q|׀(D2r +VGQV5@'V6]۲-2:{+-?M Vn5 +A!n>Cȑ -e"dO ~PGv[x"g[YPV"Gi*᳛z_X&2f0ԭb@wW'irY5IxC^V}rz=" tj[2Zi]7`hy Q}BR_-Ѫ)44|3m]ult녪޻~JNҁ븩UzguqmAi< ecHڱzarw6ѽylx%vE ն8TZ4j }ZVq[uw@wNc1 'K64Yo3ݴ Z.)j%yɟzVX :=vWZm;nw$KcnvڧZ^\d ʽy-qVV6):ް=s4v]i [=V{ZnP]ШhP*lH]u{-غYR6,-M6l..}\]^3RƁ^cWRzENOKEӆFwPն%;JQ*K1?3aӶ.*:F^L%"S(!E !TKQQIJDN +Q)Y| $ ) ' Q6CJxQiԋDJd&02BND%)O( BRKJ`#}S9A0eB@PLe( IȈLHaA0)D&rDBnK]Vd2%()FQ') GT%e&rʄJdBOr)a>P &% KZ}shjڀ}fr8>U#HPh 8H0SSx@tct +'@pe'e2%&9&p0RL:\aMgq6ȴ1yzR8C & $a9Jg7("ꄸJQ 19RLBLexz"PN9#M#()Bd<8HPp(R%SsB1U$ +| >D{?0aIM:Z%60!3aNAKR&zLA) !)H&dgJgcHaI!LGHQ@1 s(G8IE2DB` H&RA1L"!D aND$ @(G hH6P}RB&SkeE LR&FPJ aa.p@ݎJDF0 "~HH1"|L# FP3ʈ2Bp8@0 )DrRf LaHc"R8NR"}dj4;uyHXRqK8cԦGJs  +]IDS{zGQ< RڿUބ"# :BpJ%nqQR8HL֠60wN6<9̙G\ (OH(L'2a#G(vIS!!$RH$QEc,??U$ "a0>Tɜ( >PJ`TZ2r "R@ir% + a |D@J>R%M[dkug\E*-xX]1 = x]haˀDXZ08C"ZAI2L'D[j֢̤>ɃVx]hPsQ$$<~+{c®m/i چEA#G؟|7H؂t`Hx<&)dς\0',2ՙ9Rp >čf4"qZف520y]Mp+xݛ:2'/Mݭ=UL$u-!y|A(ժ"\Hzrx>5FC*0.W5*]'I d|dzCN!\`I ppȏY[GNTM 0D|,T'8J=Fj19[JknoH!KΡ?,QQqY>]AdUWm%kqNM' Q XKy ?%> kTmz85hF;E ?ΣVs}H5U w=>A.8XuujC;ȸJiM 0D|֏hwz's[kp b-ݾ" +̦ufD|R*6OHsNOL"9ǬFjڬZ2;c@fmPQ@8иaqgSz$Hpٯ[=جί.+;?l,{Fk')/k$d|X_/uyu \[dpioPB$vK]hA"kbG]fopkp$z,{jāV0DO헍)89m n۲\ZIi mU6L.sߟBBоZym!'TnH=u!$"WYu_ʶ.h+T~Q>N"~Jz~KPF^kTը:FxMUwVs],O6L8W4(m2z,TpkA]wvèH [#εڶѠW˾AKKV(T>\;Vpio) 0Q%.S@%.PTr)$P)(THH5wH,l-<|N0B\)1<*]P(`CSq%9>()O[2'PpNx<ccX.+?sAhiH[nkV-lY8Ɍ+M}B*9k!H-_1WwH> y +f٭Zypq}]>5ËLqcZNmR$x`ɏE΋iPh'<fw8xeK`k'>õ=խ[H|AVcJ&Zr\]./j8V|9-]j/YJGK'&ZaD}ʶ5 Ps\kO )8sF P> +ͣ\ToH K`Xwi <=R1++MQ70eq{J׸ (ەG$:r&ofvͦ {]D&y.xi54Zދ^}$6%n;Aеgeq?}ƳLT#at9etz8(* qE 'cmZk~f|YݧPuť:n{ JێyqX\=l\( /YU߾ңmyh1f9+̵7 +UhZzsJ6b֝˾;ոSܧ%qhVm{9ĆS–цu=F̖ONOep*YѸoGL,aMw0{Jm u~V4Mՙ1"rݪW״Z~z0@"0Lpgl7!y||V,i? 1a +u.n:$0 նE Ykk4 _6U֥H Ȝxl-FލZ{ڔę>$pKQvRp!٥slkԞKGJܴ.tlYDRx)BӟE_'ׁ>am벯?>қ:1Kbzn.!0 8+ +D{ojhԪ9!$fTt +-cOLW[k4pڶ ڵGZƞս-;`t#waq{⦱wOFtT#D}dl\0Du>QiiR8n?R%!#_4jlfH9HjzSG}|~հٹhw+kO{>Fݑ0}]fP:m#H#YݞYP`u:2=S+tڷp]FFrhFdh.vb[ܚr|^I9ZtESYa<1>bYRf뼭RߘzXrD۷l蛻2Uidt;0DtuKjw>.hQMc=GSqv]QhhBsWIuG}wOk7֒rBݱkN @ ekE ۖSjc>+_[qqgIT$s|65M/-)%p ȒogMiuū{^)H٢V]Bڗnt`3Nznk 8: sʟf-YZ  VDT\Z΀]b@[dZj·dg #gkGhdki6noWkTsp|CtӡS,\/cs18gv=̣gD"HelEÝq9.OL6i$F%o'?#gL~bӤg{Qi.y$ smG+X͐< +.Ia e΍=o4VeΤ>m/t1>9OHjycsyO^%Ժf2W36JK4hǑd]. jƊp2@=e78o޷JֺZ mj%u;䶑?)r"Ψ}FqS= p*;PY=7"D \we_cOR G )*'DA0)HDI!Qppd@P(  SM_CDzH9LQB'< HRR3\imYu'`,}ˎۡy7ɋ/~%K~Z\;OWiQΑ\Ew}/ZoFE:~FcZ\ eO;+ͫ\Sٳ;z=ʏhXr. n/[`ԡcjT c>+GWJFһaǜ oΣB˄}ktT@@ޮbHGuaujVw'ǧk6:tn@E&lq:>ԛ¸75I6̵m.k^@1 ,ohAckSDyoi2D؞q y> ԯ[:I]B?Eki:5G }]m +!:o B-.&O=YX4׸ &y*{(l;Gacr">?+k)e6“ ?}&ҿ޵}^6ɔ}d'j-mm?ĕj6ޱEhi<.摎{[Fܡqsiv!2htffddr'NgmP]=BI[kn Kӑ'KWE#\L0ݺ^:?nF}Y Z*7- >u0kKg]9+ݷ-z@'8ކ3+jz?{ <_m[VlI"DCm3Gn+S쌙JhRA̐Lbl+,?q[~@ NvsShY{Xek.}gZj$o>P;ԟ]}L4Ӂ`+(Bw>˅?Z>'Rnۊ(<ӤˋL%l],4f:=-'ޱ%!p,nΏgTF[C տVW1l:y=q `m-ZMZ`צ 3 O ?_4(`5zĬNѩ:`C) cW-p|=W?Pm0Xޙg^VXx& Hb߈Y=c]MiS[>wto +ԁkuX0fVJ=4'tGAgEˌu|޴Y֤߭HUl-A:鎗6r n41Mj<ȟ-&~{CK{:O`.0I3BR~Y y쪯yoY@[-SItZZ.nj(N̚uK{K5[k}QLaA?rm]::T nײt6UcǕaQ5j\S32[j[htMҪ:z\`]tzUj}g0k /e,ȉǏa=O޷ͅVԵ^N8|\g֥ϤSyIw:1m&ЧRGkv4w.hmmvhMsJ2OQ_Hf؎yVp'!j__S˦#"g׶Ulg';lWFIA+{%i6-Jr DFIV._[4kx,Z/.QZLz.H +lƀZǷ봅-p?Z{:]Ԅ$y͵Bc39Y6z5>YuBwKzBMpT.$` Sҳ9!}l6wU]^x.o|SOv 1-h7^f wAd n-oDZtMOn5 dDA[5FZU5H7w@_6꾣*t?>*ۣ:@XDelMD?UU7Bgى#*NΩY֥uMddI[=ɶikʌo!i_k׏u?Oo*,lhH0˼xгiq' s]#]Gr6eg\Pu6xs [Mom3UF ۙ9?A64GUL-k9ʍދL;7>qRO[MZ)CZSY}6Ɏ>Y\d.3VWW{b: kvw1FC]8kz߁ S6reAfnkԬ5CTuj?CxD- .6?1)W7aPYVu>kx0|Viku:!9Zй#75*ttuh""oLkg]k DZɷ) +mPA,HnĔO&Lʣ^)ks~wg+GRdz0#+W_@c䲴GFy U?~aoyXZևGZguXqÇ\tn\t}%tFKH`@CGϊj._ѨLgੲ+U}w3 8# I 4%\{7I.jSGܳ-{?NT$qI۬TY-4] gju=RXK]Es_s}uTRc+7Omv$4g|J8x.5sX+ۚ8)[E3 x6h%a-]i +V 2Հ xca:Xը>ǤT)6LN٦E6v4ĺ"e=ͷYm1ӌ[DQ-Y r D R櫩&>%vPs[ͭ}G4`#WیRsuVؙ+Smz+UXfK5zsrfdjOL`ɕw/w%%fiCGf=,hÂؔi8:J TwwѶ"?rVRyu2DV g^l..iT<.Mݙ-}F4̵Ǣ4}zF$VwT6+ӳjnzrݏ@aUwj:A,xΣ?KDmFƫWfF}&ɗoTKӬ[m,1$+Yv*M$CGֺCm.J!FĴ :D0>J@  @҈H*G)MNJQ tLy#$HR QS(8DBpS((JaIeI  +)I B|#D%F2[ QҜJ(K aN<FNPQ0I).P @@nA0p1L@=QA(Ha(.ODdAh"p> D&CS 0)@DB <2B|( (&JG(L XXwfR2d€NS1@dJ,& "#@8RTxP08GJ%"RANT"2OʉSAKJ: H( a6))Q2e2.DBHQ|!Ao O Dʢ&zJș@:`Dx L{WWt{Y?Bv4OkA) ><$HT\SUFQܲ:Q)DTDrP F-jpk$^T C2=S8L\ IN?DD()HBeM"S)!0!bTʂԼ +xYP !G+E_􏫙W H =S[\T 'y:8UsYd@AO=Ttz.¢p[Y;f5DY6wsvAU`Ȁ5{J DRy{ c${9ٶۋPڵAÜ:|WUEH yT[T.S?{[ٞXy~K.X4AQeMZ hq[5ePRxX5{zLU@$T5?fFNESS t  x<; o}Je79Xv kz<Zq>.Hn;wt4 DN}m%`_L֨j͠Șc;MwwVCH,?P7sxi"}ak*O]\s lȨ:e8XGKo]w˕MHt# lIq9'lh1OڷtYSs\0p;Ckw ɓ#+˶,p$_iwŕCH-=A F[eVz4P`N+ET6xsan SNsP:=V˚>&}pJDxVk4^67?yy l7S,h͓/Cm^?~aF-Zj0ƂI^uw-w4G7mhHxKO uWOX7JUocLWQ9U;W%*8xp}``qI.vhV4] %5ejNaK]|8e ҷ{U=\?jܹaIZ}Kx4cI%~mn9;W+ڮH:Ks1;M}*c^PzAc-hj~ywf|O>Ե*Zc; orV~^8RmH'@? 5ajJӪ &<+;OfLWeȑ ${5W}nǼwn놶GDD^hÝwA[ea^kl_Ts>}kT[ATL8n}> . ]'xZj?p qUˆ.y]τYݲ'+vu鷩GJclYk4px{ +l|t]dT֊FI  +*;UmEFH#onOe6-5GTC~kxXFu*65`4O ^P;2A"@=WUEGcxUuZZS{i L7ĆĀ}LO,pP֚_nRյ8xi<Ikw6Ԃ㎠@?5rV8}??bR$*.bVXId?HJ/q/.u#yqstAcjӸ5;zAl:AN E܁Df!90Vi6tZ޷˚[z隥-Yu7{GT n<G%heXAsHn}s4t&⣥ DP rPmKwVfF3(QVSvv4 ƗG,s[kCCJcZ0VHi0ZЭ-H`@hk2ZҶh*1uFzS- c:>GE/*WwHqIoi=5)cIn[Nkk i8WŴ$|TtCPxp}*>[|=R"Q`H!<' + ;)aN) Ds̤!OQN%8LDJ`(%.J`Gk7*@DtD0LҫiRC@vdgVfT,hүI>6̙\VfE^\Fp=9]ރY᳜Ht :ړ{R}W\$gҮ:xu +4SQ7W?Fca#i-:ځ}#9ǹtΞbʷ "V|NVޭn*8ufDU]AĆ $xվn.Ԧi Vo{ pf˞IfNsd'g#Xڅzz7/km\n&Y{w%hs0FBt07 ,%qu*wL?DOްJ~p:\Т矘+~7:Qu񘅁QwTmZ㨓;,7DUYt8>'(Wks$ ĈQm2K}}gjZ}jl- #uvvu|ri^nƭqnIy |IRkZ1='ZOMڕMժL!`B *{X}I4ʚq 3?bFγ 8؈gv]m})ĖS$O慬 m^'k0Heok>ꁩnb?i -;ӦpsSe]3F(T4 q1_g4\]S֙ρUWESݷzcj0Q1*4VEMJNt: $0:>CO;GB!^qϣTuQnN17RzKZ 얙J3]WPy\7fguUujXn.t*/Z֧4״MͨyEZteLg>=BTZ[kI^dLrWHUۀ-v9\TmcD<<Gjݴ+>>YmO텷u:]NK\ILW'ٮN֫\u-c_3,ҵ;Whgx2y,յB+P֩?؂>̬MkI-] Addr'VCPinz= $A*-еTtක,}VӪ C $'1=J:0;-f8^JhS` h\?gfԝiOwt0yO')U[?e:ApH>6굕Zeq8DǢޜ.g$[}!G09 okMm";OqΨ(* s|Jm}Zҽzoy dY;\_B{ZX<7}'5ᦡw ~Joִ-GdƇGe Z Ȓ| S[/ip +hbD%\ +:tyQ` k+G@U0fW kGYNz5f֡PHgn2kzݘZsJ,TKz#0WEZJ}@  +vST)q|scZq^<yY_(Q{{AakH3#B6΢u;ZWŠQpppGIsގ{0#a]M&}h |õe::u +AisIH2ٺ~T>$28[kʌl+C-чc#3]3ji}G$ڜ}Xy:g ϷN ;Ess<46"#ܴݗ6ױ>X?'6U7sCxiNh ,nE +V2Cӌ'eLi:@q^=Q͵済ēfY[ǪVujq+ԴZ7[ L`c?6vnZ@$G8Tƾr@$W9 avϪomU]J>цPٚ =6ڛAQqhOh!uJ><|Wjl{O.ni,:MD&~k&4>»!1G 4Ęz6NU{&9}DVH Nս44uKi8H ؛L՚W. .7E-f]BNk289/DkӧT4?jShIyP))C$R*% +%$tf|{ Vp*Q)pT"c6HLP3”J\$}#A+uXU-͵)p\=7WcY]ϩ{= lWe&h̬{Jzu+У5YU'ܵ{wUf]<0`++{Z J,cR]3'> ylӂ]_cƺSx]3BܹMVڝJWeq,.L]&jR= +*U* r,ŀk`Z~ #2<*7]m#7\h匣|ћz&9ܩ[\D@pm6ϑb*="dO&>k"ei=-$4|&ѱۂֿg2ljZ)t}KH1[neǰd;ݕޛRփ4KKLIm]ի%DHd3A.V?c:p8l[ RݝThʍkwLeG ȆfG=ߨMm 5ߗ6K*j7|bm+}2ZMGu02I>r5 *NyhlZmzXۊl)xk|y].=1Y@N&dVc/jh {պi8YTՃ`~EC(CA24ZZ[žMV:cr)UQw Ïj.x0r=UiqxVۜ١mvMQS=GT4_fmR&%'z4խw\<6ޓ~ߵz{FtM|1J\>ު:q $<?VN,?w,ϧVWjzyNGWqR\9ĉl>Dh#D,]._Nރ:@t> {_Wax1>W洝vt{],=r'vSSm@^P\0ǚ;=,}&KzB  Fh]]Т[F͎Lf}\ ighcn? AمheèTpD<-m)蚛\7#px?κ-_RҩQ8=! i7N\m8ً<9uPTWөTehISgOe|G+g5#tڵS/{CXn~9[< ]A+/.Pwdq"Wi:`ӨpA>r !GG^ѐI< qc)TcCLϜ ->qT8wf F 4J:p/ןf$}66Tmtjp%\ ͏߂@ȴpŸim'AuVbToDIp2 ]qεN3,h-r=^L5Gs5a8pD,[3g+:W+?f GCGBcx֎1τ[˸ljrRQtϸ`-֓Qh`\ VXj65#O֏fvq-,fȵѮ,=&ޖ\ %mypG5kk GR*:X"NMe}(8*{03ӏWPwɗ5G]g4z"xlG+ekY(0Hk.{դ9o>?xKxcSVǴ)tYp&Dyҷ-1Vi:A2 󕋡na]:&İcj܍UulQwCr[S5UI..5=r۲'5ή`wBM%ڥZ ?Q%Fݔڴ渀}LEzwJ:U=r܁Uݝ6 + <*_oܹ +f5팅 /*6FX%sO.+xYXiQ<=o̕6^{/%#3-]?W;&%O]Q.}hq }P!  B*< \G(8Q) JBOc;ǟ*B(p`B<8mCCoysXʡ=OW]kEk9 pmz%7Pas鞣-mġeTW>lB򔻼q[ѩTTA +˴F6xu*W=U}IU֋GZow]h39q]5JM@al@>KE)ԾJzz9Qv-\uYّugvN 8$[BƞFC|C<~+Wۖka0-Fӗ #9[Ihk++ws+Ɛ i>ʶA{E4$qM@=D|gZYM6g%++gw$pI෵*pHQ£M)iIY@"U֟M%ԭj`@J^Q/soI=SxyFGaڽ="VzzD\Pn@_mGQχwNy$5h5q a6Lw{NHcORouY>i%L YOϬ/"b#`,Esz>^_2 Wm[]]f{R֖-4PA$Oh4oIڄN|nKKaA-$R}"z 'z,],8 vybuʞ޶Q i [P"A--ʹ.iHL:Mio@siQoKIzCV5>+OvvYJ\8.$ӝԐǪDwI` G z5Plf[ OTouYMHRk@@ M3,MgkZl mkK&l! vImݷ龅&C*$Wi]=- 畓EZmiQ< b]w"|o(515cб=FNdʕޏFQqHYǃϖVdݸ}!>1# gecJŽcE-AfȭE cAb@$[@qi:y3"ys-2̳]ԧ< ,'A'O'VENfrkC`<1TN*}'w^*IN%*$Bd' $,%e$҈B"p:RAPP2p:Q)')8HxI@` @@GHtG(r!2GO #rj8JP% Dr!2Q"aD)HL G(LSB8J?D8GJB"SpL B9GLJ@(!!Q8@LL)B9@ THPúeQ\ (̦r)y '02%PO%2!&Ne3}}NņWtFOVҪ*g"P@PD$D0Tm1$@p"A|F +%)L +dD4!$ ('O XZNKVuu&>K4 CPppu7U_jMJs "&pJ@NS"S))& 0怪m7WH†3SۚYc pc.B9B8K2aF< +0P$ B ?l  PB`(AGILSi4r N0%(@D@0r!0A.P! a2% a& JJi HNQTyA0@AAA(J!4JD%0R) a#pXC}- +P' aI0|M9 @i a)Ls3Os~KxihӨtkQۊYAL|+RCH| \Y1*os[h~wG-XT;Up״~koqY5j7$<Ѭ  =?50V kuhS.aQK < +-vҷu1U$lvvࡨQoHtՂ<#[rOz5mZOaUUz֦eGTR"I!Ĉ sZۮ,<s9i#zN࡫r#)k:w@'e-E>-C^x/i {LS'+WmVqp։waZo[ +n\`w-+ s>"/y%>+2t][k:à?5j5ߚev=Lp&GZMRң^,=]SIғ1!ԌFI h^)=p]A# |3lh4}2(=drB]LIy=A.iw~*Ѭi%iz=Qu0ǹkok;wG y-a£ZxsCOt״Ti 7(]e"q啛n:7 t ㅦ=[89pnI֨5;G8Nk]}P488AS׵Z1ZÈ4I*ڝ;z"\HE'{MTӟӏ_Eiڍ=Qu4Ǻ<]ޖ3uTLIZ}_{ѿA}'TN8m;>}G}orA@nJ%2)KB9@)S8A); ePP0 B + L KB!;P)d7 A@k@22DP) O% %B)tB& #@0PG)%a>TDQ>8\&BipHH DKJEHhd|U\SLP<2˥0!I2И%hճtzK]mV֘0^@)+L0 9Whʵn5 Kx+' p-!~c[/}AM5.+*:ł2:iqK[}ЫR48q R'UPC\$p CO= ; ZxI[-lL7u'{fYkEMOke+um7Gh+U`.q7U%V`Y=3謪V@|KimAi@3"fO+E![W6CV[JL'KLR}-1crݗ^kw^=#EYծ-y cYUej ۲͢ Gj⭘4M_w,l>#r~Gyrkxw~v|W=A$@lE6B^";%w"\idvk@^>P&@'>\ۨY.$HΟGW@2! +s< MAҙ0% LH2 Lpa)JS*]PT '0ڛ]%$s'a ") ]*.>JDʉ1Љ $@A0N(9C$ DRG %>R%|Q$PPJ9Q%HD pB&x@p>(Ne !(DTHH%Dp2>*2!)zrL _0D!9)L %8Dp0ܮwa6}[v{mNQsVy߷p\PӭXkyY]y8~b7#!yջ+ְ hs˘AJn-m42ٴV{ hx UZ +㢑p~6E1R: fW1ήۋ?ugֻ[m7xK+A"F|NZ5(:M8Ct~3B]B{j4\)6@"DmV{il3Ős+Ϧ<@=g%j7WwlA8=4B)猬]y2u6%>Q]6Qԝ예._fԪ6y-$+FK:˽S"$+;CTmikq`Z'fE +.pcF?Iл@fM{*R2H1jegX`䭦}:z{ zTc[ow[ZRu;rڕ@Dxp2{0)Ե6Ciys|D:[p?*@%lDU,:lm#GM?aH_ڨCutҦr{/3R?eUj}G #[zQuVkZzCH$0N^YpbF8 +^B6#|Y\W5ZiBםŨ;S4C >&ض-A۷ bF7g?+V՜ |Ox4u:M} s3gQii.v~_^uJ`eC=h EmKwGzy>+/zoZ/kgw h$L|M10cJh=f)OI${C8Y NJ\r(D A|@@)AG)Sr &s@J&P2B) &B $pʐrS e0c "pJqDq(L r` `2!"P +2D؉DP!Ds9Hs&Pe" @DGcQOa2PQ +#+&B + SOJ"%B $2|eH eхE;U[xvZڔ`BҴ:H"݁ yQ-UΧKn_#ҝ)4ZLυ,껼uO~ eJiM5 (עۆ<4ăE-[hkdhJ:>> _Snwx,.KBl4t|:k0<{E1 qVJma 1E-hky´(CI&2!.Q B +"(@@J`B "'(@|Hr*HPK8J| ( +DxKRSS !2N!"$@(BB9N9G(t2 D&2G`!)La2% )&D2!(8BQʉ*DPrLe C(D 2%Ne.O8Ne p>h"RNR! LQϪsPJDJQJe'@! ࣔD[Q9CLRB8QR MF{Öe# +%BaHDBrJqj0])#3 e@Q<Da3≄Da (%P(>(Cqp$(Q,%0D0 +9) pLJA$GT.@a("'SJc DJD&r) +e.rQ!!>2QAA(R)HS?o4rD&Q0La҃F~ DO)3Dx%C) @)B@B`S"PNe)D$DG2@"a4P +9 rp0)(&&POO)  LDNPR8)BE) þX|eۙhVBc(!*KQ)x@Q%(N>H CpS9H:>hL L)J\e ( e LpA"aA%t"S$DB8INe"e'I>B=pLJ!8A 4R&S +D& +g*0@rLAJPL&H@CLKLrLL { A0R8Bs))LJL%r0q 0eD(8HJ:hCJ&S !#Je HNe r0R&Q9HQhS*! $B &B]0R8H@(qJKp\v&>*s-\TBtD R>a9D/'D%Ag0R"R@B%2!(L#((p"aHG + BQ>(&B&RRrAJ]SHN@ e"Пv<4G"KR(R aJ!|!)LHe@g(nRJe +%'a2a".S!F 2PBOwDBa4)gHL0c Ӕ*X@)r@PJJS&P2HRPa(D$L#9ڑJ\(OHDLzdXA@0aH9A1) l%rʐAD.2JAD\PTIAAH +K +4|UEH% q(jSP28CE4  0+M:3:{wjVYTO~znqUml+.m@<|V%Js(@2G) ̠AD2Ժ9a9HJ%DD)SkOwuP=rrV߄L"e$ +$ʉq(9RhSB{ +D $}Qg $c+O{v=./Nf_l*2GCHﮅY i1谶j,lNQLH<`BpZfQVͦONKJܑdž~BVln[y312Vܙy2qܛ!Z..0֎IKmkO)AS&V==0Jǽ$䠕{ұNޫgAY +=)"=)t_ c:BݴǨ|Pܦ^>亓ꔀLK'0"q()22lz@.雉lCc9G1x'G%y.ܟY{[ݰ0- #m @HIe +pJL)Ģ4"zvR%"%3%1I G)pDHAT\_@{#"1'2a JdJ!&L$'3DRw(&T$`J{GV awU'깥h] 7{w h $O]^vB+$y.PdU6vTza>hޮT[_Q4\e+curޠ^ϟԝ׆uV&l7f1@!-eMuRצs WBnZM*Z}vǜx,]vh$D mKt`H8wE~̩{En/9$-#7VD?[ۏ8])kX#i%ΞVsVX̻$Om~Rr)瓑׺m-sk7Kuw:ޣ *O<鮔(j76nƞ0ƎIe~ԭTov2C]m]6t B-=Bq+2vV[ +A摇9*Ƶf_eܷ[_Sp֎Osa6w|>p{qSX\a<[1(`&(Rgy^oZũi-ECXꔯbiqERWZ>u6:`nwW}Sdo vtΦq9jwieqq1 +7N޻kg|w.wUgVq +z>89%ho;}=>|mzZsO D"5kӷ,cp+w[( G u*z&Rx0:{K +]=N?T|4w}:h4CB{Lj="e\ͶYv =dx}[QBҷ;YMPw#KJSi'r v{p?FUF40 IdX:쫥Rݷ f8hOW57SZ$u>%k:D9^k -Bc\ߪ}˨ G ^Y7/ $}+zgێ~p_^fOh!9GذvVG8}coo'5;:J7z81I#m4Ua tSVƋE p.h5>#tQ8C,w\7}}gn(0@wT>`D+Wى}{sBk x|Qun+-:iU;uhiSy>WUjf@3<nCWEPwڶ{v;T-O2 .BRԙ4۶C:0f|}qDmfW G|뺥}%}-S苚xx9 pZ@R`60IUZk>lt蟫dyt>\ }W{{®߯Jڜ(׸+Mzmr>wEMvڥJm-~+]sSGht+/Gݵi}j깿Tj.@k^֊ :>1gTư`t fQ:i 쵭CpUQ\cdi}[5A{0 O!lFnߦGUG2m2rGV~Us+~ըw} Qk_#I cWii0Kkۚuv^=Y+/wKl4ȒaLk{v(߸TX%=R-H pL)*2BA D%"'1D‰%#p&)j\ !2a("Wq%!e3݄r NeFe>R_B*?%iWZ\'#/m+uq}cW--eH=v:ꗽirqvｻ!f88b_hN}]6xy,y +4 FPEcx񑒼UKR.D`x-ާ/>|=e2{?gi4y.B“}g\Nǯݓ)T书ZtnPO pmSrTwܱCsominC$[So?ñZNlI^ŴmK<&~˛h֏8Swe:vG4.}]gFQfsM N}2%D\뾴}*jWOV›H>Wy e - *.LNpn\~@RǦ:KʅM˗liIh>r/u+J4껲  zJl$8 ݛfw G?εuUK/̈SZSَn1'"A-kiEԑ$Xtҡ\}vSm'ưJJG.OڽA5%SZ#ņ~EbVm6ukIL뺬uα6^wisZza [2*L\E+8Km]T +U C[J~sY~ 0XYD>՜>}n+i蟖hSi0My{K +}ҍB*4NzA,- +\smh9UҾO@q%%S5 .ޝ +Vr>X9TkRo݊58H/BʈVum˔>C\"KR*o^[49|>\Н/Kz9=iѷìI.<*ՈmNU|Hyb}"25}BōJtly{lKըwm?jz\J7JZ jl;t'>>-z^Vݶx*#jm +x:2u?kG tӡ~kطwu6z ϒR~P q7-..#^b +l{5IdUpOcM㫡Б[m߷Q*SwSg QC}*]-8%uZmFM@pϊ;Qqos(DWBz\~j;ft);,IwyO}B]zCθ(S;MkZ [_ZWn}$KdvƂ**{+h>mw&ױ-Vbu Q~]*tw׶i,cfk_rjԙPsmMf_FZqU[ʭ(x&3ͨ;Z tޟ1SW,qUBZmcOȩX^ꌤӡG1#XUMFZlou;199=,޻e5W~Z ?4JP[f8}Fm:F6Pz.7J⡃V[Q?Ʒ 7#"PN7ԭZK\nuYFL9ZR9`govD3 `JT(2x .B0˫sk_/6#DEXRi_ҙ}!O?YL׶*c z(4ָ˃Z `drR2C#Lp@DHr2LH"Sr3YT2pe)0~7s(@0e9L%BH? d ./LkӉ+DV3M:vSd[ı z;ζ[iUGyeevnf {$ &a~*b%Ԝ˫п.:}~Z}ㅠӷ k5;b%۷U+fe]hGv=W(ꁆ*m#L|VU~BƍB: Z$dXݘ>ïO6s\GsZekUIի:)]6J/2Ƕ]勹uo0+jO#[ݷtлkP~O +}&ڣTUyFҫVWW/4 QW'ml.[T` $WcRj<{Ew}bScyIװUW5wzdSu;Z.=x&gX4>e' O ) ^WuzujڑЩQŹ#& x]U7;~cIT#ܺF6Ӱ:[NK 7s{@i oꥀZA zᕞN҉E*ףPkPƓ£W '[QQ*!0'OJ®_Ip#KqtacND<݃{SKs]ZdzIYj/dv9 vMO@ pd.gau-t}QvnE:}6йSAf훻VM;|8'亂rraqڮxRRIkfF}{YKz5@*ZƝSFTt4~1Zhz{t |~ۥ iX$&.wצYH89` L}D~DT4yZ]5 } +b}V~7=Ww-k?, q *w4z h3ҍ{J;M0'vt_P#x.w{wU}@CP I>(Z4:Ì5jCPsZ>X\.iCݓAk)Pg3;V6#&eF9PpKLp,cwNJ/&`KZNSL>%Jֻݻ{D5($|> unJ?@Qyh02=O:u +V9c@wk4=ZKf-m9 -h ƗP哚Zdq 궧>E[kҾPTkD4 2Mz5 +,Dm*\_UkIk@]q-<>]RuKj.k "}Wv4STUe =&5WݖH0GRu +%Ϧ -VҟadKH1ÉZk=6i`nJM6tc[[p=3wM-`4H0#z۸cXc*G 9OJ8[ HL"PR"D(̡DBE"Uu&dS&GcA ħ TC*m)LR$&D B +I#7g*!󘏆TAw 80G E1'>SO/Cr*'6P1)OȀ}J=)\78 + 3ʔJDFSk{̀gxO z$`O CNH.O#]D&JJ:MR.D,zs>ЅilPCsOр̣1-.}D3JnB]rP.%C@@=J*Py:x}&}R9OjiQ 0'D 8)e}@AՏ08H 8Qq'>8S +AſZC~QϪ ?A eI(?%vU(SENm@N}t$5p9A$A>?l&j%9M xML$B u*O%P9K<5p]"S +FN5xrD& ) +#BRC]bP\JZ0Յ6cG.1(RLB@BE0&= rG)"QBb.兙LB +(%HAL2W `@Q!RLQ 0 pc) >Pp8u a2e2peSL +0—)INe2@gBRNS9@)(p)Q(H $TI1{ 8mA&AP0B LJ#&|Le %)e.RHJN`t$QDAA@R DpB@iBH&Jc +A%s(!B*ÔgRl )p0%8R" )2G) D !PDrDF&T@}A)rA /L#QJDJE"R.=(,T)pLaH!0e4ps"!"%E~"Q('0a |N JW"P , .Mhq`b~F; 08Y ŒdMq_B +$̌] B@l&]<}'))ZMֆ1ә<:ޑ) ̠ "!#e"a %H5rH@ZmWԘܳHMDJN$B-Q*lmX5:[#29@)̧J.૧\Zӎ#<+*@ +m$JA!* ˜epOe(i)(!?$U(}N"y]#Apā鐣QPd Ax"%)pHD&D*ED@ B0RJAex%(BQ)J HI'%i/7i顂*4-ۛL0zS)0c3ڍսB ( PI{ykG]rVk"8]l##Ȕ8> |JyQ)O)eH>J'eSQ-#r}j[wtp޷&SLVjI"|o (8G(H A0!)Ha% !'KH@X .- +eO%.JSRO34"%#ǽ2!?7*S))tzL&!`ni\u2xZ.ZMdx>c71CoMzFޱ5m^`V-ֱmدyV 8Al۝>Vkwkk7ڕ:6LkM_S2GYHmEmFqyOy4rJӭo~&$233mMkFWz>Ӥ=@@%\YZ`,0F`IW&ӵ`% x|U;⭓-*܀y. 59txIY3rZ(htxJuhu$UusiMECN\ֈ#Mjz"iG!rtӣLDq׷ㄱպ_=6= +l}>\[ƹnt`pp }bujUjzF`J}FZ  +mfHgz[Q5Gu&Fh$\7}kȑL7~jZ\ۊ p}}(&Vr[ji{[ r^ZMm)n>B 5vBk^$`p]ŝػ)9W1fnb|.qhuM-Zk2쾣D:Ld[jTCXH QswߚkZīmuKrpz\D8DVf4ҡBRz Oڱn v]Z #1[U\4 xsw[ƥN桡mH߬H)NŕSZ p"q3pr;JmkxZOڱ)lS"d}LY7V{MEJNJ߃jwf~^H 9Z[MwW{*?!D9Vh:ƙw&}Bi*=K/@445]$;E SrI A\QA +%"e(L,{-eP)p@"2La"<8H8)1QK19J!ak;5&ڡ8<FA\;WD@;GЩHRn\ g+ٕ/{˓jd$pl5]N=/`4~#F8zMcD7O9Z^XmMmQ +|w,z} }LW 3QDT։#ӑ]fZs}sQZ˞?(XO̸y@ M}_/^ I<.г9>\/:U,o@wOȩ쑨E{?Zz̬5=m]@c zn-uan) +}#x Lj"a NcbNԎ<>+8H6Q Mu:U DX65mF0X; +֗tw*v#\5Gm7Vs O> fg3{9t֏U6wk 6U?bkqЛ-΋GUu#IC;&b1UֿwqRpd U=(ukUOJ@??Edmj6ߢ@wWDsr\6Oڎ'Liz +T0猜kZeŝݥKR 61P&TܞYn+aҦmy<`rV{iWTYJaS͆4CFD{H?*G cZP~j jQoNS>%2 U̮ؠaq?W :}He3ۓ'>zsWNc!-;uקi1j6mc[*1eC?1z~!aSo,$5W{&gnVQ&Y8ZBG ף*7a:>\0~덍fۣj=*ZC?;\ePj5Lʏjv%p\Fk{'gu(? rOWAYX-걄T=At3SZI+\w>|'JPVʍש=,-&L +VzVPiczR|Vciy{D\y&LBJF_ѩ@HB}Y4q =āf6ͅP >HWmF~Rn[LcZ4njjeB0j7t.ҵWKM" c)mMڽ' Ϣ쩃LPyiݐ3gꦟWж{+^תǹ!#֭9d&w~b4Nne00 LeU_g׹wsr>& \=~-g+!޸]Gzx?y])*c︮O,Щ^?~򶽤Olm(~r}+ǧXٟf0>+Vuz4WZ0s C];E:zayZGF~ZU&K<Nmťwԙdp-ںZ +ef;zooMzMs\M{6 [cfWs{4=MH+q{ں֖tZL R݇wppYKsU_VV2[㑕ьԸGOў*8>.w7Ϯ ?̬8?ܚzQ@(@S)B'( +rRe'Q(D$pG,hR8AP '!*D/N`p2R$J IyJD6ЎGSr@,z-MhVߪc4U5kn{zZ(j=΃r&?,}CS7~J5 wi&$O'>nݴuJfH >sFxVԻjFaܘVymjeZ@|x}uaOgmjTԯ1^Е7;}3$dq+7th)jV;xܧSTևqNpuG8Nntʭ3 sjLO,]_Wms✕o}Ix1fkI5" h, ^hWs޶uIJY4C8*.XjD=Cw ASMΐ^8'ڻwLpqyǠ\&īwdk[T*Orr[T:2G[E֍KM?S ~kmEzm'tRjiYoUY0ZxpXQ Zt}><-۟(:UjNqdq+[6Z9ߨAOK9mooj7O5)E&ew_U}F7>!LGOTA5iXԷ@VJrmC]cn* (Q&|pZ\yq]2|2[ҥPCZ-GE[S|i |>*[nVYwATTյMMݶv G;D'ݯ0319뀔 ^ћQu9Ȏ3+>h +kToHp%8hzHGp~<26иԝnuPy; Gw/i?iڝ6ע Sn wwm*tL$cDqѽkf8:n7UM f>֕yk4Mqx:d{]vKԆR<8y-m|oܱOo<8vUea_TpqK~uz4E@LE6vQ8L4I֢ۀq6ڭF+;4d +wjڝ+Lax>iׁk͉(TXAuBFg{CQJ6&N J`4@3UjU/@31NܫqUAXN-d[]E=Ujy'jΗp?§צ|6cn`-1(. aRm?jMuK) v$j`y4ZuມĒcWAQI?Զ%jwT9ă<|K:(ǵD%4•_\9ǞIXۣmUB́qOxw`ڃMh6ppcn4kSjUG5|G𕇰jEoKBF|nרS"Z74P +Y{Ol԰{^2.GULKcm+֔ꎗdJumjᕨ&XOVyfmsU2q{d]PhaT5[uʕ*aq8?ne8dO 6ͥ`<$uVV +DɒO~ + ݝ \ѮwGRgxi-8u6m:/svTuM>MIT4mqwr5+:=77ک=֤ +V9[ P' +.4+}iշܛbW-"0yXߔu}\u=alvf: :gKj\mkt7S +}~Z-3On>fIXzF;#-m:͸)>qYKl?JuKW$at ,wDfE19\5}1ݭQ\+3mmj]]>}V6]fJp:LAMPQ:HH:h '&RH.A8KP( r]v~g%]jzB@Q) @*Q)W0!D}P23(9L@2T$0*qHy@=<|T !ILTGRISi)<)!&aK'D +M$(=)(i>~rz0:\_Vs>B )'&H>e.H#fm ׸UCqq<)IvP ):Ryނe"e^J}E(@$# Dd}":MmE+.i2G^-Z]Ue>>H8ˉ8u% 9uBRR&Q0DEJeB +#)!!qD +'9L O py) IQ8Ng" )0mSHq]Wp IWD(5H$DeHsg0NJ T +JD>*G*!x +ny!G & +@ԋH{Hn&R <ӉDB` 9&ʓq∏D +a$Lҗ( !%E3a~ Q*$!*GWЧݱh%3 Le)*D)_O#↔d J\ eD9@ a$&(4( Q)Gډa29$dJ"m%"%J!GɔCA#OPZP8CQ0!#p‘[ʈ@j" 2RLG(8R&P ( + +B O#`$Q RQL%)( +h ֓PD2@Ha<"%(r%!B`̨@G +a?@@Ge$ $2l)( +'2$rQ) < )LE. \9H)L(BE +zYT̀‰(DD2pEФDa RDRIΔp* JIZŹ_TEfF|@斔YL2h +u+WmȊ@l[Sm3"#i> DofJ;i2 + 2Q L9Q>a 9GL)%Lwe# 9 $|UՙY՝% @tAlrLi=ra`Ug}_@Ai(kwVT%`npo(Ӭ{1W7Z7t8Adʏ)斨}Ӆ=o]K29 ARk ABG)<zk4+~`{Cnmc݇9"W-uUywEHldӅ!*B!i M"դapRZMś [ơ@?~G s+^4D]Ũշԭ(5S=M]s鑅0"£)u%+])+84ȓ*H<xRH) +}-TfyZVY8&mzp$y +tZOHBarL K<)wEVYA +-\)wdr +]%Aa GR~UUԪXG4]Yp6 wwܸs4=m!FGOQ1)c5r>ΐ +BH[B:ZM@ o&|Ml ǒ>oiF' d~A4Jۍ*o|+Iկ+]G4IZ-żn!uX!iԪjvXˋ}xLpU* uW}VOpZkukw2aYWQi}oXqwdG>U6j\^ejt۠־H2<}֕[RZr  'Ռ@HOL"%EK(+Q +uKFޘ8+ޕWs >i-fJ]K`}A,.).}O͈[6ԩwS,LF#5^nXТI + sNk vU_AIt2/n*0{2տU䲓h zzu'c;|rݖ86< +2Ө]nըꮣI-h` y}U_sn(uWV]$?EMEO~Նpw̻j`LLD/RHԦbH`U֩V.|,M6v>w}-qkJ[qFtWl\gi{[Hc@`lv&Vٔ*WsBF +4k{{j\:%b=xYۋ@B#<33VkmH8KHnwx7꾕'ͶĘ+~_iӡY歵s .)>Ce޷{p +߽h:ZH+Oi/+TmgfHk}֣p"=#Y:-@}1子$ǚTٗTuNA'"%nvUryj紝&v}ZRq= a+:EsOg<&:?>Z5K+:yLC\0TsmNG%ÅZ=<5Az*[S} a\^\6SqLz62GWjS?Ϫ趶6{>xwj46Lup&IY};W[ g@jggZMRX<ws_u>ʋ+zOGYە3}kZ8.mBH rr3Q\-f}ZkA#fʮkF.4$.WOUD<9`m ԫѩ޸ho.RZ.>kѴk{sU2D~Xvm*Nꖵ{y-8E +\DH ,3jew6!gښKOq-a0 02|zWuZkr5Wi$iI&Vmc)  Jal 2UPeG"LJrm`wwL<.-[<=9_`ժQU h'#1Ĭ54Awj+o: *Va=ҧh;]KiL|qW;M]9cq "Biz˛Τֆ5˺yq㟊ܚ{ˊz5] G|* 5*8BmuK3xa\]"'LW5XW޽Wuf Jzkl*:GtPA>ۑM6Q3ŲR꠮`'(Fuv&^t 2,s^]:/hS5MRa-Su6kV-ůvZ栬0zD#'umnHϏޱ7ޫ^h.f'H[ h] J/ hR.!d@A5vQUhH-dx+ZݣOӶMj./k<0thL*lnm[i^jP%HejZlK%݌?TLzd{gl=U瘟kvUJחTC I gn7WQ #ki^jm'8.O1A6ފAO!zQW?kAJQI}tٟ`]Ci)8x*/lE7|ct=M!mHsW!֣[{e2!Booc[4|Jm_P6ԩZ۷dnv7M; tNJڽA: #ޭ6cf}.¥NpKz">++vj+fN葐A4MWpЧqu]gĕg膱\D>>K+yj[i.c:+VXʞ.cITR) Ne(D@O9@8GQ(p>jeZJDJdJhL)M)BϹ2'"(H-3aXz}?lm(~ruk.ь\Y~+uZY%sgDRC:D40L).K]->TGdֳk:rL8|c*&uʱg Fmktjf淘w)m-֝J7e 3īZWAoPOvd3\wjVญ ׸~evb{jRkigHtyF~cpֆ=YTT xǜes}< +[>G[l^?λ.,QzI ɧO.hݹP٥akJ\QBQ o`kw>VT}s'xevn#pgVӏ;ᯒ1[rKk: s-?f"ї] +ğ)UoSM*z@.1+W֎ugըx/N2~ *ӐX͵ՅlofCb}¬T_Qu}#[Gl-)ԧv6hܜ+n\Hp,dpL';SN}֩9 4Ueۚ: 0٣=z.q[Ym~Ĺӥw/$5F<n੸l.ms] OMFѯmJ`9'Vnߥ?D:4͓fz[x^Qѕ\W0 z .?5ovVȭgPAXOͫ 3MƯjf-'?ȗkP}BiԪ\l&> >mq:[?; ]` VB-fnUU p-q'Owȭjil{n+\q̚v~>%jޚM/?XI+]jԴ} TUk^Ϩ3mϻLs#Ww]}M@.+tүnpV28>nM50 >~Kzum) qlu agm-[OYxr9 Wn?f,X\ڠ-o޺OީpW- +# D$qD$p(D JE.R!DQ{ +ԸH2.P0N_a9M3| %3HX5J/v:>rcum)є齌^O,;Wd lƁWT[AA@^ ܈">ks,q$5ڗ:/7_V2*6ZZөnkw]QEY OZ흣?Ktj/;{O$T+Mue,8:JS\N(T2|@f' \j[վtwu@+nۆ>ǰf!yeHk]si8A]'h'°ևkekUWKπY6{bWe~lԦe_kMiskiv^]qT˝K6UjtTcbA1镵n|oMt5y њAq%;fN:k8ҙֿNе:=D&UzƺuP8?nuvޛk86^4w@"#^ivКw]j\>ՍvSAmpvh еu7R.$ủUj +6Ճ@☃0EB#,MWk0^0|167Qs;ll};om?Ks̀&FIVf[>ل2}'I%Zԇt4s?ԝފ;N䞇^^׹U}q\uRe(Ì%tjmW@ k~oU/ˀ[?$9U\Twە?(RǏ-qM` +SgmSB Z+=KTsSkzd b܎UU\sY].[`a@ +iyi-s d{F겿犕tZmڎ?)u76#3ZܩмkGfNO󮂡Hh6v~k"ga]m*w o!¢m_kŭK)}R!xVvjm(Ӡ%kI{"ratզ?-EΉ߷k0R8.h4(ڝ1k]ON3负Ln}`5ùUku./%]wY蹤8}+]} #kn6fߣ^O4ڎ  %gJ̸RAm6aytn +]˽2A Gma۷¥" Fݲ..x]ksmںͽ2:h+mJz#oS|9ok=7S{}`[P}r⧏Svh߇46']CՕMo)rznԴVkjOIxȒԻ>XWi}A[}ѷkִ抠Cn+5H&%fBڝofn5^\>嬫i\Ϧ֑{Pq[͵ٷwL2e<ЯF65^5f'T[:]yY>!|IneB m2G~+CJV%ދ9Uzo߬'^hްA<-NXΥJ>IrZNT+SkI 4ھ&H?Eݚ5}R)ЩD'޳.4vX>2+uMwBzzG+am:z@Һ=Kvk[u;'[f}] Dǚ-jO o t[CQnLmxjtm ʷ̌Vo w6R ,">՗Om7<#CL"=y\gVޭJ=Y! #GؔtI{V t.=YHI4 B!EpA2DJr9AHe|L e2L$02L ! MA!L:Qe5L rD&GL(KJ# z0e i&@H(DJP鏵=CL"3Vr1NS((' !S PrL!@&"T\%(ʉAQ""H8U]X@ +\rJ(A : g!Hy:pSPJDBm"OeD% :a lԻY  D9RʉAqBAQG(8@t )LG)D` !J%#?! ZJc&?l D09APS9J%Lp +HNP(R()pZN['"~HRJ0>I,S-@D#RC ÐL|PL'(JS&2e QPq@20) =3)DH) aJ +)ҘLp@i)G % %"e1 a“YQT A>h"P +JB*1(qPR8AH)ACJiwg]8L0Ӊ_q9Ri<QG\ Bm2}PLjh0c>ktGp^:k䵭w ŝүOSX7VҲ6MVݸ?Te7kt+QwK(^VjZQS$\\ gem}Fyo\R%"ABݾjh?~յP )pDƉ>ή彯Ye@ 10`L/D-ǐUxJ qā+MjX8XxEhLじ]a"S2#$}H> 0p\"`O!7E?@!8 r7޵WL\1H]%W4Ëb jWKxd~VǻcAC z 2=5֪ U=4LuEGت7TzK'S-DJSK5;Z=SqNeƛIr9=]VĆQ03uk SQY]o ӊ8yA9'"~5wޯ)EWy n %B.3MܤL$GOP{"|O@xCGy4E~J >ah4U5Ak&Go N 2qWey{]ÁREL<4">*7c[ vz#WZ]X/DçδQ*Ts#VsꊝH+zh$HQpڸcp%H0u:g~qǘ$OPm=&$9 GvRܶN-86 +mJT>EPu6G'DH2ЈCv:CG m_Ѓ#G{Z}SFG8 &檥yNkOpVd +li.cA7{##櫡wN=>AUqxUST'8gd vwqZ棿3Rrc*V {"LH:CZ+p㼦Cg ڏEzo]GBNY>]B~հV -MCU,F=贾wwJKmޔ IJAG)DL%*<#RQ) ` |9H#D&@(!죨Aˆ)LrSk#XShUoS Hㅃt:`ő k17s;W|55 ? +wwO])Z)z$\fvO |gYo]]լ9ԫcI DBIJRʍ֠i16њUvsA $If@ ?s_Un[8QØTvgJIV\`Vg]ŵi>\ڌ^(GIry^!j.RsݵBkVHq ǁ[ٺL֤ H$pz7gQgҵU *-@ԩ/Uuta}*Vx.oѭӦzIj4)Y:Ēg?f_xw]d1 +5,lӼq˃^83JX A JϳzZG{AÈclֿLR $L'VΤ5Fu?ԋ=Sat;C;bީ2LMdiڕ Z +c85}֘ږ9cOL]MUuL-Tt2yuZmO"x\^usM!乭1gEv.cϴs$.\5%“\<#j6Ч~Ւt$Fto\Gj5oZԌ?>$i[gĹq<Ai4ֵ[YL:OlM7>Y[mRی{h\*D.zn'֬u߮:@u cݚr]R.qq9˶tijG8 U-*ԧpG"y+{M\Y\\ >RSoWkULں 9th<:ڱZnݗ.-=V^ZOf_NHv2"Uݖllnv{<-$I /{mz;z/%c9ݠ5Ċg'XOQәZTҡ @Sٖݢ(S>(ny2Cj5ejqVw8[PwKXDfi5:ZԫXr°ޓ~9c>+a]wW4_Ei&cu5J4)KI ܶם +N I.3 L@nM?% H0 O+M6 ʗx?:apO>|xI&xXwЫRk ls]jԻ˗<[m\){L`@Z'|ev:x+좨mJG> ,K;/-ƒV?%]bzxhʍ5@i#'Xwf:˪VpĸMyR}.3O5 <6T\{>m2h~n-xyS[b56|L Ul.Yc;wP{# jUGIZYԭ.Yk<}e[y+6 Kj9ϒ4UXۏC@tqY,.V/WӃm6_ӉsYݛ[mNA!$TmKktO]7BVԡ\\QA8 zq GtZZL$A#Ofv(Rzgpzu}aE4qi@Dp}gJڣ贶6u@l ]زC%'+Lj_ݺi5@ǘxS- ,c齲ֻ+\ T۶馓|kʹmsWsOvF|X2\(y+m m׽p {J췡]KQsZz{ZA-j[&< #N‹]J䘑ǹj5gRɂxąz:TI$ɖ-i7ʺBYkX_mb~jcHGA[cb[^Sshꆞ7(wU"qa>x$)ju*L ?Vd+Dkl, N`G'ܻ[Z:o< *ɔ((!( a.ADʌ JH#(Bq +s|™HA2q(Q2> ˥D?l&P +d*m 9ڶ^+k"`*-+g[&pr3 w;tZK`ǁ3p;ˡR'v&/ogF]؊U?︮gUǹ1?u~j.[&uؽ+E6-Eh}FԧP0;A,q^5߫d\)rkttܴOZˮ-.;DvAa g+f5\꿼m`g\igH&}z?oܹ>L׼+7&=^ךKX{؀?fkMB9նޙTJxj\yp}vζ4^e6kи.P<nuݟێ&$tjTP@}#;Gi qughj3wתr:q,]?PΗ-H9[ֹQi\?̓eb zU:%\H&eO޳0+8<,:6[>Ŧp\-軴 7qT\q~baJˈCn\~joޱ7"{;i|@ex ̇Ap}Qf{Kzeke=\Tisk*lic:{,0r:Z4դ2[»HƳ[ OYK.-q ]>Qi% $ai)3fOG}bet??zOXϽ[_pY:g=Ɵu>dgfPFV&$`U[}N }STkxh'$5i>\ZM.[nUu?u\ K>Z?˽w?f ~+6K뇂drc3iXJmc:{2<v+&T5(K[+wz|[ -Ԩ5>̩>G.uAhY=ևU#'tj 93>kk[jy]* 2ApW[LӃK iJC+08!twX4XcA${vMwhךM> Ɉm L^1hT-Ts\,y2-BVv]$ ZgTXW 3 mSV.#kYjw6ê l+jTyI\oeQ^!jU]vbbZfҿl?pRQ֮TI5i;6o^^>r̓-o{[:Z4J}v&$.HTX@} `rq:!f?̭YkN]}?3 hTVv=I"I/o>ӆe>蜕Ҵ,xg$VV(^Re˟YKz}1ZFУkXd'dv`~}v(K+쳧#_$}n@?.=Uh6Ie!˨}:v^ J Kк[R֒]sC,Xֈ|18_oܹOZޠ2|.fiV :>9']|**Z|Fq~l]Bڥg`W\<%Qى\?yY=}륰?j#)?bD0B +HHHA) )r9PfaQvQSLa4+2RNp%܂a 0 4jToPK]{)ou- w6^`Hefmjߔ/*wU}Ʊru:dL{nj eeՏY*GnX n*A}g#+KRa>pxztC%ܭ=kqZpjkm{uqR!t&OFj_Td>%k-tծLFFN>պP? vm},}c_mStǺ9[z{溜X"}VkC@5`b9X:m_[Tu$Xv* +X2o>+Dr3Btޢdz-sqc>RĆ cPШзH>fy>Ck.lsFͣސHO~)mf5\>Nrme<ӂ#>VҕJUx0 G:iw wTHZSbSumU*}6i="81+ihLyN!m([3&<-Eou:c:VQiU`VuMۻo\8q|֍wT|A[}i_QY܅,|MJzzZ0< "Zyw|d8ʿph(W8 <cn-)-cCs5{5k>vHlcSj}*Z {m7YJZh@A+rIwd*}&J3axPV@3J Z}յ6GtӬ[aI27}|aj6ͧ>f81W=O]qqeF}W)lc\T!VFЫ:*#Umjګ=[UguF]W}rdpbWTԢgZ +.]d+7~{@p29ʩTL @>kڃNxi|VnJzUF{[nmtQ% n}muR3>π[)h5R^m(]R=Oi0#浻tH8LJíݾ]=!r2V]D@dqnjt+vў  KDpP7z mL*mFZ^\k2OORouߤ x; ۗkH! -混E5Gc--=QRwPeJƻnm:-s>+auqvH0?{{o'B ?s|Ь+j<99HR 7kG?:ԘgliMZZ 9vljuiWYZl'ܑ` >S涻[noSu89} Q-TT4*gOa:ë .ҝ +iDyy.Y贺s)H-4WƭgsYݥ46oKֺ_'r-:!h "<\vY\:_$4}:WVقeO\-IY=+UWbWODŽƞMԄ1yZmj3Y-igo+W_c\j?s'ܺ6ҞФ!VB#HZ?q$GIsnۖ:ݻP9i4)d-=]L8@!l.D+oh'-sej}%u*ߤi6V@q0<+pz`(B絝WR{5mj)T{{^&-bӪ}%ujP| +n 1F!pw,[L0',B=BqZ[ |9<'Me1AsrY|-Nkڍ0嫥':jZǧmm   YmZ7[L2dպ֍OWmH80qʥHRki4I!0e J#H)&R9H- +<#H`=.K )(Jg cxLKMD %pPJ|% R = ( tJ'܉A(J)` '>Uq(( @!eR#p#B@"!4(1 e|(8OJS *>IĦ0e5a5X0:8>#⵴ 'ue"Oطh` hG5>%# a(Js)@HRHI pHL0H:TIQR&B@FJQ("' +'*@B@0JP  +DJJ6@DaJ B@&D""R"PDPTHF|rrH QG9QQ( +wJv?Q (D|1 + 3"IPD' GRGx d!4t$B:PJDHL4ȅeO8QmV =Qʑ3e1ȔBsDT]U04"D5?OoQōsK # +L"a rp@r(spAH(%()H@]RS8G݅M;I%eBOS@!rHG ;) sLVۆ=Ɛp/o #>hLe2jQ2e!A 4rI)Tmp Op%%ŠH()R )rJ*G BQ90RȄ ڕuExH|Q&Q{t9,㏱)Na$LXzKG$2@xYt +o< HL% D%ҐP HDJTke)}#)c)%"eSDB@Jd(PЙ!&Dd%6͕o*wNƃ>V/kHe{[{0$%MΩF4=6Dd:꽬n }{ vP=4j+82O`U׭hV'Y6ai*7y{-vҪ;+y +Z[sʧdmTZI@ߎV΁3ǚ <"p c׎8t389X5Ww3CA^(.B2=d?%c)I{t.3cf}qrPYL\!YiyJ:sD@,Z;ڻawp[4kYU>SVڕ-Et=Y ζ֪wպ#06u {VuVO>~ ٝ4>Zc|mڍGִr[;wl|mIZOp[i0fGUAd\mMJ hq}SC{XwCk j98ϽkmmbPӌr~AYkT5QB|x~K,PJ:ܼ +o-jpk<"m)8T)Umj7Bn*χC*/qj +˃+*[ IJwN@$/k<5iPwwN O .j[K=5) +zfo P><?%uv6\?b47c*@0FATݖSwAquGfT)֎I nsW8e j`3S۶S],jZ Զcê1q>ίCK 8i{TwwJ ai g;Tux +z;/1JJAnQ@5o}@p&1xSبO˾C)i[W +8*Z0ժxZidԩT"2OUNCVBtr<~K.fPoyQڴԷWwb>{̌,FkTygE絻ca9S61h>*4[OE/ҐNڋ(k9[\rI#7t͟|[z̸hM>-8\v5Տ.SZ +N{Zp ,+ij՘1PVh{B=H>&|f4sۦJ=j?dJ(jê>NJCl Q|VC +`I'Ԯ-uZT +28ӡB* >y*Os釢Vy u1Ar)^TYJ#ڱꔪU6x5[|BZGIhpx9Z;{߻eLlrn*nU ky'sm+>C_yr}W8Qԩik;'`{N{hԩ:0IpKLo}]OÒ[›jAH㏊.| +T#g3V~]S ?DϺ&VcWi rUZfԟ18"fO VB9i#0VGVoyArGZg{A > +:ࡣk V״+K +g{@ή8j[Y?h}GH Ae bIJ! c]4RBQsD! %"a7e"@ʉH8(Qr J9xQg1W Ne8D?rre#D& @"%N1eZEsiүn˛8e$*wʹivc 3+;WPT|FF-k9$\j;kׁJcrDǏ 'w6-]MCiI溄wZ3Ag +6{N6{$9Z.m4L~ŋ*n_qLt̖@[=_mYu6Ui< eelRCR=g5 +6n*]gzOmF 7v?+]mȞ}4JGp[{Ō;~>Ǹ~w[H{i1l^p,O՟p6mk~mq\`:QԟZ~6Bc!$3vijCL洑1$yooZ>0ײ#y5O.m~ lV=o*Suzē8c08XGy`oG8QoA]>ygTڹ̖Ƀ|kfTNX@55sKLe㾳h|\uoojSuRI0'Q M.zpDlM96|s,WҵFޟvZ|ki?m;xy0>k JfWEBH<*wNiV}buuL@^*À?5GU-6rdžB&)ZSUT9%U0m^A" E5M֬^}?Zݟyi|Fy mB0f^=7Sĉ̀]]2q7S? t-鲵fK  U>6c\ax +kLT`% H^p놊ˉ~`~ӻj0 #tjh֪zY{\`8ȕ_t_q +m +ͮqb$ό.ojj6+PdVs϶'Lv,,jYϗhiAC1|V֦G>s_fZq`uSI$ZݻP+xM>'Vhڵ;kc>]Y+}1;ИVGi 衧9xϯkRCG$};SZg:Z6ԻזGZVa5{ZL5LxAq'jnMoqk>@Vo}Р  x[Z0I=_8ɟzvM͝CR gy*[R`{gQ$Sďz)51+MG +T(ӮԨ %c̭gn_Ly$Q2|-ZnYPI.sA ; ѳw,ks>Wl-G`$LHֵ$РOL1BKTha5=8_zBC $`bVtŽCG 2dej6k\ң=p-χL1WyiV?N0_?%P6t(Mp\O tKT'-vW͹%sGWI #u6ݵKv 3$gc\XMJf%f6mt7/o_\=#̀4}QV5+Q ߭Yʒ L|0;WZeuykw-g[V-wYV@oNwzs^p FN龙i+k :LuFը֗9>3*x6k]I:Η}.}]'Akn*Y%b F.ļqoҰBCz8aoW`> zD1s8} I7O{C$8-ίSP鍆pV{n wҥ4y0MqeI2{'@\eE+Cڝ#HY]SJZOhګkF :9VF۴4M4$&^۸2"|,MSF6hsL1o*n* s: 0}jFI,k#JYRf^wUJ2#|V[;j)Hhq]cݟ;YҠҩ<.O)YƆ 23W]J0s<-PwUtt0wv(iÃk} mCS}.U}ilmĒH 1-< d; ӌУ֙W PqD!"R2%F +2e"PܥDA->GOkG$PSL"d&0Da rSJ*wC +Qm64rkUjը9?Uv@дo*}$usr]F{qizƗ=L$ nH׫E-faK4Y]ޝ,گh@8ZmuJR4@ 1"Fe A ??U*N_-t|+wU=fI; 4@礭+߭qmǖ ^j{4ÏKuz'H|9]-ts2#ϕm:uJ9)j +"։v' N֩/c2\1tS)v[>Tj>ηG_[N=ޭml)iM]F->ok$8>:F;LNՖVy]e+2TsXLs +G+}x|W j_[A-~doP%jV!I9Yz.-Ynʕj!#֣mVj zѰk9n iÜ.d2eqjIsP]g6w4M6wzNpr~Z*T@dH +##',ݳ]UP9>uJL|2We(J#88Ӻv/QFL-65-Jъ"10 HUjMT\m%4 1Z. l\i{^ODž;C*59W7}5\D*j$ |WCM834zVթkkpưDuD07 -RcV8G"W;}*~ê k#ܽ'om3Jc7s._kj'qѪA鵠҈'w}Ы^0t1?z8iִi g[>3mO[;R=5*6,uZ wwK>[u 3vj {K69XۡѪڟwMG[ ,.鳾cu$yr^Xh4BJ sWQA,czzai·Y@ŕ~+C{CۺY3H|2J4A&dG;;aԢP矱7R>SgO}níV߸.KdzhE;o~ +; +!ŴXڰS hO\g//.2ב0k$䓅:5;Z`Ml%*ΛHT}IpnH?oJ6)~ V+$cpWRe^ ..ݦܱa\`McNKʁI`{cTf '_~!k6}h R$Oǒ|*fV@`xGziGөR<4GE:gpW)hڛth܉ip|:z~Hsi4OG¨eGpxZݟ(E4F@$"gZ٭::T^A]Gj4z&hPK? 1+=_TNiimkRސ`Q '噱V$8"Gi{%?\M?.4\YܰIZIkuzMǴ{"Ap2 7TYZtG#[_ C]U@c11FSOe?.'Ϥs+ jOYVMC eޠ:փU yK(.pj ^͘DWڑ]v[߸.#j5{|g Q+ Xs|+{kZtz\")@$ǂBk5}(Z1- 2aС>Z$D?uҽ,/sr ^TFڅL2HQ.J%!ER*3)$L=2OC^ <ݬk)90?έES$Aê4՟͸8Gl\@pܡhpV]Zx|RijͽV +pR?\z}=UMm6S # 0 oڨx0ܐ*z֬Lۑ".Si> XOWhVUzKDhQI3~?:.{}z.Li,h7}bXmVu^_5 PCÛ,;.m yil)ެ>&9–f:hS'%ikp,yī=m O2Uۣ>jT09[WgH-nj5iܾCGL`9ekmtVx{ʀrȾm7Ш=>hӬYSm +U9ZgfZj4.a}aOC1)4yԴZ;o=cf B?DiذQ7>vmHa){BFwyI$AZ'nP['zݡdVǪ8GصZ׶ֽI HK4$-SAV[i`1 tz:{im{:pC$|t @ t-u1%+MmI~}*soPWl`m.tr\G +#mA s<,]WdZj^מK ]%6y$mM:kAsᶱ.tO=?%ZeE*M `e-a%M-\ÞI#'96 -GoԞڵp~2zxd,-'F4zC'>>i=-]a)B;=AZA"~lt + '~*7Z%̻x=88ǹgvz3i|§HٶSl.y>kt\NUF c@)زƛhS>kCuY 09M2FCx\{2.[%Oil6&ưЩi*\S>$^4jFڬ8Yk)3 M۔t=u&d&xRvd1=ۤAYKSzg2vݝQ!ǭp׸ܳKn_5d@u=I'P8-WZڷ% 8F#-f\z_Q',kOnt}zG$4*,7{"gy,+G]UCϋ oܭ6z2_N$Vش8x :.շ^Zz V}BT &ioL{ sⴚy:ݘ4=o&̹l|Q:G⹦vgh2gBm{ +:^D` dlp=gTSq#` S ~!sSj[4Z |cѶEϨ8s̑[=[J:1>K(007iԵ&U#ശݞPwxL8]BCOtPi.*v^3SuXO,&} pt#i{}Tsa]Rz1VQ !;Z// : %N-YL;tk6U^GKP`gQ +KnjG&'6ԙ6CH/z -GL'C QA%#pMDJ!  +<*3Q>SwU6+"SPa2#>%gb  M! %.J8 I1 RǢ4G .J +dJ +&B(&2LG ܤ[)Jc & +aQ !'$OQ"SB"PI(8OPJ@Al(bg a(LD$\p8Kr(hL I a0gN" 'G DJ!.RpTiڏ`s$&r2rr2E) &rNGL9]zBᦓ rlCZ8a\ TxRn=UW6TԦ74J&[m ؀R Oc (LaR"@eP- J` e(ɄLʔ((9J% ?j + +S*'*=HN%"TNJUeIKN3Lz,۔5N%"W#DyO%IBs)r#(A=> Q'H̬k J 軨4H^vTPǎSK#M,[fF_S9YUW)d "%NR% uj:`i@%er"=Lɕ +9Jac(9(ǚ%DF喌57$f:Ih$ amXhBOL^VY>^@%2(a"8T}}PJȄ@ QI0 'ӕjt6w]brH@-"S@0QA 5m^V1Ⲛ!LKli]2,k\@"GXKI w-lsY!%&BBB )L >H2x~KGk-uJdFVtLpK7A8E;XadwرumKLNI`c<a$D +MG9APG g% !D3UaRz12=.!0 [HV 0֎J6ufKrg2d!2 +#HFBe."A‹NR!!c~ӵ +zjikuo;qs1'ZNԟO< +'Э`8Zg|ZOIs[LL{4mmlUG[eX{Ϛؚխ6Zie1z '>9+hmBpk$Y2չ}tu56#pGx-v*;2O+7Dtz.l M$ReJo.k}UZ{8|>hSK;0KpԦ\`w 0ւI +ҡlݶb9ZM{@!«e`(2ņO&9/7ۦÃjL4H[Jɜpel5-i8_T\?5: Z A5z:;;>Z*]ZT Q?sOJ6 +S]eh5Mo6Pr)rIVʇ/}3⶗WLaU,o$dvniz}}Ej4}u0Ǻ<CDZ[N +NFDxQ@ -z^:hcc5з=h2[QSw%Tj^>m7 ہgIt=%~h]R1'5]Zoq #KaHhr󍉺)ikjtymHmŝWc]$fVuiT.BF =8[_SBMIs[760^Zl1p1꺚uT + G6%ַ .*1$*,wN<n5IM'\ԞD91hM0-U7蛩" tG>QTvoqPP{H@+{C2NI\hK;zU+tX=u dMUjʅZG.m)-UJNO$Gأ]]m֎^ pr@ o;iBiI9+{HM1[.[٩k4TހHw-\h""5+?,y-Y8V`h.nj$[^oM)7CD+l7ŎM1H3ZmVc^ٮmuxeo.x{`0#9oOWshy -=oK[<.Ʀ,>贉FMwTpllгRҤfό-oH; y.LJ*om7<=|7M/ X9ߖo/M2ZUmj#Y|2Gz}!s;Z}ZO2iu>P`+,3d+Vv"Ϳj1J_r"&m rW%n%@Y}m'VhGv:˥5O!Uo;"-!bɌ#9ZkmfJuZҪ:_--0 +n"D6N^ 1]Fu^ 䅭㽩t:Kx='2x4_o!>``u[2fF `kDm:>Z e֘:uu1Hk;W ׁ ]iS[>{zNA.'fSPlr<cۧn*ƝA<\Vh]Qh08E՟JiڶCOvV4h="':tydk4}F̫Y9ͫPThd+m ZvT4S@kf P+[$R$@煸oh4rֿHǗl-@6 +A…Ysz+iovJԛWC:~;otyD= +ʻ\en>Dܬѵ}˾ÜBMdΊ&?])UhU-ecgJ]i[mNLLV[L{hǴ%&>p{H?f5:Ҫ@`@) .Nݖ׭V׬d:=Z Ej5TzokMaB`ز΋5 3\Z CH2\ *:P'L};;[X 'VmiҭҦ=HɕHXֶ)R(.AA )%J?QDJNʉRP+V +Bs(LG "%%I>Q)4ۄePGGq_`ڕƪA ydWFzWphu,]HxA!wWuiY:WtT%?VI|8[h>ޛ 0r2pi+[4~⷟c+CVsSeO.ـOtכNnQH p.>BV[C|X7P]Ppa{؜;Nܴ.-In3an Ze: XGi4-6{*t0 jZ-k9u[n~}c p +׀]rUwmEJ i˰8+Y e aA献gۋkf昬':>k]WVȣIuCLA> eڭfԥn>ڙN]$q[,H6LtB֙Bq*\ ԯW.WGkJNڍy $O+_\^կtr)sۋ/y1Ni:t׼#2SBǦg0d{SCu&2wOR-)Λt{qg{v}Wy[ h,t@on6҇h{W^03?W[_z[w CA{s+Kم_QxI*͝iڕ4ľ0isH4f@*]8P`{z^ɿT:>efv]>uhF9 fuzә^ϤƂ"N7ͦI׀PG8+Ѝ;TֲEĬNj!4Oܶ魫L]|H+Ϸm۶Kfhl-/m0~IsI?X\j_efɖdVu'<>CZ̙p,mKz!Z + W5zZ-K;;$b~*7=Mx%y BgKN.[c`Z[G:c. +}פYQ5N|xP7խ6B?d53n5#;siT91q6zz*W|;Yu?r5TrFm/d'7-+zZyDZ7U;6IoOBwi,F +6=;R5uI\ Xw=]Ev ծjHx?tņz@$IeƠGKI-$[T붿sYU ugh@kt,7=?/QVߴ=5E zLNhZ@57mu*۶CL{G83]}3Fs}A.oî +,` ֿx=e{CƙWiʋm)+ +gjFO=^,Xio-Fދm.)֥)V鶖 k{`Ap{Ep] ^A?ݗqZ٥YL|H{ZT)VY:0ɢ=cjt0 NO>dݒ}\/g齾 XRm6@&3 qiB}'#hgpv師v{  y1aymʵ jPd<wC5j=Ű/czp%nNOSҪTdt0PDnoG{zx+Yͣ?\>ⶻI:͇t̽k |h2:}_:w kiu{l;XuJ0HyaOK=b"\7g4Ie_ r(}v&\dx-NihwTC9^-Z:?LV& 5.4C>+XkVWԟH[g$9YOYkO-!H%2&>(FyD! uJPPD(IBG LBʯ{ +G yL&ܥ &H{9LNaD|"S *5pJk +6guI}2V{>FٵLm&ǙWj +$Z"1.^}Q-9ԃ2StRc -큂>?bWn*09 ǵi.$;}Xyɷe[J4+Zz~+W_iwx-$ɻ(]1_MF toYQtY-poԨ~+"aQwӽZdOE;UZ``18¤S>?5+zwm=DakmuoVyexGy*mYh[$ +A  Xfw 1[:DR`1X{jJL.uM.jGu6`X +V@lHZ 'dt{֎@W4MfČ{Nk]~k8cxXZCRzmq ++v-,L:mԚyNoMi3f G]ueNF3 +mkD誡Ҷ.M: dW=2$qY!ǻ ]woO]JMs+2ڝ{M o@LPnˆU8p´VN)`p1u_wcŒ +_AڟH j=J1PH2d,;JvM40y4aåx,*:'w>+)kVHO3AhS?B&@ +4]Z V=}2}&8W`:G@'>8ޤ@G)%8$3aH#BB8Q) +M]@S8G @xP76TiL'sˡ8 R>RL0Q $Q.#RB]B:qeBQ!.(DBe>>p0PA0"Ta1AB"Q(- BeȔJQ2TI!@s( %3Q(RQ"S9I9C9DBs D!>rg  JD!DG< R'E(8AI"P I9a)> KQDBLQ&)4NI(Ą$rN +(AwH'ShwSHaHD La9)B@l{*Hj$|0) )u(򪾽eZ6$J^>`*D'&p$"a>22Vmjd-pVx#g(8s?-HL"aLCS@$1IA"e0!1(9A9X {8k*eL |b;M/#®t ϡ]^?1)BmH(& 0$VjYz $r?ma0#2!a EpH8IZN权 ?̶|"B]$&Rrt0% @< %o56uB#AȄ Q(XOKk=, ω +pfZG!) ak-!\pPJmK`DsEcևJ {Q(raknw+{ic'DG &D%(,(D Q<% Yj$깡5FMiU7mI#Fhe ?0KhtC:Qc槿uY:ްh"Oq2 +VA >iv~K\R`Wٮe?]t7:.=ll:;m7p$ScZuB!Dj-NڡM{r%]*ZO9X5+z(\WOH&8X[E @ LStѧv4xc8ȘW4:F&1*Jݗe,'oh!}f"1 ӯc?t{zO`d|U6+5|9M1湣1TOSx1FtsQf^?jE&ޥV xZ⥭i^Ϭ}`ۿR>ෛt\NkU `ϯص x76)0+i5[k + tÇ>q61gݼ>Ȟ$QNԦ!>vY\U-G~3EnZ <'k14sR{Z?[ݻ)ka 9sz?p.秪թlYRtz>_iJu-akI1Yۃv\Y g?WЁyn-wguiT sZ'IUAwHgKWR^Lw@{szwh4mjO_|E3M늦?p *\GRv2ZSiov0| mhp-;z栵]'•9$-׻oJEV<]CI%`zfyG2Vh]kTR2# +z62_Z->|Z7ozJXX]S) FXgUn6kͨm-z,iips}r[OygHq'\ppHYl GY&eV̱+޷ӵK[Q$Ԭݢ?sc#h=fI I<.RhLNҍJἹn=7B4Ju*}WğY;rЃEIs=,n\cvu^֭:r=}˦eEv:X Bo]gne{ƞSUl5rOyhBЍY}AD +sp=/R0\Q2|ǘZ+Qt]]8 r&Nm_Ru +ǀt2F7mKzNU[tMFлZ~+p(?W aϽ:i:Wnuj)9q,q^;UoI*X$x[ f^\<gZK7&gڏ8hz-nD Q֔]00ONu[iuEOk;UZK cj)}1!a.O5X N8 +^Щ'$ `}<Z@ `G]Vm/yr\ : 5 {-zw}8ۚLq@_ދZ.oDKЪjEs >2t]7{xZ^u +D2PZpZ]D;iVVwl +) bAVvSӨ}2h@5lE+A"] q7==y-a>жҩ6\ 4Lz.OLzcU$I c>*M^޻-/fg]i 9'\=˨7j;@q[}Y5窙5[tMC!̯EիL:ᡵdi3ID A %2eD"e@Dp~V6X0&e`_H“$GpM!. L, JuZPI1pڕm3i+KqvNOJchRhI$2CTnC ] vunZյKqFYf24ҹq4+Mim_T0e]Q{iuϸzܖS3xJxYn6 [ƾ$GP"koc 1/ +^nk~vPb֡9߂:??qVo-*zwUEm/T\ |-] 6wSa&|f%s>쭶)64u NJmzZw8=p.&MY\ӽ6CĭVTj絓2|ʽNUPڴ=Ec ǒsI#ZarS^NEGX0ǔ-ﵴu-X /u]Nڭ@KQ]h~u&B.[5iTywS9Yu^uSt}]AJݍӹ #(R}nITԧM5M"z%gtkHfyg6l4u-NuuZS]a:#?mqCRmεM;ezV;# ̀ +oWWe: úOEu i^=$[6M:IG)?[ڮmܺ  +cO +FBh+lӸf klCW9( Zқ܏໪^cÂQT{C6OCgԅ{tZtO#NYUrIkğqXzu/^{Əb}cbjΦJ*1ꃥG0Vgg5ӘlL.o6[]l.C[M;[W,w,Lxyڏ'Ac21I&LǏ-Jq# _ٽ*S}7SS`p"$%Fݚ{U]-eV[?ԫ=r<|gPAN:ݖڭY{ʵ^:d׫tX[&l9uNc*d /}:/>MZ\✴imvTO D~U`pcrIǂ;~VU-Og4+T8}ۮohڕ;N|j7q:ڥZa\GQr.I6?oC˺oٽ~wTipIOaԑH'0Fe=IW%WP\ת׹m֨->qjB: f~ş-%ײ}r}Vhb/,G|r?؏)!nbwC>Z}ũhMk`C̶{GTR;/iüdb_z߫r`N8r^ZUwxsVo/P~i$x]A LYm*ӗOcXXWkSPr% Jg +#%ɄD&p HR8Aʉ00Oܪ{ (R* ʔP\QǽJR"W] @2&r"R0  `@.k` +4opz\4^;[ny\QۅڕBژV|>Ҹ*Ԫ=$YiTiw{]h '氷+}7U` #8~Ӭ{Z@5mU..4 noM]x\1 +纬/-L9j8CC@}JzAPGnKzVag &<~oQ:k:fLQQ } +I{`25נ\ڥ=- IwVZ_UmY.kHa`mmݬӦzz Y{YoynNy%BFe!7DOemCJNwzvyRuV߁=B&6$ǩ[n6Z m6"$= ѫ`OMSq~k#BO/Ԝ[Q=.##ÅڥVUs؀=zEF=\OgotGjŌhXOiv)N y'55)6xI?z.\~ Nk v #VnB5Iip9:;!FSZDd>ţ]bU%X^ mmA>hK~':;m`~o-cڅ:`\u2D9&Iž7ZëEZ$e`h΍fܺ٤~Xoˀ.o\}Mt.f|(#k}rZ=Kuo-B;R!'1NN t7R@]FwUW3w;Y? +ӭZ +S@7{6w$ ֙X_WeK*ܖ&$Vnn Tj[#+wY\q}@8Ӛ ,M{տVVrLڰ:X?Ap\ff "|8 +;NԋILC9~-F9Uj<}V9n^H?FnRR.i=## [5;ҶPK:t0?:Bv|?]upAJiR~YGG}뭕o+0ҺIFUFs SG Wm iV%bw%>\Z#<x[dx4]>}q=\](7`-.tUi0cQu߸i[X +T G$'}Xn}*~ek ? +ޝ'Xji=-d谻?VNaǎ &9vhՆQqef8 ZwP-dޣM"G]>zZhx+!ݨ40Γ>JݧyyR^ +)#?jh;I}5ǥ#Åz-VM/ xl<zGD2ZHpv5]nOSsrqvsSx.Ac+6jT^Z@B +2%O]8~ncZjnUvxy_y+|i5KjvjP>- +g{P΢*G3>Sۭ{Q^ZI3yZ]'Z:Ii7vקMڍPz@o[ӟZA2pV1 H+I麼QKOkf*zjuv︮?3[ԑOX56UJ}|yY:iOo՞@=sRGOi$p7am698ZИ]sf@$5`1+gWc @[mk]_cgχ\jm5,[޷gw5{JoqmJmi `lQ6* 6oojj'4#DL|m5Mh1䴝Ru+ׂBY4&FVv*^wWk[ĎcLuot_%^ӫ_ܿXoGPm!()&(< 9IBR& + ?bATH<¦BicxeѰEgT۲8 *JF6x*-664%e8"A-ޓ`w WղpQip$G +w4[v;DaahV穔~՞*O<}F?99dL@;TgZv=hNCp# m@6B-4GOVM-4@*Z<m)Zty>e:m:@Gū.}k\#j:i4bV (Tڰ48 J#8QEO0u)6{CmiN4֟@: Q'ugN5ҝLk%Niy *@¦*_M%U4y!DRoWy:J^.ThxM:Xִg*o46yVl{޹>4ÏYGԤ<|(m! 0TձX:IKD Bi44u~kݛBށxsD< ǸSw sO%|cJ)0ЭQ>a@ YE%h̐ޝZMy>JVkOhcB3~jBZQ?5It~j.eGuD̔ N$t TkCG! +dGPkOPO T| +ΕlkOJ)'&j4|k\?[25 J<򘐓)6uL l.?5 qx(:Z@"S)i2|BqcUՍ+i 'la Bzxqn7pjSc2ZE*BcC@h Z OJaF1O'L*.Wk@ݖâCG@+ 5<EZZDFݔ sO$%tQw+{V[mk cOJX%\I*-uE-G%d +랧>nacC{>P#)h |Tt* +1>eTL|'|<]M2Z}J8^ aB]T`8|Jnq('g"DR@(( + +RHJI0Rl4p@թ)`$8 aAҀPr pa02"R3Q8R"aH @"a6M(>R&9N!0S%(L#%"!D#JcxR4J} + + 4$S(‘qH%2P0 9A# PJA2T$r!W +DC ʘP[yLa&0QGR(!1LJe2!JDJP"S.'"bPJy(@ >(&p )JdŠ (2yA M"DzA2QJ>|T/I&Bh e0iAreE(\tJ1%8JQ) 㔛 +A# `  w7<%"g*N(r 8& +dqT}D4,=b,$ܶ-!io`".kLLAHP])D:h}u E"rs䷒ 3Z=NR"A37hz- $,xHe%(+M +Mևu<'mtr~bT"2)pJ%(#ރ(hKpR!L$GHBR% 񔝔0 BDa"QTRe0$%3&"|Ha9D͜( ("PB)2BEgihK q NDL%t"J>RHr?N9I9(M0%B>*nz.Q}p% \ԎA-oQd`j|\B.Y0|YZ~J)=U2ҳ7~ޤh!ϔLOtj m'0HW>.V{{Ả4̑>+no)C\rfREPOT@杷hU.@kC0 *7VݭHӑ+>[_Th`D%`@uBefjVt +uA*[r>cH>ßP{pQ| Mjm.@yc gw/B3"Vu]\XS*0{N<o{7tq˚e<,.EvoJQ8ςh\έk>40+kz;j,e8wXYKsZuKj aps +x>a0T"xj¹:;L}!9o5Z娹k_=F AC*mE4 cI=C`|Z]f¿ +vyykNƓbaϨ}`:]fjLh ϫn]u#]&O AJXߤkHLh9[mF73oGظqh +•jk鱔Zc VF*ծtV o+3tȝik*]j75IK4 mr"9 ;Zzm6tU:ZW* t[\~k]<{El,n *u &8+JTj#M} gNh̨Hjdk6z_\s o7 /c\=m%0R0a e0e$ sS9QG!0Rd)@A(LA)'g( a&cFTc)Jq)AwE⎨?)$D$D'2ORNB` rB>˔)uuB&R0(cTcނ%)qa.(AHB Q'%H(9}ܡW!)r)0 ${22S!D)8JSQ%)r65>EmloQrݬ֝Უ`2v 쟋WoiHZ!`8\oglwtg"F?E쪥eVڳ-heHD~\l+giƞ:׿ۊx^2mitU$s,7u2唯mtnQU}:9x]%v|z.| |J;,3V~Sm[ +_h"|+vq յniL.9)iooĕԹoKDeu{F>Wgmitzө؟[k6kIh>krඅ!KS s+Yt>LOЊڮ-mv60[M(je>?i}V779[UIoYlmR-(1wm?1GMmQWyv?ݴI\>?ܥq#)io}?*{^˚}w.AEX\*=˵q} v}8ӫOڡE[/We}LWQ\eu:<5 ~}v SV¤V: 'ZZ *ڂ}\Uq#.ڴ:[ۆ u+XuYxł*mn؏@GwygQ\>ՍUaZꍦ:C &~+|]gGk4 s +332  -ةP4ڰUVvzޯoS6?Tϸ.N[Vo6jv@񟼮Kܸn.cN%J9RM a)4JN0 ) +q r@?j7ܙ(i) +ET11( e"$2a Px# !DAl$P$BdB$A@`J!! Ȕ"%2cgxd& +@g*@B"P2% aB\ rAJ! +$I"!"R8D$ʽ,l,QJ9L9G!& u&~RqL Oe[}ۖjR{yBZ[S 9mJuŽ*T\YQ .6D{#\e*R)Z|⡫geF]AűV+jvZidgUm]M0 ؟iqҥQF z-tڿ^#X;TtF12]g޺pۏR9^}U^u'Ѻ^nz$ҢYE:nn?U^pgOI,ATP2]w-5ĈVE',:KA'_+{iᏦ$n)թLҵda#ල5Z u/Dp>q7RgwJk+i4 +5)V>#XUVT+D"q#[TtdHghh7u:MJ =.<}Otۊ-s[Po|osf}bƑ3 C >-kQiG=8V&;Sm = v5+YNdJ?r;<'ao]B#V~kfOSt7H-9s 2E0KL'(@t $Dp2a(O@(DBaq t&R>pB i)("y@ NaEPPJː2  Q&PD (j:BQ) 8&pJC)u~RI&}ȘD =9DHLD$pHL(PD%d>Uifi9K |#(9R_HBL# +}R%AbVrY֥ +b^#˔m[鶴sA˨Op2rGbА=>)UЂrPڄJe :"ϊ\Gnޛ]vN>~Xږ0(\tRH 2L9]li><M- CJN|8(. +%THuaHV8IL?G&yRHQs@t)wY)婊(c*Mqn&s +}Da6O>j?zG1QhuB + NH,BF%'T%"c!HV)Dp~+7Oc$<|T+m[z F67OiP`ޔH8Q/@(@LG (iĢ!2PB8G(Q8Dea 9Q9 +E!7 ArHNRP?0PB!(-a (% &D%(GC[&(!Dy(Ġ DJ +d&G)&T\%,S!SFP$RC".R8AHQAHpzh1A(L&Ҁ3DGA) 5O Q2 $PCB!0a La>i"D:@ Ġ8LaDp(%ԘxL"LGXGX$ +r + "AGP))H@L8NSKJD!dJ&8D$ 0d@JA0NPL$R2 $ +q@0 p L&B% +%&kLa +0B"P)$ "e!LHNPJD%0!&M*|0epB&Q)Js‰2L`aDA8QH! +TJQP%0 ?NK^y.qVQK +q(S" +8mʏOރr\\8)0a'& A< B`H!D"gĥ3OGR %< +:Bx)te(ȄP! rDD%F}JAGL$SB B!0HG 2 D2LFJ)pe %>QP "e'!@RD0PL +Dn0Q)(IS9D |%׉DAJI P\!P% cޔ$J +pJsԔ`RQR!#s a1"Q("e"@GON@BQ*$BR8Q) &gOgOV@2'>S>RFBʏL&3 e3RP +C2M>R#5i)te9A)ay( !"S$uJArDc))qd؀e(A JA ģ"a"zQ"a9St?g + ʗ$]00 &0 )(8O& @ +&rpH9@(鄽DpMp򈐘Q=(!Bd`JmED#?rʑ&=j@‘2Dc"cQp H@D()0!$>8g*$)$MDBe0! )Ĥ")pHDpL!0cNڧxޥ3(rL /!!2!D|0#  .OQ0$ LQ@L@”( GL"a(Q%>)BDQ&0e)*0L9(2e.S.z$}Ƀ u $BdB3/Tk>"a6%҂eD( c %2IPp3 )DPA"%0>IL2eHN%)K0JDD(PLrDAlgڇGT%0$z)7 5ɒ`B@(ALS-#iQS9DGڐ3ʈt  8)BD"PH&RHA(IM(SQ$A)# IRHSiaŒSG +@/e32A0RQse*S )e N!H8#P0Sy#"aJҀS2P +AR$D鄑PpAJs 2J3?! "z LJa08A9@% !)82D@00J!&HHgɄ(r!e8@(JQ(e9C6COPt +At&JD +L# aIQ%D=P ]D" P%J%"N@DBFRNR-IG"  'e.!GTaʉDJD!cxgfSP`\'JrBK Na&L D='"SDJ\$&p + @`c>!9@2)&S P0LKPre DJAne>PD LHH@L$(A9B9A'?j);(>i$B@S%Q"8K p)J h QD?) + +E8 q aKlBE4c)L B`%%0! e>SK1J!Me 'DD A Aʌ$]OR&PD9J(H IC*4LJi8L%8a 9LD&8p] +Q  CHCG`BDJmʔ$28ADJPp)@=ILrJdDFQ0p (DM.Q0` ": L e8DB8J% 2:B9G%)NBN%JQ̥2rc +4H$P + 9QS(Le |-(M)R&2PHe3%B9v2AHȜBd$NeD#*%H`G)%JR')Dje)D$rQ2e!9J! 8H&NT*1(2HH HBRHB?rOߊc "0PA$#Ĕ(Le(~i%( )CrN2!&C8D(tDr(N +D"TDa +C(p@P202QE4("S"THN2@! +&L2qH a1@BHe0%1(PD((N%)C @P# rD#!G"eJ!>D e e>T]ȄJ@x20%DDpE4HO"ON%"0d"\!!|"PH' +=(!#R!EQ8A@"UVZ}#xG(%Le9_2a <$RnSN% ! 4 d DJ|A=)r(AA(pPs@&( JDN@NJDJi@LBc!(L"G$SLA LQ $D@@gވ  $L'|pd#rpݔq$ALBgDe QTA0%& Q4 Ja5R@@ BDq &e 0#4j!9M :S@J!2e!B|SM.y@&P)@y%"Rl )Al(Ģ)DD2$Q#$V:YB\D&Ȉ_@ILC +mO<28QLpkS>䛄PL%&1$24P2rB A|) )>%(N%)M2BrBG)B@&TD!"Bd\1ȔD2IBQD) BNH)Le eJ# 0 E9JNiLR"gzPH (ʓ!@RTA(HL@S*EDς`@"!@w] &<ӄ ! e"eKP] + &L D a LrJ%4)rPD!  Iʉ ])D(NJR9Q9KE5zbp +"%!8O>zWBRA\8L0a0(p2c +#6DB@%Ѐ N%F)OD')an%0! <ӈ"Q LrQ G(hDJQ) '@&JQԟV%G92惔"Q8KDJJ%l\&sE0 +OPRGM&@nQI3((#B Prs.R8eRFSQeIQGL$O2eJDDJ| 䁔a4A0SCpR"2')"a4bPLr# $RKC)L䠄JU |Qyޥr(LA)22@l 0 (0!rJ@!1@ 8d S aDeȘL52a"eB!(a S%L pJ`O(!G}vTA@@>H +NN*'I'`&=q !$2J!" L +iG(( d"r0Pp)Atr%(0 L&sap 42dBE.J(R&)OJ@} (! (L2|S !&M(8KLPJ\#J%"4RKL AEE#$B_}ܪ> )8@ _9( HNH)9@C4Nc}P "g(@!("}` +q)8O( |Q N%DLAtDL@({$L RGRh A$P r !3G!!D Bg8@! D`2AS ̨rPPr)DJ A !K(#H%Oq Bi tQ?b܈HNR A(9Q0JrI BN0 + ua{nD"SJa Q9L($D()G %*BӰ՛!% +@ &C[ /rc({'&p&D .xGT!S.CS!.P1j BN)*.hvxR&Q$%pBmOQc  Pr!#̄KIɔO܎>@OSB` +&PDC]ILpSɔ]Ҏ!j:a2a$Jp%ic(a(aDD HCrN)=ĠTg8A@SRQn +1 "%#rQH"!(pT`V=G $ GR3]HPDD#p!( % pJ`r{2%PxLAPpL%2aQ(@ e(D "&pQ%0Bf p\)S !P + (8@%r(KSQC(9J%)Q2 +OɄ%4\c +$|QG(OɔD (.PR%gL )z'D2COGbc"}GH)nH"#9G@S0#"QD( D(!(e#"pʌ(^} ("a) a3)&.T*8J&H?rAA +S D'24J&J% DD eg)4BpTa@c(L A8AADFQe(y&0rR)L)L2c x"e A#L#@&vP% e((HSG) H +"T`$LHJRPe$rJr7(bg) rD &R"S%*%3S 28H " +)9x AnC!Ae00%E!B"Q҄@l'B()9QPB^"H"pTi5EV8DJq"h@8 cޙȔBmPB:e> @5Ӕ˼L$s(&Qʗ SD(S8Iiʈha&8Da:JG(9D"PJ  ̧G)Q"1Dq‰(nP|A0A2J: l#LA8Ar0q S$ #Bit Q|0DB9H|H@@# e"!0@2NP) +8@Gޙ"Q)`N! 0a(Le0Q 4%7e& e2RAQ%B)Aʃ4YH@(D0 e> +`BY@0DeJa0!) #9NaDe0%0e)'I#K%)D&)); O4B!0Q&%J e t1BD"!G(@qB P&L0@>  Q dLDJ`"%(HȎ"&r p( !IQ)BA JP%Jq b G' O> ܨĔ +| 9MDAJ9Ha(@S"T@B~ &H~O%HH%.Ta'e"LLq +h0% L +`>Aʑp1P dHCH2y ɄS  r!DHRjxAG؈% |@G"ed~Ծ:>ϊGJr@t&HKSAJ @LHB\ D8A|BrxA;<0ҙK(8.9II P8@6S(@Cp03 %HH"! 'D (.ARKS) 20Od R"r"'=D c!(or"1peL "'s4 2AJAr CeD:Q|JJ2 )LT4VH ̣(.DW002pSDJ +@B\J&BL +%aG0 0aR2RK L)*$S!%)(eLpa RJ|#KQB9!N!$ݏT#` TAL8G߄%! a +PB9@ I<<Ɂ0R&%|%(@%))8RG9A(!BEEǪ&S@@J|%A! PBh"!HM9@AAtFO)dBA@A2Ods);Q&}yRR>R0@ pڙ4R%3RFSDA p}ܪҾ͔ @2P2L_8RK) cJPLe'!pD)0R +G(uJ Q@ )@LALH@(((QŒ2DɔGЈHG(8ALBD&p Q1~I  DBq)7@IxMRMiBPL8DJ\.8@@ a )(  #)GDJ^SsQ$R8O HOr 2SHDN(!Bc)R)>@ +m0eR}QC De #I@@ 7)%.&G&R9AH‰‹:WYpCLL Na0c <& 7)"e2<pSqɔr0% HL>R2QDB"&>Rr9M)OyN%2#(JaɄ< @)9ɸ`NQ uBD0pRQ@ e#!r1e(PR.1(I$Ja5a%0JC)pa LD Ap0P  9 SH&TL !) +2SKރA1OD +E<)R2Ǫ%&xLGGN|&!DLA SQ9Nc  /r`DB9A*$J!(KL rD`V!0%hDP +h 0c@2q8J:SLH&Ѓ%ȔJC$(RH%2`J`G(Hp"p$#Q8HPD(R8HBIJE)bC8pMne3ȈH9BAj$&\LI8DC"`!7(!tP.S ALA) +Q)'MwRL&"r!h(A10 +@Jg &RH!J((LEQ9M2PpA(&QҢB !.P0!A.JBEҜ("2))HLgSP0ʜG *P(Lp $6PD +.%$!(I-!#>y' #G"Qe0ԋPpQH ?L$"A2 @@%('  (H?$P)(G  B TfPKNޖ{Y)@2Bg)y/3) +<&GNDa?z{HL ɅS9HDfS(&<@2J"&2(yDy e )𛄡"ShC H2% +G9HM &}!J"B` s)50D"e)D0jp1GPP["2DژI %e.CDԣ@l ALe2  CpDB`&@#%RR89e9 BR&L‘cH6Ps8@ D$DBHBQD @DJQ4ȄD$aJTHA (K&PL$Q&R(Q"!2$"֟v#ZpSM9ȕA )8OrTe0eA2Da eAAQ*EG)# rOD @>('a)l2IG NP4%r(( 'eK(8JPܢg(DrSiS'@A@F|G&J%4&pS(%q RBJ`Ǫ9 QLec.P  +$ 'Q3Q.9R)H(%))pT.RLr &L5 PbB(8HHAʉ1Q&9JRQ)9#}ܩOY e)AЎS@?ilg*G @@@ +\$S8H>GC>Ġ@(2GIA +G z09R&2cpp!9 P +<LJnt& LĄ H*E"`ʈA("S"xQnSM PaE +0Jq #yLcr A0M&P\a( 2p))a"!!/U"$Ԁ`e$2S  BA)JsHHHy:&|rQ La"Cp@HpQ2QeHJa1eDQrs P JDS +(DRH(DBS D(R9Ъ4 >6a2(HeG7 L&JA}ș@l&DBdDR& +)z` x \&DR z& ') 0a2AL(G(&$iQ $0P0p2xHR@0IRndQ p@0$?or4i GQ@2TZ!E(&}PeA(h&A"a7G)$C@   ;0@ Lc uJs +#*E$D!9I͒1LH8DJ +BSqL 9GB|$Jq)'*"B$(!% + #)GU:`YJC)NL7 D%@A*'&Q(qr}(G)Be\A9DJ"2{ +a@D&q2 | &RA(9A002(.TbPDe@`&l$p"Q 2rSL!9 "P&D0 D) && +C "PJRʁ=%gރrD$A)Ĩa!Le"QLS!BT*0;(9Aq?4)L%&RNAL)O!A(-e8De0Qq 8&RAPD He3S&]D 9) '2'%Dˆ9c JLpa)9А%#a +<( +ti> $ +@%pJ #0:rT@PD a.QLa %̢# J4BM)(: D )>H!2%"!F +\iD$D0SHR)&Sy&D$pIjd" Are`(rL9RTNp

PAh&Ԋ%"!a(Pd$[$ +EJA +L$DDP84`"P2DϹ<)z8RiD& pJ% ARH@s(SG)pl'Ǣe'DBS!pO%B`^8ADB A>G= ("P1!ʉ!0e +|PvS%Ҝ x%2S8@J2ˆTD0 )&R;9—@0a! ?bs("QϹ xF(J$rPBc (RJ\>PJJ' +%D@"ҟu-W')&rB(S9I$䉈2QԈ!0@@BR}S Dɂ$R $t BD%& +@ +iHR!a(L"8R!8D $;q H&& iDJMLL#ɤ pOr\`28A&R>P @LJ|R8ASҎPq8DJ$!Dc&NJH"AHH +-3 +D N22PH2PdJ(P0|RhH@lID7#8IBw"9HQAG((R($pʲ~\=bJ@BJ0! 3mNID#  a +S +!'HRH9M.0@32|&g(pJFIL2c%9AtrA((RJSDB +SiDBa(9!0PTL2RD&RHǢ}@Osҁa3a3 +1 % 6Gڈ?bdBc*$HGT2%D:S%d) +SJ|a(R +.0 JN!OICb )>)H0e Фe ߵ)D&R" # 4O(K$8RA1`BeF !DG)aQ"IL҉@j!S"DQ  G D0%2RLA@(P(~S8<$nG"JN!HQr|>(SHarBE"aHeE8Q{VGO @!9R"B2#>z&2”BRBe(@l!TxBЈTHD"e.R''a) + +') ,](`+a #|Ӕ`64xã L!)HH$ R!"DJ`Ie )) ?ji +ERvP3G(8eС(!8A0R8G)BN +9HR9D!"CJ곆A0<2_8B  B]> ࠉRBRP0DRH A'2@A(*$BH~z# !3(N}M'Ǐ8e  pJeJQ(8Lr#L̠  @)@ D8DC@tPh("RLPL aJ8H N% c((9C"""D$O( @H0'I)LG)8Bh( Q- H;O)OP\] k a>H LLe!x A0HDHNJ"?l2(n)SP D #.R"%D (Y39TD46G)pХ("2@Ʉ* ʓg܎2p 'eJP2J| e(!Q(%r%B`BN|$DL %J! cL$h)ODD B9r)DtA) (0RHD4@NR$$ !ҙGL0HPJ$(Hޑ iG`&Q0R"P G +DQ2El%(%H{@ eB8Gg g AϪ$QD@LS 2LD 3r $R $}*6E<ᅘc<0@2I?D %N (8G*C) P )ܢ  ʒD:RM2 Da90S"aD (@D a H(@N"SQ B ea(@'HDR(% 62P"%>R8L7DH))9#GT&ҎP"Q&(@PQ rA@22KR2(9IrdǪP PxH)& L 9LJI(JO] ̥R"p(r0)$R*$6OgAs)J !2@@<SHȟWz'#C$)ĠD#P"bT %I$)a3JN2LHN!R}QS)(M$BP +FB +RBg*J<$: A2S.HA$'2P ( @Q)&%5Ld2)e2RD]Q aH:QQ +T`)HA)$rTBd9LʉG< A)L L$ +>HDCR83舔R\ +xAB0M(82a9 yP$yC*>) D%0rrA0Q0SvP2a0AM)4D'LN|hL ( aJ#QAMrHe) J)Q&O0Dr#4rGP +l)e) +즂%A2RB`(9@Ϣ8Aĉp2! 2Ja8A2"LHLDPAJe"AB"HE +' +<>ՏVtP2CD& L/2g܉4B@Ʉ{"<ԁ"cxLL4S)*$O 4D"!G`&0"R0P%050SrQ#JOG(YH47H  A'FB G<(Ʉ(A G $D L $'CHL&2%@RP2~ $\AAM0(  c)ʉ|4tx%HA0r!At$NPP 'ܔJq("0IHNa" DB20!y  ~h &S鄁DILe>PTbS&R$!I$ԑ()"Q(NTG%3}22J"R9N|R|0c? e.(D:QR"aH2 GJ8H0eFD"TI%"pU3NAY<)J2T4m / R )$pޤJa0!J!'"P%0!6!Q9G 𔒟(!&BPG(8AFBy@)za &2B S&H9O.BPG !((K)"SKHLE>R*Gr>)"0RL (, D +"x@" &L%8NaG(#9" 72Ϲ>9CYPL1 La)p@L.ILM.R ) &L[0AAJ ` J A0BDJRR%TJ +$P8jL%"PSh R|")!Bq |! cIR"PrǪ +DG (P@)) B@ Ј"9N%Je(R  *.> +\ @$@DB%I.2P 2 HJdBzA҂`c)D&P^))RA@ǢBO)JA$JgQ!(G)$ܦrJxrQPD>O e7 GLD$!RG(APD$(D )r +DDq(L$DD#pQ !>P2!)P0a)So*9%+0 "a8N2S&  $A(k)))"8R9QN @N|>))B!&JDJSRI2pJ A0P ) HJe"gމ ;M%)HDRSIO&LLea"D !8s BDJ  QQ)g)$pИ?I A% $e%3RHB2KP7`JH 0\R&R8A +S%!(S #Jxa>RxN M$D +R7ܙ?$OD 2RK'$ z( L(J!.H:\o*B:J1`P @ (P CpW1g 8B!2@8K" +=.) &rI("e +S +# +D #!HɔR9G(@)!u a"!8 ' L@(r: A 0Ba.T aHQ8B&pQyL!4PL@"QL&p(Gr0%2a<$OQA(0g䜧9J%$@Bp@0BR +CAZ|#H*C(`%, PD$8C9HHaDa Q"*.M*o#⥄`& k2Aa(w:P# H0P ģқ$J!& (@?$8Le"S@)%M 0|T\O|HA)(LNta2R(RhLHӘHya0a(M&QM"(D !%"!>R%0@ L D@ BQ9GRJ2%.D((! deA)J8D"P Ԥ"! L &tM>TNS0S%Dc>?GRDQ~H"P]?bG%HA D@L"! rʉ! 2 I(IAD‰Q"Sr]=c#R@2L) įc'( M@@RQ )@DJ!@F +% (J9GJ8DHA(QPJc(L) I60e SI("BnN"Qa (8R!GHH&O@(&RNP0Q0PGT"S(A0`@()L% +ppe(G()Bc"Q(@A(K(Dħ0 9CI%aR% BPJ% N +@dJ\ S@)njP%)&)ʈQ(G)GDE&PL QBDӕ`Eg ü`&пO܂ch' HO%8@!"PPM (!  +C(vxN!A(Q# +D  %B`HLH !(DJrLȔ2Q)Bc L @DBJs(pRL($b|%% D@e)e1(9I&r D$D'29" +|}Q HR҂% He%i)@2~)J NRN!!B  JSE3 a LI@H\  +$Jd |R$DMޫ4e>Le44BhNWQJ\g (}PJMlx3MJ%3AD"aE LL ("Q=8:"kP3J yN 4Bg*DS>e"P0Q0&|Ȕ7r  ())u.TzHFTHSp9A9N@9DJDϪrpQ>@% !9QDqSJJD J>s)@0AL@$Ȕ $2 !d Ny)$B ܎Q< L0N݄N!" $М"\&Q{(#A=e"# eBPD +DJj'9B@$Od(Q9AQ*%DQO$y~k >S@2D)L%+ "#(nP@2P]HaS@8?ꩀ˒M(@)uBPQG9@A2Bg*' +R!)Lc(9HHGO@!JDO@0HNa.SA0 pPBE- 1L%:B! ap L(J!P&r(&JyJac % g)NA1'C< +PD"e(H:S&UB">5J9 DDD@R# GR0$ܤ> &2H`B +@&!J02a zG PR"DR8H\TJiPը@` ̕|?z  +PcL(HDB9N~Ґ0 +S xsQR"8"R8LL "! &0[LpRL@2@'2)J&c(G"% +>\ ()!8B@Ber00")(P)h9LaDG" +:e8K2 Br@ RqAv"Q"tLaB!$JaR-\(\a()@B LJPG8A2g( @ L& @*2BHa ) $D)IAG  + +L EfNc(@%4<ʈ8R '2@aBDg9IHQ +D% $ + t`Aap)a%(n%>RD"Prd @@( `Aqʐ3ꉔA@A2LCy A%FBAQ(0a AR"% "r) &L҄&JP & #qJ&a< O܁(99A3R@ "rQ(&Pp$SD~(!ڎR& 9*AP!ɤp9 pD(DDsQAQ(iUX/+*ac MNR< p@ Cp˰Ԯl8VI{CwGYtrZGntZ| F<>Z +=T=%KL|J6d =SNeDTH@L$(qh HqnE9P0a# 9 )NJ}R02IGޜPSJH)pd"cOD)pe"2pxG%aPcs(J`aЀ%!s)L @2Oq )8n +' R2S' NPQQ!1>2ʋ*\a(%BFNP tP<"OAx 4&DJ0@R a%9%"G J #>("Q8HrR8KAI#eEE!@ܛ%H@2B%J|NTPR)HJS8JT]tߑKsZcG2p yNwSQ.q /{ltsR%Gdi)mih/$ 3+G^=&@yrht]O ״o=kL009βoWx.#M>  r&O"&Q(pҔ)򈄊 ! +"R1J#G)0Q ' H8G(q +%)Ĥ&3 @DD$qCJ@!2P&ZD {)2KaL L%)A)CesڃSLL$# ' &LGR D)& !98:B!"e8fPQ3.KBG(zJʉ\ܕUdVLa +HR9L:RhW'@0RB]PD%)Jt!'%qipZC m&dĐ|To喸8Grs#݅:t{wV ;h$OF޵Z}Z΢jg `㵮X+mO< YڝFhZ yچKn7.'+}5S6heKec !4rJa8u CaDSE)D}R e И!"pBra. +8LH2PQ"Qꉄr +JGO$DJ9G)(9DJ`B&TH +^I(9BS Dg$D’AQ +<G\&G1&Cp%0$rQFJPDg +'?(9d'1>(8D'0 "GT! B&%hBBg)) E!JTCz~*G + O)A uJDG + )$JE"2CDE?ԬΨB` LJg+D(IR3TL@%OJD% + 9Yٵ8kƊn=I`̓xۆ)[~ @ONһk<Өk3ഏ;PR=ͼ# aAIu'3#L|Ưh4[޶q4VgUk5[߻캥0%)C@e GL (&0"P249BJ RG( D\!'$> % MHI308La! &JRiLG)ϊ$'PcHD%G @(Dg)rJq%KJP$TC G L#L$RSyA0B&!D>zKDB`BJ%1(PJ%(HAE"JR-AaDL`l=0@&' /A 0i'L gR- +8La0%Tv9h/:3WGа.;{R 󌬺n:i4yk هRd$ǻDT@H)Ng@@L%p02N&zL.2(H;)D pLA*RJ!y2! Bp8DʉR&D # e9L92e%PaJpI'JME2cAP$hA H R(@ %A0@!0de |$$ 8GI?$AŒG)RJ`Sy$rzL cFnLB A!QA9A8AG(r*0])D((&"RqHDR8Q* US~'煗PL0) +PaɌTRi)0eS&R'R9@"!&Pܠ! #rR&LK% B +R pe0!9}T$S8H0%B SBd%0P!D"R0e(0e( ̠ pD9R  tAʉ2AS.J&S9BR@) + +JP(PGDB" fG PJ#8HeJC)L܀AAzs0%)$JSC  BDJ("PЁ) +'!>MDB\# A P D|Ro"!9VL$R7e0D&2D#>Q9P Q J`\)%( At\ (ei #S@O)s;)& +RJe@(GT%( ' rϹ3S( +$@RPp9@8!J8?@ J9O!ڜ(Le(@@0%&@(D8H?%(("\$A2hADRJR&r  )K)M \&36B9@9"e.9D DC8Ddʉ=("1%(P$D% +$pB00"Pұl[?ԭ(S.NaJqɄDr%8@Ӏ>2ms)(N #^(Kra' A OzeI)HJ)81)(&$Pa!ĥ(8L H ʈ>| RLR?j@CL"!6N&i !( epAe4A)L' 0RD& +8JeH4!!% LaB2L焝Je #%"a&rNQ3De>D >)9HL((>(Ae. +"P9A()#L J3r-H )(&fQҢ ʃ +>IY Na4Nc3JO.(2DQsV DJd H"P1P +c(O )e>)Q> ՟zd a2e(pJJa2RҔr%(Na #TH2e7LQ !>eJR&SA20& #G( SHPR@0aKS %4D$pB JAJ(RTH%R!J%0 ? (NRPJq DBG '>i &jHHBpe ((H'a#.PL0)B%@H@)\ +xH+HLNerH'd/ &q!LD#DD y a4aBq< J%(%"@JO"!(Ha4Fa8JD>I "e2RD(9KLLqLh  {)<{Ja>S"Pr)Jc!ЎJ" +QN# 2B +| $O%) >ɔ>KLB#(%HpB % 8A1"p8Je9A2 &P# +@RΤrPBpQ >"GrN0Ԃd(t!yQ" +JRG*$$rr4޶)Jg))4B' (C)$ R'D$OpADBQ(LH'IB D +@G !#p\&])9"L e0a)%AL.PH2&P2d )!0`eJaRD LC)e pGQ0a9! %K@IϢDPI@2TQ>RB9@Q!9A H"a%8OP=t &NP}  JL)!(N@HK#$L $ +yP0 "R(Jlb6gDDd)A@0‘\C|RiNd& a#ʐ*.؂aH rDB0G p2‰|%O@HODJ +G("!(T)] e>9L"e& "L(&SK(L$ '2 (S!RLHC8@ǦQԂ% (>L"PD %S +!Lt )&A0D0"aArC \"R"SJ(%!&LL&A 5r&PL$p ($|]J9DS +=R)J"TNRQ8@P*<ҒP0L1Je|_NO)%iJ +A(r2RNR!ЈJ9AI%0%@HEI$p"R&r)L| !ȉR0LH@32S@ $R&QNQp Mq OD&S|!@d#B&QiSJ`)Ppte9P%G (ꔚ#P*G +0RNeF%HHHL +rbr9@0e(8H &G(8A0dBJQ€0u aD!L +]Q.Q9CJǥY*L) $] +DJH +endstream +endobj +35 0 obj +<< +/BaseFont /Helvetica +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +36 0 obj +<< +/BaseFont /Times-Roman +/Encoding /WinAnsiEncoding +/Subtype /Type1 +/Type /Font +>> +endobj +37 0 obj +<< +/Length 218786 +/BitsPerComponent 8 +/ColorSpace /DeviceGray +/Filter /DCTDecode +/Height 2328 +/Subtype /Image +/Type /XObject +/Width 1679 +>> +stream +AdobedC  +"$*$ $+(( $)%%1/%).*++9+*./45554/;;;;;;;;;;;;;;;;;;;;;   +  m!1AQ2aq"#r3BRs$%45bcCSEdt +&'()*6789:DFGHIJTUVWXYZefghijuvwxyz?P5!J4Ȳ,(]Dž,4*2"ydo#Y,yėo#G_Jm~m]JrRkr q|Zb>^`}b>>yEyEy1K}k:רu^ֽCZk:רuP^NP5ފpF " yFphDƉ.t>CbRH`:A2U|*KrGyDRIvM¼W>!r ?!a&7iXq' OQ;XMT'9pc~Boˁ.@u]A߸p J < . cr ..xaMH|.bT6,;JI6EF%?v&טuQuydhq$ߨ(kQojMyZ_pZzՂIyz_pĚ%$~b̗O͎Z/1b^Vߙؖ})dezyz ez +:|?rHA5̜sB$O^א-s}}׿As~^]#~w/!zBZ}yz נ=r^Bq@K"яВGkU[}j"G"|zȂEK+=}A"G=}E#?oPY}H]h}H]k:שP5ފE=!$Aphq#H}6Q@aUT4v^`S_p/qxXNqoAFƾw$|H\$ +<N|P"oIO|[Дwؒ*x:lhUb#X0lW_UͰr#t:U|0O sȣ ;[ :I&1#x k~J4'Uк$"76"I*t6K%|]Jr55aے5 +%C|&>m)FralmPJ5ۡ8^Bq|&$A+|o8P5ފbșH5Γ~⩍ 1zr T$cHK(kV>5IWrBjȺ&^Cldd:ItI1bhCw+L;r)[a]P /Ju7 ҡE`O] &0w@/0iE|+Bv*$Ьk'v6Oq_!uP%`H;@CKbboF贈()XEX.D`ҡbdzhjMbMr cJU$v#`]p W j XT7/1rdq;(@ؚ64Q(}ȸ|B WdDP'OP5Σo7FlWd[f9h.6@ՀԨ;L>Mh^cN@B)$]w(`\ +5^i +R .QT2.ƛ#I9GёqKUzVj]#G%"H]]${j]wAt1 HMøRW'"'IMJߪT? z> +둧OIX4XY.d[R$יĜu@bbJ@6+A\4;.EUؓb$\Va~@ T2)!Y$E>IXJDS`4nz| .ݒvP5wEc H5d$AŨα4R .vI!\q  PӺi t+a(:It# +t4)Waݎ-=G~M`ïB?"J@ H#NՉJ# +v)P.AV$O 4 تt9!6HrtF*P 7@+`ȩyyX(Aȸ%)W#~nM7bj\*Xk?QߘXw!Bi2IyN1%A\%a _N +Wc| ;UA2U|¯%Ca& v#~CAH0KmtWc|w1& _DhP5sEcD{Z䄈1v4$,|>6*JPvJú :v%.6lo O|(z$WDty +n jvSDU|c"ߐ6!~_ %@ՃaiK1wDTliP 1$. hN(UBjƇB@ATאPwGèQtwbq.Aĕ $076L:4QQCAؒ}<&1Ьub| +.)O'4iЬa.) `CFiΉI;CJ!wc|Rcؒ pOsP5ފֈȋ䌈ȉabcACHh%]oaI!|I"KvՎۀP#T9;t (ˁUM +} +>yAa(Myt)+1D)TK4: +! MrNP]Y$T >~`Ȥ)mXr mt/x` c0. Mp.JŅr>} +]~DWpOPҲL/wDo$ +1CH"Uy wbPҠm  +m1ت?BrO'E~AA0i~FԨRW؞7?P5!jɑd;ט44$Ɛ#nAVaAykFw`94I H8N\P p4V`טA^Ab,UCpj(T.\0o9A€u` +טvu "]$IyUc\p>LWcHDkǒ_E$%Hm jH@W'.X??E(Rck+LO(ƉDHh]!G @݃8H}@'|1|PX>UNV A:v ߐU !/ &hMZ4.K X<@VBq|p;i.|]2avP5V>E-Q2 +>Aa.F;vK-1A6;0.0\0N2]H:;7BAC]DՅRCK 4+qXXct `\bQ bM`Hnr$/:'am*qK6 ; +4" @O*%DPUJ>CnHpK.ؒHq@t*A`6"'!& ym sj +Caҙ*Qa^ChW|"h#ort9:6ȵ$л3P5V.XA[_ߙp;<8"}kH# +P&(U&WqtIW_4;5+߸%BNBa!\N';Щ](.ӰyM1B@ cj |F]5 K.!B#(Ip(`!|G:CD`|Fo$4}V P4+Wb~JؒV& Pv# 剡ؠƹqCw[ 㿨ńFW nF!]T+nȯQ5|_Hb"]B$~(iآJ & BR}P5ފ#dZ4Ah\/0l! _a\".&KJ jT'1,,Lj@Nt 8vqrcbJa+~}$ƽH54;M_hwBO| "=>`hNUuW MЛ 4DSw^DT6* /1$44!b|:[bCBCjנ@v@"-6cJ"> ["Q$Fk/B`c}Ұr=ɮܒDj_qA +P5Ҩ׫+H,W4܇d7t?]$F*l}J\h:F. +T4]V+@`>m +?U2T! \ IX\jjU +|̊$t!+ 0ø_|B@6I`HNP5BzCH& Cu_ t)0!r Q%PhV'6SPȥC%Bm.(CWbJt'XMӠW!^C!9y H.r0`vՉp'V'BWquXҠO<|P4i|`>"MQ݅X%111W~? +"O+&>F1*ŏ&c7dFĕy~Jj$ұ p%+&"CJ @*6 ꄕPw"º @j +v;t%4WcJ!B-􎬓p\!Pk;7@'] ~) zXkPliX>C;}0a] ,+]GP/@ B:^^bOИP$*kOJG\hq]v+c=_"\ y#bJWȘUʁ2aP4.iXG*"DFO۰ $! +aBL%c$pDƃ1+ta^^| :)*C^}z%A~A\؛В:V&wB|`ol$Ę%b\* `ĕd!T!b^W HbCH/ir}BC6|ƝЃUmcjĕw:NؘP؜I"Ot DݲO5`#țln~C@%DW $GJ"C `>;]r/wUdd끤Ev2M?P57I|.dXA{h]ȘXc$.> |w.5`JuA}C\_;& >9v + B|V&}7*61 X5څ.zvmcjȴ1%a>{$DW$èr@;w.ВU5 H`40c+bHk|`^Av Uræ*#DIT0D\6P^aT:MvP hQ\I\r: $.V(%`.9$\ t$@\ؒcm %b b3P4hX112,a3OruKoFA4:p鰪L(iPiXv"WK H Luaۀ I0b4I:A@\1q0\`NM(T? HwbbnƁ +mq0yUa%|VCH > p_0BAniUPX.T .@|!W`V.V?) ;+נMPv+_T)r P>ՅX`äb +*q.F7P=:#d +"T 5g{?P57h0 +BdY=3dMaTJ>ąBd b ƥ>!L-0i.B-0o̓^bbRm*&#}B|!V t]aՃ}ø +_Hm>A L;aT@V/ + : k |p&t \H/i`n.].C\a> uATJbv%DWē PIT&èbJ$ dh:Gb\ u@ ).t+JN@6|n|:ZP.!%fP57iQ]"Sp|X†טUi+ +V>W.ģ+ 'CTP$0nz1QV P6I>7ؤ@N PPX0HN]#~cP%`p:~M(V%+],U|0.N@IXJ}"L w: P!QPP>D9ya]i%PߨھؐX*7B \V +\ +%,(:Wq{zW 1%+DuBCa@:"iDX.A"6`@̺/xP57iw# dMmrw|!ЉPH⁎k` XV Xv#v* +7@>X`WAaaD&F$bDGtDM! aP WXҰqXw$> +@}Ƅ@r+D~K\@6$}]N6b:XUM" &+8J"bJ"M D%aA`נ10^r:p'`1W l, ;V7 +* 8#V6D : +Ɓ5.*";P& NP554XA/pD%Ȭt: LkqHz @I_`IY! NXؚcDe| |PJT@ð7b @"`ߘ nk6+ ]$EɓCCLT.`Ej+ !4;1P Hw|7bl ȶ0} . `5>Ap j>`P5Ă0C|„/#`I T4@$OccE +AV)+bh 'JO9QEP55HbdR2-fTi>ۇ |0L`ccH}PcvON6 +#q%W4 P& +iТi"I ?0@W61 paV+U;>##IrC_#l\17A"\wHbA}~CK0UcЗĹa`y"- C]+b!vt"Bl..btAT&  > JIPSAcNPaA2-?! @$IN7(`pr)00Rؤ|CGīP57iDD&&3OqtXc\/ Cc ~n }ĉ.}T*cc +o$bГ; ˜'*V%|BhK:|* + HQ1dTzI acN )*$ З灎K!wa \`C|%dkmՊmP]`knrE|A!6¯!T!L.ƹ +5Ab|nC2?vvbJ*/xP57iBl"Й&A{x/6hvH +ICB%b%A^b顤>ë}Tøߐu`JJjpH;.۠}CJ BB*m :,T abڮAr6.! 0+5h<# T iЄ¬$$JЩ0\p*bR|  N;G$C&6%`Or4&4FD&4q B$>B@;q)/!%CMb9"fmqP5u- r6ȴE"-ϼ K%@4Ɲr ,$SvI;`4su%}w/BI r;$: cCN C +><0N9 |OvВ`1$1UCM$@8+*Iz+V$}Ĺ#2(bhkI rAc >aBIM; \r P7$iO&6 +BJc,b`r4. +c¬U_p.B(q ]CP5bAo.#\4$ 4.w: W^`G qgqP4 vF#܌Ef2|!1 0 OCHhl# >64!q]v$" Lhv.l@5 v( .Fo1XDRWϡpvE+il%a+ + H;8X|ߐIAc5恫b\`:c#.xW$+';}=)p:#dp(>0jȮG; :W V&6]Upتkv ]ߓ?Q(m W6 LrblNABupI6P45eȚ ܟ0|  PƗIhՃqh} hݶT㓚_EX6[_񯅴c S,k-k͍U IJ,̮RK\ºWOf]Qi٣GW-6/K64:ZՆjKj)Nc>>m x2N/rc)7՞/fêYEd8>M=qma?D2u0ҮQ]u{ƟFdVtzXN. OO] ,z,mWj?>.ZLQ_Ve˦9c \;mj-yviuD-T6SV&ߺbܗV/qwZ&o֖9=Z#8N15>}Ě]cC#׆jke˒8^o[źLk,zoG_Sxӝ_J|^@9 .4"]|At..|ߒv }ՃwBm +:L@ê";UU݇nAKw +nM#n;Wiuz @aۀ\ t&K|tUȘ0\Rv6$.I'` bBl!C0c +=㐠T&?li=P4@D ؙ+pTp4CX.GP 7^niF7leWr +٧{Ưo٧;=pO9?oL+HNu?^Z=eMuj ,_sw{fuxSni=K'?}`4XՅ.k4ssŏ锠wwǃ'D_\`]m+( /շ8a-a~Տ:>J:)>;'ҏ:'/CYǟRASoH!:)+ +鴙2LF],<Ɵ/xGEę'k$RO/& f sF7}Ne/\ѷ1&ogɷ\} WOKQ +8X[ރ]Dz1ʺQAi`lq,yWO¬x_.S{ cBi\;Ɠq9OˁC/K-qx:Z-d59Eaun-;W~ioGz6%l65a'47os{V[հ'u|+Fό3|c`*Rjr^=< &㎟=&cl "c;] q`H$!A%?1]`BHwAðȷHHq}C.8W Q—'Ȫ.| 9Q4K$:]w +6 jBv `Г`lVM2-P|` `wa9P!>Az@ߐq_r7izl$(%_3cDP4ϕ4DEdYEuXkɛ*D *BaV  c<y&1Vxuu:xT1UG'KΒk+3) O$k76]נś7OkfF}bN+'*P{tgNLY1N].2-Z %"W7&ocKæ߳o?DGI+ÙW!mr߬^ _DQޢiɗ:̺yd08m'EhS(Q|w>gRK{9WWW22y]f.=M7k 5qi_nQEdرOW+]&/[&tIGٻ}_3w3A.9}7v8q\">IWj.7 0E*M~%ԯy+ɕ4y=IrדfOkwZ:ivmL_VĒKe75=1J^V&-O-4ZNMrű۴FrJJK>d{I.3a=n*)wa N?+}_ xW6ŒIR?3_p>\^C\ O7 Z^j>gO_NcM-~xJ~F]sjsGWȦ1\xQ/fL,xwuƖo=T5k'Ruuwo͛4MXQwgIK/G9Ln]Q||Y-Iu9{MJ_EyQ=>MG*p)ƹ:?P4ܵ5X!22DYkktLޏ$~FblhcAvAt5 jb]Aq0\L*nȢrj>aA( 1EiWjÐHNw$5\U@bHmT68]Hg)u +ؔOo;Ck*`"]j} øUO; ;^c#|#hVVՇ<@`ՊAt.$:cvԂ.U%CJ0H*بl*\ *~~B/ h4 +#O V6/ȴ/Abl U,WZMP4lM|d"h^>e;@Ղ CCIPrKH`;i4M4 8 F<x + G`  $* +Ƅb`: :L;r*ȓȱ ع5aMy\ĕ,b@ğv>K\}V }T `V4m]dЪH@ƄT ^at6Eлɱ aT&` @bv4CK*'f·P4BbdYE,:a;1ШF;! Xҡ+}1)46t>0L]^C4>+ avAt&vmЇbh;0i %` #+h^c@ ПOv|ؘ۠ bN0L AVV4(bhl  *4;PPUw +a@۱P%BNX'.aAW*۰5}#"V:'J#%6 ʆ Bfև?P4֢!TGfC,qFD@4hCD}۱!؁q%| ⿶7#,Rꓤ(MMuiAj_4Z'ȳe9(JK֙$TBy#\~-n/#$WW+ꝏI +Jj5P.F7VL}ƅW|T6A:r.})z# ).։{U]_&b\r92rI6 4uHRua@QA.M (MpyONWqU P_ m""!aV:clU]A\P| +lLv>A!ՃXNC6X@>cc@a.F*ؓb~!GT@=ʂHS6t=P4b2P,>a(n?@\NqcjD:אcՋ%W_F4 Ci|yK'T⛩[|_'U7 Erjej1J}l>8$վQK,ס7Mk&,pښ?W|q$6:봛9{'5TߑvCOb~sBҦMU dlr]%Kcܧcq즪˧yo uN 365{~7E]y|M8j$ڎWQYʽ$ox8.+qiڮQ]zHcOJW+Fx4* M W\i> FkG}%ՒQwgr]Otm1Wwo+viuXPqOfop:8y3s_1,ӕc[Lon88,eL?8[3 *.#T7M|uس_GYZZ~l"˟A99 |/c,K(O5]T:Yc"œ*ًm10={vܩxG6-pZ`pqx壑gO.hdny>v;z'a^=^H<LcݲX3Gr|oyZ<#T\m7}z痳Xz_&|Q蛏.NK=<1N)z,se &J4Kϱg ſE$ٓzɒyd§iU]oO#5uI.na%*v6u>fWtioxZ ص[eRt~tmxumNNx"ET`pyM>O'H^EAÚz[}ߝ~Ҥ43Mޚ U̘5LzqbT=j>y=4.L՟,h맩ܰd'J2\|| 3ƖFs'|?ItI*K,M?dbWY%\X|SX*U]>1% nW%\;6AS9{f|d~$U6 ?}' IҬP\dOǷ:\qIE.b=,)*1xE NiE9G%+2xǨJO%6GgW~Oi.}Jh8Zl=|zՙwMbZ\\K`k!mΛ;ɐ5ڱ9u2JRJ$VO<1#6z91N*[\vg)cy2Gz^W9ͷ)(egpL.|^sOsHa֌)!(򬋘gTė2>يYSs{?^M~b`ÏapW~_9>=tVx3}ǤY3Ó&Iܔz͝fuz|9#;*gdq>$ŗ&` F}tig+&T]hIhgǬϩ͕utet+z7|obϣRId_[:gۥ..lrT餒n'/|!M>dv Eg4XRU'v.4hdR[Nwolʽo_E4rR5 ;M37VG$/kuL'Y=bWWskH#&ǛPiv[;dFMB3餙˭[s,;kfƛQ'O obNxy[dp^ȼIl8ַYBKIe|F,u-(߫4yd/m%vol;x94]oz~Wqxj%<\$qݏzmDeK-u[N_a.Ц۶ Fj3J'*0/Cy\g<%w9͗Apj㟳_kel3YOYtM}Y(4a<>%jFdžnx2u뇪-x3[]yrJse#7<Mw|v6ѮyLyaiZƸ|ߐtؗ"kK9y!alh]P4˕5{pE;nddIڬNn-yYI >t0r&46ƹ*^VT^: .ONE'Pm~DO')xiOM776ԡNGk`'KjٵdǟK%(ci%m]yio: \K\~)ohFe(בǙpCdU%[Q.DTgZfmZCnyzY->ZVM>s,%n6/[}&ǭS:_A`ͧU\]y"}[6a駧ɩsJYVtY59t[P^\,~,\ԣL:N9>ޒ;Xc$etn -:/my7,YבS+M5Q\z}ria3sGIpN9"Yw0xACǺwa-pM4% RKM..rWsOeݳxN/E(+;.5Iq.[:f#6ժ[qqW8R%mxKZ(c&N4Ϟr͢"Ètdq*G+-nФ)jW~fOiV8{ F-E/k(l ˫hIreݭT놗"N' <,-u%m9~4')ej_UrqJiO-'j┮> dͣ'JnPqaOgO/i$ZJ*{-KxfZun}.|~˗Iܡ7\Ye_E2RC iA\xL\أ8¾1鴸ȣ]uu_=91$DC]Ud˵A:8Woieha2q[$(S&|R.TloY 0NXty&[o)0jjrZT*Lp.Mou:XbgSRt#xꆚ/K)jŇtz}NTGĻ}6=:2)Ept͏X)`̽LvסZ.1Ow~ujxӎU^ ɋQYQיxVF\ؗwݱt(EK7m%J+Cy||L]TC*DV#SI5VKP>@bNv.%`yI9$1Rȹ>6énH;; 0s}IQ)g~oJN\1BTI| JȾ`\h~ѐswNcI~/ +U9MDpd$$i?W$~! O^ +]}1c_R@\ҷސTju301~(XjUdYK`>x#g .=IFcXqX(sV>ZT=pơ:}sǑUKLOGZ_iN~:=göqݮƧ 51y"%fM41E?&Oі]&hE6%ܩ|9YµZ{ц +)wd*O>ӗfv->\~BwUlj48Xg&W`HV_&A] Ŧ]-\jz){%w} Ec]U.|/[&^Xڳg%Ɣh˹wEњ*IvE~z< Ǣ}eG:5U_&O,# +I۞ˇs656iX9_'[?g"Y%Fٶc!pfSnnRLw8vx}$Y޶8W~TEؽשW2nl7pl2%It}K*Kʎ7q7xP`pAc\p&c?,mb.C;`bB`q1TJK~c0h67"Nd5}A.9 +myhOC*<LJiXP7BL6}P45ā D ]{;}i]C4WcLc$Xj*%ߔ0t{Huzu+6e5zgY'G$~4ӋNo\ֳZN 7L:Ӌ$d͓4!%)KXf rQ]$RMU]jaO&9'ߴrK٬+M}92KѳwK:杣s:ZNCÖ2| I.+׉tYߥz\tyg%mtyèYQr^[xkK>S PMcqB +_S9/8ɨVi#nX߹N23fU'Iwm*xK rx.:Lp-S4v G22p^1#׊JqkqW^Ynub|˛Q2NrQt&{eev?m)E~h84/.Hſ&9o +YtS;q|>bvٚrm$v+ gX9_k5gX4YIGyXw7ϧ+qm_ׄ_|ny.U.S~!hܱR~QRkӴi[W=[?cfOxŸh&ljC*(۫s8t)t,fӋ5ndas)Q>nrIGxG2R^>/upBON-u+2tו<8lfϡSVFms{uE6ˢÛߴ%Mڒk_JoөYS)w}7RəqU荽IǨQ-)9vD!-VіWJp-|SB.1˕"9w-nsㄱe.ݯ:~3{ޣU&x۬ƱgzשKǏMbu_2#W|.P45~`b#@bd$@=} +C;T wbNƇA,*ƘO,ty=ߦNa38͸J[-Zۛ5$x"OrW͖*RroϚFׇ|=fN0餾[s>ŏuu#$n->Mg')jl_V{FcC8c/.})^7ۼ=8mKR![VJJ5ѹmz#ڌ">ŸFL1ҋ~tl{V=]˦J1?\w {d%mxzw,0P`ǏóOmxЄEWu{v +&Jy+Rm3[sŦ ,:R^?ȋu3~E9$*E6i} G'8ûKI붽պV)Ôi,7fOԧ&1 6/iآd8JSVY?f{.$}^|s9ݛcźnzf]KM+;/l;o`5+*gKxz!quǚ(ͮXͨp۽nQκztW}xdY+~lur]?lYF_QG^ǭ]Fe7Fύ6x~X-2mdQfw6G]r%,zzphυჄdqR't=udNe6뱟KK.X)".kÚX훞}/R mµ_[䇳PB^O֎{;0eEX(->Vׇ;ueKe/i^?g()9E\2QxuENj7x{Q']\4̋Ԏt(\M~K\dے~";=Uy=i>Y ǩ4ˣj2I|?u'' +>LZJmB-H> ygȮmeSΛ~/>Ŧi%9]T~f]i'9#֗2n:ˇ1~)4ؖ-gz;ٝ_R1}jxU]9=&׮dNSa9RO .ͮŋI5,:%'|3'_c}].ik4QˉfԽfi{nAyjNɑI·ߤ(N2ǧŖY$W&-Ú.ܴ}92dꓺڿ 6moxZ Efmӗ7M%?~Ɋpf\&#&t9+ta}Nijrt.ë{lZ.K9t]J)6.freS\ub:Lֲ攺|Un>~6XCOZܺZ+CSjPnL^J }=rgU`Ճ;qqR&O =i^ ݧɫŒ~&a=~y{ӂlW,N$N ~WeNM$7M]d'~9%iIS6M6xJXӓ5|4dP9ϫSk+WBKj^׵~g7j3JY\ޮ.fڥdD!>mmzŶ#ɇ$nNk^}NL9O> >$'_^nP'isßOE3,;+v_lɛ4[o<ߑxr<[^MdR\_L9Qsz&tOy8.\Nr6vmy lXBM,].W 5 u/'oxfxp';4(<'dQMϧ'>|7EOtz`S˚Pm.7 FmZy!(uE˸nު[v~ߡ_:sǙMw8=쓌oգGMM^x,Ie]{lQ| <;]LR²{8+ݾxKw:\O # KS~5?TL=iyBK5\1y{<(ˇ¢^r:!Ɩ +ګf5}&~yX?HVSM>ҽ8F_h؜4iNn4Uٗ֞k,rǴ1^Fmw;|[μ{r˧`75^/a9b۴mRۏiꡋL2iOʓ|dž9ubt]V}.+sꃓi40LbIJd\E|lwө_3$o; LUϋ9X6Yc:QgmLq)rOk+J15އ~ da+BUஆmSo$|xk ˸1ZVC7]f|J00oixo’۶VW=+Yœ /|&㇣-ԗ[Ye:mdpb +](C_9>kco'?ڂ3ysoڇi%~?t;'0쑬Tm<e6=Qq3F~ +liJW>>08睪%$Ҿ99/ϣ _H4|.]Q>IžO/y +ө)O$ ChIӥ+,px?xei?/ h4KK9Rrj?Fo4Y4Wxw{>&<)U<;u N<ڜT`bGXqjTV﵏kM%)C$eRqt|Ϩ5Xr{\yTuZ3UZ4_7NF=n-*ii5 G&GrV'E>*6_~S͟K:Rp]+Tm-Fɤc%W'e/OeIѥ'[}&~íчyb_R5>0JZ,cuK|%'-SQ|qDCo,x{H97eT + PX%|MػPCdRb74P+J .d ik($0$!Տ& +6 Ht ! ~kek𶑾a pQI.v+^k^\PrwOtcJ)y%Bǧ)JqIJ}\ͧtҒNի2)1`MnQ﫟:qN/kZG׋bTUq? .< M'..Ê8LI¢9XˮP\ѯ?ǦR%c0]kTU9>iOj% +QI%q%.SĎKS#*=4}LzJM E5ʸFu.<۷J:e?VZ IF*J<~MZ~Ldz('ɵs' $g p$R|=.T8rW&UJ20GCO.W&~~N^⋗ 줢/%ŋK IϗJ3顩8ђ\ 5uVVlq [6C.s>O BJqRQvvD]_i\Uyy Ox`+(g~2krOAF(/:\Zsȵ)䊥/:' \^^iŻc[iU?4יGԳgɓ]7_qcicRHyǺ|)b|_6[}[N.%Xq嵟6LR|"jai-;˲0q->;N#-+pmEI=O:kq*YEa{L$&tUǡ&نlKmڱmTiŲfm'+L5Ȯ\Zo:XGv^lmŶjc%Wfgٶ%e˨RmvסzϦ,RfF]«KYK.ȻĤUa؜5q(txf;ÎX͏ݒ*CY^S^j*^QCG81#,e] >+iZ<^zYpXE}Xr{ɛUB lX% +&'P"H_ 3sB3P45]0dX2,4cAv1A+%C \+: ^B%;EwU*F;Q74_T6C@TČe%t vWq `\JBn€P琰]v  +.8:C(AE!P ?P|]BJ +lFV:H&tQx|ɳ,SNRFe7ToK.ϺxsEF +]-<_OgLu%5Ė k^|}Ti +Hn+G躣-_EҡǹuͪjttK:50Vj``}x#7F)-\`i"MJ}Rr}*%]wlݲ2e+&? _Q}W_(6F-]ZKV>T^kj^ҹڟ/.\J>P2 9nweW;]ޓ wԚ,U;cQi,0MǶܱF>c. q݋1 XX\+GlqDU)VlRȻEz12/W}r+I6n3P45*b6 dL-GAV !>'\רøPPRxD<{Щ/vz.Oq=Z넒č6o]fpqR}w6 ^[7UNSsݖ8?ij7H',|wsxW1Q˓Aus+NރZ}+ vƵZ9>={d"MYQ'Jr?mzYĞ=fs_JJRrNΫī>| +:_#VtvSk'nY7izY=[Mܢיx?brϖ~3iEI3fg~->)ν;77lvrpsqOzZa].IF.v1_;lz6fežCܭ'**})'Ñ\-_ 2m1Y7MD_4ob'O}_wmZoaG)7K`7KɃ5f/kvݛ|{&yLJ|MaZMWR[MKrɷ>a1kz' Wa|/'4s(ɶ3xuzͺ:m˥&9xFZ7ֲf}J%J2xϩ.뷛7|zmF}Rr7\6ݓrsa"{סG>7dȧ&^fψ)(OYc}^=M=Ow ڬJ2 ŗ>99 ˓KZ<ھa}+NL\pN1Oo3- jqC^KU1Qkpbʜ_r2a˚Y96B_FBsOnɟQ$F]=̪opWOLt̞8͙pMy>?G~Sឮ"\O[4}O,'-:7W̛-Eq.X)Wkiarj'ڻR?zytqoW ){,o4b|vFNi/}CN{L"q}I &&W ˦WԯzڵbnxSQG˵䛜c܎W:qIwlǮ𤡞e (_eG 9Ŭ<$R}hv=Lqn-wG1n2x}A].<4X$P$RdcrBΙc*~1p]QkuSyB1On [zEBR?OClqۮ-SN\-']eVڈh0Siqk69Z%6]x)4u[o7+cv:캽ϧI&6疚 +J+ +NvuSo0&Iie=>'eqR3jk8ml?ħǤ͓.T,&V-f۷hsCY4LmogsGClQK}Yԕ_'7I].VXrjglzhBSkM_&ϊWCJeyg_٣9ރ ?^w[ W?e_['"/Qe㏥ʻaWjToZVOI%nOx'w}9(Nx:/oRR٩oŷ5u{vǚKmݺq7΋|GC&I] .{9I->ӑIWT&ZxއV㌧۶LYug-I9۔cy$nFOAc1Gs̾ĿA3β6_ꮸ9Ǿ/09d֧xEF/ŷݲlzGʷZsO=I4e,]Ic=ŦϑfǙmT%S#zd{eΫt-k.kjk7q<B ]|o hVs͍MͬJܝj/KʱewrTbR! oF:Gm]~%su.'[n?̵YqIygGcKY[sw~C!!ќ0b1#=+:nnmF7'ɰsEQWm~QGUORjr5&6_gu/H?q^a3W\zom_B9 %n> +KORk_]KQFOt?wϪ54z.;[ݭͧ˓Q1J %7 +/W/eQկh7ﳃ3lJBG+F35_ƿ/yGy(9vf/,[}ȴ h<LM]@iP45kb+ "kr74C "C(bI`0%%%V a{o4\Y,9M??cN۳&MLִcҝ .ӎY:'7n i>RM ~F]mIRn?A(./*)5keCi[fՋl]m$5'Cq1nQXG)?TK_b$OI}Q뛗64 h3.۵bb])yNӋUd=RKYNNr6Zmm8WLSt4ю8*x\-$0O'z-SˉT=كu֟vw/.O>ΫmũD!k$VT.T5eV}>?m4骻\ nn(b3^(;k2CQ4FXf= t{&z|;TyvlSε?hWf]A ݗz8uRs)*o:`] 4E&o$R}4Eǡ=0J|M}gǴA )u;~lǮ^hݬަ7LYgT%WF֯aë,ҾOyyt5_yM<ɑECQڨ8׷Cl6;kaDzbǨz~J<;ydMMv]5[w49$ۭɏwZP]>MQlx<8՛ G=٪5={ Vv-طsE^?rRgɖ1FOs-+u *{n;~8`\=L5,}hݴpL{EVFn(iYMBSZL /&d<% W#˙$"rUx`[!RsR_csr-v)i5dvMPөu(*Sû +٥JMYrw.-~f]=_SSic_jQTgdK̢<#|֧ ,}vy?cϥr·eX;z5Z&Ws\[ WdܳCY+Ŗ +W=otI6h`?vj|'ЯcRW)zY=ߨZ9ZSO&76Oeњe#zR]bhW3kL{QJyu#|y׳\&K\scIܤkxg`{?g:5MWzgAۡ KpxsYձ]Kwm:bqurٿ%e׹&ƫûUrwM?gq g9z7j1T??'t'_"/N>QZ}&MI_mgi,V5u{'gǓO{fu'%⽊[(ጔzf?륋Qj}WjxK,TZ|cU6ll{.]>Z,RM8ů$aͩ(Q:x}r_c_ere٤r钿/ ,i&lr;æ{*i*wٚ;7>H5‡|zy4pnEI *q8< #B7tP+`v1Jc6s$;JkC`+&;1] S +` +n(Pw6.9~CmwP.F!;;pnFr&H/| $ :KءӰt 5c| ,oA"FO6D溹aDW=vCc"}Rq/OQ nF`6EHP6B( ٰn㌟rdxt1ɱ+9r*PUrbH@ V$vA& !B`;J/$q7b8+~dZhjOנH> i3P45bt!>H&H5܍ v*0D]$4݇`i5M^){]>Ho?XŋqTd^EDžCre.ѕjɣc[mO$V\8/4ox~$duQnZ}g.8GOCqF?vjѱ(6EGȗa"I˽ku:9ӆ$xFPl%lq2.- +1 t8 7-_q6^Bpl+ȗC#VƱ85z8ב[M>T&)h#Uԓχ =Y:̰Ƥ%UɨTS,3黻-B*nɪq+bq +*VEH(MYx3FqmWn=ۯz4hotYpUe6_ ȥ5E7&wۍo2(2;N pOwc|{m~ZP+w-hsbӸyȳG#n>HKt !5B|Za8S.)$fK8sұ]@T5+bQ]sB3P+K5 h{~(;* +tc +>bj6| +AG{ғrM6jS*8 +7qپ-/2f3W G̟LREޏ1e]K#;fl/89}u:ʒC2zY0xYKn+&>W_iQc,RqkfF,ֽDcҽZ.6Mw 84R_Ak9in5-6W8{98},{^ӹ/WOWE|v۵Wx_uˋWf!ӦɓOn=58kxvg8&߇-F4Lb}ٵ˗ĚMU'3>9(5 4΃uѿc'(Eחfs2E?u{6 Mgrмk$x.wk _t?{Oxj5OB||S%d86|ܖ_Ś9%=>ItO3o]I<:o"l3ۤ-NYJqu]9|Sg8mF'FLYcUK9|ELm^]U 59.ioϲij4ڌ/Mmzn?lmjuwmgZ^y~Fׄ7}FM&f(cj=/sݲpf_Mi5zf1f4r;My;lSݟ8uNQ ˋ6m7?Rz0ier?i,zlRq]3b{^q Sݵ~fڍ6=.',xnr\?O蟅NrSp|HM2qy_sN3M( 26Kɇ/USGQ: Sx,\<1Le.d|{Ef+аv-oݰ75G/:cy 0^_o 1iΚk-ZS',X:nY#,ްdFyM9v3E<,AtMD)F`/K'-v}mYpϧ.YMm.L%}^3wzݵOqO/JGeFާOJ|fu}7ctPٷz|dszwG=GdySi4>cwv)Eo*\N ͣ[umd } m\[ 4eX"4AԡE~z}kȱݿVhn8V(Jqksj>ӵIs -nO+wA|Z[֪]1.7lFY\qJvϫ{)Ẉ/k} *Ϣ9~nxw eEnw,rC\e-UKz<74=c~rכΧ.hR/v G#,8mqmיoj^٫iϧ\Z3i7|7 &7 iz{uk_-OMt&a޵z(j\niJ=5VZ0cakxrxRxt|GkEiz1cV]x[),f*KGS ,8'n͝xL]9)FQѤi"~˗&\5j[VJٶh'9k W2[MU |oŹjKቸIomm[]:&5I_Ko4zh2vO^k7-Yy`k։x]mj9w9pJ\H=dUUx6|QNqKr0u[൝3őٿSg# Yq%.?> mV}i`}.M{=N1iIKʏjz)({[vnx?ve[Q)a&74>4E7R/6kgWW-I1Nn͍u^HǗ#7↦=6 +M{z-NOҟowcwdédm?SS]"^>< N[kTiw}~bIZ-<9Q6[QxoDx4X'$YKi0c^|6ͩe|-mOK5>+TZi|G6Oy]]1aդh|n}=3q_E5ɇ,ÿxr֦5P\ݙ& 5wev.8Ʊ5/^h(5'|OCA@a|q!5@\tT 7t=P+u.$ hb2$YW8ig@ RXUӮܗ~V; ;5wFjvoG5{/Z%¯+;HbXRQdTUx~!OQu:)>_<k{8I&ΫqCGYLbkM,zGJYI|p`~K[R/kKKgu|ӨU.eny~ž.ȵ|M=wçǓm&^2T=b|Q}VLG^f?qj?htK w~MxbuR?شNK$iW/Z/v?'pf/E /#ەGNCO +O7ѻm.ޱ`e}=olëf-69gɑ-ܦ{z&k#:YkM?WӺr*_DC% J\dV~TZWh[-يypI(ϣ{>_W9;vfK6؎0>TcMNo +1^u)"2^թv=+^kod#gjI|y6ib.lE4dPޚwt˓Ny=Ź_xWWO.UJ¿5_ׯʭEͭOg>[j>$}F% ^(u&5GW;MSK~6WyLE/ck~+Zץ߭ϑW߿7<0E{ˢ79C: Cu$xALZgOÙb9]C3sM%iIh)^g%ܰjǨԢ8 +=}U_/s{>io=,MF^%n:Sŗ&% n?!dLj1Aj8硞xҌd(WWϤY(a*]F/oa'%Vx5=\sba/{H3}'~~èDZ/W _"F1 sAtP+u>a2-rR7a 1b645 l*Ɔ<נU}EW<998+%D~qKQŶN9g>tkǫs4Kh=O䔲][ُufW r͒xXTb%jeqG]+/@l{55)pѵsw(hvj)6Xܷ+xiw66GvQNOzSoz&ɋI& L?}:Z,y9ox;7'Rc罝~נ[vzxR٫x{_j=$>*nZqcB47ٟApcTx^}]K4sYVIǷU}b޺}SQt:]]?NgNx)>֧Q0K$JRU}_zR-ojfn2iv 'Sgǹ8{T߳R/2_6~)Brͭ6(w+|[}NP +ɥm?9vɋC6X;]_-ۥçxÕ濔}5yeIˍiôGiҟOts\g(>rOMQ~J9rIӣsf9aZI.j5RkI}?~pX6=mǶcX1*{Yyذ),=R_y]&IqJ.7]7׆0Ygk$}Nx+K,RN]jE/oorcR[enKcű»vţq3e%ɱcx3G?-t<}:|Et<$i-NO۾Xn{=&-FK45 ݦrT'].XKI*7㞛 +o~&=٣(Fruﻪ3[D7OK[O$7}i26y]TXb£)%hS˛}YnnXd2NRRb7vXcƵOpz~cwM?TV?&h/ +9K2k#wtm;D6LKM~]͆v\基}Q>G>ǽ7wG+a4Zo\v|xtKcQ}ew{I NJ%"h۵_UCN90zܫ[Ε7f?4|1NɑY"nU_kwb'j5rk3T‰l{Kkκ%4w`ub>i +Oh;BIz]p;rɊ9ybi%IRJ I;~1]pAC۰ƥU~rEGEC`B|~Oy11S$a/{]ê#cK+CjÐ1>CYWLkѫDaT+E +Wb| r~>A OD$6Uw4}bv q 0;w4nk<*RUo)E}P } Nqqp0; +1 "2Ʋ r#4V($$d\#J=g1!16Eȯj r4,a4>@0Az +@(AAz4pV|߼K mwɭ-FHtN=_etG0CRjŭ +}>-$rٮķ{dí%K~'Uj}->A&: +lT5c"5> 0LE^Á ܸ y }u_1<Q]ǺKsX|K2fSn8eRuٖ}LuXs+LsqǶ.Ş~,O|pǚXܒ: +x5xc tˉ5-knye>>@ '@f: CQ:XLWv!i?z1t\lua2K7$@I~WEc',RQtثX aVDlMSuD1xG.1eu_4?Po!bEq4 "<7t]FXhDP+5 ?T BdDfU8,,WcNr;c:ho'^{YKug/m;fSn1\Mݒ,J?z_'c'櫒`=VG_o8G.Ғ]<񏄱mŨ)_m4]hlɧK&J+3x}Ѧ3ߗ45;&ᣃ-CůQ5 tII|Wr`.=oJb=GBYdpτLy8u6xˏrţRܱǿo٣:H4/W!(t[n;׵]t-|K|Au5Fܾ/o›uɶ,j/T-~5Ƚ} m_%2%$_.݇];9cUnJA. oݰLrq^t]%˽Mis?IDCY2cfljuO6grNk\rS3zdze+J~7)=Vwj?j,Zn$4Xqbun nQj,n3Jx5k_,r~=Fѥ(iI,$a˖Wegw^oau~οgdښͿk'M.ҍ&5P22J7OdJϗ45w[8f~)SKZojʝ}z D%ZM*/=Pˁk:T]oQimCG_Z?[ɴLeˆ=O e|ߒG1e>5cqIݤ}ubmEh &~Q8|#F^+K]Gui_n[= I*ydsO+W^Qa/?/X\0>*˛3hq'W!:Mf>kf_yqbpYo{+)ri»z.]~8j!jѱVq)oyڮuzv}EPlo,h|M)ZMN7$m3c^ sFʩ./.M(B5]l[XD]EF?=8E'Iסe;7 3CSxѬnSj1/d=V9)]:~L#GA}:ȓK5{F]pTС3TG~YܣS53|Jq]7t%̴laދ lK/ƏnU->nܭt:eıiЋA&qFιI>W? g3Ά^l.?~5S{v&$iy rE!G-^Noe\|̵aKWnJ 6Ӕ)W%%'_N+#_>Q~iש|7z2lny ot%6,vpkV9.`ٚ~|Γ{;'/螧S~%׋7%*tKF .S:OيO83 vٓ_oT3_wXlwZ#b$ng?vPߩn3Xq䜽ޗrGSVuNGS,|=jT\f#ic*aql ++eU +IB+׫4e-rK$[xom}%q1}t9')+ϫ3 >$?sr_F?bf4LQ92,w? j#k>&%0H趉bRU$:? `_Nk;閫ţͱ\۹c>mNeF qQx{mIɧ%m1<9+Qy0}\:k><lѭ3K(ˡ])5i;-l:nZ_fV٠ώc57q\[\_G8OJ?:SvM]QKk_P3W?Zѯ{O3x=Bs>˒ei2PɟCN>vhn{r[5rI:?I_o?<ΧV W??iG^B\f_QAtߟcK':,z5ȩyÐܽ8z1]/Ϸ[kh9c ԗhqfpi}yG7_G-*㩻Cdܵ9%裸BQSfSGJonѹq_ajI8*( 4uYp9e)ic^itٟes/QkSۆZx)_3$wŵzd}^F'ԷxeɎcP.rN?6 +|y2+RmY^Ki7\u{[^稌e`ERtY[V,nEp:,+bG,ae7?FNCŽVla+E~S'_o#gu}{>f_'OTtKng-7u%3cZ~ 6(Ïciڵq}w4a8Ԕ$G`oK1ief,kh| }~jGM;b&s QJ t~T B$ $E MP+u>M>3GYI& N@;dQ;`:݂~` hT]jk\T^d|CR||)y?4MF8]NvIu*heOv7c%.~A n'\kӛ]^>y)+i|v,]>R}hE6Ul2u7흵-2Φ;io[׳꓏W5QJSEirzbs.k;ֶ1Eڍ|1>qMǫފYb,}m9EveaML5O&c߼3xqnaqW=KOWXE ~i/2Uǒ١[n(`X[ji? nOq}{oYpʻN4#8ϖy{) ?l0cI9)*o_ +*v ClLp~ٶߥ[TY'ewvEazYI6P(V^~av ^7'[ sR3>1kGKOSXߗ>G #LkZVz̛^aNY/|Ʊ͸.ԗtkk|#l ؕ,-K_ZK,#k Uz/ɸ;P]-U^ܲ*q4?}k?p):K7^\ZNWpMoZ|Ӻey1ZĿ{ۏK6v_g,g% lY9{Y9sf=h\VKxynŕ;K^ǽ)7ݒڥ:KvJþˆZX2j{Ķ2FMrk6?X.}'cOMT╩zlbFۍ&!놢fA7f|5aqvVd<=-Nr9II7*ѳlL+MR.2_Y>UWFяh1~m3SÞ[*Ⱥ޼=K6K{u]H;|YPj\/ޥW^Gp= DZI:Fݦ٢dݴ(u“llȳ}{[%Mæ== tͧ(n~n9%]55^Sы %muҽ>wӅ$ХxKP S\Wz9CMR()o{Q枫C%za`ny(Bv\^ L+{ez9pޜZWۓWt6=4't%eO5WӗKѕx5{bJNݼTuYu51xߕAN/Vj?*ji(EIS|aQ}U}WGIv,9:U)]pmS`׵>k4<5lso-ݫ2Y1W.uY1nr+XenOESp-n\uf4SRO5_ co5f6L]]"6\mn}\"Igɺ0Bl|8 p4!'\:.,}`@&J*&|灅 +,@{cPóOO78ݹW&0l:!IX *„TG*$Mt.`r `@(]T +"cBj@l¬K] +hV?‚ .6.ؤtact%T$| !w +q0R p\lëCY,z%g=K.E:.cR}ߛ6?4 |KH%*#.*+ޢK=UP3j2Otx0GKႨRH|wvS1baXy& 7c&&MO&]P+5?r.EZQa@?C ہ!%nڱ=FDS9|,S]K@6 z>Fy7xKoi=WEm_" \QpYi9=RUKjqnPy0˩'ML9aoi=IO :bcyۣK6S3[wJ,hiC; +w{Lhڞ.AoH,fsF;闩>xiWddo9~sKlݱnrFTh[%{}>1w}b+YYx r٢\.J1sF-KŠ/vO=cf>4O. #j͊JP}2J]E|wKP >";v&1 I g6빩qjt_]^&\64kQf:C]F zdFIך20kucy\x8:64u1Yq(˳D4z%J]<:33[s|AWc6k'IPӠjq +45[ &E$#;~XW aa5 kUٲX†&:HǟQ4^\J+fwŹ,2IѵbKw0赘FY5KK>F^t)I)ϲ6=B]R.솛S JRKyG^IcǑdJqv)HMwB|* ];],\&P+uɘ{1L5u0JFcP`2IU1ب۸ج]hr?GiZ5 \^c=LKd̩ 7Y?gv=3ho{6l2/VPhEKPGپjTh[~-8G.7odgedax6,tjӈ/7|S~X#i4Ge;F凣_fO/q3=ut[}41<}ݳ3,X2N\bsn&?jwYIh1FP9MC{a4Qgu-y٤GƢSOUMHշ wɤ8:_alo6XQl⥩]F7+T?.ڡW\붷QǓs{Nn8S|oIzg Jqf '\$)._F9p&J]:Mn<)?y#u~γƘ4'jJxҥg=BrӚwNX1wF|Ev&4*ʆE|Aƅ'A7| ~)5QP+uI]M;b@䬊Jp; \v!¨]$!]羐'É.DQ}Lk}_ٓCO"0RdWktnZWT \*}:O_~DzNaJ:|*Bs:إbw3.^[?e_N=uJ-`R>Yp%ލƣ#6#_U/R?(7{ɻA=WoeGe&c|*۵k>oQRNEۯKHi(qMIy/*9/گЉ-:ze5~%/bi}Kǣ&._gʈKdˢf͗$&/F^TO/Gk6v=>=JO yVgw(E|M}vl[\2rѷ\1觬9_4][8ۦ IO?em>Fw0ԍW/Ӊ/mo8-. LZW˯hו sƱ2QRNNH=>wYb]$ˏ ;W߫!}t.;0Ikv/27 {E~_x^*;Cyy/NŸnQsQiv^M'sI>k<npQ0;tڌSTEOD$7͇rڽ WQ~tc\7<]ɬͬūKpUQt Qަ0ԍ^͝sšch(prŪdž<_uFxN;ѢYdo,xHbi}ϼalJ{9w_Kl]x-^Oؒ{bf~3}'},_X:TjF|i?uQ}y}՚Ud]4r;WW!-DŽQxAyI~ +jpa,J]/Xo ~iݩۯ4vyW~K-nrOyɠFeZf=dɡ c˺LˁKuMq>3ۆ{ߥ'^H]DA+-zükEctK#FrJrEQ"_i'Oꖖ^m1J W8ϕqO7 Yˏ"Mt?8Yl\3>:]&qM>J=9lӚ* ﵤIh8)(.>=ZIQ/K43jImZ2ƚ^=NYM)tS0}2]נ ͣ<:'Izc 9_fi| R1vwb=Sb']_.T_Iδ ֆ>tZGX'v,AF;zy9ᇇC6՟ǎ}4^X5[]Gp&Olk%6W7².|I+}/},yıJ\}pG>I +\:B3gJV}Ko'9b08j0k1FIU&gO)sMvSZ' tZ\J }Uƴ;5.njgO9bp]ZfRe_iQa] paP1J=BP.;?hyP+u.f2)&*"Wv3QiI k0;p145D\|R*YvO]ve݉[,}U||<Lw׳>я˪͏]Yqj]4wOkRŨ!]7eM$ƣoá{~ zy]L:kpQIw+M몔ٞTڥVSxoEeg\qQMM:"h/&ۓ.ѰE.]͸:iɉ?.7?ᬚLjjO'~ZMfm{i2I%ܟ)oX4| v qJ)w9;砏9{x]yfRLJmS9Yڡx`O %v捭Gͨœ}z$^咽4*iTGgxӜioJPM>\2F]K۶mfpKƛrxCWG]r,_E|?8k6%#7nyi| nT:7Mu(ߗǣ{~ X$PNpTo~,ߔ4SPU%/u|9eN }0Ml1džőIT_'-ū%mrRYev`=<2vO+1F6HQw(/;idM.t*Sͱ255+;6ጸs~J3vfy F0Fe)nY41i}Nğ(u[&&KЖE_m36xn[$bqGdxƩ.cvè=n2+i6 زmcW,~Bݶ,n dkiGľ˨FfnrsNܟ2J,v .)Ai!r]Fmuf&4Ez6[&L[]sg8$䗍6|u, CW LzIQ]zGeԯa\|cXJVY$ߚ^g\3mz[[3$|͗Qì]R,,|!N +uɩfʖGǿjx'CcQNJSU(A&mɋpͩksIݓqӬX/itxE/9m6j=idhg\ypeUGlz9Ug㒓,[Kt2f?4sx_:v5]w~eŷP7<ߕ7˂5y 9yma5ð鵚 tg\Ǖ[,zxLYOt/ ptr:)tk4+h&8udc|͝Q=N(dȺe%m q~M_ė69kcy?mOKӕNt]8#ȒLNJ\9kv_{g 3uN!de.b'o$?yP+u?HLL`45r~/*_eIr Kv Ck`al*t7ø$4һ`VƘ7_w>=>/o4㓷T3},i9d{{I]܍Pvt? mG>܅X Xw#4iX@ wv *Usc2=@ ؛$БNL*E] +67_14v{72;Gzm۱F?6>!X%`Q:Cr6*T'C"Ս:W@è]59 H@ߐϐ瑑܈6+%z Չq}oԈSo!uy}A9'/M]AIMЛhmpNoK"` ^$ؘب fP* !>ȱ>DhU_$YGƄ:X.F$ * @(mP. =ƐӡÇY Җ8I9CK30 +0RXSCiޱnooKV~#`cv!@$C6:dJ1vŇ4uY ӌ4Ou|;nvEmx vEOMێkaueG4ݿY{tu$d.KQb憎MQU8Ҋ 6:jQ]&י/w(K_ _%>6בiۛQWV\Er +f<^YF1dJqi+M1j3M f[CoCpF7qfg`טӱ.`UaW:5V}Su6ht0QV+)sG~% Lu0Yq%D nKa~D~$>sɂzpȴҒY$Gͣ=`?!];ǦGP$|->^Q/CU GTa$:}NIsOQW:a%$:~fJ\1]uu|ѓw$!U bs~mq|;X 1 Hhyq%kn{6OQݏ~IOK8jvXKv}x&K&8~д|I c~gx5,2(yΛu|v&\KOQ:e"S]xȗRr7`~6ɣǎT;%UMEdiW/cC}RJ.1yJqF_ Y|XMӺipF/&i} 9$ :R\!c]qmv~e>GXyv QԤۯ/|K\n3DY!Tc zǓҸ6p7Joٳo{ieэX;3)08|3Lmܛ9O&OxXEӓtrġ!ʓr7Qw'$2÷疎Qkoʍm?q~UXxm91f@XL

)V>MUO/vꋽzǽCRL}%,Ңo.|أPpoˢ|f-,0eNOޟdGIsŋe/t_KjqF'q])u5&4Ĝ;/ؼQu,yDZ(7V%mCs0O9R~?5kĩ]bj8ŧe'T{ KW Y>u; 9)J;'٪kQnbqA8M/:*=qɎ2r56q$ippj^ɾb;RIߋ3K&Z+f_,s7$dtZn=7`v>G;{'O3qqfK||&4TBsmt6z2PnT˄pW;=,Wtyз ݓ V~#BCepv״|?Wq\Nײit$uZitҞ)9uuҕ#OȴS9{Re޳U ^\|M&EtC,=]æ35'&UziXKRƦ^^3ƺ]d:muN2W]UY{g%W~TP7(Ko6' Eь̟om;rYx;OGaMOzE|[}Z\5 Ŧ L?9~`eܲ?[B[?0ϢS65H.M6JMZl㋕I'Nf<4mMskoWg;ZlMqkl1QYqK/U ZxC"ҶF]Śm~r㰢<}2M8Joū,jRnݍ}_{\]0qVF˸kqŦBK[f&.5f5_+̇?qKQ>[+Ϳ"[jUO|W:]ew?<, +nPxQV^TaJTd"۴Zjf7NOm_yqgӬX>/c5+!lpKvԿ5cY5>ḭNC(nMJvF;aM<5LGGQF? .5nJ_G]$߯ Qw-2uƱENQT/>Km.<3XCCA ;-kHY?ś&f ҝ.fﵿǯ'8NJ2Y9ted4rEV~8g2h)n03CfC ]%̿Z:DnTq^,{VǺ:88z<ԫ118+x9-Veܷz}\t't* |O:wpz0F2u/_3k7<;&Qx~>UQ.mQ4qOIv%c8*KY%oφG[~ :˒X{9d`Y~}#`ZLryN>6:]+Waܗ:bPKFlhap*uOGg&'/HuydjIjq/n(5z] su]γ68UG!:;8rIG?,Դ瑫|F=E^Weu“Җ#M鴫\xmNjo% I=ǏWcZ?dxtYOO6ἳKSej<#ͦsߴߩsMV\3jsk4~F]w5 )O GIz[_ Pu\:6yZnRn,xe`)%)]W.kHbiӜ$lO ZMVŻUv_x7>&NQ~ORx?t̫sMwA龹%ysJM\Z G&o>Kh#_>BBz,Iƒ\m9M>>QOiKdΣv߫*%6FYwߪ55>#ku]x5eU]˫ɏ_j9ϳ^.aOޚv9н&>O,lI)pM[ǗGꦾT]d#Nїkyhru*~\۵k]pn&j?(rJp`ܱB,k&ӻmz)eѭ[JKo2 C厫EOFU.CgٲrIcm>]>Y%I? oBzxq"wrPHcͨˋpɃ_3Ku8S\lJt8J?M?`mZ*ǵj?.]<\yt5]]ëʢ9Пdmm.,'StYRq]ko$6\JS-^Ц 7]\6L~',rr~v!s .=&Kr'fVͫɫAeǙrf}~J0rRXӻkՖ;ͨ1BĽ qC}^1sU)9q6߅[~?y|!-N,kMбƓ_3[rɊPi/A2-UKELJ"F4Y}6س\і;ti®(mc=gO*aO,Qg6ﲲIpcW9DŽ`ZCA{4Qn[4,nK} o:t}tUNsHV۟G~bNON]w(X^lM捝E0j!Ob{^InkWgVf=I<T&Zm8KqM|FGF 芥CL,2*ܱ%v(6-&}f2J3\]-Sa珅$![~Yéj"_zS=V({oԢY=F)dXŻ 0ٺˋPbY>/mUgY~}>kQ'<ӌzZOCYb.>~,C[-Bk9ydg e|)dǚ}IÞD7zmK>6[xCWK\'m#",W-I/|?,c]2_|Ecj0NOUm Vsǭ͍Sec|4sdZڦ:#ɭcNty/SoNMOiͯ4kԲE ٪Iƒ3g{$6Oh.g)I/Wtt}%\?[,/b̗&zaPNdy/hB*,TsZݓ6jÎ =/  Y*ƒoe˥}.xId&3e8MZ`F/3w $]WɏjM OǑiJ1%]˹{7%%MhMMcV'Ǫ%<8RKѓzl1mIѨyE^| +BJN+ywə𤟕:eLo + +KV:; +DȨ4>-IŖGP*!1 +ȱ3_RSq+Xw46+!>aw?[.wuA@jT N!Y.|b;b!ST'.!7۾GT.;r'+k*©}ݍ +MNaULMr[zf(J"a=oP,r đ&>#rlO]wBqȻa8 ._|v~aܾ"n@݉;>{<m"Qmy:h{F<4^9}LfdmnohQh\?R,15Ը[ߨѾH\l`RqE 2uإ'ك͡j ;\j"n>Uĕ|Ƙ9 *~n>B!uJUbN$+.P*uF&!PYcTY4*h?D @$ 'a`X05-c1˩u%lQ[ǢY(_kz$]S>PXot'ї,c/Fͬ%(42vؓr3O]b#]/#Y(p;_*%;6lw>7䙵ʴy&1V15Y>K3>B\˙`Nsuݕf?k_N<>MHМNR%4=|})Fڵ6- JL^ATi=']*N̞_D,t&t'&; 0l;ڭPŒU,SfK4 1cʴ_j|͗.L9$);p&GǬ))(ugN`Zo#)/h)MF}яY/&Y(y&9J.զt^(LQ2]]VAtҠ@(IIZi@}q"05bV&m~X-5vIw#c}K%n* %&ZmwI2FvLt%HS5$+¨(G)4U$Zv)(./QK y#ГaUJ $ăD:lV: ]⛱H~K=7GP*ȾA1lLYy b0@hkH*ð$ / JjF pǠϙ#9b^x3Gx T5Z{6Rmaœ$bcq︷׉FJ80ڵӜ?.Ym6*fjw[6ܝ(ǖH8bcɉWQ׸sLJ]KE'IWϙO%SFmwˋ6Iw5yepŹbTw]KOޕ5hŮ-<pW +7v/b;2U$Rh9?\;vHTI+y o\qx&/op>hu$U+] ,J9P~K-f:8K,+ftgj2f^HݼQlԧ +!?aRO(Ug rUis,2Fx'8y/11KRiqnYSev_iitryFSmT> yϋ4L),`QJRtR,m[Hۜ압XQ6 jnn<.l澎Aj`kS/&^.6K)^9uu>ļIM)G.̫xMK74-ubua2żh?HwIMC9⥍Z,إOSn~% Ǯ J-:kqݱmmRK(fiM5.ɱط%׆]Tn$lI~@ čt%d{P*eݑ Bd[?"i ] ƅCLV hR`W}[cIMI5}yI+:,n^R9([nӥ=6O?jaΏ_h}"gcKJQבk T얎]=5*ixKA.?g )J*> o]tt^rxrE _ʭqn<0W\?k}MUu#_Fh8'(2E-+_jY%o7lMyj!yu)Tcx~7=^LǍJkl8(ERqG+{ Լ&Eؔ>rK,/Iz]K"_ɗ_ӿ/i$ŧ`ugA123Ѿ82R0z^\SgA4uz\Qy^ȺRK}w2?A,2ju\zk =6OdI//+fn:\sWk:-6(I'9!wÞ6; H,oq\uغN.OYO_q4S=Nߋ,=1Cś4Xjch0.ЊFt-Sꥸ`'!a4e˄ho4YV(Zyz-?r)y6g[L#54}gi飥ÏRKZTsGC&, nI9p=*_]ߢgj'8=wIV,NSN?rF䴫}FKYRm*㓬{o&H.]K}ojYƶ[JƭO%uW{}͓p .^oS쇂LzxNQSUϙ j5SIi_(BRJ.F"Jco›>=WTms*4{eɑC6ILn-s%,o.,+v'ypb{V-^&GZiQ]]ZmObљa:l**7wG, TTjoǛU(իfǍqGI +V^_5WҼ: 6{|/ok<\TwܯɣZ-Gv/KUo<0+/|Mc\RqqiSM͵bI7Lvp(G]۴s~Cᇺ*{Wx.^6^oFYw JsҾi"s5yqqnp|Ǝ:vN~߉2B+GOM§O9 +(rv6-͚{89.ٗGS<䝧?m5cѕ7MnC\45Hb˹Ğ{ƚ8rI漊~&ᇰO*Uԟb3pdNYr):Jbڼa)<1\ͽoϸj!ҍB sN[ $r/ :q,RM9I˞<>6Æ.}%t%IFQ6ix%W-z +9i˅ɸwVj: nxqj|}oM0Cmk+KGxkS>Yarqi$rݵ^֕˧ɺKp~,ri[o֛ 2)QzfUu~eŵfsˑI}p2moe=2듧d7=.]1ocMS(BqR|K 젩W9W˽3{jʜWM|ΛlǏdE5E̚]FY" \ +ȱ|3Gĺmw<$/mda qmqmzQ]{1'%F?kPt3):c?՛mÓxԜt+:D|SjqkY6HSd_"xùdbʼz,_&]^8ڧ韲M%(sIiǝ~s7Sm&yΟL/д6ߓU[6xmɨpvuuœL~vUh7#(kmڼutQu\;&-VP+rfcl'ݯ+2snͪtf: jr8\Yݧޱk75(M}K}>-;ŹBWFySo2Uko&ݏ6?s\㱥igeK,b +ui)emP,6Y7MGֳ'W}̎ Hnt6l2tEu8=>97jR"˗}M7%eߏ2ExE8 l:xM}<)u͟S'Yt9J<\)Ɋ,p5'9|y$ssҮB=3FZ?V`99p.M tdN6gI Tɥ˨⧒d<-ɧ8SktCmQ\4e$\d.ĮF[dɎI,}}$/yX,RE^ԩ׭yW:q6G:]^S~t?ig,Y-tOZ׽m87%\/vrzxC_'G#}xqKM[jJ7vZ22ӌRVF}nz5jphFtq\/3`^BqƶDz9=}uےZVQrk饇6-)dr^5<1o|}|zf?|"&jkU ~5ۣJKE mFc}4o"N#ɬ[9_ߌz]$')T-RfާA uI7. d9d4Ϣfũ,ߺ6QxZIώ827mRiNnwOGgտ &<$9FQWϟ~ɾŇFqw95_qĸe-K$QNߑm☼\Jۋ~gni,uϩUԵX钍-xϻE<(V,ry.==Om˄|x&.:<1|4Lku6%Q(C]=`´(I~NO%.,Cv@\W~`v_%F=IzʺX %Jr|?-O.Yuf+];z 9r$`I| m(?A*'@\.&n;%\WQ.*D_"8/IqI_"NVUR$FJƘנwv r2)>BZouP*#DPȱ :#,SrV.\1C|2Ch;;U>0JNqĺ^}=EXdmFIiPtVdFHbqtUr}KT>sE).cP]Ri/-goI]+C|ɖ8Y7PI&I.[}"ʔӋ]F"!a^BB^#ؐMb]riEwm(4~h}i +q~[ _!_<9cZtd<1iÒ9/f]"Vky_?PtW|-Z$b$.h?PH;Q]XFf p;JnbkvLJj^W$4|x!Mz:5 ym [ "-W$A Kr].W|O(,I ^@IP](mI_dMLbQho>;o>ؚN^BrL+P+'dB"6E,W8`F5ð&5;}# W|y +Xsť0dO/Gn{\ufX=V=JWt&LaS_izŮ]j c'\4sGHy$WG굱__w|M)~q%fYni:ե2kq~SsN=W+5>8`r+nXS 2Un)2Y$"=>p5OAdX~sɹEeL+E).n-G/W[knZqJS ^<S\#K%m. g&lqau]jCUĢؼQ3b߲FoGh}eh\?495?S6qnf?C8vCYS-n=u9E9'[ڽL4yrIF we<='ѿd]MysvkaǒMΝ 6]+߼Q&b/9V.TarnJyEۆn͖iBO;/ݑ/`X>#1jJ-$s*_U&Sœ*OxIa6uEK]pǶ撌}_):My?7y]xKi㜛QVgCwx%ԗT`xM"RƹO Ś]éBk}\p`}y1t4^ 89N[K.tzk`b ^H<L#ݒj#rcw%LvŨ-4%y1%]iJXkhebORjQ:Hc}'tyЦJuTӵ]35/K&X(<+xµmܝ.{P ? +u_i}W4E 'Ⓐbi[,ic_cʸ7WR}ۼAܟFܿOfޣQ ,^\Qe>MD9&^ן>3=NT1)|5vm;(!ė]E_|7idA1md%+ck:^I$:žƺ&oiE[nڊU-콪~%rŮjN|L;ji7쟱mw]fͯǂq9(IWt۬2}&M-t[#]ZL,$])]QOh/gUķU5ikrIx}IW?33deܫ<'6)62[~<arM nQDzczmt,rsIp↙N,'w>l&rRw50ie% r~mzmY,SI9'̹ ,'5]y7v]Ovs}j1Q'RKCqxtx1sY\{+Fm'lqOd/҄z']]PSTob9,*ՙg:Mf,L:m*ߴK75990Ԣ[^Ej,UM[ jk|X+Ǻ s}mRJ>#gjvP~thqmaPtvr;&xɆ +9~4_W~U|oͩhwSW{ro/{_ju=Jxg9 Qj5y$\cԒVdNéa+nq-G tKʯig겼r}ٻƗI/Es׎'9c +!O_eu:VՋS i#\%ǑL7mNqXծ>vXtX(')ݶfgHR~8kF:tGd*5(j|S:MlO +.\žۥ;4W9GO5QM { )u׃߄mndJ^ϕ|LIH Db8N*Qk8Ϫn*z'&-MtqQn +1\6&̧.[ ,p շe_q.#IM]lx{D$kюz,cԺx76Z}IEmZmjY#7 tnߙjk> !(`ꂔZ%~|ip~EUW5t[^=vIB xFVB*2XJ><4zf={. C\|;юi>~-g+w烓N)((8^UŊXmu==Vo|e~}(o2o_Zuk>Ei &>;wg)NC)K3.)OQbU?A~IJ١I"7 WfÇmz W&S$kG]{l- /17]5ms۽Ɖh3k1.ȫOO _2W-M% cN +F5Nu_+v!aÂ:pPrE>IGޟ S_KGyzeU_F_|aɁێ)$}NO?&:U1kc7A•tSh/ZGIcw\\aOoŷ 'W\Gog]rߛ\ploǡۧQQNPm/[F/t<Ŋ[FyGJ|ru>LMԽf"QjX}[%kjxLRiu%:MSU8U}/n84 piy>9aN1i:kb/yǟ߶/SV$}#Q}h[ikM$jqKXK4+?ahD\?il Vw:<GXD&.mD{<}u8#=Cˑ\|?!ԭ:MwHhfY9"^p4 +N'Ef hrK \=#g۲QqqM;]ܴKުqfDՇ`u,:0JLwW}0&Ӫ?R3DD1QeTYd}Olky;Jɨp:}B 9485Wrk3{lk}[M_mrkOK?uEN0Mpf)gŹ^>iWه*n' nnF¤|2KKzɖO.c횟kt,thtrpFQ'm'v)oeFm[ՋS\Sii@| 8JN9вtpW(̬=şQ5=LiOY3'촋'E9}!cWq}9tv̸t%ߥRXyCTɣ1mپܲwj#kxI5$i{EiOU`G鵮28&J"{5X5*RcjFǸux7rU^Lu1K.L}v;zzO%˧G֟K-_ɒx7}4z>eq[.7IqZ-&գΩudI9F*,tŭ 5,b~K˱o;LwR%k8O4w)CPE6\o:|)_K{ӼP$~hxSMI+كǟXqrjWexrQߏ'gLJEͧs\|޿I$]W:mGS('[Ey~Cy+skfzxOJʟo}:q,x#8۟ .<|Y+UZ#IZ^G7Ա>ͨR^VT)GCK=͋ IB/R/|iuuKŤhaV嬵ߦ{5^ _IsbϷJ?kOc KF?hڔ k7^|$-\x '#)ZU4KSWNWMzgqq8Z4Ǹn8hcX$EQDFM6~i˦z@9)ERGatqJǻxLӤɚ]Gk8cȒ+Qk'z윕> ~8-NF$e)F5,{ 0$y#o<}XLj( 7ڦIV?5t 4m.,Y'RifwSN5uɡi8cG.%=,7=Q)ƣiK;<(&n&|UUL])/+o8"&^xC(~r5w]D>L]\+bckp u .a~l}OſP~_% S? +Un;6tsO}yztռx&mבƱW R_p{߭o&>+`ҩR_T5"79KN}OId%/"8Io߬i.>DcEKJu_5_+̍FB}2}'tj]:=mӺWDF.5.7P>| ?.+.Jw_|ʅ<\u&d_,,]PvO.A_'Y=&(5u%IR. s'^)*>DJO֐t#ۅ:UҺ\yRZYRd_cI%ВQIW>t09MzO4X^(IW_Wg%,J/y"jXI/J6>bQQ]4Ҹ"W y. (~ >CMSJ?]5(pjۯ#o%_`WDo֑7?R`.$zjh?(kOF)41PI7X[K! 'Iϊ9I&V"'$ףVBUǗj^nr:zUvY !ߊXB:uPI/ϊ9L⤾*Ň0~Htk1a꒳-ϧRKJ`cbJ٨v? ,dŎ8ԕǂ8[IuwD]Vtߒ/(XXGTf=FNoգ&8QIz.Xcmבߋ"FdɭoőlEҤG%t$<* S]-&t%W v#})+C%O晃ً "FlY\0:i.˱>䂓kbIIt0cqb}q/Tw<' 75_k,Ϣ-&8ar)!"^BBLrv~AuA@Л4XE|R3E_`|lV&EP:rc@'C0\|Al + +CL;8܁k.D6@b&B`W`ݎ +*E$mp8I;>—T`b4x Չb"|wC"$1w%$ hI V+0lUC:B"cq#}LiPG'5ȦEqbCurc`B@z 5ϐ!ߑ !J5۸ >Öh:hLWcH# *O6)/"IzI0AatQcc +v uX@>DR9Km XoR3E]5bdA3G_,P!CBP$;&CqB4;>jev^4^ϿEjcIy]- VYԔ?eZ$kgt% +^6┪Q?40f8M5MgTxRuwI/y4qW\onɻ`/g,N6U%v֞qQ^vc߳e_vNYb%'-)&J+ͰY8E%]m$_fs.S J%%kj]Y$tb$}6WW~Fwʹe: )/X|IEzɤbub?d ٳG3_{gl®MEvR1i_Dӧt[Qp-&S'aNsi/W׆TdKKQ<|mVnΫ:paSj1O&ʿh^r{'k7_naKM*rM$S}7 8S261Qi杕v,ZRUǣWq sR{M>Nӏ0ōF?,ԽNnto1tpF&&-A)Ko|.E][i j=JZͶaGM5/WRnNCޥنZNOtm^=WW]rK[i%01f}0/E$3]v,oY"6bWu۱sy'$~Mc/2e78TtJ|ŦQpʼnO$T*V}o=vmF-cu)_ci$RkֺOЄfqM9.0E&}<6. E4 dX{5%ԼZL4ߺJ1'D55~iƮz-$bu$Wܱ{g>y2H:贫.&/kǣtpm}]qKVxxksϢ|M˙:YEStn|#T2 )5fITUǛQ ѕS]I| Y9\);kD}ULزIAزmSRxri,7ϕW}DSVj Rm&w$һkǚ9' $RL4nGk^tF9"Jj,P6 U'!I.]ñJժ/YkR3ʶD[#bb6:$!cB|Aat y  0N!U .Dl27-]Gv9|6φ&MRUK̖⮝Cʩ|,pX('j)[vcXՊ.ķN9x7e6z ]0Yx_37Ҧ/iN>8 K}M`D vz\\c/ȆHQ̳ŧGɳ)GtR5~όqˠ}0Ҭ<5sMI?̸͡mɊsY:`KȬ/04ϩ^˲t3iW5:oOl#Y8-<#$nZ(ws0 ]yS듶MI<7 Y;_U/%FËqZKXgڦ1oaj/nZh,[)˥Xx}&y zpڣƹՆ95RW';m7KX4eצK?C>M>PNq^M5xѧn\#dӄ2\8#k[=hުo͟ G\8Z2}[9oe:;1K}OW=tϩkpٷFmX-V.t{IԒ͏[֛XŖ{188RiEЭ,镣9-M,g7NcBuޡF]?^I\kEhڭu w_^FQ_cK}>G]+Z/'#]?FuP—QI 2k^0ѸϩuejODKa"S_;g._6NvVYKOSo1itk5%З#O}:n5i7M|Qo26sN1~`4[Vjg RVGL.xmȫ1nTܡ nlV-]t,$4w\{~?-f9 Qe}]fx_[7>>(ܓt $[~ O>qlT>$]f&-/R0X\R6ۑ{[OȠ#52w?;{7 (L-`)(RȜnX-+sœ^7ͯV&C$s(?'>F gY$&6|+g^L}Xyx_7qno>l1*v7{\6 O{sZoI[6',9O*O"!Mmuy;^ٶK䌲')J\D5mRbY`˨Զr}_ɑ+|Gazy>4Q-V볥Px.{ԍ,|^:ԿS5w=\'X>W3nZKhsoL^8Y%ezٳxO<1$So<_ϏQn8(5'}32>pNM_IfLZm5]78Sur?KenVKY4a}1'biv}2ws _Zb/ceroB:]&쑖Lnx'Ճ,m+glpsH9?J޴sCބ"h>uh!Aq,hKRaͺ8c{USW[ߗFqoW ,i.yfΧO8i2^)խY sOt~ =ty#骝=,>-Bt'#99E;mV)dZ8m?Vfő4wޗbYNJP-=uɗ0E%DܵiOe&˴yjͶыMZ ˿1wx?9!ig#"sOeWzwwmhuXŏ+(EӰ&Ƙ@$ F.Wq%%!URYòR3ETiڇ8>Gt r;@Wq,I>1i~@Rcp}Q/x ^<5>.ox:3h$R]0D!eԗK61EPHF$0d9X(EFj#_]m''CmvYcu}o>Fǀ|MZX`% \&W!c̤~&\kpƾ 8XRO#gǚk4c}Qs^iIi|qSX˺cN:bڤޚ_Sa]xWZEN߷=h>>f|A`Fˋ(.kϱa;^ # 4}ٻgɞJM'KAŹLKl~+۴GL݄`[d)+銤^x~_F澑pzU8P[^7Ҭ*jiˡ.]v*g׏Q&+|l'y5_AGhx/ianEm.r)Qu"]Zly[Nrq~.c|em/%= VxuŸh2O ⤓k7ѶSpEWY211'nz/ n0|-O،>5|S[:Lu3e͍uK +GO(㌒. *^c-iSkԼQ9?Lo 1k̴O51C?{R/Gjc"ЛYVSM> M-6Xb\<=-re߁`GR5fY=O*^D/O->)u}_.OcL8&G2m4G5>=-Wpy#3jJJox?]]&LT1Dž5QWd4ڭ^9FRoV}IO]| 9dϤ=^WYc+G-M~=YǥR;&l;ֲ<:ze)r)m>0˓> U9J :7dQ˧&ʟejrN =b^գj#Jܰ=]tzkȢtzmY1ꄦXnzO.I{/mVE?a˅w~XVUG66%Ӯju^K.8ռt}":(lɧr)ocm7&Hӛh|}z㋧|(ɟk/(f(ɴ玧E41,Q%Iyܫ4}Yig% Ayoz> RX)Gx[u:a4mYݿ\1)4ca(Ю/y_4t3gҭ^^Qx w~1#g[g!:x>ʬ'{t]Iyϱk2viy5doE7[ei>>cb{Q1~8n0Wjg' 只Y]E'vWN,}J||Y.8ޓU694GI-Tpi)ts]K3_,|o%nlr67_\OM2W&a&!?@ov-a|R3E_a%bEF}|ԉ"H;& +/ d"Ƈ@*ԨvM6b\tf^,xM$fbZhpU#[Q`ˮxҳsV$^Kt]ŗsW\Sqh5:Xj'ZdRiӮE$EO *qTSwO2IdS{6C͆:d}$åڰiPޢ3G ad?\~Æ8WD]T(zW_𫓝޵ZͿ?=KIZ+wLi!xq.J/cƱbF4wߤ[K5˃I">],zI)%y.0PO?ug_I\xFPT5б(GyWe*yyv%^*̙Ӕ";Z\zx9gU\N:S*ՓˍfDq}q B $$]VӃXc\8pQlìjYqMvmrgY#(-q6=>^ꢍ̩f]3JI>PB* +$ XzV6M> {H゗H8-A%n*tnI˻KgP'UL8M'>Ɩ`i^5 q]]ᦄaTWGkXiB*쑋[Ů](Zm2p(.ؠ*KzM zMEbJI%. x4ۄT\m.3asrfմebzӋ ˰Eb(tZ Zӆ*+q<\&SK8zn~S*xWI9{G7Ĕb.v4bSvGot[Hϭc.S_+0v\4RKE>TbݴºMDGZ`PQ\#I *kTz%K SS{7!ǖ*Q~LGAe*1F]L._# #tA(y=>yycZw,O/ֺW6S S|ԾaN ݿiös6M \z2Iz4W|/GcGV2EJ>ȗM%y4(i8u-fT{Zd`/q~O+4n-z4Qos8&ƧGR,MoW>㋗rl81xb04PAȺ8XRxQT(投;Vl&SET|%'YgREvo isAbxGpnσlo65:xjcEJ>CG.^i!Ŗ=QdA(ERKnR"?CYJ3)GfM^x0N8{$c!B)K'טiXSRGrkZݻGǫڿ&lڒijj趼Z )w^_!_qh₌޸ : x,N}ߘkvz=J.^$ϟO94RQj-]Iek>ef +7&~FVX'/^ͷضц*7[~7jz8Y=V:Y]%”#RPUp&ӱX;><6F|B-a|R3ʶ%@E&&EêFm"HaC] ]DWb1Y.7\PX!\ +cpI!.`br?!&VE +U& mخ«+X'MAQl:H'aAbNC?f(p XҾpFiЪ_I:䋗W Co` t&I CM&P &hEv9rUtC&ĕ@!جhU]t,]>aa@æ h*r`t%%I!;_!q K7+ ]l^`tFm5A݂t)Iഇe?R3E_p25@ȉb5wt?I1CCN!vIؚQ)[d>*R^宎o>8ո75&~vI{5&oBK'ԾM?Rwɵ$bee֕;}sf?i ~[<9$j T7qyp͚i[̼5\ZkANGRԹO +RPM%t,MMuEP_V:1,"wGHeRKv̓GMQ V .'G\'1ԦדF &$\zsdzXKQʮ-?}7ϑN9>d^I&uZfˣn3{&6'mv7d$kh+M5vƺ_E5' Ib2SRmjYcNQO)CAcR8\#iޚ`1gG\z:r/fR|E&SթqߞV.zl55n4ZV&MJJIz~!Ѧ%?!$p\_ŤJ5>SMzd[2/r>.5Xxt\>i4e˺QMy8՛~,7=.xj1w^O֩u6dWɦOPJIyq}IÛ"pסE=| 7.u[Oy0q_ ձ%Zk9ntY*Iԗeiu3ax&n{$(5i 2 O%բӡ7ԛMJI.x$v*b9m/];t|SJS=&.X:"g/cܷ\1ts^]QVB%(}N '%M=^'xKڶw3o״٣7Grk>{݆j]'cQ52Z4ˍԔiՎ]N ~uJ5oДc|*6 ;5vX>v:]I-a|R3E]'`E&Л"$u2iqC +V0\ c+IuPvt4>veҽS˪C{O۴Y>Ɇɾz| +/[ƞSB)g]~zO^]:XA(Ǯy(\%JYeɴ㟳;H}Pyq]ҫwE>Ͳh]^U<ꚬjƗTfg{QSmY?lw7H/uTrjN՚F'Hǧcn¯loqѝYtTޝ',w]:OW.4WُU&%&-6˟99e.LGK}>hҗz}{v^񦟴ʎI$qe4m~,3βnYvǛS9ϩp#7=_oMQqRwF<źܰ&tVcτiNꋕ-7-;v)ÉQ_Œ}ԹO,չu5MS96sTvФvGjPɒk 'c*:{^;v$PMe_acj^FJRm;/<G,oZ$ړf/<},}{ӛGz\\rx$Rt]F9n]P$u1mݷN$4oxh˧ŋ Ol"ϣfu5cG!u/ioO5w&qmDm/,Ug.ؼ/M){<IwKKK )pbYr \=485'u/z}/]ʜEΔW͍] \XruK,|^qhK$ճS~[6(k\zo}#liwԺ#ߊl{^%n1o,9讕Zi8{ tk2aϓ:zm& k4YWԚ :mÑ\sI8. zTv}WM$cNNyìc[]j'jmXӧF}qzYN#˓iQgC{o.JM.[3[Zwlq>l;&MU)N %>eFzmQ/OQMNe'"M)LcǛ QID5ÑG6ٖFIio$a&^ g~b3Vds#g[ԷMYdwMFRro -mkW81ǟ6ilI<Ȫ-3Ц+|TGk8>8³販y+_Po=O6i2gyc}٫HêY[W9 +ޥ<൭ 2MQUN%-\'%tLϹVGK>~HźlZz<W寉ěD7je֔O) +) 1A*@ %~bA܌kR3+a2, -41: +~ zC|abNsI_(~62pui +z?(ŻkKn J_I uӚ.N+yIYTaȚqw_3wŚU -IE] +c۵bFii:W +QǴ]~ Z FUD`E~p|tu̟IpËX]E_tPxɽUܚp|_]O=G6nnLڌQ~)_!xC/ dyKEW%'m:kM?5'_8?e͓]+(NUn {KW)(7a2Ğ!%"ܠE"W3tW,Yh7L[WCW7*#٣_ڊ]:mO4o#='-x^5 +ǼjݕBt]&z|uӕ9J=CA^|ʿ;|0SMErq.|%I&kqB/p~=Yd{?鿻4iqǭj%jicvӰ;^4jzF3YT[gH,:Yi%) > 0d>˦m/Duopkq:TTU9 Io](0#ybqA_JU| 1$m OKqI9%͎;L}f[_QܸXrfÅbWv<2SyI'?Zϒ3#Jb٠bJuÓ ȼxOy"ӇdsFSSfOg-uf RAֻGl:\4|8m[~=U*8cWv.=\JP|Ex3IˋF9ozc.o${!%JZ' :qV1GO潤\qOO/ba~FQx44sj)EnkU%ՏJiz3o.յ*=*7s2lśE. O% ~|>C8]Q G&*MFX:Ӕ;$t>W\?QxR[K.߫}9FOLc3aP_zmuN8$>~fV?<hx+p 95mw-J畫q$KǺ?h1`Lh>vmwzَdM[_WfM>XO.*י|9OcItux qq|R8cnɋC:r]˼N0ݱJN|}rOO TmÍit|O 0cx(ˇ7 6e2SĒoG;qpCsEwqopǑF-.:▫XMBUVOO~ڔr9\_Qe.LPy'ђ1Iŧv?w Fd8YvYCjҸrCûbE_sT~W>2V,_1s-^rVڰ`ܲVepm۷m1KJrIF2λMF1JQT (|OQ1}"q-'] Y]IgS깶ox*:MXB'3gÏ#">*O9#ΓMCW$Z GFH;#R3Ec`FbKtXM$;r:`~c`w`j`!B|iaŒ*Pt~çۣzSv]Wt{IN^Gǣ$Cߏ1JsCYǯ$3 :ӖXE)i06[P%jkt81%oɣ>u)i8)?_Wu^=/K*!CGTbyV{DKΈnN+x(L-4PXq.Dz%nZ]|\I׷2ft٠K\#WZ z~$(Fۆ;]==8x]Coxi|{F-ǧ;yr >%؞ߊx֚POT+p+E^bV[keJJ`미xcK͗v~ +a]O,P/&lAbòD#bGQ^J0.t炓^~<1pXO\Ĵ:xPUiuTm/M44qXEF+tf-۵b*)wIoUҽ9y{]yGQZ.1h8IǥRgqC>?Ti&v\;T\0CIͲtuɞrJ l^ +jK x乄c(A$kn;^tg]xkM>XҗqΛsR] YxDFy¾3kYFVi|ҷ%URvoccǦ7trWj%Ӥͬ[M8ǍFQT6?kr@=z.?>ɇ?Rs]^ۏ[('q~t(,R_M&[]h6{T2Zi|9b\Ze6˯ޭ\{UK Z 40XG*|[LJyxut},`W'o7x84OQI/ENYNu߰<;''|YbpÂ}NN=)n|bwo6bcϘS)q,͏5w7 e=QNbPCW|~N^k}?{qEcJ1aHjtEȔOK.i?%'Eյbڣ%a RU&3j:H,kNª%2NKL6RGG EvF*Ycff<=Ew'o-3iq!'(US)_4iL=O-u]z<2ZhG0xJɩӵwJn)A)B-S:6ُM9fjy;c&%.WwL4}_顥ƺ`TxK3Ga?Sw(DžHmsljܟ.ՏMz*Nz$5W<^첫W%*@\|B77C6$|ೇe?ReқA!lO,BOrXM~&4F iX  HXvb]r=ð:`@'amnWP]Aې I *q_rT*ĸ_x.[\6& +ƹ`ՑbAM &ؚDt&|p>aJ X r6&\UC߸] + 1WV1t<&0..x:D}ۄ'*K. P#0|ET4{SBW 'KBr〠\Ԩ*m r>ABj b B4 ` +GuYYiS\Y\ .&Eq,_Q؜Xn4;Chi`\04h,:FՇ67Q&F}/n-DsjV?v #i1ᶣԹf\۵QQEZkGB|ra룷㖧'u7h}g1c?yž${g,z3u4YwdCtؽ +#A.;k~^ +2dW *pAǤ5I‡u:eA-. ҚetAWd>1 s1nXmvmZ*4I}K_x풆zW^F{]9q;떢X\á Y̯j}^r\~EL5J9c|Xt!uv!R\5Pxɻil}(IEˁ5bfms:N?k>ʋ}vͷ}~ѥ:=_[\YbXq,?TX4C4٣qA%a(Fݿ=V61N֋Wȡ%6MD+ 53cgY^mv0`,R~@>K$I:bn,\jHv_#SuЄЈݑlL]m~A`@##ܕJwi`FNoS=&3'A}\3?QgɛIG4mpUxKA9s8W:3iuu~,ͤf).);*mu姝S:-.=qVv|tO'dW>YLOqyxI.+]<<`)U{ 3Y_TMh袺y9%c.lu[Xak]k/w=daĤ%,_Z}|mJ0m4/ } ܥ[|Yi(]0?7Z"˚q T_iVIOtM^)޿#iKv͔K]gj'fL+_%7vIfjWYU} 2i,éR%˃sRR0{ǚ˦aNKHFZ^MK*2R}V;^tȕ#ӧ>"/kChd9}ߟ"J,<|j4١.nQ਽~oFfa{)q_fVǤoSJE D5+RK-?Or>1rs4pyKWܛf9egF.ԝ\vֵh?JO0DSfT؄%I#o`Og~K?iqꄛinyu:&Gnz[_vO7YˎK4il6)c+wkm^7ǸebQjjN,65ziuvL~Nj/uhĿZ3xuɟ>=O.摣]MO&5mJvwv-Ua?bzܹZm|Yoyd8U1n:{~ x+ݷ`6״8MiMZjIPv+]T=t3Yc8Ű5^-ĵY.igf[Δ-gxjtQ GWjՋ3sR2ɾxVxuyWl|Vov55Ij&)v8mڍzOVߒ-v.G˓>IK4Dox'Q-FLM;oލ xX:t/oSqGsF?/JS?oW}_f(-E$eMz>L>m4rr?›NhϨ`$;~lm2<wDmf]T9V/u&eXS7QG◌5[kK5\S-6y1KEx9jk1Mj)i[^VP ]zK˹xS6 xMFQ!Ť1䷒q^Txj}onpq䕩+Qe\Xe_C.MFy$g̮Y'ܯɛU3qVߢ);WjL\z~%۵u)8F]:_xmZ_GȗOU=Tl,We#c.3yߪ:5Ge6zy<:u{ǙtY<2iJ3x/M*+ѯFMd|J_eUQ&i3y5~bO,g9#KeIvt_{EOૄ{B-.mYvKr^=}^%+[&/(Ǧ0~r\N_An0i[ +KٗŚ|c)JYr}kw ~Ö>OW$2+D?\g<q#.I;U͓I99`q&kegrNMw|YCKM 'pY%rk4=s˪hKJ)~#V Ҝe٣?HVMR^4bfhLn0EÑ'ro_kM]+ӱӸ?'`+ +t'9K_a@G7djqZERS"adjȲ"cbJ͖Ƈw1p}+ hOƐ!6Ov&rIX?:LzxG;QkrFY=L*Ydipe>D4=,V,J*+4Qn> +$#FT`o6񩟅tx:%m::G4ZqS\N;J8w=F,t}wZLFG%|Ze׈BHƗ^I%̦񬜵)>ZuH9KkR(tYF'+-Sv4N̼6{6鱵wj(7>.V>?CO5sI_.S$pm'6T9orT_f8'KÌ91?n:O'._2O=RxOCau9WJ>8fG^K +&/?OWWMU^2m^ ξN>fgzͷ6<^U>?x[֩`|?etrK,)Tc./=IcǏ\KЯE4|8z6޻EvlkݖYF>nKrj]|z=(>]_K]nx[9 nbu [QѯNjO{qGH^mۮVN!8t}yqgMWK{q ѽ~ٟ{S|7drY`ڒiYc:}lpaRh+Rcf!~í_5/vヂpOڌϚqNJT]&6&Ѫaӯ,'ۮܶy~5'|aTt_9~C^5ɨ$zz3{t߶y]FK ŏMaoߒ|-l;}\+qKwq[Nimߚ1yÑR|~9׭&$%]YLW'ڰtv:/?Gѣ?q֯~ +Zg-M[㑛Eޅ~?tzIdz#63v=M^KrRqM;ŷ9dQދ}]ɗ۩jq].]IU =\Gu{NZMTٱKK|IxWpGSqu'gIig&ܲs~'w"Es w~bWWS\Z69dmX$Ҩۼ/bN].)ؗ0izHéIMʟ'9-χߙE_8\mGizW?cSG Dg6#+ &yۊ6:#ڴ^+=i镣,Nm#ɊXT>]j4_|"yaw㏻m+'SzH,l꣞1Ƴu.gݿgK2{Vz:MC1D}/I^F,&;|r|IEx jeWSZMQ ~/q^Β-+e`j|#vxw l-*fOszvqx;wrov!`J$P !]BRJ +-S"&.D"5o=Kɣ`$>ñ4`@ FP.aZHk`e]Pt=/O.$FSn?kvr6ڿPv{L^cҾFӲc(Oݳ}psi%_\ڕwRO%k"y1X٧R_y[:HFQ\Ȳ˱˧OUU 6qbM4vmI6l&-2NJrwݓ,53Ojfr)G8Zko7+r]pR&]m[N-+WڏiMMSx1o87 O;tiq-,j5MGn5_ IY+ރc~ Ҽo}Nܤ_kEqocu_mבf4we>;IpQJ3˒y]7 pj:Aciu&μm ZJ\{3Sk'9eҥ?%,5w}cZ~k)tG\N5\)ɴ}eDzj.W˳Cs>pBo7vo`ٓ+>|疺)IG;^)]l88+w,SrN_n}98 ƱtN]YC9u7KOS&důˏU{3n{v-tRi])6E%K ];4v)Y[Gw0\y ߥORM-tis(z18dSOlOz~5óPo6͓#9pm0q=>V]_Or?FzH."_ 햻lJRS\+}'8qMG7 iYĚMwR:!CU"ꄻskM|}: 4XN:j\z E m>MiՍi_JoċٱPH`Rx]I}xMܧ(^]I~%eq7 ΟY6qw>=_Z~š=/3Gʛ oS-_a٥9aM{FypKAO&|wՕܭbz[ܺ?3;L&#(h2E,J$kg0A%q݂ .MN;X&<筍Tx1'}X[&woG;?ۋS|2uvُmÅTWz ݬiAJ}y$JrEK֝+cOӱCM6\ɤ^mn= QeF85y?|5hnp9w%f[CkEc= '.6mο3o,z}4q]ǯeW~-/pu)h9pZ=J8orfx5y`R|7I;7p2yarNهt-v_\7quuY6kq6Nb_ }cDzxqvn%lXxޏ%Ef/rR˒sQ.w=)i$->81-/x(Pq:~|;Opy' +S,t¨V&l h;MlA[SSudZ Ց"KqUFtK& h% ;\ +$4.Alp„`@o+ `w +uwCLNBW& fXA@@F*6`*ZЛNvy@ t$:vbJh; HB_h| Sv&La@T6¼$HwbXP|G~H; y>,@ט1|DCB\> +C\ +DiE۠Hw ;-q Sem`hD[#$ALY`Ɖvav ;S&li2HMXA,vCHOaI !"UG `^@n1K>GᎦTtsgO V<6瓦ouiv2 m.ȧ-9%(9.walABqoef8踻4PM ELj ^ .]TXSo0~"Pkȅz`Ⱦ%?7l}s[⼑Sz)!TE@zc9#ۏRiV\FWד(iS;dLݛŷkȵqT/"J `ADEm[NLӧe- 8M)7nnJX4Ql2m-f|-::yV+$9%0\_Ȥ='$G_KlWXOoرC,Rny]I/f))i;]J?U 2]-Ů@_Wqwo!J%V-\\y KSWl#Pd3⌧~eMI_Z4ؒo̐c`!bJ0\ b-S\b"Ѝm_4o45$Hd!܏SDi +I &61;CN{]鶟h<-&woղ}Z|'WMSdiWuۖzy75MK +`,j1\q(ZN}.Y]GhdV\mE| 27RO҅R̥?Wk8p%Mtn^?sEgom7Gl87pMsJUŖOXT?qeߤm'J47.}mя3\yiitk_s46Uh2576N>\m;zL\'>mqq܊]דfw߳lfԦ#N-$㒫=|%\yùOdf^D.pϣ7&l7/[]F8N٧C֣,m5f7^tUY4XEVF,ֻAâ({zNѫqeҌbco^!ׁ-,u5̾VlzNQ] 4MN=fا5)E&ҍn4>RrǿAx֢Y6jFw8iN-:(m]6 sP9?#gU34v]4qj2ŕaI%rfϩh5?S~wVUrYtn_4ү3jw=CF mfMwr2R]5%~bJt1rq_#cYnT55ƣEnh矾R~'OEɛZeهp߰;̱&w]D/x_чo2<6MBtt5r$jn8ϵY|h#+ޔZOxm]fz&ۂM LSqmyי}nWK9$ǂ x#3O>.oњ?IY&xM~mpʽ%~FKS dU%m~%1{5a-1Y4ڵ7E|5ڟfɋO?e$dQjgqftT*|cԭf +ʗT7}ӥ4z"oR]7j ;ɎsQ(7.͂IOSS?iW_co;ݴN\jJ_4:oڨB2k,v=vC{n~JQkrhq^WO<2{,1Qˢ`ipjqD5|_w^<_Ur?TOoOWmx/x˫ytsʜQ]px6Hi{]ZV*yUNjyX:~:_a.,NL?j.][BMO<]JI}Qx{SHG'D!nhuYyHe\7~$KjumuɭejX+I/iXJRȢy# 0Q6ZQ_h_8{g,}5w:l=9!'1l'~T|۲ZZt^|% | q"ǒI*ދ3S""؈A5雲hqBG4* X$ NK-c/gI~z]3IKf=?1KQ憧'K~^igxr$jN]FsȏCKfۧz6O8zg6iv7JеCO"sK#C/ybOүO,u,sJ>79Fw3?\#5.Un6WP͎k-o2$I]ݙ|![ |E/+6-ؾ9gv}{,~fsuqԩ~%~F_Ds^ujc_JT0ySY4YFJߧk'ʍtřM()&pDw}.LOu>xM?C~LON3a2_.,dkSқt94Pp͓J%5N2=6IDA$bQǿދSSekV LDXV7!cbWB>ñDHt>W/)8MK}BnWDvmPӦڂh6ۯ1=N)Wó Y6Ts6M;lzI7eIҚjڶ,z ?_څ4TY4cM<jY>4Oޜ3ޏشRwv\&΃W2Ñ\'ej _iz&˝cDZ'r-t>QY7,xb`jI1JP_^&:s[#?&OS(9&7ݸk[\'9ͧ۵R)[k"c8'q|=$ƋE¯^Ȳ%'/i>݌{t$~w Gpȵx)3NyM7}ŶGw$ҋ+Y0\ϵd9YܳK.5z>mrŞ6Tv)[ʽ#tO&7qۗ"c,YR55~Ůg'7]M I4b$}_V{`,y|㳼2rwcŨriKu/3)I&?8gU_~Ũ mʹc1{>3ñGg7'6sնv^F KtL&Q5.:J'ٿ/9|2><_kϏ"EZXCvh;v̹uo39eZ|9w]O53ϖs'ߧ VPrkI?6xoXK⩮25'0va`^dRK-"84#@8؃`ZSem#Du?ܻo +$>;vc@0rU>hI!/ՄR~a}Ę۰Rq 5Ch-IWv؟q]^bT.bՍPЪA/.CJ2C]i՗e/Z͡ba\ *@ uA0*#qtWPb + Il]@ XC)!'c.j%.yA +'(OEݎ\ y MXwaU?S="FM?g QO֋'+v$&TbqzVI(:W ^8`Lm;ƣ; rJC|#ߖǎ9.rκXS*e.|ŰoޖG) +;*/k%lsWAq4@ .q|%ޫ8!pJTմٕxa:6ߴzF ߵJ{ X(J)$z`C&Og:|o8wV*D"أ'%7맿 M,=R,})4\wEf-ŷwūpE4[awebeɷXdŎZ лv `=uω2Jip=Na-JV:||L_u)t_&o&l;X0f~L-GKOˠ}os8$FtXw TtJ Fx5лmzQn0qQcލW\=xsyqപMcɢLJݮ zh8N6+L{z]L4j E rWxwk_3wK*u2 ?!AVi_~A2G R<2S_:]m`'+vȲdpJ|,w]. 苻I6+UA(r5UK]R}C0T̶?S",X] l Q~L.^dp +l}+P +rIIze ۞xc;rk xǣ>R=ZE,9:U*r?#}^x1ǍӜ?Z<]Tʚ}֬㍤\wm? +Wc|Yb('4/w{i.|Zkb(vjcC f$tQxm|x6MCQȕBZ #()K9{67a aIl8JqIZ2#ÍO$F>í/NĒ+_[5tNqq㓏T6v}7?'j^(FR -5<_b hSʲ6{wY>Ƞ.-zxF1k.E[x~Xʚ NJ/S X+|ʻ^Vjm5џwݣᖫ'h_C7ʌhxcsd%wx&oO3VR4x[J229$k-( ]Y&҄W)jM<~8+p]ٷxc ^7^|%dQCUcj/Qqxo%F7nIje':KQM]A>8)FM9{E-G^ۭVGOG:,TWhVhj~YRpT|\d%8$osE9Ԛ:YKBhnXIMF_q5{eOFrRR1SIdTtҟyY[Ǘ$_qJÇU~ħ- Sb%c+rkȴu8䊎\2\/[Ry=yڿc%Ik'R}WtdV=M-Lr]&=zE^\mq1>ݛi2Q͆U*42SfAu)ϵ5*mqi3B*Y&ZZe׊7mo )\۵>Rf #EKQ_=fpKtqOo٦ 5)Gf-tnECMޟ4|rB'tnl\ꢖXǩJ=+_fk%Ʀ]?:# O(wH7g 4Q(okOᛷM]O˺nZo8KJ_{]9ʦezlY2ބ$~"︖m< נh'Vg78j^}GC,nn޼WEz,q_obfdZu]*?ewb/>ׇ$zsbu%-2- Rv y !XtH oeSUq)d,C\^}M%cӡ/Aǀrwo@I + LTrIґoiqҪ5U7iIVLjgtF1]]Xi3rL[lV F?4M}ϒ{ҽ㖧Zl},eYW.8'OS>8e>})/+(.o]0ۢ?+;4-\GO1Sbsn^\ܢ(6-&,q'1rh[V.,9I_3f-]sCi[:3ZWi~ө&5{Uk_Vȿ~˫׳ӧ{e^cOΓ}ܶ׹>MLHwӳg +:mwnW.>MHɷi RI7$GZgͬ[Ycr}ۦ/uwSfdkWN'Wy{8ǃm5]QfO|?ܑ+^}+&;Vy4'ѝs?i# 9qT[v%JnTҿq|٫[_]iY=tɫNV5f G-.(o$qJw_fx:M}h:"K.WjRtlء,zJ G,˒iu} WTS*xa~\g??hd׿%f]{2Lǻ?OKسݚ }i#(rr_WmȨipq(6>wm_k_]/ȆVٿY#Oq'kky0k^8G5 uiO|T1er5m͛RzVG=0ѫʒѯfo]:98K-v ;XsR5n:YMqXu:c6ccO K6;%ʏxɷm,I{\j]wT~XlI4}zVugUr{ݳ<~Tgrn3VחkC<"֥FbAzA݇q9B#]¼8rO/-S  ȑc\ȿQ.]CA@qX@&סQ⽁K4lZ OF~ xylJRw9柷R">en),rW},: +#Bk4OjwiGQ̞H5_e#߶HoX7X꯵_2ea`z\or~m_{4Xd7lRgɜ֋cܶ[X]Diڂ^I7z~-tb4l5*^Wx¹c)ڗ0w\iB9/Or\HWS}d^1xyOUqlͷx{6-M.H %Waj tػGo hZl+Nz?Vx46Eχ|= ܧ'1c`˦RNRsw-է%&)ZxzZn-MttӰV(jOyFVvzx +N"ݶiI,keiM:tEUG«&;^IvK;Fc1Ei*~z|9LSǕ<ydMٟ>ϓ>IIfR4FUU<.{Fo_&45lE~^UZ*+]n/Tb;f'ǏvU٩j\Y_{͵鷭FIh:q+6dnډkvrF|^c*~7( >BBvw >o$vͧSM6,eR쪌^ͧRRqo] 5dzC>[h͏ݚL=^PgŸW^IbfMYnUY:Z+wZJquEU}_>X,7W-"rٖm+5̚]+L9TT_ +(x[Y/cԥJ62þ}<o7^L+8J zi|]%dϖRMf%`yuzCM3[ k_xs&6=vj1FXw4~/g/_5V VhWB[^LzROmmWǏ wQk-jPyRSM_fmUYֿ2Os>íR5UÑݧD$Kڏ75uU6exz:/b+Z}^0ߢ1W* 93fo+N-\ȵzy,o8x?.$skrEj+ev^ʤJaq4jq*|3~D,]]SrK-\TO4V^ͶAI.Q -nk*L#_UK]=597[jx|)+þ9jrfW/ji+EJǚjSFثZ41O} ]4}9/il񓾬^AMW.F1>A*%V& ػ +n<5S~hF\b`mr_~uda.}Ćv`Lr@ ʅ}B)QuD!NkKO:&۰aaM,X5\bNbAA&. U$(tܨJ@yؒȻ*o I{\j~n.x_M?i7?IE|i }YJ | Qٱ,]O5W~F^H~aVo`P>GTE1I!> chH$ ğrI}BAC ^~BT>BO0BFj>tb]M/dS4,L]LLb`mg91/F@$:;hv'! ; 4 r.:A}iupWm=~lX_^܆~ǬϓIԱwmpX%cL]B v4 +,iupWm=~\h,mHkJ6:!7]ori`^3ܱj2KM^H+kϒ~.OUM=|ŽAEӵN̙V$E6Gc߱opyqut~?0]@;۶l, p: Uh×.~.oޣZMs7ڮV1P>>LBLr䍌%|ȮIw+L Ɓ/dS\~@O1X?R,Wn t ! %B c\* y'E~CdOyw m4}]F_m/Z7#' S((ɮ= }N9c9m[/2f:(f]>F-51_T~wWp&l_Xφw$WciΔk}'=ZW|Es}Q}]ʽ/u\1VT~p͉ԣ)q*wLqɒb}жY8Y+ tVvţ^vsCj1i컥'.;{%8|(8˭]>Y1ʗ?fYG3Iġ_ٔ]wG?XOKe^WkřfN.oԷdI.=2x}֭kZѴӧ߹oxq-?k{NycXfrNө7Ã7|CZ|}G=Z +(x.8^Dr'ZxSī|RїDŴo+Q$w9Mt_$p%=&.Z|+q[&C'Q̺O?T44=|/ɟzͦkt)5o\4]_&ʍM>tgY9fzM5qt ?OƱ&ߊGOaڼAqԱtwoYǡ§n~"ipfk:xXԲJ<+u~'(D4إj_jEٿCrz [q~N= /z.=6ګÛOwJW5,n}q]ZkvԳ4btΓ[bS^ZR'Un_oɖ+w^juBY0MxY].&tVwoʻ9Jt$?M>N_2?5OLbIM&ϧZ%$jߓ42FX0;ˎnxO:4z#,QAC+Wdc1飏.˽ۇ5d~ '.aҽ~5kI')t~&n]6roXgďvsG6'RHwm:?YÆ>˺MԚ4|=~R%> ,mIKw>'Խk& PcY3UI2G*9Fx'oz1bl΢SgK6&~ͻVuX泥8M}3reasCKbڌA.{I4ןiw ^a}7ڷk\i?.vo6 ^st['nZOGLwlo$*i`gL"l/]nuRC=뾐ZGM*{^ 9 4 ՕSݷ,A+q^cK[&v k(%]."Gn~V/%/ygþ.˻jri5gϽhs(q8$|U= nv)5F5kLon㕬p _ |BWJuv%l-Fx41F7R?7茻_δبI= uKC }}P]W5,IcӃ|'ݫU^뷥HծIWcY4R^noYk2GǨh3֭J0i+OlX(ur>ij}k^>8<_PekaeύgNkš~Kh1k|>ECY&SWkFUS,jpuq)c}Zw|w卖:YDhqnn,$vf64סi6 |Ӟ5H%zV[/^9ja]S37CYF/S57W|Ty}x7ηwE4bßofϖP~ז?t&^~~?._d˪߭_HSkg?- +zL8i.?RZǡQ?کi}GnYoF0EFjIŵ/.c_dx]cRW^Nدҧ(d2fDŽ]k87[x /ktHK$Z4w)j^%Ps5Ҳ_2xn) +3ToAhx24UN`İFgP^o C jt«7|L:kJ}?%ة=wK~ecͨɉAĿYw_E7nZjckIg7:mФus^]Tlj,qW>[*~u5p&4|K=acyT58qq|]̛,1ڧH궽\7 pϏ)g[,6QN.~lߴ:$9b#*Zu[ŒQmOe~Nd}ׯMq{Lc9Hũ>Fh5Xdzevq^R{VUn.X_ɸ`bߺ'PmصvIWEnt~Xe/y"{JL͕ܟÓjydTb˺ b:.g/o-n=KكQ& vQ8|W~-&UU62WrWZt2T}Һ4n2i5ء/m2mKNm(^F/=piџf[ڷ=?Vrkeo{~ +M(n%ۅq*A']s?u;^i..9y%²/`#=wLqcv6obKKMߢ/8˳TlzQt7j2}O]Ǭ(dJ|$]b˻<~ji}O4eť)|#OmKKۗg|H۶Mas)6MYm:5|,u{L=zg4mt0c3K.ݏKZ*4柩Yx_U(;޵0}iSU.ͻ; ~:rϴ߷[~C&5:i kyVUy|g_ K_:43}+u.㽥U(Cj;ľz*`]^qcLR襯>AǧASXE$6<׽} +0yqkuȶ&]Zqk>VQ}jzVq(;wFߌ5o((ҵLAnZ"׳/co ~bj3oд4 m 2ӟNזZqQPkF]yֳ_(Pc ln z:щS^|!r”_cO&Œ[zuWr`ǧKlgfɮmZlFs G9c?xC6٫zܳSꋶ,Z^ko>fJ~IxkYd v̲'P䡛f ns ^(qm(l#k623Jڟ1n%XE+,Cegj9x]pQhҶM,gi9W)6 +dh5NdCvh7G rsrZ4xfzq$8q݇+ݞL˴yieg$|;.ZoEܟ~dvvյ<}UG=z]S _پ>CGf&&[YEuƤtW5Oxy?in44lQN'}9<Ms-BWG׹:2ϋݗ3CSn;}y߼hl.kvj)iZjc׭5ұטEǸ:2Ϗ2?c^4ڂě-7j !1K)7Kh|k4eNG932frRUZ,ոZT~+̿6 쿿g9ai#|Y׳윗H<;<' loe% F\NVì"j2e6?MI[[y}2썽OI3ϯ3㮖|8tћ{GLM .at!V(tdhcQ'NѾS&ȋBN wFCCA"K>?: bHhhBhFfcܱ?GX&W9h᠂=1~| OԔyȝǰ۲J6 IT?! X$ؚNmpvM * Jm c|mXSCa!ÑuFJ9}b9rF?Rt^6- +mlNRV.!9?"+)`NvCN5m9fPMw9P6AtDo'/!Cl![BlN6JO,nxԻIX5>w@22qrdM?M"jٰ1xƯ}n``lIыsYNiRfd CK/T`4Q \h4Q/ +6خרX+ & lLa?v:cI0XUUDBL>+2H?Sl䈄3y.EmjBc@2A@ߨ22}/b+$ȇH>{qEXl1PeW4t~)eNO|_ZIWFn.Wi5PAe%(˳F\q -[7E)/(ose2C7\;bR5{۷9]nJ؃_xO5ҩ?%7Y"&LtG.u27QzM\5YK3X@o׸9('I.Õe]Qi杓kv}$rתvI/tajc͑lH +`@(:jɓ,S.@OvѩפY„Hv>qt0N4tVb6A#LqQ9U"SO`n\W=Wbzl3}߉qoX_Xuͧ5bط $yd7m;nl:YE^EG1oYOrmB< +Vu8({){8)1 "V}N[{ۓJqz7OZlj?7>tk Ĥĩ~W&k:4Ti0Ct,IaRohb龪?:yų%ݿBx&]>Hc_2Y_kV} +lH>9$J#x:9%mw_ڱ&Dӝt/XjYdǍ>{L ,M^)pm5eRq&XEӔW\eĥnW\{39'ɧW; zg 9`pWV +/=d/D.7oCEء,Wxm.ǯղQȪF}v9B9k*}!z|Tzkգ296R 3ʢ=,6c:(䇽*hxweKowlؾ4ڴ|No}KJK͖>! + O#mƺ?|uZ}F/êūҩawk/2駣Y?i/zI?f}W[æ<>eX^< 1n3U.JhBZy/oɏ)'SԤZ/2q4i%llT~;q4_Ȝ1ܬe5a,KZ/vtmx(/->GYGQ[Wc\+V>͍v QnYnnn: <|t:*};VLXWf_ذDիI$gŹG&^꯸]+勌9Iy#'s<[GŭѼ_=]7)L|8~QW:oxn&74B[׋qlRT/dˉjRFp%.kLY,:^6r-6 (? >.ץ\rŖ9beگwя~%ݿBS?X>֋˧zj +-xPCǿ\~S_j/mSiZ88KK~ F]DeEG7e˕&Gq^|Q\Ue0iZ䎟W74|Z \FOݙu~/`OPۗگZU'1]?6{uzu^냓xxKmut5 Hӏ[E]z7,3Ǘ+SS-$O0} I?Rz1>SRLWɦk]|/ +xx((ʹf_d/kJRu6_nGcY5v7Gk=$-J%4gj>]60ӯeWW{oX,?[NNʻn}soI~u"&[$^<rm[~㩎,11(+${o1產ekoޣK<\OK<}V| x#]EbDX'Z6L}zmx>% +xY8c/g߿گuo8LU.KktS(ppT1ϻBnIxz1eJvf%J:lqs>_s.mjZ*8ꋺSNN;k= H5a҆Մ4Lzy"S+" ȱ9 c\!%> r (=HI>A:v¬>aՏ_g.hc_LJ: )/{o+>GS%D~qXaλB/|ORz}(=u;%œ]L<+ڳE#òG4:y po?gVԮzsN5TizQy/<_yII9ZMܲHy&5ߣ-5;޳S a-{=>ߡ͇QJ⌿Ft +^j0<ٱiYK#)$\sL9xiuECk8}V]:}*ZlX*>iFӷ9=~P;vS'Q~Lߔt'.=g7KIKEw o~^ll?};şf/iC>_˼G]co%'Cg[l_8jcH{y_J>&σIu~MS8%ã{O_#$Rw~} ^YS0x'eOșf=dK%ɇĚhtђ?#Q,Z56}_8٪Ŭɩ*.գW?5"I^~~cM~,}%Zi4vYGWuB_>q;O/V +k[4"n_ijˮܲ)BX1׽5v-6٠aΒu6 GcEs;mE|v[vU:+5?GZ|9bK55ϵ矴PG1XtyZmH距-dc4ۮ|OSMZsGIs̟\QE,+UGMMuo͢_gL4έɧmŧͮ4'#7j: +8Ԧ0f9agv$ObZ{VVK$YI> ezk/TpVO%~2롦4189˙:w~eM]afX>r]:ͼ+Wӎp>It>uϑEn{Tz*Uvtk[5{fYiԢxs¡ۡ2^Ԭv9 o#/?8f,.~)󴿎1x<}}קg 垳O4_qnúiU)9~FN+O]]peGOO5|+jIEu6 N>hy#];?&Wdy*.QX~ 1u͝ק s72nQ±G,dErƮrI~<)KO58c%vkc26)Zs,x,T5{Vp``gL6hEB#j=2e.dͳi!G9T\MSe5RqVSmZ9}?ǗDj5W8zǃgAdǺeԸXRo.lˋr˫qܱimri5S'TבW GcKݴZx{=V7ٯCCSn:=ı˓zG'<Ϳ %bőTU,wG~UY?l$8}QuX5R$<=?C= 9.rhѷ&t)_N׶{TV +œ%'tmAEjy%M.";&O[)Jp|Z5uKO^6u|VqbޫLKx .GsaqP|3'6 e,n?gFw-<>?NF>eѳe7<|ؤ>z-.["Wdɥ88xֻ9<>ZR6|Wjt8ÖW)BI/E_94:8a'.̳4o_&ÜZG/n͟tON’i/[-^X)&Qk)(VxTc2M/Ǚ㚗K[irs+;_roחodǖ-JSI4KLYǧs"oV X&7}q}wUx}j_Y̲֯J~fv&J&}=Wi+y+:10qkG/ g3.qÛzeɸ{dܣ7L!< +v4kphVoǒ03k0ge>'Ĝ,dڴTd%߳nuq_lxk9McՖ8x,-JzT&GS(ᝣ.QˑT2GƻF]ig_. ->FY;_-pb +&&×fO8^9&l%}-L6-~-NH%POvΓ>1ˉ|QQY8&ˬ]91M7UfװuZ'q\pz=M/fL%l5{{gL'֓MMK3nO_cr^R7v ,spմITbEٶ)yk5Uw'{8cjN ❃&׵Ӵ}ϋ_Eȣ-4䝶K;Nl=&Uݓ.ϓf,yi7Ne~d:py&|uɓUtbN7v/Xg-NL.isEgon'8ɱ 0ylAM0mP)_+ V$vmWCBl}$nírɡt+57M;=F[MjŠId[ 1]c~AlNA917|M2U%}X<1{F$SU;o}Bu_w"B``"l}Fcݡs+_q;k=FOf{~_3v{^5ª+_b]$$!0KQn#`ݍ %X܃ NOW.&.uW!DHŊ2 + +XESW^Ki1v +֛@!%`PӰV6ƝUrId9%9vIWo"u0%SJR%DjaR'(wI * 2wqBD|ja 'Ӻ~NtKуI zϞ:e2IF>rqNV|JQOdV|N<\>$P4E +@Rv NƝ  {54-kx2{͛LO"j7liUV,ZNR'8wI\1qIK'噪 lbm>@!ݑP~CCv 9,1y$1V10Ae%(˳Fd7dP]MϛWޯ +^c +Ums \ؔIGcA!ߑܱO,T/uPYQ:X:4{-f\h7ׇ޴-zǴdJI*^lɺn.itm$j8៳~J3n~/Bsm_Wom-mx6jfh\WۤG9xv]=n +OnRIӔb}ײV?e̿o |%}^]sǹY;W!wŏ:[WUC]->YtJՕ>).kŨ%Lk).ʊ xGIUL5Y(I:h<4u>_jYQJIF=6?ao7w=_̯k"WK鿙-ƚM^SrkBZhuYK/47i,yl{70njkT.JĚ}1V._5\2|%7}"?.RI(%߬Ǹf%(?574cNe]9hWTr{0 u ~bْf]rqYƛQ%Jxܻ O.9xMtɺxג83-_gU?m.9%(Pq}?;/zL2ն8Ǫ>Oi3V#u7=<-}ˉ"&E.rqOT[ڼIr~\'ߦJ=8vVhaF FnMRiw>ϯ4+S5 +Oߓ[?c8M5o-˩8srבNdڬ4syq+/SϺϭy1dcbfd~J,WPs#ǃ":NEǮƵ㒻ǰqyTxrw[ËF\4/A%)JRJ1CyOJ|Epmxɍg}=j<||~5Ū6Nqm'4oovL^i*U|mj5ꟸ!ZjSTF-0ݧKE~_FsxاE;yR.3PtikCZ9Nq\t^:'yO]%^H׫sŴWQK$?ÒmpZ|ƪ*Ms1VP3O>GrIi_riö xgyRJkt!6Oe8V`Vec[Sjwb!K~u;0꡷4bI kNf*1FI䎟QXrHN\89~k*+G_y^Xqu>X|v#$K?<ĝb_ǻ:U5sy|ض,#c 3nqjqR~Mwٲ4ܳ:˞ψX^JդW'D|灑Sw$i]r&$.S7SW^#I!v +bdXVOΨyٴ>H`;.hC1Am!չiߺ6N|KL}vg?,RO-M^TLo߆aJ +';c[f<\}N+~|!R~KOtLJO$?S-4SĠ8]٥mcZ8M9dm[SSQ#vT=NUSqzK. >hǑ> ԵkFK*)noŏ AAүaYr$k%OYYbie:- I=>5.1C:S5Uu㚸v[.o-eҗLxMǭڱ>NtFɥVig*5jK՘f jsJ9۱zCIei6V^4RRmy(yi˴2ƻfZPK/4/XSy`ܛW}ߣLWũqK"4ͪˊy2O#QRKwO0j2Bpn~)[-]eJO7rѷi%)isWtN:uqѢ[Wt~]*5u>ND' PL.яQgȔ2V#ҒIy.xlۦ(7,r[DcϤMOrƵ J}Uϑ_>CġZI%vTYK9L>\mC0nnrRՎKUz7w?RoF|1ФmiۃsXOCx%wn(^RԳI' v骞EkM'E4e'Ԣi}J1aPiƢ<k.%~{_z%J^ne*?FgA24v-tQI/B;}_{GUgz}>lʿG8e^ ıZDŽHd ~.ۡL9s\1+CIy:]y^>ۖ[.ͻ.MI%I$*).ߚe߁tá”WۃrrC RdIu,)וtpXi`M-s:g]KtEZK^_=6L}uNNY})i֦zLR,N%~(鯻ȣu[v?aucQ,|n;VYB6կ1_yϷqRJ}I[2852eHSO.|-/rMcUp}&iWV,f:<8cI%ysO|dcwG Mf? NNmOlߟ=?xhtLoIsm;VSpZapez˼r^%FoףRYOϻ!I{mNsrM+;MV%2$:Z.'g6HGsξEբ/R9 =s}c,z>/etGci5qHy~.Ek*;VKIAћsk,YsW`%R:_«ͽ뿚4?OYIQͫ-v,ZŚ.ߴ 7Ǒ Gy&^Wx{GJv^hі7lǍd1uK uiivqp﨤fOn$$ (qDR`\ Iv3`W%7S[Z#MB$H#S֣xcLh`Ɓ t%P 0Plj4 aYןKˢ 6_'eO-JXpKNGưYqӮܙ|+jrnֺa/R(6}<2xo]Txix]# \} 4:LQ[k$%~E-6H[Uد?i}` VSJs-NLiR3f>| Z8O:skDKM<.ɶn?3&ɡ͓]k$SNUYg}=;Qrb9?}W~o›'b'&ci-ltҵM)n|7K̹tqtV\fJ.Pi?BKe UG9rh}xJ9;ϕG%Z8emZl7}!i"NT+[x.4br wZ<1i2M,YS]Yu\3[E̙1K`'(+6!,nku'6py%ɨps9n*'.)Zrv}}eӮ2Fi>9@ Ok_f-\w-|#Ys%cjEw=[ZRi[:ڣNۖ-WDЛ,L+^s5y7]D\:QF_.4ծ"m58eĜM.z}{Ñqk\.= sT9HQRA}4Qljå).߭;fzJˎmgq͏2{.6:R:-nᨖ *q\'ox94z>Jx5|MYZyaM+rUȷɆOjTUstm7 6] S9[~LsRY;_3{:IbI56d|s7ܢ懺x&Z}ܢrJKϹ?} QJ; kmɎqe&_g:VƻKG x'K6En[͊P_oJ[%eÎ0iSwm6]W"-B_ ^>2{Y4ɹ䒮زn,1_jMzܹ(4q"<|r]n:Q 3ɓq[S*-F>8+K%;d[Gպ_Mt.|-鴸1T~ENǢɇqZOCEdQ2x^9O \9k׃zk/5X|Ҧm]$t+~\\r$z w_r]>|8GJ0i̫z_,k+jZ8tY/. o7u J +5UW`kJ/uE^< NE)/5۹,Fߗ]y޻T#UivۓR9B2xlɹ}rr1lɯaǎ7(N 6_uԡ 86CCۦ/WBs\}a:lӖJi.GKrKs{&pcҭ-Fʾ!5&KOpͷFv8UHQVg&-_T 6ɢ5z)Gڟ$$PioUGHprNR˓W]Oͤ^?˺IWbjenݷnzh><*-jPrk,ϨڵzVHf;wXqKm/v =ԡi٧m[~q~OW.۩\88NV\`]f?_7lBR<: s,rVE'1|;8^?ixOnm[F}T-Rj;lYnZJR$kk}?G_5:XTCj¼ƨQcT*T!OI)SW]lL"4Da&sHP;#l(7A `:@ +WbI,p;`ps:nlNv.1\Y'Bm|0y>_ԟG15!_V+UX_b'|S(θJKshjor+` ;K_(JWM]PrKߙ%dpVҾbRmyY u{ڋBwh}oHNA.C4u_2)>N}_7ܹ]UG#]99y^dTN݊mBPQi~o>%_W +LW|uX%>1unn]íؐ6݅ :^du119t3+w?g&(tʇ}fX)7ۈԫ^mN=tدr7zG 1v$bnm_pq->OvkpxGSK=T.rd)ݲ2sCNmP9ט65*E@И5iI,R +P&]#SW_|>J E*i_ПL.CP# + %`BIRIZ~WT? +V>JlRt`7Da$NC*b}|hUaI4~`p(%%@T$>,/hv4.#j/$||PQAlCUV+  1$}Bj%a>`HlWBRCL(wBv!{J-.Êp@T%#rAAB) H_SnI!8q~l/aDHXX\>xYŎ(ͥ|S[ZF #d_ YWC1@.ECIk: WeZG*ը5h`e}0vķ ^.icj^/hKei~%j+]UpAgE'ǯuAn839%Xۤ\dV9,ژk"b_5o|NPH}}}t,reV9-/Z(WoE6Rx +վlwM֯<[컿پior)5֫[JQs~ev0K<-N*qi4,댓t_>caqœ'7ɭVE/g*R]>SBqp]qaDrfOqv;rt"*4KD5& `}X]ߨ5Bb|dnb.RT4 ݇~G;&l;@UpDiӠVEJCn Uc%ȮW] >A0NDR@RC+aAc%cOV68N!DDZXBT +45!C`¨I".G߁{Q92itSW]|115a؈]:䙺 Hhk$!@:&6UL]G'oEOC&'|bI! +j4gW%NYczw==/~';d`b~5رfӽNXIur2^#!a].|ia-B)6$ckIp#BJ8AcƣBqHt~Lb芏((H:F$z` 6*!^lOUCJȤJ"|:vqw V*R! CG6¬MB|!*B%a*KLI !b hI !U]HE+""'.*!3&rnSW_|!5C816(}hiP$J„CLvbn>Ղ ]")`}[_5x"7mB拊PI.,wLIغWw1~tJr(tO<Wן)c7d}r&-/$T;NjΗw"2.&OIF eIC7_;2By5O .LI>4v?v̙qc]ON]6$i2G9<~Щ4,ٵ2Ȝ\i*=T&-D.Fܾ1{X`C7(qD<{#~G7jIMS:lB/rSZA rBLhV>$ X5chI|CqVpQc^b4;.A.8 + vhk$ XyLc@:PwUXjT*@טp PUA^C|Qam EV%i\iؗƗ2i}tSW]|6BdlLK$WCChx>`At:#l*0Jw.(Q~!5^`88(?ZDuz?E.eJw\$X<"#~*j)%}A8I5ՋcJ8)i6ZIKH+I%\ T8KC61±^Q J)lmMԻ:W 6LM P7ah}b @6lĕX/A|"&$ P|؛'hmzb2|AT4IXPV$|D 5t((;XJ=}V\ +_]C: ?P КA F~@ |a$!HCt&;иCc4 ɧk6SS_|F *b/ PXk4t1P!T'$ JDdzb)*%*C޼bLlj"LPq5C +.(ñX"ݍ0`M6:;]c + D*!XGIc q8Pp: +tIP$!U + CJv&0%!]!@A`$T& r>(MrWa4(4Ch]#H.r  ,i +;ddSW\_3RՊbdX1.Id`1.v0 j%ԐpQX4(ұW*`;PF DT>WP6 r6]:m XK$V*/Qz\$Eb1BG~BІ$7\ !҃ (*r P|T>j‡bVB|P>,ccH.B; >H$X`l;r .T;ߑ6 X& ɇ]!V*%ۀ㐿0 RߐLՉ />±K,%PɧTͳSW]|6X>|[,.;1ߐ.5wk d +.'.ץPƈCq.<*VEq}$tc"P'`Ȯ~GbBl*q)Y%Ș>AUA * tv V P4a>@V'* X.q7CG}.@N#nq`"@`|b|:j +i"- .@(H**ڰ#AA.y0q]47..q;NT;T`$aA۸cH@AVD\]@ȶtͳSK_X!V&F@ȶ(M-}|c *G`끮v`CPV XvaL `h]I'BN*$:h +K.W FĐUA} P +/Pjĕ ZULvoBw@"q€R_ac\T$6T'|DU`#JzDBh.v.v7# +@%ڰP ± X$`ݠAU?P%w $ cjĆkj Ջ5Hlm!>"3 +KĊ|:$\ zHɥtSK_Bȴ'ȄĻ{/,4>wBLV v;I X4=P6u"C|?A..hﰾHO ! |A߂*@ ;@Ð V%&ortA!`@#75;+T");C0 JNq `л]* +B~B\ lN!.D Iz DPl`Nb@w +V +Br@P"wfSO]|Vbb"G9plva@L(;c^V6@aHT5TUS%$J4;t v5Uj"c |] +a .MPKv+$'B!*  + +ƕ!]`l] +t$z * ĝBHߠUb^A@ݱ7 T1HȊConw끦 oF%Bc|0`.~JEP'cw RIܫP>yFݍp* mX'\ :\ @ݎВEqw?SO]jՊ\ MWGbr40!m(B%7@.): ؕ'ԃ_6)0~C5! +$MNC.Gde0PX ]BcAOHCh>a\  C\' л < ,UDLKU@FqB|U`ߐدLaϐ}è v&ڱ%\nBOk +*ꈶK0L,$a piPU- o,Vw`!B +7||H.ˆDr "TlhpSS[j>Hˁ&&*ɧ6&EP NJ+ $$\;A0InG +10D#Dio :o ++: ETw!W$l|kI I>ðD]OqQ?P0G)~+~Շ`ATAC>Gw z>GV/>P1?A*6$iUoh]@В]t0| +Q\}C^R v0IXrU|`„t@s0LHJUa@U]tlM~I!\t SuyȍpqG,oJZ7mSO[|Q0h" Ci/e C4 BpV P%A@H"_ A'@PlHKQ$';GBNwvna(% +1R$+dHt'$"r= 8U$$a ;X" |p;Rh; $;r6j"_d}߸7C| i\v +`k/*Jߑ%L %LCJ(IPFب +Pt+ _lW\\ #O y>*7Fև7SS[&BbV&E$-l>. 5aےT4I M!P*:%W:ScB2/qTb1.B_kH(v OJ]jh +%@a$! tH@4j +4%t+,7.CQ``غhXu MXv0J@%].~@ՃX6>&XX2.#F".>AY&t4n=HUCjtF#C&L]¬@X~7b||+2_p&46t]ٸSO[B؄6 $k@q,b`JN@`p.v*~ךX$/XEiت*1bC`.EuCK]@ؘw> ^b 5 C?P4*@%n] \ !;XW*C\0L;6 +Lߐ>5"Aߐn¬Ot$%DЗ^c@E8 +';dS)܋BTz7SO[|eȀ&E4w-X i r;IPpJƕp.kS@;-y(M}@\zbN:\PX ؚĮȡ.h*Z/!r(C. v +[_$w"; R#bnN}b>F 0ؔ!$ l,*T|! L|0 OXDFP p ۰djawq4'h/v >{ +o]rEN0lA!U18 hAͽ SO[|aPD{RIf7V 1A*I0:yK; +4yk +"cĸT;woR(}@¬(=$U@Wø;I"@߁ t;4r \aC $;P) +;K:d\Sø7c ";;@ ĸ J JtEߨXiBa: ! 'ACآ$2AO_N AGbt&%Ȼ!a5`% +bhR +1nF֋SS[(]ȱÓ6.+$:l# 0HiB\_1Յ Q67.HjU=h(],}^A+Aۑ ++^BǐĐ ..C\:S%PĕJ> wC\ >2$͎^BnA/AЮ \h;/:dJ6:T4$6V $ %#h]q +V%&Q"W`Ђè|n$ + +]ji`Ȯ/@o !'! v >a<4ט.C@ 1vȾ{|H%͎B\H#pSOYHdB,M jNK#cJU>1MbJMPH|9t V)0D)  23V8 PXj\ .Ga^blmq|15@`ߠ|$@Շ`qbT 4E(M48MPEX:PF4IVA.v4&|G A&%*ȿ%&;a4T +V 0b [46)r:G#;+ERQ +Bh̊qr$M 숿Rdcv0$e0||ŇP>ؗ :SKW,M1>]]T7Bܕ!;ՉpI1.+CIB6$'݊B/0N|@$?U.T\$bbak/B"DCkyT%WWb@pT*¼r0T: +%I'ȫ #5cl;TVd[:A.V P,oP\p)*M:DJ>%*hk)*kKMP$0|at$!NqP4^l鑔k&m>;~cbHt( L"Վ.k@fSKU̾'B~DF,DpIPm~ ӡy+`/@:"0j(H^v!7;cA]M1r 1z`.=A:L.ˆpF9 pE}^aVS}1;8 U7ð +BP11H &mX?A%HW)"JCB\ P8 +jd#C$>+h  Hh]:D{b</ 04c nē ~P5܍qWXvqU|]E*d1U +OG7OSKUĬ",V GM?lIk04OH"Ô}~DR T ` +\.9V6ب/| =ؓAkA@!`A*'aV5 +u!*V'0 *i DI"nu&HXb\!!T:a*(wv ! +ГBO|taT>Ak&165v |Ɨ450XIГV BS%CLW݅wqU !>9 6R|{{fSKU}"`&+ m4!44Ciは"M~@]OxOe&W}>%$3j#7QʨF7;?fjbf.JJ.?37a&śoЋT;^RC'  *v Ю`} #D*v \>) hJW@`ߘy 0N]QXyXð.BhoX#F7\ +Ɛ;ʄ|t'* +PP#@7E!U߱+fSKTk_ _oMA.!AF}P` ~AW}#{h qfˎ;n1.2z_9 e&>^v\n(ًL~"yvWOƙ=FP||Qy#.|w9ucXR~UV;tXOe)'mZ5bvxMy^?CjQVߓJ><è1au+Yx Pv״|?"?H:^t&.] u6\mێ=υdWn,璽+doadF3Tٻ{\I6Zt֞,w?v,U`и_#ؼ&~[QKȞhh{V<(v}la$\r5UɸG1'E&O=/gqHڦ*wiv{<W\soqnQ%$;zK'j|jupEcZkz[Q6$W{٩-l>?$JH)FYװf>uV}FRKW~TUN$rǪY9o8!lG̚ ћ`4 ;":i h(OP%@Bh}M +D NX L*@V$|NIQ$IIj4$v c  ;XP4bhKhv$644`r( W|wbJD~ ݍ. 4$adzWpihƑ$,"ЪL?SKW7ȗ@D?oJ&.\h,hkiaV$!_IUGf'ZXEdב:irE|[$fN/r)0a˒ԳI_1j";TC?Sj1\]< &EKo}GΑ*W'Xo/+YƚfW,˻QVuC$o]DZ}"i֧&MdKT%cŢƔWoo\.*_QQ,3˒Yڊ^n7<3\|Stå8Jk;-~ߏYXe'Uc>rrJSu N=#_{4&]![iJQ]M/΃Ap.?\K'jt;V=긳6HCنX6 qtFuWnȧ\kUE|@X%B5`| _x6+C +a@wQ<82#|C 0X 1_> +\B')ynF1Gؤ.>5vu@vva^Z"ט!?J; ʍ +GSKUB"#}NK`68 D1"T$U,zl(,|_i\qdrtydm4^ 2lg-\JJx`ɛ,7 -{|]%it֪RrUiomv'ri~cúF2z(5.+П4ir₹J-$Oi 7\{26w%Eaۍ˟mh[iƒFƧWkx"|nZQ˖=>9=,ҸEFv\^8,??gA]1NsKв|]mǓj.`Η=>uM~tlj%bqQB *v#4t.Pv00vqk;M +o@ %Pz +<@PӠl@ET @Blt kcO&拳6OSKU}-AdhL?k\ԄaݏP~܅yW#i` q@Pܟa o:i͑v%Мߑ'!9z9 J~.ݿI"%%VI_kSC~HI/Kc o1B EZVJpYiv68]2!K"QFGM.JWJ/B>&k?dnT4äHn6&"뀠X5BaCk̏ +V: :;ÿ拳'SKWAPv&`K7,L.ðD #}X 䒕U D;ڭpum `&V4]CcQOM L;@>(m48 HUD'4 PU6 j T.Gv +V:P"P'a`lI4|acv% Pt$#L]c.'X7%@: @ W/A ?><0QO_h*ð'`ĆA &C^|av"\\­z>?SGWX2-ŷB>}ƹ1_.{Nð"U߁7I; + ?oGG/.7o3S"}]=V1{l91N-MtzǨ aӌr"Qic,b{>tPmcW̸ܩ􅧃j11n%ݸcܠaT_.rrj4.vThty(>XyqҹDFk{skoy(ϫ$!+wmZQPQi[7< eU)WS|Y{go_)%?y]]_G 27_Ѵ;}g77Ss),,U5 ͒1oɵfm.=xX0'% +%*ĜҊ1eYҔq}j귌7ѓ$bÒ9_fBz'(E8jF>P!2j?}L)ddQy9>[[oGY^'DT`j?595')͹˭)?#:,,,oW`A.(j4s )~Lhd bQBMB}uy>Ͷ_;6''k,vQI)A6hlK6tI+5|[f1ʧ7 u'S-/~O\q185H0*܂cUvI BH:P$a^`!BHhv XuXw*.#1b*G?$`:]v* v*Uw)WȐ9AoW;4  bJcr U&Ę1 HJ${+ 'SKTсbX f=w6¬$>. +_#\XUA%Er||VY>}8o*z~&e{LB~/>crI}fx6njz"HxOk[|W?x:,Q.N=L>Y,xr}*oXZV|I#I>˗72 OWkSqn<'eS9B5&hþa_mºHI(X/vs^CdϚRmǩ>C6o2cw*u{f/ڮ/K͋xf43o[~rCMNP3j1lzlk6T)3e|,mAIœro QiCҦm-|;aŧ<]Ż^7i5iU B꠻v1pR=AUX7@.A`uPP$v,@'v$ Hj&7*pav +AV5* ]ݐ$\n$ZBA"?t{B?SKU0w(!12:l6;I PЪ];,,;A@И'ġnǛK> \om2..>aQ=YPFĶuKO uyYMn&,Qrk4Eɛmż0σTyׇv 5Xs[\|Ż'<8bG㬚->Ok>ʴZxG&P>WdVM,9uni,Z7 ]w塖R 5WoCٰ,9-\m<@ ^lr9æY-rlz{*&[|ͣXu.Zys%nrj~, 2rZQWτ6{cũ-ϚNg˶qs/pѯ.N'vq_JO?gf8/ktl.Z)>j+'~ǗtǝOu3sźZm^N1t4ߒK+ÆjrW+emx-|& 0lKJqI{Û=S%lV+?ůl'} 2DuU!㖝(f-p۫kgb2ty͏5iw5+$Sۭ['fGdYO궏3n/_إM<5{Eqi_stӪ9cG]WZed||_uB*2MiQOC&`ԲQ _fNZ\/$?aҹ?Oe/_?ix/sYHƕ $_Ð*b|ȩ+>1w9_x„ט1q.B,QC|>E~jtELb`0`pj4&}6CS+ Ƹ}T1&&!@ ] +; +7Cv |y M fSKRZ-P5d[#V B۹W3la:j2W@w,Ms@$Hɷm9n 9 >/Q)ЛP%"]vdc*bI|DgS[aNI:hYG&dKݫʌb8Ҍ*1e#Y%ͮW|ˊ9̒tZ}LNۏ>HSɍTeG&ߎyco$SJ_jvZN7S:JfnǶaUK79{J$Jfvi) +nٻX,Y%%baycqMrg. Qjj׶aUJLzs͍TBtUJ?!ë +0 uX6+.B] T лr;7BV:(i4+v p*JF..r"Dq'CmV/{6$m@ Kjĸ +N)4A&S7t=?R?bDȂ@f=62,2T`6.}ðvcHhia.:M_wʇ 9G.K]\fY>ZC&hJSj*Db( JA t(#"7x|AwI "FlUD"0b←t.æD J}< j +.`L}0It tbخB l>BNY~C\E%%_ C|.ߡ&].{ _cרĹPi|vAT)jP>H +A1ЄcJƕp7/ WE AlMPXKLo!.F$@8Aߐ&(VI~jdTk$$JͽflRP&&"- O&/7&l7CN'L$!C cXUR ~Uxxe￳*7mNLxӓriWß$jO5ݒ^ q'/eԔjxi >)$rդ[n;-1y%JMF-5}6lGOoIJ%uI]#Q J/rOZQ ߰>L"IF'\è?ik]P^gcg,fhȿz#td/NKuf!kG/Dg:L:C yMQY:Z?ܲhpyRmsi,_ًCN_2xr;@ +*ĸI1E; +FcC.u_p:+J@+*VLнI+aۀH]!t>s`RAz瀪:X{)J'$")z~!|.#%.2@$nhJ̓R?lI&&EMo~vtmPaccAcP¨IX>{#YF/*g_֯frZ5>fȥI|Q Cl]WHN۱# +ޮolk4Xg4b6mXK_<;m,}TQi"#ߑͯ-(.-Mrcno7^2ǹɚMRW#uX5:e ϝ$[Vsik_>\~9V'rxe7;Ic+w_8͝f n-TPNpe6aoa2ŋQ0&$TӊZzWrו-Zꛩ2R|<E&F&˭8:xnǸiO&:wng2zmFgSv1k79Y&/Y#uU8I(v.ծqKQ=mF c#cz\W5b`OQ $R',+ņy%OڋgJGUrƧ9j7rksT^xOu{ޖi|k5K3D>DZCqȬ:ON.&wb. X0ATv4]r7U As%:1XqXcj@5aۑ%0Ubl.c`.q`F&l,_ɉ0ko5c| za8" H4~9R:L&!blB_uh?al(bDCQED "Am,t:& +c.b,[7OQҭ1|sފ Qi3xj<gƓ7I#,qmC, +HH1ҺĻ٠.VҨ9RD6(1L_>MY/rEoK?dum;߻s-f<gJrJfwMvjhLrK1-谧7Ke1O׺N.864N|H^9֯݋8}[n?՜/]lX}$mKbqr^ իĵ8ݴ |s.gT]ttmLyqvk&oX ~6ӺvڭY(I_x@1/,O1!{H8ݣ97]v=6ob#]Ϊz}~ǩu t$vO5σo3_TY|h.V7Nrl j2ai40MZwM,usyiutyAG -JW>YxScƓa⊥H_xopHeǑc>|3LJ.L)'uv6<^k3޸Û~CK~}zd׻i}\C``7J!ȢkI0h>pW%bn.X jK.B!Dvj.b|P]]PP0n il(NU@X +@ + TE1| ℯBLmP~~dR-bxHQ)sMOw3R?@DO6+A v64>@l`c\p4 +Ju8OO>Ua S')d~`︦TW5(E$d):uӎ*+ȥDzT)fՓumy=.t₊P!dn/(Z=jQ%jџǡٰkeחdF,>w0aRI/$aZ߬]?1hT=gv76 ߊdZ,5Ybo/֙,~d6l;<=7ݿ=)Z,W{9m,Y乩QٿmFi+Ki[VGU9Qvh;tݯU?<N +OTZ}*MM*Ͳb˨ߴiz$uw5NX6x}Ogz*4>šS2dZ#C~ G6Xe_|# '\tNVx/?\7Ax;?\eGm{ŏqˏS&ԱvBXO4tZL~8Ei_mpK*_ezq܄1Udk!XV6 :Gu]MW$1P7 r1>w o]O` EI C!]Đ$;t(_Xy V&;M}CAvbhŬC]g\x3EW\$/oH Ev6ø0~t .$1 p&hbat*ػ6>HA^` ۠N].Ȼp4 +V4*۸cnliЛP]*#d(;v b=;cvI;j슏&I8&+Xy7~R:L!B|j=CFIY;.ITIr *ø +jC0R8p1`¬UȪb!݉_xWJAU@!|O\ &0 !5:D&Cv 1IФiX€+KGaV$9Ot0}…VD[om tP ~@* N!'C'C(8a@7@ؗ M@?MP)y0Bh}a;]L}"êL;@RP{_OP*7~R?=#`jx#_ۢdQ$ \I aA$ćB" C\tH]x +  `6@F;y." $ \T ~T*$khb1v\myOJM~2)MPv`Hi$ p + }ˑ!P߱%P.v 0 P;BJ/0sXl660BNa 1 +r/ĘI6UcN oB|V*P'07RPLU!,@ gdt~b}v 6u@ $}> ]븾#H*'L8b|;$C|17cbByT!;BW@ <45! ?P TBH,I(V;Ƙv1v$ +vВ +.lT1];@w).؍ X64&L}5aT .H@aXIXp! $6$m@X + 67*Eac7f?RP1'`&$E&`a'$dǥ!1P'c T>pHb\$CXE,}R]17cB BL}1 Jɉ?PCR&6A`P>@vE>]]IW]vlIخMqVL`"!b#Kð6 hr ,.;CP $'"Kk;X|Az$7_T*aKГWJ"X  U@~7`XEW!Bl;¬Jջ$ؒ +/ :غ\6cBLU`r@$:hiۯyRQ3M +_t)"zI_lHcӡ``XwI~NT^c_k?T ) ~sCJbJ*v;(ИW^j +IvN=}.D+ A!lH.b +*\ (&bj0k]?h;I:W頻bQRt bF& '|ƸBC|$Kw@C)$$I +CHU`M~@IXPW6 ! \wDuY5u `\Gq3RP&$ŮWpڋ$1@*lmv>Bÿ"jhJaUCn5]dnI71'Dk 9sȁzǞ +H` +#i"m$ }JB"6V?G^cLMʾ'v +%LcaChC`Pa!B|`]rIr&wЗa* T6$&+xX4 ;aAt +NWo..A 0!'bMP4 ]D"Bh ]zR,Al6'Y14}j!!Յ\cAV:x^AV kv`_$ 1(л]"K4 ! yBbq]v;tln6!z !>jEkuXĕ o+ˁW  ;bT%+ȗ~גT!Acn9 +6%!p:+Ab\t$R%!UyMPCD{ V1?@*%|;Wc K@+C46.v" ?!|p:4C"104)yXwa&)|LR##'bn*]M +f,ǥ\I6$>Q~`cH1|P'C%X8v @v*` Г껄W _RbLkal<`߰..1PUȓ$6 П %.>JI۱w$t4j,ɋ.9 y !wjøBOE7ܔE +BBC*` . +; z$C\uȪbaX%"\Cn]^br`BGR}1>&&C/)Ү~aD|Dc]tIr =DHlXǎGB CJvțB]Ę|*D9Bl` *+_HI;.+u$;\ÁLt ;&4  >_J.V0M +WiGuDdbܔGt`bhnUy B\P#cF$Q4|" $ P1.],,P]a0H7cBj2)R}&D%gvqUw$ⱓ 4*!Սp6 r44+b_#|j2  & 7\ &:U\\ $t7 v 4&‡Bj݋myV 8pv*#$x(v|rBNЃk]/$MX!Ta`#0l+ + &$i`D _hb L p&*3rYie?R}ȫ#}%־a2/\!D;#V+ N}!@.;`7D|qvFv&@¨,%*yp!J6:`@v*or*#>tt A>DB`]pBH}C+ +w5B$mZ7}H !#511PA\И9t A"t`N`:av4wB + Ɋ(CXUĐ6L¬}* @Wȫ IaTFm ? V;@ؘ>HH㿘).܉N+d?R'"ЂEYIо+!$~A&k&(!A b.|+wU}p$E/"Mz $q r$X:hT41$ XPD{?!}J Ɛ4&pC]aPtzhآAwP; +@16 T0OUMȷcHL JC +v>cn> ؓ +*«Չp ]T1wChLQWctP>XU_ DjA(e_#!R'Bh!3~bяDhLipd @[$_",hab.BAbp`D/]:`@ p 灀 +]$`P`in^u"c\dSh`\B_hhHLyJX mr&X^ac"ӰN}nAT@0RC\mPl]p>N +#ccnVlW`c6 ( +ؒט .C ; R"wOE &6]ȶR}]i GF]CipRR\? ؆^S Cٿ'q + w>$.ąLk7C`Ɠ\ Mr2/KC +AXw]v~\T*T&Cj119_$]^/V4:P+]_q7I*(!~C|r% K_W0lVvpI>#nvB|k(V4: ZAi#|]7a`qXĐؚ\T \I,,")s` +|\R1C$v!Ց|лRDnw|$X]?R}/O!.!4& AMzT$ o Aa )y&c +$>@ `~B^ƃ]J];p@AH<Hݒ@~B|uuF\ + B?QIqX4`N pAA۸w^c +@ +@M(,$r(LkiLbk;'&ƘКЬ,IOHX h;r$N e|T >oȗp&&5}I2Wb лк; p *NlMXU p@`uߐ4+,2R}Ȳ(ЬB#%iC;2> q 5CHC*qqAOhUH WoMyPW&ר۱4 U_x(;HtM7o(T4P./ )* ؚ݂I>@vϘ(5l$0(IP(\v!*c +'].B64bv Л>C P& V! :PwcNj[aUW|qՉ b; T>Q JTT ڡX =#AߐhR~^C"_u|I:+B>D!!Q;I}Q荆l$;!> +0~` +i +`t/@x&OU\w V* Bn1HM&T;?݁ $ ƙa۸U'a0] M AAaWCB Bv&$ubv! p%6+p@W@wbFR%w 1? W"`$Lv8[a(P؂p4"}%AxXY?+^bR7J6pYE|Iv+aXُQKŶs +#l$6C@0v: *:A;ƇaaM]mb_g@@(ctv66E?"JVBCt54+$bl_./R7'!BcF`u`r%F¼ð7B2IPXB W<yX, a]'4r>«]>hdl<.z`|n>F;A` a:~`ƐA`/Mw +\M !>au܈r-P nwǘuA'&7O9eg"#v","gedvtۢ-XV45ñ+PPv^  v4&CHm`~Ab1 >lW$w\[(I QEXJÔ4):y +A`F!ClMzߐY$︬Mא7DW&:q#ؔCW݂v4 W` +n jVS(`ߐv4'!t ?aؚbCnHu`"=w jƐwJWP%\ #&WaC5BƂ@\(JH yaȍnAO< F!UQ؋:Aq*zR_g9ecO'@ +& ou܈'# +l(uA'CjiF\P%||pv 0F0Aۑ& X1>A J(_#cA~v5a57]dc.,r cO"7`)PU.,Q!Iĕ`VEU"07\ :tqAr/4:lRt*;abNB,iX0Ccb`"漀}ACJлpBu&.L"AT^cRBI")Y.77dT`5 r)W,~ Hv_"G9"r +,Lf<ɝqp` V:Ɓ!0Jp1ՇO +Nb/w)a.FՑ.J_$GdU<4 Q +IbNP`~a߹qu~NP>F|Ɔ(CBBq݉!Ur mr%+^awu`Չ +:BtҠ^V +w\IkmV ]4VT }T(܍r5D 4 W P ȷCa>av:vcK^A"$1 y )XQiȑ9e[l'B#5ihWulø|ƽFc鱮ð]ǎ` wV1wP6 ?PK.IJ2=7T@ʂ_LM5aۂI\*v4Av'0|JI>HM@/!WaBc\t$aEpb +(w]į& y t*X&0!A/A;w>BC\ Hk>A; Lh] +>B#t0LMX( &U􃍅$`˜.8Ct6F$5+-#g9ejTEM `}ܛ6Ytt5Y*v$; +Pؾ#N;7AtH(|AC$;qbLiH1P'a t.0}^`+CGt$A;$ j~aaVP aTb4r}«6>cU,Iy>0&';h"\ ;IR r:a$+nc7: +nbBhliwՇay 1*Vr44El\ø'>|ȎLe$Iv+b»R&M4hUuC鱡4Jc;S}!)1?07 +Mnivaciػ`^A(W`R^#Wqpkkub:Ьt&x?P|v*cLU`;]JÿhQ~CA ^B&"klLhJ,m +"Ab| p @>B`|P07at_П&*T;ȟAT|Ec| z] AtDEpIW5`TZǰ9ebb`"!ݗɆ6_$XI h,*i& '&;$&Fpc nB0 +"*q5bAtL,MB\wM MQ",t?(o4\ ;BC 0X5CD{|]H}O,t+Я A0 t*ꄆ.*]ab | ۡTFua@ awl0L"\wH`.Ghhr&M/P*cNF%%g?9egp#VE| L[gm6E&p ~$$ wV*$ƹ +55}$6.۸.5ab|ð8ۮ?u@>a~b]bSQ/A݋`O.AT t`ؓ;BHw@ wkJƈR}4`aDX:\C|waHU$;BIF z|Gv&+*@=%ȮcN C7bnN5bK:w]]6ؔ 0umP9ejTFMЄ_v_&-M/>B| !LK44 RK1u l}7 Ac|`1Н0`"0\ +}I-± LnV6; r'$As.GIy ^`t.tIV IXh\t$4 !Ubh?!$;V%1݋Ili"); L,"rlmP4&~C«; rT+ \+Lj 1%\VDJ7iC`&vEr$|@) 4F둯Q\ rK).l#9eZv+"%&EtC//#{Ф \&,cnðu4?.¯!P /1æI6'br>GM 0 -yЛA +64 I>!V;#]|D}݃bF:q`Պ.4wL(.Ăr M݅ÿӰc@XnM^hHȊT .kjÔ7u,LiWvMX ݅y(`J |ۑ`v }.{t.7]U Q*|D9e[FHMP؎E_ɑ}mv# 1] *@.C(;AGavA0n…LO7\14; B\ +t%#4%*5Dk5| _U^@b|r>|ð6@4p (&6* +``h*qt XPȦc⌧zCy!LOcخ#vJ.7BI6Di@&] ?,+R@  !U +N%@p "DøG|kUDRrA`>EtL;+\zi%~e{ GE `؛!ԡkl17ALph?p7:@ rEp ;P0hP;P]}=ϐ] 4 ?$;&A0]J*%wvfB y P>C $w. $.ª4O!PP5@l]\ +J(IP7D@ĸcJt4&(Hv^`6I!|ȍ XBc"MXba^^ @P|Nt&qCR(tEAw$pD+wBnrI_cQ^Lbj>lu] Y%Edաt4r ;qJ?@ :at|*К+o%ȊR +@ӱXAC>9țLLJՃ5@DݰX P.I]\Bi ~Hu@ +lFaH.īavV>a} _(}`p?1PX>P6WPT rKN0߈wqPإAؚH,` +C +t>ubS +1: +*ڠ +he$+lBLB2,IoG)5"]Ć2MЉ] :a.B| P ?Pa|v+>9VV;XU ].!мr>T0rk(My 1>Az~1>A6ð]v.ܑN=Ɲ5CH4I%F?dʂ.vݑ_p\ HUCLDWƣd 됓_ p%ۡU,kA: +7;r:_Ur7!.8t);HEtМ0AV%7w *LK9y!Ղ_qD|p5'U4V6+lDhCgd6mYX1ب]T cc\`},`bP vt\]#; $! U*"$ F XE wUpI=t,]bH!T:0j] ?@lIXv& _cZ$.A߸vpUjǘkH: +טvp.H.v%/Ac#VHnè!mvc@bI'| +ߐI"%CNbV>H"p:c9&\lLb2AT'%bTO~.-@+P4EyA.3#lt40vV7 A`r6_dImv&B8]=\A߰.~c]7.W?0|v>ջ .L: Z ?"OB X CMBJ$jF *Udl}C*'|B7&5@IEX ; bJB +6>nWܕY|&$_cCHqhi`c|1&뫐hm~Bo*ߑ'!Pr^mpk X" P$.hMw$d܊`yJ;-+PQH%mulCLyHiT5`+  +B}u!@ M@17C|@CUp:鍡/%a%ГV%@bAc\ nVJOBI;I'.;! $u4X!My+ +H9_4Cw:b I`Nb&>V]J a46߀IP '@i |4K +.ɢ5C|U$T+ hO(w + ;I1"7C9 Q'N1G~+ȃ gd6q!;U *`$> +`銇@C$n*14.J>EF] U C^P$\ZPqAWi !`C" EPW#$ +:@`, X|:Ȩ4 @CqЮ#P#H%t&' JGߑU6ėT'Ȝ +*#0`; >EG݌;\ .aܕXYlKOwb| OpJCf+lRbKYبui;|:#^.Fð!P_tI z +ҡ%44 lЁ NIzp|p:@oE`viz nX(}ClLՊؚiAZ6 +na@$øi+@ך *%b;aAtB4;"N@ ] +*b &4U@6\Bli 4M0hz s8T+KI| p!.Gt:$ tIr&U`|48>2G&<bd[ #smmQ;خ]4C@j nPE 7jhI1~&1H8`#. (}Aht/A@ ((]ð1ߐ7B\$ār4.q5Al;bHجwL}i w + +b¬.PvBqliT Xh; .@Up*;^bLo1;ڱ`4;  !(I劬tvJ"#JlM%CH..yHIbq`B<ݑJcwWZ+j\5DD'(] CC bHcbd M~!T4ȡF%`k'A.b/Гt'coȋc kdhWë!a.W|"B aMX!7CXU +}4Ir1?@6>$l>!a`1~|ƹva u\JI$]*KcJz @P'aCj]dzFؐخE66!DT ynhwa&Au~PN(b$V>DU|@?GhIv "! 32f^nð!Lv0L&!&ƘX a%$F'. v +1 h"`?&1 q~j48ФA;|]},/_Kphw}4ӡWW`|~bBt BK øP&tr+lt oКcbhwAXc" !uBRB >HTIso,]&%v#b*`|ƅ`0r lU /1_ПwA<Ƀp%;&oÔZ+XFBDuOYF͂qIJȲMנ60CLkE5A%*w6Hm$A$5~wB ! .zPWaù*Ԁ~`4V ;"_ۢ*Vr4JCؗ vp?;vav$_.AA@k/ `+hV +AAB;@$R븂 |VJ*6CbкDl}!bCLM OOCHl2%aNW+#V L]V:L!+h KyacdX\-kl  H]-A0 #Q9X'H:|q'c/P%lCU*H !!I] !IP5 ^'jj'A ACLaV`O&8bm܋K:|UhBB0CNP!wV Q^\<Pu sw265A9r/t}4G V;tb.Dc"ߒC+V&& 7bQ&5u\AːQ%@AA!7dZ>y"Rd[M| ?0\>FQ!CD"|ƹ>$jG+~kВcAd~#NJXAcc_bH OarT XPu;t (FAۀ=A:` Wbqk@+v%?Q0n6a$ &DiMtE".$ +j$&+HcP/*j߁Bnט U$.t16 ] rv$+ +ybj^aP(ɵbIC'L%n@1>{CRI1t"X,g| 0%?\/Tnf$> nXҠT;v!>Hqv"L.w"hOaػ?P 70lT!ػk|0R$JQT&T^CHRb_^BOÀt/)X?|0j46&«Յ s.!ǐ鿸N?Ir;´L l*0 q.?1`=|FE>c x ぷ]%@>bh+JêՅy^@tZCvcDD;r>)Mv.7AOLKXg&*2/2,Di{(,ƂvǞA}@k_db\ +Xۡ C.BJ 1ա_,}T Jߘ_$k%+hVʁAEm' M;cb + ȃ +A1>`ˑ! 1{A@*$@$.p a64;\ w.B`>}ПPv ;v~C X芈0hv.X4 y1К\7T"b@kP=W~A%t !0J'?gB"&Ȁy2$D 1v'!v V!bhv?. qC*LO:S\61`(vBh.MPܫȏHOH(h"ð A X& b@]BȪ/⫁8^@ P`>B CLIkIXЗ!t hIИꆄ6êĸtD\.!:u+1.I?@\ W;bk(r@at.XT تUU & hQ'Wȓ%܊vժO!bQ=4U?b?yBP$Xcă+%aTJ:`mWט6&j0Av ~BA$JP %4 |ؚ#|nGm I "!c$©.F5 P>R$Ę +.AppP>D_0n.݉&* +bChV6t&BaDZ AWaCUbUנ P7hU`Wu[GlD#\c@אa\ C&!Lw$qwHygC#&"cԿ/K/5ȓv1N6 XwlhH(h#V1X.Bƣ& +^CvubA`Ɛ(Ɖw:>v*lnDCՑ|}@ r$;t`ðlbjW+>cLR}B^aw J܏4U'Ȑ1uy)HHU@$Ɓ. + ^(VWcl*ATD~Bv%߰?A +|U +8uvTkV'ax$@݊2 D7alM8?QE}\ 21dӡ'@|7Z ]Dl;b|Ǫ%%m \hj<lav X/Pa` :"tD|ip: +a .PPG*K1uXir4J%Ap>$;AbQAcHӾy 0hO;qa 5|;H+B*,Pw.DpN>` kMĹ%!aV ۀm|b` b\\u$&5b=ƕ `ÿa6 y +CJ;'|ghv El,\%TWT+Ɛ k'.wa¯oht$܏1m2]‡VEAt>^`..a@4߀av*IXH*:.A]^*BvW0  +R;v J>Vl(Ua*~l.`  U؟#j.T;mdW C|(l;P!]4>D$J IP!4 zK0 ?5hibWhcLK}|PpY-:?gh0b&ȶ",Ln=JxÃ+Hc`>1w v!C +jd` Ra~c\c|UCRHwDmN!UT6¼ğ/]ECH%C `%~ JBGO+OPEX5lj t.9c&d0I1A~`  XFT+y_!Hz> +Av +ă7HtI'hmMbu14H&|ȷ SPUøNA`E*$.D#i#\%k]8O͙4QgablDD$S~[z~7fX!b_eP"W@ Hl`%_> #WJB| $7AV ؃6 V5P[ J!נ14` yWA`1L]JC +BK/p.p]]l=av)0 @>XUmC y0n +m L*iQLn)U`aȪXP0^#z\_hl,V w#AV\ !0O.F`>AA1W.B@m;䍸N_3&$?_W(VEL0|3F +)%&& >7+5au]÷0^v (0j| }݅6] +]@XJ.(Ry"d5c\بra> wB1A;y4V:TEsȚؚvauWqVJaԟ4RH]U6MmUA'ےMX7憹*mwW $>aA@j ^aAT0%?@LjtE P. +\%@4%k"!@v4 o_u *ȧN!+MN"K]W!ɧ_iYdkѢb116F@GQ.I e/@1XC\` }Pv+E2MX4T/&w`}!KX+DmyFט| J:EWbN N +1 " A\'`>`b#lHJPES.40آ a_{.r5 !A'AT;*$a(1EO V >A !\Ib%;2RdXA&KJ_2wdi5@ȷ|| _s|/QwHq`@T7@`L6!%c~C4LKC%+It ;wC`ВAT+Bm!'ACN0݇; qVI$X]a6* H}^Lv a7C\HK^y>~%`t.p|` 'v%肼.| +r14BnV +6 Nr^|5UlƐ]@vT ;tMR%̒#;îu%ez|6.bq21s˥#2 +øvq؆ؒ@J]nC_H%cHH]5a@6'; KȚt `.. PjaHb 1w\ +.vaAA`=]6*¨]TäWCjU|`.r3Z y>h"C~RЪJ_q r + +W"n]DF`0@ +H*>r  %%]ÿBp6@4"_'auLnAB\@@!r)[;*_y&¨`+@ KГt*w$)pFN13&%7div"-P*1jE|aT };]:  +V$9yv%tat>mU H,iL}BL.t%*,NB]$ІШJø]+X'@%Hwba (؟|Da,w}V:`~%cb H"b)ƘU15C6 ?!~@(;:+Bm^LmXv]ø .( $'a. V\ /!]biԘ_!y 2w%~b섹%+lU no{7wdi4."1쯑1XâTV0@ ]4c!_AcHi7A@r4%C'6>X5C|B7mJW!C +DZv +Sawh`HN+kOc?{݇U"䐓p &nGiNmPXhl;c_06 R\:V *Ƙ!P]@\ KMXU@ ҰnEc }#bhh5v ; y`'@}ōHRC2' ƹ2ݳxwe4,L@G4"DdP | QƇۀ|Cbb%AT6ck7C|/Gt^a}zqЪvD@ڱD]7cd>V#;rCtPڠChTHa؁P U_Hb +$E+&0J/|DlU|p+QcL; +4 76.Hq] ;P +HqI8`b^h}V4r,]&<%AMJNAv)Jn Nwdiva 2,A>%t2K`6bcC # +T wt(^cMXBbhiPR_ +T$'t V*|H"`.cPTJ DDbȗ:I>EC +!U +jæPФ5E I.@]"N&Ew0 +* $J< "=~!߀ +ruzV:H7acaBLkA( +C~BJ7.r4av'*ˑDW%. etdi_v&'Ȥ "7.fhB`H;i}vKn J!&K dzA1T +o#5Uq7`7C z +jBЇ@ēv!di,]6 av>  + q АIy* LרX¬]#h$v4CJzn@C~Bt%cbc\bb&>BlIO JM4' Īc.,K ÎM$* Ä P!5]z$!uu2_7@e4".f-l +0| 1Vv0|!.00|Uy +,I2]~ 65E|ؾb+l<7bNƣ%BBBt "A1Q_C ]]`(,t. I7& 1vbn@ v` Xv ( +CCaB)a,}ت.VPh-Ux!~:G.U@u;"ՂTH UMM t_q{|&B"&{64쯑w HH4:㈒44iX!p `!Ǒn +) At7 r>@cM bQ+t  +`|H: P:a44LAvD}t5`&.B}B +Pwc +ج}b6;XUblAC>AaG]Q bl(;*L +@ P .@,AX5*&+BA"Iإ0Nu?we4&,V.`gӯ lm !=t .ݍU&`t;@] G:]DڠnˆvEv/%ۀ #/a`h;&o a%^bHt.r>╉ru"=D H(u$V:І߸Ӳ_1 jñ~C\.*HvtkP]'@,; 1 p %>t UTJ¨*;A` + +Ɓ p_KJ VBuC_L8>$ y@ D j(aVd;fe4XHv0kyla_e|l4p>Dub6:&Ƥ+.qNiBOoɋ#" >"`lI**¨5ck4(*F@.x$)p'8#p.ȓAaC\At(weabJv `(FАبt U\~ c| +B†~B|Blk.$AvIPEQҠvct+ {IIt Q$%T zPWMQ"47p`C1$&O5Dndivb|lLC}3b+d nù%'CJ$aD t 1ab\ +%*hk.UT'OUBUڮzG'}s`0`ߐ%@5cNȥbN!T6AAA]I$J%B`dyՏ}6J\ s]!; +|V$*%T@r +w% ;;@4:@ KA!i_A@ھX̀uøp P>{ .H(B0*dKUa$7;&; +Ճd>8⁉u%ȑ* Wd>M?t#R@]܋L5PiyXI|4JPл~c:F6];`"LlV PQT9lF P"_pA4$6ߐ .+ 9`@(x%`5||z1|!۔ *|T&#nb6Rr)2_C بkԍv5"$*nz] +"7Cnv.i6 (WK 9ON(aVKÆ` B.r%q%6T:ÿ P5\s0OȂ"V4.Aw#F}+mou5X&&=Fjy; عKdhqC/!PP |pIUwoAO1W\>x#]DH;X{M3Fkk |"beJL in $ û +t1b5uPt.]D,} +Nc.wV 1v +v$+Cr1Rr? +@',mP.t>]P`,ۀ:bhmABh:>К7]⫀ B +]@X;c\ H]è(RAwUQcqt ha)X\ߠWPȤ6 WA*QU$0}6ot&AB0H>C ڡ7]Ղb' |.1W6܌tT6ða| ; J<¨X Ьq|vAB!pkoN<%܈I顩л3i;hjF@~B!3Wp/2]Uc\ UCJ4qv +.V'45IXp]V0P!] +bc~l}.s݀BcB46MX& +P'&]$bbm + PX]r@q]t`6 $ʻ0C7\ Htk'*ڡ4 ':י] + N"h '`])F]b `W VT.G]od_$X +Tg*lcr"#@ȅ xW OV: +]^c`k5c M +t1$!b<:F r60 +۰HHmOv%ܬ:A: +A$ X؜kUT7.&cJøt* Qhr w ;5Blu`B + V*>`]rțBV ; v! 6 pAb!A_PMQvC\#t5*$" +q@*nH}º*}G"L;}* _!vDA mo)|ͼK&6I!;'` C + +|F6|MAa`ap42T): *MX7aT Lb| } A.?0& C#&9!.AK2#AT Л݃u +B|%BCHHoh]61UI GV\8cN0^Ib$;$%aԇuEz8 .hit+ta&6nDbhiDDW$8w@c~w\ Eaáкv$ +H˕h)!z .E|/gtk"bHLB5VCk*M+`V0J |\p4Л!جlP_"v7ȃAv y&h*۰C|t !Wߨ¨60| ` Ȫߐp |Dn!T ww }݃ Vi F +QI.MX>ApUDCAa]ð"nPw`A>X bNߨPWcJ\"R#۰cvBU IX茝&scF@gM !1wMZ7t :I !頻Rd]_chTV4 +#uaBВl>k>.vV>߰>` JACh,!WP5t|u0lU`)0F]\2*==ؗ#@t0ȒLuDl`X0 N45`BcXX +t*w$0 @r.chT`$wp.EbW9 ..܍s]vЯKQ1U7.Y*B38m_tk&&&&FXNFh.` 4:v%O!ƟIyt +m}\ 4I sv.mb|N$HUQ]``5Ȅ;P]$=TBOA.F*&S`EI!}AHJVIr+.hMؐWC1%D}cO \IXIwv'C%Ĺ + + :Bb$琠\P ۡ *$T 0 TAqؚ:$b"A$Tvsb| 3d_ؤ$ &&adgD 1P]>Ac|9p+$,,h&bVNĒaXv1X$zDFߘUcqUr:P/?hKv&v*" ":t&vau}ĐBB@4*Hi^@` t`U$:@E'^L}Cjp %*%dF+:iil}]zt7P!!'\mX!0H.Ƹ"qKrQ!vƝUBmqIn{%Li[fgu5&')~fx_pT @>cl}Đ44@X$ +@adWJ.L~4E:ybNI%`˜.;mľ!bqOaT jcX4&o2%۔FJ>JÄ #.* Ip~NƸd"#D{PnBl|@t!t*@ø}ø%@ ^^bH H :#%ch}B^RuCܨ,;avB %&.¦ wAT6;E% XĕA*;}OO3dotk0| XLL{GoÄC~LLA~bK̗v.xCCp\.F^ FPt'*T'A7(%CbEXvƐ/@>y$q} @ Cbv;"/i +<$ 7'aV*hRPPi Iҡ5 z<~TLHu.X1%& + + q%\;T>bnBAI +*cCjL,mbc}Ć/1U*"W$y&H.ĂX|C(Pl.c| +슏K64ٲ_/0!.D* "mô~fWr%@*P&q0$JڱP&;@0P}'۾_6 iл^A^Ac\ՇwUv'UG4;t>} y2-יĦ*t $@UH]o섆!.Bv+\~%# yKjǔ?܀."LlQwcR46C\|0cn;5`Fub)X7^AA 6  b@IP,w|P!" Ur>܉0 V%IYr^bJ@E3i]}S_q;Eʹ0| LRCq @:+V5Ic /J# +5NV&4F$6XB\Ɛ6Zȓ!i0!`/Bat AhV$ƽF LbLMvL¼``@=cJH8A^`u戤 47.¬;M +|GCL(D]Lmr$ luIPÄ9ApT+p(%BNp! 'cNCh*cߠ4av6AsHmH'B頿!QKϤwfW`| + LBj٭_JK͖ qP]CV*"ܛh#v5!4&''^h]%G@4KV5!0@U9r7.갺 \HnB뀿 | :#dK`BAVbBj@|Ap ;i_q!GhMP !%.&UKnߘجqX* +^bn¨m !@d. R SC !wܐ[mWip4Ć W *w[|`Li &.aE l1upU }EZlҮp?W"'&ȈŨ+mvI0 '@I;݌\cN$4!85\r*U}Շ~a> UClOT&Ղv'4 HߘDՍL7ؒPUPƟ SACr4! P * dZ  1|Cw]@{CbCJPMJ uPK> UAAT6.1 +Q\PtЬ;ofn`q1 +E $yqFtwB~lC]Q Đ=HCr6aCb%BCqШmX@Hߘ!WvA!DC\u`O̓UʇD$̒~'H%"r.FrWIW` [\`0$.;C*q@U"PPoV Ta%Cj@ꘇ! L +'lhUE70M#T4].|]@Պ,u4 頰J&$d_#"`%@Aہ12O4zЗ݅y>iPU>D퍑},t !غGvAt._@I>x;.>1G݃HiS| -E:T4N "p"Nl{38_s ЬL`Ɉ mt 46.iJ@&Aa&0_JbkZD!U*4.BX.N7vt&>Ș +$`+X1]r?;`|TBj"Bbj'`טZ}Ą\ 5.]$%_!`cBlubM.x ~cNл >Ոo\X]v61 qX|bDno^V*l} 1r ]7ML]P1E$\i$Z$ \aHT&\ ăv +\"HEҘ;*ND\lT%`R +H9 #WX%\ &at &ali#"A| Do.JB|/KRX`QAT'&*f4.A~AU**@F4Bh+cl%>>@ج(!.F*Æ*$Hb +$B"]B;d1'`60|.>F$I$6W8H*؈Bid#i jCvvfp?_abB"&F:?FnG1X1+6%} |+ + @ +WAT a1w`>Յ >mT+ +XbX%ht$ FAÿAI$ +jaw +!Xiab:1v66^p@Cb4BJv>|ؔ P @"j vt:D @r0AhbH.,/KhЛ q.]IDƸ KWa@$ȱ nM$⢠Y!4 XĆ܇nGb\00.V%]~aP +qV$#lQmXv#Ms UyT;#&4Uq L:@.Aa5C +$ נ 5'H}ȍ +%0j.:6?M0 0vW@ :$½P!!'cQ +MP T Mm Ap T XvKɂ` o}%;Ț`טv UhL~4;AU;6tꑘ_s!12/"=]?nb\1t0\.Ë@b."TI!| +*v;P9y'c\MI(4$&y:n' >| r(%J$'j44R^`XX±4:;`]qFO]@5/!7amê 1. *Bav ]*a1]؏PDmWҡIXMW#LC"PcHK> wt'?A#aV;IWCqJ19X]pF*yXk6\}WP +>Du$~k(}⡃t x;q!@r01>t0Wi v60'@~^aܗ; q;"rJmWC 0s۾݉s$}H>xw\0oI +4$Bho.1́'X$/ lW@4 EP?@hbܓ +5\$hQo@44 bOp@lUc^byjäL:k>AR BLmy%|` +dSr$Ю!Aߐo+,,t%WnBH#%6Đ_ .yb>M*gWa #ϦP`BƐ4*qxmT.݆tpiiIW#+ `|jȻX'@סwƐ7$UX85|@\l+ARo'bhwbH.M%OC8tEjB,M1#l} +_}.X)w/Q k.6r>; +7Ⱥ] + $7XPP BؒDe/"K*CW| +CM + LlX(.XyVFIǑu4>cDZpL$ 5li{38lIdXX6*DXMMad +*ð7CN}K(h*y~C˜*טv +țo߁qqAW W9In*1G!"-y *%=ƸQTBk()qB\;4@dZ@J\y~ +؋$`4F ; :%a"?X\b`MIмkI +tFQ$#@10h*7bBX P5+Ev$_ +!C~T tAߐ:]:j^cAVErJĕr?2D{JD\ ph Xæ:A;\ .݃`n)ZF﹵T\ . q5DY[\Q鍊Hk+mXp@(Ɓs"I,uBTT В`LmZ CA9 :>acV:I }$_.T&KAb)P!T.Ɖv ;*5ȒwM)!:FAv&`¨]6aX5i@P7bqX$ +*&4*Iyq1U~Bc>9 +>`cJĸL$C@t7 HT1?o)>⒠AH81 0d$iIwOZWh\ɐ| 1ШBdL:u8Fn&}v4.@hMQ+ h)t y +PuPqDln]<1]>B|w +@blv#ܐv Ew`>*}r'țp|~bMw'}>B Wb7c _ +n6b] ػ}!]Jt >@5CaXGk%C +5 ߘ! Y&(t4 ؁‚+(aQ` ȗ"6SX:.G]T+o1j.PO6l3X;Md{5ZWIŃ*(,~*}h#.B4l?1U:$;clVI;,(,KIXv+`ےHCbkTȷ`yMFN; 1Ur"^c UZuK2l1^b&'ȊXFv%vcLjA@pT yL%CCq`]p'P@v +a>~/&6BJK` Upt'J!BHW¬9'. +D|b5C|M+q䌣Abl%C`]w QUcQX! DW##-.țUH] 6}#i] +vEvC#ٍ,`!V `%ȚXa7q :,D4;vxUallv$1:Q%1uP5m`d\2 T&&&ȱ7ba͛$aѺ +XvK|*Tv+I ȒtT&:|/A5c_aՍ0AO"; p U (WB +UqD[ƂA.ȲwB0I> >M + hmy +('(u*]RxbH}!AUUP +Q$ A`:MH +WعAA߀ 0P(}ø.1 +v.@NĸC OcUT+W~@8@t5H8yvK*kЋ]FޝR2mB"WU_CLw% +tŅed!`4` +|1 mp*v+v My +¨$_0$XX4 V)s +ȶ>0nU s'؁0r4   y aEAmU 6G %Cl|LRbN'}ÿ +ǘL} `!r> 瑰|WpB>hWB Xv$!V$pH*:lJ^a^ck +1@.:|ͽ7c(lو7d["FB[SL}CH$(C\H;XQ`X?>C$O +>C>1P ]wܗr*CNiBn &  Y*@v! Y5_#qqX1'! P>i;v G X.Ap $ø5bq8؛@(`&aUL+Uc1ƄO :m WvpI +D _47>jߐ SCm4;+.L*B\4  $ؔ`d,uF֝2l1"؟Xڋ7Pƀh,.}V6.ÿ @w P Rhx+XW hIpyQ$v aJT+NטuB +BbEITT/u~$D]DnAR(m5 q&6aBP 0¬,U@c=mUE$bn/1U;0H tb ND1j$%h@ET; +@0X|A^;6LIdYQ,;hi#(*k>RBhߟ1`(.5`>G$AV ;E!_ .9P.DˀCL>r&>h:^c$*ڠ`"L*E.GacߠuPIyqؓȬ*J CHM tPПkU065WȂ*qP *q"61 p7V ~@ NV:%?A-!'Aρ@6v2Lخ&Eȱ3_UAyYt!r4/atBK̒:BiMXD F#}A>#_N5q~~@I!Pu IXp&Лv+ +h@}QN,aDP1Ad|ƀIa܈ƾPHi}dZ$UbOȐly>\4.ĻwJ +Oߨ&1>BĆ `}ƕx>hiXNГ%F0.I%De*}|.~BvN&柱LM`!]#",Lŗ߁D6 6>t6V$ !pJ#L(hkK*6%@Wiydð4a|?Z 49C!As7w` JB=h|<& HACU  nt1ߐ>hTa\|BD`/jJ^~C C|V m +uC@ؘI%/#HMtV qR'̏~ $:hحJr;#NٵT)F!>DȱUMV@pA6yqՃ`F +mb a;:bぶ |ErK?ꄘuXw$/@7U?@M>Tl R`r p +v y0v&>B4T ت} !$4 %B>" +h}$+Cy +(L؆ð1v%q^@B4; bm_R}Ȥ4 FpĦӮ܋Ol(uU|5Ⱥ,a1U j*ͭ;e9ȱ1vb| hMYdL'.GCl^a@*lubaV1P.^a.Oڱv7`~t&H*钪ھ 0B(IDv;T+c_ ˞P> @L +^BI V>V*|uyB$X4c#IPp5cJ^~Bc,loƇO7/Pq0 Hn@0nz +4AT X1>6&tm꠱WwE/ z+tcɏm B1NN@%]}Lx X# &b||1v"E?@Nb$1_#T>WƸ}hm&];v D]Ca>y vB(v%N+V AlkP#i I?Q?P#w H:+ 1 5.^`M> b\+?A.;}„P \ t䂐v.ÿp1M P>x_I(C0CHt+HJV 〠+4 V1ؘ>F vBN\);aBqM]0?)Ya!6E{7cM?QPðX}"RcLCJ6 ㋠Jt;J0q 1|FW.P(I(^a'`>UjDm +p4Bt:D_`J%\lI~p&$6 a t $@ HH + +` PXXX|A A r P z+)pI6+oђ.c8 yЭ"? b4kB]p_ 6._E"`)Yb&Fُ6;6 U&: *t5+%t ! E}ɱ!'c`4O>Hy2+h}TOLvuhD[ +|`jp7 *ؔJ 1ؐ) :.&ć@Л꠪?0Al.ðX qP@\M(;J>S\  WӠch +DƸCV*H$ "$ZCBXKUU Ȑ;ubЛнJ +L/_] Pu +J71vD2/aT&dX95_qƢ6'64;:T1!c%t +B\C|lUM&o=!^CP*'@؟"AؓZ#Ut:pv:H}ՎP>|B݀nl!w@X_4!V&Ƙ[^bJBL PL݅u @,l4Qt+ a v Q60BHw8 Hh!MQ++ Y$@6 +/^bwo•4$"`ȃ "#`E|>LahkcL.*o]ĝ #@ XȻ. +:~b\wPoEWNl,5 ^`}>c +4 ~9t8!@/Չ>]tC h>bcTݎ X7`iv>t.AT b + +_ ;ě_)W(*B.b$c"PƹT6T>;70bluB~BA| PP,ϑtĉ'@T +-0|j`hNͼ]0? >_q Ȥ "~FXӡ!DAUmcq]t0DՅ^bƥcr*v*VB^b]40@X!8`TB`#$.F\ +0K(`_qU;8(lVJ(Q_;\ +5H ;!.{pat4+lMxa wЛ |$blr*ܑ:+aAB;1؜k݃.ך$F^` +. p$VJ r \#JMXtM¨Vjś44lkk7z.21zmn=_8vfY?qX>2$AXT~h%aT4a }c`+ +WcK*BQ% t`o>A!`L,}#ߐ|9.lWCR\(ac!4 HV>`IP|b`w 6; + L^ӡvmМr6U0~ap P8 ] ] +\rQ v.`%+$1b|ðBH;^achI!V+U@]@ y p,#5zLrQo:vO.VڛJ7؞G4ͨ8-~wŏO4^M>82}^]fM% at'a]Ir4MͼN&$ȫblП_#+",C> .%V* Aq~J5B|~C%}ƓaDZPC + +H; na5`Вq*CLCJð7B@8 ^" PuPЅCЗ# HF +1I06EtG.!HQ.G8` zG^`|w]K?xN4 p +.qwaV@|6ӱ[ b;p nE߀t#v[X82$5CՇM@$B6 PP6 bF Ht&u{6NP"Jc| ++7%h">{H; L]}+>#bũPwtaM/$t'h/< u!\G`mP ~N.aX +"$hX{U:%]㰘q *]vpr>mX]q8^ idʢ7ߗEfb|w(Ҫ~e-QLygגQu\q]M~8j9#'ԟC?p=:EeJ\Y;]G*[Qci֭t+V۫G3gKYpL_dh}<؅u`Хϑ&1 ~ 27DƘaC IJOIP;`טI XuQ+  @nF! s>p&Ir&AU Mzc$ؓ@ X r\W OyȁAՅPP +*U(uA,.6%`* r h/%b PI􀕱# جdSkalTvcTvhT MT&|yC\ +1P")z 1F׳jKU//EG9xOʮq{?4l3H,jsy>]S{t1Q3%X4>TnBI; X"@w"WB1f{I}@ \ !1Kn>cOv%dXآLK}ĕ %'ҰJi|dd=уX~(ƥ|H`{ 1ػ6؜FaM0걩0Ԭט +Nb$ՂM1,;@ *QW5$Eߐ\rE˒}נ.8kck&V +cV ma(WȘ(>>Cj  +(~Ch.!4  +\`ƃ'a$ L%! *+ 4\X>}$y +#^`}/I9Y&U&ABB#[S^ 0\Ƃ +ՒUӰj `R AA;_Iӱ>CĆՋ0HmP>ECrMwypk خXl<]c@k%}aw$T66;$t mP#'cqtAw! V:*(.TU@Ոm d1Bt ArJ?v#~| ʅH +CW@bK*0\wcDwq%+XX k)W !&V}"X"`Mb5Bl5rs?M@ݒ:.AaFaՅM"U|'A!vO 0A\!(K||øw\vKb@^A&I` !Ȫ +P$P%`Yp@~Cr .ؾ#|ø$ND BllR(t P'b^cؐP.D+o>8~Ccjo$r, *@Eq]~dlR} y _CҮA P&b1u%Ut }6K>Ivqf%I"`nTE B ڗAACHt_P ƹcl!}ƹ;^Hdn!XJðl@,m +/_'&%44 C${]..@48)*` rخ;w'@ *W*c0OhOUc X|BGbF 1IP\}S v ,I qW`U,:C5b$П< V4QDw@6︚Clu\~Aȍ*'mSmU ?18c| w +1vtUP턕BK#D, õd{d ؆.+X& cN'TKUpAy]WrJ灾F H@ ]T_.=ȧNj1 +  `øU|;H` =Dh,LboS^~C5?`EA~v +븬i%@ABl>a`<..W¬:P\ K HhȹqH%P.Bir:4BHOHCn~6>'CBc:~aA~H]B@Ĺ .Z*rT(݈_ BlIn"ؘeo݁.UI n65i.T1EypnGbXMTJ.G@]W];]1*c>s C|T%aUv 6M|B@&4AAAK$wa~ACNOɏP: r ПiXUI $.T`إ6uC>І݂\R/:T4;DzخЬubH:o|qڐP)HKDoZAi0HM25BD #Wk#}0$$amVp6d44ÿq1tP8 &aBMXH*XFI+^byؔhAt6J6WU; 劬/mPUr; +0NCnvWp@V;¬Pv UXX>>*Uv)z +IMMi +øw6>T6C\v @.,|w$ĸWo @IhPHa ;"a'mǰ*6&'/_ꍻhi ݍè9*c+ ؗ TaX%ACA>vt;ACL +a5;| ! VbHMPvȅW!&;+_.P8ǐH;V4m +y"-EG TAnD`> :t/@k=Aעf/dz/=_Bx>@}ibG+W}^>x>/"U}V!X"U}Z=i5H_UC"/Jik?0/0CzEO#: JCEO=+ՅQY~!gV#v ZfOL=30zyR!,,bko=h=I ؿAšKBqMOSKKE`6 +- v:JLH!!Xtjv +Ap l: + @ "\ +.iat*c !` +bJt| q- $rƕ1 +"6A$J:h%P ]]]H]4 +Vww64m`PV(:C:C:PtA҃J'1{%z^W,Iyğ{z^엠{%z !}YӦ?`釰C 1_WAtW@&/Eo֟O~a}] iRՐ-2@Ӧ?ĴywӶ d1,,ر6%ر{7cxc~l}KC!,m{6ȸ44T6k$ Ptca.j &l +endstream +endobj +38 0 obj +<< +/Length 135 +/ID [<98FAC637B447FB59A262EEEA8DF59A1D> <500EE72E1340A54283912D22BF432FCC>] +/Info 8 0 R +/Root 1 0 R +/Type /XRef +/Size 39 +/Index [0 38] +/W [1 3 0] +/Filter /FlateDecode +>> +stream +x ̱ +_R7R(Jҩx62(yI #M_}UTȶrD=h~E#CKD&:{ћ~W "mQEv-Vs]rNSp-: +endstream +endobj +startxref +850457 +%%EOF diff --git a/files.transfemscience.org/pdfs/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung [Hormonal Substitution Therapy for Breast Enlargement].pdf b/files.transfemscience.org/pdfs/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung [Hormonal Substitution Therapy for Breast Enlargement].pdf new file mode 100644 index 00000000..db955d09 Binary files /dev/null and b/files.transfemscience.org/pdfs/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung [Hormonal Substitution Therapy for Breast Enlargement].pdf differ diff --git a/files.transfemscience.org/pdfs/Lyons, Li, & Johnson (1958) - The Hormonal Control of Mammary Growth and Lactation [In Recent Progress in Hormone Research, Volume 14 (Pincus)].pdf b/files.transfemscience.org/pdfs/Lyons, Li, & Johnson (1958) - The Hormonal Control of Mammary Growth and Lactation [In Recent Progress in Hormone Research, Volume 14 (Pincus)].pdf new file mode 100644 index 00000000..ec47f9ca Binary files /dev/null and b/files.transfemscience.org/pdfs/Lyons, Li, & Johnson (1958) - The Hormonal Control of Mammary Growth and Lactation [In Recent Progress in Hormone Research, Volume 14 (Pincus)].pdf differ diff --git a/files.transfemscience.org/pdfs/Malini, Smith, & Goldzieher (1985) - Measurement of Breast Volume by Ultrasound During Normal Menstrual Cycles and With Oral Contraceptive Use.pdf b/files.transfemscience.org/pdfs/Malini, Smith, & Goldzieher (1985) - Measurement of Breast Volume by Ultrasound During Normal Menstrual Cycles and With Oral Contraceptive Use.pdf new file mode 100644 index 00000000..5cc205a0 Binary files /dev/null and b/files.transfemscience.org/pdfs/Malini, Smith, & Goldzieher (1985) - Measurement of Breast Volume by Ultrasound During Normal Menstrual Cycles and With Oral Contraceptive Use.pdf differ diff --git a/files.transfemscience.org/pdfs/Müller (1953) - Zur hormonalen Kosmetik der weiblichen Brust; Wirkung und Nebenwirkung östrogenhaltiger kosmetischer Präparate.pdf b/files.transfemscience.org/pdfs/Müller (1953) - Zur hormonalen Kosmetik der weiblichen Brust; Wirkung und Nebenwirkung östrogenhaltiger kosmetischer Präparate.pdf new file mode 100644 index 00000000..7ee384a2 Binary files /dev/null and b/files.transfemscience.org/pdfs/Müller (1953) - Zur hormonalen Kosmetik der weiblichen Brust; Wirkung und Nebenwirkung östrogenhaltiger kosmetischer Präparate.pdf differ diff --git a/files.transfemscience.org/pdfs/Skarda, Fremrová, _ Bezecný (1989) - Progesterone Alone is Responsible for Stimulation of the Growth of Ducts and of Mammary Alveolar Structures in Mice.pdf b/files.transfemscience.org/pdfs/Skarda, Fremrová, _ Bezecný (1989) - Progesterone Alone is Responsible for Stimulation of the Growth of Ducts and of Mammary Alveolar Structures in Mice.pdf new file mode 100644 index 00000000..311e3a0f Binary files /dev/null and b/files.transfemscience.org/pdfs/Skarda, Fremrová, _ Bezecný (1989) - Progesterone Alone is Responsible for Stimulation of the Growth of Ducts and of Mammary Alveolar Structures in Mice.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust.pdf b/files.transfemscience.org/pdfs/translations/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust.pdf new file mode 100644 index 00000000..d6eec282 Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Bruck & Müller (1967) - Zur Hormontherapie der Hypoplastischen Weiblichen Brust.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung.pdf b/files.transfemscience.org/pdfs/translations/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung.pdf new file mode 100644 index 00000000..c7b8cc7c Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Cernea (1944) - Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Göretzlehner & Lauritzen (1992_2007) - Hormontherapie bei Gynäkologischen Erkrankungen_ Mammahypoplasie.pdf b/files.transfemscience.org/pdfs/translations/Göretzlehner & Lauritzen (1992_2007) - Hormontherapie bei Gynäkologischen Erkrankungen_ Mammahypoplasie.pdf new file mode 100644 index 00000000..7d0a206c Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Göretzlehner & Lauritzen (1992_2007) - Hormontherapie bei Gynäkologischen Erkrankungen_ Mammahypoplasie.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie.pdf b/files.transfemscience.org/pdfs/translations/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie.pdf new file mode 100644 index 00000000..2df4647a Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Kaiser & Leidenberger (1991) - Hormonbehandlung bei Benign Mammaerkrankungen_ Mammahypoplasie.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Lauritzen (1980) - Hormonkur Kann Hypoplastischer Mamma Aufhelfen.pdf b/files.transfemscience.org/pdfs/translations/Lauritzen (1980) - Hormonkur Kann Hypoplastischer Mamma Aufhelfen.pdf new file mode 100644 index 00000000..97198cda Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Lauritzen (1980) - Hormonkur Kann Hypoplastischer Mamma Aufhelfen.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung.pdf b/files.transfemscience.org/pdfs/translations/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung.pdf new file mode 100644 index 00000000..ddcfbf1f Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Lauritzen (1989) - Hormonelle Substitutionstherapie zur Brustvergrößerung.pdf differ diff --git a/files.transfemscience.org/pdfs/translations/Müller (1953) - Zur Hormonalen Kosmetik der Weiblichen Brust_ Wirkung und Nebenwirkung Östrogenhaltiger Kosmetischer Präparate.pdf b/files.transfemscience.org/pdfs/translations/Müller (1953) - Zur Hormonalen Kosmetik der Weiblichen Brust_ Wirkung und Nebenwirkung Östrogenhaltiger Kosmetischer Präparate.pdf new file mode 100644 index 00000000..48253b50 Binary files /dev/null and b/files.transfemscience.org/pdfs/translations/Müller (1953) - Zur Hormonalen Kosmetik der Weiblichen Brust_ Wirkung und Nebenwirkung Östrogenhaltiger Kosmetischer Präparate.pdf differ diff --git a/transfemscience.org/articles-by-author/aly/index.html b/transfemscience.org/articles-by-author/aly/index.html index d12490bd..87b64269 100644 --- a/transfemscience.org/articles-by-author/aly/index.html +++ b/transfemscience.org/articles-by-author/aly/index.html @@ -1 +1 @@ -Articles by Aly - Transfeminine Science Link

Articles by Aly (Latest First)

   Filter by author: Aly | Lain | Sam | Mitzi | All

\ No newline at end of file +Articles by Aly - Transfeminine Science Link

Articles by Aly (Latest First)

   Filter by author: Aly | Lain | Sam | Mitzi | All

\ No newline at end of file diff --git a/transfemscience.org/articles-by-date/index.html b/transfemscience.org/articles-by-date/index.html index 84881aff..ff104822 100644 --- a/transfemscience.org/articles-by-date/index.html +++ b/transfemscience.org/articles-by-date/index.html @@ -1 +1 @@ -Articles by Date - Transfeminine Science Link

Articles by Date (Latest First)

   Filter by author: Aly | Lain | Sam | Mitzi

\ No newline at end of file +Articles by Date - Transfeminine Science Link

Articles by Date (Latest First)

   Filter by author: Aly | Lain | Sam | Mitzi

\ No newline at end of file diff --git a/transfemscience.org/articles/bica-adoption/index.html b/transfemscience.org/articles/bica-adoption/index.html index 8b5b6916..efdbdddd 100644 --- a/transfemscience.org/articles/bica-adoption/index.html +++ b/transfemscience.org/articles/bica-adoption/index.html @@ -1 +1 @@ -Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy - Transfeminine Science Link

Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy

By Aly | First published July 1, 2020 | Last modified March 20, 2024

Abstract / TL;DR

Bicalutamide is an antiandrogen which was introduced for the treatment of prostate cancer many years ago. Cost precluded its widespread use for other indications for many years. However, its cost has since come down and bicalutamide is now seeing significant adoption for use in transfeminine hormone therapy as well as for treatment of androgen-dependent conditions in other populations like cisgender women. Bicalutamide has risks of certain rare adverse effects like liver toxicity which have generated concerns about its safety and have limited its use in transfeminine people. However, while still significant, these risks are low with appropriate monitoring and clinical management. Prominent researchers in transgender medicine have recently shown openness to bicalutamide for potential use in transfeminine people and have written positively about it. Bicalutamide could eventually come to be regarded as acceptably safe for use in transfeminine hormone therapy, similarly to other antiandrogens with rare risks like spironolactone and cyproterone acetate. However, more studies and characterization of bicalutamide in transfeminine people will likely be needed before it could see wider adoption in transgender medicine.

History of Bicalutamide for Transfeminine People

Bicalutamide (Casodex) is a nonsteroidal antiandrogen and selective antagonist of the androgen receptor which was originally introduced for the treatment of prostate cancer in cisgender men in 1995. Prostate cancer is an androgen-dependent disease, so antiandrogens are effective in treating it. Bicalutamide has major advantages over other antiandrogens such as spironolactone (Aldactone) and cyproterone acetate (Androcur) in terms of antiandrogenic potency, clinical effectiveness, pharmacological selectivity, and tolerability. It also has improved potency, pharmacokinetic properties, and tolerability, as well as far better safety, compared to the older nonsteroidal antiandrogens flutamide (Eulexin) and nilutamide (Anandron, Nilandron). However, use of bicalutamide as an antiandrogen in transfeminine hormone therapy is very recent. The employment of bicalutamide for transfeminine people was largely precluded for many years by the fact that bicalutamide had pharmaceutical patent protection and was very expensive. However, this changed with the availability of generic versions of bicalutamide starting in 2007 to 2009. In addition, newer and more effective antiandrogens like abiraterone acetate (Zytiga) in 2011 and enzalutamide (Xtandi) in 2012 were introduced and superseded bicalutamide as the standard-of-care antiandrogen for the treatment of prostate cancer. These developments have greatly reduced the cost of bicalutamide and it has gradually become much more affordable in the last decade.

Before 2015, there were only a few mentions in the literature of bicalutamide for transfeminine people and a handful of anecdotal reports online of transfeminine people using it. The earliest clear mention of bicalutamide in the literature in the context of transfeminine hormone therapy was by Louis Gooren in 2011 (Gooren, 2011). Gooren is a major longtime researcher in the field of transgender medicine and is one of the coauthors of the Endocrine Society’s transgender hormone therapy guidelines (Hembree et al., 2009; Hembree et al., 2017). He and his colleagues at the Center of Expertise on Gender Dysphoria of the Vrije Universiteit Medical Center (VUMC) in Amsterdam, Netherlands had conducted studies on nilutamide (Anandron, Nilandron) as an antiandrogen for transfeminine people in the late 1980s and early 1990s (de Voogt et al., 1987a; de Voogt et al., 1987b; Gooren et al., 1987; Johannes et al., 1987; Rao et al., 1988; Asscheman, Gooren, & Peereboom-Wynia, 1989; van Kemenade et al., 1989; Wiki). However, they seem to have abandoned it—probably due to its high incidence of lung toxicity and other off-target side effects. Nonetheless, Gooren began including nonsteroidal antiandrogens like flutamide and nilutamide in his publications as potential treatment options for transfeminine hormone therapy starting in the 1990s (Asscheman & Gooren, 1992; Gooren, 1999). Subsequently, flutamide was included in transgender health guidelines and other publications, though not necessarily favorably (e.g., Israel & Tarver, 1997; Levy, Crown, & Reid, 2003; Dahl et al., 2006a; Dahl et al., 2006b; Hembree et al., 2009; Moreno-Pérez et al., 2012). As a researcher interested in nonsteroidal antiandrogens for transfeminine people, bicalutamide—with its far better safety profile than flutamide and nilutamide—may have been appealing to Gooren. However, Gooren and his colleagues didn’t conduct clinical studies on bicalutamide for transfeminine people and never went beyond brief mention of it for such uses in their publications. Nor did any other academics.

Besides transfeminine people and men with prostate cancer, bicalutamide has been studied for use in the treatment of androgen-dependent conditions in other populations. For example, it has been used in the treatment of hirsutism (excessive facial/body hair growth) in cisgender women with and without polycystic ovary syndrome (PCOS) (Müderris, Bayram, & Güven, 1999; Müderris et al., 2002; Bahceci et al., 2004; Müderris & Öner, 2009; Moretti et al., 2016; Moretti et al., 2018; Wiki). Bicalutamide has also been studied in combination with anastrozole (Arimidex), an aromatase inhibitor, for the treatment of gonadotropin-independent precocious puberty in cisgender boys (Kreher et al., 2006; Lewis et al., 2009; Mitre & Lteif, 2009; Stenger et al., 2009; Lenz et al., 2010; Reiter et al., 2010; Tessaris et al., 2012; Özcabı et al., 2015; Kor, 2018; Arya & Davies, 2019; Nabhan & Eugster, 2019; Finkle et al., 2020; Gurnurkar, DiLillo, & Carakushansky, 2021; Wiki). This is a rare form of precocious puberty in which gonadotropin-releasing hormone modulators are not effective. A phase 2 clinical trial was completed and a New Drug Application (NDA) was submitted in the United States for treatment of the condition with bicalutamide and anastrozole, but the application was not approved due to inadequate evidence of effectiveness on the primary efficacy endpoint of limiting height (AstraZeneca, 2008). However, bicalutamide is still used off-label for this indication, and information on bicalutamide for this use is provided in the the Casodex Food and Drug Administration (FDA) label (FDA, 2017).

Although there was little discussion or use of bicalutamide in transfeminine people prior to 2015, this started to change in mid-2015. At that time, the Wikipedia content for bicalutamide was greatly expanded, which made information about bicalutamide more accessible. In addition, certain transfeminine people, noting its advantages over existing options and its excellent potential for use in transfeminine hormone therapy, began advocating for use of bicalutamide in transfeminine people in online circles. A number of open-minded clinicians started adopting bicalutamide in transfeminine people around this time and thereafter as well. The first clinical study of bicalutamide in transfeminine people, which began in 2013, was published as an abstract in 2017 and as a full paper in 2019 (Neyman, Fuqua, & Eugster, 2017; Neyman, Fuqua, & Eugster, 2019). It was a small retrospective chart review of bicalutamide alone as a second-line puberty blocker in adolescent transgender girls for whom gonadotropin-releasing hormone analogues were denied by insurance. As of present, it remains the only published clinical data on bicalutamide in transfeminine people. It’s not exactly great data by any means, but it’s a study at least. The researchers who conducted the study had previously published on bicalutamide as a puberty blocker in boys with gonadotropin-independent precocious puberty (e.g., Lenz et al., 2010; Haddad & Eugster, 2012). While limited in its findings, Neyman, Fuqua, and Eugster (2019) helped to generate significant interest among clinicians and researchers in bicalutamide for use in transfeminine hormone therapy.

In any case, due to the recent nature of bicalutamide as an option for use in transfeminine hormone therapy, as well as the lack of studies and characterization of bicalutamide in transfeminine people and concerns about its safety (see next section), bicalutamide isn’t widely used in transfeminine people at this time. In fact, transgender hormone therapy guidelines largely don’t even mention it still. At present, the use of bicalutamide in transfeminine people is mostly limited to a number of more flexible clinicians and to people in the transgender do-it-yourself (DIY) hormone therapy community.

Concerns About Bicalutamide Limiting its Use

The transgender medical community has been reluctant to endorse the use of bicalutamide in transfeminine people to date. This is because of the lack of clinical studies and characterization of bicalutamide in transfeminine people, most importantly in terms of safety. There have been concerns about rare instances of liver failure that have occurred with bicalutamide in men with prostate cancer (Wiki). The reported cases of liver toxicity with bicalutamide have generally been sudden-onset and severe. Rare liver toxicity is an acceptable risk in men with prostate cancer because the risk–benefit ratio of bicalutamide therapy is very favorable, with the benefit of treating prostate cancer vastly outweighing the harm of the very rare instances of liver problems. But transfeminine people are typically young and healthy, and bicalutamide isn’t treating a terminal illness when it’s used in us. If a transfeminine person develops liver failure and dies because of bicalutamide, that’s unnecessary harm and a life needlessly lost. Accordingly, the University of California San Francisco (UCSF) transgender care guidelines warn against use of bicalutamide in transfeminine people currently due to potential liver risks (Deutsch, 2016). Aside from risks, there is also a lack of data to guide appropriate dosing of bicalutamide in transfeminine people at this time. A typical bicalutamide dosage of 50 mg/day is being used and recommended, but this has been arbitrarily chosen with little basis to support it.

To date, there are 10 published case reports of serious liver toxicity in association with bicalutamide (Table). All of these cases were in men with prostate cancer and all occurred within 6 months of initiation of bicalutamide therapy, with two of the cases resulting in death. While this is not a lot of cases and may seem reassuring, it must be noted that quantity of published case reports tends to vastly underestimate the true incidence of rare adverse reactions. As an example, there are around 50 published case reports of meningioma with cyproterone acetate (Table), but a recent large study by the French government found that there were more than 500 operated instances of meningioma in association with high-dose cyproterone acetate over an 8-year period in France alone (Aly, 2020). Accordingly, as of writing there are 40 reports of liver failure, including 25 consequent deaths, in association with bicalutamide in the U.S. FDA’s international MedWatch/FAERS database. (As well as 240 cases of interstitial lung disease associated with bicalutamide notably—relative to only 14 published case reports; Table.) Even with this database however, fewer than 10% of serious adverse reactions are estimated to be reported (Graham, Ahmad, & Piazza-Hepp, 2002). Hence, the true numbers may be much greater. These instances are merely co-occurrences, and causality in terms of bicalutamide and liver toxicity has not been established. But they are concerning nonetheless. There is additionally an unpublished case anecdote of death in a young transfeminine person associated with bicalutamide that’s been making its rounds through the transgender medical community. Per certain very credible people in the field of transgender medicine (e.g., Asa Radix and Zil Goldstein), she is said to have been a 20-year-old transgender girl in Texas taking bicalutamide with rapid-onset liver failure and no warning signs. This case has given clinicians and researchers who are aware of it reservations about the use of bicalutamide in hormone therapy for transfeminine people. Another case of liver failure and death in a transgender person over 60 years of age who was treated with bicalutamide has also been informally reported (QueerDoc).

In any case, the reported cases of serious liver toxicity with bicalutamide in transgender people have not been published nor properly confirmed. In addition, the absolute incidence of liver toxicity with bicalutamide is likely to be very low. For instance, the incidence of abnormal liver function tests (i.e., elevated liver enzymes on blood work) was only 3.4% with high-dose (150 mg/day) bicalutamide monotherapy relative to 1.9% for placebo (a 1.5% difference attributable to bicalutamide) at 3.0 years of follow-up in the Early Prostate Cancer (EPC) clinical programme, a series of three phase 3 randomized controlled trials consisting of over 8,000 patients in which bicalutamide was evaluated for treatment of early prostate cancer (Anderson, 2003; Iversen et al., 2004; Wiki; Wiki). Moreover, there were no cases of serious liver toxicity or liver failure with bicalutamide in the initial clinical development programme of bicalutamide for advanced prostate cancer, in which almost 4,000 men were treated with bicalutamide (Blackledge, 1996; Kolvenbag & Blackledge, 1996; McLeod, 1997; Anderson, 2003; Iversen et al., 2004; Wiki). However, it should be noted that this was with careful monitoring of liver function in patients and with prompt discontinuation of bicalutamide upon detection of clinically concerning hepatic abnormalities. About 0.5 to 1.5% of men taking 50 to 150 mg/day bicalutamide in the major clinical programmes of bicalutamide for prostate cancer developed liver changes sufficiently marked that they required discontinuation (Blackledge, 1996; See et al., 2002; Wiki). Hence, regular liver monitoring is essential with bicalutamide to ensure that the possibility of severe liver toxicity is avoided.

Bicalutamide has a much lower risk of liver toxicity than its analogue flutamide (Kolvenbag & Blackledge, 1996; Schellhammer et al., 1997; Thole et al., 2004; Manso et al., 2006; Table). However, it retains a small risk of liver toxicity of its own—one with the potential for serious consequences. Hence, caution is warranted with its use, and careful liver monitoring is a necessity for anyone taking it.

Recent Developments and the Future

Bicalutamide is currently being adopted and characterized for use in the treatment androgen-dependent skin and hair conditions in cisgender women. For instance, a rigorous Italian phase 3 randomized controlled trial of bicalutamide for hirsutism was recently published (Moretti et al., 2018). Retrospective chart reviews of bicalutamide for scalp hair loss in cisgender women have also been published recently (Fernandez-Nieto et al., 2019; Ismail et al., 2020; Fernandez-Nieto et al., 2020; Moussa et al., 2021). The hair loss studies have observed low though significant rates of liver changes with bicalutamide.

Certain transgender medical researchers are showing interest in bicalutamide as well. Perhaps most notably, Wylie Hembree—the lead author of the Endocrine Society’s 2009 and 2017 transgender hormone therapy guidelines (Hembree et al., 2009; Hembree et al., 2017)—wrote positively about bicalutamide for transfeminine people in a recent review (Fishman, Paliou, Poretsky, & Hembree, 2019). He and his colleagues cited the recent phase 3 trial of bicalutamide for hirsutism in cisgender women and the study of bicalutamide as a puberty blocker in transgender girls in support of potential use of bicalutamide for transfeminine people. Guy T’Sjoen—another major researcher in transgender medicine and co-author of the Endocrine Society guidelines (Hembree et al., 2017; Mitchell, 2020)—seemed to show openness to bicalutamide with his colleagues in a recent review as well (Iwamoto et al., 2019). Researchers outside of the United States in particular may be more open to bicalutamide, owing to accumulating health concerns with cyproterone acetate—the most commonly used antiandrogen outside of the United States (Aly, 2020). John Randolph, a researcher at the University of Michigan, has also written positively about bicalutamide (Randolph, 2018), though he may have since changed his mind on it (Michigan Medicine, 2020). On the other hand, other authors have not been as welcoming of bicalutamide for transfeminine people (e.g., Hamidi & Davidge-Pitts, 2019; Cocchetti et al., 2020).

The small risks of bicalutamide with appropriate monitoring may prove to be acceptable to the transgender medical community. This would perhaps be analogous to the rare incidences of serious adverse effects with say spironolactone (e.g., hyperkalemia) or cyproterone acetate (e.g., benign brain tumors, blood clots, breast cancer, liver toxicity). It’s possible that bicalutamide may not ultimately be recommended as a first-line therapy due to its risks. However, it could still be allowed as a second-line option when other antiandrogens are less feasible or not possible due to being for instance inadequately effective, poorly tolerated, contraindicated, or unavailable. The transgender medical community isn’t there at this time though. More developments—namely studies and characterization of bicalutamide in actual transfeminine people—are likely to be needed before bicalutamide could become more accepted for use in transfeminine people or recommended in transgender hormone therapy guidelines.

Updates

Update 1: Thompson et al. (2021) [Fenway Health Guidelines]

In March 2021, the Fenway Health transgender health clinical practice guidelines were updated from the last version (October 2015) to the following latest edition (Aly, 2020):

  • Thompson, J., Hopwood, R. A., deNormand, S., & Cavanaugh, T. (2021). Medical Care of Trans and Gender Diverse Adults. Boston: Fenway Health. [URL] [PDF]

This update is notable as these guidelines included bicalutamide as an antiandrogen option for transfeminine people. While they did not recommend bicalutamide as a first-line agent due to its limited characterization in transfeminine people and its known small risk of liver toxicity, they were cautiously permissive of its use in transfeminine hormone therapy:

Bicalutamide can be used for [gender-affirming hormone therapy], but there are very few studies examining its use and the relative risk/benefit for this purpose. Because of reported cases of fulminant hepatitis, consensus is that its use in gender affirming hormonal regimen should be carefully considered, used only after alternative options have been trialed or offered, and an in-depth discussion of these potential risks have been had.

These are the first transgender care guidelines to allow the use of bicalutamide, and only the second guidelines to include bicalutamide. Previously, only the UCSF guidelines mentioned bicalutamide, but they were not permissive of its use in transfeminine people.

Update 2: Tomson et al. (2021) [SAHCS Guidelines]

In September 2021, the Southern African HIV Clinicians Society (SAHCS) published clinical guidelines for transgender care for the first time:

  • Tomson, A., McLachlan, C., Wattrus, C., Adams, K., Addinall, R., Bothma, R., Jankelowitz, L., Kotze, E., Luvuno, Z., Madlala, N., Matyila, S., Padavatan, A., Pillay, M., Rakumakoe, M. D., Tomson-Myburgh, M., Venter, W., & de Vries, E. (2021). Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa. Southern African Journal of HIV Medicine, 22(1), a1299. [DOI:10.4102/sajhivmed.v22i1.1299] [PDF]

Surprisingly, these guidelines not only included bicalutamide but recommended it as the preferred antiandrogen over spironolactone and cyproterone acetate. The reason stated for this was “less risk of neurosteroid depletion (does not cross blood-brain-barrier readily).” However, this supposed effect isn’t a known concern with antiandrogens besides 5α-reductase inhibitors, and bicalutamide actually does appear to be centrally permeable in humans (Wiki). Also surprisingly, no mention of liver toxicity or liver enzyme monitoring with bicalutamide was made in these guidelines. Considering these apparent oversights and others, these guidelines’s recommendations should probably be interpreted with caution.

Update 3: Coleman et al. (2022) [WPATH SOC8 Guidelines]

In September 2022, the World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8) were published (Coleman et al., 2022). The WPATH SOC8 are among the most important if not the most important transgender care guidelines that exist and that are consulted by health care professionals. These guidelines briefly discussed bicalutamide including in the following two instances:

Bicalutamide is an antiandrogen that has been used in the treatment of prostate cancer. It competitively binds to the androgen receptor to block the binding of androgens. Data on the use of bicalutamide in trans feminine populations is very sparse and safety data is lacking. One small study looked at the use of bicalutamide 50 mg daily as a puberty blocker in 23 trans feminine adolescents who could not obtain treatment with a GnRH analogue (Neyman et al., 2019). All adolescents experienced breast development which is also commonly seen in men with prostate cancer who are treated with bicalutamide. Although rare, fulminant hepatotoxicity resulting in death has been described with bicalutamide (O’Bryant et al., 2008). Given that bicalutamide has not been adequately studied in trans feminine populations, we do not recommend its routine use.

When selecting a medication, we advise using those which have been studied in multiple transgender populations (i.e., estrogen, cyproterone acetate, GnRH agonists) rather than medications with little to no peer-reviewed scientific studies (i.e., bicalutamide, rectal progesterone, etc.) (Angus et al., 2021; Butler et al., 2017; Efstathiou et al., 2019; Tosun et al., 2019).

As can be seen, the WPATH SOC8 did not recommend the routine use of bicalutamide in transfeminine people owing to the lack of studies of it in this population and its potential risks. As touched on in the present article, it is likely that more studies of bicalutamide in transfeminine people will be needed before bicalutamide could become endorsed by major transgender care guidelines.

Update 4: Jamie Reed 2023 Bicalutamide Liver Toxicity Case

In February 2023, Jamie Reed, a former case manager at the The Washington University Transgender Center at St. Louis Children’s Hospital in St. Louis, Missouri, published the op-ed “I Thought I Was Saving Trans Kids. Now I’m Blowing the Whistle.” in a conservative online news outlet called The Free Press. In this article, Reed expressed that she had become disillusioned with the medical care of transgender youth and layed out her grievances. In addition however, she briefly described an additional case of liver toxicity with bicalutamide in a transfeminine person that had allegedly occurred at her center. This individual was said to be 15 years of age and was given bicalutamide as a puberty blocker by Dr. Christopher Lewis, one of the co-founders of the center. She was said to have subsequently developed liver toxicity and was taken off of bicalutamide. In an electronic message to the center, her mother said that they were “lucky her family was not the type to sue”. This instance, and Reed’s op-ed in general, were subsequently widely reported on in conservative news media, for instance on Fox News and in the Daily Mail (Google). In addition to her op-ed, Reed provided a sworn affidavit to the office of Republican Missouri attorney general Andrew Bailey, who proceeded to launch an investigation of the clinic (Missouri Government, 2023a). The following further information was released in the affidavit:

One doctor at the Center, Dr. Chris Lewis, is giving patients a drug called Bicalutamide. The drug has a legitimate use for treating pancreatic cancer [sic], but it has a side effect of causing breasts to grow, and it can poison the liver. There are no clinical studies for using this drug for gender transitions, and there are no established standards of care for using this drug.

Because of these risks and the lack of scientific studies, other centers that do gender transitions will not use Bicalutamide. The adult center affiliated with Washington University will not use this medication for this reason. But the Center treating children does.

I know of at least one patient at the Center who was advised by the renal department to stop taking Bicalutamide because the child was experiencing liver damage. The child’s parent reported this to the Center through the patient’s online self-reporting medical chart (MyChart). The parent said they were not the type to sue, but “this could be a huge PR problem for you.”

While unpublished and unverified like the earlier reports of liver toxicity with bicalutamide in transfeminine people, this case represents yet another report, and is notably by far the best-documented one. No other clinical details on the case were provided, and it is unclear whether it involved serious liver toxicity, merely asymptomatic liver function test abnormalities, or a clinical situation somewhere in-between these extremes. In any case, it does seem clear that this instance is not likely to have a positive influence on the further adoption of bicalutamide in transfeminine hormone therapy.

Subsequent to the investigation of the clinic being launched, in April 2023, Missouri greatly restricted gender-affirming care for transgender youth and adults, with some of the most severe limits that have been enacted in the United States (Associated Press, 2023a; Missouri Government, 2023b). Bicalutamide and the liver toxicity instance were not further described with these developments. The new state law restricting gender-affirming care took effect August 28, 2023, and Washington University announced that it would stop prescribing puberty blockers and hormone therapy to transgender youth shortly thereafter (Associated Press, 2023b).

A New York Times article with additional information on the case was also subsequently published (Ghorayshi, 2023 [Excerpts]). It was noted that the adolescent had been on bicalutamide for 1 year and definitely experienced hepatotoxicity. However, she also had a complicated medical history, including being immunocompromised, having recently had COVID-19, and having taken another drug known to be associated with hepatotoxicity. As such, the hepatotoxicity cannot be definitively attributed to bicalutamide, but it simultaneously cannot be ruled out that bicalutamide was involved or causative.

Subsequent Burgener et al. (2023, 2024) Findings

Following the preceding case, Dr. Lewis and colleagues went on to publish a conference abstract and preprint of a study of bicalutamide in transfeminine youth and young adults in which they stated that it does not increase liver enzymes in this population (Burgener et al., 2023; Burgener et al., 2024). However, a closer look at their data show that bicalutamide did statistically significantly elevate certain liver parameters relative to other antiandrogens, namely rates of elevated aspartate aminotransferase (AST) (upper limit of normal 10.7% vs. 1.5%, P = 0.02) (Burgener et al., 2024). Likewise, rates of elevated alanine aminotransferase (ALT) appeared to trend in the direction of being increased, though this was not statistically significant (upper limit of normal 16.7% vs. 11.6%, P = 0.37) (Burgener et al., 2024). In any case, rates of clinically significant elevations in liver enzymes with bicalutamide, defined as greater than three times the upper limit of normal, were not significantly increased in the study.

On the basis of the relevant research in men with prostate cancer (Wiki), Dr. Lewis and colleagues’ study, with a bicalutamide-group sample size of only 84 transfeminine individuals, was clearly greatly underpowered for evaluating liver function changes. Per the Early Prostate Cancer trial of high-dose bicalutamide monotherapy in men with prostate cancer, elevated liver enzymes appear to occur with bicalutamide at a rate of only about 1.5% more than placebo, or roughly an additional 1 in every 66 people (Wiki). Based on power analysis, this would require a far larger sample size to have adequate statistical power and actually have a chance of achieving statistical significance.

As such, it seems to the present author premature to conclude that bicalutamide does not elevate liver enzymes in transfeminine people.

Dr. Lewis and colleagues didn’t mention in their study paper the transfeminine adolescent liver toxicity case reported by Jamie Reed that was said to have occurred at their clinic nor have they published a case report about this instance. Instead, only the following is stated:

One case report published in 2024 described a transgender female adolescent prescribed bicalutamide 50 mg daily who presented to a hospital with liver toxicity that resolved after stopping bicalutamide (Wilde et al., 2024). This appears to be the first documented case of bicalutamide-induced hepatoxicity in a transgender female.

While this case was, coincidentally, also a 17-year-old transfeminine adolescent (Wilde et al., 2024), this instance, per the medical histories and reporting authors/institutions, appears to be distinct from Dr. Lewis’s that was reported by Jamie Reed.

However, Dr. Lewis and colleagues did note the following in their paper, which plausibly might have been the Jamie Reed case:

There was one individual in whom bicalutamide was stopped after the follow-up period designated for the study. This individual developed ALT and AST >2x ULN after an episode of COVID and had a thorough hepatology evaluation. As ALT and AST were never > 3x ULN, it was not recommended that bicalutamide be stopped; however, ultimately a clinical decision was made to stop the medication and ALT and AST normalized.

Another concern with Dr. Lewis and colleagues’ paper pertains to the following statements:

Whereas bicalutamide doses for prostate cancer reach 150 mg daily, doses used in the care of AMAB transfeminine individuals are much lower (25-50 mg daily).

Bicalutamide doses used in prostate cancer are up to 150 mg daily. Due to these concerns of liver toxicity, bicalutamide has not been routinely used as an anti-androgen in AMAB transfeminine individuals, despite the much lower doses needed in this population (∼25-50 mg daily).

In actuality, bicalutamide is most widely used in prostate cancer, in the form of combined androgen blockade with surgical or medical castration, at a dosage of 50 mg/day, whereas the 150 mg/day dosage is used less commonly, in the form of monotherapy (Wiki). Among the published case reports of hepatotoxicity with bicalutamide in men with prostate cancer, half have been at a dose of 50 mg/day and the other half have been at a dose of 80 to 150 mg/day (Wiki). The two instances of death due to hepatotoxicity with bicalutamide were both at 50 mg/day. There is currently no evidence that the hepatotoxicity of bicalutamide is dose-dependent across its clinically used dosage range (Wiki), although employment of the lowest effective dose in transfeminine people nonetheless seems prudent just in case. Hence, in contrast to Dr. Lewis and colleague’s claims, a bicalutamide dosage of 50 mg/day is not less than that used in prostate cancer, and clearly retains substantial hepatotoxic potential.

Update 5: New 2022, 2023, and 2024 Bicalutamide Publications

2022

  • Angus, L., Nolan, B., Zajac, J., & Cheung, A. (November 2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 280). [URL] [PDF] [Full Abstract Book]

2023

  • Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (November 2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. AusPATH 2023 Symposium. [URL] [PDF] [Slides] [Trans Health Research Blog Post]
  • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
  • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (May 2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]): 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
  • Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. Clinical Toxicology, 61(Suppl 1 [43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain]), 81–82 (abstract no. 170). [DOI:10.1080/15563650.2023.2192024] [PDF] [Reactions Weekly]
  • Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. Journal of Clinical Research in Pediatric Endocrinology, 15(3), 276–284. [DOI:10.4274/jcrpe.galenos.2023.2023-1-13]
  • Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (May 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. National Transgender Health Summit (NTHS) 2023 Symposium. [Event Agenda PDF] [Symposium Session] [Symposium Abstracts/Program Book]
  • Vierregger, K. S. (November 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH 2023 Symposium. [Symposium Schedule]
  • Warus, J. (November 2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH 2023 Symposium. [Symposium Schedule]
  • Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. Journal of Adolescent Health, 74(1), 202–204. [DOI:10.1016/j.jadohealth.2023.08.024]

2024

  • Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. medRxiv, preprint. [DOI:10.1101/2024.02.21.24302999v1] [PDF]
  • Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2023.2294321]
  • Shumer, D., & Roberts, S. A. (2024). Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. Journal of Adolescent Health, 74(1), 5–6. [DOI:10.1016/j.jadohealth.2023.10.010]

Update 6: Original Bicalutamide Liver and Lung Toxicity Analysis by Sam

A few years ago back in 2021, Transfeminine Science author Sam conducted an original analysis of the incidence of liver and lung toxicity with bicalutamide in the published clinical trial literature. This project was never finished or made publicly available. However, with bicalutamide being increasingly studied and adopted for use in transfeminine people, it seems quite valuable and relevant today. As such, we have opted to now publish Sam’s analysis in this section.

Sam’s analysis can be found in the provided document here. In terms of methodology, she searched PubMed for all clinical trials of bicalutamide, collated all of the relevant results into a table, and then calculated the incidences of serious liver toxicity and lung toxicity from those data. In clinical trials, adverse events are rated in terms of grades of severity, with a Grade 3 adverse event defined as “severe”, Grade 4 as “life-threatening”, and Grade 5 as “death” (Wiki).

Of 229 results, 33 trials were found to be relevant and were included. Most of the trials were in men with prostate cancer, but a few were in women with cancer and boys with precocious puberty. Sam found that of a total of 7,703 evaluable participants, there were 2 instances of serious liver toxicity and 2 instances of serious lung toxicity with bicalutamide. This resulted in the same incidence rate of 0.026% (95% CI: 0.003% to 0.094%) or approximately 1 in 3,846 individuals for both liver toxicity and lung toxicity. Combining these toxicities resulted in a total incidence of serious liver or serious lung toxicity with bicalutamide of 0.052% (95% CI: 0.014% to 0.133%) or approximately 1 in 1,923 individuals. All of the observed toxicity events were rated as Grade 3 or 4. It should be noted that clinical trials of bicalutamide typically employ careful laboratory monitoring and assessment of clinical adverse events as well as prompt medication discontinuation upon unfavorable laboratory changes.

While the confidence intervals (CIs) in Sam’s analysis were wide and hence the estimates are very rough, they provide an idea of the potential real-world risk of serious toxicity with bicalutamide in transfeminine people based on high-quality clinical data. Notably, they do not suffer from the problem of under-reporting of adverse events that occurs with published case reports, pharmacovigilance databases, and certain types of observational studies. However, limitations of Sam’s analysis include (1) toxicity incidence rates for no-bicalutamide controls not being assessed and (2) most of the patients having cancer and being of older age, and hence the generalizability of the findings to healthy transfeminine people not being fully clear. In any case, I was surprised by how high the incidence rates were when I first saw her analysis, and I suspect that others may be as well.

References

  • Anderson, J. (2003). The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU International, 91(5), 455–461. [DOI:10.1046/j.1464-410X.2003.04026.x]
  • Angus, L., Nolan, B., Zajac, J., & Cheung, A. (2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 280). [URL] [PDF] [Full Abstract Book]
  • Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. AusPATH 2023 Symposium. [URL] [PDF] [Slides] [Trans Health Research Blog Post]
  • Arya, V. B., & Davies, J. H. (2019). Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required? Journal of Pediatric Endocrinology & Metabolism: JPEM, 32(4), 403–407. [DOI:10.1515/jpem-2018-0419]
  • Asscheman, H., Gooren, L. J., & Peereboom-Wynia, J. D. (1989). Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals—experiences with a novel androgen receptor blocker. Clinical and Experimental Dermatology, 14(5), 361–363. [DOI:10.1111/j.1365-2230.1989.tb02585.x]
  • Asscheman, H., & Gooren, L. J. (1992). Hormone Treatment in Transsexuals. In Bocking, W. O., Coleman, E. (Eds). Gender Dysphoria: Interdisciplinary Approaches in Clinical Management (pp. 39–54). Binghamton: Haworth Press. / Journal of Psychology & Human Sexuality, 5(4), 39–54. [Google Scholar] [Google Books] [DOI:10.1300/J056v05n04_03]
  • AstraZeneca. (2008). Clinical Review. NDA. 22-310/S-001. Casodex (bicalutamide) for Testotoxicosis. Food and Drug Administration/AstraZeneca Pharmaceuticals. [URL] [PDF]
  • Bahceci, M., Tuzcu, A., Canoruc, N., Tuzun, Y., Kidir, V., & Aslan, C. (2004). Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Hormone Research in Paediatrics, 62(6), 283–287. [DOI:10.1159/000081973]
  • Bailey, A. (2023 February 9). Missouri Attorney General Andrew Bailey Confirms Launch of Multi-Agency Investigation into St. Louis Transgender Center for Harming Hundreds of Children. Attorney General Andrew Bailey, Missouri Government. [URL] [Affadavit of Jamie Reed]
  • Bailey, A. (2023 April 13). Missouri Attorney General Andrew Bailey Promulgates Emergency Regulation Targeting Gender Transition Procedures for Minors. Attorney General Andrew Bailey, Missouri Government. [URL] [Emergency Regulation PDF]
  • Ballentine, S., & Hollingsworth, H. (2023 April 13). Missouri to limit gender-affirming care for minors, adults. Associated Press. [URL]
  • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
  • Blackledge, G. R. P. (1996). Clinical progress with a new antiandrogen, Casodex™ (bicalutamide). European Urology, 29(Suppl 2), 96–104. [DOI:10.1159/000473847]
  • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]): 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
  • Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. medRxiv, preprint. [DOI:10.1101/2024.02.21.24302999v1] [PDF]
  • Cocchetti, C., Ristori, J., Romani, A., Maggi, M., & Fisher, A. D. (2020). Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. Journal of Clinical Medicine, 9(6), 1609. [DOI:10.3390/jcm9061609]
  • Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F., Monstrey, S. J., Motmans, J., Nahata, L., … & Arcelus, J. (2022). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. [DOI:10.1080/26895269.2022.2100644] [URL] [PDF]
  • Dahl, M., Feldman, J. L., Goldberg, J. M., & Jaberi, A. (2006). Physical aspects of transgender endocrine therapy. International Journal of Transgenderism, 9(3–4), 111–134. [DOI:10.1300/J485v09n03_06]
  • Dahl, M., Feldman, J. L., Goldberg, J., & Jaberi, A. (2006). Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines. Physical Aspects of Transgender Endocrine Therapy. Vancouver: Vancouver Coastal Health. [Google Scholar] [PDF]
  • de Voogt, H. J., Rao, B. R., Gooren, L. J. G., Geldof, A. A., & Bouman, F. G. (1987). Considerations About the Use of Anti-Androgenic Drugs in Male-to-Female Transsexuals. Tenth International Symposium on Gender Dysphoria, Diagnosis and Treatment of Transsexualism, Vrije Universiteit Amsterdam, The Netherlands, June 9–12, 1987. Harry Benjamin International Gender Dysphoria Association. [PDF]
  • de Voogt, H. J., Rao, B. R., Geldof, A. A., Gooren, L. J. G., & Bouman, F. G. (1987). Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate. The Prostate, 11(4), 305–311. [DOI:10.1002/pros.2990110403]
  • Deutsch, M. B. (2016). Overview of feminizing hormone therapy. In Deutsch, M. B. (Ed.). Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition (pp. 26–48). San Francisco: University of California, San Francisco/UCSF Transgender Care. [URL] [PDF]
  • Fernandez-Nieto, D., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O., Jimenez-Cauhe, J., Ortega-Quijano, D., & Vano-Galvan, S. (2019). Oral bicalutamide for female pattern hair loss: A pilot study. Dermatologic Therapy, 32(6), e13096. [DOI:10.1111/dth.13096]
  • Fernandez-Nieto, D., Saceda-Corralo, D., Jimenez-Cauhe, J., Moreno-Arrones, O. M., Rodrigues-Barata, R., Hermosa-Gelbard, A., & Vano-Galvan, S. (2020). Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss. Journal of the American Academy of Dermatology, 83(5), e355–e356. [DOI:10.1016/j.jaad.2020.04.054]
  • Finkle, A., Zavertnik, S., Myers, S., Cormier, D., Heithaus, J., & Augustyn, M. (2020). Growing Up Fast: Managing Autism Spectrum Disorder and Precocious Puberty. Journal of Developmental and Behavioral Pediatrics: JDBP, 41(9), 740–742. [DOI:10.1097/DBP.0000000000000865]
  • Fishman, S. L., Paliou, M., Poretsky, L., & Hembree, W. C. (2019). Endocrine Care of Transgender Adults. In Poretsky, L., & Hembree, W. C. (Eds.). Transgender Medicine (pp. 143–163). Cham: Humana Press. [DOI:10.1007/978-3-030-05683-4_8]
  • Food and Drug Administration (FDA). (2017). CASODEX (bicalutamide) tablet, for oral use. [URL] [PDF]
  • Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2023.2294321]
  • Ghorayshi, A. (2023 August 29). How a Small Gender Clinic Landed in a Political Storm. The New York Times. [URL]
  • Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. Clinical Toxicology, 61(Suppl 1 [43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain]), 81–82 (abstract no. 170). [DOI:10.1080/15563650.2023.2192024] [PDF] [Reactions Weekly]
  • Gooren, L., Spinder, T., Spijkstra, J. J., Van Kessel, H., Smals, A., Rao, B. R., & Hoogslag, M. (1987). Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen. The Journal of Clinical Endocrinology & Metabolism, 64(4), 763–770. [DOI:10.1210/jcem-64-4-763]
  • Gooren, L. J. G. (1999). Hormonal Sex Reassignment. International Journal of Transgenderism, 3(3), 1–7. [Google Scholar] [URL] [Alt]
  • Gooren, L. J. (2011). Care of transsexual persons. New England Journal of Medicine, 364(13), 1251–1257. [DOI:10.1056/NEJMcp1008161]
  • Graham, D. J., Ahmad, S. R., & Piazza‐Hepp, T. (2002). Spontaneous Reporting—USA. In Mann, R. D., & Andrews, E. B. (Eds.). Pharmacovigilance (pp. 219–227). Chichester: John Wiley & Sons. [DOI:10.1002/0470853093.ch17]
  • Gurnurkar, S., DiLillo, E., & Carakushansky, M. (2021). A Case of Familial Male-limited Precocious Puberty with a Novel Mutation. Journal of Clinical Research in Pediatric Endocrinology, 13(2), 239–244. [DOI:10.4274/jcrpe.galenos.2020.2020.0067]
  • Haddad, N. G., & Eugster, E. A. (2012). Peripheral Precocious Puberty: Interventions to Improve Growth. In Preedy, V. R. (Ed.). Handbook of Growth and Growth Monitoring in Health and Disease (pp. 1199–1212). New York: Springer. [DOI:10.1007/978-1-4419-1795-9_71]
  • Hamidi, O., & Davidge-Pitts, C. J. (2019). Transfeminine Hormone Therapy. Endocrinology and Metabolism Clinics, 48(2), 341–355. [DOI:10.1016/j.ecl.2019.02.001]
  • Hembree, W. C., Cohen-Kettenis, P., Delemarre-Van De Waal, H. A., Gooren, L. J., Meyer III, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009). Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 94(9), 3132–3154. [DOI:10.1210/jc.2009-0345]
  • Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 102(11), 3869–3903. [DOI:10.1210/jc.2017-01658] [PDF]
  • Ismail, F. F., Meah, N., de Carvalho, L. T., Bhoyrul, B., Wall, D., & Sinclair, R. (2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. Journal of the American Academy of Dermatology, 83(5), 1478–1479. [DOI:10.1016/j.jaad.2020.03.034]
  • Israel, G. E., & Tarver, D. E. (1997). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts (p. 66). Philadelphia: Temple University Press. [Google Scholar] [Google Books]
  • Iversen, P., Johansson, J. E., Lodding, P., Lukkarinen, O., Lundmo, P., Klarskov, P., Tammela, T. L., Tasdemir, I., Morris, T., Carroll, K., & Scandinavian Prostatic Cancer Group. (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. The Journal of Urology, 172(5 Part 1), 1871–1876. [DOI:10.1097/01.ju.0000139719.99825.54]
  • Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 2042018819871166. [DOI:10.1177/2042018819871166]
  • Johannes, F. L. M., van Kemenade, M. A., Cohen-Kettenis, P. T., Cohen, L., & Gooren, L. J. G. (1987). Effects of RU 23.903 (Anandron) on Lateralization and Spatial Ability in Male-to-Female-Transsexuals. Tenth International Symposium on Gender Dysphoria, Diagnosis and Treatment of Transsexualism, Vrije Universiteit Amsterdam, The Netherlands, June 9–12, 1987. Harry Benjamin International Gender Dysphoria Association. [PDF]
  • Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. Journal of Clinical Research in Pediatric Endocrinology, 15(3), 276–284. [DOI:10.4274/jcrpe.galenos.2023.2023-1-13]
  • Kolvenbag, G. J., & Blackledge, G. R. (1996). Worldwide activity and safety of bicalutamide: a summary review. Urology, 47(1), 70–79. [DOI:10.1016/S0090-4295(96)80012-4]
  • Kor, Y. (2018). Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring. Hormones, 17(2), 275–278. [DOI:10.1007/s42000-018-0029-1]
  • Kreher, N. C., Pescovitz, O. H., Delameter, P., Tiulpakov, A., & Hochberg, Z. E. (2006). Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. The Journal of Pediatrics, 149(3), 416–420. [DOI:10.1016/j.jpeds.2006.04.027]
  • Lenz, A. M., Shulman, D., Eugster, E. A., Rahhal, S., Fuqua, J. S., Pescovitz, O. H., & Lewis, K. A. (2010). Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics, 126(3), e728–e733. [DOI:10.1542/peds.2010-0596]
  • Levy, A., Crown, A., & Reid, R. (2003). Endocrine intervention for transsexuals. Clinical Endocrinology, 59(4), 409–418. [DOI:10.1046/j.1365-2265.2003.01821.x]
  • Lewis, K. A., Lenz, A., Eugster, E. A., Fuqua, J. S., Pescovitz, O. H., Rahhal, S., & Shulman, D. (2009). Long term bicalutamide and 3rd generation aromatase inhibitor therapy in two boys with testotoxicosis. Hormone Research [in Paediatrics], 72(Suppl 3), 266–267 (PO2-189). [Google Scholar] [DOI:10.1159/000239668]
  • Manso, G., Thole, Z., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2006). Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiology and Drug Safety, 15(4), 253–259. [DOI:10.1002/pds.1168]
  • McLeod, D. G. (1997). Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer. The Oncologist, 2(1), 18–27. [DOI:10.1634/theoncologist.2-1-18]
  • Michigan Medicine. (2020). Feminizing Gender-Affirming Hormone Care: The Michigan Medicine Approach. Ann Arbor: Michigan Medicine/University of Michigan. [URL] [PDF]
  • Mitchell, F. (2020). Guy T’Sjoen: collaborating to improve transgender wellbeing. The Lancet Diabetes & Endocrinology, 8(7), 568–568. [DOI:10.1016/S2213-8587(20)30192-3]
  • Mitre, N., & Lteif, A. (2009). Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor. Journal of Pediatric Endocrinology and Metabolism, 22(12), 1163–1168. [DOI:10.1515/JPEM.2009.22.12.1163]
  • Moreno-Pérez, Ó., De Antonio, I. E., & Grupo de Identidad y Diferenciación Sexual de la SEEN (GIDSEEN. (2012). Clinical practice guidelines for assessment and treatment of transsexualism. SEEN Identity and Sexual Differentiation Group (GIDSEEN). Endocrinología y Nutrición (English Edition), 59(6), 367–382. [DOI:10.1016/j.endoen.2012.07.004]
  • Moretti, C. G., Guccione, L., Di Giacinto, P., Cannuccia, A., Meleca, C., Lanzolla, G., Andreadi, A., & Lauro, D. (2016). Efficacy and Safety of Myo-Inositol Supplementation in the Treatment of Obese Hirsute PCOS Women: Comparative Evaluation with OCP+Bicalutamide Therapy. Endocrine Reviews, 37(2 Suppl 1) (SUN-153). [URL] [DOI:10.1093/edrv/37.supp.1]
  • Moretti, C., Guccione, L., Di Giacinto, P., Simonelli, I., Exacoustos, C., Toscano, V., Motta, C., De Leo, V., Petraglia, F., & Lenzi, A. (2018). Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double-blind randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 103(3), 824–838. [DOI:10.1210/jc.2017-01186]
  • Moussa, A., Kazmi, A., Bokhari, L., & Sinclair, R. D. (2022). Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients. Journal of the American Academy of Dermatology, 87(2), 488–490. [DOI:10.1016/j.jaad.2021.10.048]
  • Muderris, I. I., Bayram, F., & Guven, M. (1999). Bicalutamide 25 mg/day in the treatment of hirsutism. Human Reproduction, 14(Suppl 3), 366–366 (R-196). [DOI:10.1093/humrep/14.Suppl_3.366-a]
  • Müderris, I. I., Bayram, F., Özçelik, B., & Güven, M. (2002). New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecological Endocrinology, 16(1), 63–66. [DOI:10.1080/gye.16.1.63.66]
  • Müderris, İ. İ., & Öner, G. (2009). Hirsutizm Tedavisinde Flutamid ve Bikalutamid Kullanımı. [Flutamide and Bicalutamide Treatment in Hirsutism.] Türkiye Klinikleri Endokrinoloji-Özel Dergisi, 2(2), 110–112. [ISSN:1308-0954] [URL] [PDF] [Translation]
  • Nabhan, Z. M., & Eugster, E. A. (2019). Testotoxicosis with an episodic course: an unusual case within a series. AACE Clinical Case Reports, 5(1), e50–e53. [DOI:10.4158/ACCR-2018-0246]
  • Neyman, A., Fuqua, J. S., & Eugster, E. A. (2017). Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics, 88(Suppl 1 [10th Individual Abstracts for International Meeting of Pediatric Endocrinology: Free Communication and Poster Sessions, Abstracts]), 477–477 (abstract no. P3-605). [DOI:10.1159/000481424] [PDF]
  • Neyman, A., Fuqua, J. S., & Eugster, E. A. (2019). Bicalutamide as an androgen blocker with secondary effect of promoting feminization in male-to-female transgender adolescents. Journal of Adolescent Health, 64(4), 544–546. [DOI:10.1016/j.jadohealth.2018.10.296]
  • Özcabı, B., Ceylaner, S., Özcan, R., Büyükünal, C., Ercan, O., Tüysüz, B., & Evliyaoğlu, O. (2015). Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene. Journal of Clinical Research in Pediatric Endocrinology, 7(3), 242–248. [DOI:10.4274/jcrpe.2067]
  • Randolph Jr, J. F. (2018). Gender-Affirming Hormone Therapy for Transgender Females. Clinical Obstetrics and Gynecology, 61(4), 705–721. [DOI:10.1097/GRF.0000000000000396] [URL]
  • Rao, B. R., De Voogt, H. J., Geldof, A. A., Gooren, L. J. G., & Bouman, F. G. (1988). Merits and considerations in the use of anti-androgen. Journal of Steroid Biochemistry, 31(4), 731–737. [DOI:10.1016/0022-4731(88)90024-6]
  • Reed, J. (2023 February 9). I Thought I Was Saving Trans Kids. Now I’m Blowing the Whistle. The Free Press. [URL]
  • Reiter, E. O., Mauras, N., McCormick, K., Kulshreshtha, B., Amrhein, J., De Luca, F., O’Brien, S., Armstrong, J., & Melezinkova, H. (2010). Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). Journal of Pediatric Endocrinology & Metabolism: JPEM, 23(10), 999–1009. [DOI:10.1515/jpem.2010.161]
  • Salter, J., & Ballentine, S. (2023 September 12). Missouri clinics halt transgender care for minors in wake of new state law. Associated Press. [URL]
  • Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., Sarosdy, M. F., Vogelzang, N. J., Schellenger, J. J., Kolvenbag, G. J., & Casodex Combination Study Group. (1997). Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology, 50(3), 330–336. [DOI:10.1016/s0090-4295(97)00279-3]
  • Shumer, D., & Roberts, S. A. (2024). Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. Journal of Adolescent Health, 74(1), 5–6. [DOI:10.1016/j.jadohealth.2023.10.010]
  • See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D. M., Delaere, K. P., Vaage, S., Tammela, T. L., Lukkarinen, O., Persson, B. E., Carroll, K., Kolvenbag, G. J., & Casodex Early Prostate Cancer Trialist Group. (2002). Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. The Journal of Urology, 168(2), 429–435. [DOI:10.1016/S0022-5347(05)64652-6]
  • Stenger, P. J., Wagner, L., Egelhoff, J., & Rose, S. R. (2009). Bicalutamide and letrozole treatment of precocious puberty due to elevated levels of human chorionic gonadotropin (hCG). Hormone Research [in Paediatrics], 72(Suppl 3), 391–391 (PO3-149). [Google Scholar] [DOI:10.1159/000239668]
  • Tessaris, D., Matarazzo, P., Mussa, A., Tuli, G., Verna, F., Fiore, L., & Lala, R. (2012). Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome. Endocrine Journal, 59(2), 111–117. [DOI:10.1507/endocrj.ej11-0214]
  • Thole, Z., Manso, G., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2004). Hepatotoxicity induced by antiandrogens: a review of the literature. Urologia Internationalis, 73(4), 289–295. [DOI:10.1159/000081585]
  • Thompson, J., Hopwood, R. A., deNormand, S., & Cavanaugh, T. (2021). Medical Care of Trans and Gender Diverse Adults. Boston: Fenway Health. [URL] [PDF]
  • Tomson, A., McLachlan, C., Wattrus, C., Adams, K., Addinall, R., Bothma, R., Jankelowitz, L., Kotze, E., Luvuno, Z., Madlala, N., Matyila, S., Padavatan, A., Pillay, M., Rakumakoe, M. D., Tomson-Myburgh, M., Venter, W., & de Vries, E. (2021). Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa. Southern African Journal of HIV Medicine, 22(1), a1299. [DOI:10.4102/sajhivmed.v22i1.1299] [PDF]
  • van Kemenade, J. F., Cohen-Kettenis, P. T., Cohen, L., & Gooren, L. J. (1989). Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals. Archives of Sexual Behavior, 18(3), 217–228. [DOI:10.1007/BF01543196]
  • Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. National Transgender Health Summit (NTHS) 2023 Symposium. [Event Agenda PDF] [Symposium Session] [Symposium Abstracts/Program Book]
  • Vierregger, K. S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH 2023 Symposium. [Symposium Schedule]
  • Warus, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH 2023 Symposium. [Symposium Schedule]
  • Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. Journal of Adolescent Health, 74(1), 202–204. [DOI:10.1016/j.jadohealth.2023.08.024]
\ No newline at end of file +Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy - Transfeminine Science Link

Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy

By Aly | First published July 1, 2020 | Last modified March 23, 2024

Abstract / TL;DR

Bicalutamide is an antiandrogen which was introduced for the treatment of prostate cancer many years ago. Cost precluded its widespread use for other indications for many years. However, its cost has since come down and bicalutamide is now seeing significant adoption for use in transfeminine hormone therapy as well as for treatment of androgen-dependent conditions in other populations like cisgender women. Bicalutamide has risks of certain rare adverse effects like liver toxicity which have generated concerns about its safety and have limited its use in transfeminine people. However, while still significant, these risks are low with appropriate monitoring and clinical management. Prominent researchers in transgender medicine have recently shown openness to bicalutamide for potential use in transfeminine people and have written positively about it. Bicalutamide could eventually come to be regarded as acceptably safe for use in transfeminine hormone therapy, similarly to other antiandrogens with rare risks like spironolactone and cyproterone acetate. However, more studies and characterization of bicalutamide in transfeminine people will likely be needed before it could see wider adoption in transgender medicine.

History of Bicalutamide for Transfeminine People

Bicalutamide (Casodex) is a nonsteroidal antiandrogen and selective antagonist of the androgen receptor which was originally introduced for the treatment of prostate cancer in cisgender men in 1995. Prostate cancer is an androgen-dependent disease, so antiandrogens are effective in treating it. Bicalutamide has major advantages over other antiandrogens such as spironolactone (Aldactone) and cyproterone acetate (Androcur) in terms of antiandrogenic potency, clinical effectiveness, pharmacological selectivity, and tolerability. It also has improved potency, pharmacokinetic properties, and tolerability, as well as far better safety, compared to the older nonsteroidal antiandrogens flutamide (Eulexin) and nilutamide (Anandron, Nilandron). However, use of bicalutamide as an antiandrogen in transfeminine hormone therapy is very recent. The employment of bicalutamide for transfeminine people was largely precluded for many years by the fact that bicalutamide had pharmaceutical patent protection and was very expensive. However, this changed with the availability of generic versions of bicalutamide starting in 2007 to 2009. In addition, newer and more effective antiandrogens like abiraterone acetate (Zytiga) in 2011 and enzalutamide (Xtandi) in 2012 were introduced and superseded bicalutamide as the standard-of-care antiandrogen for the treatment of prostate cancer. These developments have greatly reduced the cost of bicalutamide and it has gradually become much more affordable in the last decade.

Before 2015, there were only a few mentions in the literature of bicalutamide for transfeminine people and a handful of anecdotal reports online of transfeminine people using it. The earliest clear mention of bicalutamide in the literature in the context of transfeminine hormone therapy was by Louis Gooren in 2011 (Gooren, 2011). Gooren is a major longtime researcher in the field of transgender medicine and is one of the coauthors of the Endocrine Society’s transgender hormone therapy guidelines (Hembree et al., 2009; Hembree et al., 2017). He and his colleagues at the Center of Expertise on Gender Dysphoria of the Vrije Universiteit Medical Center (VUMC) in Amsterdam, Netherlands had conducted studies on nilutamide (Anandron, Nilandron) as an antiandrogen for transfeminine people in the late 1980s and early 1990s (de Voogt et al., 1987a; de Voogt et al., 1987b; Gooren et al., 1987; Johannes et al., 1987; Rao et al., 1988; Asscheman, Gooren, & Peereboom-Wynia, 1989; van Kemenade et al., 1989; Wiki). However, they seem to have abandoned it—probably due to its high incidence of lung toxicity and other off-target side effects. Nonetheless, Gooren began including nonsteroidal antiandrogens like flutamide and nilutamide in his publications as potential treatment options for transfeminine hormone therapy starting in the 1990s (Asscheman & Gooren, 1992; Gooren, 1999). Subsequently, flutamide was included in transgender health guidelines and other publications, though not necessarily favorably (e.g., Israel & Tarver, 1997; Levy, Crown, & Reid, 2003; Dahl et al., 2006a; Dahl et al., 2006b; Hembree et al., 2009; Moreno-Pérez et al., 2012). As a researcher interested in nonsteroidal antiandrogens for transfeminine people, bicalutamide—with its far better safety profile than flutamide and nilutamide—may have been appealing to Gooren. However, Gooren and his colleagues didn’t conduct clinical studies on bicalutamide for transfeminine people and never went beyond brief mention of it for such uses in their publications. Nor did any other academics.

Besides transfeminine people and men with prostate cancer, bicalutamide has been studied for use in the treatment of androgen-dependent conditions in other populations. For example, it has been used in the treatment of hirsutism (excessive facial/body hair growth) in cisgender women with and without polycystic ovary syndrome (PCOS) (Müderris, Bayram, & Güven, 1999; Müderris et al., 2002; Bahceci et al., 2004; Müderris & Öner, 2009; Moretti et al., 2016; Moretti et al., 2018; Wiki). Bicalutamide has also been studied in combination with anastrozole (Arimidex), an aromatase inhibitor, for the treatment of gonadotropin-independent precocious puberty in cisgender boys (Kreher et al., 2006; Lewis et al., 2009; Mitre & Lteif, 2009; Stenger et al., 2009; Lenz et al., 2010; Reiter et al., 2010; Tessaris et al., 2012; Özcabı et al., 2015; Kor, 2018; Arya & Davies, 2019; Nabhan & Eugster, 2019; Finkle et al., 2020; Gurnurkar, DiLillo, & Carakushansky, 2021; Wiki). This is a rare form of precocious puberty in which gonadotropin-releasing hormone modulators are not effective. A phase 2 clinical trial was completed and a New Drug Application (NDA) was submitted in the United States for treatment of the condition with bicalutamide and anastrozole, but the application was not approved due to inadequate evidence of effectiveness on the primary efficacy endpoint of limiting height (AstraZeneca, 2008). However, bicalutamide is still used off-label for this indication, and information on bicalutamide for this use is provided in the the Casodex Food and Drug Administration (FDA) label (FDA, 2017).

Although there was little discussion or use of bicalutamide in transfeminine people prior to 2015, this started to change in mid-2015. At that time, the Wikipedia content for bicalutamide was greatly expanded, which made information about bicalutamide more accessible. In addition, certain transfeminine people, noting its advantages over existing options and its excellent potential for use in transfeminine hormone therapy, began advocating for use of bicalutamide in transfeminine people in online circles. A number of open-minded clinicians started adopting bicalutamide in transfeminine people around this time and thereafter as well. The first clinical study of bicalutamide in transfeminine people, which began in 2013, was published as an abstract in 2017 and as a full paper in 2019 (Neyman, Fuqua, & Eugster, 2017; Neyman, Fuqua, & Eugster, 2019). It was a small retrospective chart review of bicalutamide alone as a second-line puberty blocker in adolescent transgender girls for whom gonadotropin-releasing hormone analogues were denied by insurance. As of present, it remains the only published clinical data on bicalutamide in transfeminine people. It’s not exactly great data by any means, but it’s a study at least. The researchers who conducted the study had previously published on bicalutamide as a puberty blocker in boys with gonadotropin-independent precocious puberty (e.g., Lenz et al., 2010; Haddad & Eugster, 2012). While limited in its findings, Neyman, Fuqua, and Eugster (2019) helped to generate significant interest among clinicians and researchers in bicalutamide for use in transfeminine hormone therapy.

In any case, due to the recent nature of bicalutamide as an option for use in transfeminine hormone therapy, as well as the lack of studies and characterization of bicalutamide in transfeminine people and concerns about its safety (see next section), bicalutamide isn’t widely used in transfeminine people at this time. In fact, transgender hormone therapy guidelines largely don’t even mention it still. At present, the use of bicalutamide in transfeminine people is mostly limited to a number of more flexible clinicians and to people in the transgender do-it-yourself (DIY) hormone therapy community.

Concerns About Bicalutamide Limiting its Use

The transgender medical community has been reluctant to endorse the use of bicalutamide in transfeminine people to date. This is because of the lack of clinical studies and characterization of bicalutamide in transfeminine people, most importantly in terms of safety. There have been concerns about rare instances of liver failure that have occurred with bicalutamide in men with prostate cancer (Wiki). The reported cases of liver toxicity with bicalutamide have generally been sudden-onset and severe. Rare liver toxicity is an acceptable risk in men with prostate cancer because the risk–benefit ratio of bicalutamide therapy is very favorable, with the benefit of treating prostate cancer vastly outweighing the harm of the very rare instances of liver problems. But transfeminine people are typically young and healthy, and bicalutamide isn’t treating a terminal illness when it’s used in us. If a transfeminine person develops liver failure and dies because of bicalutamide, that’s unnecessary harm and a life needlessly lost. Accordingly, the University of California San Francisco (UCSF) transgender care guidelines warn against use of bicalutamide in transfeminine people currently due to potential liver risks (Deutsch, 2016). Aside from risks, there is also a lack of data to guide appropriate dosing of bicalutamide in transfeminine people at this time. A typical bicalutamide dosage of 50 mg/day is being used and recommended, but this has been arbitrarily chosen with little basis to support it.

To date, there are 10 published case reports of serious liver toxicity in association with bicalutamide (Table). All of these cases were in men with prostate cancer and all occurred within 6 months of initiation of bicalutamide therapy, with two of the cases resulting in death. While this is not a lot of cases and may seem reassuring, it must be noted that quantity of published case reports tends to vastly underestimate the true incidence of rare adverse reactions. As an example, there are around 50 published case reports of meningioma with cyproterone acetate (Table), but a recent large study by the French government found that there were more than 500 operated instances of meningioma in association with high-dose cyproterone acetate over an 8-year period in France alone (Aly, 2020). Accordingly, as of writing there are 40 reports of liver failure, including 25 consequent deaths, in association with bicalutamide in the U.S. FDA’s international MedWatch/FAERS database. (As well as 240 cases of interstitial lung disease associated with bicalutamide notably—relative to only 14 published case reports; Table.) Even with this database however, fewer than 10% of serious adverse reactions are estimated to be reported (Graham, Ahmad, & Piazza-Hepp, 2002). Hence, the true numbers may be much greater. These instances are merely co-occurrences, and causality in terms of bicalutamide and liver toxicity has not been established. But they are concerning nonetheless. There is additionally an unpublished case anecdote of death in a young transfeminine person associated with bicalutamide that’s been making its rounds through the transgender medical community. Per certain very credible people in the field of transgender medicine (e.g., Asa Radix and Zil Goldstein), she is said to have been a 20-year-old transgender girl in Texas taking bicalutamide with rapid-onset liver failure and no warning signs. This case has given clinicians and researchers who are aware of it reservations about the use of bicalutamide in hormone therapy for transfeminine people. Another case of liver failure and death in a transgender person over 60 years of age who was treated with bicalutamide has also been informally reported (QueerDoc).

In any case, the reported cases of serious liver toxicity with bicalutamide in transgender people have not been published nor properly confirmed. In addition, the absolute incidence of liver toxicity with bicalutamide is likely to be very low. For instance, the incidence of abnormal liver function tests (i.e., elevated liver enzymes on blood work) was only 3.4% with high-dose (150 mg/day) bicalutamide monotherapy relative to 1.9% for placebo (a 1.5% difference attributable to bicalutamide) at 3.0 years of follow-up in the Early Prostate Cancer (EPC) clinical programme, a series of three phase 3 randomized controlled trials consisting of over 8,000 patients in which bicalutamide was evaluated for treatment of early prostate cancer (Anderson, 2003; Iversen et al., 2004; Wiki; Wiki). Moreover, there were no cases of serious liver toxicity or liver failure with bicalutamide in the initial clinical development programme of bicalutamide for advanced prostate cancer, in which almost 4,000 men were treated with bicalutamide (Blackledge, 1996; Kolvenbag & Blackledge, 1996; McLeod, 1997; Anderson, 2003; Iversen et al., 2004; Wiki). However, it should be noted that this was with careful monitoring of liver function in patients and with prompt discontinuation of bicalutamide upon detection of clinically concerning hepatic abnormalities. About 0.5 to 1.5% of men taking 50 to 150 mg/day bicalutamide in the major clinical programmes of bicalutamide for prostate cancer developed liver changes sufficiently marked that they required discontinuation (Blackledge, 1996; See et al., 2002; Wiki). Hence, regular liver monitoring is essential with bicalutamide to ensure that the possibility of severe liver toxicity is avoided.

Bicalutamide has a much lower risk of liver toxicity than its analogue flutamide (Kolvenbag & Blackledge, 1996; Schellhammer et al., 1997; Thole et al., 2004; Manso et al., 2006; Table). However, it retains a small risk of liver toxicity of its own—one with the potential for serious consequences. Hence, caution is warranted with its use, and careful liver monitoring is a necessity for anyone taking it.

Recent Developments and the Future

Bicalutamide is currently being adopted and characterized for use in the treatment androgen-dependent skin and hair conditions in cisgender women. For instance, a rigorous Italian phase 3 randomized controlled trial of bicalutamide for hirsutism was recently published (Moretti et al., 2018). Retrospective chart reviews of bicalutamide for scalp hair loss in cisgender women have also been published recently (Fernandez-Nieto et al., 2019; Ismail et al., 2020; Fernandez-Nieto et al., 2020; Moussa et al., 2021). The hair loss studies have observed low though significant rates of liver changes with bicalutamide.

Certain transgender medical researchers are showing interest in bicalutamide as well. Perhaps most notably, Wylie Hembree—the lead author of the Endocrine Society’s 2009 and 2017 transgender hormone therapy guidelines (Hembree et al., 2009; Hembree et al., 2017)—wrote positively about bicalutamide for transfeminine people in a recent review (Fishman, Paliou, Poretsky, & Hembree, 2019). He and his colleagues cited the recent phase 3 trial of bicalutamide for hirsutism in cisgender women and the study of bicalutamide as a puberty blocker in transgender girls in support of potential use of bicalutamide for transfeminine people. Guy T’Sjoen—another major researcher in transgender medicine and co-author of the Endocrine Society guidelines (Hembree et al., 2017; Mitchell, 2020)—seemed to show openness to bicalutamide with his colleagues in a recent review as well (Iwamoto et al., 2019). Researchers outside of the United States in particular may be more open to bicalutamide, owing to accumulating health concerns with cyproterone acetate—the most commonly used antiandrogen outside of the United States (Aly, 2020). John Randolph, a researcher at the University of Michigan, has also written positively about bicalutamide (Randolph, 2018), though he may have since changed his mind on it (Michigan Medicine, 2020). On the other hand, other authors have not been as welcoming of bicalutamide for transfeminine people (e.g., Hamidi & Davidge-Pitts, 2019; Cocchetti et al., 2020).

The small risks of bicalutamide with appropriate monitoring may prove to be acceptable to the transgender medical community. This would perhaps be analogous to the rare incidences of serious adverse effects with say spironolactone (e.g., hyperkalemia) or cyproterone acetate (e.g., benign brain tumors, blood clots, breast cancer, liver toxicity). It’s possible that bicalutamide may not ultimately be recommended as a first-line therapy due to its risks. However, it could still be allowed as a second-line option when other antiandrogens are less feasible or not possible due to being for instance inadequately effective, poorly tolerated, contraindicated, or unavailable. The transgender medical community isn’t there at this time though. More developments—namely studies and characterization of bicalutamide in actual transfeminine people—are likely to be needed before bicalutamide could become more accepted for use in transfeminine people or recommended in transgender hormone therapy guidelines.

Updates

Update 1: Thompson et al. (2021) [Fenway Health Guidelines]

In March 2021, the Fenway Health transgender health clinical practice guidelines were updated from the last version (October 2015) to the following latest edition (Aly, 2020):

  • Thompson, J., Hopwood, R. A., deNormand, S., & Cavanaugh, T. (2021). Medical Care of Trans and Gender Diverse Adults. Boston: Fenway Health. [URL] [PDF]

This update is notable as these guidelines included bicalutamide as an antiandrogen option for transfeminine people. While they did not recommend bicalutamide as a first-line agent due to its limited characterization in transfeminine people and its known small risk of liver toxicity, they were cautiously permissive of its use in transfeminine hormone therapy:

Bicalutamide can be used for [gender-affirming hormone therapy], but there are very few studies examining its use and the relative risk/benefit for this purpose. Because of reported cases of fulminant hepatitis, consensus is that its use in gender affirming hormonal regimen should be carefully considered, used only after alternative options have been trialed or offered, and an in-depth discussion of these potential risks have been had.

These are the first transgender care guidelines to allow the use of bicalutamide, and only the second guidelines to include bicalutamide. Previously, only the UCSF guidelines mentioned bicalutamide, but they were not permissive of its use in transfeminine people.

Update 2: Tomson et al. (2021) [SAHCS Guidelines]

In September 2021, the Southern African HIV Clinicians Society (SAHCS) published clinical guidelines for transgender care for the first time:

  • Tomson, A., McLachlan, C., Wattrus, C., Adams, K., Addinall, R., Bothma, R., Jankelowitz, L., Kotze, E., Luvuno, Z., Madlala, N., Matyila, S., Padavatan, A., Pillay, M., Rakumakoe, M. D., Tomson-Myburgh, M., Venter, W., & de Vries, E. (2021). Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa. Southern African Journal of HIV Medicine, 22(1), a1299. [DOI:10.4102/sajhivmed.v22i1.1299] [PDF]

Surprisingly, these guidelines not only included bicalutamide but recommended it as the preferred antiandrogen over spironolactone and cyproterone acetate. The reason stated for this was “less risk of neurosteroid depletion (does not cross blood-brain-barrier readily).” However, this supposed effect isn’t a known concern with antiandrogens besides 5α-reductase inhibitors, and bicalutamide actually does appear to be centrally permeable in humans (Wiki). Also surprisingly, no mention of liver toxicity or liver enzyme monitoring with bicalutamide was made in these guidelines. Considering these apparent oversights and others, these guidelines’s recommendations should probably be interpreted with caution.

Update 3: Coleman et al. (2022) [WPATH SOC8 Guidelines]

In September 2022, the World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People Version 8 (SOC8) were published (Coleman et al., 2022). The WPATH SOC8 are among the most important if not the most important transgender care guidelines that exist and that are consulted by health care professionals. These guidelines briefly discussed bicalutamide including in the following two instances:

Bicalutamide is an antiandrogen that has been used in the treatment of prostate cancer. It competitively binds to the androgen receptor to block the binding of androgens. Data on the use of bicalutamide in trans feminine populations is very sparse and safety data is lacking. One small study looked at the use of bicalutamide 50 mg daily as a puberty blocker in 23 trans feminine adolescents who could not obtain treatment with a GnRH analogue (Neyman et al., 2019). All adolescents experienced breast development which is also commonly seen in men with prostate cancer who are treated with bicalutamide. Although rare, fulminant hepatotoxicity resulting in death has been described with bicalutamide (O’Bryant et al., 2008). Given that bicalutamide has not been adequately studied in trans feminine populations, we do not recommend its routine use.

When selecting a medication, we advise using those which have been studied in multiple transgender populations (i.e., estrogen, cyproterone acetate, GnRH agonists) rather than medications with little to no peer-reviewed scientific studies (i.e., bicalutamide, rectal progesterone, etc.) (Angus et al., 2021; Butler et al., 2017; Efstathiou et al., 2019; Tosun et al., 2019).

As can be seen, the WPATH SOC8 did not recommend the routine use of bicalutamide in transfeminine people owing to the lack of studies of it in this population and its potential risks. As touched on in the present article, it is likely that more studies of bicalutamide in transfeminine people will be needed before bicalutamide could become endorsed by major transgender care guidelines.

Update 4: Jamie Reed 2023 Bicalutamide Liver Toxicity Case

In February 2023, Jamie Reed, a former case manager at the The Washington University Transgender Center at St. Louis Children’s Hospital in St. Louis, Missouri, published the op-ed “I Thought I Was Saving Trans Kids. Now I’m Blowing the Whistle.” in a conservative online news outlet called The Free Press. In this article, Reed expressed that she had become disillusioned with the medical care of transgender youth and layed out her grievances. In addition however, she briefly described an additional case of liver toxicity with bicalutamide in a transfeminine person that had allegedly occurred at her center. This individual was said to be 15 years of age and was given bicalutamide as a puberty blocker by Dr. Christopher Lewis, one of the co-founders of the center. She was said to have subsequently developed liver toxicity and was taken off of bicalutamide. In an electronic message to the center, her mother said that they were “lucky her family was not the type to sue”. This instance, and Reed’s op-ed in general, were subsequently widely reported on in conservative news media, for instance on Fox News and in the Daily Mail (Google). In addition to her op-ed, Reed provided a sworn affidavit to the office of Republican Missouri attorney general Andrew Bailey, who proceeded to launch an investigation of the clinic (Missouri Government, 2023a). The following further information was released in the affidavit:

One doctor at the Center, Dr. Chris Lewis, is giving patients a drug called Bicalutamide. The drug has a legitimate use for treating pancreatic cancer [sic], but it has a side effect of causing breasts to grow, and it can poison the liver. There are no clinical studies for using this drug for gender transitions, and there are no established standards of care for using this drug.

Because of these risks and the lack of scientific studies, other centers that do gender transitions will not use Bicalutamide. The adult center affiliated with Washington University will not use this medication for this reason. But the Center treating children does.

I know of at least one patient at the Center who was advised by the renal department to stop taking Bicalutamide because the child was experiencing liver damage. The child’s parent reported this to the Center through the patient’s online self-reporting medical chart (MyChart). The parent said they were not the type to sue, but “this could be a huge PR problem for you.”

While unpublished and unverified like the earlier reports of liver toxicity with bicalutamide in transfeminine people, this case represents yet another report, and is notably by far the best-documented one. No other clinical details on the case were provided, and it is unclear whether it involved serious liver toxicity, merely asymptomatic liver function test abnormalities, or a clinical situation somewhere in-between these extremes. In any case, it does seem clear that this instance is not likely to have a positive influence on the further adoption of bicalutamide in transfeminine hormone therapy.

Subsequent to the investigation of the clinic being launched, in April 2023, Missouri greatly restricted gender-affirming care for transgender youth and adults, with some of the most severe limits that have been enacted in the United States (Associated Press, 2023a; Missouri Government, 2023b). Bicalutamide and the liver toxicity instance were not further described with these developments. The new state law restricting gender-affirming care took effect August 28, 2023, and Washington University announced that it would stop prescribing puberty blockers and hormone therapy to transgender youth shortly thereafter (Associated Press, 2023b).

A New York Times article with additional information on the case was also subsequently published (Ghorayshi, 2023 [Excerpts]). It was noted that the adolescent had been on bicalutamide for 1 year and definitely experienced hepatotoxicity. However, she also had a complicated medical history, including being immunocompromised, having recently had COVID-19, and having taken another drug known to be associated with hepatotoxicity. As such, the hepatotoxicity cannot be definitively attributed to bicalutamide, but it simultaneously cannot be ruled out that bicalutamide was involved or causative.

Subsequent Burgener et al. (2023, 2024) Findings

Following the preceding case, Dr. Lewis and colleagues went on to publish a conference abstract and preprint of a study of bicalutamide in transfeminine youth and young adults in which they stated that it does not increase liver enzymes in this population (Burgener et al., 2023; Burgener et al., 2024). However, a closer look at their data show that bicalutamide did statistically significantly elevate certain liver parameters relative to other antiandrogens, namely rates of elevated aspartate aminotransferase (AST) (upper limit of normal 10.7% vs. 1.5%, P = 0.02) (Burgener et al., 2024). Likewise, rates of elevated alanine aminotransferase (ALT) appeared to trend in the direction of being increased, though this was not statistically significant (upper limit of normal 16.7% vs. 11.6%, P = 0.37) (Burgener et al., 2024). In any case, rates of clinically significant elevations in liver enzymes with bicalutamide, defined as greater than three times the upper limit of normal, were not significantly increased in the study.

On the basis of the relevant research in men with prostate cancer (Wiki), Dr. Lewis and colleagues’ study, with a bicalutamide-group sample size of only 84 transfeminine individuals, was clearly greatly underpowered for evaluating liver function changes. Per the Early Prostate Cancer trial of high-dose bicalutamide monotherapy in men with prostate cancer, elevated liver enzymes appear to occur with bicalutamide at a rate of only about 1.5% more than placebo, or roughly an additional 1 in every 66 people (Wiki). Based on power analysis, this would require a far larger sample size to have adequate statistical power and actually have a chance of achieving statistical significance.

As such, it seems to the present author premature to conclude that bicalutamide does not elevate liver enzymes in transfeminine people.

Dr. Lewis and colleagues didn’t mention in their study paper the transfeminine adolescent liver toxicity case reported by Jamie Reed that was said to have occurred at their clinic nor have they published a case report about this instance. Instead, only the following is stated:

One case report published in 2024 described a transgender female adolescent prescribed bicalutamide 50 mg daily who presented to a hospital with liver toxicity that resolved after stopping bicalutamide (Wilde et al., 2024). This appears to be the first documented case of bicalutamide-induced hepatoxicity in a transgender female.

While this case was, coincidentally, also a 17-year-old transfeminine adolescent (Wilde et al., 2024), this instance, per the medical histories and reporting authors/institutions, appears to be distinct from Dr. Lewis’s that was reported by Jamie Reed.

However, Dr. Lewis and colleagues did note the following in their paper, which plausibly might have been the Jamie Reed case:

There was one individual in whom bicalutamide was stopped after the follow-up period designated for the study. This individual developed ALT and AST >2x ULN after an episode of COVID and had a thorough hepatology evaluation. As ALT and AST were never > 3x ULN, it was not recommended that bicalutamide be stopped; however, ultimately a clinical decision was made to stop the medication and ALT and AST normalized.

Another concern with Dr. Lewis and colleagues’ paper pertains to the following statements:

Whereas bicalutamide doses for prostate cancer reach 150 mg daily, doses used in the care of AMAB transfeminine individuals are much lower (25-50 mg daily).

Bicalutamide doses used in prostate cancer are up to 150 mg daily. Due to these concerns of liver toxicity, bicalutamide has not been routinely used as an anti-androgen in AMAB transfeminine individuals, despite the much lower doses needed in this population (∼25-50 mg daily).

In actuality, bicalutamide is most widely used in prostate cancer, in the form of combined androgen blockade with surgical or medical castration, at a dosage of 50 mg/day, whereas the 150 mg/day dosage is used less commonly, in the form of monotherapy (Wiki). Among the published case reports of hepatotoxicity with bicalutamide in men with prostate cancer, half have been at a dose of 50 mg/day and the other half have been at a dose of 80 to 150 mg/day (Wiki). The two instances of death due to hepatotoxicity with bicalutamide were both at 50 mg/day. There is currently no evidence that the hepatotoxicity of bicalutamide is dose-dependent across its clinically used dosage range (Wiki), although employment of the lowest effective dose in transfeminine people nonetheless seems prudent just in case. Hence, in contrast to Dr. Lewis and colleague’s claims, a bicalutamide dosage of 50 mg/day is not less than that used in prostate cancer, and clearly retains substantial hepatotoxic potential.

Update 5: New 2022, 2023, and 2024 Bicalutamide Publications

2022

  • Angus, L., Nolan, B., Zajac, J., & Cheung, A. (November 2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 280). [URL] [PDF] [Full Abstract Book]

2023

  • Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (November 2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. AusPATH 2023 Symposium. [URL] [PDF] [Slides] [Trans Health Research Blog Post]
  • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
  • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (May 2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]), 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
  • Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. Clinical Toxicology, 61(Suppl 1 [43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain]), 81–82 (abstract no. 170). [DOI:10.1080/15563650.2023.2192024] [PDF] [Reactions Weekly]
  • Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. Journal of Clinical Research in Pediatric Endocrinology, 15(3), 276–284. [DOI:10.4274/jcrpe.galenos.2023.2023-1-13]
  • Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (May 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. National Transgender Health Summit (NTHS) 2023 Symposium. [Event Agenda PDF] [Symposium Session] [Symposium Abstracts/Program Book]
  • Vierregger, K. S. (November 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH 2023 Symposium. [Symposium Schedule]
  • Warus, J. (November 2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH 2023 Symposium. [Symposium Schedule]
  • Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. Journal of Adolescent Health, 74(1), 202–204. [DOI:10.1016/j.jadohealth.2023.08.024]

2024

  • Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. medRxiv, preprint. [DOI:10.1101/2024.02.21.24302999v1] [PDF]
  • Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2023.2294321]
  • Shumer, D., & Roberts, S. A. (2024). Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. Journal of Adolescent Health, 74(1), 5–6. [DOI:10.1016/j.jadohealth.2023.10.010]

Update 6: Original Bicalutamide Liver and Lung Toxicity Analysis by Sam

A few years ago back in 2021, Transfeminine Science author Sam conducted an original analysis of the incidence of liver and lung toxicity with bicalutamide in the published clinical trial literature. This project was never finished or made publicly available. However, with bicalutamide being increasingly studied and adopted for use in transfeminine people, it seems quite valuable and relevant today. As such, we have opted to now publish Sam’s analysis in this section.

Sam’s analysis can be found in the provided document here. In terms of methodology, she searched PubMed for all clinical trials of bicalutamide, collated all of the relevant results into a table, and then calculated the incidences of serious liver toxicity and lung toxicity from those data. In clinical trials, adverse events are rated in terms of grades of severity, with a Grade 3 adverse event defined as “severe”, Grade 4 as “life-threatening”, and Grade 5 as “death” (Wiki).

Of 229 results, 33 trials were found to be relevant and were included. Most of the trials were in men with prostate cancer, but a few were in women with cancer and boys with precocious puberty. Sam found that of a total of 7,703 evaluable participants, there were 2 instances of serious liver toxicity and 2 instances of serious lung toxicity with bicalutamide. This resulted in the same incidence rate of 0.026% (95% CI: 0.003% to 0.094%) or approximately 1 in 3,846 individuals for both liver toxicity and lung toxicity. Combining these toxicities resulted in a total incidence of serious liver or serious lung toxicity with bicalutamide of 0.052% (95% CI: 0.014% to 0.133%) or approximately 1 in 1,923 individuals. All of the observed toxicity events were rated as Grade 3 or 4. It should be noted that clinical trials of bicalutamide typically employ careful laboratory monitoring and assessment of clinical adverse events as well as prompt medication discontinuation upon unfavorable laboratory changes.

While the confidence intervals (CIs) in Sam’s analysis were wide and hence the estimates are very rough, they provide an idea of the potential real-world risk of serious toxicity with bicalutamide in transfeminine people based on high-quality clinical data. Notably, they do not suffer from the problem of under-reporting of adverse events that occurs with published case reports, pharmacovigilance databases, and certain types of observational studies. However, limitations of Sam’s analysis include (1) toxicity incidence rates for non-bicalutamide-treated controls not being assessed and (2) most of the patients having cancer and being of older age, and hence the generalizability of the findings to healthy transfeminine people not being fully clear. In any case, I was surprised by how high the incidence rates were when I first saw her analysis, and I suspect that others may be as well.

References

  • Anderson, J. (2003). The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU International, 91(5), 455–461. [DOI:10.1046/j.1464-410X.2003.04026.x]
  • Angus, L., Nolan, B., Zajac, J., & Cheung, A. (2022). Use of bicalutamide as an androgen receptor antagonist in transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 280). [URL] [PDF] [Full Abstract Book]
  • Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. AusPATH 2023 Symposium. [URL] [PDF] [Slides] [Trans Health Research Blog Post]
  • Arya, V. B., & Davies, J. H. (2019). Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required? Journal of Pediatric Endocrinology & Metabolism: JPEM, 32(4), 403–407. [DOI:10.1515/jpem-2018-0419]
  • Asscheman, H., Gooren, L. J., & Peereboom-Wynia, J. D. (1989). Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals—experiences with a novel androgen receptor blocker. Clinical and Experimental Dermatology, 14(5), 361–363. [DOI:10.1111/j.1365-2230.1989.tb02585.x]
  • Asscheman, H., & Gooren, L. J. (1992). Hormone Treatment in Transsexuals. In Bocking, W. O., Coleman, E. (Eds). Gender Dysphoria: Interdisciplinary Approaches in Clinical Management (pp. 39–54). Binghamton: Haworth Press. / Journal of Psychology & Human Sexuality, 5(4), 39–54. [Google Scholar] [Google Books] [DOI:10.1300/J056v05n04_03]
  • AstraZeneca. (2008). Clinical Review. NDA. 22-310/S-001. Casodex (bicalutamide) for Testotoxicosis. Food and Drug Administration/AstraZeneca Pharmaceuticals. [URL] [PDF]
  • Bahceci, M., Tuzcu, A., Canoruc, N., Tuzun, Y., Kidir, V., & Aslan, C. (2004). Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Hormone Research in Paediatrics, 62(6), 283–287. [DOI:10.1159/000081973]
  • Bailey, A. (2023 February 9). Missouri Attorney General Andrew Bailey Confirms Launch of Multi-Agency Investigation into St. Louis Transgender Center for Harming Hundreds of Children. Attorney General Andrew Bailey, Missouri Government. [URL] [Affadavit of Jamie Reed]
  • Bailey, A. (2023 April 13). Missouri Attorney General Andrew Bailey Promulgates Emergency Regulation Targeting Gender Transition Procedures for Minors. Attorney General Andrew Bailey, Missouri Government. [URL] [Emergency Regulation PDF]
  • Ballentine, S., & Hollingsworth, H. (2023 April 13). Missouri to limit gender-affirming care for minors, adults. Associated Press. [URL]
  • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
  • Blackledge, G. R. P. (1996). Clinical progress with a new antiandrogen, Casodex™ (bicalutamide). European Urology, 29(Suppl 2), 96–104. [DOI:10.1159/000473847]
  • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]), 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
  • Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. medRxiv, preprint. [DOI:10.1101/2024.02.21.24302999v1] [PDF]
  • Cocchetti, C., Ristori, J., Romani, A., Maggi, M., & Fisher, A. D. (2020). Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. Journal of Clinical Medicine, 9(6), 1609. [DOI:10.3390/jcm9061609]
  • Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F., Monstrey, S. J., Motmans, J., Nahata, L., … & Arcelus, J. (2022). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. [DOI:10.1080/26895269.2022.2100644] [URL] [PDF]
  • Dahl, M., Feldman, J. L., Goldberg, J. M., & Jaberi, A. (2006). Physical aspects of transgender endocrine therapy. International Journal of Transgenderism, 9(3–4), 111–134. [DOI:10.1300/J485v09n03_06]
  • Dahl, M., Feldman, J. L., Goldberg, J., & Jaberi, A. (2006). Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines. Physical Aspects of Transgender Endocrine Therapy. Vancouver: Vancouver Coastal Health. [Google Scholar] [PDF]
  • de Voogt, H. J., Rao, B. R., Gooren, L. J. G., Geldof, A. A., & Bouman, F. G. (1987). Considerations About the Use of Anti-Androgenic Drugs in Male-to-Female Transsexuals. Tenth International Symposium on Gender Dysphoria, Diagnosis and Treatment of Transsexualism, Vrije Universiteit Amsterdam, The Netherlands, June 9–12, 1987. Harry Benjamin International Gender Dysphoria Association. [PDF]
  • de Voogt, H. J., Rao, B. R., Geldof, A. A., Gooren, L. J. G., & Bouman, F. G. (1987). Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate. The Prostate, 11(4), 305–311. [DOI:10.1002/pros.2990110403]
  • Deutsch, M. B. (2016). Overview of feminizing hormone therapy. In Deutsch, M. B. (Ed.). Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition (pp. 26–48). San Francisco: University of California, San Francisco/UCSF Transgender Care. [URL] [PDF]
  • Fernandez-Nieto, D., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O., Jimenez-Cauhe, J., Ortega-Quijano, D., & Vano-Galvan, S. (2019). Oral bicalutamide for female pattern hair loss: A pilot study. Dermatologic Therapy, 32(6), e13096. [DOI:10.1111/dth.13096]
  • Fernandez-Nieto, D., Saceda-Corralo, D., Jimenez-Cauhe, J., Moreno-Arrones, O. M., Rodrigues-Barata, R., Hermosa-Gelbard, A., & Vano-Galvan, S. (2020). Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss. Journal of the American Academy of Dermatology, 83(5), e355–e356. [DOI:10.1016/j.jaad.2020.04.054]
  • Finkle, A., Zavertnik, S., Myers, S., Cormier, D., Heithaus, J., & Augustyn, M. (2020). Growing Up Fast: Managing Autism Spectrum Disorder and Precocious Puberty. Journal of Developmental and Behavioral Pediatrics: JDBP, 41(9), 740–742. [DOI:10.1097/DBP.0000000000000865]
  • Fishman, S. L., Paliou, M., Poretsky, L., & Hembree, W. C. (2019). Endocrine Care of Transgender Adults. In Poretsky, L., & Hembree, W. C. (Eds.). Transgender Medicine (pp. 143–163). Cham: Humana Press. [DOI:10.1007/978-3-030-05683-4_8]
  • Food and Drug Administration (FDA). (2017). CASODEX (bicalutamide) tablet, for oral use. [URL] [PDF]
  • Fuqua, J. S., Shi, E., & Eugster, E. A. (2024). A retrospective review of the use of bicalutamide in transfeminine youth; a single center experience. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2023.2294321]
  • Ghorayshi, A. (2023 August 29). How a Small Gender Clinic Landed in a Political Storm. The New York Times. [URL]
  • Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. Clinical Toxicology, 61(Suppl 1 [43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain]), 81–82 (abstract no. 170). [DOI:10.1080/15563650.2023.2192024] [PDF] [Reactions Weekly]
  • Gooren, L., Spinder, T., Spijkstra, J. J., Van Kessel, H., Smals, A., Rao, B. R., & Hoogslag, M. (1987). Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen. The Journal of Clinical Endocrinology & Metabolism, 64(4), 763–770. [DOI:10.1210/jcem-64-4-763]
  • Gooren, L. J. G. (1999). Hormonal Sex Reassignment. International Journal of Transgenderism, 3(3), 1–7. [Google Scholar] [URL] [Alt]
  • Gooren, L. J. (2011). Care of transsexual persons. New England Journal of Medicine, 364(13), 1251–1257. [DOI:10.1056/NEJMcp1008161]
  • Graham, D. J., Ahmad, S. R., & Piazza‐Hepp, T. (2002). Spontaneous Reporting—USA. In Mann, R. D., & Andrews, E. B. (Eds.). Pharmacovigilance (pp. 219–227). Chichester: John Wiley & Sons. [DOI:10.1002/0470853093.ch17]
  • Gurnurkar, S., DiLillo, E., & Carakushansky, M. (2021). A Case of Familial Male-limited Precocious Puberty with a Novel Mutation. Journal of Clinical Research in Pediatric Endocrinology, 13(2), 239–244. [DOI:10.4274/jcrpe.galenos.2020.2020.0067]
  • Haddad, N. G., & Eugster, E. A. (2012). Peripheral Precocious Puberty: Interventions to Improve Growth. In Preedy, V. R. (Ed.). Handbook of Growth and Growth Monitoring in Health and Disease (pp. 1199–1212). New York: Springer. [DOI:10.1007/978-1-4419-1795-9_71]
  • Hamidi, O., & Davidge-Pitts, C. J. (2019). Transfeminine Hormone Therapy. Endocrinology and Metabolism Clinics, 48(2), 341–355. [DOI:10.1016/j.ecl.2019.02.001]
  • Hembree, W. C., Cohen-Kettenis, P., Delemarre-Van De Waal, H. A., Gooren, L. J., Meyer III, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009). Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 94(9), 3132–3154. [DOI:10.1210/jc.2009-0345]
  • Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 102(11), 3869–3903. [DOI:10.1210/jc.2017-01658] [PDF]
  • Ismail, F. F., Meah, N., de Carvalho, L. T., Bhoyrul, B., Wall, D., & Sinclair, R. (2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. Journal of the American Academy of Dermatology, 83(5), 1478–1479. [DOI:10.1016/j.jaad.2020.03.034]
  • Israel, G. E., & Tarver, D. E. (1997). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts (p. 66). Philadelphia: Temple University Press. [Google Scholar] [Google Books]
  • Iversen, P., Johansson, J. E., Lodding, P., Lukkarinen, O., Lundmo, P., Klarskov, P., Tammela, T. L., Tasdemir, I., Morris, T., Carroll, K., & Scandinavian Prostatic Cancer Group. (2004). Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. The Journal of Urology, 172(5 Part 1), 1871–1876. [DOI:10.1097/01.ju.0000139719.99825.54]
  • Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 2042018819871166. [DOI:10.1177/2042018819871166]
  • Johannes, F. L. M., van Kemenade, M. A., Cohen-Kettenis, P. T., Cohen, L., & Gooren, L. J. G. (1987). Effects of RU 23.903 (Anandron) on Lateralization and Spatial Ability in Male-to-Female-Transsexuals. Tenth International Symposium on Gender Dysphoria, Diagnosis and Treatment of Transsexualism, Vrije Universiteit Amsterdam, The Netherlands, June 9–12, 1987. Harry Benjamin International Gender Dysphoria Association. [PDF]
  • Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. Journal of Clinical Research in Pediatric Endocrinology, 15(3), 276–284. [DOI:10.4274/jcrpe.galenos.2023.2023-1-13]
  • Kolvenbag, G. J., & Blackledge, G. R. (1996). Worldwide activity and safety of bicalutamide: a summary review. Urology, 47(1), 70–79. [DOI:10.1016/S0090-4295(96)80012-4]
  • Kor, Y. (2018). Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring. Hormones, 17(2), 275–278. [DOI:10.1007/s42000-018-0029-1]
  • Kreher, N. C., Pescovitz, O. H., Delameter, P., Tiulpakov, A., & Hochberg, Z. E. (2006). Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. The Journal of Pediatrics, 149(3), 416–420. [DOI:10.1016/j.jpeds.2006.04.027]
  • Lenz, A. M., Shulman, D., Eugster, E. A., Rahhal, S., Fuqua, J. S., Pescovitz, O. H., & Lewis, K. A. (2010). Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics, 126(3), e728–e733. [DOI:10.1542/peds.2010-0596]
  • Levy, A., Crown, A., & Reid, R. (2003). Endocrine intervention for transsexuals. Clinical Endocrinology, 59(4), 409–418. [DOI:10.1046/j.1365-2265.2003.01821.x]
  • Lewis, K. A., Lenz, A., Eugster, E. A., Fuqua, J. S., Pescovitz, O. H., Rahhal, S., & Shulman, D. (2009). Long term bicalutamide and 3rd generation aromatase inhibitor therapy in two boys with testotoxicosis. Hormone Research [in Paediatrics], 72(Suppl 3), 266–267 (PO2-189). [Google Scholar] [DOI:10.1159/000239668]
  • Manso, G., Thole, Z., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2006). Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiology and Drug Safety, 15(4), 253–259. [DOI:10.1002/pds.1168]
  • McLeod, D. G. (1997). Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer. The Oncologist, 2(1), 18–27. [DOI:10.1634/theoncologist.2-1-18]
  • Michigan Medicine. (2020). Feminizing Gender-Affirming Hormone Care: The Michigan Medicine Approach. Ann Arbor: Michigan Medicine/University of Michigan. [URL] [PDF]
  • Mitchell, F. (2020). Guy T’Sjoen: collaborating to improve transgender wellbeing. The Lancet Diabetes & Endocrinology, 8(7), 568–568. [DOI:10.1016/S2213-8587(20)30192-3]
  • Mitre, N., & Lteif, A. (2009). Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor. Journal of Pediatric Endocrinology and Metabolism, 22(12), 1163–1168. [DOI:10.1515/JPEM.2009.22.12.1163]
  • Moreno-Pérez, Ó., De Antonio, I. E., & Grupo de Identidad y Diferenciación Sexual de la SEEN (GIDSEEN. (2012). Clinical practice guidelines for assessment and treatment of transsexualism. SEEN Identity and Sexual Differentiation Group (GIDSEEN). Endocrinología y Nutrición (English Edition), 59(6), 367–382. [DOI:10.1016/j.endoen.2012.07.004]
  • Moretti, C. G., Guccione, L., Di Giacinto, P., Cannuccia, A., Meleca, C., Lanzolla, G., Andreadi, A., & Lauro, D. (2016). Efficacy and Safety of Myo-Inositol Supplementation in the Treatment of Obese Hirsute PCOS Women: Comparative Evaluation with OCP+Bicalutamide Therapy. Endocrine Reviews, 37(2 Suppl 1) (SUN-153). [URL] [DOI:10.1093/edrv/37.supp.1]
  • Moretti, C., Guccione, L., Di Giacinto, P., Simonelli, I., Exacoustos, C., Toscano, V., Motta, C., De Leo, V., Petraglia, F., & Lenzi, A. (2018). Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double-blind randomized controlled trial. The Journal of Clinical Endocrinology & Metabolism, 103(3), 824–838. [DOI:10.1210/jc.2017-01186]
  • Moussa, A., Kazmi, A., Bokhari, L., & Sinclair, R. D. (2022). Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients. Journal of the American Academy of Dermatology, 87(2), 488–490. [DOI:10.1016/j.jaad.2021.10.048]
  • Muderris, I. I., Bayram, F., & Guven, M. (1999). Bicalutamide 25 mg/day in the treatment of hirsutism. Human Reproduction, 14(Suppl 3), 366–366 (R-196). [DOI:10.1093/humrep/14.Suppl_3.366-a]
  • Müderris, I. I., Bayram, F., Özçelik, B., & Güven, M. (2002). New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecological Endocrinology, 16(1), 63–66. [DOI:10.1080/gye.16.1.63.66]
  • Müderris, İ. İ., & Öner, G. (2009). Hirsutizm Tedavisinde Flutamid ve Bikalutamid Kullanımı. [Flutamide and Bicalutamide Treatment in Hirsutism.] Türkiye Klinikleri Endokrinoloji-Özel Dergisi, 2(2), 110–112. [ISSN:1308-0954] [URL] [PDF] [Translation]
  • Nabhan, Z. M., & Eugster, E. A. (2019). Testotoxicosis with an episodic course: an unusual case within a series. AACE Clinical Case Reports, 5(1), e50–e53. [DOI:10.4158/ACCR-2018-0246]
  • Neyman, A., Fuqua, J. S., & Eugster, E. A. (2017). Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents. Hormone Research in Paediatrics, 88(Suppl 1 [10th Individual Abstracts for International Meeting of Pediatric Endocrinology: Free Communication and Poster Sessions, Abstracts]), 477–477 (abstract no. P3-605). [DOI:10.1159/000481424] [PDF]
  • Neyman, A., Fuqua, J. S., & Eugster, E. A. (2019). Bicalutamide as an androgen blocker with secondary effect of promoting feminization in male-to-female transgender adolescents. Journal of Adolescent Health, 64(4), 544–546. [DOI:10.1016/j.jadohealth.2018.10.296]
  • Özcabı, B., Ceylaner, S., Özcan, R., Büyükünal, C., Ercan, O., Tüysüz, B., & Evliyaoğlu, O. (2015). Testotoxicosis: Report of Two Cases, One with a Novel Mutation in LHCGR Gene. Journal of Clinical Research in Pediatric Endocrinology, 7(3), 242–248. [DOI:10.4274/jcrpe.2067]
  • Randolph Jr, J. F. (2018). Gender-Affirming Hormone Therapy for Transgender Females. Clinical Obstetrics and Gynecology, 61(4), 705–721. [DOI:10.1097/GRF.0000000000000396] [URL]
  • Rao, B. R., De Voogt, H. J., Geldof, A. A., Gooren, L. J. G., & Bouman, F. G. (1988). Merits and considerations in the use of anti-androgen. Journal of Steroid Biochemistry, 31(4), 731–737. [DOI:10.1016/0022-4731(88)90024-6]
  • Reed, J. (2023 February 9). I Thought I Was Saving Trans Kids. Now I’m Blowing the Whistle. The Free Press. [URL]
  • Reiter, E. O., Mauras, N., McCormick, K., Kulshreshtha, B., Amrhein, J., De Luca, F., O’Brien, S., Armstrong, J., & Melezinkova, H. (2010). Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). Journal of Pediatric Endocrinology & Metabolism: JPEM, 23(10), 999–1009. [DOI:10.1515/jpem.2010.161]
  • Salter, J., & Ballentine, S. (2023 September 12). Missouri clinics halt transgender care for minors in wake of new state law. Associated Press. [URL]
  • Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., Sarosdy, M. F., Vogelzang, N. J., Schellenger, J. J., Kolvenbag, G. J., & Casodex Combination Study Group. (1997). Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology, 50(3), 330–336. [DOI:10.1016/s0090-4295(97)00279-3]
  • Shumer, D., & Roberts, S. A. (2024). Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. Journal of Adolescent Health, 74(1), 5–6. [DOI:10.1016/j.jadohealth.2023.10.010]
  • See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D. M., Delaere, K. P., Vaage, S., Tammela, T. L., Lukkarinen, O., Persson, B. E., Carroll, K., Kolvenbag, G. J., & Casodex Early Prostate Cancer Trialist Group. (2002). Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. The Journal of Urology, 168(2), 429–435. [DOI:10.1016/S0022-5347(05)64652-6]
  • Stenger, P. J., Wagner, L., Egelhoff, J., & Rose, S. R. (2009). Bicalutamide and letrozole treatment of precocious puberty due to elevated levels of human chorionic gonadotropin (hCG). Hormone Research [in Paediatrics], 72(Suppl 3), 391–391 (PO3-149). [Google Scholar] [DOI:10.1159/000239668]
  • Tessaris, D., Matarazzo, P., Mussa, A., Tuli, G., Verna, F., Fiore, L., & Lala, R. (2012). Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome. Endocrine Journal, 59(2), 111–117. [DOI:10.1507/endocrj.ej11-0214]
  • Thole, Z., Manso, G., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2004). Hepatotoxicity induced by antiandrogens: a review of the literature. Urologia Internationalis, 73(4), 289–295. [DOI:10.1159/000081585]
  • Thompson, J., Hopwood, R. A., deNormand, S., & Cavanaugh, T. (2021). Medical Care of Trans and Gender Diverse Adults. Boston: Fenway Health. [URL] [PDF]
  • Tomson, A., McLachlan, C., Wattrus, C., Adams, K., Addinall, R., Bothma, R., Jankelowitz, L., Kotze, E., Luvuno, Z., Madlala, N., Matyila, S., Padavatan, A., Pillay, M., Rakumakoe, M. D., Tomson-Myburgh, M., Venter, W., & de Vries, E. (2021). Southern African HIV Clinicians’ Society gender-affirming healthcare guideline for South Africa. Southern African Journal of HIV Medicine, 22(1), a1299. [DOI:10.4102/sajhivmed.v22i1.1299] [PDF]
  • van Kemenade, J. F., Cohen-Kettenis, P. T., Cohen, L., & Gooren, L. J. (1989). Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals. Archives of Sexual Behavior, 18(3), 217–228. [DOI:10.1007/BF01543196]
  • Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. National Transgender Health Summit (NTHS) 2023 Symposium. [Event Agenda PDF] [Symposium Session] [Symposium Abstracts/Program Book]
  • Vierregger, K. S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH 2023 Symposium. [Symposium Schedule]
  • Warus, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH 2023 Symposium. [Symposium Schedule]
  • Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. Journal of Adolescent Health, 74(1), 202–204. [DOI:10.1016/j.jadohealth.2023.08.024]
\ No newline at end of file diff --git a/transfemscience.org/articles/index.html b/transfemscience.org/articles/index.html index 6e2ec955..2c0f7ef1 100644 --- a/transfemscience.org/articles/index.html +++ b/transfemscience.org/articles/index.html @@ -1 +1 @@ -Articles - Transfeminine Science Link

Articles

General Articles

Special Topics

Estrogens

Antiandrogens

Progestogens

Other Medications

General Effects and Risks

Miscellaneous

Data, Analysis, and Literature

\ No newline at end of file +Articles - Transfeminine Science Link

Articles

General Articles

Special Topics

Estrogens

Antiandrogens

Progestogens

Other Medications

General Effects and Risks

Miscellaneous

Data, Analysis, and Literature

\ No newline at end of file diff --git a/transfemscience.org/articles/progestogens-breast-dev/index.html b/transfemscience.org/articles/progestogens-breast-dev/index.html index 3e842ae1..c38b2782 100644 --- a/transfemscience.org/articles/progestogens-breast-dev/index.html +++ b/transfemscience.org/articles/progestogens-breast-dev/index.html @@ -1 +1 @@ -Considerations in Understanding the Possible Role and Influence of Progestogens in Terms of Breast Development - Transfeminine Science Link

Considerations in Understanding the Possible Role and Influence of Progestogens in Terms of Breast Development

By Aly | First published February 14, 2020 | Last modified May 15, 2023

Notice: This page was originally posted as a thread on Reddit and has not yet been properly or fully revised since being moved to Transfeminine Science.

Studies of Progestogen Therapy and Breast Development in Transfeminine People

As of writing, only a handful of studies have specifically assessed breast development with progestogens—either bioidentical progesterone or a progestin (synthetic progestogen) like medroxyprogesterone acetate (MPA) or cyproterone acetate (CPA)—in transfeminine people. The subject of progestogen therapy and breast development in transfeminine people has also been partly reviewed in papers like Wierckx, Gooren, & T’Sjoen (2014) and Reisman, Goldstein, & Safer (2019).

Meyer et al. (1986) assessed the effects of progestogens added to estrogen therapy on breast development and other clinical parameters in transfeminine people. Of the 60 transfeminine people in the study, 15 (25%) received an oral progestogen, usually MPA at a dosage of 10 mg/day, for “at least for a short time” (with only 8 (13.3%) receiving progestogen therapy for the full treatment period). In an earlier report of the study, it was noted that in 90% of observation periods the dose was 10 mg/day and for the remainder it was 20 mg/day (Meyer et al., 1981). A dosage of 10 mg/day MPA is roughly comparable to luteal-phase progesterone exposure in terms of progestogenic potency (Wiki). Breast development was measured in the study via breast hemicircumference (Diagram). Progestogen therapy was reported to not modify estrogen-induced changes, including laboratory measurements, hormone levels, and physical parameters like weight and breast growth. The lack of apparent changes in hormone levels is unexpected, as MPA in higher-quality studies has shown clear testosterone suppression (e.g., Jain, Kwan, & Forcier, 2019; Wiki). Meyer and colleagues concluded that adding progestogens to estrogen does not seem to enhance breast development in transfeminine people. However, they noted that the number of individuals who received progestogens was small and further studies were needed.

Prior et al. (1986) and Prior, Vigna, & Watson (1989) studied estrogen, high-dose spironolactone (100–600 mg/day), and MPA (10–20 mg/day cylically or continuously) in transfeminine people who were either pre-hormone therapy or had previously been on higher doses of estrogens (and/or progestogens) without spironolactone prior to the study. The researchers reported that following 12 months of treatment with the study’s hormone therapy regimen, there was increased breast size and increased nipple development. Most individuals reached an A cup size, or approximately 8 to 14 cm in diameter of breast tissue, by the end of the study. Breast development was measured in part with photographic documentation. Although breast development reportedly improved, the researchers themselves noted that it was difficult to determine whether the enhanced breast development could be attributed to spironolactone or to MPA. Moreover, testosterone suppression was inadequate before the study and improved with the study’s hormone therapy regimen, which may have helped to improve breast development regardless of any potential direct progestogenic action of MPA on the breasts. Finally, it is possible that breast development with estrogen may not yet have been complete, and that the improved breast development may have simply been continued progression due to estrogen alone. In other publications, Jerilynn Prior, the lead study author, has claimed that progesterone enhances breast development, and has cited the preceding studies by her in support of this claim (Prior, 2011; Prior, 2019a; Prior, 2019b; Prior, 2020). However, her claim is not well-supported due to the study limitations discussed here and elsewhere (Aly, 2019).

Dittrich et al. (2005) reported that the combination of oral estradiol valerate and a gonadotropin-releasing hormone (GnRH) agonist for 2 years resulted in self-reported breast cup sizes of C cup or greater in 5%, B cup in 30%, A cup in 35%, and less than A cup in 30% in transfeminine people. They noted however that 70% were unsatisfied with their breast development and wished to undergo breast augmentation. The researchers claimed that the regimen had similar effectiveness in terms of feminization, including increases in breast size, compared to prior reported treatment regimens of ethinylestradiol and CPA. No other details or specifics were given. The claim about similar breast development to regimens containing CPA is relevant as CPA is a very strong progestogen at the doses used historically in transfeminine people. It should be cautioned however that this study did not actually employ or study progestogens itself. In addition, self-reported breast cup size is a subjective and low-quality means of measuring breast development and size. As such, the findings of this study are of questionable value in terms of understanding progestogens and breast development.

Estrogen is primarily involved in ductal development of the breasts, whereas progesterone is mainly involved in lobuloalveolar development. Kanhai et al. (2000) compared histological breast tissue changes with estrogen and CPA 100 mg/day (i.e. very-high-dose progestogen) therapy in 14 transfeminine people versus nonsteroidal antiandrogen monotherapy with flutamide or bicalutamide in 2 cisgender men with prostate cancer. Both types of treatments block androgens, increase estrogen levels, and are known to induce breast development or gynecomastia at similarly high rates. However, nonsteroidal antiandrogen monotherapy differs from combined estrogen and progestogen therapy in that it lacks any progestogenic effects. In the transfeminine people, full lobuloalveolar formation was apparent in the biopsied breast tissue, whereas in the men with prostate cancer, only “moderate” and incomplete lobuloalveolar maturation was found. It was also noted that lobuloalveolar formation tended to regress upon discontinuation of CPA following gonadectomy in transfeminine people. The researchers concluded that progestogenic exposure is needed for the breasts to fully develop on a histological level and for the breast tissue of transfeminine people to completely mimic the histology of the mature female breast. While the findings of this study are interesting, they only concern tissue characteristics and do not actually provide any information about breast development in terms of physical form or appearance. With regard to this, tissue-level differences may or may not translate to relevant differences in for instance breast size or shape. As such, the study is of limited value in understanding whether progestogens improve breast development in transfeminine people in the ways that are actually valued.

Jain, Kwan, & Forcier (2019) studied sublingual estradiol and spironolactone with and without MPA in 92 transfeminine people. MPA was given at a dose of 5 to 10 mg/day sublingually or at a dose of 150 mg once every 3 months by intramuscular injection. Of 39 transfeminine people who received MPA, 26 (67%) self-reported improved breast development. No further details were provided, but measurement of breast development was presumably subjective and anecdotal. Igo & Visram (2021) studied addition of progesterone to hormone therapy in transfeminine people. Progesterone was provided as 100 mg micronized progesterone (probably oral) and was prescribed when progesterone was specifically requested by the patient or when the patient expressed dissatisfaction with feminization and/or breast development. Of 190 individuals, 51 (26.8%) received progesterone therapy. Treatment with progesterone on average began after 12.7 months of estradiol therapy, and the mean total follow-up time was 14.3 months of hormone therapy. Of those who received progesterone, only 6 (11.8%) reported benefit to breast development. No further details were provided, but as with other studies, breast development was likely quantified anecdotally via self-report. As breast development does not appear to have been objectively measured or compared to a control group in either Jain, Kwan, & Forcier (2019) or Igo & Visram (2021), the findings of these studies are limitedly informative.

Nolan and colleagues assessed the short-term effects of low-dose oral micronized progesterone on breast development in transfeminine people on stable hormone therapy in a prospective controlled study (Nolan et al., 2022a; Nolan et al., 2022b). Progesterone was given at a dose of 100 mg/day for 3 months to 23 transfeminine people and findings were compared to those of a control group of 19 transfeminine people. Breast development was measured using self-reported Tanner stage, with participants provided photographs of different Tanner stages to self-select from. At the end of the 3 months, Tanner stage was not significantly different between groups (mean 3.5, 95% CI 3.2–3.7 for progesterone vs. mean 3.6, 95% CI 3.3–3.9 for controls; p = 0.42). A limitation of this study is that oral progesterone has very low bioavailability and 100 mg/day oral progesterone achieves very low progesterone levels that are well below normal luteal-phase progesterone levels (Aly, 2018). As such, progestogenic exposure in this study, and notably also in Igo & Visram (2021), is likely to have been inadequate. Besides the issue of progestogenic strength, the very short duration of the study (3 months) and the reliance on self-reported subjective Tanner stages (as opposed to more objective physical breast measurements) are also major methodological limitations. In any case, this study is of noticeably higher quality than previous studies, and is notably likely to continue and report further follow-up at later points in the future.

Aside from the above studies, a variety of other studies have also reported breast development with estrogen and CPA in transfeminine people, often with objective physical measurements (e.g., breast volume, breast–chest difference, breast cup size, breast hemicircumference), but have lacked comparison groups and so have not been discussed in the present section. These studies are instead briefly discussed elsewhere (see the section below). In any case, to briefly summarize the findings, breast development in transfeminine people has unfortunately usually been poor in these studies.

The findings from the preceding studies in transfeminine people are of very low-quality due to methodological limitations, including lack of control groups, lack of randomization, reliance on poor measures of breast development (e.g., subjective and self-report), short treatment durations, and small sample sizes, among others. This is likely to explain the conflicting results of the studies. More research is still needed to assess the influence of progestogens on breast development in transfeminine people. A 2014 review on hormone therapy in transfeminine people summarizes the state of research on progestogens and breast development in transfeminine people (Wierckx, Gooren, & T’Sjoen, 2014):

Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in trans women is extremely sparse and based on low quality of evidence. Current evidence does not provide evidence that progestogens enhance breast development in trans women. Neither do they prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions.

Fortunately, several studies of progesterone and other progestogens in transfeminine people are currently underway. These studies include (1) a randomized controlled trial of oral progesterone added to hormone therapy by Dr. Sandeep Dhindsa and colleagues in St. Louis, Missouri in the United States (ClinicalTrials.gov; MediFind; ICH GCP); (2) prospective observational studies and a randomized controlled trial of addition of oral progesterone to hormone therapy by Ada Cheung and colleagues in Melbourne, Australia (University of Melbourne; University of Melbourne; University of Melbourne); (3) a randomized controlled trial of estradiol plus spironolactone versus estradiol plus CPA by Ada Cheung and colleagues in Melbourne, Australia (ANZCTR; WHO ICTRP; Trans Health Research [Flyer] [Poster]; University of Melbourne); and (4) a large randomized controlled trial of oral progesterone at different doses added to hormone therapy by Martin den Heijer and colleagues at the Vrije Universiteit University Medical Center (VUMC) in Amsterdam, the Netherlands (General Info/Links; Info Sheet Dutch; Info Sheet English Translated). Unfortunately however, all of the studies of progesterone employ oral progesterone, which has major bioavailability and potency problems (Aly, 2018). In any case, it was said that the VUMC researchers may follow their trial up with studies of other progesterone routes (General Info/Links).

Progesterone and its Role in Breast Development During Normal Female Puberty

The role of progesterone in breast development and its possible usefulness for helping with breast development in transfeminine hormone therapy can be informed by the normal biological circumstances of puberty in cisgender females. Puberty in cisgender girls takes an average of 3 to 4 years, though with a possible range of about 2 to 6 years in most cases. Progesterone essentially doesn’t appear during puberty until ovulatory menstrual cycles begin. Menarche, the onset of menstruation and hence menstrual cycling, occurs on average at Tanner breast stage 4, although it occurs at Tanner breast stage 3 or Tanner breast stage 5 (complete breast development) in significant subsets of girls (Marshall & Tanner, 1969; Marshall, 1978; Hillard, 2007). Hence, a significant portion of girls reach Tanner breast stage 5 (complete breast development) before experiencing menarche or any progesterone production. This indicates that progesterone is not essential to reach Tanner breast stage 5, at least for a subset of girls. Tanner breast stage 4 is on average about 2.5 years into breast development, while breast development as a whole takes on average about 3.5 years. As such, the appearance of progesterone in normal female puberty is a relatively late event (Marshall, 1978; Begley, Firth, & Hoult, 1980; Drife, 1986).

The reproductive axis in pubertal and adolescent cisgender girls is immature (Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019; Sun et al., 2019). In the first 1 to 2 years postmenarche, most menstrual cycles are anovulatory (i.e., ovulation does not occur) (Döring, 1963 [Table]; Apter, 1980; Lemarchand-Béraud et al., 1982; Talbert et al., 1985; Venturoli et al., 1987; Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019). Without ovulation, the corpus luteum doesn’t form from a ruptured ovarian follicle and progesterone production doesn’t commence. Only about half of menstrual cycles are ovulatory by Tanner breast stage 5 (Talbert et al., 1985). In addition, menstrual cycles are unusually long for some time after menarche (e.g., 50 days vs. 28 days for adult cycles) and thus there are fewer menstrual cycles per reproductive year (Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019). Luteal-phase progesterone levels are also lower in postmenarche adolescents than in adulthood even when ovulation does occur (McArthur, 1966 [Figure]; Lemarchand-Béraud et al., 1982; Apter et al., 1987; Venturoli et al., 1987; Venturoli et al., 1989; Sun et al., 2019). Consequently, progesterone exposure is sporadic and limited even during late female puberty. Moreover, this is the case not only by the time of Tanner stage 5, but for many years after it as well. It takes more than 6 years after menarche for menstrual cycling to become fully mature and consistently ovulatory (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987; Carlson & Shaw, 2019). Over this period of time, the rate of ovulatory cycles increases progressively until it reaches approximately 100% (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987; Carlson & Shaw, 2019). Only then is full adult-level exposure to progesterone finally achieved (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987). A handful of studies provide progesterone levels during puberty across Tanner stages or by age, and show how limited progesterone exposure is during this time (e.g., Sizonenko, 1978 [Graph]; Lee, 2001 [Table]; Aly, 2020).

Taken together, production of progesterone is a late event in normal female puberty, and even once it does begin, exposure to progesterone is low and sporadic until well after puberty has completed. Moreover, a subset of girls complete breast development before progesterone production starts. These facts call into some question the role of progesterone in breast development in female puberty.

Progesterone and Mammary Development in Animals

Pubertal Mammary Development

Knockout of the progesterone receptor in female rice results in complete infertility and severely compromised ovarian, uterine, and reproductive–behavioral functions (Lydon et al., 1995; Ismail et al., 2003). Conversely however, pubertal ductal mammary development in progesterone receptor knockout mice is normal and in fact morphologically indistinguishable from that of regular mice (Ismail et al., 2003). This is in contrast to the case of estrogen receptor alpha knockout mice, in which pubertal mammary development is abolished (Ismail et al., 2003; Wiki; Wiki). However, subsequent studies revealed that mammary ductal development during puberty is in fact delayed though eventually normal in female mice that have loss of progesterone production, loss of the progesterone receptor, or progesterone receptor antagonism (Shi, Lydon, & Zhang, 2004). In other words, progesterone stimulates and accelerates ductal development during puberty and hence appears to have a significant physiological role in early mammary development during puberty. The stimulation of ductal development by progesterone appears to be mediated by induction of the expression of amphiregulin in mammary ducts and terminal end buds (Kariagina et al., 2010; Aupperlee et al., 2013). This growth factor is an agonist of the epidermal growth factor receptor (EGFR), and is also notably the major growth factor that estrogen induces the expression of to mediate mammary gland development during puberty (Ciarloni, Mallepell, & Brisken, 2007; LaMarca & Rosen, 2007; McBryan et al., 2008). However, as mammary ductal development during puberty without progesterone is delayed but eventually completely normal, it has been stated that progesterone is dispensable for pubertal mammary gland development in mice (Ismail et al., 2003).

Breast Composition and Lobuloalveolar Content

Progestogens are involved primarily in lobuloalveolar development of the breasts. This type of breast development is necessary for lactation and breastfeeding and occurs mainly during pregnancy. The breasts are made up of two main types of tissue: (1) epithelial tissue (the actual internal mammary glandular tissue, including ducts and alveoli or lobules); and (2) stromal tissue (a mixture of connective tissue and adipose (fat) tissue). Lobuloalveolar development refers to growth and maturation of the alveoli and lobules and hence is a form of epithelial or glandular development. In women who are not pregnant or lactating, only about 5 to 20% of the volume of the breasts on average is composed of epithelial tissue, while the remaining 80 to 95% is composed of stromal tissue (Hutson, Cowen, & Bird, 1985; Drife, 1986; Bryant et al., 1998; Gertig et al., 1999; Howard & Gusterson, 2000; Cline & Wood, 2006; Lorincz & Sukumar, 2006; Wilson et al., 2006; Xu et al., 2010; Pandya & Moore, 2011; Hagisawa, Shimura, & Arisaka, 2012; Sandhu et al., 2016; Rosenfield, Cooke, & Radovick, 2021). More specifically, one study found that about 10 to 20% is epithelial tissue, about 10 to 35% is fat tissue, and about 60 to 80% is connective tissue in reproductive-age women (Hutson, Cowen, & Bird, 1985; Wilson et al., 2006). Similarly, in women with macromastia (breast hypertrophy), only a small proportion of the breasts is glandular tissue (e.g., 1–7%) (Bames, 1948; Cruz-Korchin et al., 2001). During pregnancy and lactation however, the breasts undergo dramatic changes, and epithelial tissue comes to make up a much greater proportion of the breasts (Ramsay et al., 2005; Bland, Copeland, & Klimberg, 2018). In fact, sources state that glandular tissue comprises a majority of the breast during pregnancy and lactation, with one study of lactating women finding that the breasts were composed 63% (range 46–83%) of glandular tissue (Ramsay et al., 2005). In any case, under more normal physiological circumstances and progesterone exposure, the contribution of lobuloalveolar tissue to the size of the breasts is quite small. In relation to this, the significance of progestogen-mediated breast lobuloalveolar growth in terms of breast size is unclear but seemingly questionable (Wierkcx, Gooren, & T’Sjoen, 2014).

Complete Androgen Insensitivity Syndrome, Progesterone, and Breast Development

It has been claimed that progesterone helps to move transfeminine people and cisgender females from Tanner stage 4 to 5 breast development and that it helps to round out the breasts at this time (e.g., Prior, 2011; Prior, 2019a; Prior, 2020). It has also been claimed in the online transgender community that cisgender women with complete androgen insensitivity syndrome (CAIS), an experiment of nature of women who lack progesterone, are stuck at Tanner stage 4 breast development and have “cone-shaped” breasts due to their absence of progesterone. In actuality however, there is no good evidence at this time that progesterone is required for normal pubertal breast development, that it is needed to reach Tanner stage 5, or that it helps to round out the breasts. Moreover, such claims are contradicted by significant available literature and evidence, including notably on CAIS women themselves.

Women with CAIS are individuals who have a 46,XY karyotype (i.e. are genetically “male”), testes, and who would otherwise have physically developed as males, but did not because they have a mutation in the gene encoding the androgen receptor which makes them completely insensitive to the effects of androgens. CAIS women have a male-typical hormonal profile, generated by their testes, including high male-range levels of testosterone, low female-range but nonetheless significant estradiol levels, and no significant progesterone production with very low progesterone levels. Instead of developing physically as males however, CAIS women are perfectly phenotypically female, with a normal female body, vagina, and breasts (Wiki; Photo). Their testosterone has been unable to masculinize them, while their estradiol, unopposed by androgens, is able to feminize them. The internal reproductive system in CAIS women is essentially that of an underdeveloped male, with testes instead of ovaries, and no uterus or fallopian tubes. The vagina is often short and is blind-ending with no cervix, which is related to the lack of a uterus.

Women with CAIS have breast development that is described throughout the literature as “good”, “excellent”, “normal”, “full”, “complete”, “well-developed”, “generous”, “typically above-average”, “large”, and even “voluptuous” (Morris, 1953; Hertz et al., 1966; Valentine, 1969; Adams et al., 1970; Polani, 1970; Weisberg, Malkasian, & Pratt, 1970; Dewhurst, 1971; Perez-Palacios & Jaffe, 1972; Glenn, 1976; Dewhurst & Spence, 1977; Rutgers & Scully, 1991; Patterson, McPhaul, & Hughes, 1994; Quigley et al., 1995; McPhaul, 2002; Galani et al., 2008; Oakes et al., 2008; Tiefenbacher & Daxenbichler, 2008; Barbieri, 2017). The gynecologist, John McLean Morris, who reviewed and summarized all of the existing scientific literature on CAIS women in 1953 (including 82 cases) and gave their condition the since-abandoned name “testicular feminization”, described their breasts as “unusually large” and “jumbo-sized” (Morris, 1953; Quigley et al., 1995). He additionally said in his famous 1953 review that they had “normal female breasts, often with a tendency to be overdeveloped” (Morris, 1953). In actuality however, some CAIS women have large breasts, while some have small breasts (Wisniewski et al., 2000), and we have no clear data that their breasts are actually larger on average. The variation in breast growth in CAIS women parallels the same large variation in breast size between individuals that is seen in natal women in general. Here is a collection of photos of CAIS women and their breast development from published case reports and reviews throughout the literature. As can be seen from these photos, breast development in CAIS women is normal and excellent, although subject to considerable variation between individuals in terms of breast size and shape as in women in general.

CAIS women have never been described as having “cone-shaped”, “pointy”, or otherwise abnormal breasts. The only exception is that they are often said to have “juvenile”—or relatively “small” and “pale”—areolas/nipples (e.g., Photo) (e.g., Morris, 1953; Morris & Mahesh, 1963; Khoo & Mackay, 1972; Perez-Palacios & Jaffe, 1972; Dewhurst & Spence, 1977; many others). This is probably because estradiol levels in CAIS women are only about 35 pg/mL on average (Table). This is relevant as estrogens dose-dependently induce nipple and areolar enlargement and pigmentation (Davis et al., 1945; Kennedy & Nathanson, 1953). Hence, higher estrogen levels may be necessary for full adult-like nipple and areolar maturation.

CAIS women also don’t have only Tanner stage 4 breast development. They reach full Tanner stage 5 breast development similarly to normal women (Quigley, 1988; Quigley et al., 1995; Fortner, 2007; Cheikhelard et al., 2008; Ramos et al., 2018). An excerpt on this matter (Quigley et al., 1995):

Individuals with complete [androgen insensitivity syndrome (AIS)] have excellent feminization at puberty, with normal or augmented breast development, and clear, smooth, acne-free complexions. Feminization of the breasts and body contours occurs in response to estrogen (produced mainly by testicular and, to a lesser extent, peripheral aromatization of androgens) that is unopposed by the effects of androgens. […] Breast development, ranging from mild gynecomastia to abundant Tanner stage V female breasts, can occur with all grades of AIS, tending to be more pronounced with the more severe grades.

By “more severe grades”, they mean CAIS, the complete form of the syndrome, as opposed to the incomplete forms of androgen insensitivity syndrome (AIS), including the partial and mild presentations (Quigley, 1988). The condition is a spectrum, and those with CAIS, the most “severe” grade, are the only ones who are completely insensitive to the androgen receptor-mediated actions of androgens and who have a fully feminized body. Even individuals with partial androgen insensitivity syndrome (PAIS) likewise have substantial breast development however (e.g., Saito et al., 2014; Lee et al., 2015).

As already touched on, CAIS women are notable because they have very low and negligible levels of progesterone (<2 ng/mL) due to their testes and lack of progesterone production (Table; Barbieri, 2017). CAIS women, perhaps more convincingly than any other evidence available at this time, suggest that progesterone is not needed for normal and complete breast development (Barbieri, 2017):

A genetic experiment of nature, androgen insensitivity syndrome, provides a clinical example of the important interplay between estrogens and androgens in the regulation of breast growth.38 In androgen insensitivity due to mutations in the androgen receptor (AR), genetic males (46,XY) do not have a fully functional AR. Testosterone is produced by the testis, but target tissues are not capable of responding to the high levels of circulating androgens. In this syndrome, circulating estradiol concentration is in the range of 50 pg/mL, comparable to early follicular-phase levels observed in women. Breast volume in individuals with androgen insensitivity is typically above average. This suggests that, in the complete absence of androgen inhibition, modest levels of estradiol are capable of stimulating significant breast growth. Progesterone levels are low in individuals with loss of the AR. This suggests that breast volume is not absolutely dependent on progesterone stimulation.

Despite their often large breasts, CAIS women are said to have relatively little breast glandular tissue (as opposed to fat and connective tissue) and minimal lobuloalveolar development (Morris, 1953; Morris & Mahesh, 1963; Simmer, Pion, & Dignam, 1965; McMillan, 1966; Perez-Palacios & Jaffe, 1972; Dewhurst & Spence, 1977; Shapiro, 1982). This is potentially in accordance with their lack of progesterone, as progesterone is involved in lobuloalveolar maturation. It is notable that in women in general, the breasts are mostly composed of stromal fat and connective tissue (~80–90%), rather than glandular tissue (10–20%) (Wiki). Additionally, when lobuloalveolar development occurs, for instance during pregnancy, it replaces stromal tissue (Alex, Bhandary, & McGuire, 2020). Hence, greater glandular or lobuloalveolar formation in the breasts may not necessarily translate to greater breast size, as seems apparent in CAIS women. Also in spite of their well-developed breasts, breast cancer has never been reported in CAIS women (Aly, 2020a; Aly, 2020b). This may be related to factors like their lack of progesterone and lobuloalveolar maturation and/or their absence of a second X chromosome (Aly, 2020a; Aly, 2020b).

Early Progestogen Exposure and the Possibility of Suboptimal Breast Development

There have been suggestions in the literature that early or premature exposure to progestogens may result in suboptimal breast development. Animal studies using progestogens including progesterone and chlormadinone acetate (a progestin closely related to CPA) found that this was the case for mammary gland development in rabbits with high doses of these progestogens, though notably not with lower doses (Lyons & McGinty, 1941; Beyer, Cruz, & Martinez-Manautou, 1970). Besides animal studies, a number of clinical publications have warned that early or premature exposure to progestogens might result in suboptimal breast development in cisgender girls and transfeminine people (Zacharin, 2000; Bondy et al., 2007; Colvin, Devineni, & Ashraf, 2014; Wierckx, Gooren, & T’Sjoen, 2014; Kaiser & Ho, 2015; Bauman, Novello, & Kreitzer, 2016; Gawlik et al., 2016; Randolph, 2018; Donaldson et al., 2019; Heath & Wynne, 2019a; Heath & Wynne, 2019b; Iwamoto et al., 2019; Crowley & Pitteloud, 2020; Naseem, Lokman, & Fitzgerald, 2021; Federici et al., 2022; Lucien et al., 2022; Rothman & Iwamoto, 2022). The full relevant excerpts from these sources can be found here. In relation to these claims, a progestogen is not added to estrogen therapy during puberty induction in girls with delayed puberty until after about 2 to 3 years of treatment, when breast development is generally considered complete.

However, species differences in mammary gland development and hormonal responses exist, and no hard data or evidence has been published to substantiate the claims of the clinical publications. As such, it is unknown whether suboptimal breast development could occur with early progestogen exposure in humans. Moreover, if it does occur in humans, it is unknown what level of progestogen exposure would be required to produce it. In any case, a few other areas of research interest are also relevant to the issue of progestogens possibly resulting in worse breast development, including the antiestrogenic effects of progestogens in the breasts, clinical studies of breast development with estrogen and CPA (a very strong progestogen) in transfeminine people, case reports of progestogens for treatment of macromastia in cisgender females, and theoretical suggestions of poor breast development in cisgender girls with 17α-hydroxylase/17,20-lyase deficiency being related to high progesterone exposure. These topics will be discussed in the subsequent sections.

Antiestrogenic Effects of Progestogens in the Breasts

Progestogens are well-known to have potent functional antiestrogenic effects in tissues such as the uterus, vagina, and cervix (Wiki). The antiestrogenic effects of progestogens in the uterus are in fact the reason that they are used in menopausal hormone therapy—to prevent the risks of endometrial hyperplasia and endometrial cancer that unopposed estrogen therapy otherwise produces (Wiki). Progestogens also appear to have antiestrogenic effects in the breasts (Mauvais-Jarvis, Kuttenn, & Gompel, 1986; Mauvais-Jarvis, Kuttenn, & Gompel, 1987; Mauvais-Jarvis et al., 1987; Kuttenn et al., 1994; Wren & Eden, 1996; Plu-Bureau, Touraine, & Mauvais-Jarvis, 1999; Wiki). This may include by inhibiting estrogen synthesis and enhancing estrogen inactivation in the breasts (Pasqualini, 2007; Pasqualini, 2009) and by reducing expression of the estrogen receptors in the breasts (Malet et al., 1991; Kuttenn et al., 1994; Wren & Eden, 1996; Plu-Bureau, Touraine, & Mauvais-Jarvis, 1999). Clinical studies have found that direct application of topical progesterone to the breasts suppresses estradiol-mediated breast cell proliferation, although this may be due to the delivery of supraphysiological levels of progesterone in the breasts (Barrat et al., 1990; Chang et al., 1995; Foidart et al., 1996; Spicer, Ursin, & Pike, 1996; Foidart et al., 1998; de Lignières, 2002; Gompel & Plu-Bureau, 2018; Trabert et al., 2020). In accordance with their antiestrogenic effects in the breasts, progestogens are considered to be useful in treating estrogen-dependent benign breast disorders such as breast pain, nodularity, and fibrocystic breast disease (Mauvais-Jarvis, Sitruk-Ware, & Kuttenn, 1981; Winkler et al., 2001; Schindler, 2011; Wiki; Wiki; Wiki). The antiestrogenic effects of progestogens in the breasts provide a plausible potential mechanism by which they might limit estrogen-mediated breast development.

Breast Development with Cyproterone Acetate in Transfeminine People

The possibility of suboptimal breast development with progestogens is of particular relevance to CPA. This is because CPA is a potent progestogen in addition to antiandrogen and is used in transfeminine people at doses that result in very strong progestogenic exposure (Aly, 2019). Studies using estrogen plus CPA in transfeminine people have generally reported poor breast development (Kanhai et al., 1999; Sosa et al., 2003; Sosa et al., 2004; Wierckx et al., 2014; Fisher et al., 2016; Tack et al., 2017; de Blok et al., 2018; Reisman, Goldstein, & Safer, 2019; de Blok et al., 2020; Meyer et al., 2020). However, transfeminine people could simply have poor breast development in general without this necessarily being related to CPA or progestogen exposure. Indeed, a study in transfeminine people who underwent pubertal suppression in adolescence presumably with GnRH agonists and then hormone therapy showed similarly poor breast development as in adults (Boogers et al., 2022). A randomized controlled trial of estradiol plus spironolactone versus estradiol plus CPA assessing breast development in transfeminine people is underway in Australia and may provide more insight on this issue (ANZCTR).

Progestogens in the Treatment of Breast Hypertrophy

Low progesterone levels have been suggested as a possible contributing factor in the development of pubertal macromastia (breast hypertrophy) (Sun et al., 2018). A number of case reports and series of progestogens in the treatment of pubertal macromastia have been published (Sperling & Gold, 1973; Boyce, Hoffman, & Mathes, 1984; Ryan & Pernoll, 1985; Gliosci & Presutti, 1993; Sridhar & Jaya Sinha, 1995; Baker et al., 2001; Dancey et al., 2008; Bland, Howard, Romrell, 2009; Hoppe et al., 2011; Sun et al., 2018). Progestogens such as dydrogesterone and MPA were employed for this purpose in an attempt to stop or slow the growth of the breasts under the assumption that they are functionally antiestrogenic in breast tissue. Clinical success in these limited cases was mixed. Due to the self-resolving nature of pubertal macromastia (i.e., breast development stops on its own eventually) and other methodological limitations, it is difficult to draw reliable conclusions from these reports.

Poor Breast Development in 17α-Hydroxylase/17,20-Lyase Deficiency

Poor breast development with estrogen therapy has been reported in girls with 17α-hydroxylase/17,20-lyase deficiency, and prior exposure to high progesterone levels secondary to the condition has been hypothesized to be responsible for this (Turan et al., 2009; Athanasoulia et al., 2013; Deeb et al., 2015; Çamtosun et al., 2017; Fernández-Cancio et al., 2017; Kardelen et al., 2018). However, this is only a theory, and at this time, there is no causal evidence that progesterone specifically is responsible.

Additional Content

References

  • Adams, R. D., Kliman, B., Federman, D. D., Ulfelder, H. S., & Holmes, L. B. (1970). Syndromes of Testicular Feminization. Clinical Pediatrics, 9(3), 165–178. [DOI:10.1177/000992287000900312]
  • Alex, A., Bhandary, E., & McGuire, K. P. (2020). Diseases of the Breast during Pregnancy and Lactation. In Alipour, S., & Omranipour, R. (Eds.). Diseases of the Breast during Pregnancy and Lactation (Advances in Experimental Medicine and Biology, Volume 1252). Cham: Springer International Publishing. [DOI:10.1007/978-3-030-41596-9]
  • Apter, D. (1980). Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clinical Endocrinology, 12(2), 107–120. [DOI:10.1111/j.1365-2265.1980.tb02125.x]
  • Apter, D., Räisänen, I., Ylöstalo, P., & Vihko, R. (1987). Follicular growth in relation to serum hormonal patterns in adolescent compared with adult menstrual cycles. Fertility and Sterility, 47(1), 82–88. [DOI:10.1016/s0015-0282(16)49940-1]
  • Athanasoulia, A., Auer, M., Riepe, F., & Stalla, G. (2013). Rare Missense P450c17 (CYP17A1) Mutation in Exon 1 as a Cause of 46,XY Disorder of Sexual Development: Implications of Breast Tissue ‘Unresponsiveness’ despite Adequate Estradiol Substitution. Sexual Development, 7(4), 212–215. [DOI:10.1159/000348301]
  • Aupperlee, M. D., Leipprandt, J. R., Bennett, J. M., Schwartz, R. C., & Haslam, S. Z. (2013). Amphiregulin mediates progesterone-induced mammary ductal development during puberty. Breast Cancer Research, 15(3), R44. [DOI:10.1186/bcr3431]
  • Baker, S. B., Burkey, B. A., Thornton, P., & LaRossa, D. (2001). Juvenile Gigantomastia: Presentation of Four Cases and Review of the Literature. Annals of Plastic Surgery, 46(5), 517–526. [DOI:10.1097/00000637-200105000-00011]
  • Bames, H. O. (1948). Reduction of massive breast hypertrophy. Plastic and Reconstructive Surgery, 3(5), 560–569. [DOI:10.1097/00006534-194809000-00006]
  • Barbieri, R. L. (2019). Breast. In Strauss, J. F., & Barbieri, R. L. (Eds.). Yen and Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 8th Edition (pp. 248–255.e3). Philadelphia: Elsevier. [Google Books] [DOI:10.1016/B978-0-323-47912-7.00010-X]
  • Barrat, J., de Lignières, B., Marpeau, L., Larue, L., Fournier, S., Nahoul, K., Linares, G., Giorgi, H., & Contesso, G. (1990). Effet in vivo de l’administration locale de progestérone sur l’activité mitotique des galactophores humains. Résultat d’une étude pilote. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 19(3), 269–274. [Google Scholar 1] [Google Scholar 2] [PubMed]
  • Bässler, R. (1970). The Morphology of Hormone Induced Structural Changes in the Female Breast. In Altmann, H.-W., et al. (Eds.). Current Topics in Pathology: Ergebnisse der Pathology, Volume 53 (pp. 1–89). Heidelberg: Springer Berlin. [DOI:10.1007/978-3-662-30514-0_1] [PDF]
  • Bauman, A., Novello, L., & Kreitzer, P. (2016). Endocrine Disorders and Delayed Puberty. In Appelbaum, H. (Ed.). Abnormal Female Puberty: A Clinical Casebook (pp. 87–107). Cham: Springer. [DOI:10.1007/978-3-319-27225-2_5]
  • Begley, D. J., Firth, J. A., & Hoult, J. R. (1980). The Breast and Lactation. In Begley, D. J., Firth, J. A., & Hoult, J. R. Human Reproduction and Developmental Biology (pp. 204–219). London: Macmillan Education UK. [DOI:10.1007/978-1-349-16260-4_14]
  • Beyer, C., Cruz, M. L., & Martinez-Manautou, J. (1970). Effect of Chlormadinone Acetate on Mammary Development and Lactation in the Rabbit. Endocrinology, 86(5), 1172–1174. [DOI:10.1210/endo-86-5-1172]
  • Bland, K. I., Copeland, E. M., & Klimberg, V. S. (2018). Anatomy of the Breast, Axilla, Chest Wall, and Related Metastatic Sites. In Bland, K. I., Copeland, E. M., Klimberg, V. S., Gradishar, W. J., White, J., & Korourian, S. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th Edition (pp. 20–36.e2). Philadelphia: Elsevier. [DOI:10.1016/b978-0-323-35955-9.00002-7]
  • Bland, K. I., Harrison Howard, J., & Romrell, L. J. (2009). Congenital and Acquired Disturbances of Breast Development and Growth. In Bland, K. I., & Copeland, E. M. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 4th Edition (pp. 189–207). Philadelphia: Saunders/Elsevier. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Bondy, C. A., & Turner Syndrome Consensus Study Group. (2007). Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. The Journal of Clinical Endocrinology & Metabolism, 92(1), 10–25. [DOI:10.1210/jc.2006-1374]
  • Boogers, L., Infirri, S. S., Bouchareb, A., de Blok, C., Liberton, N., van Trotsenburg, P., Dreijerink, K., den Heijer, M., Wiepjes, C., & Hannema, S. (2022). The effect of timing of puberty suppression on breast development in trans girls; a cross-sectional study. Hormone Research in Paediatrics, 95(Suppl 2) [60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Rome, Italy, September 15–17, 2022], 390–391 (abstract no. P1-379). [Google Scholar] [DOI:10.1159/000525606] [URL] [PDF 1] [PDF 2]
  • Boyce, S. W., Hoffman, P. G., & Mathes, S. J. (1984). Recurrent Macromastia after Subcutaneous Mastectomy. Annals of Plastic Surgery, 13(6), 511–518. [DOI:10.1097/00000637-198412000-00008]
  • Bryant, R., Underwood, A., Robinson, A., Stephenson, T., & Underwood, J. (1998). Determination of breast tissue composition for improved accuracy in estimating radiation doses and risks in mammographic screening. The Breast, 7(2), 95–98. [DOI:10.1016/s0960-9776(98)90064-9]
  • Çamtosun, E., Şıklar, Z., Ceylaner, S., Kocaay, P., & Berberoğlu, M. (2017). Delayed Diagnosis of a 17-Hydroxylase/17,20-Lyase Deficient Patient Presenting as a 46,XY Female: A Low Normal Potassium Level Can Be an Alerting Diagnostic Sign. Journal of Clinical Research in Pediatric Endocrinology, 9(2), 163–167. [DOI:10.4274/jcrpe.3839]
  • Carlson, L. J., & Shaw, N. D. (2019). Development of Ovulatory Menstrual Cycles in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, 32(3), 249–253. [DOI:10.1016/j.jpag.2019.02.119]
  • Chang, K., Lee, T. T., Linares-Cruz, G., Fournier, S., & de Ligniéres, B. (1995). Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility, 63(4), 785–791. [DOI:10.1016/s0015-0282(16)57482-2]
  • Cheikhelard, A., Morel, Y., Thibaud, E., Lortat-Jacob, S., Jaubert, F., Polak, M., & Nihoul-Fekete, C. (2008). Long-Term Followup and Comparison Between Genotype and Phenotype in 29 Cases of Complete Androgen Insensitivity Syndrome. Journal of Urology, 180(4), 1496–1501. [DOI:10.1016/j.juro.2008.06.045]
  • Ciarloni, L., Mallepell, S., & Brisken, C. (2007). Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development. Proceedings of the National Academy of Sciences, 104(13), 5455–5460. [DOI:10.1073/pnas.0611647104]
  • Cline, J. M., & Wood, C. E. (2006). Hormonal Effects on the Mammary Gland of Postmenopausal Nonhuman Primates. Breast Disease, 24(1), 59–70. [DOI:10.3233/bd-2006-24105]
  • Colvin, C., Devineni, G., & Ashraf, A. P. (2014). Delayed Puberty. In Bandeira, F., Gharib, H., Golbert, A., Griz, L., & Faria, M. (Eds.). Endocrinology and Diabetes (pp. 203–217). New York: Springer. [DOI:10.1007/978-1-4614-8684-8_17]
  • Crowley, W. F., & Pitteloud, N. (2020). Approach to the patient with delayed puberty. UpToDate. [Google Scholar] [URL]
  • Cruz-Korchin, N., Korchin, L., González-Keelan, C., Climent, C., & Morales, I. (2002). Macromastia. Plastic and Reconstructive Surgery, 109(1), 64–68. [DOI:10.1097/00006534-200201000-00011]
  • de Blok, C. J., Dijkman, B. A., Wiepjes, C. M., Staphorsius, A. S., Timmermans, F. W., Smit, J. M., Dreijerink, K. M., & den Heijer, M. (2020). Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. The Journal of Clinical Endocrinology & Metabolism, 106(2), e782–e790. [DOI:10.1210/clinem/dgaa841]
  • de Blok, C. J., Klaver, M., Wiepjes, C. M., Nota, N. M., Heijboer, A. C., Fisher, A. D., Schreiner, T., T’Sjoen, G., & den Heijer, M. (2017). Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. The Journal of Clinical Endocrinology & Metabolism, 103(2), 532–538. [DOI:10.1210/jc.2017-01927]
  • de Lignières, B. (2002). Effects of progestogens on the postmenopausal breast. Climacteric, 5(3), 229–235. [DOI:10.1080/cmt.5.3.229.235]
  • Dancey, A., Khan, M., Dawson, J., & Peart, F. (2008). Gigantomastia – a classification and review of the literature. Journal of Plastic, Reconstructive & Aesthetic Surgery, 61(5), 493–502. [DOI:10.1016/j.bjps.2007.10.041]
  • Davis, M. E., Boynton, M. W., Ferguson, J. H., & Rothman, S. (1945). Studies on Pigmentation of Endocrine Origin. The Journal of Clinical Endocrinology & Metabolism, 5(3), 138–146. [DOI:10.1210/jcem-5-3-138]
  • Deeb, A., Al Suwaidi, H., Attia, S., & Al Ameri, A. (2015). 17-hydroxylase/17,20-lyase deficiency due to a R96Q mutation causing hypertension and poor breast development. Endocrinology, Diabetes & Metabolism Case Reports, 2015(1), 15-0069. [DOI:10.1530/EDM-15-0069]
  • Dewhurst, C. (1971). The XY female. American Journal of Obstetrics and Gynecology, 109(5), 675–688. [DOI:10.1016/0002-9378(71)90753-8]
  • Dewhurst, C., & Spence, J. E. (1977). The XY female. British Journal of Hospital Medicine, 17(5), 498, 501–506. [Google Scholar] [PubMed] [PDF]
  • Dittrich, R., Binder, H., Cupisti, S., Hoffmann, I., Beckmann, M., & Mueller, A. (2005). Endocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone Agonist. Experimental and Clinical Endocrinology & Diabetes, 113(10), 586–592. [DOI:10.1055/s-2005-865900]
  • Donaldson, M., Kriström, B., Ankarberg-Lindgren, C., Verlinde, S., van Alfen-van der Velden, J., Gawlik, A., van Gelder, M., Sas, T., & (2019). Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy. Hormone Research in Paediatrics, 91(3), 153–163. [DOI:10.1159/000500050]
  • Drife, J. O. (1986). Breast Development in Puberty. Annals of the New York Academy of Sciences, 464(1) [Endocrinology of the Breast: Basic and Clinical Aspects], 58–65. [DOI:10.1111/j.1749-6632.1986.tb15993.x]
  • Döring, G. K. (1963). Über die relative Häufigkeit des anovulatorischen Cyclus im Leben der Frau. Archiv für Gynäkologie, 199(2), 115–123. [DOI:10.1007/bf00668062]
  • Federici, S., Goggi, G., Quinton, R., Giovanelli, L., Persani, L., Cangiano, B., & Bonomi, M. (2021). New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature. Endocrine Reviews, 43(5), 824–851. [DOI:10.1210/endrev/bnab043]
  • Fernández-Cancio, M., García-García, E., González-Cejudo, C., Martínez-Maestre, M., Mangas-Cruz, M., Guerra-Junior, G., Pandi de Mello, M., Arnhold, I. J., Nishi, M. Y., Bilharinho Mendonça, B., García-Arumí, E., Audí, L., Tizzano, E., & Carrascosa, A. (2017). Discordant Genotypic Sex and Phenotype Variations in Two Spanish Siblings with 17α-Hydroxylase/17,20-Lyase Deficiency Carrying the Most Prevalent Mutated CYP17A1 Alleles of Brazilian Patients. Sexual Development, 11(2), 70–77. [DOI:10.1159/000468160]
  • Finkenzeller, D. A., & Loveless, M. B. (2007). Pediatric Gynecology. In Fortner, K. B., Szymanski, L. M., Fox, H. E., & Wallach, E. E. (Eds.). The Johns Hopkins Manual of Gynecology and Obstetrics, 3rd Edition (Spiral Manual Series) (pp. 363–379). Philadelphia: Lippincott Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Fisher, A. D., Castellini, G., Ristori, J., Casale, H., Cassioli, E., Sensi, C., Fanni, E., Amato, A. M., Bettini, E., Mosconi, M., Dèttore, D., Ricca, V., & Maggi, M. (2016). Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data. The Journal of Clinical Endocrinology & Metabolism, 101(11), 4260–4269. [DOI:10.1210/jc.2016-1276]
  • Foidart, J. M., Colin, C., Denoo, X., Desreux, J., Fournier, S., & de Linières, B. (1996). Influence of percutaneous administration of estradiol and progesterone on the proliferation of human breast epithelial cells. In Calvo, F., Crépin, M., & Magdelenat, H. (Eds.). Breast Cancer. Advances in Biology and Therapuetics. John Libbey Eurotext, 329–334. [Google Scholar] [Google Books]
  • Foidart, J., Colin, C., Denoo, X., Desreux, J., Béliard, A., Fournier, S., & de Lignières, B. (1998). Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells. Fertility and Sterility, 69(5), 963–969. [DOI:10.1016/s0015-0282(98)00042-9]
  • Galani, A., Kitsiou-Tzeli, S., Sofokleous, C., Kanavakis, E., & Kalpini-Mavrou, A. (2008). Androgen insensitivity syndrome: clinical features and molecular defects. Hormones, 7(3), 217–229. [DOI:10.14310/horm.2002.1201]
  • Gawlik, A., Hankus, M., Such, K., Drosdzol-Cop, A., Madej, P., Borkowska, M., Zachurzok, A., & Malecka-Tendera, E. (2016). Hypogonadism and Sex Steroid Replacement Therapy in Girls with Turner Syndrome. Journal of Pediatric and Adolescent Gynecology, 29(6), 542–550. [DOI:10.1016/j.jpag.2016.03.005]
  • Gertig, D. M., Stillman, I. E., Byrne, C., Spiegelman, D., Schnitt, S. J., Connolly, J. L., Colditz, G. A., & Hunter, D. J. (1999). Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiology, Biomarkers & Prevention, 8(10), 873–879. [Google Scholar] [PubMed] [URL]
  • Glenn, J. F. (1976). Testicular feminization syndrome current clinical considerations. Urology, 7(6), 569–577. [DOI:10.1016/0090-4295(76)90079-0]
  • Gliosci, A., & Presutti, F. (1993). Virginal gigantomastia: Validity of combined surgical and hormonal treatments. Aesthetic Plastic Surgery, 17(1), 61–65. [DOI:10.1007/bf00455051]
  • Gompel, A., & Plu-Bureau, G. (2018). Progesterone, progestins and the breast in menopause treatment. Climacteric, 21(4), 326–332. [DOI:10.1080/13697137.2018.1476483]
  • Gunn, H. M., Tsai, M., McRae, A., & Steinbeck, K. S. (2018). Menstrual Patterns in the First Gynecological Year: A Systematic Review. Journal of Pediatric and Adolescent Gynecology, 31(6), 557–565.e6. [DOI:10.1016/j.jpag.2018.07.009]
  • Hagisawa, S., Shimura, N., & Arisaka, O. (2012). Effect of Excess Estrogen on Breast and External Genitalia Development in Growth Hormone Deficiency. Journal of Pediatric and Adolescent Gynecology, 25(3), e61–e63. [DOI:10.1016/j.jpag.2011.11.005]
  • Heald, F. P. (Ed.). (1966). Adolescent Gynecology. Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Heath, R. A., & Wynne, K. (2019). Children and Adolescents. In Heath, R. A., & Wynne, K. A Guide to Transgender Health: State-of-the-art Information for Gender-Affirming People and Their Supporters (pp. 87–106). Santa Barbara: Praeger/ABC-CLIO. [Google Books]
  • Heath, R. A., & Wynne, K. (2019). Hormone and Surgical Therapies for Adults. In Heath, R. A., & Wynne, K. A Guide to Transgender Health: State-of-the-art Information for Gender-Affirming People and Their Supporters (pp. 107–146). Santa Barbara: Praeger/ABC-CLIO. [Google Books]
  • Hertz, R., Odell, W. D., & Ross, G. T. (1966). Diagnostic Implications of Primary Amenorrhea: Combined Clinical Staff Conference at the National Institutes of Health. Annals of Internal Medicine, 65(4), 800–820. [DOI:10.7326/0003-4819-65-4-800]
  • Hillard, P. J. A. (2007). Benign Diseases of the Female Reproductive Tract. In Berek, J. S., & Novak, E. (Eds.). Berek & Novak’s Gynecology, 14th Edition (pp. 431–496). Philadelphia: Lippincott Williams and Wilkins, 431–496. [Google Scholar] [OpenLibrary] [WorldCat] [Archive.org]
  • Hoppe, I. C., Patel, P. P., Singer-Granick, C. J., & Granick, M. S. (2011). Virginal Mammary Hypertrophy: A Meta-Analysis and Treatment Algorithm. Plastic and Reconstructive Surgery, 127(6), 2224–2231. [DOI:10.1097/prs.0b013e3182131bd1]
  • Howard, B. A., & Gusterson, B. A. (2000). Human Breast Development. Journal of Mammary Gland Biology and Neoplasia, 5(2), 119–137. [DOI:10.1023/a:1026487120779]
  • Hutson, S. W., Cowen, P. N., & Bird, C. C. (1985). Morphometric studies of age related changes in normal human breast and their significance for evolution of mammary cancer. Journal of Clinical Pathology, 38(3), 281–287. [DOI:10.1136/jcp.38.3.281]
  • Igo, J., & Visram, H. (2021). Progesterone Therapy Use and Safety in Male to Female Transgender Patients. Canadian Journal of Diabetes, 45(7 Suppl), S39–S39 (abstract no. 109). [DOI:10.1016/j.jcjd.2021.09.119]
  • Ismail, P. M., Amato, P., Soyal, S. M., DeMayo, F. J., Conneely, O. M., O’Malley, B. W., & Lydon, J. P. (2003). Progesterone involvement in breast development and tumorigenesis—as revealed by progesterone receptor “knockout” and “knockin” mouse models. Steroids, 68(10–13), 779–787. [DOI:10.1016/s0039-128x(03)00133-8]
  • Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 204201881987116. [DOI:10.1177/2042018819871166]
  • Jain, J., Kwan, D., & Forcier, M. (2019). Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study. The Journal of Clinical Endocrinology & Metabolism, 104(11), 5148–5156. [DOI:10.1210/jc.2018-02253]
  • Kaiser, U., & Ho, K. K. (2015). Pituitary Physiology and Diagnostic Evaluation. In Melmed, S., Polonsky, K. S., Larsen, P. R., Kronenberg, & H. M. (Eds.). Williams Textbook of Endocrinology, 13th Edition (pp. 176–231). Philadelphia: Elsevier. [DOI:10.1016/B978-0-323-29738-7.00008-3] [Google Books]
  • Kanhai, R. C., Hage, J. J., Asscheman, H., Mulder, W. J., & Hage, J. J. (1999). Augmentation Mammaplasty in Male-to-Female Transsexuals. Plastic and Reconstructive Surgery, 104(2), 542–549. [DOI:10.1097/00006534-199908000-00040]
  • Kanhai, R. C., Hage, J. J., van Diest, P. J., Bloemena, E., & Mulder, J. W. (2000). Short-Term and Long-Term Histologic Effects of Castration and Estrogen Treatment on Breast Tissue of 14 Male-to-Female Transsexuals in Comparison With Two Chemically Castrated Men. The American Journal of Surgical Pathology, 24(1), 74–80. [DOI:10.1097/00000478-200001000-00009]
  • Kardelen, A. D., Toksoy, G., Baş, F., Yavaş Abalı, Z., Gençay, G., Poyrazoğlu, Ş., Bundak, R., Altunoğlu, U., Avcı, Ş., Najaflı, A., Uyguner, O., Karaman, B., Başaran, S., & Darendeliler, F. (2018). A Rare Cause of Congenital Adrenal Hyperplasia: Clinical and Genetic Findings and Follow-up Characteristics of Six Patients with 17-Hydroxylase Deficiency Including Two Novel Mutations. Journal of Clinical Research in Pediatric Endocrinology, 10(3), 206–215. [DOI:10.4274/jcrpe.0032]
  • Kariagina, A., Xie, J., Leipprandt, J. R., & Haslam, S. Z. (2010). Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers. Hormones and Cancer, 1(5), 229–244. [DOI:10.1007/s12672-010-0048-0]
  • Kennedy, B. J. (1953). Effects of intensive sex steroid hormone therapy in advanced breast cancer. JAMA, 152(12), 1135–1141. [DOI:10.1001/jama.1953.63690120004013]
  • Khoo, S. K., & Mackay, E. V. (1972). Testicular Feminization: The Clinical Features, Endocrine Function and Gonadal Pathology in Six Patients. The Australian and New Zealand Journal of Obstetrics and Gynaecology, 12(1), 1–13. [DOI:10.1111/j.1479-828x.1972.tb00721.x]
  • Kutten, F., Malet, C., & Leygue, E. (1994). Antiestrogen action of progestogens in human breast cells. In Berg, G., & Hammar, M. (Eds.). The Modern Management of the Menopause: A Perspective for the 21st Century [The Proceedings of the VII International Congress on the Menopause, Stockholm, Sweden 1993] (pp. 419–433). Canforth: Parthenon. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
  • LaMarca, H. L., & Rosen, J. M. (2007). Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Research, 9(4), 304. [DOI:10.1186/bcr1740]
  • Lee, P. A. (2001). Physiology of Puberty. In Becker, K. L., Bilezikian, J. P., Bremner, W. J., Hung, W., Kahn, C. R., Loriaux, D. L., Nylén, E. S., Rebar, R. W., Robertson, G. L., Snider, R. H., Wartofsky, L. (Eds.). Principles and Practice of Endocrinology and Metabolism, 3rd Edition (pp. 885–893). Philadelphia: Lippincott Williams & Wilkins. [Google Scholar] [Google Books] [Archive.org] [OpenLibrary] [WorldCat]
  • Lee, S. W., Kwak, D. S., Jung, I. S., Kwak, J. H., Park, J. H., Hong, S. M., Lee, C. B., Park, Y. S., Kim, D. S., Choi, W. H., & Ahn, Y. H. (2015). Partial Androgen Insensitivity Syndrome Presenting with Gynecomastia. Endocrinology and Metabolism, 30(2), 226–230. [DOI:10.3803/enm.2015.30.2.226]
  • Lemarchand-Béraud, T., Zufferey, M., Reymond, M., & Rey, I. (1982). Maturation of the Hypothalamo-Pituitary-Ovarian Axis in Adolescent Girls. The Journal of Clinical Endocrinology & Metabolism, 54(2), 241–246. [DOI:10.1210/jcem-54-2-241]
  • Lorincz, A. M., & Sukumar, S. (2006). Molecular links between obesity and breast cancer. Endocrine-Related Cancer, 13(2), 279–292. [DOI:10.1677/erc.1.00729]
  • Lucien, J. N., Ortega, M. T., Calvert, M. E., Smith, C., White, X., Rogers, H., Mosley, B., Agrawal, R., Drude, A., McGee, C., George, M., Brown, A., Downey, K., Wild, C., Njunge, A., Kuzmiak, C. M., Zava, D., Zava, T., Pollard, J., Francis, J., Beery, B. L., Harlin, M., Gonzalez, G. R., & Shaw, N. D. (2022). The Launch of A Girl’s First Period Study: Demystifying Reproductive Hormone Profiles in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, 35(4), 420–425. [DOI:10.1016/j.jpag.2021.12.018]
  • Lydon, J. P., DeMayo, F. J., Funk, C. R., Mani, S. K., Hughes, A. R., Montgomery, C. A., Shyamala, G., Conneely, O. M., & O’Malley, B. W. (1995). Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities.. Genes & Development, 9(18), 2266–2278. [DOI:10.1101/gad.9.18.2266]
  • Lyons, W. R., & McGinty, D. A. (1941). Effects of estrone and progesterone on male rabbit mammary glands. I. Varying doses of progesterone. Proceedings of the Society for Experimental Biology and Medicine, 48(1), 83–86. [DOI:10.3181/00379727-48-13227]
  • Malet, C., Gompel, A., Yaneva, H., Cren, H., Fidji, N., Mowszowicz, I., Kuttenn, F., & Mauvais-Jarvis, P. (1991). Estradiol and Progesterone Receptors in Cultured Normal Human Breast Epithelial Cells and Fibroblasts: Immunocytochemical Studies. The Journal of Clinical Endocrinology & Metabolism, 73(1), 8–17. [DOI:10.1210/jcem-73-1-8]
  • Marshall, W. A., & Tanner, J. M. (1969). Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood, 44(235), 291–303. [DOI:10.1136/adc.44.235.291]
  • Marshall, W. A. (1978). Puberty. In Falkner, F., & Tanner, J. M. (Eds.). Human Growth: Postnatal Growth (pp. 141–181). Boston: Springer US. [DOI:10.1007/978-1-4684-2622-9_6]
  • Mauvais-Jarvis, P., Sitruk-Ware, R., & Kuttenn, F. (1981). Benign Breast Disease. In McGuire, W. L. (Ed.). Breast Cancer 4: Advances in Research and Treatment (pp. 51–94). Boston: Springer US. [DOI:10.1007/978-1-4615-6571-0_3]
  • Mauvais-Jarvis, P., Kuttenn, F., & Gompel, A. (1986). Antiestrogen action of progesterone in breast tissue. Breast Cancer Research and Treatment, 8(3), 179–188. [DOI:10.1007/bf01807330]
  • Mauvais-Jarvis, P., Kuttenn, F., & Gompel, A. (1987). Antiestrogen Action of Progesterone in Breast Tissue. Hormone Research, 28(2–4), 212–218. [DOI:10.1159/000180946]
  • Mauvais-Jarvis, P., Kuttenn, F., Gompel, A., & Benotmane, A. (1987). Action anti-estrogène de la progestérone dans le sein. [Antiestrogen action of progesterone in the breast]. Pathologie-Biologie, 35(7), 1081–1086. [Google Scholar 1] [Google Scholar 2] [PubMed]
  • McBryan, J., Howlin, J., Napoletano, S., & Martin, F. (2008). Amphiregulin: Role in Mammary Gland Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 13(2), 159–169. [DOI:10.1007/s10911-008-9075-7]
  • McDonough, P. G., Spicer, D. V., Ursin, G., & Pike, M. C. (1996). Progesterone Concentrations—Physiologic or Pharmacologic? Fertility and Sterility, 65(5), 1077–1078. [DOI:10.1016/s0015-0282(16)58295-8]
  • McMillan, M. (1966). Five cases of testicular feminisation including one with a teratoma of the testis. The Journal of Pathology and Bacteriology, 91(2), 417–427. [DOI:10.1002/path.1700910216]
  • McPhaul, M. J. (2002). Androgen receptor mutations and androgen insensitivity. Molecular and Cellular Endocrinology, 198(1–2), 61–67. [DOI:10.1016/s0303-7207(02)00369-6]
  • Meyer, W. J., Finkelstein, J. W., Stuart, C. A., Webb, A., Smith, E. R., Payer, A. F., & Walker, P. A. (1981). Physical and hormonal evaluation of transsexual patients during hormonal therapy. Archives of Sexual Behavior, 10(4), 347–356. [DOI:10.1007/bf01565538]
  • Meyer, W. J., Webb, A., Stuart, C. A., Finkelstein, J. W., Lawrence, B., & Walker, P. A. (1986). Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior, 15(2), 121–138. [DOI:10.1007/bf01542220]
  • Meyer, G., Mayer, M., Mondorf, A., Flügel, A. K., Herrmann, E., & Bojunga, J. (2020). Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. European Journal of Endocrinology, 182(2), 149–156. [DOI:10.1530/eje-19-0463]
  • Morris, J. M. (1953). The syndrome of testicular feminization in male pseudohermaphrodites. American Journal of Obstetrics and Gynecology, 65(6), 1192–1211. [DOI:10.1016/0002-9378(53)90359-7]
  • Morris, J. M., & Mahesh, V. B. (1963). Further observations on the syndrome, “testicular feminization”. American Journal of Obstetrics and Gynecology, 87(6), 731–748. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF]
  • Naseem, H., Lokman, M., & Fitzgerald, C. (2021). Management of congenital hypogonadotropic hypogonadism in females. Human Fertility, advance online publcation. [DOI:10.1080/14647273.2021.1998929]
  • Nolan, B. J., Frydman, A. S., Leemaqz, S. Y., Carroll, M., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2022). Effects Of Low-dose Oral Micronised Progesterone On Sleep, Psychological Distress And Breast Development In Transgender Individuals Undergoing Feminising Hormone Therapy: A Prospective Controlled Study. Journal of the Endocrine Society, 6(Suppl 1), A653–A654 (abstract no. LBODP089). [DOI:10.1210/jendso/bvac150.1351]
  • Nolan, B. J., Frydman, A. S., Leemaqz, S. Y., Carroll, M., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2022). Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocrine Connections, 11(5), e220170. [DOI:10.1530/EC-22-0170]
  • Oakes, M. B., Eyvazzadeh, A. D., Quint, E., & Smith, Y. R. (2008). Complete Androgen Insensitivity Syndrome—A Review. Journal of Pediatric and Adolescent Gynecology, 21(6), 305–310. [DOI:10.1016/j.jpag.2007.09.006]
  • Pandya, S., & Moore, R. G. (2011). Breast Development and Anatomy. Clinical Obstetrics & Gynecology, 54(1), 91–95. [DOI:10.1097/grf.0b013e318207ffe9]
  • Pasqualini, J. R. (2007). Progestins and breast cancer. Gynecological Endocrinology, 23(Suppl 1), 32–41. [DOI:10.1080/09513590701585003]
  • Pasqualini, J. R. (2009). Breast cancer and steroid metabolizing enzymes: The role of progestogens. Maturitas, 65(Suppl 1), S17–S21. [DOI:10.1016/j.maturitas.2009.11.006]
  • Patterson, M. N., McPhaul, M. J., & Hughes, I. A. (1994). Androgen insensitivity syndrome. Baillière’s Clinical Endocrinology and Metabolism, 8(2), 379–404. [DOI:10.1016/s0950-351x(05)80258-7]
  • Perez-Palacios, G., & Jaffe, R. B. (1972). The Syndrome of Testicular Feminization. Pediatric Clinics of North America, 19(3), 653–667. [DOI:10.1016/s0031-3955(16)32744-4]
  • Plu-Bureau, G., Touraine, P., & Mauvais-Jarvis, P. (1999). Interactions Between Estradiol and Progesterone in Normal Breast: Implications for Mammary Carcinogenesis. In Manni, A. (Ed.). Endocrinology of Breast Cancer (Contemporary Endocrinology, Volume 11) (pp. 21–37). Totowa, New Jersey: Humana Press. [DOI:10.1007/978-1-59259-699-7_2] [OpenLibrary] [Archive.org]
  • Polani, P. E. (1970). Hormonal and clinical aspects of hermaphroditism and the testicular feminizing syndrome in man. Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 259(828), 187–206. [DOI:10.1098/rstb.1970.0058]
  • Prior, J. C., Vigna, Y. M., Watson, D., Diewold, P., & Robinow, O. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information & Education Council of Canada, 1(1), 1–7. [Google Scholar] [PDF]
  • Prior, J. C., Vigna, Y. M., & Watson, D. (1989). Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Archives of Sexual Behavior, 18(1), 49–57. [DOI:10.1007/bf01579291]
  • Prior J. C. (2011). Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn, 3(2), 109–120. [PubMed] [PubMed Central] [PDF]
  • Prior, J. C. (2019). Progesterone is Important for Transwomen’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1181–1186, [DOI:10.1210/jc.2018-01777]
  • Prior, J. C. (2019). Response to Letter to the Editor: “Progesterone is Important for Transwomen’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen”, The Journal of Clinical Endocrinology & Metabolism, 104(8), 3129–3130. [DOI:10.1210/jc.2019-00524]
  • Prior, J. C. (2020). Women’s Reproductive System as Balanced Estradiol and Progesterone Actions—A revolutionary, paradigm-shifting concept in women’s health. Drug Discovery Today: Disease Models, 32(Part B), 31–40. [DOI:10.1016/j.ddmod.2020.11.005]
  • Ramsay, D. T., Kent, J. C., Hartmann, R. A., & Hartmann, P. E. (2005). Anatomy of the lactating human breast redefined with ultrasound imaging. Journal of Anatomy, 206(6), 525–534. [DOI:10.1111/j.1469-7580.2005.00417.x]
  • Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2021). Puberty in the Female and Its Disorders. In Sperling, M. A., Majzoub, J. A., Menon, R. K., & Stratakis, C. A. (Eds.). Sperling Pediatric Endocrinology, 5th Edition (pp. 528–626). Philadelphia: Elsevier. [DOI:10.1016/B978-0-323-62520-3.00016-6]
  • Quigley, C. A., Bellis, A. D., Marschke, K. B., El-Awady, M. K., Wilson, E. M., & French, F. S. (1995). Androgen Receptor Defects: Historical, Clinical, and Molecular Perspectives. Endocrine Reviews, 16(3), 271–321. [DOI:10.1210/edrv-16-3-271]
  • Quigley, C. A. (1998). The androgen receptor: Physiology and pathophysiology. In Nieschlag, E., & Behre, H. M. (Eds.). Testosterone: Action · Deficiency · Substitution, 2nd Edition (pp. 33–106). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-72185-4_2]
  • Ramos, L., Chávez, B., Mares, L., Valdés, E., & Vilchis, F. (2018). Mutational analysis of the androgen receptor (NR3C4) gene in patients with 46,XY DSD. Gene, 641, 86–93. [DOI:10.1016/j.gene.2017.10.038]
  • Randolph, J. F. (2018). Gender-Affirming Hormone Therapy for Transgender Females. Clinical Obstetrics & Gynecology, 61(4), 705–721. [DOI:10.1097/grf.0000000000000396]
  • Reisman, T., Goldstein, Z., & Safer, J. D. (2019). A Review of Breast Development in Cisgender Women and Implications for Transgender Women. Endocrine Practice, 25(12), 1338–1345. [DOI:10.4158/ep-2019-0183]
  • Rosenfield, R. L. (2013). Adolescent Anovulation: Maturational Mechanisms and Implications. The Journal of Clinical Endocrinology & Metabolism, 98(9), 3572–3583. [DOI:10.1210/jc.2013-1770]
  • Rothman, M. S., & Iwamoto, S. J. (2022). Feminizing Gender-Affirming Hormone Therapy: Special Considerations for Older Adults. In Davis, T. F. (Ed.). A Case-Based Guide to Clinical Endocrinology (pp. 513–523). Cham: Springer International Publishing. [DOI:10.1007/978-3-030-84367-0_58]
  • Rutgers, J. L., & Scully, R. E. (1991). The Androgen Insensitivity Syndrome (Testicular Feminization). International Journal of Gynecological Pathology, 10(2), 126–144. [DOI:10.1097/00004347-199104000-00002]
  • Ryan, R. F., & Pernoll, M. L. (1985). Virginal Hypertrophy. Plastic and Reconstructive Surgery, 75(5), 737–742. [DOI:10.1097/00006534-198505000-00024]
  • Saito, R., Yamamoto, Y., Goto, M., Araki, S., Kubo, K., Kawagoe, R., Kawada, Y., Kusuhara, K., Igarashi, M., & Fukami, M. (2014). Tamoxifen Treatment for Pubertal Gynecomastia in Two Siblings with Partial Androgen Insensitivity Syndrome. Hormone Research in Paediatrics, 81(3), 211–216. [DOI:10.1159/000356923]
  • Sandhu, R., Chollet-Hinton, L., Kirk, E. L., Midkiff, B., & Troester, M. A. (2016). Digital histologic analysis reveals morphometric patterns of age-related involution in breast epithelium and stroma. Human Pathology, 48, 60–68. [DOI:10.1016/j.humpath.2015.09.031]
  • Schindler, A. E. (2010). Dydrogesterone and other progestins in benign breast disease: an overview. Archives of Gynecology and Obstetrics, 283(2), 369–371. [DOI:10.1007/s00404-010-1456-7]
  • Shapiro, L. R. (1982). Disorders of Female Sex Differentiation. In Blaustein, A. (Ed.). Pathology of the Female Genital Tract, 2nd Edition (pp. 479–510). New York: Springer New York. [DOI:10.1007/978-1-4757-1767-9_20]
  • Shi, H. Y., Lydon, J. P., & Zhang, M. (2004). Hormonal Defect in Maspin Heterozygous Mice Reveals a Role of Progesterone in Pubertal Ductal Development. Molecular Endocrinology, 18(9), 2196–2207. [DOI:10.1210/me.2004-0052]
  • Simmer, H. H., Pion, R. J., & Dignam, W. J. (1965). Testicular Feminization: Endocrine Function of Feminizing Testes, Comparison with Normal Testes. Springfield, Illinois: Thomas. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Sizonenko, P. C. (1978). Endocrinology in Preadolescents and Adolescents. American Journal of Diseases of Children, 132(7), 704–712. [DOI:10.1001/archpedi.1978.02120320064015]
  • Sosa, M., Jódar, E., Arbelo, E., Domínguez, C., Saavedra, P., Torres, A., Salido, E., de Tejada, M. J., & Hernández, D. (2003). Bone Mass, Bone Turnover, Vitamin D, and Estrogen Receptor Gene Polymorphisms in Male to Female Transsexuals. Journal of Clinical Densitometry, 6(3), 297–304. [DOI:10.1385/jcd:6:3:297]
  • Sosa, M., Jódar, E., Arbelo, E., Domı́nguez, C., Saavedra, P., Torres, A., Salido, E., Limiñana, J., Gómez de Tejada, M. J., & Hernández, D. (2004). Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. European Journal of Internal Medicine, 15(4), 231–237. [DOI:10.1016/j.ejim.2004.04.009]
  • Sperling, R. L., & Gold, J. J. (1973). Use of an anti-estrogen after a reduction mammaplasty to prevent recurrence of virginal hypertrophy of breasts. Plastic and Reconstructive Surgery, 52(4), 439–442. [DOI:10.1097/00006534-197352040-00030]
  • Sridhar, G. R., & Sinha, M. J. (1995). Macromastia in adolescent girls. Indian Pediatrics, 32(4), 496–499. [Google Scholar] [PubMed] [PDF]
  • Sun, B. Z., Kangarloo, T., Adams, J. M., Sluss, P. M., Welt, C. K., Chandler, D. W., Zava, D. T., McGrath, J. A., Umbach, D. M., Hall, J. E., & Shaw, N. D. (2018). Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity. The Journal of Clinical Endocrinology & Metabolism, 104(2), 613–623. [DOI:10.1210/jc.2018-00595]
  • Sun, S. X., Bostanci, Z., Kass, R. B., Mancino, A. T., Rosenbloom, A. L., Klimberg, V. S., & Bland, K. I. (2018). Breast Physiology: Normal and Abnormal Development and Function. In Bland, K. I., Copeland, E. M., Klimberg, V. S., Gradishar, W. J., White, J., & Korourian, S. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th Edition (pp. 37–56.e6). Philadelphia: Elsevier. [DOI:10.1016/b978-0-323-35955-9.00003-9]
  • Tack, L. J., Heyse, R., Craen, M., Dhondt, K., Bossche, H. V., Laridaen, J., & Cools, M. (2017). Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents. The Journal of Sexual Medicine, 14(5), 747–757. [DOI:10.1016/j.jsxm.2017.03.251]
  • Talbert, L. M., Hammond, M. G., Groff, T., & Udry, J. R. (1985). Relationship of age and pubertal development to ovulation in adolescent girls. Obstetrics & Gynecology, 66(4), 542–544. [Google Scholar] [URL]
  • Tiefenbacher, K., & Daxenbichler, G. (2008). The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care, 3(5), 325–331. [DOI:10.1159/000158055]
  • Trabert, B., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2019). Progesterone and Breast Cancer. Endocrine Reviews, 41(2), 320–344. [DOI:10.1210/endrev/bnz001]
  • Turan, S., Bereket, A., Guran, T., Akcay, T., Papari-Zareei, M., & Auchus, R. J. (2009). Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair. European Journal of Endocrinology, 160(2), 325–330. [DOI:10.1530/eje-08-0632]
  • Valentine, G. H. (1969). The Chromosome Disorders: An Introduction for Clinicians, 2nd Edition. London: W. Heinemann Medical Books. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Venturoli, S., Porcu, E., Fabbri, R., Magrini, O., Paradisi, R., Pallotti, G., Gammi, L., & Flamigni, C. (1987). Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities. Fertility and Sterility, 48(1), 78–85. [DOI:10.1016/s0015-0282(16)59294-2]
  • Venturoli, S., Fabbri, R., Porcu, E., Paradisi, R., Orsini, L. F., Brondelli, L., Ruggeri, S., & Flamigni, C. (1989). Endocrine and ovarian parameters at various frequencies of ovulation in adolescents. Archives of Gynecology and Obstetrics, 246(2), 107–114. [DOI:10.1007/bf00934127]
  • Weisberg, M. G., Malkasian, G. D., & Pratt, J. H. (1970). Testicular feminization syndrome. American Journal of Obstetrics and Gynecology, 107(8), 1181–1187. [DOI:10.1016/s0002-9378(15)30367-7]
  • Wierckx, K., Gooren, L., & T’Sjoen, G. (2014). Clinical Review: Breast Development in Trans Women Receiving Cross-Sex Hormones. The Journal of Sexual Medicine, 11(5), 1240–1247. [DOI:10.1111/jsm.12487]
  • Wierckx, K., Van Caenegem, E., Schreiner, T., Haraldsen, I., Fisher, A., Toye, K., Kaufman, J. M., & T’Sjoen, G. (2014). Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine, 11(8), 1999–2011. [DOI:10.1111/jsm.12571]
  • Wilson, C. L., Sims, A. H., Howell, A., Miller, C. J., & Clarke, R. B. (2006). Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocrine-Related Cancer, 13(2), 617–628. [DOI:10.1677/erc.1.01165]
  • Winkler, U. H., Schindler, A. E., Brinkmann, U. S., Ebert, C., & Oberhoff, C. (2001). Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecological Endocrinology, 15(Suppl 6), 37–43. [DOI:10.1080/gye.15.s6.37.43]
  • Wisniewski, A. B., Migeon, C. J., Meyer-Bahlburg, H. F., Gearhart, J. P., Berkovitz, G. D., Brown, T. R., & Money, J. (2000). Complete Androgen Insensitivity Syndrome: Long-Term Medical, Surgical, and Psychosexual Outcome. The Journal of Clinical Endocrinology & Metabolism, 85(8), 2664–2669. [DOI:10.1210/jcem.85.8.6742]
  • Wren, B. G., & Eden, J. A. (1996). Do Progestogens Reduce The Risk of Breast Cancer? A Review of the Evidence. Menopause, 3(1), 4–12. [DOI:10.1097/00042192-199603010-00003]
  • Xu, P., Ye, W., Zhong, S., Li, H., Feng, E., Lin, S. H., Kuo, C. T., Liu, J. Y., & Lin, Y. C. (2010). Leptin and zeranol up-regulate cyclin D1 expression in primary cultured normal human breast pre-adipocytes. Molecular Medicine Reports, 3(6), 983–990. [DOI:10.3892/mmr.2010.370]
  • Zacharin, M. (2000). Use of androgens and oestrogens in adolescents - A review of hormone replacement treatment. Journal of Pediatric Endocrinology and Metabolism, 13(1), 3–12. [DOI:10.1515/JPEM.2000.13.1.3]
\ No newline at end of file +A Comprehensive Review of the Potential of Progestogens for Enhancing Breast Development in Transfeminine People - Transfeminine Science Link

A Comprehensive Review of the Potential of Progestogens for Enhancing Breast Development in Transfeminine People

By Aly | First published February 14, 2020 | Last modified March 29, 2024

Abstract / TL;DR

The major female sex hormones are estrogen and progesterone. Both of these hormones are known to be importantly involved in the development of the breasts at different stages of life. Speculation, use, and anecdotes of progestogens for enhancing breast development in transfeminine people date back to at least the 1960s. A limited number of clinical studies have assessed breast development with progestogens in transfeminine people, but current evidence on progestogens for improving breast development is of very low quality and is inconclusive. Studies of progestogens and breast development in cisgender girls and women are similarly limited. In any case, more studies evaluating progestogens and breast development are currently underway. The possible role of progestogens in enhancing breast development can also be informed by indirect and circumstantial evidence, including notably findings on progesterone and breast changes during normal puberty, the menstrual cycle, and pregnancy in humans and animals. Available evidence overall is not suggestive of an essential role for progesterone in breast growth during puberty, but progesterone does have a clear and key role in lobuloalveolar development of the breasts during pregnancy. However, breast changes in pregnancy revert following cessation of lactation and breastfeeding. Progesterone may additionally contribute to reversible breast enlargement during the luteal phase of the menstrual cycle. There are some findings to suggest that progestogens may have antiestrogenic effects in the breasts and may have a stunting influence on breast development if introduced too early following initiation of hormone therapy. However, more research is needed to assess this possibility. In any case, if progestogens are used, it may be advisable to delay their introduction until most or all estrogen-mediated breast development is complete. Options for progestogen therapy in transfeminine people include bioidentical progesterone and progestins. However, oral progesterone has major bioavailability problems and does not achieve satisfactory progesterone levels. Progestogens, including progesterone, have been variously linked to significant health risks, which is an important consideration in terms of their use in transfeminine people. Overall, based on current knowledge, progestogens do not seem to be promising for lastingly improving breast development in transfeminine people, but more research and data are still needed for clear conclusions.

Introduction

Breast development in terms of size and shape is often less than desired in transfeminine people, and there is a need for therapeutic approaches that improve breast growth in this population. There are two major types of female hormones, estrogens and progestogens. Estrogens are almost universally employed in transfeminine hormone therapy, while progestogens are used in a subset of transfeminine people. Progestogens that have been commonly employed in transfeminine people include bioidentical progesterone, the progestin (synthetic progestogen) medroxyprogesterone acetate (MPA), and the strongly progestogenic antiandrogen cyproterone acetate (CPA). Estrogens are the major mediators of feminization and breast development in females. However, progestogens also have physiological effects on the breasts, and in relation to this, may or may not provide benefits to breast development as well.

The topic of progestogens and breast development has been discussed for many years in the transgender community and is a controversial subject (Coleman et al., 2012). Use of progestogens to improve breast development in transfeminine people goes back at least as far as Harry Benjamin and Christian Hamburger in the 1960s (Benjamin, 1966; Benjamin, 1967; Hamburger & Benjamin, 1969; Wiki). Arguments have been made both for (e.g., Bevan, 2012; Bellwether, 2019; Bevan, 2019) and against (e.g., Curtis, 2009) a possible role of progestogens in terms of breast development. It is often claimed that progestogens can enhance breast development or are even required for full breast development in cisgender females and transfeminine people. With respect to the latter, it is sometimes said that progestogens are necessary for people to move from Tanner stage 4 to Tanner stage 5 pubertal breast development and that progestogens help to fill and round out the breasts (e.g., Vorherr, 1974a; Basson & Prior, 1998; Kaiser & Ho, 2015; Prior, 2011; Prior, 2019a; Prior, 2020). It has even been claimed by some that without progestogens, the breasts will remain conical and “pointy” like they are in the earlier Tanner stages. On the other extreme, certain critics have claimed that there are “no biologically significant progesterone receptor sites for biological males” and that progesterone is not produced during normal female puberty until after breast development has been fully completed (Barrett, 2009; Seal, 2017; Coxon & Seal, 2018; Price, McManus, & Barrett, 2019; Richards & Barrett, 2020). In turn, these particular authors have argued against the use of progestogens in transfeminine people in various of their publications (Google Scholar). In general, the use of progestogens in transfeminine people has longstandingly been controversial, with positions both for and against (Sam, 2020).

The purpose of this article is to review the available direct and circumstantial evidence on the topic of progestogens and breast development in order to help inform whether progestogen therapy may be able to enhance breast development in transfeminine people. Aside from an involvement in breast development, progestogens are not otherwise currently thought to be or known to be involved in physical feminization (e.g., Coleman et al., 2012; Gooren, 2016). In relation to this, the present article will limit its discussion to breast development with progestogens, and will not explore feminization in general.

Progestogen Therapy and Breast Development in Humans

Progestogens and Breast Development in Transfeminine People

At present, only a limited number of studies have assessed breast development with progestogen therapy in transfeminine people. These studies have employed either bioidentical progesterone or a progestin like MPA or CPA. The subject of and the available data on progestogens and breast development in transfeminine people has also been partly reviewed in papers including Wierckx, Gooren, & T’Sjoen (2014), Reisman, Goldstein, & Safer (2019), Patel et al. (2020), Patel et al. (2022), Milionis, Ilias, & Koukkou (2022), Coleman et al. (2022), and Berliere et al. (2023).

Orentreich & Durr (1974) was one of the earliest studies on breast development in transfeminine people. They employed combinations of estrogens and progestogens as well as gonadectomy to produce feminization and breast development in a case series of 5 transfeminine people. The employed estrogens were estradiol valerate 30 mg/2 weeks by intramuscular injection and oral conjugated estrogens 1.25–5.0 mg/day and the used progestogens were “60 mg medroxyprogesterone caproate” every 2 weeks by intramuscular injection and oral medroxyprogesterone acetate 0–10 mg/day. Medroxyprogesterone caproate (MPC) has never been used pharmaceutically, so this was likely a typo and the actual progestogen employed was likely either MPA or hydroxyprogesterone caproate (OHPC). The authors reported that estrogen and progestogen therapy produced modest to significant breast development in the transfeminine people that was not strictly dose-related and included clinical photographs of the breasts. They concluded that the breast development was comparable to that of adult cisgender women. Orentreich and colleagues also discussed the topic of lobuloalveolar maturation of the breasts, which was known to be progestogen-dependent, but noted that they had not done histological assessment and that the degree of lobuloalveolar development of the breasts does not necessarily correlate with clinical breast size per findings in cisgender women. The findings of Orentreich and colleagues are limited by methodological problems like lack of objective measurements, lack of estrogen-only controls, and the small sample size of only 5 transfeminine people, and hence the study is of limited value in terms of assessing the involvement of progestogens in breast development.

Meyer et al. (1986) assessed the effects of progestogens added to estrogen therapy on breast development and other clinical parameters in transfeminine people. Of the 60 transfeminine people in the study, 15 (25%) received an oral progestogen, usually MPA at a dosage of 10 mg/day, for “at least for a short time”, and with only 8 (13.3%) receiving progestogen therapy for the full treatment period. In an earlier report of the study, it was noted that in 90% of observation periods the dose was 10 mg/day and for the remainder it was 20 mg/day (Meyer et al., 1981). A dosage of 10 mg/day MPA is roughly comparable to luteal-phase progesterone exposure in terms of progestogenic potency (Wiki). Breast development was measured in the study via breast hemicircumference (Diagram). Progestogen therapy was reported to not modify estrogen-induced changes, including laboratory measurements, hormone levels, and physical parameters like weight and breast growth. The lack of apparent changes in hormone levels is unexpected, as MPA in higher-quality studies has shown clear testosterone suppression (e.g., Jain, Kwan, & Forcier, 2019; Wiki). Meyer and colleagues concluded that adding progestogens to estrogen does not seem to enhance breast development in transfeminine people. However, they noted that the number of individuals who received progestogens was small and further studies were needed.

Prior et al. (1986) and Prior, Vigna, & Watson (1989) studied estrogen, high-dose spironolactone (100–600 mg/day), and MPA (10–20 mg/day cylically or continuously) in transfeminine people who were either pre-hormone therapy or had previously been on higher doses of estrogens (and/or progestogens) without spironolactone prior to the study. The researchers reported that following 12 months of treatment with the study’s hormone therapy regimen, there was increased breast size and increased nipple development. Most individuals reached an A cup size, or approximately 8 to 14 cm in diameter of breast tissue, by the end of the study. Breast development was measured in part with photographic documentation. Although breast development reportedly improved, the researchers themselves noted that it was difficult to determine whether the enhanced breast development could be attributed to spironolactone or to MPA. Moreover, testosterone suppression was inadequate before the study and improved with the study’s hormone therapy regimen, which may have helped to improve breast development regardless of any potential direct progestogenic action of MPA on the breasts. Finally, it is possible that breast development with estrogen may not yet have been complete, and that the improved breast development may have simply been continued progression due to estrogen alone. In other publications, Jerilynn Prior, the lead study author, has claimed that progesterone enhances breast development, and has cited the preceding studies by her in support of this claim (Prior, 2011; Prior, 2019a; Prior, 2019b; Prior, 2020). However, her claim is not well-supported due to the study limitations discussed.

Dittrich et al. (2005) reported that the combination of oral estradiol valerate and a gonadotropin-releasing hormone (GnRH) agonist for 2 years in transfeminine people resulted in self-reported breast cup sizes of C cup or greater in 5%, B cup in 30%, A cup in 35%, and less than A cup in 30%. They noted however that 70% of the individuals were unsatisfied with their breast development and wished to undergo breast augmentation surgery. The researchers claimed that the regimen had similar effectiveness in terms of feminization, including increases in breast size, compared to prior reported treatment regimens of ethinylestradiol and CPA. No other details or specifics were given. The claim about similar breast development to regimens containing CPA is relevant as CPA is a very strong progestogen at the doses used historically in transfeminine people (Aly, 2019). It should be cautioned however that this study did not actually employ or study progestogen therapy itself. In addition, self-reported breast cup size is a subjective and low-quality means of measuring breast development and size. As such, the findings of this study are of questionable value in terms of understanding progestogens and breast development.

Estrogen is primarily involved in ductal development of the breasts, whereas progesterone is mainly involved in lobuloalveolar development. Kanhai et al. (2000) compared internal histological breast tissue changes with estrogen and CPA 100 mg/day (i.e. very-high-dose progestogen) therapy in 14 transfeminine people versus nonsteroidal antiandrogen monotherapy with flutamide or bicalutamide in 2 cisgender men with prostate cancer. Both types of treatments block androgens, increase estrogen levels, and are known to induce breast development or gynecomastia at similarly high rates. However, nonsteroidal antiandrogen monotherapy differs from combined estrogen and progestogen therapy in that it lacks any progestogenic effects. In the transfeminine people, full lobuloalveolar formation was apparent in the biopsied breast tissue, whereas in the men with prostate cancer, only “moderate” and incomplete lobuloalveolar maturation was found. It was also noted that lobuloalveolar formation tended to regress upon discontinuation of CPA following gonadectomy in transfeminine people. The researchers concluded that progestogenic exposure is needed for the breasts to fully develop on a histological level and for the breast tissue of transfeminine people to completely mimic the histology of the mature female breast. While the findings of this study are interesting, they only concern tissue characteristics and do not actually provide any information about breast development in terms of physical form or appearance. With regard to this, tissue-level differences may or may not translate to relevant differences in for instance breast size or shape. As such, the study is of limited value in understanding whether progestogens improve breast development in transfeminine people in the ways that are actually valued.

Seal and colleagues conducted a retrospective chart review assessing clinical predictors for surgical breast augmentation in transfeminine people (Seal et al., 2012). In the transfeminine people who underwent breast augmentation, significantly more of them were taking spironolactone than were those who did not undergo breast augmentation. Conversely, the differential rates of use of specific antiandrogens were not significantly discordant between those who did and did not undergo breast augmentation in the case of the other prescribed antiandrogens, including cyproterone acetate, the 5α-reductase inhibitors, and GnRH analogues. However, this study had many methodological limitations, including the use of almost three dozen t-tests with no adjustment for multiple comparisons (and hence risk of false positives and concerns about p-hacking), small sample sizes for individual antiandrogens, use of undergoing breast augmentation as a surrogate for breast development with no actual physical measurement of the breasts or breast sizes, and a correlational design with lack of control for potential confounding variables. As such, the study does not show that different antiandrogens result in differences in breast development, and its findings must be considered with due caution.

Jain, Kwan, & Forcier (2019) studied sublingual estradiol and spironolactone with and without MPA in 92 transfeminine people. MPA was given at a dose of 5 to 10 mg/day sublingually or at a dose of 150 mg once every 3 months by intramuscular injection. Of 39 transfeminine people who received MPA, 26 (67%) self-reported improved breast development. No further details were provided, but measurement of breast development was presumably subjective and anecdotal. Igo & Visram (2021) studied addition of progesterone to hormone therapy in transfeminine people. Progesterone was provided as 100 mg micronized progesterone (probably oral) and was prescribed when progesterone was specifically requested by the patient or when the patient expressed dissatisfaction with feminization and/or breast development. Of 190 individuals, 51 (26.8%) received progesterone therapy. Treatment with progesterone on average began after 12.7 months of estradiol therapy, and the mean total follow-up time was 14.3 months of hormone therapy. Of those who received progesterone, only 6 (11.8%) reported benefit to breast development. No further details were provided, but as with other studies, breast development was likely quantified anecdotally via self-report. As breast development does not appear to have been objectively measured or compared to a control group in either Jain, Kwan, & Forcier (2019) or Igo & Visram (2021), the findings of these studies are limitedly informative.

Nolan and colleagues assessed the short-term effects of low-dose oral micronized progesterone on breast development in transfeminine people on stable hormone therapy in a prospective controlled study (Nolan et al., 2022a; Nolan et al., 2022b). Progesterone was given at a dose of 100 mg/day for 3 months to 23 transfeminine people and findings were compared to those of a control group of 19 transfeminine people. Breast development was measured using self-reported Tanner stage, with participants provided photographs of different Tanner stages to self-select from. At the end of the 3 months, Tanner stage was not significantly different between groups (mean 3.5, 95% CI 3.2–3.7 for progesterone vs. mean 3.6, 95% CI 3.3–3.9 for controls; p = 0.42). A limitation of this study is that oral progesterone has very low bioavailability and 100 mg/day oral progesterone achieves very low progesterone levels that are well below normal luteal-phase progesterone levels (Aly, 2018a; Wiki). As such, progestogenic exposure in this study, and notably also in Igo & Visram (2021) and other studies, is likely to have been inadequate. Besides the issue of progestogenic strength, the very short duration of the study (3 months) and the reliance on self-reported subjective Tanner stages (as opposed to more objective physical breast measurements) are also major limitations. In any case, this study is of higher quality than previous studies, and is notably likely to continue and report further follow-up at later points in the future.

Bahr et al. (2024) conducted a retrospective chart review at their clinic and compared 29 transfeminine people who had received progestogens versus 59 transfeminine people who had not. The form of progestogen used was oral or rectal progesterone in 93% of cases and MPA by intramuscular injection in the remaining 7% of cases. Of those who took progesterone, 25 (93%) used it orally and 2 (7%) used oral progesterone capsules rectally. Progestogen doses were not reported, except that 100 mg progesterone capsules were employed. Most of those in the progestogen-treated group (59%) had started it 1 to 6 months following initiation of standard hormone therapy. The researchers found that progestogen-treated group had significantly better self-reported breast development satisfaction (rated as satisfied, neutral, or unsatisfied) compared to the group that did not receive progestogens at 6 months (satisfied: 53.8% vs. 19.6%; p = 0.004) and 9 months (satisfied: 71.4% vs. 20.8%; p = 0.003) of hormone therapy. Limitations of this study include the lack of objective measurement of breast development, the restrospective nature of the study, and the lack of randomization of treatment, among others.

Aside from the above studies, a variety of other studies have also reported breast development with estrogen and CPA in transfeminine people. These studies have often employed objective physical measurements of breast development (e.g., breast volume, breast–chest difference, breast cup size, breast hemicircumference). However, they have lacked comparison groups, thereby precluding comparison of progestogenic versus non-progestogenic hormone therapy. In addition, CPA is unusual among progestogens in that it is employed at very high doses in transfeminine people (Aly, 2019), which may result in different and potentially stunted outcomes in terms of breast development than more physiological progestogenic exposure. As such, most studies of breast development with estrogen and CPA in transfeminine people have not been discussed in the present section and are instead discussed elsewhere in this article (see the section below). In any case, to briefly summarize the findings, breast development in transfeminine people with estrogen and CPA has generally been poor in these studies. The outcomes have included incomplete maturation in terms of Tanner staging (stage 2–4), small cup sizes, small breast volumes, and breasts much smaller in size than those in cisgender women.

The findings from the preceding studies in transfeminine people are of very low-quality due to methodological limitations, including lack of control groups, lack of randomization, reliance on poor measures of breast development (e.g., subjective and self-report) rather than objective physical measurements (Wiki), short treatment durations, and small sample sizes, among others. This may explain the conflicting results of the studies. More research is still needed to assess the influence of progestogens on breast development in transfeminine people. There is specifically a need for randomized controlled trials (RCTs) of feminizing hormone therapy with versus without progestogen therapy that employ objective measures of breast development, have adequate sample sizes, and have sufficient follow-up durations. Additional variables like progestogen type, route, dose, and timing of introduction would also be of value to explore. A 2014 review on hormone therapy in transfeminine people summarizes the state of research on progestogens and breast development in transfeminine people, with their conclusions still holding true today (Wierckx, Gooren, & T’Sjoen, 2014):

Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in trans women is extremely sparse and based on low quality of evidence. Current evidence does not provide evidence that progestogens enhance breast development in trans women. Neither do they prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions.

Accordingly, reviews and guidelines have concluded that there is currently no reliable evidence that progestogens included in hormone therapy are of benefit or are not of benefit for breast development in transfeminine people (Wierckx, Gooren, & T’Sjoen, 2014; Reisman, Goldstein, & Safer, 2019; Patel et al., 2022; Milionis, Ilias, & Koukkou, 2022; Coleman et al., 2022; Berliere et al., 2023).

Future Studies Currently Underway

Several studies of progesterone and other progestogens in transfeminine people are currently underway. These studies include (1) an RCT of oral progesterone added to hormone therapy by Sandeep Dhindsa and colleagues in St. Louis, Missouri in the United States (ClinicalTrials.gov; MediFind; ICH GCP); (2) a prospective observational study and/or RCT of addition of oral progesterone to hormone therapy by Ada Cheung and colleagues in Melbourne, Australia (University of Melbourne; University of Melbourne); (3) an RCT of estradiol plus spironolactone versus estradiol plus CPA also by Ada Cheung and colleagues (update: see below) (ANZCTR; WHO ICTRP; Trans Health Research [Flyer] [Poster]; University of Melbourne); and (4) a large RCT of oral progesterone at different doses added to hormone therapy by Martin den Heijer and colleagues at the Vrije Universiteit University Medical Center (VUMC) in Amsterdam, the Netherlands (Dijkman et al., 2023a; General Info/Links; Info Sheet Dutch; Info Sheet English Translated). Unfortunately however, all of the studies using progesterone employ oral progesterone, which has major bioavailability and potency problems (Aly, 2018a; Wiki). In any case, it was said that the VUMC researchers may follow their trial up with studies of other progesterone routes (General Info/Links). The preceding studies may provide more insight on the question of whether progestogen therapy is of therapeutic benefit to breast development in transfeminine people.

Progestogens and Breast Development in Cisgender Females

To date, there appear to be no useful studies on breast development with progesterone or other progestogens in cisgender females. There seem to mostly only be a few brief and conflicting anecdotal clinical statements in this area that are scattered throughout the literature. These include the following literature excerpts, which are specifically in the context of progestogens as part of puberty induction in cisgender girls and women with delayed or absent puberty due to hypogonadism:

I […] performed studies on three women lacking mammary development and exhibiting signs of marked hypogonadism. […] Corpus luteum extract, 5 international units daily for a period of thirty days, when given alone produced no detectable change in the breasts. This is in accord with the experimental observations on animals of Turner,2 Corner 3 and others. When, however, patients were given alternate daily injections of 1 international unit of progesterone and from 20,000 to 50,000 international units of estrone or of estradiol benzoate, breast growth was more rapid than that produced by the estrogenic hormones alone. The simultaneous use of the corpus luteum and estrogenic therapy definitely produced a much firmer breast growth, which was distinctly lobular to palpation, whereas the growth produced by the estrogenic hormones alone was smooth and the borders of the glandular tissue were difficult to define. Rapid regression in the size of the breasts followed the omission of the hormone injections, but the regression was less rapid when the combined therapy had been used. [MacBryde (1939)]

There are authorities who consider that breast growth is better if a progestogen is combined with oestrogen for the latter part of the cycle of treatment (Capraro, 1971). Shearman (1971) employs sequential therapy in his cases. Huffman (1971) however, does not believe that there is any improvement with the addition of progestogens. [Dewhurst (1971a)]

The effects of progesterone on the human breast remain obscure. Although widely stated to cause glandular development, the evidence for this is slender (Benson et al 1959). [Shearman (1972a)]

Many people use oestrogens alone, but the addition of a progestin for 6 or 10 days each month gives much better cycle control and appears to cause better breast development. [Shearman (1972b)]

Some authorities consider that breast growth is better if a progestogen is given for the latter part of each course of treatment. [Capraro & Dewhurst (1975)]

It has been suggested that progestins be added during the last week of each cycle of estrogen therapy in order to develop more rounded breasts rather than the conical breasts many of these patients develop, but we have been unable to detect any difference in breast contour with or without progestins. [Davajan & Kletzky (1979)]

I have been satisfied that the addition of a progestogen was necessary to get a good breast response to hormone treatment although the progestogen, as I have said, is required after the first year if the uterus is present. [Dewhurst (1982)]

In addition to the preceding instances, Werner (1935) and Geschickter (1945) assessed the effects of progesterone on the breasts in cisgender women. Werner (1935) attempted to induce lactation in 8 surgically gonadectomized cisgender women with combinations of estrogen, progesterone, and prolactin, all in the form of crude extracts by injection. In two women who were given progesterone, he claimed that a marked increase in the size of the breasts beyond that with estrogen alone was observed. Additionally, he claimed that the breasts were more firm, the glandular tissue “more tortuous and nodular”, and the nipples more prominent. He was not successful in inducing lactation in the women in this study. The doses of hormones used were unclear as they were in the form of extracts, and were likely supraphysiological, potentially pregnancy-like due to the nature of the experiment. Werner’s study was also briefly discussed by Nelson (1936), among other citations. Geschickter (1945) observed lobuloalveolar growth on histological examination with administration of progesterone for 6 weeks to 2 months in one woman but not in another woman. However, the exterior physical changes of the breasts were not assessed or reported by this author and hence his findings are limitedly informative.

Surprisingly, there have been few analogous studies of the effects of progestogens on the breasts in cisgender girls and women following the preceding reports and anecdotes. Although there are very little data on progestogens and breast growth in cisgender females, clinical studies are finally starting to look more closely at the specifics of hormonal medications, including progestogens, in terms of breast development in girls undergoing puberty induction (e.g., Rodari et al., 2023). As such, future studies may provide more insight on the subject of progestogens and breast development in cisgender females.

Progesterone and its Physiological Role in Breast Development in Humans

Progesterone and Breast Development in Puberty

The role of progesterone in breast development and its possible usefulness for helping with breast development in transfeminine hormone therapy can be informed by the normal biological circumstances of puberty in cisgender females. Puberty in cisgender girls usually starts around age 11 (range 8–13 years) and completes around age 15 years (range 12–19 years), taking on average 3 to 4 years (but with a range of about 1.5–6 years in most cases) (Schauffler, 1942; Marshall & Tanner, 1969; Marshall, 1978; Begley, Firth, & Hoult, 1980; Drife, 1986). Progesterone essentially does not appear during puberty until ovulatory menstrual cycles begin. Menarche, the onset of menstruation and hence of menstrual cycling, occurs on average at Tanner breast stage 4 or about 13 years of age, although it occurs at Tanner breast stage 3 or Tanner breast stage 5 in significant subsets of girls (26% for Tanner stage 3, 62% for Tanner stage 4, and 10% for Tanner stage 5) (Marshall & Tanner, 1969; Marshall, 1978; Drife, 1986; Hillard, 2007). Hence, the appearance of progesterone in normal female puberty is a relatively late event (Scott et al., 1950; Marshall, 1978; Begley, Firth, & Hoult, 1980; Drife, 1986), and most breast development appears to be complete by menarche and thus by the time that progesterone is first produced (Huffman, Dewhurst, & Capraro, 1981; Drife, 1982). Moreover, a small but significant subset of girls reaches Tanner breast stage 5 and hence fully developed breasts before menarche (Edmonds, 1989), which suggests that progesterone may not be essential for complete pubertal breast development.

The reproductive axis in pubertal and adolescent cisgender girls is immature (Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019; Sun et al., 2019). In the first 1 to 2 years postmenarche, most menstrual cycles are anovulatory (i.e., ovulation does not occur) (Döring, 1963 [Table]; Apter, 1980; Lemarchand-Béraud et al., 1982; Talbert et al., 1985; Venturoli et al., 1987; Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019). Without ovulation, the corpus luteum doesn’t form from a ruptured ovarian follicle and progesterone production doesn’t commence. Only about half of menstrual cycles are ovulatory by Tanner breast stage 5 (Talbert et al., 1985). In addition, menstrual cycles are unusually long for some time after menarche (e.g., 50 days vs. 28 days for adult cycles) and thus there are fewer menstrual cycles per reproductive year (Rosenfield, 2013; Gunn et al., 2018; Carlson & Shaw, 2019). Luteal-phase progesterone levels are also lower in postmenarche adolescents than in adulthood even when ovulation does occur (McArthur, 1966 [Figure]; Lemarchand-Béraud et al., 1982; Apter et al., 1987; Venturoli et al., 1987; Venturoli et al., 1989; Sun et al., 2019). Consequently, progesterone exposure is sporadic and relatively limited even during late female puberty. Moreover, this is the case not only by the time of Tanner stage 5, but for many years after it as well. It takes more than 6 years after menarche for menstrual cycling to become fully mature and consistently ovulatory (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987; Carlson & Shaw, 2019). Over this period of time, the rate of ovulatory cycles increases progressively until it reaches approximately 100% (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987; Carlson & Shaw, 2019). Only then is full adult-level exposure to progesterone finally achieved (Lemarchand-Béraud et al., 1982; Venturoli et al., 1987).

Only a handful of studies and sources have reported progesterone levels during puberty across Tanner stages or by age in cisgender girls (e.g., Sizonenko, 1978 [Graph]; Kühnel, 2000; Lee, 2001 [Table]; Aly, 2020a). They corroborate the above findings with regard to limited progesterone exposure during puberty. The “A Girl’s First Period Study” is an ambitious research project announced in 2022 that aims to better characterize reproductive hormone levels in pubertal and adolescent girls and may shed more light on the physiological role of progesterone during puberty (Lucien et al., 2022). The researchers have specifically highlighted the possible role of progesterone in breast development as part of their interests:

Does exposure to low levels of [progesterone (P4)], as occurs before menarche, during anovulatory cycles with some degree of follicle luteinization, and during early, immature ovulatory cycles play an important role in normal breast development during puberty? This question has important clinical implications as hormone replacement during puberty does not typically include low-dose P4; rather, it is conducted using a staggered approach of estrogen-only therapy followed by the addition of full adult doses of exogenous P4 only after 2 years or when breakthrough bleeding occurs.27 This is done to avoid development of tubular breasts, although there are limited data linking early P4 exposure to suboptimal breast development.28

Taken together, production of progesterone is a late event in normal female puberty, and even once it does begin, exposure to progesterone is low and sporadic until well after puberty has completed. Moreover, a subset of girls complete breast development before progesterone production starts. These facts call into some question the role of progesterone in breast development in female puberty, as most breast development appears to be complete prior to the appearance of progesterone. However, more research is still needed on the role of progesterone in breast development during normal puberty.

On the basis of normal female puberty, it seems it may be advisable that if progestogens are introduced in an attempt to enhance breast development in transfeminine people, their introduction be delayed until after 2 or 3 years of hormone therapy, so as to mimic the normal progestogenic exposure of puberty.

Progesterone and Breast Development in Pregnancy

During pregnancy, under the influence of ovarian hyperstimulation and placental formation, there are profound changes in hormonal profiles, including of hormones like estrogen, progesterone, and prolactin, among many others (Table 1). Comparing hormone levels during the menstrual cycle to those during the third trimester of pregnancy, estradiol levels increase on the order of 100-fold, progesterone levels increase on the order of 10- to 20-fold, and prolactin levels increase by around 10-fold (Table 1). Levels of numerous other hormones also change considerably during pregnancy, for instance other estrogens besides estradiol, androgens, gonadotropins (e.g., human choronic gonadotropin or hCG), human placental lactogen (hPL), relaxin, adrenocorticotropic hormone (ACTH), cortisol, aldosterone, growth hormone (GH), and insulin-like growth factor 1 (IGF-1), among others (Goodman, 2009 [Figure]; Mesiano, 2019). These hormones are variously produced by the ovaries, the placenta, and the pituitary gland, among other glands. In response to the myriad hormonal changes during pregnancy, there are dramatic changes to the breasts, which prepare the mother for postpartum lactation and breastfeeding.

Table 1: Changes in hormone levels (estradiol, progesterone, and prolactin) during normal pregnancy:

HormoneNon-PregnantFirst TrimesterSecond TrimesterThird Trimester
Estradiol100 (~5–750) pg/mL1,000–5,000 pg/mL5,000–15,000 pg/mL10,000–40,000 pg/mL
Progesterone8.9 (1.0–24) ng/mLa22 (5–75 ng/mL)35 (15–85) ng/mL102 (25–280) ng/mL
Prolactin13.0 (4.6–37) ng/mL16 (3.2–43 ng/mL)49 (13–166) ng/mL113 (13–318) ng/mL

Note: Values are median (range) or range. Footnotes: a Specifically during the luteal phase of the menstrual cycle. Sources: estradiol (Aly, 2018b; Wiki; Wiki); progesterone (Kühnel, 2000; Aly, 2020a; Wiki; Wiki); and prolactin (Kühnel, 2000; Wiki).

Prior to pregnancy, there is significant although fairly minimal lobuloalveolar development of the breasts with each menstrual-cycle luteal phase (Scott et al., 1950; Drife, 1984; Drife, 1989; Drife, 1990; Pocock, Richards, & Richards, 2013; Johnson & Cutler, 2016; Alekseev, 2021). During pregnancy however, the breasts undergo much more considerable lobuloalveolar development and achieve full maturity. This allows for milk production and lactation following childbirth. During pregnancy, the breasts progressively and considerably increase in size (Hytten, 1954a; Hytten, 1954b; Baird, Hytten, & Thomson,1958; Hytten & Thomson, 1965; Hytten & Leitch, 1971a; Hytten & Leitch, 1971b; Hytten, 1976; Thoresen & Wesche, 1988; Cox et al., 1994; Whiteley, 1994; Cox et al., 1999; Cregan & Hartmann, 1999; Kent et al., 1999; Galbarczyk, 2011; Abduljalil et al., 2012; Bayer et al., 2014; Lawrence & Lawrence, 2015; Żelaźniewicz & Pawłowski, 2015; Dallman et al., 2017; Drąsutis, 2017; Żelaźniewicz & Pawłowski, 2019). Quantitative clinical studies have found the breasts to increase on average by about 100 to 300 mL (range -20 to 880 mL) in volume, or by about 200 to 400 g in mass, going from early pregnancy to late pregnancy or early postpartum (Hytten & Thomson, 1965; Hytten & Thomson, 1968; Hytten & Leitch, 1971a; Hytten & Leitch, 1971b; Hytten, 1976; Thoresen & Wesche, 1988; Whiteley, 1994; Hartmann et al., 1996; Cox et al., 1999; Cregan & Hartmann, 1999; Kent et al., 1999; Wright, 2015; Bayer et al., 2014; Żelaźniewicz & Pawłowski, 2015; Drąsutis, 2017; Żelaźniewicz & Pawłowski, 2019). The breasts can reportedly increase as much two to three times in size in some women (Greydanus et al., 2010). There is marked variation between individuals in the breast size increases during pregnancy (Hytten & Thomson, 1965; Hytten & Leitch, 1971a; Hassiotou & Geddes, 2013; Bayer et al., 2014). Increases in breast size are inversely associated with age, with considerably greater increases in younger women than in older women (e.g., +234–258 mL in <20 years vs. +79–131 mL in >30 years) (Hytten & Baird, 1958; Hytten & Leitch, 1971a [Excerpt]; Hytten, 1976). In addition to overall breast size, the nipples and areolae increase in size during pregnancy (Hytten & Baird, 1958; Hytten & Leitch, 1971a; Rohn, 1989; Cox et al., 1999; Hassiotou & Geddes, 2013; Thanaboonyawat et al., 2013; Park et al., 2014). They also become more darkly pigmented, reaching a dark brown or even black color (Dickson & Hewer, 1950; Thody & Smith, 1977; Wade, Wade, & Jones, 1978; Wong & Ellis, 1984; Elling & Powell, 1997; Muzaffar, Hussain, & Haroon, 1998; Muallem & Rubeiz, 2006; Nussbaum & Benedetto, 2006; Olanrewaju et al., 2017). The breasts become capable of lactation by 3 to 4 months of pregnancy (Walker, Baker, & Lamb, 2013; Pipkin, 2019; Pocock, Richards, & Richards, 2013; Wright, 2015; Lawrence & Lawrence, 2015). However, maturation of the breasts for lactation does not appear to be complete until at least about 6.5 months of pregnancy (Hassiotou & Geddes, 2013). Photographic timelines of women throughout pregnancy provide a visual impression of the breast changes that occur during this time (caution—NSFW: Reddit; More).

There are large and dramatic changes in levels of numerous hormones during pregnancy, and the exact hormones responsible for the breast changes during pregnancy are not known (Hytten & Leitch, 1971a; Hytten, 1976). However, it is considered likely, on the basis of animal studies, that a variety of hormones, including estrogen, progesterone, prolactin, placental lactogen, glucocorticoids, and growth hormone, are all importantly involved in different aspects of the maturation (Hytten & Leitch, 1971a; Hytten, 1976; Cox et al., 1999). Moreover, in a quantitative clinical study of breast changes during pregnancy, increases in breast volume and areola size were positively correlated with levels of hPL, while increases in nipple size were positively correlated with levels of prolactin (Cox et al., 1999). Progesterone and prolactin have specifically been implicated in the lobuloalveolar development of the breasts during pregnancy (Bässler, 1970; Lee & Ormandy, 2012; Obr & Edwards, 2012). Both hormones appear to be independently essential in normal lobuloalveolar growth per animal studies (Obr & Edwards, 2012; McNally & Stein, 2017; Hannan et al., 2023). Prolactin likewise appears to be essential in humans, based on case reports of lactation failure in women with isolated prolactin deficiency (Buhimschi, 2004). Conversely, hPL may not be essential for lactation based on case reports of normal lactation in women with very low levels of hPL during pregnancy (Gaede, Trolle, & Pedersen, 1978; Hannan et al., 2023).

Following childbirth and lactation, the breasts undergo a process known as post-lactational involution and return to a pre-pregnancy-like state (Dickson & Hewer, 1950; Ingleby, Moore, & Gershon-Cohen, 1957; Harley, 1969; Gershon-Cohen, 1970; Petrakis, 1978; Huffman, Dewhurst, & Capraro, 1981; Drife, 1986; Caro, 1987; Tanos & Brisken, 2008; Radisky & Hartmann, 2009; Fridriksdottir, Petersen, & Rønnov-Jessen, 2011; Hassiotou & Geddes, 2013; Sun et al., 2018; Alex, Bhandary, & McGuire, 2020). This involves massive cell death and regression of the lobuloalveolar development and other breast changes that occurred during pregnancy (Radisky & Hartmann, 2009; Alex, Bhandary, & McGuire, 2020). With involution, there is, on the basis of quantitative clinical studies, a complete reversion to pre-pregnancy breast size, or even to a slightly smaller breast size (Kent et al., 1999 [Figure]; Jernström et al., 2005; Dorgan et al., 2013; Lim et al., 2018). The same reversion has also been observed in gestational macromastia (breast hypertrophy of pregnancy), with striking and complete or near-complete regressions in breast size reported—although often with concomitant sagging and deformity that necessitates surgical intervention (Moss, 1968; van der Meulen, 1974 [Figure]; Swelstad et al., 2006; Naik et al., 2015). Following involution, it is also impossible to reliably distinguish between nulliparous and parous breasts even with internal histological examination (Drife, 1986). However, the parous breasts are not exactly the same as they were before pregnancy—the breasts remain more complex on a histological level (Dickson & Hewer, 1950; Gershon-Cohen, 1970; Hytten, 1976; Drife, 1986; Drife, 1989; Jeruss, 2006; Fridriksdottir, Petersen, & Rønnov-Jessen, 2011; Hassiotou & Geddes, 2013; Lewin, 2016; Sun et al., 2019), tend to be looser, more flaccid, and more pendulous due to stretching of skin and ligaments (Begley, Firth, & Hoult, 1980; Duncan, 2010; Rauh et al., 2013; Lewin, 2016), and the nipples and areolae remain more maturely developed and pigmented (Dickson & Hewer, 1950; Hytten & Baird, 1958; Hytten, 1976; Nussbaum & Benedetto, 2006; Sanuki, Fukuma, & Uchida, 2009; Thanaboonyawat et al., 2013; Park et al., 2014). In terms of subjective perceptions, some women perceive their breasts to be larger following pregnancy, whereas others perceive them to be smaller (Rauh et al., 2013; Lewin, 2016). Pregnancy can temporarily improve breast size in women with small breasts (Capraro & Dewhurst, 1975; Petrakis, 1978; Huffman, Dewhurst, & Capraro, 1981), but it has been said that the subsequent regressions in breast size after pregnancy can be “disturbing” (Capraro & Dewhurst, 1975). Following the first pregnancy and post-lactational involution, the breasts undergo the same cycle of expansion and regression with each subsequent pregnancy (Hassiotou & Geddes, 2013).

On the basis of the preceding, in spite of rather extreme hormonal stimulation, the breast changes of pregnancy, although quite dramatic, are essentially temporary and fully reversible, remaining only as long as continuous hormonal exposure is maintained. This hormonal stimulation includes exposure to extremely high levels of progesterone. It would seem, based on pregnancy, that once pubertal breast development is completed, the breasts are rather unamenable to permanent further growth, whether that involves exposure to progestogens or to a variety of other hormones known to act on the breasts.

Breast Composition and Lobuloalveolar Tissue Proportion

The breasts are made up of two main types of tissue: (1) epithelial tissue, the actual functional internal mammary glandular tissue, including ducts and alveoli or lobules; and (2) stromal tissue, a mixture of connective tissue and adipose (fat) tissue. Lobuloalveolar development refers to growth and maturation of the alveoli and lobules, and hence is a form of epithelial or glandular development. Progestogens are involved primarily in lobuloalveolar development of the breasts, which is the type of breast development that is necessary for lactation and breastfeeding and that occurs mainly during pregnancy.

In women who are not pregnant or lactating, studies have found that only about 5 to 20% of the volume of the breasts is composed of epithelial tissue on average, while the remaining 80 to 95% is composed of stromal tissue (Hutson, Cowen, & Bird, 1985; Drife, 1986; Drife, 1989; Bryant et al., 1998; Gertig et al., 1999; Howard & Gusterson, 2000; Cline & Wood, 2006; Lorincz & Sukumar, 2006; Wilson et al., 2006; Xu et al., 2010; Pandya & Moore, 2011; Hagisawa, Shimura, & Arisaka, 2012; Sandhu et al., 2016; Rosenfield, Cooke, & Radovick, 2021; Wiki). More specifically, one major study in in reproductive-age women found that the breasts are about 10 to 20% epithelial tissue, 10 to 35% fat tissue, and 60 to 80% connective tissue (Hutson, Cowen, & Bird, 1985; Wilson et al., 2006). Conflictingly however, a couple of studies that employed mammography have reported higher breast glandular proportions ranging from 35 to 48% (Klein et al., 1997; Jamal et al., 2004; Duncan, 2010). Aside from glandular tissue, other studies have found breast fat percentages of mean 26 to 48% (range 2 to 78%) (Lejour, 1994; Lejour, 1997; Vandeweyer & Hertens, 2002). Similarly to the findings of most studies of women’s breasts in general, only a small proportion of the breasts is glandular tissue (e.g., 1–7%) in women who have macromastia (breast hypertrophy, or extremely large breasts) (Bames, 1948; Cruz-Korchin et al., 2001).

During pregnancy and lactation in humans, the breasts undergo dramatic changes, and epithelial tissue comes to make up a much greater proportion of the breasts (Ramsay et al., 2005; Bland, Copeland, & Klimberg, 2018). In fact, sources state that glandular tissue comprises a majority of the breast during pregnancy and lactation, with one study of lactating women finding that the breasts were composed 63% (range 46–83%) of glandular tissue (Ramsay et al., 2005). This is not merely due to lobuloalveolar development and glandular growth, but is also due to a marked reversible reduction in mammary adipose tissue (Wang & Scherer, 2019; Alex, Bhandary, & McGuire, 2020). In any case, under more normal physiological circumstances and progesterone exposure, the contribution of lobuloalveolar tissue to the size of the breasts would appear to be quite small. In relation to this, outside of pregnancy levels of progesterone, the significance of progestogen-mediated breast lobuloalveolar growth in terms of breast size is unclear but seemingly questionable (Orentreich & Durr, 1974; Wierkcx, Gooren, & T’Sjoen, 2014).

Breast Development in Cisgender Women with Complete Androgen Insensitivity Syndrome and Consequent Absence of Progesterone

It has been claimed that progesterone helps to move transfeminine people and cisgender females from Tanner stage 4 to 5 breast development and that it helps to round out the breasts (e.g., Vorherr, 1974a; Prior, 2011; Prior, 2019a; Prior, 2020). It has also sometimes been claimed in the online transgender community that cisgender women with complete androgen insensitivity syndrome (CAIS), an experiment of nature of women who lack progesterone, are stuck at Tanner stage 4 breast growth and have “cone-shaped” breasts due to their absence of progesterone. In actuality however, there is no good evidence at this time that progesterone is required for normal pubertal breast development, that progesterone is needed to reach Tanner stage 5, or that it helps to round out the breasts. Such claims are contradicted by extensive available literature and evidence, including notably the literature on CAIS women themselves.

Women with CAIS are individuals who have a 46,XY karyotype (i.e., are genetically “male”), testes, and who would otherwise have physically developed as males, but did not because they have a mutation in the gene encoding the androgen receptor that makes them completely insensitive to the effects of androgens. There are also incomplete forms of the syndrome, like partial androgen insensitivity syndrome (PAIS) and mild androgen insensitivity syndrome (MAIS). CAIS women have a male-typical hormonal profile, generated by their testes, including high male-range levels of testosterone, low female-range estradiol levels, and negligible progesterone levels (Wiki; Table). Instead of developing physically as males however, CAIS women are perfectly phenotypically female, with a normal female body, vagina, and breasts (Wiki; Photo). Their testosterone has been unable to masculinize them, while their estradiol, unopposed by androgens, is able to fully feminize them. The internal reproductive system in CAIS women is essentially that of an underdeveloped male, with testes instead of ovaries, and no uterus. The vagina is often short and is blind-ending with no cervix, which is related to their lack of a uterus. CAIS women are also described as feminine in terms of behavior, gender, and sexuality.

Women with CAIS have breast development that is described throughout the literature as “good”, “excellent”, “normal”, “full”, “complete”, “well-developed”, “overdeveloped”, “generous”, “enhanced”, “typically above-average”, “large”, and even “voluptuous” (Morris, 1953; Simmer, Pion, & Dignam, 1965; Hertz et al., 1966; Valentine, 1969; Adams et al., 1970; Polani, 1970; Weisberg, Malkasian, & Pratt, 1970; Dewhurst, 1971b; Perez-Palacios & Jaffe, 1972; Glenn, 1976; Dewhurst & Spence, 1977; Rutgers & Scully, 1991; Patterson, McPhaul, & Hughes, 1994; Quigley et al., 1995; McPhaul, 2002; Galani et al., 2008; Oakes et al., 2008; Tiefenbacher & Daxenbichler, 2008; Barbieri, 2019). John McLean Morris, the gynecologist who reviewed and summarized all of the existing scientific literature on CAIS women in 1953 (including 82 cases) and gave their condition the now-abandoned name “testicular feminization”, described their breasts as “unusually large” and “jumbo-sized” (Morris, 1953; Quigley et al., 1995). He additionally said in his famous 1953 review that they had “normal female breasts, often with a tendency to be overdeveloped” (Morris, 1953). Per another author, “Probably under no other circumstance does breast development in the [‘male’] reach the florid degree seen in testicular feminization” (Wilson, 1968).

Despite claims that CAIS women have generous breast sizes however, in actuality, some CAIS women have large breasts, while some have small breasts, with one study finding a wide range of breast size measurements of 16×14 cm to 41×31 cm (Wisniewski et al., 2000). Moreover, the breasts of CAIS women have never been directly compared to those of normal women. Hence, there are no clear data at this time that the breasts of CAIS women are actually larger than average for women. The variation in breast growth in CAIS women parallels the same large variation in breast size between individuals that is seen in cisgender women in general. Here is a collection of photos of CAIS women and their breast development from published case reports and reviews throughout the literature. As can be seen from these photos, breast development in CAIS women is normal and often excellent, although subject to considerable variation between individuals in terms of breast size and shape as in women generally.

If CAIS women truly do have enhanced breast development and breast sizes compared to normal women, it may be that their androgen insensitivity, and hence lack of inhibition of estrogen-mediated breast development by androgens, is responsible for this (Wilson, 1968; Sobrinho, Kase, & Grunt, 1971; Andler & Zachmann, 1979; Zachmann et al., 1986; Patterson, McPhaul, & Hughes, 1994; Barbieri, 2019). Another theoretical possibility is that the high testosterone levels may be aromatized into greater amounts of estradiol locally within the breasts and other tissues in CAIS women and that this may somehow allow for enhanced breast development (Ladjouze & Donaldson, 2019).

Baron evaluated a total of 41 people with androgen insensitivity syndrome (AIS) and found that 97% of CAIS women had normal breast development while 63% of individuals with “incomplete AIS” (likely PAIS) had normal breast development (Baron, 1993; Baron, 1994a; Baron, 1994b). In another earlier published study of 50 CAIS females by Sir Christopher John Dewhurst, 76% were rated as having full breast development, 7% as having moderate breast development, 5% as having “mild” breast development, and 0% as having absent breast development (Dewhurst, 1971b). Hence, based on findings in large samples of CAIS females, most to almost all have normal or full breast development. That a minority of CAIS females have had less breast growth may be due to factors like low and inadequate estradiol levels in some individuals, young age at time of assessment by which breast development has not fully completed, and/or a small subset of women in general having underdeveloped or small breasts.

CAIS women have never been described in the literature as having “cone-shaped”, “pointy”, or otherwise abnormal breasts. The only exception is that they are often said to have nipples and areolas that are described as “juvenile”, “infantile”, “small”, “pale”, and “non-pigmented” (e.g., Photo) (e.g., Morris, 1953; Morris & Mahesh, 1963; Simmer, Pion, & Dignam, 1965; Dewhurst, 1967; Khoo & Mackay, 1972; Perez-Palacios & Jaffe, 1972; Dewhurst & Spence, 1977). This has been said to be the case regardless of breast size or maturation (Khoo & Mackay, 1972). A possible reason for this phenomenon is that estradiol levels in CAIS women are relatively low, only about 35 pg/mL (130 pmol/L) on average (Wiki; Table). This is relevant as estrogens are known to concentration-dependently produce nipple and areolar pigmentation and enlargement (Davis et al., 1945; Kennedy & Nathanson, 1953). In contrast to estrogens, progestogens have not been implicated in nipple or areolar pigmentation. Hence, it seems that higher estrogen levels may be necessary for full adult-like nipple and areolar maturation.

CAIS women are able to reach Tanner stage 5 breast development and hence full maturation of the breasts similarly to normal women (Quigley, 1988; Quigley et al., 1995; Gordon & Laufer, 2005; Finkenzeller & Loveless, 2007; Cheikhelard et al., 2008; Ramos et al., 2018; Arya et al., 2021; Zhang et al., 2021). One gynecologist, Robert Rebar, has claimed in his publications over several decades, including in reviews and book chapters, that CAIS women usually only reach Tanner stage 3 breast development (Kustin & Rebar, 1987; Rebar, 1988; Rebar, 1990; Simpson & Rebar, 1990; Rebar, 1993; Rebar, 1996; Wellons & Rebar, 2013; Wellons, Weeber, & Rebar, 2017). However, this claim conflicts with the statements of other researchers and with studies and case reports of CAIS women. In one book chapter, Rebar said that CAIS females undergo breast development and feminization and that the breasts contain normal ductal and glandular tissue, but stated that “the areolae are pale and poorly developed (Tanner stage 3)” (Rebar, 1993). This suggests that he may have been meant Tanner stage 3 in terms of nipple and areolar maturation rather than breast growth as a whole (Rebar, 1993). Aside from CAIS females, even individuals with PAIS often have substantial breast growth and female-like breasts (e.g., Saito et al., 2014; Lee et al., 2015). Additionally, PAIS females treated with estrogen therapy have similarly been reported to reach Tanner breast stage 5 (Guaragna-Filho et al., 2023).

Despite their often large breasts, CAIS women are said to have relatively little breast glandular tissue, as opposed to fat and connective tissue, and to have minimal breast lobuloalveolar development (Morris, 1953; Morris & Mahesh, 1963; Simmer, Pion, & Dignam, 1965; McMillan, 1966; Perez-Palacios & Jaffe, 1972; Dewhurst & Spence, 1977; Shapiro, 1982). This is in accordance with the lack of progesterone in CAIS women, since progesterone is important in mediating lobuloalveolar growth. The retained breast sizes of CAIS women despite reduced glandular and lobuloalveolar structures is consistent with the fact that the breasts are composed mostly of stromal adipose and connective tissue. Hence, as touched on previously in this article, greater glandular or lobuloalveolar formation in the breasts may not necessarily translate to greater breast size, which seems readily apparent in CAIS women.

The normal and excellent breast development of CAIS women is notable because these individuals, owing to their testes and hence absence of significant gonadal progesterone production, have very low and negligible levels of progesterone (Wiki; Table; Barbieri, 2019). CAIS womens’ normal breast development, often large breasts, and ability to reach complete breast maturation, as measured by the Tanner scale, are collectively suggestive that progesterone is not required for normal or complete pubertal breast development (Barbieri, 2019). In any case, it must be noted and cautioned again that the breasts of CAIS women have never been directly compared to those in normal women. In addition, quantitative studies of the breasts of CAIS women are very scarce, and much of our knowledge in this area is based on anecdotal clinical experience and subjective breast evaluation. This in large part due to the rarity of CAIS women and the difficulty in obtaining decent samples of them for study. Furthermore, CAIS women also have other differences from regular women besides their lack of progesterone, for instance their relatively low circulating estradiol levels, high testosterone levels (which can be aromatized into estradiol within tissues like the breasts), androgen insensitivity, and XY karyotype, among others. Hence, the insights into breast development provided by CAIS women come with a variety of caveats.

Interestingly, in spite of their well-developed breasts, breast cancer has never been reported in CAIS women, and would appear to be very rare in these individuals (Aly, 2020b; Aly, 2020c). This may be related to factors like the lack of progesterone and lobuloalveolar maturation in CAIS women and/or their absence of a second X chromosome (Aly, 2020b; Aly, 2020c). CAIS women suggest that breast cancer is not an inherent eventual consequence of excellent breast development.

Menstrual Cycles and Temporary Cyclic Breast Enlargement

The breasts fluctuate in size across the menstrual cycle, with significant enlargement apparent during the luteal phase of each cycle (Shuttleworth, 1938 [Figure]; Ingleby, 1949; Scott et al., 1950; Milligan, Drife, & Short, 1975; Drife, 1982; Malini, Smith, & Goldzieher, 1985; Drife, 1989; Fowler et al., 1990; Graham et al., 1995; Jemström & Olsson, 1997; Hussain et al., 1999; Hussain, Brooks, & Percy, 2008; Wang et al., 2019; Rix et al., 2023). This is experienced by women as a sense of fullness, as well as tingling sensations and tenderness (Shuttleworth, 1938 [Figure]; Milligan, Drife, & Short, 1975; Laessle et al., 1990; Jemström & Olsson, 1997). The change in the volume of the breasts has been reported to be approximately 75 to 100 mL on average, with volume falling to as low as 90% of mean volume during the follicular phase or at ovulation and increasing to up to 110% of average volume during the luteal phase (or about 15 to 20% mean total change from smallest to largest volume) (Milligan, Drife, & Short, 1975; Malini et al., 1985; Drife, 1989; Fowler et al., 1990; Hussain et al., 1999; Hussain, Brooks, & Percy, 2008; Rix et al., 2023). However, more recent studies using better measurement methods of breast volume suggest more modest changes, like a decrease in breast volume of 4 to 10% during the follicular phase and an increase in breast volume of 3 to 21% during the luteal phase (Rix et al., 2023). The changes in breast size have also been described as an increase of one-third of a bra cup size (37 mL or 35 g) on average and up to one bra cup size in some (Rix et al., 2023). There is substantial variation between individuals in the changes in breast volume across the menstrual cycle, ranging from no change to up to a 40 to 45% increase in the most extreme cases (Ingleby, 1949; Malini, Smith, & Goldzieher, 1985; Fowler et al., 1990; Hussain et al., 1999; Hussain, Brooks, & Percy, 2008; Rix et al., 2023).

The enlargement of the breasts during the luteal phase of the menstrual cycle is believed to be due to temporary glandular and stromal tissue growth, luminal dilation of the ducts and alveoli, fluid retention in the glandular and stromal structures, and increased vascularization and blood flow (Scott et al., 1950; Drife, 1989; Fowler et al., 1990; Hussain et al., 1999; Alekseev, 2021; Biswas et al., 2022). However, studies suggest that most of the changes are merely due to water fluctuations and that change in breast glandular volume change is relatively small (Rix et al., 2023). The breast changes during the menstrual cycle have been positively correlated with increased levels of estradiol and progesterone during the luteal phase (Jemström & Olsson, 1997; Clendenen et al., 2013; Rix et al., 2023). In addition, estrogen therapy has been found to reversibly increase breast size (e.g., Hartmann et al., 1998) and estradiol levels are positively associated with breast tenderness (e.g., de Lignières & Mauvais-Jarvis, 1981; Sitruk-Ware et al., 1984). Both estradiol and progesterone can promote water retention via distinct hormonal mechanisms as well as mediate breast glandular growth and changes (Rix et al., 2023). As such, the breast changes during the menstrual cycle are assumed to be due to changing levels of estradiol and progesterone, though it is noteworthy that progesterone has been particularly implicated owing to the breast volume increase occurring during the luteal phase (Lawrence & Lawrence, 2015; Rix et al., 2023). There is a delay in breast volume increases following the peaks of estradiol and progesterone levels during the menstrual cycle and hence the changes are not instantaneous (Rix et al., 2023).

Combined oral contraceptives, which are estrogen–progestogen preparations, as well as menopausal estrogen–progestogen hormone therapy, may produce temporary breast enlargement and feelings of breast fullness analogous to those that occur during the luteal phase of the menstrual cycle (Milligan, Drife, & Short, 1975; Dennerstein et al., 1980 [Figure]; Malini, Smith, & Goldzieher, 1985; Jemström & Olsson, 1997; Jernström et al., 2005). In one study, breast volume was around 100 mL greater (~30% higher) in women who were currently taking oral contraceptives relative to those who had not taken or had previously taken oral contraceptives (Jemström & Olsson, 1997). In some women, the increase in breast size with oral contraceptives was subjectively reported to be up to a single bra cup size in volume (Jemström & Olsson, 1997). However, in another study by the same group of researchers that had a much larger sample size (n=258 vs. n=65), breast volumes were not significantly different between current hormonal contraceptive users and non-users (Jernström et al., 2005). Additionally, another study found no significant differences in breast volume in women between different estrogen–progestogen oral contraceptives that had 6.25-fold variation in dose of the same progestin (0.4 to 2.5 mg/day norethisterone) as well as non-users (Malini, Smith, & Goldzieher, 1985). However, this study was underpowered due to small sample sizes (n=5 to n=15 per group) (Malini, Smith, & Goldzieher, 1985).

Engman et al. (2008) conducted an RCT of treatment with mifepristone, a selective progesterone receptor modulator (SPRM) with predominantly antiprogestogenic effects, versus placebo for 3 months in normally cycling premenopausal cisgender women, and evaluated the effects of this progesterone receptor blockade on the breasts. They found that mifepristone significantly reduced Ki-67 index, a measure of cellular proliferation in the breasts, and reduced subjectively rated symptom scores on the Breast Symptom Index (BSI). More specifically, breast soreness, breast swelling, sense of increased breast volume, and the total breast symptoms score were all significantly reduced on the BSI. However, breast volume was not objectively measured in this study. A major limitation of this study is that mifepristone inhibits ovulation and modifies levels of estradiol and other hormones (Spitz et al., 1989; Spitz et al., 1994; Engman et al., 2008, Spitz, 2010). As such, it is unclear whether the effects observed by Engman and colleagues were specifically due to progesterone receptor antagonism in the breasts or due to disruption of the hypothalamic–pituitary–gonadal (HPG) axis, for instance lowered estradiol levels.

An interesting case report of an adult woman with CAIS documented a significant increase in breast volume with combined estrogen–progestogen therapy relative to estrogen monotherapy (Dijkman et al., 2023b). The woman was started on cyclic oral estradiol 2 mg/day and dydrogesterone 10 mg/day and subjectively experienced breast pain and fluctuations in breast volume of about one cup size while on this regimen. Subsequently, she was switched to oral estradiol valerate 3 mg/day monotherapy and the fluctuations in breast volume ceased. However, her overall breast volume was reduced as well, and the woman decided to resume combined estradiol and dydrogesterone therapy. Her clinicians proceeded to measure her breast volume using 3D body scanning. Her left breast was 758 mL and right breast was 673 mL with estrogen monotherapy, and her breasts increased to respective volumes of 875 mL and 784 mL during combined estrogen–progestogen therapy, giving net volume increases of 117 mL (+16%) and 111 mL (+17%). These differences in volume corresponded to an almost one bra cup difference in size. The researchers noted that estradiol and progesterone are associated with cyclical breast changes, and hypothesized that the changes in their patient were due to increased fluid retention in the breasts. Taken together, the case report demonstrates that progestogens can cause rapid and considerable reversible breast enlargement in some women analogous to that during the normal menstrual cycle.

Progesterone and Mammary Development in Animals

Progesterone and Pubertal Mammary Development in Animals

Knockout of the progesterone receptor (PR) in female mice results in complete infertility and severely compromised ovarian and uterine functions (Lydon et al., 1995; Ismail et al., 2003). On the other hand, pubertal mammary development in progesterone-receptor knockout mice is normal and morphologically indistinguishable from that of regular mice (Soyal et al., 2002; Ismail et al., 2003; Fernandez-Valdivia et al., 2005). This is in contrast to the case of estrogen receptor alpha (ERα) knockout mice, in which pubertal mammary development is abolished (Ismail et al., 2003; Fernandez-Valdivia et al., 2005; Wiki; Wiki). However, subsequent studies revealed that mammary ductal development during puberty, while eventually normal, is delayed in female mice that have loss of progesterone production, loss of the progesterone receptor, or progesterone receptor antagonism with mifepristone (Shi, Lydon, & Zhang, 2004). In other words, progesterone stimulates and accelerates ductal development during puberty, and hence appears to have a significant physiological role in early mammary development during puberty. The stimulation of ductal development by progesterone appears to be mediated by induction of the expression of amphiregulin in mammary ducts and terminal end buds (Kariagina et al., 2010; Aupperlee et al., 2013). This growth factor is an agonist of the epidermal growth factor receptor (EGFR), and is also notably the major growth factor that estrogen induces the expression of to mediate mammary gland development during puberty (Ciarloni, Mallepell, & Brisken, 2007; LaMarca & Rosen, 2007; McBryan et al., 2008). In any case, as mammary ductal development during puberty without progesterone is delayed, but eventually normal, it has been concluded that progesterone is dispensable for pubertal mammary gland development in mice (Soyal et al., 2002; Ismail et al., 2003; Fernandez-Valdivia et al., 2005).

Although progesterone does not seem to be essential in normal pubertal mammary development in mice, studies have interestingly found that it is able to substitute for estrogen in mediating pubertal ductal mammary development in this species. Ruan, Monaco, & Kleinberg (2005) studied the effects of various combinations of exogenous estradiol, progesterone, and IGF-1 on mammary development in oophorectomized female IGF-1-knockout mice. In terms of stimulation of ductal development to occupy the mammary gland fat pad, the combination of progesterone and IGF-1 produced 92% occupation, estradiol and IGF-1 resulted in 92% occupation, estradiol, progesterone, and IGF-1 achieved 96% occupation, and IGF-1 alone resulted in only 28% occupation (Ruan, Monaco, & Kleinberg, 2005; Kleinberg & Ruan, 2008). In terms of gross anatomical appearance, the ductal tree with progesterone and IGF-1 was said to resemble that of a normal fully developed pubertal mammary gland (Ruan, Monaco, & Kleinberg, 2005). However, differences in mammary development between the combination of estradiol and IGF-1 and the combination of progesterone and IGF-1 were apparent, with estradiol and IGF-1 having greater effect on terminal end bud formation, ductal decorations, and slight alveolar maturation, and progesterone and IGF-1 having more effect on ductal formation, extension, and branching (Ruan, Monaco, & Kleinberg, 2005; Kleinberg & Ruan, 2008). The effects of progesterone on mammary development were reversed by the progesterone receptor antagonist mifepristone (Ruan, Monaco, & Kleinberg, 2005). Only the combination of estradiol, progesterone, and IGF-1 produced mammary development that resembled that during mid-pregnancy, with full maturation of secretory alveolar structures (Ruan, Monaco, & Kleinberg, 2005; Kleinberg & Ruan, 2008).

Aside from the preceding studies, a number of other studies have also found increased ductal branching of mammary glands during puberty with exogenous progesterone administration in mice (Atwood et al., 2000; Hovey et al., 2001; Satoh et al., 2007; Aupperlee et al., 2013).

A limitation of studies that have used exogenous progesterone to stimulate pubertal ductal mammary development in mice is that the doses of progesterone employed, in conjunction with other hormones like estradiol, have been sufficient to mediate mammary growth to a level typical of pregnancy, with robust maturation of mammary lobuloalveolar structures (e.g., Skarda, Fremrová, & Bezecnyý, 1989; Ruan, Monaco, & Kleinberg, 2005). Pregnancy is a time when hormone levels are much higher than usual. Hence, the progesterone exposure in these studies may have been supraphysiological relative to normal puberty, and may have produced effects on mammary growth that would not otherwise occur during this time. Accordingly, Skarda, Fremrová, & Bezecnyý (1989) found that whereas untreated normal female mice naturally grew to a mammary gland area of 26.4 mm2 and normal female mice treated with exogenous estradiol grew to a mammary gland area of 25.3 mm2, normal female mice treated with exogenous estradiol and progesterone grew to a mammary gland area of 43.5 mm2 and with exogenous progesterone alone to a mammary gland area of 64.6 mm2. The untreated control mice did not show alveolar buds, whereas the progesterone-treated groups did have alveolar maturation, indicating supraphysiological and pregnancy-like development compared to non-pregnant mice (Skarda, Fremrová, & Bezecnyý, 1989). In any case, one study employed low doses of progesterone (0.1 mg/day), one-tenth of that used in most other studies (1 mg/day), and found that progesterone still stimulated significant ductal development in mice at these doses (Aupperlee et al., 2013; Berryhill, Trott, & Hovey, 2016). Hence, progesterone is still able to stimulate some level of ductal growth in mice even at lower levels.

Although progestogens by themselves can apparently stimulate normal pubertal mammary development in lieu of estrogen exposure in mice, it is not clear that they do so similarly in humans. It is well-known that progestogens alone, without concomitant estrogenic activity, do not generally produce breast development in humans. As an example, progestogens, for instance MPA and CPA, have been used as puberty blockers in boys and girls at very high doses, and do not produce breast development in this context, instead causing arrest and regression of breast development via gonadal suppression (Lyon, De Bruyn, & Grant, 1985; Fuqua & Eugster, 2022). Cases of gynecomastia in boys have occurred with CPA, but only in a minority and with this easily attributable to other causes than progestogenic activity, for instance the antiandrogenic activity of CPA and disruption of the HPG axis (Kauli et al., 1984; Laron & Kauli, 2000). Similarly, progestogens like MPA and CPA have been used at very high doses in men to treat prostate conditions and sexual disorders, and likewise do not usually produce gynecomastia under these circumstances. Rates of gynecomastia with CPA used in the treatment of prostate cancer are low and are not noticeably different from the rates with surgical or medical castration (~10%) (Fourcade & McLeod, 2004; Di Lorenzo et al., 2005). This is in major contrast to the high rates of gynecomastia with estrogens and nonsteroidal antiandrogens (up to 70–80%) (Fourcade & McLeod, 2004; Di Lorenzo et al., 2005; Deepinder & Braunstein, 2012). Species differences may be present such that progestogens can produce robust pubertal mammary development in mice but do not do so in humans.

Progesterone and Gestational Mammary Development in Animals

As in humans, pregnancy results in increased levels of estrogen, progesterone, prolactin, and many other hormones in various animal species like rodents and non-human primates (Hasan, 1974; Cowie, Forsyth, & Hart, 1980; Pasqualini & Kincl, 1985; Günzel et al., 1987; Seibert & Günzel, 1994). Along with this, there are dramatic changes in the mammary glands (Cowie, Forsyth, & Hart, 1980; Richert et al., 2000; Cline & Wood, 2008; McNally & Stein, 2017). This includes extensive lobuloalveolar maturation of the mammary glands in preparation of lactation and nursing (Cowie, Forsyth, & Hart, 1980; Richert et al., 2000; Cline & Wood, 2008; McNally & Stein, 2017). Permanently enlarged breasts, mainly due to accumulation of abundant adipose tissue during puberty, is unique to humans, and in animal species, although there is significant growth with puberty (e.g., Geschickter, 1945 [Figure]), the exterior mammae enlarge considerably only with pregnancy (Pawłowski & Żelaźniewicz, 2021). In the case of macaques, there is a roughly 10- to 20-fold increase in the glandular tissue during pregnancy (Cline & Wood, 2008).

Administration of exogenous estradiol and progesterone in specific amounts to virgin adult females of various animal species, including rodents, results in mammary development that is very similar to that which occurs normally during pregnancy (Nelson, 1936; Turner, 1939; Folley, 1940; Folley, 1947; Folley & Malpress, 1948; Folley, 1950; Folley, 1952; Folley, 1956; Lyons, 1958; Lyons, Li, & Johnson, 1958; Cowie & Folley, 1961; Jacbosohn, 1961; Cole & Hopkins, 1962; Lloyd & Leathem, 1964; Meites, 1966; Bässler, 1970; Ceriani, 1974; Vorherr, 1974b; Cowie, Forsyth, & Hart, 1980; Tucker, 2000; Kleinberg, 2006; Kleinberg & Ruan, 2008; Kleinberg et al., 2009; Kleinberg & Barcellos-Hoff, 2011). High levels of prolactin also occur in this context, as estrogen and progesterone induce production and secretion of prolactin from the pituitary gland (Ceriani, 1974; Bethea, Kohama, & Pecins-Thompson, 1997; Camilletti et al., 2019). Although estradiol and progesterone alone seem to be adequate for producing full pregnancy-type mammary development in many species, the combination of estradiol, progesterone, and placental lactogen in rhesus monkeys produced considerably less lactational activity than occurs during normal pregnancy in this species (Beck, 1972; Cowie, Forsyth, & Hart, 1980). In relation to this, placental lactogen and/or additional hormonal factors may also be necessary for complete pregnancy-like mammary gland maturation in primates (Beck, 1972; Cowie, Forsyth, & Hart, 1980).

As with humans, following cessation of lactation and nursing, the mammary glands are well-known to undergo post-lactational involution and to return to a pre-pregnancy-like state in animals, including in rodents and monkeys (Richert et al., 2000; Cline & Wood, 2006; Cline & Wood, 2008; Fridriksdottir, Petersen, & Rnnov-Jessen, 2011; McNally & Stein, 2017).

Breast Changes with Therapeutic Pseudopregnancy

Therapeutic or pharmacological pseudopregnancy is a type of hormone therapy that attempts to replicate the hormonal mileu of pregnancy for certain medical indications in cisgender females by administering exogenous hormones. In practice, this has involved the administration of very high doses of estrogens and progestogens, with most other pregnancy hormones not included. Therapeutic pseudopregnancy was first developed in the 1950s and is largely no longer used in medicine today (Kaiser, 1993).

The effects of therapeutic pseudopregnancy on the breasts are of interest due to the breast changes that occur during pregnancy, for instance lobuloalveolar development and substantial reversible breast enlargement. In the 1980s, Lauritzen and colleagues conducted a study of therapeutic pseudopregnancy for treatment of breast hypoplasia (small/underdeveloped breasts) in cisgender women (Lauritzen, 1980; Lauritzen, 1982; Lauritzen, 1989; Göretzlehner & Lauritzen, 1992). They employed the estrogen estradiol valerate 40 mg/week and the progestogen hydroxyprogesterone caproate (OHPC) 250 to 500 mg/week both by intramuscular injection for 4 to 5 months. The estradiol valerate dosage employed was very high, with other studies by the same authors reporting that this dosage of estradiol valerate resulted in first-trimester pregnancy levels of estradiol in women (~3,000 pg/mL [~11,000 pmol/L]) (Ulrich, Pfeifer, & Lauritzen, 1994; Ulrich et al., 1995). These estradiol levels are roughly 30 times the normal concentrations outside of pregnancy (Aly, 2018b). Similarly, the OHPC doses were very high, with 250 to 500 mg per month being similar in strength to luteal-phase progestogenic exposure (Wiki). Hence, as the same OHPC doses were used weekly in the study, the doses were roughly around 4.5 times luteal-phase exposure and thus were analogously similar to first- or second-trimester progesterone levels in terms of strength (Aly, 2020d). The authors noted that they had initially tried lower hormone doses, similar to those originally used in the 1950s, but did not achieve significant breast growth with these doses, and so increased the dosage. Breast changes were measured in the study with a tape measure (applied horizontally and vertically to the breast area), photographs, breast imaging using mammography and sonography, and, later in the study, plasticine impressions/molds with determination of the filling volume.

Lauritzen and colleagues reported the study findings in four different publications with different follow-up times and growing sample sizes. In the final follow-up, a total of 221 women had been treated. In the second follow-up, when 78 women had been treated, it was noted that 29 of the cases (37%) were less than 18 years old. However, in the final follow-up of 221 women, the age range was listed as 18 to 42 years. The researchers found that breast volume increased by 10 to 30% above baseline in 65% of the women. This was also accompanied by breast tenderness in almost all of the women, though the breast tenderness progressively declined during the treatment period. Other breast-related side effects like pigmentation and stretch marks were rarely observed. Prolactin levels slightly increased to 14 to 28 pg/mL by the end of treatment. Breast imaging showed an increase in the density of breast glandular tissue. The researchers claimed that the increase in breast size in their study was due to increased adipose tissue, water retention, and moderate hypertrophy of the glandular tissue.

Following treatment discontinuation, the increases in breast volume gradually and partially regressed in 40% of the women, to an increase of 10 to 20% above baseline. However, the authors claimed that the regression in breast volume could be reduced with adequate-dose combined estrogen–progestogen birth control pills or with topical estrogen and progestogen therapy applied to the breasts. In addition, they noted that therapeutic pseudopregnancy could be repeated to increase breast volume again. This was performed in a subset of the women, with treatment repeated 1 to 2 times after 6 months. In the second follow-up, which had 78 women, it was noted that 12 women (15%) had undergone multiple treatments. Aside from Lauritzen and colleagues, many other researchers have also reported substantial or full regression in breast size following estrogen and/or progestogen therapy to increase breast size in cisgender women (e.g., Cernea, 1944; Müller, 1953; Anderson, 1962; Bruck & Müller, 1967; Keller, 1984; Kaiser & Leidenberger, 1991; Keller, 1995; Hartmann et al., 1998).

The findings of Lauritzen and colleagues were reported very informally, in the form of non-peer-reviewed book chapters, conference papers, and medical magazines, and were never published in a peer-reviewed journal article. In relation to this, the methodology and results of the study were only briefly and imprecisely described. There are also additional concerns related to study design, such as lack of controls, randomization, and the quality of the breast measurement methods. As a result of the preceding issues, it is difficult to fully interpret the results of the study and to have complete confidence in its findings. In any case, Lauritzen and colleages’ results suggest that treatment with high-dose combined estrogen–progestogen therapy, achieving earlier-pregnancy estrogenic and progestogenic exposure, may be able to produce a significant temporary increase in breast size and a smaller long-term increase. The findings of a permanent increase in breast size conflict with those of other researchers who have reported complete regression in breast changes following treatment discontinuation. Moreover, the results are contradicted by findings in pregnant women, who, as described previously, show complete reversion to pre-pregnancy breast size or to even slightly smaller breasts following cessation of lactation.

It is difficult to evaluate the relative roles of the estrogen and the progestogen in the findings of Lauritzen and colleagues, as there were no comparison groups employing estrogen or progestogen therapy alone in the study. Both estrogens and progestogens have been implicated in causing breast enlargement and plausibly could have contributed to the breast changes. As such, it is unclear to what extent the breast changes were specifically due to progestogenic exposure rather than to estrogenic exposure.

The breast size increases observed by Lauritzen and colleagues were seemingly more modest relative to those that occur normally during pregnancy. They also lacked certain characteristics of pregnancy-related breast changes, like nipple and areolar pigmentation. The reasons for this are not fully clear. The subject populations between these studies were different, for instance in terms of factors like initial breast size and age, which may be contributing reasons. Another possible contributing factor is that only estrogen and progestogen levels increased in the study, whereas levels of other pregnancy hormones, besides the slight increase in prolactin levels, did not increase. These other pregnancy hormones, for instance hPL and IGF-1, may also be involved in breast development during pregnancy. Finally, the treatment duration was only 4 to 5 months, and the estrogen and progestogen exposure was only similar to that during early-to-mid pregnancy, whereas normal pregnancy lasts 9 months and involves continued dramatic increases in estrogen and progesterone levels through to childbirth.

It should be noted that, owing to the highly supraphysiological estrogen and progestogen levels required, which can cause serious health complications like blood clots and cardiovascular problems (Aly, 2020e), as well as the small to negligible lasting increase in breast volume, therapeutic pseudopregnancy is inadvisable for transfeminine people and should not be pursued or employed. Nonetheless, the historical findings of therapeutic pseudopregnancy for increasing breast size in cisgender females are of significant theoretical interest in exploring the roles of estrogens and progestogens in breast growth.

Early Progestogen Exposure and the Possibility of Suboptimal Breast Development

While progestogens are typically sought after by transfeminine people for their potential in improving breast development, there have also been various suggestions in the literature that early or premature exposure to progestogens may result in suboptimal breast development and that progestogens may suppress or reduce estrogen-mediated breast development. These suggestions include progestogens having known antiestrogenic effects in the breasts, animal studies finding stunted mammary development with high doses of progestogens, clinical publications cautioning against premature introduction of progestogens in female puberty induction due to concerns about possibly stunted breast growth, clinical use of progestogens to treat macromastia in cisgender females, poor breast development with estrogen therapy in cisgender girls with a disorder of sexual development that results in high progesterone exposure, and breast development with estrogen and CPA (a very strong progestogen) typically being poor in transfeminine people. As with the question of whether progestogens can enhance breast development, it is currently unknown whether progestogens could worsen breast development. It is also unknown what dosage level and timing of introduction would be required for such an effect. In any case, for informational purposes, the preceding topics will each be discussed in the subsequent sections.

Antiestrogenic Effects of Progestogens in the Breasts

Progestogens are well-known to have potent functional antiestrogenic effects in tissues such as the uterus, vagina, and cervix (Wiki). The antiestrogenic effects of progestogens in the uterus are in fact the reason that they are used in menopausal hormone therapy—to prevent the risks of endometrial hyperplasia and endometrial cancer that unopposed estrogen therapy otherwise produces (Wiki). Progestogens also appear to have antiestrogenic effects in the breasts (Mauvais-Jarvis, Kuttenn, & Gompel, 1986a; Mauvais-Jarvis, Kuttenn, & Gompel, 1986b; Mauvais-Jarvis, Kuttenn, & Gompel, 1987; Mauvais-Jarvis et al., 1987; Kuttenn et al., 1994; Wren & Eden, 1996; Plu-Bureau, Touraine, & Mauvais-Jarvis, 1999; Wiki). This may include by inhibiting estrogen synthesis and enhancing estrogen inactivation in the breasts (Pasqualini, 2007; Pasqualini, 2009) and by reducing expression of the estrogen receptors in the breasts (Mauvais-Jarvis, Kuttenn, & Gompel, 1986b; Malet et al., 1991; Kuttenn et al., 1994; Wren & Eden, 1996; Graham & Clarke, 1997; Plu-Bureau, Touraine, & Mauvais-Jarvis, 1999). Clinical studies have found that direct application of topical progesterone to the breasts suppresses estradiol-mediated breast cell proliferation, although this may be due to the delivery of supraphysiological levels of progesterone in the breasts (Barrat et al., 1990; Chang et al., 1995; Foidart et al., 1996; Spicer, Ursin, & Pike, 1996; Foidart et al., 1998; de Lignières, 2002; Gompel & Plu-Bureau, 2018; Trabert et al., 2020). In accordance with their antiestrogenic effects in the breasts, progestogens are considered to be useful in treating estrogen-dependent benign breast disorders such as breast pain, nodularity, and fibrocystic breast disease (Mauvais-Jarvis, Sitruk-Ware, & Kuttenn, 1981; Winkler et al., 2001; Schindler, 2011; Wiki; Wiki; Wiki). Progestogens have also been reported to antagonize nipple and areolar hyperpigmentation induced by high-dose estrogen therapy (Crowley & Macdonald, 1965). In contrast to the preceding findings however, the addition of a progestogen to an estrogen in menopausal hormone therapy has been shown to significantly increase the risk of breast cancer (Aly, 2020a; Wiki). In any case, the antiestrogenic effects of progestogens in the breasts provide a plausible potential mechanism by which they might limit estrogen-mediated breast development. However, an alternative possible mechanism is that such actions may be related to simultaneous induction of ductal development and lobuloalveolar maturation, the latter of which is notably not normal for puberty (Randolph, 2018).

Stunted Mammary Growth with Progestogens in Animal Studies

Animal studies using progestogens including bioidentical progesterone and chlormadinone acetate (CMA), a progestin closely related to CPA, have found that high doses of these progestogens substantially stunt mammary gland development in rabbits, whereas lower doses do not do so (Lyons & McGinty, 1941; Beyer, Cruz, & Martinez-Manautou, 1970). See here for relevant literature excerpts as well as figures from these studies. Lyons & McGinty (1941) [Figure] found that estrogen alone induced ductal mammary development and estrogen plus progesterone 0.25 to 1 mg/day produced ductal development and slight to “fair” lobuloalveolar development. Conversely, estrogen plus progesterone 4 to 8 mg/day, which were 4- to 8-fold higher doses of progesterone than the most optimal dose, produced stunted mammary development with inhibited ductal development, only slight lobuloalveolar development, and, at the highest dosage, resulted in a much smaller mammary gland in terms of size than in the ≤1 mg/day groups. They concluded that high doses of progesterone are inhibitory and result in relatively poor mammary development. In the paper, doses of progesterone in international units (IU) were reported, but a citing review, Pfeiffer (1943), indicated that 1 IU progesterone is equal to 1 mg progesterone. As such, the milligram doses are listed above instead. Beyer, Cruz, & Martinez-Manautou (1970) [Figure] found that estrogen alone produced good ductal development without lobuloalveolar growth (mean mammary area = 376 mm2) and both estrogen plus CMA 0.5 mg/day and estrogen plus progesterone 2.5 mg/day produced optimal ductal and lobuloalveolar development (mean mammary area = 765 mm2 and mean mammary area = 688 mm2, respectively). Conversely, estrogen plus CMA 2.5 mg/day, a 5-fold higher dose of CMA than the optimal dose, resulted in dramatically reduced ductal development and mammary gland size albeit with significant lobuloalveolar growth (mean mammary area = 284 mm2). The authors concluded that moderate doses of progestogens stimulate mammary gland growth whereas large doses inhibit mammary gland development.

While these animal studies are suggestive that high doses of progestogens may be able to stunt breast development in humans, this is far from a certainty. There are species differences in hormone-mediated mammary development such that findings in one species, such as rabbits, may not translate to another species, like humans, or sometimes even to closely related species, like rats or guinea pigs (Bässler, 1970). As far as the present author is aware, stunted mammary development with high doses of progestogens has not been studied or reported in other animal species, for instance other rodent species or monkeys. It is also unclear that the doses employed in these animal studies are necessarily relevant to progestogen therapy in humans. This is because pregnancy levels of progesterone, which are much higher than luteal-phase progesterone levels, are necessary for substantial mammary lobuloalveolar development, and the doses of progestogens used in these studies were above that magnitude of progestogenic exposure. Hence, the doses may have corresponded to what in humans would be extremely high doses. However, such doses could still be relevant in the case of CPA used as an antiandrogen in humans, as CPA is used in this context at very high doses (see section below). The present author is unaware of any animal studies finding that physiological non-pregnancy levels of progesterone have any stunting or other adverse influence on mammary development, suggesting that only high doses of progestogens may have such effects. Finally, it seems notable that the estrogen and progestogen were initiated simultaneously in these animal studies and yet produced optimal pregnancy-like mammary development at the right doses. This suggests that early or immediate progestogen exposure might not be unfavorable in terms of breast development in humans. However, once again species differences may be present and confirmatory clinical studies are needed in humans.

Clinical Publications Cautioning Against Premature Introduction of Progestogens Due to Possibly Stunted Breast Development

A large number of clinical publications largely in the pediatric endocrinology literature have warned that premature exposure to progestogens during for instance puberty induction may result in suboptimal breast development in cisgender girls and/or transfeminine people (Zacharin, 2000; Bondy et al., 2007; Colvin, Devineni, & Ashraf, 2014; Wierckx, Gooren, & T’Sjoen, 2014; Kaiser & Ho, 2015; Bauman, Novello, & Kreitzer, 2016; Gawlik et al., 2016; Randolph, 2018; Donaldson et al., 2019; Heath & Wynne, 2019a; Heath & Wynne, 2019b; Iwamoto et al., 2019; Crowley & Pitteloud, 2020; Naseem, Lokman, & Fitzgerald, 2021; Federici et al., 2022; Lucien et al., 2022; Rothman & Iwamoto, 2022). The full relevant excerpts from these sources can be found here. In relation to these claims, and in order to mimic normal female puberty, a progestogen is not typically added to estrogen therapy during puberty induction in cisgender girls with delayed puberty until after about 2 to 3 years of treatment, by which point breast growth is generally considered complete. Additionally, progestogens are generally never added as part of puberty induction in transfeminine adolescents. Despite the preceding widespread literature statements and accepted clinical practices in the field of puberty induction however, it is important to note that the claims that premature introduction of progestogens might stunt breast development in this context are currently not based on any actual reliable clinical evidence and hence remain unsubstantiated. It is not even clear that these statements are based on anecdotal clinical experience as opposed to simple conjecture. The absence of data in this area may finally change in the future as more clinical studies of progestogens in puberty induction in cisgender girls are conducted (e.g., Rodari et al., 2023).

Rodari and colleagues studied optimization of puberty induction with estrogen therapy followed by eventual introduction of progestogen therapy in 49 cisgender girls with hypogonadism (e.g., Rodari et al., 2022; Rodari, 2022; Rodari et al., 2023). The researchers employed incrementally titrated low-dose transdermal estradiol to mimic the low and gradually increasing estradiol levels during normal puberty and added a progestogen only once menstrual bleeding began. The total duration of treatment was mean 2.65 ± 1 years, the time of first menstrual bleeding occurrence was 2.3 ± 1 years, and the time of progestogen introduction was median 2.22 years (IQR 1.56–2.87 years). Of the girls, 90% reached Tanner breast stage 4, but only 41% reached Tanner breast stage 5. Reaching the final Tanner breast stage was significantly associated with the number of estradiol dose increases (i.e., gradual estradiol dose titration) and the estradiol dose at progestogen introduction. The researchers interpreted the latter finding as progestogen exposure potentially hampering breast development. They questioned introducing progestogen therapy in the presence of incompletely developed breasts and suggested that instead of adding a progestogen upon onset of menstrual bleeding, clinicians should consider slightly reducing the estradiol dosage to delay progestogen introduction until the breasts complete maturation. While interesting, it must be noted that the findings of Rodari and colleagues are merely correlational, are open to multiple interpretations, and do not causally show that progestogens impair breast maturation.

Progestogens in the Treatment of Breast Hypertrophy

Low progesterone levels have been suggested as a possible contributing factor in the development of pubertal macromastia (breast hypertrophy) (Sun et al., 2018). A number of case reports and series of progestogens in the treatment of pubertal macromastia have been published (Sperling & Gold, 1973; Boyce, Hoffman, & Mathes, 1984; Ryan & Pernoll, 1985; Aritaki et al., 1992; Gliosci & Presutti, 1993; Sridhar & Jaya Sinha, 1995; Baker et al., 2001; Dancey et al., 2008; Bland, Howard, Romrell, 2009; Hoppe et al., 2011; Sun et al., 2018). Progestogens such as dydrogesterone, MPA, and CPA were used for this purpose in an attempt to stop or slow the growth of the breasts under the assumption that they are functionally antiestrogenic in breast tissue. Clinical success in these limited cases was mixed. Due to the self-resolving nature of pubertal macromastia (i.e., breast development stops on its own eventually) and other methodological limitations, such as very small numbers of individuals and lack of untreated control groups, it is difficult to draw any reliable conclusions about effectiveness from these reports.

More recently, a couple of studies, both by the same group of researchers, assessed the impact of different types of hormonal contraception on macromastia in adolescent cisgender females with macromastia (Nuzzi et al., 2021; Nuzzi et al., 2022). They found that use of progestin-only contraceptives were associated with significantly more breast tissue removed upon surgical breast reduction (959.9 g/m2 vs. 735.9 g/m2 [+30%]; p = 0.04) and worse clinical symptoms (e.g., breast pain—odds ratio, 4.94, p = 0.005) relative to non-users of hormonal contraception (Nuzzi et al., 2021). Conversely, use of combined oral contraceptives, which are estrogen–progestogen preparations, were associated with significantly less breast tissue removed with breast reduction (639.5 g/m2 vs. 735.9 g/m2 [−13%]; p = 0.003), though not with any differences in clinical symptoms, relative to those naive to hormonal contraception (Nuzzi et al., 2022). It should be noted that progestin-only contraceptives suppress the HPG axis and result in low estradiol levels, whereas combined oral contraceptives suppress the HPG axis and lower estradiol production but simultaneously supplement estrogen signaling by delivering exogenous estrogen. This difference may somehow be responsible for the opposite influence of estrogen–progestogen therapy versus progestogen-alone therapy on macromastia severity. While the findings of Nuzzi and colleagues are interesting, it is noteworthy that the methodology and findings of their research were criticized on various grounds in a letter to the editor concerning one of the articles (Karp, 2022).

Poor Breast Development in 17α-Hydroxylase/17,20-Lyase Deficiency

Poor breast development with exogenous estrogen therapy has been reported in cisgender girls with 17α-hydroxylase/17,20-lyase deficiency, and prior exposure to high progesterone levels consequent to the condition has been hypothesized to be responsible for this (Turan et al., 2009; Athanasoulia et al., 2013; Deeb et al., 2015; Çamtosun et al., 2017; Fernández-Cancio et al., 2017; Kardelen et al., 2018). However, this is only speculation, and at this time, there is no causal evidence or other substantiation that progesterone specifically is responsible for the observations of poor breast growth.

Non-Comparative Clinical Studies of Breast Development with Estrogen and Cyproterone Acetate in Transfeminine People

The possibility of suboptimal breast development with premature exposure to progestogens is of particular relevance in the case of CPA used as an antiandrogen in transfeminine people. This is because CPA is a potent progestogen in addition to antiandrogen, starts to be taken at the initiation of hormone therapy, and happens to be used in transfeminine people at doses that result in very strong to profound progestogenic exposure (Aly, 2019). In terms of progestogenic strength, CPA at a dosage of 2 mg/day is comparable to the progesterone exposure during the luteal phase of the menstrual cycle (Aly, 2019; Wiki). For comparison, CPA has been used in transfeminine people at doses ranging from 10 to 100 mg/day (Aly, 2019). This would mean that CPA provides roughly 6.25 times the progestogenic impact of luteal-phase progesterone exposure at a dosage of 12.5 mg/day, 12.5 times the impact at 25 mg/day, 25 times the impact at 50 mg/day, and 50 times the impact at 100 mg/day. Moreover, this does not consider the fact that progesterone is only produced during the luteal phase, or half of the menstrual cycle, whereas CPA is taken continuously every day of the month. The preceding magnitudes of progestogenic exposure with CPA are on par with and even beyond those during pregnancy. Only recently have lower doses of CPA (e.g., ≤12.5 mg/day) started to be used in transfeminine hormone therapy.

Studies in pubertal and adolescent transfeminine people given GnRH agonists to block puberty plus estrogen therapy have reported good breast development in these individuals as assessed by subjective clinical impression or Tanner staging (de Vries et al., 2010; Hannema et al., 2017). However, quality objective measures of breast development were not employed in these studies. Conversely, non-comparative studies using estrogen plus CPA in adult transfeminine people have commonly reported modest breast development, including incomplete breast development only to Tanner stage 2 to 4, small breast cup sizes, and small breast volumes (Kanhai et al., 1999; Sosa et al., 2003; Sosa et al., 2004; Wierckx et al., 2014; Fisher et al., 2016; Tack et al., 2017; de Blok et al., 2018; Reisman, Goldstein, & Safer, 2019; Meyer et al., 2020; de Blok et al., 2021). Additionally, breast sizes smaller than those in cisgender women have been reported (Asscheman & Gooren, 1992; Kanhai et al., 1999). In one study, breast development with estrogen plus CPA was also poor in late-adolescent transfeminine people (Tack et al., 2017). However, in this particular study, the estrogen dose used was likely too low and resulted in inadequate estradiol levels, as noted by the authors themselves, and this is a potential confounding factor in their findings (Tack et al., 2017). In any case, breast growth with estrogen plus CPA in transfeminine people would seem to consistently be poor. In contrast to the regimen of estrogen and CPA, breast development with other hormone therapy regimens, for instance estrogen with non-progestogenic antiandrogens like spironolactone, bicalutamide, and GnRH modulators, has not been nearly as well-studied in comparison, and hence comparisons of outcomes between regimens is difficult.

In one of the highest quality studies of estrogen and CPA and breast development in adult transfeminine people, breast volume measured with 3D body scanning (Vectra XT) was approximately mean 100 mL (95% CI ~75–125 mL; range up to ~750 mL), equating to less than an A cup size on average, after 3 years of hormone therapy with estrogen and CPA in 69 transfeminine people (de Blok et al., 2021 [Figure]). In this study, breast changes over time had clearly plateaued, suggesting that breast development was either complete or was nearly so (de Blok et al., 2021 [Figure]). Although most of the transfeminine people in this study had less than an A cup breast size (71%), a minority had cup sizes ranging from an A cup (9%), B cup (16%), C cup (3%), to E cup (1%) (de Blok et al., 2021 [Figure]). For comparison, a study of normative data on breast volumes in cisgender women, using a different 3D body scanning device (Artec Eva 3D), found breast volumes of median ~515 mL and mean ~650 mL (IQR ~310–850 mL; range ~50–3,100 mL) in 378 cisgender women (Coltman, Steele, & McGhee, 2017). As such, adult transfeminine people treated with estrogen and CPA would appear to have substantially smaller breasts than cisgender women. However, it must be emphasized that the preceding data come from separate clinical studies and hence are not directly comparative. It is noteworthy in this regard that breast volumes can vary considerably between different studies even using similar measurement methods (e.g., magnetic resonance imaging) (Sindi et al., 2019 [Table]). Hence, there is a need for studies directly comparing breast volumes in transfeminine people to those in cisgender women using the same measurement method in order to comparatively evaluate breast development.

Regardless of the preceding, transfeminine people could simply have poor breast development in general without this necessarily being related to CPA or progestogenic exposure. Indeed, a more recent study in transfeminine people who underwent pubertal suppression in adolescence, presumably with GnRH agonists and then estrogen therapy, found similarly poor breast development as has been reported in adults (Boogers et al., 2022; c.f. de Blok et al., 2021). This study used breast volume via 3D body scanning to measure breast development and found a mean breast volume of 114 mL (IQR 58–203 mL), equating to less than an A cup size, after 4.2 years of hormone therapy (Boogers et al., 2022). It was notably conducted by the same group of researchers who did the earlier higher-quality study in adult transfeminine people, and hence likely used the same 3D scanning method (de Blok et al., 2021).

No directly comparative studies of breast development with CPA versus other antiandrogens in transfeminine people are currently available. Hence, it’s not fully known whether the findings are specific to CPA or also generalize to other antiandrogens that are not also strongly progestogenic. The RCT of estradiol and spironolactone versus estradiol and CPA in transfeminine people by Ada Cheung and colleagues that is currently underway in Australia may provide more insight on this issue, as spironolactone is only a weakly or clinically non-progestogenic antiandrogen (Aly, 2018b; Wiki).

Additional Considerations for Progestogen Therapy and Breast Development in Transfeminine People

Anecdotes About Progestogens and Breast Development

Many transfeminine people who have taken progestogens as part of hormone therapy have anedotally reported that the progestogens improved their breast development. At the same time, many other transfeminine people have anecdotally reported no benefit of progestogens to breast development. It must be cautioned in general that anecdotal reports are unreliable and represent a very low form of medical evidence. This is because subjective observations and attributions are often erroneous. Perceptions can be faulty and inaccurate, especially with slowly developing physical changes, and true physical changes can be due to coincidence and unrelated confounding factors rather than due to a person’s causal attributions. A couple notable examples of potential confounding factors with regard to progestogens and breast development include: (1) continued breast development from estrogen acting on its own; and (2) temporary breast enlargement due to local fluid retention, increased blood flow, and reversible lobuloalveolar growth caused by progestogens. Such factors have the potential to mislead, and may contribute significantly to anecdotal reports of enhanced breast development with progestogens in transfeminine people. Clinical studies that are well-designed, controlled, and employ reliable objective measures, with long-term follow-up and eventual discontinuation of the progestogen to control for reversible effects, are needed to properly evaluate the effects of progestogens on breast development.

Therapeutic Limitations of Oral Progesterone

Oral progesterone producles very low progesterone levels and has only weak progestogenic effects even at high doses (Aly, 2018a; Wiki). These low progesterone levels are likely to be inadequate in terms of desired physiological progestogenic effects, for instance in the breasts. Oral progesterone also uniquely has potent neurosteroid actions via active metabolites like allopregnanolone, which can result in prominent side effects such as alcohol-like central nervous system inhibition as well as mood swings (Aly, 2018b; Wiki; Wiki). These neurosteroid effects are dose-dependent and are more severe at high doses. Non-oral progesterone forms like rectal or injectable progesterone or progestins, which do not have the preceding problems, can be used instead to avoid such concerns (Aly, 2018a; Aly, 2018b).

Tolerability and Safety Considerations for Progestogens

Progestogens have a variety of tolerability issues and safety risks (Aly, 2018b). Examples of such risks variously include adverse mood changes, breast cancer, blood clots, cardiovascular complications, benign brain tumors including prolactinomas and meningiomas, and off-target actions with undesirable effects (e.g., androgenic or glucocorticoid activity), among others (Aly, 2018b). CPA at high doses also uniquely has a significant risk of serious liver toxicity (Aly, 2018b). The risks of progestogens vary depending on the specific progestogen and dosage, but all progestogens, including even bioidentical progesterone, have significant known risks. The risks of progestogens, along with lack of evidence of beneficial effects in terms of feminization, well-being, and health, in transfeminine people, are why there are concerns about and restrictions on their use in transfeminine people (Aly, 2018b). However, cisgender women naturally have progesterone in their bodies, and the absolute risks of progestogens are low (Aly, 2018b). The risks of progestogens can be minimized by use for a limited duration of time (e.g., a few years), by using the lowest dosages expected to be effective in terms of desired effects, and by selection of progestogens with more favorable pharmacological profiles (Aly, 2018a; Aly, 2018b).

Updates

Update 1: Angus et al. (2023–2024)

It was previously reported in this article that an RCT assessing breast development with estradiol plus spironolactone versus estradiol plus CPA in transfeminine people was being conducted by Ada Cheung and colleagues. This study could provide more insight into breast development with progestogens, as CPA is a very potent progestogen whereas spironolactone is not meaningfully progestogenic. Cheung and colleagues’ study, led by Lachlan Angus, has now been published in the form of the following two conference abstracts, with a journal article also currently in the process of being published:

  • Angus, L. M., Leemaqz, S., Zajac, J. D., & Cheung, A. S. (November 2023). A randomised controlled trial of spironolactone versus cyproterone in trans people commencing estradiol. AusPATH 2023 Symposium. [URL] [PDF] [Trans Health Research Blog Post]
  • Angus, L. M., Leemaqz, S. Y., Zajac, J. D., & Cheung, A. S. (November 2023). The effect of cyproterone and spironolactone on breast development in transgender women: a randomised controlled trial. ESA/SRB/ENSA 2023 ASM 26-29 November, Brisbane, 54–55 (abstract no. 132). [URL] [PDF] [Full Abstract Book] [Trans Health Research Blog Post]

The study assessed estradiol plus spironolactone 100 mg/day versus estradiol plus CPA 12.5 mg/day in 55 transfeminine people, with 27 in the spironolactone group and 28 in the CPA group. Hormone therapy duration, at least at this follow-up point in the study, was 6 months. The measures of breast development included breast–chest difference (primary) and estimated breast volume (secondary).

Breast development, measured by breast–chest difference (mean ± SD), was 8.3 ± 2.7 cm with spironolactone and 9.2 ± 3.0 cm with CPA, with the differences between groups not statistically significant (p = 0.27). In addition, breast development, measured by estimated breast volume (mean ± SD), was 158 ± 112 mL with spironolactone and 190 ± 159 mL with CPA, with the differences between groups not statistically significant (p = 0.39). There was variability between individuals in estimated breast volume, with breast volume measurements ranging from 20 to 788 mL. Besides breast growth, the researchers found that CPA also resulted in a greater increase in body fat percentage and gynoid fat compared to spironolactone. Estradiol levels were comparable between antiandrogen groups, whereas total testosterone levels were (mean ± SD) 4.29 ± 5.44 nmol/L (124 ± 157 ng/dL) with spironolactone and 1.48 ± 3.45 nmol/L (43 ± 99 ng/dL) with CPA, a difference that was statistically significant (p = 0.04).

The researchers concluded that there was no difference in breast development with spironolactone versus CPA in their study and that antiandrogen choice should be individualized based on patient and clinician preference as well as consideration of associated side effects. Moreover, they concluded that further research is needed to optimize breast development in transfeminine people.

The measure of breast volume in the study was the BreastIdea Volume Estimator, a freely available web app that employs 2D photography to provide an estimate of breast volume (Mikołajczyk, Kasielska-Trojan, & Antoszewski, 2019; Kasielska-Trojan, Mikołajczyk, & Antoszewski, 2020). This breast volume measure has been validated in both cisgender women and cisgender men (Mikołajczyk, Kasielska-Trojan, & Antoszewski, 2019; Kasielska-Trojan, Mikołajczyk, & Antoszewski, 2020). Additionally, Cheung and Angus, along with other colleagues, notably including some of the original developers of the BreastIdea Volume Estimator, validated the BreastIdea Volume Estimator in cisgender men and transfeminine people in the following 2022 conference abstract study:

  • Angus, L., Mikolajczyk, M., Cheung, A., Zajac, J., Antoszewski, B., & Kasielska-Trojan, A. (2022). Estimation of breast volume in transgender women using 2D photography: validation of the BreastIdea Volume Estimator in men and transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 279). [URL] [PDF] [Full Abstract Book]

In studies by the developers of the BreastIdea Volume Estimator, they reported breast volumes measured with the tool in cisgender women. These estimated breast volumes can provide comparison to the breast-volume findings in transfeminine people by Cheung and Angus and colleagues. The developers of the BreastIdea Volume Estimator reported that breast volume (mean ± SD) in cisgender women with normal breasts (n=30) was 283 ± 144 mL and in cisgender women with macromastia or gigantomastia (n=35) was 888 ± 277 mL (Kasielska-Trojan, Zawadzki, & Antoszewski, 2022). In another study, they reported that breast volume (mean ± SD) in cisgender women was 272 ± 150 mL, with a range of 99 to 694 mL (Kasielska-Trojan, Mikołajczyk, & Antoszewski, 2020).

Although the BreastIdea Volume Estimator is an interesting and promising tool for quantifying breast development, it has notable limitations, such as its resolution and accuracy being much less than that with 3D scanners like the Artec Eva and Vectra XT (Mikołajczyk, Kasielska-Trojan, & Antoszewski, 2019). Vectra and Artec 3D scanners have been and are being employed to measure breast development with hormone therapy in other studies in transfeminine people (de Blok et al., 2021; Boogers et al., 2022; Dijkman et al., 2023a; Dijkman et al., 2023b; Lopez et al., 2023). The accuracy limitations of the BreastIdea Volume Estimator may explain why the breast volume findings with it in transfeminine people and cisgender women were different from those seen in other studies that employed more advanced 3D scanning methods. Aside from the breast volume measurement, breast–chest difference also has limitations as a measure of breast development in transfeminine people, for instance failing to identify continued breast growth that can be detected with breast volume measurement (de Blok et al., 2021).

Besides the employed measurement methods for breast development, limitations of Lachlan Angus and colleagues’ RCT of breast development with spironolactone and CPA in transfeminine people include its limited duration of follow-up of only 6 months, the fact that testosterone levels were non-equivalent between the spironolactone and CPA groups, and its limited sample size. The incompletely suppressed testosterone levels with spironolactone are notable as androgens oppose estrogen-mediated breast development and could have reduced breast development in the spironolactone group. The limited sample size of the study was responsible for the numeric difference in breast measurements between antiandrogen groups not being statistically significant. In any case, Angus and colleagues’ findings are suggestive that CPA, which is highly progestogenic, neither enhances nor stunts breast development, at least relative to non-progestogenic spironolactone for up to 6 months of hormone therapy. It seems likely that the RCT will continue to longer follow-up times and durations of hormone therapy in the future.

Update 2: Tim, Jeroen, & T’Sjoen (2023) and Yang et al. (2024)

The following two recent studies provide additional information on the topic of breast development with progestogen exposure—specifically with CPA—in transfeminine people:

  • Tim, F., Jeroen, V., & T’Sjoen, G. (November 2023). Dose Reduction of Cyproterone Acetate in Trans Women and the Effect on Patient-reported Outcomes: Results from the ENIGI Study. Endocrine Abstracts, 97 [Belgian Endocrine Society 2023], 5–5 (abstract no. 007). [URL] [PDF]
  • Yang, W., Hong, T., Chang, X., Han, M., Gao, H., Pan, B., Zhao, Z., & Liu, Y. (2024). The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2024.2323514]

In the first study, Tim, Jeroen, & T’Sjoen (2023), clinical outcomes in transfeminine people at the University of Ghent, Belgium clinic were compared in 72 people taking CPA at low doses (10–12.5 mg/day) or high doses (25–50 mg/day). Testosterone suppression was equivalent between the two dose groups. Breast development satisfaction, measured with the Body Image Scale, was not significantly different with low-dose CPA versus high-dose CPA following 1 year of hormone therapy (p = 0.078). However, the p-value indicates that there was almost a statistically significant difference between groups, though it was not stated which group was numerically higher in terms of satisfaction. In any case, the researchers stated that breast development satisfaction was “non-inferior” with low-dose CPA compared to high-dose CPA, which seems suggestive that satisfaction may have been higher in the high-dose CPA group. These findings suggest that higher doses of CPA may not stunt breast development relative to doses of CPA that are lower, although still quite high in terms of progestogenic activity.

In the second study, Yang et al. (2024), clinical outcomes in transfeminine people at the Peking University Third Hospital in China with estradiol plus spironolactone (n=43) versus estradiol plus CPA (n=53) were retrospectively compared. Testosterone levels were much higher in the spironolactone group relative to the CPA group (374 ng/dL [13.0 nmol/L] vs. 20 ng/dL [0.7 nmol/L]; p < 0.001) and duration of hormone therapy was shorter in the spironolactone group than in the CPA group (median 12 months vs. 18 months). Breast development satisfaction, measured with a visual analogue scale (VAS), was median 6.0 (IQR 4.0–7.0) with spironolactone and 6.0 (IQR 4.0–7.0) with CPA, and was not statistically different. On the other hand, the CPA group outperformed the spironolactone group in terms of several other VAS-based clinical-outcome measures, including figure feminization, testicular atrophy, decreased penile erections, and in terms of a composite overall satifaction score. These findings suggest, as with the RCT by Lachlan Angus and colleagues, that spironolactone and CPA result in similar breast development in transfeminine people despite differences in testosterone levels and other clinical outcomes.

A major limitation of both Tim, Jeroen, & T’Sjoen (2023) and Yang et al. (2024) is the use of subjective self-report measures of breast development as opposed to objective physical measurements.

References

  • Abduljalil, K., Furness, P., Johnson, T. N., Rostami-Hodjegan, A., & Soltani, H. (2012). Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy. Clinical Pharmacokinetics, 51(6), 365–396. [DOI:10.2165/11597440-000000000-00000]
  • Adams, R. D., Kliman, B., Federman, D. D., Ulfelder, H. S., & Holmes, L. B. (1970). Syndromes of Testicular Feminization. Clinical Pediatrics, 9(3), 165–178. [DOI:10.1177/000992287000900312]
  • Alekseev, N. P. (2021). Origin and Development of the Mammary Glands. In Alekseev, N. P. Physiology of Human Female Lactation (pp. 11–66). Cham: Springer. [DOI:10.1007/978-3-030-66364-3_2]
  • Alex, A., Bhandary, E., & McGuire, K. P. (2020). Anatomy and Physiology of the Breast during Pregnancy and Lactation. In Alipour, S., & Omranipour, R. (Eds.). Diseases of the Breast during Pregnancy and Lactation (Advances in Experimental Medicine and Biology, Volume 1252) (pp. 3–7). Cham: Springer. [DOI:10.1007/978-3-030-41596-9]
  • Anderson, W. A. (1962). Experimental stimulation of breast development in the teen-age female. The Journal of the Medical Society of New Jersey, 59, 541–543. [Google Scholar] [PubMed] [PDF]
  • Andler, W., & Zachmann, M. (1979). Spontaneous breast development in an adolescent girl with testicular feminization after castration in early childhood. The Journal of Pediatrics, 94(2), 304–305. [DOI:10.1016/s0022-3476(79)80852-5]
  • Angus, L. M., Leemaqz, S., Zajac, J. D., & Cheung, A. S. (2023). A randomised controlled trial of spironolactone versus cyproterone in trans people commencing estradiol. AusPATH 2023 Symposium. [URL] [PDF] [Trans Health Research Blog Post]
  • Angus, L. M., Leemaqz, S. Y., Zajac, J. D., & Cheung, A. S. (2023). The effect of cyproterone and spironolactone on breast development in transgender women: a randomised controlled trial. ESA/SRB/ENSA 2023 ASM 26-29 November, Brisbane, 54–55 (abstract no. 132). [URL] [PDF] [Full Abstract Book] [Trans Health Research Blog Post]
  • Angus, L., Mikolajczyk, M., Cheung, A., Zajac, J., Antoszewski, B., & Kasielska-Trojan, A. (2022). Estimation of breast volume in transgender women using 2D photography: validation of the BreastIdea Volume Estimator in men and transgender women. ESA/SRB/APEG/NZSE ASM 2022, November 13-16, Christchurch, Abstracts and Programme, 127–127 (abstract no. 279). [URL] [PDF] [Full Abstract Book]
  • Apter, D. (1980). Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clinical Endocrinology, 12(2), 107–120. [DOI:10.1111/j.1365-2265.1980.tb02125.x]
  • Apter, D., Räisänen, I., Ylöstalo, P., & Vihko, R. (1987). Follicular growth in relation to serum hormonal patterns in adolescent compared with adult menstrual cycles. Fertility and Sterility, 47(1), 82–88. [DOI:10.1016/s0015-0282(16)49940-1]
  • Aritaki, S., Miyazawa, H., Ogihara, M., Ushio, M., & Izumizawa, A. (1992). An Endocrinological Study of Persistent Pubertal Macromastia. The Tohoku Journal of Experimental Medicine, 167(3), 189–196. [DOI:10.1620/tjem.167.189]
  • Arya, S., Barnabas, R., Lila, A. R., Sarathi, V., Memon, S. S., Bhandare, V. V., Thakkar, K., Patil, V., Shah, N. S., Kunwar, A., & Bandgar, T. (2021). Clinical, Hormonal, Genetic, and Molecular Characteristics in Androgen Insensitivity Syndrome in an Asian Indian Cohort from a Single Centre in Western India. Sexual Development, 15(4), 253–261. [DOI:10.1159/000517763]
  • Asscheman, H., & Gooren, L. J. (1992). Hormone Treatment in Transsexuals. In Bocking, W. O., Coleman, E. (Eds). Gender Dysphoria: Interdisciplinary Approaches in Clinical Management (pp. 39–54). Binghamton: Haworth Press. / Journal of Psychology & Human Sexuality, 5(4), 39–54. [Google Scholar] [Google Books] [DOI:10.1300/J056v05n04_03]
  • Athanasoulia, A., Auer, M., Riepe, F., & Stalla, G. (2013). Rare Missense P450c17 (CYP17A1) Mutation in Exon 1 as a Cause of 46,XY Disorder of Sexual Development: Implications of Breast Tissue ‘Unresponsiveness’ despite Adequate Estradiol Substitution. Sexual Development, 7(4), 212–215. [DOI:10.1159/000348301]
  • Atwood, C., Hovey, R., Glover, J., Chepko, G., Ginsburg, E., Robison, W., & Vonderhaar, B. (2000). Progesterone induces side-branching of the ductal epithelium in the mammary glands of peripubertal mice. Journal of Endocrinology, 167(1), 39–52. [DOI:10.1677/joe.0.1670039]
  • Aupperlee, M. D., Leipprandt, J. R., Bennett, J. M., Schwartz, R. C., & Haslam, S. Z. (2013). Amphiregulin mediates progesterone-induced mammary ductal development during puberty. Breast Cancer Research, 15(3), R44. [DOI:10.1186/bcr3431]
  • Bahr, C., Ewald, J., Dragovich, R., & Gothard, M. D. (2024). Effects of progesterone on gender affirmation outcomes as part of feminizing hormone therapy. Journal of the American Pharmacists Association, 64(1), 268–272. [DOI:10.1016/j.japh.2023.08.001]
  • Baird, D., Hytten, F. E., & Thomson, A. M. (1958). Age and Human Reproduction. BJOG, 65(6), 865–876. [DOI:10.1111/j.1471-0528.1958.tb08582.x]
  • Baker, S. B., Burkey, B. A., Thornton, P., & LaRossa, D. (2001). Juvenile Gigantomastia: Presentation of Four Cases and Review of the Literature. Annals of Plastic Surgery, 46(5), 517–526. [DOI:10.1097/00000637-200105000-00011]
  • Bames, H. O. (1948). Reduction of massive breast hypertrophy. Plastic and Reconstructive Surgery, 3(5), 560–569. [DOI:10.1097/00006534-194809000-00006]
  • Barbieri, R. L. (2019). Breast. In Strauss, J. F., & Barbieri, R. L. (Eds.). Yen and Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 8th Edition (pp. 248–255.e3). Philadelphia: Elsevier. [Google Books] [DOI:10.1016/B978-0-323-47912-7.00010-X]
  • Baron, J. (1993). Zespół braku wrazliwości na androgeny. Studium kliniczne i endokrynologiczne 40 osobników [Androgen insensitivity syndrome. Clinical and endocrinologic study of 40 cases]. Endokrynologia Polska, 44(2), 175–186. [Google Scholar] [PubMed]
  • Baron, J. (1994). Klasyczne i niepełne zespoły braku wrazliwości na androgeny [Classical and incomplete androgen insensitivity syndromes]. Ginekologia Polska, 65(7), 377–386. [Google Scholar] [PubMed]
  • Baron, J. (1994). Niepełny lub cześciowy zespół braku wrazliwości na androgeny [Partial androgen insensitivity syndrome]. Ginekologia Polska, 65(6), 319–325. [Google Scholar] [PubMed]
  • Barrat, J., de Lignières, B., Marpeau, L., Larue, L., Fournier, S., Nahoul, K., Linares, G., Giorgi, H., & Contesso, G. (1990). Effet in vivo de l’administration locale de progestérone sur l’activité mitotique des galactophores humains. Résultat d’une étude pilote. [The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study.] Journal de Gynecologie, Obstetrique et Biologie de la Reproduction, 19(3), 269–274. [Google Scholar 1] [Google Scholar 2] [PubMed]
  • Barrett, J. (2009). The clinical risks associated with the diagnosis and management of disorders of gender identity. Clinical Risk, 15(4), 131–134. [DOI:10.1258/cr.2008.080069]
  • Bässler, R. (1970). The Morphology of Hormone Induced Structural Changes in the Female Breast. In Altmann, H.-W., et al. (Eds.). Current Topics in Pathology: Ergebnisse der Pathology, Volume 53 (pp. 1–89). Heidelberg: Springer Berlin. [DOI:10.1007/978-3-662-30514-0_1] [PDF]
  • Basson, R., & Prior, J. C. (1998). Hormonal Therapy of Gender Dysphoria: The Male-to-Female Transsexual. In Denny, D. (Ed.). Concepts in Transgender Identity (Garland Gay and Lesbian Studies, Volume 11) (pp. 277–296). New York: Garland Publishing Inc. [Google Scholar] [Google Books] [DOI:10.4324/9780203775134-19] [PDF]
  • Bauman, A., Novello, L., & Kreitzer, P. (2016). Endocrine Disorders and Delayed Puberty. In Appelbaum, H. (Ed.). Abnormal Female Puberty: A Clinical Casebook (pp. 87–107). Cham: Springer. [DOI:10.1007/978-3-319-27225-2_5]
  • Bayer, C. M., Bani, M. R., Schneider, M., Dammer, U., Raabe, E., Haeberle, L., Faschingbauer, F., Schneeberger, S., Renner, S. P., Fischer, D., Schulz-Wendtland, R., Fasching, P. A., Beckmann, M. W., & Jud, S. M. (2014). Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. European Journal of Cancer Prevention, 23(3), 151–157. [DOI:10.1097/cej.0b013e3283651ccb]
  • Beck, P. (1972). Lactogenic Activity of Human Chorionic Somatomammotropin in Rhesus Monkeys. Experimental Biology and Medicine, 140(1), 183–187. [DOI:10.3181/00379727-140-36422]
  • Begley, D. J., Firth, J. A., & Hoult, J. R. (1980). The Breast and Lactation. In Begley, D. J., Firth, J. A., & Hoult, J. R. Human Reproduction and Developmental Biology (pp. 204–219). London: Macmillan Education UK. [DOI:10.1007/978-1-349-16260-4_14]
  • Bellwether, C. J. (2020). Why Should a Transfeminine Person Consider Progesterone? Google Docs. [URL]
  • Benjamin, H. (1966). Nonsurgical Management of Transsexualism. In Benjamin, H. The Transsexual Phenomenon (pp. 86–99). New York: Julian Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Benjamin, H. (1967). Transvestism and Transsexualism in the male and female. Journal of Sex Research, 3(2), 107–127. [DOI:10.1080/00224496709550519]
  • Berliere, M., Coche, M., Lacroix, C., Riggi, J., Coyette, M., Coulie, J., Galant, C., Fellah, L., Leconte, I., Maiter, D., Duhoux, F. P., & François, A. (2022). Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women. Cancers, 15(1), 245. [DOI:10.3390/cancers15010245]
  • Berryhill, G. E., Trott, J. F., & Hovey, R. C. (2016). Mammary gland development—It’s not just about estrogen. Journal of Dairy Science, 99(1), 875–883. [DOI:10.3168/jds.2015-10105]
  • Bethea, C. L., Kohama, S. G., & Pecins-Thompson, M. (1997). Pituitary and Brain Actions of Estrogen and Progesterone in the Regulation of Primate Prolactin Secretion. In Pavlik, E. J. (Ed.). Estrogens, Progestins, and Their Antagonists: Functions and Mechanisms of Action (pp. 3–46). Boston: Birkhäuser. [DOI:10.1007/978-1-4612-2004-6_1]
  • Bevan, D. J. (2012). Progesterone for Breast Development? / Should Male-to-Female Transsexuals Take Progesterone as part of Hormone Therapy (HT) for Better Breast Development? Biopsychology of TSTG / Transgender Forum. [URL 1] [URL 2]
  • Bevan, D. J. (2019). Grow Your Own : Breast Development Update. Transgender Forum. [URL]
  • Beyer, C., Cruz, M. L., & Martinez-Manautou, J. (1970). Effect of Chlormadinone Acetate on Mammary Development and Lactation in the Rabbit. Endocrinology, 86(5), 1172–1174. [DOI:10.1210/endo-86-5-1172]
  • Biswas, S. K., Banerjee, S., Baker, G. W., Kuo, C., & Chowdhury, I. (2022). The Mammary Gland: Basic Structure and Molecular Signaling during Development. International Journal of Molecular Sciences, 23(7), 3883. [DOI:10.3390/ijms23073883]
  • Bland, K. I., Copeland, E. M., & Klimberg, V. S. (2018). Anatomy of the Breast, Axilla, Chest Wall, and Related Metastatic Sites. In Bland, K. I., Copeland, E. M., Klimberg, V. S., Gradishar, W. J., White, J., & Korourian, S. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th Edition (pp. 20–36.e2). Philadelphia: Elsevier. [DOI:10.1016/b978-0-323-35955-9.00002-7]
  • Bland, K. I., Harrison Howard, J., & Romrell, L. J. (2009). Congenital and Acquired Disturbances of Breast Development and Growth. In Bland, K. I., & Copeland, E. M. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 4th Edition (pp. 189–207). Philadelphia: Saunders/Elsevier. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Bondy, C. A., & Turner Syndrome Consensus Study Group. (2007). Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. The Journal of Clinical Endocrinology & Metabolism, 92(1), 10–25. [DOI:10.1210/jc.2006-1374]
  • Boogers, L., Infirri, S. S., Bouchareb, A., de Blok, C., Liberton, N., van Trotsenburg, P., Dreijerink, K., den Heijer, M., Wiepjes, C., & Hannema, S. (2022). The effect of timing of puberty suppression on breast development in trans girls; a cross-sectional study. Hormone Research in Paediatrics, 95(Suppl 2) [60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Rome, Italy, September 15–17, 2022], 390–391 (abstract no. P1-379). [Google Scholar] [DOI:10.1159/000525606] [URL] [PDF 1] [PDF 2]
  • Boyce, S. W., Hoffman, P. G., & Mathes, S. J. (1984). Recurrent Macromastia after Subcutaneous Mastectomy. Annals of Plastic Surgery, 13(6), 511–518. [DOI:10.1097/00000637-198412000-00008]
  • Bruck, H. G., & Müller, G. (1967). Zur Hormontherapie der Hypoplastischen Weiblichen Brust. [On Hormonal Therapy of the Hypoplastic Female Breast.] Ästhetische Medizin [Ästhetische Medizin : Kongreß-Organ der Deutschen Gesellschaft für die Ästhetische Medizin und ihre Grenzgebiete], 16(12), 365–366. [ISSN:0400-6755] [Google Scholar] [PubMed] [WorldCat] [PDF] [Translation]
  • Bryant, R., Underwood, A., Robinson, A., Stephenson, T., & Underwood, J. (1998). Determination of breast tissue composition for improved accuracy in estimating radiation doses and risks in mammographic screening. The Breast, 7(2), 95–98. [DOI:10.1016/s0960-9776(98)90064-9]
  • Buhimschi, C. S. (2004). Endocrinology of lactation. Obstetrics and Gynecology Clinics of North America, 31(4), 963–979. [DOI:10.1016/j.ogc.2004.08.002]
  • Camilletti, M. A., Abeledo-Machado, A., Faraoni, E. Y., Thomas, P., & Díaz-Torga, G. (2019). New insights into progesterone actions on prolactin secretion and prolactinoma development. Steroids, 152, 108496. [DOI:10.1016/j.steroids.2019.108496]
  • Çamtosun, E., Şıklar, Z., Ceylaner, S., Kocaay, P., & Berberoğlu, M. (2017). Delayed Diagnosis of a 17-Hydroxylase/17,20-Lyase Deficient Patient Presenting as a 46,XY Female: A Low Normal Potassium Level Can Be an Alerting Diagnostic Sign. Journal of Clinical Research in Pediatric Endocrinology, 9(2), 163–167. [DOI:10.4274/jcrpe.3839]
  • Capraro, V. J., & Dewhurst, C. J. (1975). Breast Disorders in Childhood and Adolescence. Clinical Obstetrics and Gynecology, 18(2), 25–50. [DOI:10.1097/00003081-197506000-00003]
  • Carlson, L. J., & Shaw, N. D. (2019). Development of Ovulatory Menstrual Cycles in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, 32(3), 249–253. [DOI:10.1016/j.jpag.2019.02.119]
  • Caro, T. M. (1987). Human breasts: Unsupported hypotheses reviewed. Human Evolution, 2(3), 271–282. [DOI:10.1007/bf03016112]
  • Ceriani, R. L. (1974). Hormones and Other Factors Controlling Growth in the Mammary Gland: A Review. Journal of Investigative Dermatology, 63(1), 93–108. [DOI:10.1111/1523-1747.ep12678104]
  • Cernea, R. (1944). Lokale Hormonbehandlung bei Mammaatrophie und Unterentwicklung. [Local Hormone Treatment in Mammary Atrophy and Underdevelopment.] Medizinische Klinik, 40(11/12), 169–170. [Google Scholar] [PDF] [Translation]
  • Chang, K., Lee, T. T., Linares-Cruz, G., Fournier, S., & de Ligniéres, B. (1995). Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertility and Sterility, 63(4), 785–791. [DOI:10.1016/s0015-0282(16)57482-2]
  • Cheikhelard, A., Morel, Y., Thibaud, E., Lortat-Jacob, S., Jaubert, F., Polak, M., & Nihoul-Fekete, C. (2008). Long-Term Followup and Comparison Between Genotype and Phenotype in 29 Cases of Complete Androgen Insensitivity Syndrome. Journal of Urology, 180(4), 1496–1501. [DOI:10.1016/j.juro.2008.06.045]
  • Ciarloni, L., Mallepell, S., & Brisken, C. (2007). Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development. Proceedings of the National Academy of Sciences, 104(13), 5455–5460. [DOI:10.1073/pnas.0611647104]
  • Clendenen, T. V., Kim, S., Moy, L., Wan, L., Rusinek, H., Stanczyk, F. Z., Pike, M. C., & Zeleniuch-Jacquotte, A. (2013). Magnetic Resonance Imaging (MRI) of hormone-induced breast changes in young premenopausal women. Magnetic Resonance Imaging, 31(1), 1–9. [DOI:10.1016/j.mri.2012.06.022]
  • Cline, J. M., & Wood, C. E. (2006). Hormonal Effects on the Mammary Gland of Postmenopausal Nonhuman Primates. Breast Disease, 24(1), 59–70. [DOI:10.3233/bd-2006-24105]
  • Cline, J. M., & Wood, C. E. (2008). The Mammary Glands of Macaques. Toxicologic Pathology, 36(7 Suppl), 130S–141S. [DOI:10.1177/0192623308327411]
  • Cole, R. D., & Hopkins, T. R. (1962). A Biochemical Test of Artificial Mammogenesis and Lactogenesis As Models of the Natural Processes. Endocrinology, 70(3), 375–380. [DOI:10.1210/endo-70-3-375]
  • Coleman, E., Bockting, W., Botzer, M., Cohen-Kettenis, P., DeCuypere, G., Feldman, J., Fraser, L., Green, J., Knudson, G., Meyer, W. J., Monstrey, S., Adler, R. K., Brown, G. R., Devor, A. H., Ehrbar, R., Ettner, R., Eyler, E., Garofalo, R., Karasic, D. H., Lev, A. I., Mayer, G., Meyer-Bahlburg, H., Hall, B. P., Pfaefflin, F., Rachlin, K., Robinson, B., Schechter, L. S., Tangpricha, V., van Trotsenburg, M., Vitale, A., Winter, S., Whittle, S., Wylie, K. R., & Zucker, K. (2012). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. International Journal of Transgenderism, 13(4), 165–232. [DOI:10.1080/15532739.2011.700873] [URL] [PDF]
  • Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F., Monstrey, S. J., Motmans, J., Nahata, L., … & Arcelus, J. (2022). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. [DOI:10.1080/26895269.2022.2100644] [URL] [PDF]
  • Coltman, C. E., Steele, J. R., & McGhee, D. E. (2017). Breast volume is affected by body mass index but not age. Ergonomics, 60(11), 1576–1585. [DOI:10.1080/00140139.2017.1330968]
  • Colvin, C., Devineni, G., & Ashraf, A. P. (2014). Delayed Puberty. In Bandeira, F., Gharib, H., Golbert, A., Griz, L., & Faria, M. (Eds.). Endocrinology and Diabetes (pp. 203–217). New York: Springer. [DOI:10.1007/978-1-4614-8684-8_17]
  • Cowie, A. T., & Folley, S. J. (1961). The Mammary Gland and Lactation. In Young, W. C. (Ed.). Sex and Internal Secretions, 3rd Edition, Volume I (pp. 590–642). Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Cowie, A. T., Forsyth, I. A., & Hart, I. C. (1980). Growth and Development of the Mammary Gland. In Cowie, A. T., Forsyth, I. A., & Hart, I. C. Hormonal Control of Lactation (Monographs on Endocrinology, Volume 15) (pp. 58–145). Berlin/Heidelberg: Springer Berlin Heidelberg. [DOI:10.1007/978-3-642-81389-4_3]
  • Cox, D. B., Kent, J. C., Casey, T. M., Owens, R. A., & Hartmann, P. E. (1999). Breast Growth and the Urinary Excretion of Lactose During Human Pregnancy and Early Lactation: Endocrine Relationships. Experimental Physiology, 84(2), 421–434. [DOI:10.1111/j.1469-445x.1999.01807.x]
  • Cox, C. B., Kent, J. C., Owens, R., & Hartmann, P. E. (1994). Mammary morphological and functional changes during pregnancy in women. In Thompson, J. (Ed.). Proceedings of the Twenty-Sixth Annual Conference, Hilton Hotel, Brisbane, 26–28 September, 1994 [The Australian Society for Reproductive Biology Inc., Twenty Sixth Annual Conference, The Hilton Hotel, Brisbane, September 26 - 28 1994, Programme and Miniposters of Papers] (pp. 47–47). Australia: Australian Society for Reproductive Biology. [Google Scholar] [WorldCat] [URL] [PDF]
  • Coxon, J., & Seal, L. (2018). Hormone management of trans women. Trends in Urology & Men’s Health, 9(6), 10–14. [DOI:10.1002/tre.663]
  • Cregan, M. D., & Hartmann, P. E. (1999). Computerized Breast Measurement from Conception to Weaning: Clinical Implications. Journal of Human Lactation, 15(2), 89–96. [DOI:10.1177/089033449901500202]
  • Crowley, L. G., & Macdonald, I. (1965). Delalutin and estrogens for the treatment of advanced mammary carcinoma in the postmenopausal woman. Cancer, 18(4), 436–446. [DOI:10.1002/1097-0142(196504)18:4<436::aid-cncr2820180407>3.0.co;2-d]
  • Crowley, W. F., & Pitteloud, N. (2020). Approach to the patient with delayed puberty. UpToDate. [Google Scholar] [URL]
  • Cruz-Korchin, N., Korchin, L., González-Keelan, C., Climent, C., & Morales, I. (2002). Macromastia. Plastic and Reconstructive Surgery, 109(1), 64–68. [DOI:10.1097/00006534-200201000-00011]
  • Curtis, R. J. (2009 July 10). The Lowdown on Progesterone. London: The London Gender Clinic. [Google Scholar] [URL] [PDF]
  • Dallmann, A., Ince, I., Meyer, M., Willmann, S., Eissing, T., & Hempel, G. (2017). Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy. Clinical Pharmacokinetics, 56(11), 1303–1330. [DOI:10.1007/s40262-017-0539-z]
  • Dancey, A., Khan, M., Dawson, J., & Peart, F. (2008). Gigantomastia – a classification and review of the literature. Journal of Plastic, Reconstructive & Aesthetic Surgery, 61(5), 493–502. [DOI:10.1016/j.bjps.2007.10.041]
  • Davajan, V., & Kletzky, O. A. (1979). Amenorrhea without Galactorrhea or Hirsutism. In Mishell, D. R., & Davajan, V. (Eds.). Reproductive Endocrinology, Infertility, and Contraception (pp. 219–248). Philadelphia: F. A. Davis Co. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Davis, M. E., Boynton, M. W., Ferguson, J. H., & Rothman, S. (1945). Studies on Pigmentation of Endocrine Origin. The Journal of Clinical Endocrinology & Metabolism, 5(3), 138–146. [DOI:10.1210/jcem-5-3-138]
  • de Blok, C. J., Dijkman, B. A., Wiepjes, C. M., Staphorsius, A. S., Timmermans, F. W., Smit, J. M., Dreijerink, K. M., & den Heijer, M. (2021). Sustained Breast Development and Breast Anthropometric Changes in 3 Years of Gender-Affirming Hormone Treatment. The Journal of Clinical Endocrinology & Metabolism, 106(2), e782–e790. [DOI:10.1210/clinem/dgaa841]
  • de Blok, C. J., Klaver, M., Wiepjes, C. M., Nota, N. M., Heijboer, A. C., Fisher, A. D., Schreiner, T., T’Sjoen, G., & den Heijer, M. (2017). Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study. The Journal of Clinical Endocrinology & Metabolism, 103(2), 532–538. [DOI:10.1210/jc.2017-01927]
  • de Lignières, B. (2002). Effects of progestogens on the postmenopausal breast. Climacteric, 5(3), 229–235. [DOI:10.1080/cmt.5.3.229.235]
  • de Lignières, B., & Mauvais-Jarvis, P. (1981). Hormonal Dependence of Benign Breast Disease, Gynecomastia and Breast Cancer. In Hollman, K. H., Brux, J., & Verley, J. M. (Eds.). New Frontiers in Mammary Pathology (pp. 287–308). Boston: Springer US. [DOI:10.1007/978-1-4757-0019-0_17]
  • de Vries, A. L., Steensma, T. D., Wagemaar, E. C. F., Doreleijers, T. A., & Cohen-Kettenis, P. T. (2010). Puberty suppression followed by cross-sex hormones and gender reassignment surgery: A prospective follow-up of gender dysphoric adolescents into adulthood. In de Vries, A. L. (Ed.). Gender Dysphoria in Adolescents: Mental Health and Treatment Evaluation (pp. 91–106). (Doctoral thesis, Vrije Universiteit Amsterdam.) [Google Scholar] [URL] [PDF]
  • Deeb, A., Al Suwaidi, H., Attia, S., & Al Ameri, A. (2015). 17-hydroxylase/17,20-lyase deficiency due to a R96Q mutation causing hypertension and poor breast development. Endocrinology, Diabetes & Metabolism Case Reports, 2015(1), 15-0069. [DOI:10.1530/EDM-15-0069]
  • Deepinder, F., & Braunstein, G. D. (2012). Drug-induced gynecomastia: an evidence-based review. Expert Opinion on Drug Safety, 11(5), 779–795. [DOI:10.1517/14740338.2012.712109]
  • Dennerstein, L., Burrows, G. D., Hyman, G. J., & Sharpe, K. (1980). Some clinical effects of oestrogen-progestogen therapy in surgically castrated women. Maturitas, 2(1), 19–28. [DOI:10.1016/0378-5122(80)90056-0]
  • Dewhurst, C. J. (1967). The XY Female. BJOG, 74(3), 353–366. [DOI:10.1111/j.1471-0528.1967.tb03959.x]
  • Dewhurst, C. J. (1971). Sex Chromosome Abnormalities and the Gynaecologist. BJOG, 78(12), 1058–1076. [DOI:10.1111/j.1471-0528.1971.tb00227.x]
  • Dewhurst, C. J. (1971). The XY female. American Journal of Obstetrics and Gynecology, 109(5) [Transactions of the Eighty-First Annual Meeting of the American Association of Obstetricians and Gynecologists], 675–688. [DOI:10.1016/0002-9378(71)90753-8]
  • Dewhurst, C. J., & Spence, J. E. (1977). The XY female. British Journal of Hospital Medicine, 17(5), 498, 501–506. [Google Scholar] [PubMed] [PDF]
  • Dewhurst, J. (1982). Breast Hypoplasia. In Bruni, V., Gasparri, F., Dewhurst, J., & Rey-Stocker, I. (Eds.). Pediatric and Adolescent Gynaecology [Proceedings of the IVth International Symposium, Florence, October 5-7, 1978] (pp. 205–212). Rome, Italy: Serono Symposia. [Google Scholar] [Google Books] [WorldCat] [PDF]
  • Di Lorenzo, G., Autorino, R., Perdonà, S., & De Placido, S. (2005). Management of gynaecomastia in patients with prostate cancer: a systematic review. The Lancet Oncology, 6(12), 972–979. [DOI:10.1016/s1470-2045(05)70464-2]
  • Dickson, L. M., & Hewer, E. E. (1950). The structure of the breast. In Saner, F. D. (Ed.). The Breast: Structure, Function, Disease (pp. 1–52). Baltimore: William & Wilins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Dijkman, B. A., Blok, C. J., Dreijerink, K. M., & den Heijer, M. (2023). Progestin-related breast volume changes in a woman with complete androgen insensitivity syndrome (CAIS). Endocrinology, Diabetes & Metabolism Case Reports, 2023(2), 22-0346. [DOI:10.1530/edm-22-0346]
  • Dijkman, B. A., Helder, D., Boogers, L. S., Gieles, N. C., van Heesewijk, J. O., Slaa, S. t., Liberton, N. P., Wiepjes, C. M., de Blok, C. J., den Heijer, M., & Dreijerink, K. M. (2023). Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial. BMC Pharmacology and Toxicology, 24(1), 80. [DOI:10.1186/s40360-023-00724-4]
  • Dittrich, R., Binder, H., Cupisti, S., Hoffmann, I., Beckmann, M., & Mueller, A. (2005). Endocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone Agonist. Experimental and Clinical Endocrinology & Diabetes, 113(10), 586–592. [DOI:10.1055/s-2005-865900]
  • Donaldson, M., Kriström, B., Ankarberg-Lindgren, C., Verlinde, S., van Alfen-van der Velden, J., Gawlik, A., van Gelder, M., Sas, T., & (2019). Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy. Hormone Research in Paediatrics, 91(3), 153–163. [DOI:10.1159/000500050]
  • Dorgan, J. F., Klifa, C., Deshmukh, S., Egleston, B. L., Shepherd, J. A., Kwiterovich, P. O., Van Horn, L., Snetselaar, L. G., Stevens, V. J., Robson, A. M., Lasser, N. L., & Hylton, N. M. (2013). Menstrual and reproductive characteristics and breast density in young women. Cancer Causes & Control, 24(11), 1973–1983. [DOI:10.1007/s10552-013-0273-2]
  • Döring, G. K. (1963). Über die relative Häufigkeit des anovulatorischen Cyclus im Leben der Frau. [On the relative frequency of the anovulatory cycle in women’s lives.] Archiv für Gynäkologie, 199(2), 115–123. [DOI:10.1007/bf00668062]
  • Drąsutis, J. (2017). Changes in breast morphological parameters, body size and shape, blood serum prolactin and lipids during pregnancy, multiple relationships of these indicators and morphological markers for health risk. (Doctoral dissertation, Vilniaus Universitetas.) [Google Scholar] [URL]
  • Drife, J. O. (1982). The effects of parity and the menstrual cycle on the normal mammary gland and their possible relationship to malignant change. (Doctoral dissertation, University of Edinburgh). [Google Scholar] [Google Books] [WorldCat] [URL 1] [URL 2] [PDF]
  • Drife, J. O. (1984). The pill and the breast. IPPF Medical Bulletin, 18(6), 1–2. [Google Scholar] [PubMed]
  • Drife, J. O. (1986). Breast Development in Puberty. Annals of the New York Academy of Sciences, 464(1) [Endocrinology of the Breast: Basic and Clinical Aspects], 58–65. [DOI:10.1111/j.1749-6632.1986.tb15993.x]
  • Drife, J. O. (1989). Breast modifications during the menstrual cycle. Supplement to International Journal of Gynecology and Obstetrics, 1, 19–24. / International Journal of Gynecology and Obstetrics, 1989(Suppl 1), 19–24. [Google Scholar] [PubMed] [Archive.org]
  • Drife, J. O. (1990). Premenopausal Hormone Therapy. In Drife, J. O., & Studd, J. W. W. (Eds.). HRT and Osteoporosis (pp. 351–362). London: Springer London. [DOI:10.1007/978-1-4471-1799-5_25]
  • Duncan, M. (2010). Sexual Selection and Human Breast Morphology. (Doctoral dissertation, Te Herenga Waka-Victoria University of Wellington.) [Google Scholar] [URL]
  • Edmonds, D. K. (1989). Normal Puberty. In Edmonds, D. K. Dewhurst’s Practical Paediatric and Adolescent Gynaecology, 2nd Edition (pp. 56–62). London: Butterworths. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [URL] [Archive.org]
  • Elling, S. V., & Powell, F. C. (1997). Physiological changes in the skin during pregnancy. Clinics in Dermatology, 15(1), 35–43. [DOI:10.1016/s0738-081x(96)00108-3]
  • Engman, M., Skoog, L., Soderqvist, G., & Gemzell-Danielsson, K. (2008). The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Human Reproduction, 23(9), 2072–2079. [DOI:10.1093/humrep/den228]
  • Federici, S., Goggi, G., Quinton, R., Giovanelli, L., Persani, L., Cangiano, B., & Bonomi, M. (2021). New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature. Endocrine Reviews, 43(5), 824–851. [DOI:10.1210/endrev/bnab043]
  • Fernández-Cancio, M., García-García, E., González-Cejudo, C., Martínez-Maestre, M., Mangas-Cruz, M., Guerra-Junior, G., Pandi de Mello, M., Arnhold, I. J., Nishi, M. Y., Bilharinho Mendonça, B., García-Arumí, E., Audí, L., Tizzano, E., & Carrascosa, A. (2017). Discordant Genotypic Sex and Phenotype Variations in Two Spanish Siblings with 17α-Hydroxylase/17,20-Lyase Deficiency Carrying the Most Prevalent Mutated CYP17A1 Alleles of Brazilian Patients. Sexual Development, 11(2), 70–77. [DOI:10.1159/000468160]
  • Fernandez-Valdivia, R., Mukherjee, A., Mulac-Jericevic, B., Conneely, O. M., DeMayo, F. J., Amato, P., & Lydon, J. P. (2005). Revealing Progesterone’s Role in Uterine and Mammary Gland Biology: Insights from the Mouse. Seminars in Reproductive Medicine, 23(1), 22–37. [DOI:10.1055/s-2005-864031]
  • Finkenzeller, D. A., & Loveless, M. B. (2007). Pediatric Gynecology. In Fortner, K. B., Szymanski, L. M., Fox, H. E., & Wallach, E. E. (Eds.). The Johns Hopkins Manual of Gynecology and Obstetrics, 3rd Edition (Spiral Manual Series) (pp. 363–379). Philadelphia: Lippincott Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Fisher, A. D., Castellini, G., Ristori, J., Casale, H., Cassioli, E., Sensi, C., Fanni, E., Amato, A. M., Bettini, E., Mosconi, M., Dèttore, D., Ricca, V., & Maggi, M. (2016). Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data. The Journal of Clinical Endocrinology & Metabolism, 101(11), 4260–4269. [DOI:10.1210/jc.2016-1276]
  • Foidart, J. M., Colin, C., Denoo, X., Desreux, J., Fournier, S., & de Linières, B. (1996). Influence of percutaneous administration of estradiol and progesterone on the proliferation of human breast epithelial cells. In Calvo, F., Crépin, M., & Magdelenat, H. (Eds.). Breast Cancer: Advances in Biology and Therapeutics [21st Meeting of the International Association for Breast Cancer Research, July 3-4-5, 1996, Paris] (pp. 329–334). Montrouge/Paris: John Libbey Eurotext. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Foidart, J., Colin, C., Denoo, X., Desreux, J., Béliard, A., Fournier, S., & de Lignières, B. (1998). Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells. Fertility and Sterility, 69(5), 963–969. [DOI:10.1016/s0015-0282(98)00042-9]
  • Folley, S. J. (1940). Lactation. Biological Reviews, 15(4), 421–458. [DOI:10.1111/j.1469-185x.1940.tb00947.x]
  • Folley, S. J. (1947). Endocrine Control of the Mammary Gland. British Medical Bulletin, 5(2–3), 130–134. [DOI:10.1093/oxfordjournals.bmb.a073121]
  • Folley, S. J. (1950). Lactational Physiology. In Bowes, K. (Ed.). Modern Trends in Obstetrics and Gynaecology (pp. 441–453). London: Butterworth. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Folley, S. J. (1952). Lactation. In Parkes, A. S. (Ed.). Marshall’s Physiology of Reproduction, 3rd Edition, Volume II (pp. 525–647). Longmans, Green & Co.: London. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Folley, S. J. (1956). Recent Studies on the Development of the Mammary Gland. In Folley, S. J. The Physiology and Biochemistry of Lactation, 1st Edition (pp. 1–22). Edinburgh: Oliver & Boyd. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Folley, S. J., & Malpress, F. H. (1948). Hormonal Control of Mammary Growth. In Pincus, G., & Thimann, K. V. (Eds.). The Hormones: Physiology, Chemistry and Applications, Volume I (pp. 695–743). New York: Academic Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Fourcade, R., & McLeod, D. (2004). Tolerability of Antiandrogens in the Treatment of Prostate Cancer. UroOncology, 4(1), 5–13. [DOI:10.1080/1561095042000191655]
  • Fowler, P. A., Casey, C. E., Cameron, G. G., Foster, M. A., & Knight, C. H. (1990). Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging. BJOG, 97(7), 595–602. [DOI:10.1111/j.1471-0528.1990.tb02546.x]
  • Fridriksdottir, A. J., Petersen, O. W., & Rnnov-Jessen, L. (2011). Mammary gland stem cells: current status and future challenges. The International Journal of Developmental Biology, 55(7–8–9), 719–729. [DOI:10.1387/ijdb.113373af]
  • Fuqua, J. S., & Eugster, E. A. (2022). History of Puberty: Normal and Precocious. Hormone Research in Paediatrics, 95(6), 568–578. [DOI:10.1159/000526464]
  • Gaede, P., Trolle, D., & Pedersen, H. (1978). Extremely low placental lactogen hormone (hpl) values in an otherwise uneventful pregnancy preceding delivery of a normal baby. Acta Obstetricia et Gynecologica Scandinavica, 57(3), 203–209. [DOI:10.3109/00016347809154883]
  • Galani, A., Kitsiou-Tzeli, S., Sofokleous, C., Kanavakis, E., & Kalpini-Mavrou, A. (2008). Androgen insensitivity syndrome: clinical features and molecular defects. Hormones, 7(3), 217–229. [DOI:10.14310/horm.2002.1201]
  • Galbarczyk, A. (2011). Unexpected changes in maternal breast size during pregnancy in relation to infant sex: An evolutionary interpretation. American Journal of Human Biology, 23(4), 560–562. [DOI:10.1002/ajhb.21177]
  • Gawlik, A., Hankus, M., Such, K., Drosdzol-Cop, A., Madej, P., Borkowska, M., Zachurzok, A., & Malecka-Tendera, E. (2016). Hypogonadism and Sex Steroid Replacement Therapy in Girls with Turner Syndrome. Journal of Pediatric and Adolescent Gynecology, 29(6), 542–550. [DOI:10.1016/j.jpag.2016.03.005]
  • Gershon-Cohen, J. (1970). The Normal Breast. In Gershon-Cohen, J. Atlas of Mammography (pp. 23–38). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-85678-5_4] [Google Books]
  • Gertig, D. M., Stillman, I. E., Byrne, C., Spiegelman, D., Schnitt, S. J., Connolly, J. L., Colditz, G. A., & Hunter, D. J. (1999). Association of age and reproductive factors with benign breast tissue composition. Cancer Epidemiology, Biomarkers & Prevention, 8(10), 873–879. [Google Scholar] [PubMed] [URL]
  • Geschickter, C. F. (1945). Endocrine Physiology of the Breast. In Geschickter, C. F. Diseases of the Breast: Diagnosis, Pathology, Treatment, 2nd Edition (pp. 42–81). Philadelphia: J.B. Lippincott. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Glenn, J. F. (1976). Testicular feminization syndrome current clinical considerations. Urology, 7(6), 569–577. [DOI:10.1016/0090-4295(76)90079-0]
  • Gliosci, A., & Presutti, F. (1993). Virginal gigantomastia: Validity of combined surgical and hormonal treatments. Aesthetic Plastic Surgery, 17(1), 61–65. [DOI:10.1007/bf00455051]
  • Gompel, A., & Plu-Bureau, G. (2018). Progesterone, progestins and the breast in menopause treatment. Climacteric, 21(4), 326–332. [DOI:10.1080/13697137.2018.1476483]
  • Goodman, H. M. (2009). Hormonal Control of Pregnancy and Lactation. In Goodman, H. M. Basic Medical Endocrinology, 4th Edition (pp. 277–301). Amsterdam: Academic Press/Elsevier. [DOI:10.1016/b978-0-12-373975-9.00014-8]
  • Gooren, L. J. (2016). Hormone Treatment of Adult Transgender People. In Ettner, R., Monstrey, S., & Coleman, E. (Eds.). Principles of Transgender Medicine and Surgery, 2nd Edition (pp. 167–179). New York: Routledge. [Google Scholar] [Google Books] [DOI:10.4324/9781315718972-11]
  • Gordon, C. M., & Laufer, M. R. (2005) The Physiology of Puberty. In Emans, S. J., Laufer, M. R., & Goldstein, D. P. (Eds.). Pediatric and Adolescent Gynecology, 5th Edition (pp. 120–155). Philadelphia: Lippincott Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Göretzlehner, G. & Lauritzen, C. (1992). Hormontherapie bei Gynäkologischen Erkrankungen [Hormone Therapy for Gynecological Diseases]. In Göretzlehner, G. & Lauritzen, C. Praktische Hormontherapie in der Gynäkologie, 1. Auflage [Practical Hormone Therapy in Gynecology, 1st Edition] (pp. 245–299). Berlin/New York: de Gruyter. [DOI:10.1515/9783112417706-007] [Google Books] [PDF] [Translation]
  • Graham, J. D., & Clarke, C. L. (1997). Physiological Action of Progesterone in Target Tissues. Endocrine Reviews, 18(4), 502–519. [DOI:10.1210/edrv.18.4.0308]
  • Graham, S. J., Stanchev, P. L., Lloyd‐Smith, J. O., Bronskill, M. J., & Plewes, D. B. (1995). Changes in Fibroglandular Volume and Water Content of Breast Tissue During the Menstrual Cycle Observed by MR Imaging at 1.5 T. Journal of Magnetic Resonance Imaging, 5(6), 695–701. [DOI:10.1002/jmri.1880050613]
  • Greydanus, D. E., Omar, H. A., Matytsina, L. A., & Tsitsika, A. (2010). Breast Disorders in Children and Adolescents. In Omar, H. A., Greydanus, D. E., Tsitsika, A. K., Patel, D. R., & Merrick, J. (Eds.). Pediatric and Adolescent Sexuality and Gynecology: Principles for the Primary Care Clinician (pp. 245–316). Hauppauge: Nova Science Publishers. [Google Scholar] [Google Books] [URL] [OpenLibrary] [WorldCat] [PDF]
  • Guaragna-Filho, G., Guerra-Junior, G., Tadokoro-Cuccaro, R., Hughes, I. A., Barros, B. A., Hiort, O., Balsamo, A., Guran, T., Holterhus, P. M., Hannema, S., Poyrazoglu, S., Darendeliler, F., Bryce, J., Ahmed, S. F., & Quigley, C. A. (2023). Pubertal and Gonadal Outcomes in 46,XY Individuals with Partial Androgen Insensitivity Syndrome Raised as Girls. Sexual Development, 17(1), 16–25. [DOI:10.1159/000526997]
  • Gunn, H. M., Tsai, M., McRae, A., & Steinbeck, K. S. (2018). Menstrual Patterns in the First Gynecological Year: A Systematic Review. Journal of Pediatric and Adolescent Gynecology, 31(6), 557–565.e6. [DOI:10.1016/j.jpag.2018.07.009]
  • Günzel, P., Hasan, S. H., Düsterberg, B., Hümpel, M., Putz, B., & Lehmann, M. (1987). Zur toxikologischen Prüfung von Steroidhormonen. [For the Toxicological Testing of Steroid Hormones.] In Burger, O. K., Grosdanoff, P., Henschler, D., Kraupp, O., & Schnieders, B. (Eds.). Aktuelle Probleme der Biomedizin (pp. 93–112). Berlin/New York: De Gruyter. [Google Scholar] [Google Books] [DOI:10.1515/9783110898231-014]
  • Hagisawa, S., Shimura, N., & Arisaka, O. (2012). Effect of Excess Estrogen on Breast and External Genitalia Development in Growth Hormone Deficiency. Journal of Pediatric and Adolescent Gynecology, 25(3), e61–e63. [DOI:10.1016/j.jpag.2011.11.005]
  • Hamburger, C., & Benjamin, H. (1969). Endocrine Treatment of Male and Female Transsexualism / Appendix for the Practicing Physician: Suggestions and Guidelines for the Management of Transsexuals. In Green, R., & Money, J. (Eds.). Transsexualism and Sex Reassignment (pp. 291–307). Baltimore: John Hopkins University Press. [Google Scholar] [Google Books] [PDF]
  • Hannan, F. M., Elajnaf, T., Vandenberg, L. N., Kennedy, S. H., & Thakker, R. V. (2022). Hormonal regulation of mammary gland development and lactation. Nature Reviews Endocrinology, 19(1), 46–61. [DOI:10.1038/s41574-022-00742-y]
  • Hannema, S. E., Schagen, S. E., Cohen-Kettenis, P. T., & Delemarre-van de Waal, H. A. (2017). Efficacy and Safety of Pubertal Induction Using 17β-Estradiol in Transgirls. The Journal of Clinical Endocrinology & Metabolism, 102(7), 2356–2363. [DOI:10.1210/jc.2017-00373]
  • Harley, J. M. G. (1969). The endocrine control of the breasts. The Practitioner, 203(1214), 153–157. [Google Scholar] [Google Books] [PubMed] [DOI:10.5555/19700402477] [HathiTrust]
  • Hartmann, B. W., Laml, T., Albrecht, A. E., Huber, J. C., & Kirchengast, S. (1998). Hormonal Breast Augmentation: Prognostic Relevance of Insulin-Like Growth Factor-I. Gynecological Endocrinology, 12(2), 123–127. [DOI:10.3109/09513599809024960]
  • Hartmann, P. E., Owens, R. A., Cox, D. B., & Kent, J. C. (1996). Breast Development and Control of Milk Synthesis. Food and Nutrition Bulletin, 17(4), 1–12. [DOI:10.1177/156482659601700404]
  • Hasan, S. (1974). Steroid Hormone Levels During Pregnancy in Various Species. In Bernhard, S., & Raspé, G. (Ed.). Hormones and Embryonic Development (Advances in the Biosciences, Volume 13) (pp. 181–197). Oxford/New York: Pergamon Press. [Google Scholar] [Google Books] [DOI:10.1016/b978-0-08-018239-1.50014-3] [OpenLibrary] [Archive.org]
  • Hassiotou, F., & Geddes, D. (2012). Anatomy of the human mammary gland: Current status of knowledge. Clinical Anatomy, 26(1), 29–48. [DOI:10.1002/ca.22165]
  • Heath, R. A., & Wynne, K. (2019). Children and Adolescents. In Heath, R. A., & Wynne, K. A Guide to Transgender Health: State-of-the-art Information for Gender-Affirming People and Their Supporters (pp. 87–106). Santa Barbara: Praeger/ABC-CLIO. [Google Books]
  • Heath, R. A., & Wynne, K. (2019). Hormone and Surgical Therapies for Adults. In Heath, R. A., & Wynne, K. A Guide to Transgender Health: State-of-the-art Information for Gender-Affirming People and Their Supporters (pp. 107–146). Santa Barbara: Praeger/ABC-CLIO. [Google Books]
  • Hertz, R., Odell, W. D., & Ross, G. T. (1966). Diagnostic Implications of Primary Amenorrhea: Combined Clinical Staff Conference at the National Institutes of Health. Annals of Internal Medicine, 65(4), 800–820. [DOI:10.7326/0003-4819-65-4-800]
  • Hillard, P. J. A. (2007). Benign Diseases of the Female Reproductive Tract. In Berek, J. S., & Novak, E. (Eds.). Berek & Novak’s Gynecology, 14th Edition (pp. 431–496). Philadelphia: Lippincott Williams and Wilkins. [Google Scholar] [OpenLibrary] [WorldCat] [Archive.org]
  • Hoppe, I. C., Patel, P. P., Singer-Granick, C. J., & Granick, M. S. (2011). Virginal Mammary Hypertrophy: A Meta-Analysis and Treatment Algorithm. Plastic and Reconstructive Surgery, 127(6), 2224–2231. [DOI:10.1097/prs.0b013e3182131bd1]
  • Hovey, R. C., Trott, J. F., Ginsburg, E., Goldhar, A., Sasaki, M. M., Fountain, S. J., Sundararajan, K., & Vonderhaar, B. K. (2001). Transcriptional and spatiotemporal regulation of prolactin receptor mRNA and cooperativity with progesterone receptor function during ductal branch growth in the mammary gland. Developmental Dynamics, 222(2), 192–205. [DOI:10.1002/dvdy.1179]
  • Howard, B. A., & Gusterson, B. A. (2000). Human Breast Development. Journal of Mammary Gland Biology and Neoplasia, 5(2), 119–137. [DOI:10.1023/a:1026487120779]
  • Huffman, J., Dewhurst, C. J., & Capraro, V. J. (1981). The Breast and its Disorders in Childhood and Adolescence. In Huffman, J., Dewhurst, J., & Capraro, V. The Gynecology of Childhood and Adolescence, 2nd Edition (pp. 542–559). Philadelphia: Saunders. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
  • Hussain, Z., Brooks, J., & Percy, D. (2008). Menstrual variation of breast volume and T2 relaxation times in cyclical mastalgia. Radiography, 14(1), 8–16. [DOI:10.1016/j.radi.2006.07.003]
  • Hussain, Z., Roberts, N., Whitehouse, G. H., García-Fiñana, M., & Percy, D. (1999). Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. The British Journal of Radiology, 72(855), 236–245. [DOI:10.1259/bjr.72.855.10396212]
  • Hutson, S. W., Cowen, P. N., & Bird, C. C. (1985). Morphometric studies of age related changes in normal human breast and their significance for evolution of mammary cancer. Journal of Clinical Pathology, 38(3), 281–287. [DOI:10.1136/jcp.38.3.281]
  • Hytten, F. E. (1954). Clinical and Chemical Studies in Human Lactation–VI. BMJ, 1(4867), 912–915. [DOI:10.1136/bmj.1.4867.912]
  • Hytten, F. E. (1954). Observations on Human Lactation. (Doctor’s thesis, University of Aberdeen.) [Google Scholar] [Google Books] [URL] [WorldCat]
  • Hytten, F. E. (1976). The physiology of lactation. International Journal of Food Sciences and Nutrition, 30(4), 225–232. [DOI:10.3109/09637487609142745]
  • Hytten, F. E., & Baird, D. (1958). The Development of the Nipple in Pregnancy. The Lancet, 271(7032), 1201–1204. [DOI:10.1016/s0140-6736(58)91908-1]
  • Hytten, F. E., & Leitch, I. (1971). Preparations for Breast Feeding. In Hytten, F. E., & Leitch, I. The Physiology of Human Pregnancy, 2nd Edition (pp. 234–241). Oxford: Blackwell Scientific Publications. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Hytten, F. E., & Leitch, I. (1971). Preparations for Breast Feeding. In Hytten, F. E., & Leitch, I. The Physiology of Human Pregnancy, 2nd Edition (pp. 234–241). Oxford: Blackwell Scientific Publications. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Hytten, F. E., & Thomson, A. M. (1965). Pregnancy, childbirth and lactation. In Edholm, O. G., & Bacharach, A. L. (Eds.). The Physiology of Human Survival (pp. 327–350). London/New York: Academic Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Hytten, F. E., & Thomson, A. M. (1968). Maternal physiological adjustments. In Assali, N. S. (Ed.). The Maternal Organism, Volume I (Biology of Gestation) (pp. 449–479). New York: Academic Press. [Google Scholar] [Google Books] [WorldCat]
  • Igo, J., & Visram, H. (2021). Progesterone Therapy Use and Safety in Male to Female Transgender Patients. Canadian Journal of Diabetes, 45(7 Suppl), S39–S39 (abstract no. 109). [DOI:10.1016/j.jcjd.2021.09.119]
  • Ingleby, H. (1949). Changes in breast volume in a group of normal young women. Bulletin of the International Association of Medical Museums, 29, 87–92. [Google Scholar] [Google Books] [HathiTrust]
  • Ingleby, H., Moore, L., & Gershon-Cohen, J. (1957). Gestational breast changes: x-ray studies of the human breast. Obstetrics & Gynecology, 10(2), 149–157. [Google Scholar] [PubMed] [URL]
  • Ismail, P. M., Amato, P., Soyal, S. M., DeMayo, F. J., Conneely, O. M., O’Malley, B. W., & Lydon, J. P. (2003). Progesterone involvement in breast development and tumorigenesis—as revealed by progesterone receptor “knockout” and “knockin” mouse models. Steroids, 68(10–13), 779–787. [DOI:10.1016/s0039-128x(03)00133-8]
  • Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 204201881987116. [DOI:10.1177/2042018819871166]
  • Jacobsohn, D. (1961). Hormonal Regulation of Mammary Gland Growth. In Kon, S. K., & Cowie, A. T. (Eds.). Milk: The Mammary Gland and Its Secretion, Volume 1 (pp. 127–160). New York: Academic Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [PDF]
  • Jain, J., Kwan, D., & Forcier, M. (2019). Medroxyprogesterone Acetate in Gender-Affirming Therapy for Transwomen: Results From a Retrospective Study. The Journal of Clinical Endocrinology & Metabolism, 104(11), 5148–5156. [DOI:10.1210/jc.2018-02253]
  • Jamal, N., Ng, K., McLean, D., Looi, L., & Moosa, F. (2004). Mammographic Breast Glandularity in Malaysian Women: Data Derived from Radiography. American Journal of Roentgenology, 182(3), 713–717. [DOI:10.2214/ajr.182.3.1820713]
  • Jemstrom, H., & Olsson, H. (1997). Breast Size in Relation to Endogenous Hormone Levels, Body Constitution, and Oral Contraceptive Use in Healthy Nulligravid Women Aged 19-25 Years. American Journal of Epidemiology, 145(7), 571–580. [DOI:10.1093/oxfordjournals.aje.a009153]
  • Jernström, H., Sandberg, T., Bågeman, E., Borg, Å., & Olsson, H. (2005). Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. British Journal of Cancer, 92(5), 857–866. [DOI:10.1038/sj.bjc.6602389]
  • Jeruss, J. S. (2006). Molecular Basis of Breast Cancer. In Winchester, D. J., Winchester, D. P., Hudis, C. A., & Norton, L. (Eds.). Breast Cancer, 2nd Edition (pp. 83–95). Hamilton: B.C. Decker. [Google Scholar] [Google Books] [WorldCat]
  • Johnson, M. C., & Cutler, M. L. (2016). Anatomy and Physiology of the Breast. In Jatoi, I., & Rody, A. (Eds.). Management of Breast Diseases (pp. 1–39). Cham: Springer. [DOI:10.1007/978-3-319-46356-8_1]
  • Kaiser, R. (1993). Gestagen-Östrogen-Kombinationen in der Gynäkologie. Zur Geschichte, Dosierung und Anwendung eines Hormonprinzips. [Gestagen-Oestrogen Combinations in Gynaecology. History, Dosage and Use of a Hormonal Principle.] Geburtshilfe und Frauenheilkunde, 53(7), 503–513. [Google Scholar] [PubMed] [DOI:10.1055/s-2007-1022924]
  • Kaiser, R., & Leidenberger, F. (1991). Hormonbehandlung bei Benign Mammaerkrankungen: Mammahypoplasie. [Hormonal Treatment in Benign Breast Diseases: Breast Hypoplasia.] In Kaiser, R., & Leidenberger, F. Hormonbehandlung in der Gynäkologischen Praxis, 7. Auflage [Hormone Treatment in Gynecological Practice, 7th Edition] (pp. 138–138). Stuttgart: Georg Thieme Verlag. [Google Books] [OpenLibrary] [WorldCat] [PDF] [Translation]
  • Kaiser, U., & Ho, K. K. (2015). Pituitary Physiology and Diagnostic Evaluation. In Melmed, S., Polonsky, K. S., Larsen, P. R., Kronenberg, & H. M. (Eds.). Williams Textbook of Endocrinology, 13th Edition (pp. 176–231). Philadelphia: Elsevier. [DOI:10.1016/B978-0-323-29738-7.00008-3] [Google Books]
  • Kanhai, R. C., Hage, J. J., Asscheman, H., Mulder, W. J., & Hage, J. J. (1999). Augmentation Mammaplasty in Male-to-Female Transsexuals. Plastic and Reconstructive Surgery, 104(2), 542–549. [DOI:10.1097/00006534-199908000-00040]
  • Kanhai, R. C., Hage, J. J., van Diest, P. J., Bloemena, E., & Mulder, J. W. (2000). Short-Term and Long-Term Histologic Effects of Castration and Estrogen Treatment on Breast Tissue of 14 Male-to-Female Transsexuals in Comparison With Two Chemically Castrated Men. The American Journal of Surgical Pathology, 24(1), 74–80. [DOI:10.1097/00000478-200001000-00009]
  • Kardelen, A. D., Toksoy, G., Baş, F., Yavaş Abalı, Z., Gençay, G., Poyrazoğlu, Ş., Bundak, R., Altunoğlu, U., Avcı, Ş., Najaflı, A., Uyguner, O., Karaman, B., Başaran, S., & Darendeliler, F. (2018). A Rare Cause of Congenital Adrenal Hyperplasia: Clinical and Genetic Findings and Follow-up Characteristics of Six Patients with 17-Hydroxylase Deficiency Including Two Novel Mutations. Journal of Clinical Research in Pediatric Endocrinology, 10(3), 206–215. [DOI:10.4274/jcrpe.0032]
  • Kariagina, A., Xie, J., Leipprandt, J. R., & Haslam, S. Z. (2010). Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers. Hormones and Cancer, 1(5), 229–244. [DOI:10.1007/s12672-010-0048-0]
  • Karp, N. S. (2022). Discussion: The Impact of Combined Oral Contraceptives on Adolescents with Macromastia. Plastic & Reconstructive Surgery, 150(4), 739–740. [DOI:10.1097/prs.0000000000009514]
  • Kasielska-Trojan, A., Mikołajczyk, M., & Antoszewski, B. (2020). BreastIdea Volume Estimator: A New Tool for Breast Volume Estimation—Presentation and Validation for Women. Plastic & Reconstructive Surgery, 146(6), 744e–748e. [DOI:10.1097/prs.0000000000007373]
  • Kasielska-Trojan, A., Zawadzki, T., & Antoszewski, B. (2022). Breast Fluctuating Asymmetry in Women with Macromastia/Gigantomastia. International Journal of Environmental Research and Public Health, 19(24), 16895. [DOI:10.3390/ijerph192416895]
  • Kauli, R., Pertzelan, A., Ben‐Zeev, Z., Lewin, R. P., Kaufman, H., Schally, A. C., Schally, A. V., & Laron, Z. (1984). Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate—further experience. Clinical Endocrinology, 20(4), 377–387. [DOI:10.1111/j.1365-2265.1984.tb03433.x]
  • Keller, P. J. (1984). Diagnostik und Therapie wichtiger hormonaler Störungen: Mammahypoplasie. [Diagnosis and Treatment of Important Hormonal Disorders: Mammary Hypoplasia.] In Keller, P. J. Hormonale Störungen in der Gynäkologie: Diagnostik und Behandlung, 3. Auflage [Hormonal Disorders in Gynecology: Diagnosis and Treatment, 3rd Edition] (Kliniktaschenbücher) (pp. 133–134). Berlin/Heidelberg: Springer. [Google Books] [DOI:10.1007/978-3-662-00442-5_3]
  • Keller, P. J. (1995). Diagnostik und Therapie wichtiger Störungen: Mammahypoplasie. [Diagnosis and Treatment of Important Disorders: Mammary Hypoplasia.] In Keller, P. J. Hormon- und Fertilitätsstörungen in der Gynäkologie, 4. Auflage [Hormonal and Fertility Disorders in Gynecology, 4th Edition] (pp. 145–146). Berlin/Heidelberg: Springer. [Google Books] [DOI:10.1007/978-3-662-12026-2_3]
  • Kennedy, B. J. (1953). Effects of intensive sex steroid hormone therapy in advanced breast cancer. JAMA, 152(12), 1135–1141. [DOI:10.1001/jama.1953.63690120004013]
  • Kent, J. C., Mitoulas, L., Cox, D. B., Owens, R. A., & Hartmann, P. E. (1999). Breast Volume and Milk Production During Extended Lactation in Women. Experimental Physiology, 84(2), 435–447. [DOI:10.1111/j.1469-445x.1999.01808.x]
  • Khoo, S. K., & Mackay, E. V. (1972). Testicular Feminization: The Clinical Features, Endocrine Function and Gonadal Pathology in Six Patients. Australian and New Zealand Journal of Obstetrics and Gynaecology, 12(1), 1–13. [DOI:10.1111/j.1479-828x.1972.tb00721.x]
  • Klein, R., Aichinger, H., Dierker, J., Jansen, J. T., Joite-Barfuß, S., Säbel, M., Schulz-Wendtland, R., & Zoetelief, J. (1997). Determination of average glandular dose with modern mammography units for two large groups of patients. Physics in Medicine and Biology, 42(4), 651–671. [DOI:10.1088/0031-9155/42/4/004]
  • Kleinberg, D. L. (2006). Endocrinology of lactation. In DeGroot, L. J., & Jameson, J. L. (Eds). Endocrinology, 5th Edition (pp. 3461–3473). Philadelphia: Elsevier Saunders. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Kleinberg, D. L., & Barcellos-Hoff, M. H. (2011). The Pivotal Role of Insulin-Like Growth Factor I in Normal Mammary Development. Endocrinology and Metabolism Clinics of North America, 40(3), 461–471. [DOI:10.1016/j.ecl.2011.06.001]
  • Kleinberg, D. L., & Ruan, W. (2008). IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development. Journal of Mammary Gland Biology and Neoplasia, 13(4), 353–360. [DOI:10.1007/s10911-008-9103-7]
  • Kleinberg, D. L., Wood, T. L., Furth, P. A., & Lee, A. V. (2008). Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions. Endocrine Reviews, 30(1), 51–74. [DOI:10.1210/er.2008-0022]
  • Kühnel, W. (2000). IMMULITE® and IMMULITE® 2000 Reference Range Compendium, First English Edition. Los Angeles, California: Diagnostic Products Corporation. [Google Scholar] [URL] [PDF 1] [PDF 2]
  • Kustin, J., & Rebar, R. W. (1987). Menstrual Disorders in the Adolescent Age Group. Primary Care: Clinics in Office Practice, 14(1), 139–166. [DOI:10.1016/s0095-4543(21)01004-6]
  • Kutten, F., Malet, C., & Leygue, E. (1994). Antiestrogen action of progestogens in human breast cells. In Berg, G., & Hammar, M. (Eds.). The Modern Management of the Menopause: A Perspective for the 21st Century [The Proceedings of the VII International Congress on the Menopause, Stockholm, Sweden 1993] (pp. 419–433). Canforth: Parthenon. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org] [PDF]
  • Ladjouze, A., & Donaldson, M. (2019). Primary gonadal failure. Best Practice & Research Clinical Endocrinology & Metabolism, 33(3), 101295. [DOI:10.1016/j.beem.2019.101295]
  • Laessle, R. G., Tuschi, R. J., Schweiger, U., & Pirke, K. M. (1990). Mood changes and physical complaints during the normal menstrual cycle in healthy young women. Psychoneuroendocrinology, 15(2), 131–138. [DOI:10.1016/0306-4530(90)90021-z]
  • LaMarca, H. L., & Rosen, J. M. (2007). Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Research, 9(4), 304. [DOI:10.1186/bcr1740]
  • Laron, Z., & Kauli, R. (2000). Experience with Cyproterone Acetate in the Treatment of Precocious Puberty. Journal of Pediatric Endocrinology and Metabolism, 13(Suppl 1), 805–810. [DOI:10.1515/jpem.2000.13.s1.805]
  • Lauritzen, C. (1980 October 27). Hormonkur Kann Hypoplastischer Mamma Aufhelfen. [Hormone Therapy Can Help Hypoplastic Breasts.] Selecta: Medizin aktuell; das Magazin für ärztliche Fortbildung [Selecta: Medicine Currently; the Magazine for Medical Training], 22(43), 3798–3801. Planegg: Selecta-Verlag. [ISSN:0582-4877] [WorldCat] [PDF] [Translation]
  • Lauritzen, C. (1982). Treatment of mammary- and uterus hypoplasia by estrogen-progestagen pseudopregnancy. In Richter, K., Huber, A., Terruhn, V. (Eds.) 1. Europäisches Symposium für Kinder- und Jugendgynäkologie. München 19.-21.3.1981, Band 2 [First European Symposium on Pediatric and Adolescent Gynaecology. München, March 19–21, 1981, Volume 2] (pp. 487–489). Friedrichsdorf/Taunus: Milupa-Aktiengesellschaft, Wissenschaftliche Abteilung. [Google Scholar] [PDF]
  • Lauritzen, C. (1989). Hormonelle Substitutionstherapie zur Brustvergrößerung. [Hormonal Substitution Therapy for Breast Enlargement.] In Beller, F. K. & Seitzer, D. (Eds.). 7. Siebte Wissenschaftliche Tagung der Deutschen Gesellschaft für Senologie, Münster, 25. - 27. September 1987: Ausgewählte Referate [7th Scientific Conference of the German Society for Senology, Münster, [Germany,] September 25–27, 1987: Selected Papers] (pp. 39–41). Mülheim, Germany: H.U.F. Verlag. [Google Scholar] [WorldCat 1] [WorldCat 2] [WorldCat 3] [Cited By 1] [Cited By 2] [Cited By 3] [PDF] [Translation]
  • Lawrence, R. A., & Lawrence, R. M. (2015). Physiology of Lactation. In Lawrence, R. A., & Lawrence, R. M. Breastfeeding: A Guide for the Medical Profession, 8th Edition (pp. 56–90). Philadelphia: Elsevier. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Lee, H. J., & Ormandy, C. J. (2012). Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Molecular and Cellular Endocrinology, 357(1–2), 101–107. [DOI:10.1016/j.mce.2011.09.020]
  • Lee, P. A. (2001). Physiology of Puberty. In Becker, K. L., Bilezikian, J. P., Bremner, W. J., Hung, W., Kahn, C. R., Loriaux, D. L., Nylén, E. S., Rebar, R. W., Robertson, G. L., Snider, R. H., Wartofsky, L. (Eds.). Principles and Practice of Endocrinology and Metabolism, 3rd Edition (pp. 885–893). Philadelphia: Lippincott Williams & Wilkins. [Google Scholar] [Google Books] [Archive.org] [OpenLibrary] [WorldCat]
  • Lee, S. W., Kwak, D. S., Jung, I. S., Kwak, J. H., Park, J. H., Hong, S. M., Lee, C. B., Park, Y. S., Kim, D. S., Choi, W. H., & Ahn, Y. H. (2015). Partial Androgen Insensitivity Syndrome Presenting with Gynecomastia. Endocrinology and Metabolism, 30(2), 226–230. [DOI:10.3803/enm.2015.30.2.226]
  • Lejour, M. (1994). Vertical Mammaplasty and Liposuction of the Breast. Plastic and Reconstructive Surgery, 94(1), 100–114. [DOI:10.1097/00006534-199407000-00010]
  • Lejour, M. (1997). Evaluation of Fat in Breast Tissue Removed by Vertical Mammaplasty. Plastic and Reconstructive Surgery, 99(2), 386–393. [DOI:10.1097/00006534-199702000-00012]
  • Lemarchand-Béraud, T., Zufferey, M., Reymond, M., & Rey, I. (1982). Maturation of the Hypothalamo-Pituitary-Ovarian Axis in Adolescent Girls. The Journal of Clinical Endocrinology & Metabolism, 54(2), 241–246. [DOI:10.1210/jcem-54-2-241]
  • Lewin, R. (2016). Breast Hypertrophy and Outcome of Breast Reduction Surgery. (Doctoral thesis, University of Gothenburg. Sahlgrenska Academy.) [Google Scholar] [URL]
  • Lim, L. Y., Ho, P. J., Liu, J., Chay, W. Y., Tan, M., Hartman, M., & Li, J. (2018). Determinants of breast size in Asian women. Scientific Reports, 8(1), 1201. [DOI:10.1038/s41598-018-19437-4]
  • Lloyd, C. W., & Leathem, J. H. (1964). Growth and development of the breast and lactation. In Lloyd, C. W. (Ed.). Human Reproduction and Sexual Behavior (pp. 117–134). Philadelphia: Lea & Febiger. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Lopez, X., Panton, J., Nagarkar, P., Preston, S., Abramowitz, J., & Amirlak, B. (2023). Initial Assessment of VECTRA Three-Dimensional Imaging to Accurately Simulate Breast Volume Changes in Transfeminine Patients: A Mannequin Study. Aesthetic Surgery Journal Open Forum, 5, online ahead of print. [DOI:10.1093/asjof/ojad015]
  • Lorincz, A. M., & Sukumar, S. (2006). Molecular links between obesity and breast cancer. Endocrine-Related Cancer, 13(2), 279–292. [DOI:10.1677/erc.1.00729]
  • Lucien, J. N., Ortega, M. T., Calvert, M. E., Smith, C., White, X., Rogers, H., Mosley, B., Agrawal, R., Drude, A., McGee, C., George, M., Brown, A., Downey, K., Wild, C., Njunge, A., Kuzmiak, C. M., Zava, D., Zava, T., Pollard, J., Francis, J., Beery, B. L., Harlin, M., Gonzalez, G. R., & Shaw, N. D. (2022). The Launch of A Girl’s First Period Study: Demystifying Reproductive Hormone Profiles in Adolescent Girls. Journal of Pediatric and Adolescent Gynecology, 35(4), 420–425. [DOI:10.1016/j.jpag.2021.12.018]
  • Lydon, J. P., DeMayo, F. J., Funk, C. R., Mani, S. K., Hughes, A. R., Montgomery, C. A., Shyamala, G., Conneely, O. M., & O’Malley, B. W. (1995). Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes & Development, 9(18), 2266–2278. [DOI:10.1101/gad.9.18.2266]
  • Lyon, A. J., De Bruyn, R., & Grant, D. B. (1985). Isosexual Precocious Puberty in Girls. Acta Paediatrica, 74(6), 950–955. [DOI:10.1111/j.1651-2227.1985.tb10063.x]
  • Lyons, W. R. (1958). Hormonal synergism in mammary growth. Proceedings of the Royal Society of London. Series B - Biological Sciences, 149(936), 303–325. [DOI:10.1098/rspb.1958.0071]
  • Lyons, W. R., & McGinty, D. A. (1941). Effects of estrone and progesterone on male rabbit mammary glands. I. Varying doses of progesterone. Proceedings of the Society for Experimental Biology and Medicine, 48(1), 83–86. [DOI:10.3181/00379727-48-13227]
  • Lyons, W. R., Li, C. H., & Johnson, R. E. (1958). The Hormonal Control of Mammary Growth and Lactation. In Pincus, G. (Ed.). Recent Progress in Hormone Research, Volume 14 [Proceedings of the Laurentian Hormone Conference 1957, Held at Mont Tremblant, Quebec] (pp. 219–254). New York/London: Academic Press. [Google Scholar] [Google Books] [PubMed] [OpenLibrary] [WorldCat] [PDF]
  • MacBryde, C. M. (1939). The Production of Breast Growth in the Human Female. Journal of the American Medical Association, 112(11), 1045–1049. [DOI:10.1001/jama.1939.02800110025006]
  • Malet, C., Gompel, A., Yaneva, H., Cren, H., Fidji, N., Mowszowicz, I., Kuttenn, F., & Mauvais-Jarvis, P. (1991). Estradiol and Progesterone Receptors in Cultured Normal Human Breast Epithelial Cells and Fibroblasts: Immunocytochemical Studies. The Journal of Clinical Endocrinology & Metabolism, 73(1), 8–17. [DOI:10.1210/jcem-73-1-8]
  • Malini, S., Smith, E. O., & Goldzieher, J. W. (1985). Measurement of breast volume by ultrasound during normal menstrual cycles and with oral contraceptive use. Obstetrics and Gynecology, 66(4), 538–541. [Google Scholar] [PubMed] [URL] [PDF]
  • Marshall, W. A. (1978). Puberty. In Falkner, F., & Tanner, J. M. (Eds.). Human Growth: Postnatal Growth (pp. 141–181). Boston: Springer US. [DOI:10.1007/978-1-4684-2622-9_6]
  • Marshall, W. A., & Tanner, J. M. (1969). Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood, 44(235), 291–303. [DOI:10.1136/adc.44.235.291]
  • Mauvais-Jarvis, P., Kuttenn, F., & Gompel, A. (1986). Antiestrogen action of progesterone in breast tissue. Breast Cancer Research and Treatment, 8(3), 179–188. [DOI:10.1007/bf01807330]
  • Mauvais-Jarvis, P., Kuttenn, F., & Gompel, A. (1986). Estradiol/Progesterone Interaction in Normal and Pathologic Breast Cells. Annals of the New York Academy of Sciences, 464(1), 152–167. [DOI:10.1111/j.1749-6632.1986.tb16002.x]
  • Mauvais-Jarvis, P., Kuttenn, F., & Gompel, A. (1987). Antiestrogen Action of Progesterone in Breast Tissue. Hormone Research, 28(2–4), 212–218. [DOI:10.1159/000180946]
  • Mauvais-Jarvis, P., Kuttenn, F., Gompel, A., & Benotmane, A. (1987). Action anti-estrogène de la progestérone dans le sein. [Antiestrogen action of progesterone in the breast]. Pathologie-Biologie, 35(7), 1081–1086. [Google Scholar 1] [Google Scholar 2] [PubMed]
  • Mauvais-Jarvis, P., Sitruk-Ware, R., & Kuttenn, F. (1981). Benign Breast Disease. In McGuire, W. L. (Ed.). Breast Cancer 4: Advances in Research and Treatment (pp. 51–94). Boston: Springer US. [DOI:10.1007/978-1-4615-6571-0_3]
  • McArthur, J. W. (1966). The Reproductive Endocrinology of Adolescence. In Heald, F. P. (Ed.). Adolescent Gynecology (pp. 9–20). Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • McBryan, J., Howlin, J., Napoletano, S., & Martin, F. (2008). Amphiregulin: Role in Mammary Gland Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 13(2), 159–169. [DOI:10.1007/s10911-008-9075-7]
  • McDonough, P. G., Spicer, D. V., Ursin, G., & Pike, M. C. (1996). Progesterone Concentrations—Physiologic or Pharmacologic? Fertility and Sterility, 65(5), 1077–1078. [DOI:10.1016/s0015-0282(16)58295-8]
  • McMillan, M. (1966). Five cases of testicular feminisation including one with a teratoma of the testis. The Journal of Pathology and Bacteriology, 91(2), 417–427. [DOI:10.1002/path.1700910216]
  • McNally, S., & Stein, T. (2016). Overview of Mammary Gland Development: A Comparison of Mouse and Human. In Martin, F., Stein, T., & Howlin, J. (Eds.). Mammary Gland Development (Methods in Molecular Biology, Volume 1501) (pp. 1–17). New York: Springer New York. [DOI:10.1007/978-1-4939-6475-8_1]
  • McPhaul, M. J. (2002). Androgen receptor mutations and androgen insensitivity. Molecular and Cellular Endocrinology, 198(1–2), 61–67. [DOI:10.1016/s0303-7207(02)00369-6]
  • Meites, J. (1966). Control of mammary growth and lactation. In Martini, L., & Ganong, W. F. (Eds.). Neuroendocrinology, Volume I (pp. 669–707). New York: Academic Press. [Google Scholar] [Google Books] [DOI:10.1016/B978-1-4832-3228-7.50023-2] [OpenLibrary] [WorldCat]
  • Mesiano, S. (2019). Endocrinology of Human Pregnancy and Fetal-Placental Neuroendocrine Development. In Strauss, J. F., & Barbieri, R. L. (Eds.). Yen and Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 8th Edition (pp. 256–284.e9). Philadelphia: Elsevier. [Google Books] [DOI:10.1016/b978-0-323-47912-7.00011-1]
  • Meyer, G., Mayer, M., Mondorf, A., Flügel, A. K., Herrmann, E., & Bojunga, J. (2020). Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria. European Journal of Endocrinology, 182(2), 149–156. [DOI:10.1530/eje-19-0463]
  • Meyer, W. J., Finkelstein, J. W., Stuart, C. A., Webb, A., Smith, E. R., Payer, A. F., & Walker, P. A. (1981). Physical and hormonal evaluation of transsexual patients during hormonal therapy. Archives of Sexual Behavior, 10(4), 347–356. [DOI:10.1007/bf01565538]
  • Meyer, W. J., Webb, A., Stuart, C. A., Finkelstein, J. W., Lawrence, B., & Walker, P. A. (1986). Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior, 15(2), 121–138. [DOI:10.1007/bf01542220]
  • Mikołajczyk, M., Kasielska-Trojan, A., & Antoszewski, B. (2019). A New Tool for Breast Anthropometric Measurements: Presentation and Validation for Women and Men. Aesthetic Plastic Surgery, 43(5), 1160–1170. [DOI:10.1007/s00266-019-01467-6]
  • Milionis, C., Ilias, I., & Koukkou, E. (2022). Progesterone in gender-affirming therapy of trans women. World Journal of Biological Chemistry, 13(3), 66–71. [DOI:10.4331/wjbc.v13.i3.66]
  • Milligan, D., Drife, J. O., & Short, R. V. (1975). Changes in breast volume during normal menstrual cycle and after oral contraceptives. BMJ, 4(5995), 494–496. [DOI:10.1136/bmj.4.5995.494]
  • Morris, J. M. (1953). The syndrome of testicular feminization in male pseudohermaphrodites. American Journal of Obstetrics and Gynecology, 65(6), 1192–1211. [DOI:10.1016/0002-9378(53)90359-7]
  • Morris, J. M., & Mahesh, V. B. (1963). Further observations on the syndrome, “testicular feminization”. American Journal of Obstetrics and Gynecology, 87(6), 731–748. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF]
  • Moss, W. M. (1968). Gigantomastia With Pregnancy. Archives of Surgery, 96(1), 27–32. [DOI:10.1001/archsurg.1968.01330190029007]
  • Muallem, M. M., & Rubeiz, N. G. (2006). Physiological and biological skin changes in pregnancy. Clinics in Dermatology, 24(2), 80–83. [DOI:10.1016/j.clindermatol.2005.10.002]
  • Müller, C. (1953). Zur Hormonalen Kosmetik der Weiblichen Brust: Wirkung und Nebenwirkung Östrogenhaltiger Kosmetischer Präparate. [Hormonal Cosmetics of the Female Breast: Effects and Side Effects of Estrogen-Containing Cosmetic Preparations.] Schweizerische Medizinische Wochenschrift [Swiss Medical Weekly], 83(4), 81–84. [Google Scholar 1] [Google Scholar 2] [PubMed] [PDF] [Translation]
  • Muzaffar, F., Hussain, I., & Haroon, T. S. (1998). Physiologic skin changes during pregnancy: a study of 140 cases. International Journal of Dermatology, 37(6), 429–431. [DOI:10.1046/j.1365-4362.1998.00281.x]
  • Naik, M., Diwakar, R. K., Patre, S., & Singh, S. (2015). Gigantomastia: A Rare Complication In Pregnancy. Journal of Medical Science and Clinical Research, 3(7), 6873–6876. [Google Scholar] [URL] [PDF]
  • Naseem, H., Lokman, M., & Fitzgerald, C. (2021). Management of congenital hypogonadotropic hypogonadism in females. Human Fertility, 26(3), 622–631. [DOI:10.1080/14647273.2021.1998929]
  • Nelson, W. O. (1936). Endocrine Control of the Mammary Gland. Physiological Reviews, 16(3), 488–526. [DOI:10.1152/physrev.1936.16.3.488]
  • Nolan, B. J., Frydman, A. S., Leemaqz, S. Y., Carroll, M., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2022). Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocrine Connections, 11(5), e220170. [DOI:10.1530/EC-22-0170]
  • Nolan, B. J., Frydman, A. S., Leemaqz, S. Y., Carroll, M., Grossmann, M., Zajac, J. D., & Cheung, A. S. (2022). Effects Of Low-dose Oral Micronised Progesterone On Sleep, Psychological Distress And Breast Development In Transgender Individuals Undergoing Feminising Hormone Therapy: A Prospective Controlled Study. Journal of the Endocrine Society, 6(Suppl 1), A653–A654 (abstract no. LBODP089). [DOI:10.1210/jendso/bvac150.1351]
  • Nussbaum, R., & Benedetto, A. V. (2006). Cosmetic aspects of pregnancy. Clinics in Dermatology, 24(2), 133–141. [DOI:10.1016/j.clindermatol.2005.10.007]
  • Nuzzi, L. C., Pramanick, T., Massey, G. G., Walsh, L. R., McNamara, C. T., Firriolo, J. M., DiVasta, A. D., & Labow, B. I. (2021). The Impact of Progestin-only Contraception on Adolescents with Macromastia. Plastic and Reconstructive Surgery - Global Open, 9(2), e3421. [DOI:10.1097/gox.0000000000003421]
  • Nuzzi, L. C., Pramanick, T., Massey, G. G., Walsh, L. R., McNamara, C. T., Firriolo, J. M., DiVasta, A. D., & Labow, B. I. (2022). The Impact of Combined Oral Contraceptives on Adolescents with Macromastia. Plastic and Reconstructive Surgery, 150(4), 731–738. [DOI:10.1097/prs.0000000000009513]
  • Oakes, M. B., Eyvazzadeh, A. D., Quint, E., & Smith, Y. R. (2008). Complete Androgen Insensitivity Syndrome—A Review. Journal of Pediatric and Adolescent Gynecology, 21(6), 305–310. [DOI:10.1016/j.jpag.2007.09.006]
  • Obr, A. E., & Edwards, D. P. (2012). The biology of progesterone receptor in the normal mammary gland and in breast cancer. Molecular and Cellular Endocrinology, 357(1–2), 4–17. [DOI:10.1016/j.mce.2011.10.030]
  • Olanrewaju, F., Onayemi, O., Olasode, O., Adeyemi, A., Oninla, A., Oripelaye, M., Ezejiofor, O., & Oke, O. (2017). Prevalence and Pattern of Pigmentary Changes among Primigravidae Attending a Tertiary Health Facility in South-Western Nigeria. British Journal of Medicine and Medical Research, 21(5), 1–9. [DOI:10.9734/bjmmr/2017/33382]
  • Orentreich, N., & Durr, N. P. (1974). Mammogenesis in Transsexuals. Journal of Investigative Dermatology, 63(1), 142–146. [DOI:10.1111/1523-1747.ep12678272]
  • Pandya, S., & Moore, R. G. (2011). Breast Development and Anatomy. Clinical Obstetrics & Gynecology, 54(1), 91–95. [DOI:10.1097/grf.0b013e318207ffe9]
  • Park, I. Y., Kim, M. R., Jo, H. H., Lee, M. K., & Kim, M. J. (2014). Association of the Nipple-Areola Complexes with Age, Parity, and Breastfeeding in Korean Premenopausal Women. Journal of Human Lactation, 30(4), 474–479. [DOI:10.1177/0890334414549049]
  • Pasqualini, J. R. (2007). Progestins and breast cancer. Gynecological Endocrinology, 23(Suppl 1), 32–41. [DOI:10.1080/09513590701585003]
  • Pasqualini, J. R. (2009). Breast cancer and steroid metabolizing enzymes: The role of progestogens. Maturitas, 65(Suppl 1), S17–S21. [DOI:10.1016/j.maturitas.2009.11.006]
  • Pasqualini, J. R., & Kincl, F. A. (1985). Hormone Production and Concentrations During Pregnancy in Humans and in Other Mammalian Species. In Pasqualini, J. R., & Kincl, F. A. Hormones and the Fetus, Volume I: Production, Concentration and Metabolism During Pregnancy (pp. 173–334). Oxford: Pergamon Press. [DOI:10.1016/b978-0-08-019708-1.50007-6]
  • Patel, H., Arruarana, V., Yao, L., Cui, X., & Ray, E. (2020). Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review. Endocrine, 68(1), 6–15. [DOI:10.1007/s12020-020-02197-5]
  • Patel, K. T., Adeel, S., Rodrigues Miragaya, J., & Tangpricha, V. (2022). Progestogen Use in Gender-Affirming Hormone Therapy: A Systematic Review. Endocrine Practice, 28(12), 1244–1252. [DOI:10.1016/j.eprac.2022.08.012]
  • Patterson, M. N., McPhaul, M. J., & Hughes, I. A. (1994). Androgen insensitivity syndrome. Baillière’s Clinical Endocrinology and Metabolism, 8(2), 379–404. [DOI:10.1016/s0950-351x(05)80258-7]
  • Pawłowski, B., & Żelaźniewicz, A. (2021). The evolution of perennially enlarged breasts in women: a critical review and a novel hypothesis. Biological Reviews, 96(6), 2794–2809. [DOI:10.1111/brv.12778]
  • Perez-Palacios, G., & Jaffe, R. B. (1972). The Syndrome of Testicular Feminization. Pediatric Clinics of North America, 19(3), 653–667. [DOI:10.1016/s0031-3955(16)32744-4]
  • Petrakis, N. (1978). Recurrent extreme breast involution following pregnancy and susceptibility to breast cancer: A hypothesis. Medical Hypotheses, 4(3), 268–272. [DOI:10.1016/0306-9877(78)90006-3]
  • Pfeiffer, C. A. (1943). Endocrinology of Reproduction. Annual Review of Physiology, 5(1), 413–452. [DOI:10.1146/annurev.ph.05.030143.002213]
  • Pipkin, F. B. (2019). Physiological Changes in Pregnancy. In Symonds, I. M., & Arulkumaran, S. (Eds.). Essential Obstetrics and Gynaecology, 6th Edition (pp. 22–40). Edinburgh: Elsevier. [Google Books] [OpenLibrary] [WorldCat]
  • Plu-Bureau, G., Touraine, P., & Mauvais-Jarvis, P. (1999). Interactions Between Estradiol and Progesterone in Normal Breast: Implications for Mammary Carcinogenesis. In Manni, A. (Ed.). Endocrinology of Breast Cancer (Contemporary Endocrinology, Volume 11) (pp. 21–37). Totowa, New Jersey: Humana Press. [DOI:10.1007/978-1-59259-699-7_2] [OpenLibrary] [Archive.org]
  • Pocock, G., Richards, C. D., & Richards, D. A. (2013). Fertilization, Pregnancy, and Lactation. In Pocock, G., Richards, C. D., & Richards, D. A. Human Physiology, 4th Edition (pp. 655–752). Oxford: Oxford University Press. [Google Scholar] [Google Books]
  • Polani, P. E. (1970). Hormonal and clinical aspects of hermaphroditism and the testicular feminizing syndrome in man. Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 259(828), 187–206. [DOI:10.1098/rstb.1970.0058]
  • Price, S., McManus, J., & Barrett, J. (2019). The transgender population: improving awareness for gynaecologists and their role in the provision of care. The Obstetrician & Gynaecologist, 21(1), 11–20. [DOI:10.1111/tog.12521]
  • Prior, J. C. (2011). Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts, Views & Vision in ObGyn, 3(2), 109–120. [PubMed] [PubMed Central] [PDF]
  • Prior, J. C. (2019). Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1181–1186. [DOI:10.1210/jc.2018-01777]
  • Prior, J. C. (2019). Response to Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen”. The Journal of Clinical Endocrinology & Metabolism, 104(8), 3129–3130. [DOI:10.1210/jc.2019-00524]
  • Prior, J. C. (2020). Women’s Reproductive System as Balanced Estradiol and Progesterone Actions—A revolutionary, paradigm-shifting concept in women’s health. Drug Discovery Today: Disease Models, 32(Part B), 31–40. [DOI:10.1016/j.ddmod.2020.11.005]
  • Prior, J. C., Vigna, Y. M., & Watson, D. (1989). Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Archives of Sexual Behavior, 18(1), 49–57. [DOI:10.1007/bf01579291]
  • Prior, J. C., Vigna, Y. M., Watson, D., Diewold, P., & Robinow, O. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information & Education Council of Canada, 1(1), 1–7. [Google Scholar] [PDF]
  • Quigley, C. A. (1998). The androgen receptor: Physiology and pathophysiology. In Nieschlag, E., & Behre, H. M. (Eds.). Testosterone: Action · Deficiency · Substitution, 2nd Edition (pp. 33–106). Berlin/Heidelberg: Springer. [DOI:10.1007/978-3-642-72185-4_2]
  • Quigley, C. A., Bellis, A. D., Marschke, K. B., El-Awady, M. K., Wilson, E. M., & French, F. S. (1995). Androgen Receptor Defects: Historical, Clinical, and Molecular Perspectives. Endocrine Reviews, 16(3), 271–321. [DOI:10.1210/edrv-16-3-271]
  • Radisky, D. C., & Hartmann, L. C. (2009). Mammary Involution and Breast Cancer Risk: Transgenic Models and Clinical Studies. Journal of Mammary Gland Biology and Neoplasia, 14(2), 181–191. [DOI:10.1007/s10911-009-9123-y]
  • Ramos, L., Chávez, B., Mares, L., Valdés, E., & Vilchis, F. (2018). Mutational analysis of the androgen receptor (NR3C4) gene in patients with 46,XY DSD. Gene, 641, 86–93. [DOI:10.1016/j.gene.2017.10.038]
  • Ramsay, D. T., Kent, J. C., Hartmann, R. A., & Hartmann, P. E. (2005). Anatomy of the lactating human breast redefined with ultrasound imaging. Journal of Anatomy, 206(6), 525–534. [DOI:10.1111/j.1469-7580.2005.00417.x]
  • Randolph, J. F. (2018). Gender-Affirming Hormone Therapy for Transgender Females. Clinical Obstetrics & Gynecology, 61(4), 705–721. [DOI:10.1097/grf.0000000000000396]
  • Rauh, C., Faschingbauer, F., Haeberle, L., Jud, S. M., Heusinger, K., Fasching, P. A., Goecke, T. W., Rajakaruna, N., Voigt, F., Bani, M. R., Lux, M. P., Renner, S. P., Loehberg, C. R., Hartmann, A., Schulz-Wendtland, R., Beckmann, M. W., & Bayer, C. M. (2013). Factors influencing breast changes after pregnancy. European Journal of Cancer Prevention, 22(3), 259–261. [DOI:10.1097/cej.0b013e328359cb81]
  • Rebar, R. W. (1988). The Ovaries. In Wyngaarden, J. B., & Smith, L. H. (Eds.). Cecil Textbook of Medicine, 18th Edition (pp. 1425–1446). Philadelphia: W. B. Saunders. [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Rebar, R. W. (1990). Disorders of Menstruation, Ovulation, and Sexual Response. In Becker, K. L., Bilezikian, J. P., Bremner, W. J., Hung, W., Kahn, C. R., Loriaux, D. L., Rebar, R. W., Robertson, G. L., & Wartofsky, L. (Eds.). Principles and Practice of Endocrinology and Metabolism, 1st Edition (pp. 798–814). Philadelphia: Lippincott. [Google Scholar—3rd/2001 Edition] [Google Books—3rd/2001 Edition] [OpenLibrary] [WorldCat] [Archive.org]
  • Rebar, R. W. (1993). Normal and Abnormal Sexual Differentiation and Pubertal Development. In Moore, T. R., Reiter, R. C., Rebar, R. W., & Baker, W. (Eds.). Gynecology & Obstetrics: A Longitudinal Approach (pp. 97–133). New York: Churchill Livingstone. [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Rebar, R. W. (1996). Puberty. In Berek, J. S., Adashi, E. Y., & Hillard, P. A. (Eds.). Novak’s Gynecology, 12th Edition (pp. 771–807). Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Reisman, T., Goldstein, Z., & Safer, J. D. (2019). A Review of Breast Development in Cisgender Women and Implications for Transgender Women. Endocrine Practice, 25(12), 1338–1345. [DOI:10.4158/ep-2019-0183]
  • Richards, C., & Barrett, J. (2020). Physical Treatments for Trans People and Their Interactions with Psychiatric Treatments. In Richards, C., & Barrett, J. Trans and Non-binary Gender Healthcare for Psychiatrists, Psychologists, and Other Health Professionals (pp. 31–44). Cambridge: Cambridge University Press. [DOI:10.1017/9781108628419.003]
  • Richert, M. M., Schwertfeger, K. L., Ryder, J. W., & Anderson, S. M. (2000). An Atlas of Mouse Mammary Gland Development. Journal of Mammary Gland Biology and Neoplasia, 5(2), 227–241. [DOI:10.1023/a:1026499523505]
  • Rix, J., Mills, C., Ross, E., Allen, S., Lai, A., & Wakefield-Scurr, J. (2023). Breast volume fluctuations are associated with oestradiol and progesterone changes across the menstrual cycle. Research Square, preprint. [Google Scholar] [DOI:10.21203/rs.3.rs-3753080/v1] [PDF]
  • Rodari, G. (2022). Pubertal induction in girls with hypogonadism: estrogen replacement therapy outcomes and optimization of progesterone introduction. (Doctoral thesis, Università degli Studi di Milano.) [URL]
  • Rodari, G., Federici, S., Cattoni, A., Todisco, T., Ubertini, G., Giacchetti, F., Profka, E., Dall’Antonia, A., Cangiano, B., Arosio, M., Bonomi, M., Cappa, M., & Giavoli, C. (2022). Pubertal induction in girls with hypogonadism: insight into estrogen replacement therapy outcomes and optimization of progesterone introduction. Endocrine Abstracts, 81 [24th European Congress of Endocrinology 2022 21–24 May 2022, Milan, Italy], 107–107 (abstract no. RC12.7). [DOI:10.1530/endoabs.81.rc12.7] [PDF]
  • Rodari, G., Federici, S., Todisco, T., Ubertini, G., Cattoni, A., Pagano, M., Giacchetti, F., Profka, E., Citterio, V., Messetti, D., Collini, V., Soranna, D., Carbone, E., Arosio, M., Mantovani, G., Persani, L., Cappa, M., Bonomi, M., & Giavoli, C. (2023). Towards an individualized management of pubertal induction in girls with hypogonadism: insight into the best replacement outcomes from a large multicentre registry. European Journal of Endocrinology, 188(6), 467–476. [DOI:10.1093/ejendo/lvad056]
  • Rohn, R. D. (1989). Nipple (papilla) development in girls: III. Journal of Adolescent Health Care, 10(1), 39–40. [DOI:10.1016/0197-0070(89)90045-4]
  • Rosenfield, R. L. (2013). Adolescent Anovulation: Maturational Mechanisms and Implications. The Journal of Clinical Endocrinology & Metabolism, 98(9), 3572–3583. [DOI:10.1210/jc.2013-1770]
  • Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2021). Puberty in the Female and Its Disorders. In Sperling, M. A., Majzoub, J. A., Menon, R. K., & Stratakis, C. A. (Eds.). Sperling Pediatric Endocrinology, 5th Edition (pp. 528–626). Philadelphia: Elsevier. [DOI:10.1016/B978-0-323-62520-3.00016-6]
  • Rothman, M. S., & Iwamoto, S. J. (2022). Feminizing Gender-Affirming Hormone Therapy: Special Considerations for Older Adults. In Davis, T. F. (Ed.). A Case-Based Guide to Clinical Endocrinology (pp. 513–523). Cham: Springer. [DOI:10.1007/978-3-030-84367-0_58]
  • Ruan, W., Monaco, M. E., & Kleinberg, D. L. (2005). Progesterone Stimulates Mammary Gland Ductal Morphogenesis by Synergizing with and Enhancing Insulin-Like Growth Factor-I Action. Endocrinology, 146(3), 1170–1178. [DOI:10.1210/en.2004-1360]
  • Rutgers, J. L., & Scully, R. E. (1991). The Androgen Insensitivity Syndrome (Testicular Feminization). International Journal of Gynecological Pathology, 10(2), 126–144. [DOI:10.1097/00004347-199104000-00002]
  • Ryan, R. F., & Pernoll, M. L. (1985). Virginal Hypertrophy. Plastic and Reconstructive Surgery, 75(5), 737–742. [DOI:10.1097/00006534-198505000-00024]
  • Saito, R., Yamamoto, Y., Goto, M., Araki, S., Kubo, K., Kawagoe, R., Kawada, Y., Kusuhara, K., Igarashi, M., & Fukami, M. (2014). Tamoxifen Treatment for Pubertal Gynecomastia in Two Siblings with Partial Androgen Insensitivity Syndrome. Hormone Research in Paediatrics, 81(3), 211–216. [DOI:10.1159/000356923]
  • Sandhu, R., Chollet-Hinton, L., Kirk, E. L., Midkiff, B., & Troester, M. A. (2016). Digital histologic analysis reveals morphometric patterns of age-related involution in breast epithelium and stroma. Human Pathology, 48, 60–68. [DOI:10.1016/j.humpath.2015.09.031]
  • Sanuki, J., Fukuma, E., & Uchida, Y. (2008). Morphologic Study of Nipple-Areola Complex in 600 Breasts. Aesthetic Plastic Surgery, 33(3), 295–297. [DOI:10.1007/s00266-008-9194-y]
  • Satoh, K., Hovey, R. C., Malewski, T., Warri, A., Goldhar, A. S., Ginsburg, E., Saito, K., Lydon, J. P., & Vonderhaar, B. K. (2007). Progesterone enhances branching morphogenesis in the mouse mammary gland by increased expression of Msx2. Oncogene, 26(54), 7526–7534. [DOI:10.1038/sj.onc.1210555]
  • Schauffler, G. C. (1942). Disorders During Adolescence—The Onset of Menstruation. In Schauffler, G. C. Pediatric Gynecology; with Sections on Urology and Proctology, 1st Edition (pp. 169–211). Chicago: Year Book. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [URL]
  • Schindler, A. E. (2010). Dydrogesterone and other progestins in benign breast disease: an overview. Archives of Gynecology and Obstetrics, 283(2), 369–371. [DOI:10.1007/s00404-010-1456-7]
  • Scott, P. P., Greene, R., Lane-Roberts, C. S., & Swain, V. (1950). The Function of the Breast. In Saner, F. D. (Ed.). The Breast: Structure, Function, Disease (pp. 53–86). Baltimore: Williams and Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [URL] [PDF]
  • Seal, L. (2017). Adult Endocrinology. In Richards, C., Bouman, W. P., & Barker, M.-J. (Eds.). Genderqueer and Non-Binary Genders (Critical and Applied Approaches in Sexuality, Gender and Identity) (pp. 183–223). London: Palgrave Macmillan UK. [DOI:10.1057/978-1-137-51053-2_10]
  • Seal, L. J., Franklin, S., Richards, C., Shishkareva, A., Sinclaire, C., & Barrett, J. (2012). Predictive Markers for Mammoplasty and a Comparison of Side Effect Profiles in Transwomen Taking Various Hormonal Regimens. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4422–4428. [DOI:10.1210/jc.2012-2030]
  • Seibert, B., & Günzel, P. (1994). Animal toxicity studies performed for risk assessment of the once-a-month injectable contraceptive Mesigyna®. Contraception, 49(4), 303–333. [DOI:10.1016/0010-7824(94)90030-2]
  • Shapiro, L. R. (1982). Disorders of Female Sex Differentiation. In Blaustein, A. (Ed.). Pathology of the Female Genital Tract, 2nd Edition (pp. 479–510). New York: Springer New York. [DOI:10.1007/978-1-4757-1767-9_20]
  • Shearman, R. P. (1972). Ovarian Function and its Control. In Shearman, R. P. (Ed.). Human Reproductive Physiology, 1st Edition (pp. 45–90). Oxford: Blackwell Scientific Publications. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Shearman, R. P. (1972). Primary Ammenorhoea. In Dewhurst, C. J. (Ed.). Integrated Obstetrics and Gynaecology for Postgraduates, 1st Edition (pp. 55–62). Oxford: Blackwell Scientific Publications. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • Shi, H. Y., Lydon, J. P., & Zhang, M. (2004). Hormonal Defect in Maspin Heterozygous Mice Reveals a Role of Progesterone in Pubertal Ductal Development. Molecular Endocrinology, 18(9), 2196–2207. [DOI:10.1210/me.2004-0052]
  • Shuttleworth, F. K. (1938). The Adolescent Period: A Graphic and Pictorial Atlas (Monographs of the Society for Research in Child Development, Volume 3, Number 3 / Serial No. 16). Washington, D. C.: Society for Research in Child Development. [Google Scholar] [Google Books] [DOI:10.2307/1165482]
  • Simmer, H. H., Pion, R. J., & Dignam, W. J. (1965). Testicular Feminization: Endocrine Function of Feminizing Testes, Comparison with Normal Testes. Springfield, Illinois: Thomas. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Simpson, J. L., & Rebar, R. W. (1990). Normal and Abnormal Sexual Differentiation and Development. In Becker, K. L., Bilezikian, J. P., Bremner, W. J., Hung, W., Kahn, C. R., Loriaux, D. L., Rebar, R. W., Robertson, G. L., & Wartofsky, L. (Eds.). Principles and Practice of Endocrinology and Metabolism, 1st Edition (pp. 710–739). Philadelphia: Lippincott. [Google Scholar] [Google Books—3rd/2001 Edition] [OpenLibrary] [WorldCat] [Archive.org]
  • Sindi, R., Sá Dos Reis, C., Bennett, C., Stevenson, G., & Sun, Z. (2019). Quantitative Measurements of Breast Density Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 8(5), 745. [DOI:10.3390/jcm8050745]
  • Sitruk-Ware, R., Basdevant, A., de Lignières, B., & Mauvais-Jarvis, P. (1984). Percutaneous oestrogen therapy. In van Herendael, H., van Herendael, B., Riphagen, F. E., Goessens, L., & van der Plas, H. (Eds.). The Climacteric: An Update: Proceedings of the fourth Jan Palfijn Symposium, European Conference on the Menopause, held in Antwerp, Belgium, on September 1–2, 1983, under the auspices of ‘De Vereniging voor Nederlandstalige gynecologen van België’ and ‘The International Menopause Society’ (pp. 127–139). Lancaster: MTP Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [DOI:10.1007/978-94-009-5608-7_14]
  • Sizonenko, P. C. (1978). Endocrinology in Preadolescents and Adolescents. American Journal of Diseases of Children, 132(7), 704–712. [DOI:10.1001/archpedi.1978.02120320064015]
  • Skarda, J., Fremrová, V., & Bezecný, I. (1989). Progesterone alone is responsible for stimulation of the growth of ducts and of mammary alveolar structures in mice. Endocrinologia Experimentalis, 23(1), 17–28. [Google Scholar] [PubMed] [PDF]
  • Sobrinho, L. G., Kase, N., & Grunt, J. A. (1971). Spontaneous pubertal breast growth in a castrated patient with the syndrome of testicular feminization. The Yale Journal of Biology and Medicine, 44(2), 225–9. [Google Scholar] [PubMed] [PubMed Central] [PDF]
  • Sosa, M., Jódar, E., Arbelo, E., Domínguez, C., Saavedra, P., Torres, A., Salido, E., de Tejada, M. J., & Hernández, D. (2003). Bone Mass, Bone Turnover, Vitamin D, and Estrogen Receptor Gene Polymorphisms in Male to Female Transsexuals. Journal of Clinical Densitometry, 6(3), 297–304. [DOI:10.1385/jcd:6:3:297]
  • Sosa, M., Jódar, E., Arbelo, E., Domı́nguez, C., Saavedra, P., Torres, A., Salido, E., Limiñana, J., Gómez de Tejada, M. J., & Hernández, D. (2004). Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. European Journal of Internal Medicine, 15(4), 231–237. [DOI:10.1016/j.ejim.2004.04.009]
  • Soyal, S., Ismail, P. M., Li, J., Mulac-Jericevic, B., Conneely, O. M., & Lydon, J. P. (2002). Progesterone receptors - animal models and cell signaling in breast cancer: Progesterone’s role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics. Breast Cancer Research, 4(5), 191. [DOI:10.1186/bcr451]
  • Sperling, R. L., & Gold, J. J. (1973). Use of an anti-estrogen after a reduction mammaplasty to prevent recurrence of virginal hypertrophy of breasts. Plastic and Reconstructive Surgery, 52(4), 439–442. [DOI:10.1097/00006534-197352040-00030]
  • Spitz, I. M., Shoupe, D., Sitruk-Ware, R., & Mishell, D. R. (1989). Response to the antiprogestagen RU 486 (mifepristone) during early pregnancy and the menstrual cycle in women. Journal of Reproduction and Fertility Supplement, 37, 253–260. [Google Scholar] [PubMed]
  • Spitz, I., Croxatto, H., Lahteenmaki, P., Heikinheimo, O., & Bardin, C. (1994). Effect of mifepristone on inhibition of ovulation and induction of luteolysis. Human Reproduction, 9(Suppl 1), 69–76. [DOI:10.1093/humrep/9.suppl_1.69]
  • Spitz, I. M. (2010). Mifepristone: where do we come from and where are we going? Contraception, 82(5), 442–452. [DOI:10.1016/j.contraception.2009.12.012]
  • Sridhar, G. R., & Sinha, M. J. (1995). Macromastia in adolescent girls. Indian Pediatrics, 32(4), 496–499. [Google Scholar] [PubMed] [PDF]
  • Sun, B. Z., Kangarloo, T., Adams, J. M., Sluss, P. M., Welt, C. K., Chandler, D. W., Zava, D. T., McGrath, J. A., Umbach, D. M., Hall, J. E., & Shaw, N. D. (2018). Healthy Post-Menarchal Adolescent Girls Demonstrate Multi-Level Reproductive Axis Immaturity. The Journal of Clinical Endocrinology & Metabolism, 104(2), 613–623. [DOI:10.1210/jc.2018-00595]
  • Sun, S. X., Bostanci, Z., Kass, R. B., Mancino, A. T., Rosenbloom, A. L., Klimberg, V. S., & Bland, K. I. (2018). Breast Physiology: Normal and Abnormal Development and Function. In Bland, K. I., Copeland, E. M., Klimberg, V. S., Gradishar, W. J., White, J., & Korourian, S. (Eds.). The Breast: Comprehensive Management of Benign and Malignant Diseases, 5th Edition (pp. 37–56.e6). Philadelphia: Elsevier. [DOI:10.1016/b978-0-323-35955-9.00003-9]
  • Swelstad, M. R., Swelstad, B. B., Rao, V. K., & Gutowski, K. A. (2006). Management of Gestational Gigantomastia. Plastic and Reconstructive Surgery, 118(4), 840–848. [DOI:10.1097/01.prs.0000232364.40958.47]
  • Tack, L. J., Heyse, R., Craen, M., Dhondt, K., Bossche, H. V., Laridaen, J., & Cools, M. (2017). Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents. The Journal of Sexual Medicine, 14(5), 747–757. [DOI:10.1016/j.jsxm.2017.03.251]
  • Talbert, L. M., Hammond, M. G., Groff, T., & Udry, J. R. (1985). Relationship of age and pubertal development to ovulation in adolescent girls. Obstetrics & Gynecology, 66(4), 542–544. [Google Scholar] [PubMed] [URL]
  • Tanos, T., & Brisken, C. (2008). What Signals Operate in the Mammary Niche? Breast Disease, 29(1), 69–82. [DOI:10.3233/bd-2008-29108]
  • Thanaboonyawat, I., Chanprapaph, P., Lattalapkul, J., & Rongluen, S. (2013). Pilot Study of Normal Development of Nipples during Pregnancy. Journal of Human Lactation, 29(4), 480–483. [DOI:10.1177/0890334413493350]
  • Thody, A. J., & Smith, A. G. (1977). Hormones and Skin Pigmentation in the Mammal. International Journal of Dermatology, 16(8), 657–664. [DOI:10.1111/j.1365-4362.1977.tb01876.x]
  • Thoresen, M., & Wesche, J. (1988). Doppler measurements of changes in human mammary and uterine blood flow during pregnancy and lactation. Acta Obstetricia et Gynecologica Scandinavica, 67(8), 741–745. [DOI:10.3109/00016349809004301]
  • Tiefenbacher, K., & Daxenbichler, G. (2008). The Role of Androgens in Normal and Malignant Breast Tissue. Breast Care, 3(5), 325–331. [DOI:10.1159/000158055]
  • Tim, F., Jeroen, V., & T’Sjoen, G. (2023). Dose Reduction of Cyproterone Acetate in Trans Women and the Effect on Patient-reported Outcomes: Results from the ENIGI Study. Endocrine Abstracts, 97 [Belgian Endocrine Society 2023], 5–5 (abstract no. 007). [URL] [PDF]
  • Trabert, B., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2019). Progesterone and Breast Cancer. Endocrine Reviews, 41(2), 320–344. [DOI:10.1210/endrev/bnz001]
  • Tucker, H. (2000). Hormones, Mammary Growth, and Lactation: a 41-Year Perspective. Journal of Dairy Science, 83(4), 874–884. [DOI:10.3168/jds.s0022-0302(00)74951-4]
  • Turan, S., Bereket, A., Guran, T., Akcay, T., Papari-Zareei, M., & Auchus, R. J. (2009). Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair. European Journal of Endocrinology, 160(2), 325–330. [DOI:10.1530/eje-08-0632]
  • Turner, C. W. (1939). The Mammary Glands. In Allen, E., Danforth, C. H., & Doisy, E. A. (Eds.). Sex and Internal Secretions: A Survey of Recent Research, 2nd Edition (pp. 740–803). Baltimore: Williams & Wilkins. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Ulrich, U., Pfeifer, T., & Lauritzen, C. (1994). Rapid Increase in Lumbar Spine Bone Density in Osteopenic Women by High-Dose Intramuscular Estrogen-Progestogen Injections. Hormone and Metabolic Research, 26(9), 428–431. [DOI:10.1055/s-2007-1001723]
  • Ulrich, U., Pfeifer, T., Buck, G., Keckstein, J., & Lauritzen, C. (1995). High-dose estrogen-progestogen injections in gonadal dysgenesis, ovarian hypoplasia, and androgen insensitivity syndrome: Impact on bone density. Adolescent and Pediatric Gynecology, 8(1), 20–23. [DOI:10.1016/s0932-8610(12)80156-3]
  • Valentine, G. H. (1969). Chromosome Anomalies in the Female. In Valentine, G. H. The Chromosome Disorders: An Introduction for Clinicians, 2nd Edition (pp. 126–143). London: W. Heinemann Medical Books. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat] [Archive.org]
  • van der Meulen, A. J. (1974). An unusual case of massive hypertrophy of the breasts. South African Medical Journal=Suid-Afrikaanse Tydskrif vir Geneeskunde, 48(34), 1465–1466. [Google Scholar] [PubMed] [URL 1] [URL 2]
  • Vandeweyer, E., & Hertens, D. (2002). Quantification of glands and fat in breast tissue: An experimental determination. Annals of Anatomy - Anatomischer Anzeiger, 184(2), 181–184. [DOI:10.1016/s0940-9602(02)80016-4]
  • Venturoli, S., Fabbri, R., Porcu, E., Paradisi, R., Orsini, L. F., Brondelli, L., Ruggeri, S., & Flamigni, C. (1989). Endocrine and ovarian parameters at various frequencies of ovulation in adolescents. Archives of Gynecology and Obstetrics, 246(2), 107–114. [DOI:10.1007/bf00934127]
  • Venturoli, S., Porcu, E., Fabbri, R., Magrini, O., Paradisi, R., Pallotti, G., Gammi, L., & Flamigni, C. (1987). Postmenarchal evolution of endocrine pattern and ovarian aspects in adolescents with menstrual irregularities. Fertility and Sterility, 48(1), 78–85. [DOI:10.1016/s0015-0282(16)59294-2]
  • Vorherr, H. (1974). Development of the Female Breast. In Vorherr, H. The Breast: Morphology, Physiology, and Lactation (pp. 1–19). New York: Academic Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Vorherr, H. (1974). Morphology of the Mature Female Breast. In Vorherr, H. The Breast: Morphology, Physiology, and Lactation (pp. 20–70). New York: Academic Press. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Wade, T. R., Wade, S. L., & Jones, H. E. (1978). Skin changes and diseases associated with pregnancy. Obstetrics and Gynecology, 52(2), 233–242. [Google Scholar] [PubMed] [URL]
  • Walker, M., Baker, G., & Lamb, M. (2013). Physiology of the Breast During Pregnancy and Lactation. In Mannel, R., Martens, P. J., & Walker, M. (Eds.). Core Curriculum for Lactation Consultant Practice, 3rd Edition (pp. 287–300). Burlington: Jones & Bartlett Learning. [Google Scholar] [Google Books—2013/3rd Edition] [Google Books—2008/2nd Edition] [OpenLibrary] [WorldCat]
  • Wang, C., Luan, J., Cheng, H., Chen, L., Li, Z., Panayi, A. C., & Liu, C. (2018). Menstrual Cycle-Related Fluctuations in Breast Volume Measured Using Three-Dimensional Imaging: Implications for Volumetric Evaluation in Breast Augmentation. Aesthetic Plastic Surgery, 43(1), 1–6. [DOI:10.1007/s00266-018-1243-6]
  • Wang, Q. A., & Scherer, P. E. (2019). Remodeling of Murine Mammary Adipose Tissue during Pregnancy, Lactation, and Involution. Journal of Mammary Gland Biology and Neoplasia, 24(3), 207–212. [DOI:10.1007/s10911-019-09434-2]
  • Weisberg, M. G., Malkasian, G. D., & Pratt, J. H. (1970). Testicular feminization syndrome. American Journal of Obstetrics and Gynecology, 107(8), 1181–1187. [DOI:10.1016/s0002-9378(15)30367-7]
  • Wellons, M. F., & Rebar, R. W. (2013). Amenorrhea. In Falcone, T., & Hurd, W. W. (Eds.). Clinical Reproductive Medicine and Surgery: A Practical Guide, 2nd Edition (pp. 105–112). New York: Springer New York. [DOI:10.1007/978-1-4614-6837-0_7]
  • Wellons, M. F., Weeber, K. M., & Rebar, R. W. (2017). Amenorrhea. In Falcone, T., & Hurd, W. W. (Eds.). Clinical Reproductive Medicine and Surgery, 3rd Edition (pp. 109–122). Cham: Springer International Publishing. [DOI:10.1007/978-3-319-52210-4_6]
  • Werner, A. A. (1935). Experiment to produce lactation in castrate women. Endocrinology, 19(2), 144–150. [DOI:10.1210/endo-19-2-144]
  • Whiteley, S. (1994). Predictors of Milk Production in Lactating Women. (Master’s thesis, The Open University.) [Google Scholar] [DOI:10.21954/ou.ro.0000fe02] [URL]
  • Wierckx, K., Gooren, L., & T’Sjoen, G. (2014). Clinical Review: Breast Development in Trans Women Receiving Cross-Sex Hormones. The Journal of Sexual Medicine, 11(5), 1240–1247. [DOI:10.1111/jsm.12487]
  • Wierckx, K., Van Caenegem, E., Schreiner, T., Haraldsen, I., Fisher, A., Toye, K., Kaufman, J. M., & T’Sjoen, G. (2014). Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence. The Journal of Sexual Medicine, 11(8), 1999–2011. [DOI:10.1111/jsm.12571]
  • Wilson, J. D. (1968 March 28). Medical Grand Rounds: Testicular Feminization. Parkland Memorial Hospital, UT Southwestern Medical Center. [Google Scholar] [URL] [PDF]
  • Wilson, C. L., Sims, A. H., Howell, A., Miller, C. J., & Clarke, R. B. (2006). Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocrine-Related Cancer, 13(2), 617–628. [DOI:10.1677/erc.1.01165]
  • Winkler, U. H., Schindler, A. E., Brinkmann, U. S., Ebert, C., & Oberhoff, C. (2001). Cyclic progestin therapy for the management of mastopathy and mastodynia. Gynecological Endocrinology, 15(Suppl 6), 37–43. [DOI:10.1080/gye.15.s6.37.43]
  • Wisniewski, A. B., Migeon, C. J., Meyer-Bahlburg, H. F., Gearhart, J. P., Berkovitz, G. D., Brown, T. R., & Money, J. (2000). Complete Androgen Insensitivity Syndrome: Long-Term Medical, Surgical, and Psychosexual Outcome. The Journal of Clinical Endocrinology & Metabolism, 85(8), 2664–2669. [DOI:10.1210/jcem.85.8.6742]
  • Wong, R. C., & Ellis, C. N. (1984). Physiologic skin changes in pregnancy. Journal of the American Academy of Dermatology, 10(6), 929–940. [DOI:10.1016/s0190-9622(84)80305-9]
  • Wren, B. G., & Eden, J. A. (1996). Do Progestogens Reduce The Risk of Breast Cancer? A Review of the Evidence. Menopause, 3(1), 4–12. [DOI:10.1097/00042192-199603010-00003]
  • Wright, E. M. (2015). Breastfeeding and the Mother–Newborn Dyad (pp. 1157–1182). In King, T. L., Brucker, M. C., Kriebs, J. M., Fahey, J. O., Gegor, C. L., & Varney, H. (Eds.). Varney’s Midwifery, 5th Edition. Burlington: Jones & Bartlett Learning. [Google Scholar] [Google Books] [OpenLibrary] [WorldCat]
  • Xu, P., Ye, W., Zhong, S., Li, H., Feng, E., Lin, S. H., Kuo, C. T., Liu, J. Y., & Lin, Y. C. (2010). Leptin and zeranol up-regulate cyclin D1 expression in primary cultured normal human breast pre-adipocytes. Molecular Medicine Reports, 3(6), 983–990. [DOI:10.3892/mmr.2010.370]
  • Yang, W., Hong, T., Chang, X., Han, M., Gao, H., Pan, B., Zhao, Z., & Liu, Y. (2024). The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women. International Journal of Transgender Health, advance online publication. [DOI:10.1080/26895269.2024.2323514]
  • Zacharin, M. (2000). Use of androgens and oestrogens in adolescents - A review of hormone replacement treatment. Journal of Pediatric Endocrinology and Metabolism, 13(1), 3–12. [DOI:10.1515/JPEM.2000.13.1.3]
  • Zachmann, M., Prader, A., Sobel, E. H., Crigler, J. F., Ritzén, E. M., Atarés, M., & Ferrandez, A. (1986). Pubertal growth in patients with androgen insensitivity: Indirect evidence for the importance of estrogens in pubertal growth of girls. The Journal of Pediatrics, 108(5), 694–697. [DOI:10.1016/s0022-3476(86)81043-5]
  • Żelaźniewicz, A., & Pawłowski, B. (2015). Breast size and asymmetry during pregnancy in dependence of a fetus’s sex. American Journal of Human Biology, 27(5), 690–696. [DOI:10.1002/ajhb.22716]
  • Żelaźniewicz, A., & Pawłowski, B. (2018). Maternal breast volume in pregnancy and lactation capacity. American Journal of Physical Anthropology, 168(1), 180–189. [DOI:10.1002/ajpa.23734]
  • Zhang, D., Yao, F., Tian, T., Deng, S., Luo, M., & Tian, Q. (2021). Clinical characteristics and molecular genetics of complete androgen insensitivity syndrome patients: a series study of 30 cases from a Chinese tertiary medical center. Fertility and Sterility, 115(5), 1270–1279. [DOI:10.1016/j.fertnstert.2020.12.008]
\ No newline at end of file diff --git a/transfemscience.org/articles/progestogens-sexual-desire/index.html b/transfemscience.org/articles/progestogens-sexual-desire/index.html index d124665d..bcb3fb7c 100644 --- a/transfemscience.org/articles/progestogens-sexual-desire/index.html +++ b/transfemscience.org/articles/progestogens-sexual-desire/index.html @@ -1 +1 @@ -The Influence of Progesterone and Other Progestogens on Sexual Desire and Function - Transfeminine Science Link

The Influence of Progesterone and Other Progestogens on Sexual Desire and Function

By Aly | First published January 9, 2020 | Last modified March 16, 2023

Abstract / TL;DR

Many transfeminine people believe on the basis of anecdotes that progesterone increases sexual desire. A review was conducted to assess the available evidence for the possibility that progesterone and/or progestogens increase sexual desire. Both animal studies as well as clinical studies with progesterone and progestins were considered. Progesterone has shown no indication of stimulatory effects on sexual desire or behavior in humans and non-human primates. High doses of progestogens have however been found to inhibit sexual desire in humans and non-human primates. More research is necessary to further characterize the role of progesterone and other progestogens in sexual desire in humans. In any case, available evidence does not support a positive role of these hormonal agents in sexual desire. Instead, sexual desire is more related to androgens and estrogens in men and women, respectively.

Introduction

Based on anecdotal experience, some people in the transfeminine community believe that progesterone has positive effects on sexual desire. In addition, some researchers have theorized that progesterone may be positively involved in sexual desire in women (Regan, 1999). Some people have also argued that the neurosteroid metabolites of progesterone like allopregnanolone and pregnanolone might provide special benefits on sexual desire that are not shared with progestins. I’ve reviewed the available evidence and literature to assess whether progesterone or other progestogens indeed improve sexual desire function in women and might be useful for this in transfeminine people.

Animal Studies

Correlational

Progesterone levels are strongly and consistently negatively associated with female sexual desire and behavior in most animal species (Roney, 2015). This includes in monkeys and apes (Roney, 2015).

Experimental

Non-Human Primates

Progesterone, both alone and when added to an estrogen, has been shown to inhibit sexual behavior and receptivity in female monkeys in many studies (Luttge, 1971; Baum et al., 1976; Baum et al., 1977a; Michael et al., 1967). This inhibition is often marked. Likewise, subcutaneous implants of progesterone were shown to suppress sexual behavior in testosterone-treated castrated male monkeys (Zumpe, Clancy, & Michael, 1997). As the male monkeys were castrated and treated with testosterone, this was not due to decreased testosterone levels (which remained unchanged), and could only have been due to the other effects of progesterone. Similar findings have been made for the progestin medroxyprogesterone acetate (MPA) (Michael & Zumpe, 1993; Zumpe et al., 1991; Zumpe & Michael, 1988).

The following excerpt from a review is notable on the topic of progesterone and sexual behavior in primates (Baum, 1983):

The early work of Ball (1941) and of Michael et al. (1968) showed that progesterone acts in the female rhesus monkey to reduce the likelihood of copulation. In contrast to non primate females, no facilitatory action of progesterone on any aspect of feminine sexuality has ever been convincingly demonstrated in primates.

One study in female monkeys found that MPA inhibited sexual behavior while progesterone did not (Pazol et al., 2004). However, MPA is a much more potent progestogen than progesterone, and the progesterone levels were very low (2 ng/mL). Hence, the progesterone levels in this study may have been too low for adequate physiological effect, which might explain the conflicting finding compared to other studies. Another study found increased sexual receptivity in castrated female monkeys treated with a combination of an estrogen and parenteral progesterone (Baum et al., 1977b). However, this was relative to a baseline of castration, and the changes may have only been due to the estrogen. Indeed, the same researchers reported decreased sexual receptivity with the addition of progesterone to estrogen in other studies (Baum et al., 1976; Baum et al., 1977a).

Mifepristone, a progesterone receptor antagonist, showed no apparent effect on sexual behavior in either female or male monkeys (Nadler et al., 1985).

Rodents

A notable exception when it comes to progesterone and sexual behavior in animals is female rodents, in which progesterone is stimulatory and induces lordosis (Frye, 2007). Allopregnanolone is involved in the facilitatory effects of progesterone on female sexual behavior in rodents, but has mixed effects, showing either augmentation or inhibition depending on the specifics (King, 2013; Frye, 2007). However, progesterone stimulates sexual behavior in female rodents only acutely, and is actually inhibitory with continuous administration (Pazol et al., 2004; Pazol et al., 2006). Studies in estrogen-primed intact male rats have found that progesterone given systemically does not induce lordosis (Ward et al., 1977). Interestingly however, lordosis was found to be induced in some male rats when progesterone was injected directly into a specific part of the hypothalamus (Ward et al., 1977). The prosexual effects of progesterone in female rodents may be mediated via non-genomic mechanisms, for instance actions of progesterone’s neurosteroid metabolites (Delville, 1991).

In addition to female rodents, research has found that progesterone is involved in normal sexual behavior in male rats (Witt et al., 1995; Andersen & Tufik, 2006). In male rats, castration greatly decreases levels of both testosterone and progesterone and markedly reduces sexual behavior (Witt et al., 1995). Low-dose progesterone administration, resulting in low but physiological male-range levels of progesterone, significantly restores sexual behavior (Witt et al., 1995). Additionally, when testosterone is concomitantly administered, progesterone augments the improvement caused by testosterone and is required for sexual behavior to be fully restored (Witt et al., 1995). The effects are mimicked by progestins like promegestone and blocked by the progesterone receptor antagonist mifepristone, suggesting that they are due specifically to activation of the progesterone receptor (Witt et al., 1995).

However, the findings in male rats probably do not apply to primates. As already described, mifepristone, in contrast to male rats, has no influence on sexual behavior in male monkeys (Nadler et al., 1985). Similarly, a study in castrated male monkeys given testosterone in combination with a relatively low dose of progesterone—resulting in roughly doubled progesterone levels relative to normal male levels—found no difference in sexual behavior compared to castrated male monkeys given testosterone alone (Buhl, Jensen, & Phoenix, 1978). Hence, neither progesterone receptor antagonism nor restoration of progesterone levels following castration seems to influence sexual behavior in male primates. It’s also notable that unlike in male rodents, castration doesn’t appear to reduce progesterone levels in either male monkeys (Zumpe, Clancy, & Michael, 1997) or humans (Waxman et al., 2013). As such, even if the rodent findings did apply to humans, castrated men have normal male-range progesterone levels and would in theory have all the progesterone needed to maintain sexual desire.

The findings on male-range progesterone levels and sexual behavior in male rats are also in contrast to research with higher, supraphysiological levels of progesterone (Hawley & Mosura, 2019). This degree of progesterone exposure has been shown to inhibit sexual behavior in males of most or all species examined, notably including male rats (Hawley & Mosura, 2019). This is the case regardless of influence on testosterone levels (Hawley & Mosura, 2019).

Other Species

Progestogens are used to inhibit heat in female dogs and cats (Neumann, 1978).

Clinical Research

Correlational

Progesterone levels in women are negatively associated, in some studies strongly, with sexual desire and behavior in women (Shirazi et al., 2019; Roney, 2015; Roney & Simmons, 2013; Roney & Simmons, 2016; Roney, 2019). One conflicting study reported a positive association of luteal-phase progesterone levels with initiation of sexual activity with partners, but the same researchers had contradictory findings in a subsequent study (Holder & Mong, 2017; Roney, 2015; Jones et al., 2019).

Sexual desire is progressively decreased in women during pregnancy, a state characterized by very high levels of estrogens, progesterone, and prolactin (Regan et al., 2003; Gałązka et al., 2014). However, many confounding factors exist (e.g., the other hormonal changes, or being pregnant), and hence causation of the changes can’t necessarily be attributed to progesterone. The observations do suggest that very high levels of an estrogen and progesterone may be unlikely to increase sexual desire however.

Experimental

Progestins

A 2013 meta-analysis reported that combined birth control pills, containing both ethinylestradiol and a progestogen, result in either unchanged or increased sexual desire in most women (85%) and decreased sexual desire in a small percentage of women (15%) (Pastor et al., 2013). However, changes in sexual desire seem to be related to the ethinylestradiol component rather than to the progestin component; decreased sexual desire was only associated with birth control pills containing low-dose estrogen (20 μg ethinylestradiol) (Pastor et al., 2013). The fact that combined birth control pills infrequently decrease sexual desire in women is notable because these medications suppress ovulation and hence completely prevent the increase in progesterone levels during the luteal phase. As such, progesterone levels, and by extension circulating levels of allopregnanolone and pregnanolone, remain very low at all times. This suggests little or no importance of the neurosteroid metabolites of progesterone for sexual desire in women.

The fact that combined birth control pills don’t generally affect sexual desire in women is also potentially surprising because total and free testosterone levels are greatly decreased by them due to the ethinylestradiol component (Zimmerman et al., 2014). This is, however, in accordance with accumulating evidence suggesting that physiological levels of androgens in women have little or no involvement in sexual desire (Cappelletti & Wallen, 2016). Rather than progesterone or androgens, what seems to be important for sexual desire in women is estradiol, especially acutely at periovulatory levels (Cappelletti & Wallen, 2016).

A small minority of women treated with depot medroxyprogesterone acetate (DMPA) alone for birth control report decreased libido and only 2.3% cite it as a reason for discontinuation (Schaffir, 2006). A study of 80 women treated with DMPA alone for birth control monitored sexual function and found no difference from baseline to 4 months of therapy (Schaffir, 2006). Findings have been similar for subcutaneous birth control implants with nomegestrol acetate and levonorgestrel (Schaffir, 2006). A randomized controlled trial of 150 women given combined birth control pills, progestin-only birth control pills, and placebo found no difference in sexual desire or activity between progestin-only pills and placebo (Schaffir, 2006).

The addition of a progestin to an estrogen in hormone therapy for menopausal women has been found not to improve sexual desire or function to a greater extent than an estrogen alone in individual studies (Çayan et al., 2008; Myers et al., 1990; Sherwin, 1991; Savolainen-Peltonen et al., 2014; Dennerstein et al., 1980; Alexander et al., 2004; Saadat et al., 2002; Davis et al., 2004; Modelska & Milián, 2004; Sandhu et al., 2011). A couple of studies have found that improvement in sexual desire/function is better with an estrogen alone than with an estrogen plus a progestin, suggesting that progestins might have an adverse influence (Çayan et al., 2008; Dennerstein et al., 1980; Kovalevsky, 2005; Castelo-Branco et al., 2007). Overall however, the available research suggests no change in sexual desire/function with addition of a progestin to an estrogen in menopausal hormone therapy (Sandhu et al., 2011).

Interestingly, a 2018 meta-analysis reported a higher standardized mean difference (SMD) for improvement of sexual desire/function in studies with an estrogen plus a progestogen relative to studies using an estrogen alone (Javadivala et al., 2019). However, there was differing methodology (e.g., sexual measures) and high heterogeneity across studies, as well as a limited number of included studies (particularly of estrogen only). These issues make conclusions on the basis of the differing SMDs problematic. Indeed, the finding is contradicted by individual studies that have included both estrogen only and estrogen plus progestogen groups (see the sources above).

Besides progestogenic activity, it has been suggested that androgenic progestins, like most of the testosterone derivatives, might provide better effects on sexual desire/function than non-androgenic progestins (Graziottin & Serafini, 2011). However, aside from the case of the atypical agent tibolone (Biglia et al., 2010), this has not actually been assessed or shown in any clinical trials (Schaffir, 2006).

The addition of dydrogesterone to hormone therapy for transgender women to improve sexual desire showed no effect, whereas transdermal testosterone was effective (Kronawitter et al., 2009).

A 1975 study published as an abstract with little additional information claimed that some premenopausal women with “frigidity” had high progesterone levels and that treatment with levonorgestrel alone to suppress progesterone levels could increase libido in these women (Kristoffersen & Lebech, 1975). This is very low-quality information however.

Progesterone

Available clinical studies of progesterone and sexual desire in women have observed no changes (Worsley et al., 2016). Neither 200 mg/day oral progesterone nor 10 mg/day oral MPA had any influence on mood or libido in estrogen-treated postmenopausal women in a randomized controlled trial (Saadat et al., 2002). Likewise, treatment of pharmacologically hypogonadal women with 400 mg/day vaginal progesterone suppositories alone did not significantly alter any domain of sexual function in another randomized controlled trial (Schmidt et al., 2009). Treatment of women with subcutaneous implants of progesterone alone for gynecological disorders has been reported to decrease sexual desire in an uncontrolled clinical study (Regan, 1999). Conversely, a retrospective chart review of 137 women with severe premenstrual syndrome treated during the luteal phase with 100–200+ mg/day vaginal progesterone suppositories alone for birth control reported that decreased libido was a side effect in 1 woman (0.7%) (Dalton, Guthrie, & Dalton, 1987).

One study assessed the influence on mood and libido of estradiol plus cyclic 200 mg/day oral progesterone in premenopausal women and estradiol plus cyclic 200 mg/day vaginal progesterone in perimenopausal women (Nappi et al., 2004). The premenopausal women were suffering from menstrual irregularities, depression, and sexual dysfunction, while the perimenopausal women were presumably experiencing menopausal symptoms. A significant improvement in libido, sexual arousal, and pain was observed with therapy in the premenopausal women who had a concomitant improvement in anxiety, irritability, and appetite, but not in those who remained depressed. The findings in the perimenopausal women were similar; the hormonal therapy improved sexual desire only in those who experienced improvement in anxiety, panic, and tension, but not in those in whom depression remained. The findings of this study, although interesting, are unfortunately confounded by the lack of an estradiol-only control group, and so can’t necessarily be attributed to progesterone. Moreover, the findings are confounded by the presence and alleviation of the mood symptoms, anxiety, and other problems in the women; it’s possible that estradiol and progesterone did not increase sexual desire themselves but rather it was the improvement of the other symptoms that produced the changes.

Another randomized controlled trial found that an estrogen plus 1.25 mg/day methyltestosterone and 100 mg/day oral progesterone significantly improved sexual desire and function relative to placebo in postmenopausal women (Blümel et al., 2008). However, this study was confounded by the presence of methyltestosterone and the lack of a no-progesterone control group.

Transdermal progesterone cream at a dosage of 32 mg/day had no influence on sexual desire or other parameters in postmenopausal women (Wren et al., 2003; Worsley et al., 2016).

A recent chapter in a book on progestogens included the following passage (Nadjafi-Triebsch, 2015):

Progesterone improves sexual performance in [male] rats [13]. Consequently, progesterone should also improve sexual performance in men due to similarities to human neuro-endocrine mechanisms. Indeed, patients receiving progesterone reported more frequent morning erections and distinctively improved sexual performance.

However, no source or other information (e.g., study design, route/dosage, etc.) was provided. The claim was probably based on anecdotal clinical experience. In addition, the chapter makes some problematic statements like “progesterone prevents prostate cancer” and “progesterone treats autism”, along with ample reference to low-quality unpublished clinical experience, that seriously hurt its credibility.

High-Dose Progestogens in Men

High-dose progestogen monotherapy with cyproterone acetate (CPA) or MPA is widely used to suppress sexual desire and function in men with sexual deviance, including hypersexuality, paraphilias, and sex offenses (Wiki; Codispoti, 2008). This therapy results in strong sexual suppression and is very effective. Its efficacy is thought to be due to suppression of testosterone levels. However, there is some evidence that progestogenic activity in the brain itself and/or increased prolactin levels secondary to progestogenic activity may also be involved (Zumpe, Clancy, & Michael, 1997; Rastrelli, Corona, & Maggi, 2015; Wiki). Although estrogens suppress testosterone levels and increase prolactin levels similarly to progestogens and have likewise been used in the treatment of male sexual deviance (Wiki; Wiki), they are also known to have beneficial effects on sexual desire in both women and men (Wallen et al., 1984; Wibowo, Schellhammer, & Wasserug, 2011; Cappelletti & Wallen, 2016; Santoro et al., 2016; Gilbert et al., 2017). In relation to this, estrogens may not result in the same degree of suppression of sexual desire and function as progestogens. As with CPA and MPA, progesterone alone by intramuscular injection has been found to substantially suppress sexual desire and function in men (Wiki; Regan, 1999).

Conclusion

Taken together, there appears to be little or no evidence that progesterone or other progestogens improve sexual desire or function in humans. Instead, the available evidence suggests that progestogens are likely to result in either unchanged or decreased sexual desire and function. Decreased sexual desire/function may be especially likely at high doses. In any case, more research on progestogens and sexual desire, particularly with non-oral progesterone, is warranted.

References

  • Alexander, J. L., Kotz, K., Dennerstein, L., Kutner, S. J., Wallen, K., & Notelovitz, M. (2004). The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause, 11(6), 749–765. [DOI:10.1097/01.gme.0000142887.31811.97]
  • Andersen, M. L., & Tufik, S. (2006). Does male sexual behavior require progesterone? Brain Research Reviews, 51(1), 136–143. [DOI:10.1016/j.brainresrev.2005.10.005]
  • Baum, M. J., Everitt, B. J., Herbert, J., Keverne, E. B., & de Greef, W. J. (1976). Reduction of sexual interaction in rhesus monkeys by a vaginal action of progesterone. Nature, 263(5578), 606–608. [DOI:10.1038/263606a0]
  • Baum, M. J., Everitt, B. J., Herbert, J., & Keverne, E. B. (1977). Hormonal basis of proceptivity and receptivity in female primates. Archives of Sexual Behavior, 6(3), 173–192. [DOI:10.1007/bf01541126]
  • Baum, M., Keverne, E., Everitt, B., Herbert, J., & De Greef, W. (1977). Effects of progesterone and estradiol on sexual attractivity of female rhesus monkeys. Physiology & Behavior, 18(4), 659–670. [DOI:10.1016/0031-9384(77)90064-6]
  • Baum, M. J. (1983). Hormonal Modulation of Sexuality in Female Primates. BioScience, 33(9), 578–582. [DOI:10.2307/1309209]
  • Biglia, N., Maffei, S., Lello, S., & Nappi, R. E. (2010). Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecological Endocrinology, 26(11), 804–814. [DOI:10.3109/09513590.2010.495437]
  • Blümel, J. E., Del Pino, M., Aprikian, D., Vallejo, S., Sarrá, S., & Castelo-Branco, C. (2008). Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecological Endocrinology, 24(12), 691–695. [DOI:10.1080/09513590802454919]
  • Buhl, A. (1978). Influence of progesterone on sexual behavior in castrated male rhesus monkeys treated with testosterone. Hormones and Behavior, 10(3), 258–263. [DOI:10.1016/0018-506x(78)90070-3]
  • Cappelletti, M., & Wallen, K. (2016). Increasing women’s sexual desire: The comparative effectiveness of estrogens and androgens. Hormones and Behavior, 78, 178–193. [DOI:10.1016/j.yhbeh.2015.11.003]
  • Castelo-Branco, C., Cancelo, M. J., & Chedraui, P. (2007). Female sexual dysfunction in postmenopausal women. Expert Opinion on Therapeutic Patents, 17(6), 639–647. [DOI:10.1517/13543776.17.6.639]
  • Çayan, F., Dilek, U., Pata, Ö., & Dilek, S. (2008). Comparison of the Effects of Hormone Therapy Regimens, Oral and Vaginal Estradiol, Estradiol+Drospirenone and Tibolone, on Sexual Function in Healthy Postmenopausal Women. The Journal of Sexual Medicine, 5(1), 132–138. [DOI:10.1111/j.1743-6109.2007.00635.x]
  • Codispoti, V. L. (2008). Pharmacology of Sexually Compulsive Behavior. Psychiatric Clinics of North America, 31(4), 671–679. [DOI:10.1016/j.psc.2008.06.002]
  • Dalton, M. E., Guthrie, K. A., & Dalton, K. (1987). A preliminary study into the efficacy of progesterone suppositories as a contraceptive for women with severe premenstrual syndrome. The British Journal of Family Planning, 13(3), 87–89. [Google Scholar] [PDF]
  • Davis, S. R., Guay, A. T., Shifren, J. L., & Mazer, N. A. (2004). Endocrine Aspects of Female Sexual Dysfunction. The Journal of Sexual Medicine, 1(1), 82–86. [DOI:10.1111/j.1743-6109.2004.10112.x]
  • Delville, Y. (1991). Progesterone-facilitated sexual receptivity: A review of arguments supporting a nongenomic mechanism. Neuroscience & Biobehavioral Reviews, 15(3), 407–414. [DOI:10.1016/s0149-7634(05)80033-8]
  • Dennerstein, L., Burrows, G. D., Wood, C., & Hyman, G. (1980). Hormones and sexuality: effect of estrogen and progestogen. Obstetrics & Gynecology, 56(3), 316–322. [Google Scholar] [PubMed] [URL] [PDF]
  • Frye, C. A. (2007). Progestins influence motivation, reward, conditioning, stress, and/or response to drugs of abuse. Pharmacology Biochemistry and Behavior, 86(2), 209–219. [DOI:10.1016/j.pbb.2006.07.033]
  • Gałązka, I., Drosdzol-Cop, A., Naworska, B., Czajkowska, M., & Skrzypulec-Plinta, V. (2015). Changes in the Sexual Function During Pregnancy. The Journal of Sexual Medicine, 12(2), 445–454. [DOI:10.1111/jsm.12747]
  • Gilbert, D. C., Duong, T., Kynaston, H. G., Alhasso, A. A., Cafferty, F. H., Rosen, S. D., Kanaga-Sundaram, S., Dixit, S., Laniado, M., Madaan, S., Collins, G., Pope, A., Welland, A., Nankivell, M., Wassersug, R., Parmar, M. K., Langley, R. E., & Abel, P. D. (2016). Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU International, 119(5), 667–675. [DOI:10.1111/bju.13687]
  • Graziottin, A., & Serafini, A. (2011). Medical Treatments for Sexual Problems in Women. In Mulhall, J. P., Incrocci, L., Goldstein, I., & Rosen, R. (Eds.). Cancer and Sexual Health (pp. 627–641). Totowa, New Jersey: Humana Press. [DOI:10.1007/978-1-60761-916-1_40]
  • Hawley, W. R., & Mosura, D. E. (2019). Effects of progesterone treatment during adulthood on consummatory and motivational aspects of sexual behavior in male rats. Behavioural Pharmacology, 30(7), 617–622. [DOI:10.1097/fbp.0000000000000490]
  • Holder, M. K., & Mong, J. A. (2017). The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation. Current Sexual Health Reports, 9(4), 262–270. [DOI:10.1007/s11930-017-0131-4]
  • Javadivala, Z., Merghati-Khoei, E., Asghari Jafarabadi, M., Allahverdipour, H., Mirghafourvand, M., Nadrian, H., & Kouzekanani, K. (2018). Efficacy of pharmacological and non-pharmacological interventions on low sexual interest/arousal of peri- and post-menopausal women: a meta-analysis. Sexual and Relationship Therapy, 34(2), 242–270. [DOI:10.1080/14681994.2018.1446515]
  • Jones, B. C., Hahn, A. C., & DeBruine, L. M. (2019). Ovulation, Sex Hormones, and Women’s Mating Psychology. Trends in Cognitive Sciences, 23(1), 51–62. [DOI:10.1016/j.tics.2018.10.008]
  • King, S. R. (2012). Neurosteroids and the Nervous System. In King, S. R. Neurosteroids and the Nervous System (pp. 1–122). New York: Springer New York. [DOI:10.1007/978-1-4614-5559-2_1]
  • Kovalevsky, G. (2005). Female Sexual Dysfunction and Use of Hormone Therapy in Postmenopausal Women. Seminars in Reproductive Medicine, 23(2), 180–187. [DOI:10.1055/s-2005-869486]
  • Kristoffersen, K., & Lebech, P. E. (1975). May Hyperprogesteronaemia Cause Frigidity? Acta Obstetricia et Gynecologica Scandinavica, 54(S47), 42–42. [DOI:10.3109/00016347509158744]
  • Kronawitter, D., Gooren, L. J., Zollver, H., Oppelt, P. G., Beckmann, M. W., Dittrich, R., & Mueller, A. (2009). Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. European Journal of Endocrinology, 161(2), 363–368. [DOI:10.1530/eje-09-0265]
  • Luttge, W. G. (1971). The role of gonadal hormones in the sexual behavior of the rhesus monkey and human: A literature survey. Archives of Sexual Behavior, 1(1), 61–88. [DOI:10.1007/bf01540937]
  • Michael, R. P., Saayman, G. S., & Zumpe, D. (1967). Inhibition of sexual receptivity by progesterone in rhesus monkeys. Journal of Endocrinology, 39(2), 309–310. [DOI:10.1677/joe.0.0390309]
  • Michael, R. P., & Zumpe, D. (1993). Medroxyprogesterone acetate decreases the sexual activity of male cynomolgus monkeys (Macaca fascicularis): An action on the brain? Physiology & Behavior, 53(4), 783–788. [DOI:10.1016/0031-9384(93)90189-m]
  • Modelska, K., & Milián, M. L. (2004). Treatment of female sexual dysfunction in postmenopausal women—What is the evidence? Reviews in Gynaecological Practice, 4(2), 121–132. [DOI:10.1016/j.rigp.2004.01.001]
  • Myers, L. S., Dixen, J., Morrissette, D., Carmichael, M., & Davidson, J. M. (1990). Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 70(4), 1124–1131. [DOI:10.1210/jcem-70-4-1124]
  • Nadjafi-Triebsch, C. (2015). Progestogens in Non-gynecological Indications. In Carp, H. J. A. (Ed.). Progestogens in Obstetrics and Gynecology (pp. 191–202). Cham: Springer International Publishing. [DOI:10.1007/978-3-319-14385-9_14]
  • Nadler, R. D., Roth-Meyer, C., & Baulieu, E.-E. (1985). Behavioral and Endocrine Consequences of Long-Term Antiprogesterone (RU 486) Administration to Cynomolgus Monkeys: Preliminary Results. In Baulieu, E.-E., & Segal, S. J. (Eds.). The Antiprogestin Steroid RU 486 and Human Fertility Control (pp. 169–177). Boston: Springer US. [DOI:10.1007/978-1-4684-1242-0_14]
  • Nappi, R. E., Sommacal, A., Sances, G., Abbiati, I., Ferdeghini, F., Vercesi, C., Albani, F., & Polatti, F. (2004). Progesterone supplementation on mood and sexual well-being. Gynecological Endocrinology, 18(Suppl 1 [Abstracts of the 11th World Congress of Gynecological Endocrinology, Florence, Italy, February 26-29, 2004]), 133–134 (abstract no. S9). [Google Scholar] [PubMed] [URL] [PDF]
  • Neumann, F. (1978). The physiological action of progesterone and the pharmacological effects of progestogens – a short review. Postgraduate Medical Journal, 54(Suppl 2), 11–24. [Google Scholar] [PubMed] [PDF]
  • Pastor, Z., Holla, K., & Chmel, R. (2013). The influence of combined oral contraceptives on female sexual desire: A systematic review. The European Journal of Contraception & Reproductive Health Care, 18(1), 27–43. [DOI:10.3109/13625187.2012.728643]
  • Pazol, K., Wilson, M. E., & Wallen, K. (2004). Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques. The Journal of Clinical Endocrinology & Metabolism, 89(6), 2998–3006. [DOI:10.1210/jc.2003-032086]
  • Pazol, K., Northcutt, K. V., Wilson, M. E., & Wallen, K. (2006). Medroxyprogesterone acetate acutely facilitates and sequentially inhibits sexual behavior in female rats. Hormones and Behavior, 49(1), 105–113. [DOI:10.1016/j.yhbeh.2005.05.008]
  • Rastrelli, G., Corona, G., & Maggi, M. (2015). The role of prolactin in andrology: what is new? Reviews in Endocrine and Metabolic Disorders, 16(3), 233–248. [DOI:10.1007/s11154-015-9322-3]
  • Regan, P. C. (1999). Hormonal correlates and causes of sexual desire: A review. The Canadian Journal of Human Sexuality, 8(1), 1–16. [Google Scholar] [URL] [PDF 1] [PDF 2]
  • Regan, P. C., Lyle, J. L., Otto, A. L., & Joshi, A. (2003). Pregnancy and changes in female sexual desire: a review. Social Behavior and Personality, 31(6), 603–611. [DOI:10.2224/sbp.2003.31.6.603]
  • Roney, J. R., & Simmons, Z. L. (2013). Hormonal predictors of sexual motivation in natural menstrual cycles. Hormones and Behavior, 63(4), 636–645. [DOI:10.1016/j.yhbeh.2013.02.013]
  • Roney, J. R. (2014). An Evolutionary Functional Analysis of the Hormonal Predictors of Women’s Sexual Motivation. In Shackelford, T. K., & Hansen, R. D. (Eds.). The Evolution of Sexuality (pp. 99–121). Cham: Springer International Publishing. [DOI:10.1007/978-3-319-09384-0_6]
  • Roney, J. R., & Simmons, Z. L. (2016). Within-cycle fluctuations in progesterone negatively predict changes in both in-pair and extra-pair desire among partnered women. Hormones and Behavior, 81, 45–52. [DOI:10.1016/j.yhbeh.2016.03.008]
  • Roney, J. R. (2019). Evolutionary Perspectives on Hypoactive Sexual Desire Disorder in Women. Current Sexual Health Reports, 11(4), 243–250. [DOI:10.1007/s11930-019-00223-w]
  • Saadat, P., Boostanfar, R., Poysky, J., Munevar, C., Stanczyk, F., Buckwalter, G., & Roy, S. (2002). A randomized prospective study comparing the effects of micronized progesterone and medroxyprogesterone acetate on mood and libido. Fertility and Sterility, 77(Suppl 3 [Abstracts of the 50th Annual Meeting of the Pacific Coast Reproductive Society. April 17-21, 2002. Rancho Mirage, California, USA]), S21–S21 (abstract no. P-28). [Google Scholar] [PubMed] [DOI:10.1016/s0015-0282(02)03053-4]
  • Sandhu, K. S., Melman, A., & Mikhail, M. S. (2011). Impact of Hormones on Female Sexual Function and Dysfunction. Female Pelvic Medicine & Reconstructive Surgery, 17(1), 8–16. [DOI:10.1097/spv.0b013e318204491f]
  • Santoro, N., Worsley, R., Miller, K. K., Parish, S. J., & Davis, S. R. (2016). Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. The Journal of Sexual Medicine, 13(3), 305–316. [DOI:10.1016/j.jsxm.2015.11.015]
  • Savolainen-Peltonen, H., Hautamäki, H., Tuomikoski, P., Ylikorkala, O., & Mikkola, T. S. (2014). Health-related quality of life in women with or without hot flashes. Menopause, 21(7), 732–739. [DOI:10.1097/gme.0000000000000120]
  • Schaffir, J. (2006). Hormonal Contraception and Sexual Desire: A Critical Review. Journal of Sex & Marital Therapy, 32(4), 305–314. [DOI:10.1080/00926230600666311]
  • Schmidt, P. J., Steinberg, E. M., Negro, P. P., Haq, N., Gibson, C., & Rubinow, D. R. (2008). Pharmacologically Induced Hypogonadism and Sexual Function in Healthy Young Women and Men. Neuropsychopharmacology, 34(3), 565–576. [DOI:10.1038/npp.2008.24]
  • Sherwin, B. B. (1991). The Impact of Different Doses of Estrogen and Progestin on Mood and Sexual Behavior in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 72(2), 336–343. [DOI:10.1210/jcem-72-2-336]
  • Shirazi, T. N., Self, H., Dawood, K., Rosenfield, K. A., Penke, L., Carré, J. M., Ortiz, T., & Puts, D. A. (2019). Hormonal predictors of women’s sexual motivation. Evolution and Human Behavior, 40(3), 336–344. [DOI:10.1016/j.evolhumbehav.2019.02.002]
  • Wallen, K. (1984). Periovulatory changes in female sexual behavior and patterns of ovarian steroid secretion in group-living rhesus monkeys. Hormones and Behavior, 18(4), 431–450. [DOI:10.1016/0018-506x(84)90028-x]
  • Ward, I. L., Franck, J. E., & Crowley, W. R. (1977). Central progesterone induces female sexual behavior in estrogen-primed intact male rats. Journal of Comparative and Physiological Psychology, 91(6), 1417–1423. [DOI:10.1037/h0077419]
  • Waxman, J. H., Wass, J. A., Hendry, W. F., Whitfield, H. N., Bary, P., Besser, G. M., Malpas, J. S., & Oliver, R. T. (1983). Treatment of Advanced Prostatic Cancer with Buserelin, an Analogue of Gonadotrophin Releasing Hormone. British Journal of Urology, 55(6), 737–742. [DOI:10.1111/j.1464-410x.1983.tb03416.x]
  • Wibowo, E., Schellhammer, P., & Wassersug, R. J. (2011). Role of Estrogen in Normal Male Function: Clinical Implications for Patients With Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology, 185(1), 17–23. [DOI:10.1016/j.juro.2010.08.094]
  • Witt, D. M., Young, L. J., & Crews, D. (1995). Progesterone modulation of androgen-dependent sexual behavior in male rats. Physiology & Behavior, 57(2), 307–313. [DOI:10.1016/0031-9384(94)00247-3]
  • Worsley, R., Santoro, N., Miller, K. K., Parish, S. J., & Davis, S. R. (2016). Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens—Findings From the Fourth International Consultation on Sexual Medicine. The Journal of Sexual Medicine, 13(3), 283–290. [DOI:10.1016/j.jsxm.2015.12.014]
  • Wren, B. G., Champion, S. M., Willetts, K., Manga, R. Z., & Eden, J. A. (2003). Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause, 10(1), 13–18. [DOI:10.1097/00042192-200310010-00004]
  • Zimmerman, Y., Eijkemans, M. J., Coelingh Bennink, H. J., Blankenstein, M. A., & Fauser, B. C. (2013). The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update, 20(1), 76–105. [DOI:10.1093/humupd/dmt038]
  • Zumpe, D., & Michael, R. P. (1988). Effects of medroxyprogesterone acetate on plasma testosterone and sexual behavior in male cynomolgus monkeys (Macaca fascicularis). Physiology & Behavior, 42(4), 343–349. [DOI:10.1016/0031-9384(88)90275-2]
  • Zumpe, D. (1991). Medroxyprogesterone acetate, aggression, and sexual behavior in male cynomolgus monkeys (Macaca fascicularis). Hormones and Behavior, 25(3), 394–409. [DOI:10.1016/0018-506x(91)90010-f]
  • Zumpe, D., Clancy, A. N., & Michael, R. P. (1997). Effects of Progesterone on the Sexual Behavior of Castrated, Testosterone-Treated Male Cynomolgus Monkeys (Macaca Fascicularis). Physiology & Behavior, 62(1), 61–67. [DOI:10.1016/s0031-9384(97)00135-2]
\ No newline at end of file +The Influence of Progesterone and Other Progestogens on Sexual Desire and Function - Transfeminine Science Link

The Influence of Progesterone and Other Progestogens on Sexual Desire and Function

By Aly | First published January 9, 2020 | Last modified March 22, 2024

Abstract / TL;DR

Many transfeminine people believe on the basis of anecdotes that progesterone increases sexual desire. A review was conducted to assess the available evidence for the possibility that progesterone and/or progestogens increase sexual desire. Both animal studies as well as clinical studies with progesterone and progestins were considered. Progesterone has shown no indication of stimulatory effects on sexual desire or behavior in humans and non-human primates. High doses of progestogens have however been found to inhibit sexual desire in humans and non-human primates. More research is necessary to further characterize the role of progesterone and other progestogens in sexual desire in humans. In any case, available evidence does not support a positive role of these hormonal agents in sexual desire. Instead, sexual desire is more related to androgens and estrogens in men and women, respectively.

Introduction

Based on anecdotal experience, some people in the transfeminine community believe that progesterone has positive effects on sexual desire. This is such that even memes about progesterone and libido have been made (Reddit). In addition to anecdotes, some researchers have theorized that progesterone may be positively involved in sexual desire in cisgender women (Regan, 1999). Some have also argued that the neurosteroid metabolites of progesterone like allopregnanolone and pregnanolone may provide special benefits on sexual desire that are not shared with progestins. I’ve reviewed the available evidence and literature to assess whether progesterone or other progestogens indeed improve sexual desire function in cisgender women and might be useful for this in transfeminine people.

Animal Studies

Correlational

Progesterone levels are strongly and consistently negatively associated with female sexual desire and behavior in most animal species (Roney, 2015). This includes in monkeys and apes (Roney, 2015).

Experimental

Non-Human Primates

Progesterone, both alone and when added to an estrogen, has been shown to inhibit sexual behavior and receptivity in female monkeys in many studies (Luttge, 1971; Baum et al., 1976; Baum et al., 1977a; Michael et al., 1967). This inhibition is often marked. Likewise, subcutaneous implants of progesterone were shown to suppress sexual behavior in testosterone-treated castrated male monkeys (Zumpe, Clancy, & Michael, 1997). As the male monkeys were castrated and treated with testosterone, this was not due to decreased testosterone levels (which remained unchanged), and could only have been due to the other effects of progesterone. Similar findings have been made for the progestin medroxyprogesterone acetate (MPA) (Michael & Zumpe, 1993; Zumpe et al., 1991; Zumpe & Michael, 1988).

The following excerpt from a review is notable on the topic of progesterone and sexual behavior in primates (Baum, 1983):

The early work of Ball (1941) and of Michael et al. (1968) showed that progesterone acts in the female rhesus monkey to reduce the likelihood of copulation. In contrast to non primate females, no facilitatory action of progesterone on any aspect of feminine sexuality has ever been convincingly demonstrated in primates.

One study in female monkeys found that MPA inhibited sexual behavior while progesterone did not (Pazol et al., 2004). However, MPA is a much more potent progestogen than progesterone, and the progesterone levels were very low (2 ng/mL). Hence, the progesterone levels in this study may have been too low for adequate physiological effect, which might explain the conflicting finding compared to other studies. Another study found increased sexual receptivity in castrated female monkeys treated with a combination of an estrogen and parenteral progesterone (Baum et al., 1977b). However, this was relative to a baseline of castration, and the changes may have only been due to the estrogen. Indeed, the same researchers reported decreased sexual receptivity with the addition of progesterone to estrogen in other studies (Baum et al., 1976; Baum et al., 1977a).

Mifepristone, a progesterone receptor antagonist, showed no apparent effect on sexual behavior in either female or male monkeys (Nadler et al., 1985).

Rodents

A notable exception when it comes to progesterone and sexual behavior in animals is female rodents, in which progesterone is stimulatory and induces lordosis (Frye, 2007). Allopregnanolone is involved in the facilitatory effects of progesterone on female sexual behavior in rodents, but has mixed effects, showing either augmentation or inhibition depending on the specifics (King, 2013; Frye, 2007). However, progesterone stimulates sexual behavior in female rodents only acutely, and is actually inhibitory with continuous administration (Pazol et al., 2004; Pazol et al., 2006). Studies in estrogen-primed intact male rats have found that progesterone given systemically does not induce lordosis (Ward et al., 1977). Interestingly however, lordosis was found to be induced in some male rats when progesterone was injected directly into a specific part of the hypothalamus (Ward et al., 1977). The prosexual effects of progesterone in female rodents may be mediated via non-genomic mechanisms, for instance actions of progesterone’s neurosteroid metabolites (Delville, 1991).

In addition to female rodents, research has found that progesterone is involved in normal sexual behavior in male rats (Witt et al., 1995; Andersen & Tufik, 2006). In male rats, castration greatly decreases levels of both testosterone and progesterone and markedly reduces sexual behavior (Witt et al., 1995). Low-dose progesterone administration, resulting in low but physiological male-range levels of progesterone, significantly restores sexual behavior (Witt et al., 1995). Additionally, when testosterone is concomitantly administered, progesterone augments the improvement caused by testosterone and is required for sexual behavior to be fully restored (Witt et al., 1995). The effects are mimicked by progestins like promegestone and blocked by the progesterone receptor antagonist mifepristone, suggesting that they are due specifically to activation of the progesterone receptor (Witt et al., 1995).

However, the findings in male rats probably do not apply to primates. As already described, mifepristone, in contrast to male rats, has no influence on sexual behavior in male monkeys (Nadler et al., 1985). Similarly, a study in castrated male monkeys given testosterone in combination with a relatively low dose of progesterone—resulting in roughly doubled progesterone levels relative to normal male levels—found no difference in sexual behavior compared to castrated male monkeys given testosterone alone (Buhl, Jensen, & Phoenix, 1978). Hence, neither progesterone receptor antagonism nor restoration of progesterone levels following castration seems to influence sexual behavior in male primates. It’s also notable that unlike in male rodents, castration doesn’t appear to reduce progesterone levels in either male monkeys (Zumpe, Clancy, & Michael, 1997) or humans (Waxman et al., 2013). As such, even if the rodent findings did apply to humans, castrated men have normal male-range progesterone levels and would in theory have all the progesterone needed to maintain sexual desire.

The findings on male-range progesterone levels and sexual behavior in male rats are also in contrast to research with higher, supraphysiological levels of progesterone (Hawley & Mosura, 2019). This degree of progesterone exposure has been shown to inhibit sexual behavior in males of most or all species examined, notably including male rats (Hawley & Mosura, 2019). This is the case regardless of influence on testosterone levels (Hawley & Mosura, 2019).

Other Species

Progestogens are used to inhibit heat in female dogs and cats (Neumann, 1978).

Clinical Research

Correlational

Progesterone levels in women are negatively associated, in some studies strongly, with sexual desire and behavior in women (Shirazi et al., 2019; Roney, 2015; Roney & Simmons, 2013; Roney & Simmons, 2016; Roney, 2019). One conflicting study reported a positive association of luteal-phase progesterone levels with initiation of sexual activity with partners, but the same researchers had contradictory findings in a subsequent study (Holder & Mong, 2017; Roney, 2015; Jones et al., 2019).

Sexual desire is progressively decreased in women during pregnancy, a state characterized by very high levels of estrogens, progesterone, and prolactin (Regan et al., 2003; Gałązka et al., 2014). However, many confounding factors exist (e.g., the other hormonal changes, or being pregnant), and hence causation of the changes can’t necessarily be attributed to progesterone. The observations do suggest that very high levels of an estrogen and progesterone may be unlikely to increase sexual desire however.

Experimental

Progestins

A 2013 meta-analysis reported that combined birth control pills, containing both ethinylestradiol and a progestogen, result in either unchanged or increased sexual desire in most women (85%) and decreased sexual desire in a small percentage of women (15%) (Pastor et al., 2013). However, changes in sexual desire seem to be related to the ethinylestradiol component rather than to the progestin component; decreased sexual desire was only associated with birth control pills containing low-dose estrogen (20 μg ethinylestradiol) (Pastor et al., 2013). The fact that combined birth control pills infrequently decrease sexual desire in women is notable because these medications suppress ovulation and hence completely prevent the increase in progesterone levels during the luteal phase. As such, progesterone levels, and by extension circulating levels of allopregnanolone and pregnanolone, remain very low at all times. This suggests little or no importance of the neurosteroid metabolites of progesterone for sexual desire in women.

The fact that combined birth control pills don’t generally affect sexual desire in women is also potentially surprising because total and free testosterone levels are greatly decreased by them due to the ethinylestradiol component (Zimmerman et al., 2014). This is, however, in accordance with accumulating evidence suggesting that physiological levels of androgens in women have little or no involvement in sexual desire (Cappelletti & Wallen, 2016). Rather than progesterone or androgens, what seems to be important for sexual desire in women is estradiol, especially acutely at periovulatory levels (Cappelletti & Wallen, 2016).

A small minority of women treated with depot medroxyprogesterone acetate (DMPA) alone for birth control report decreased libido and only 2.3% cite it as a reason for discontinuation (Schaffir, 2006). A study of 80 women treated with DMPA alone for birth control monitored sexual function and found no difference from baseline to 4 months of therapy (Schaffir, 2006). Findings have been similar for subcutaneous birth control implants with nomegestrol acetate and levonorgestrel (Schaffir, 2006). A randomized controlled trial of 150 women given combined birth control pills, progestin-only birth control pills, and placebo found no difference in sexual desire or activity between progestin-only pills and placebo (Schaffir, 2006).

The addition of a progestin to an estrogen in hormone therapy for menopausal women has been found not to improve sexual desire or function to a greater extent than an estrogen alone in individual studies (Çayan et al., 2008; Myers et al., 1990; Sherwin, 1991; Savolainen-Peltonen et al., 2014; Dennerstein et al., 1980; Alexander et al., 2004; Saadat et al., 2002; Davis et al., 2004; Modelska & Milián, 2004; Sandhu et al., 2011). A couple of studies have found that improvement in sexual desire/function is better with an estrogen alone than with an estrogen plus a progestin, suggesting that progestins might have an adverse influence (Çayan et al., 2008; Dennerstein et al., 1980; Kovalevsky, 2005; Castelo-Branco et al., 2007). Overall however, the available research suggests no change in sexual desire/function with addition of a progestin to an estrogen in menopausal hormone therapy (Sandhu et al., 2011).

Interestingly, a 2018 meta-analysis reported a higher standardized mean difference (SMD) for improvement of sexual desire/function in studies with an estrogen plus a progestogen relative to studies using an estrogen alone (Javadivala et al., 2019). However, there was differing methodology (e.g., sexual measures) and high heterogeneity across studies, as well as a limited number of included studies (particularly of estrogen only). These issues make conclusions on the basis of the differing SMDs problematic. Indeed, the finding is contradicted by individual studies that have included both estrogen only and estrogen plus progestogen groups (see the sources above).

Besides progestogenic activity, it has been suggested that androgenic progestins, like most of the testosterone derivatives, might provide better effects on sexual desire/function than non-androgenic progestins (Graziottin & Serafini, 2011). However, aside from the case of the atypical agent tibolone (Biglia et al., 2010), this has not actually been assessed or shown in any clinical trials (Schaffir, 2006).

The addition of dydrogesterone to hormone therapy for transgender women to improve sexual desire showed no effect, whereas transdermal testosterone was effective (Kronawitter et al., 2009).

A 1975 study published as an abstract with little additional information claimed that some premenopausal women with “frigidity” had high progesterone levels and that treatment with levonorgestrel alone to suppress progesterone levels could increase libido in these women (Kristoffersen & Lebech, 1975). This is very low-quality information however.

Progesterone

Available clinical studies of progesterone and sexual desire in women have observed no changes (Worsley et al., 2016). Neither 200 mg/day oral progesterone nor 10 mg/day oral MPA had any influence on mood or libido in estrogen-treated postmenopausal women in a randomized controlled trial (Saadat et al., 2002). Likewise, treatment of pharmacologically hypogonadal women with 400 mg/day vaginal progesterone suppositories alone did not significantly alter any domain of sexual function in another randomized controlled trial (Schmidt et al., 2009). Treatment of women with subcutaneous implants of progesterone alone for gynecological disorders has been reported to decrease sexual desire in an uncontrolled clinical study (Regan, 1999). Conversely, a retrospective chart review of 137 women with severe premenstrual syndrome treated during the luteal phase with 100–200+ mg/day vaginal progesterone suppositories alone for birth control reported that decreased libido was a side effect in 1 woman (0.7%) (Dalton, Guthrie, & Dalton, 1987).

One study assessed the influence on mood and libido of estradiol plus cyclic 200 mg/day oral progesterone in premenopausal women and estradiol plus cyclic 200 mg/day vaginal progesterone in perimenopausal women (Nappi et al., 2004). The premenopausal women were suffering from menstrual irregularities, depression, and sexual dysfunction, while the perimenopausal women were presumably experiencing menopausal symptoms. A significant improvement in libido, sexual arousal, and pain was observed with therapy in the premenopausal women who had a concomitant improvement in anxiety, irritability, and appetite, but not in those who remained depressed. The findings in the perimenopausal women were similar; the hormonal therapy improved sexual desire only in those who experienced improvement in anxiety, panic, and tension, but not in those in whom depression remained. The findings of this study, although interesting, are unfortunately confounded by the lack of an estradiol-only control group, and so can’t necessarily be attributed to progesterone. Moreover, the findings are confounded by the presence and alleviation of the mood symptoms, anxiety, and other problems in the women; it’s possible that estradiol and progesterone did not increase sexual desire themselves but rather it was the improvement of the other symptoms that produced the changes.

Another randomized controlled trial found that an estrogen plus 1.25 mg/day methyltestosterone and 100 mg/day oral progesterone significantly improved sexual desire and function relative to placebo in postmenopausal women (Blümel et al., 2008). However, this study was confounded by the presence of methyltestosterone and the lack of a no-progesterone control group.

Transdermal progesterone cream at a dosage of 32 mg/day had no influence on sexual desire or other parameters in postmenopausal women (Wren et al., 2003; Worsley et al., 2016).

A recent chapter in a book on progestogens included the following passage (Nadjafi-Triebsch, 2015):

Progesterone improves sexual performance in [male] rats [13]. Consequently, progesterone should also improve sexual performance in men due to similarities to human neuro-endocrine mechanisms. Indeed, patients receiving progesterone reported more frequent morning erections and distinctively improved sexual performance.

However, no source or other information (e.g., study design, route/dosage, etc.) was provided. The claim was probably based on anecdotal clinical experience. In addition, the chapter makes some problematic statements like “progesterone prevents prostate cancer” and “progesterone treats autism”, along with ample reference to low-quality unpublished clinical experience, that seriously hurt its credibility.

High-Dose Progestogens in Men

High-dose progestogen monotherapy with cyproterone acetate (CPA) or MPA is widely used to suppress sexual desire and function in men with sexual deviance, including hypersexuality, paraphilias, and sex offenses (Wiki; Codispoti, 2008). This therapy results in strong sexual suppression and is very effective. Its efficacy is thought to be due to suppression of testosterone levels. However, there is some evidence that progestogenic activity in the brain itself and/or increased prolactin levels secondary to progestogenic activity may also be involved (Zumpe, Clancy, & Michael, 1997; Rastrelli, Corona, & Maggi, 2015; Wiki). Although estrogens suppress testosterone levels and increase prolactin levels similarly to progestogens and have likewise been used in the treatment of male sexual deviance (Wiki; Wiki), they are also known to have beneficial effects on sexual desire in both women and men (Wallen et al., 1984; Wibowo, Schellhammer, & Wasserug, 2011; Cappelletti & Wallen, 2016; Santoro et al., 2016; Gilbert et al., 2017). In relation to this, estrogens may not result in the same degree of suppression of sexual desire and function as progestogens. As with CPA and MPA, progesterone alone by intramuscular injection has been found to substantially suppress sexual desire and function in men (Wiki; Regan, 1999).

Conclusion

Taken together, there appears to be little or no evidence that progesterone or other progestogens improve sexual desire or function in humans. Instead, the available evidence suggests that progestogens are likely to result in either unchanged or decreased sexual desire and function. Decreased sexual desire/function may be especially likely at high doses. In any case, more research on progestogens and sexual desire, particularly with non-oral progesterone, is warranted.

References

  • Alexander, J. L., Kotz, K., Dennerstein, L., Kutner, S. J., Wallen, K., & Notelovitz, M. (2004). The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause, 11(6), 749–765. [DOI:10.1097/01.gme.0000142887.31811.97]
  • Andersen, M. L., & Tufik, S. (2006). Does male sexual behavior require progesterone? Brain Research Reviews, 51(1), 136–143. [DOI:10.1016/j.brainresrev.2005.10.005]
  • Baum, M. J., Everitt, B. J., Herbert, J., Keverne, E. B., & de Greef, W. J. (1976). Reduction of sexual interaction in rhesus monkeys by a vaginal action of progesterone. Nature, 263(5578), 606–608. [DOI:10.1038/263606a0]
  • Baum, M. J., Everitt, B. J., Herbert, J., & Keverne, E. B. (1977). Hormonal basis of proceptivity and receptivity in female primates. Archives of Sexual Behavior, 6(3), 173–192. [DOI:10.1007/bf01541126]
  • Baum, M., Keverne, E., Everitt, B., Herbert, J., & De Greef, W. (1977). Effects of progesterone and estradiol on sexual attractivity of female rhesus monkeys. Physiology & Behavior, 18(4), 659–670. [DOI:10.1016/0031-9384(77)90064-6]
  • Baum, M. J. (1983). Hormonal Modulation of Sexuality in Female Primates. BioScience, 33(9), 578–582. [DOI:10.2307/1309209]
  • Biglia, N., Maffei, S., Lello, S., & Nappi, R. E. (2010). Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecological Endocrinology, 26(11), 804–814. [DOI:10.3109/09513590.2010.495437]
  • Blümel, J. E., Del Pino, M., Aprikian, D., Vallejo, S., Sarrá, S., & Castelo-Branco, C. (2008). Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecological Endocrinology, 24(12), 691–695. [DOI:10.1080/09513590802454919]
  • Buhl, A. (1978). Influence of progesterone on sexual behavior in castrated male rhesus monkeys treated with testosterone. Hormones and Behavior, 10(3), 258–263. [DOI:10.1016/0018-506x(78)90070-3]
  • Cappelletti, M., & Wallen, K. (2016). Increasing women’s sexual desire: The comparative effectiveness of estrogens and androgens. Hormones and Behavior, 78, 178–193. [DOI:10.1016/j.yhbeh.2015.11.003]
  • Castelo-Branco, C., Cancelo, M. J., & Chedraui, P. (2007). Female sexual dysfunction in postmenopausal women. Expert Opinion on Therapeutic Patents, 17(6), 639–647. [DOI:10.1517/13543776.17.6.639]
  • Çayan, F., Dilek, U., Pata, Ö., & Dilek, S. (2008). Comparison of the Effects of Hormone Therapy Regimens, Oral and Vaginal Estradiol, Estradiol+Drospirenone and Tibolone, on Sexual Function in Healthy Postmenopausal Women. The Journal of Sexual Medicine, 5(1), 132–138. [DOI:10.1111/j.1743-6109.2007.00635.x]
  • Codispoti, V. L. (2008). Pharmacology of Sexually Compulsive Behavior. Psychiatric Clinics of North America, 31(4), 671–679. [DOI:10.1016/j.psc.2008.06.002]
  • Dalton, M. E., Guthrie, K. A., & Dalton, K. (1987). A preliminary study into the efficacy of progesterone suppositories as a contraceptive for women with severe premenstrual syndrome. The British Journal of Family Planning, 13(3), 87–89. [Google Scholar] [PDF]
  • Davis, S. R., Guay, A. T., Shifren, J. L., & Mazer, N. A. (2004). Endocrine Aspects of Female Sexual Dysfunction. The Journal of Sexual Medicine, 1(1), 82–86. [DOI:10.1111/j.1743-6109.2004.10112.x]
  • Delville, Y. (1991). Progesterone-facilitated sexual receptivity: A review of arguments supporting a nongenomic mechanism. Neuroscience & Biobehavioral Reviews, 15(3), 407–414. [DOI:10.1016/s0149-7634(05)80033-8]
  • Dennerstein, L., Burrows, G. D., Wood, C., & Hyman, G. (1980). Hormones and sexuality: effect of estrogen and progestogen. Obstetrics & Gynecology, 56(3), 316–322. [Google Scholar] [PubMed] [URL] [PDF]
  • Frye, C. A. (2007). Progestins influence motivation, reward, conditioning, stress, and/or response to drugs of abuse. Pharmacology Biochemistry and Behavior, 86(2), 209–219. [DOI:10.1016/j.pbb.2006.07.033]
  • Gałązka, I., Drosdzol-Cop, A., Naworska, B., Czajkowska, M., & Skrzypulec-Plinta, V. (2015). Changes in the Sexual Function During Pregnancy. The Journal of Sexual Medicine, 12(2), 445–454. [DOI:10.1111/jsm.12747]
  • Gilbert, D. C., Duong, T., Kynaston, H. G., Alhasso, A. A., Cafferty, F. H., Rosen, S. D., Kanaga-Sundaram, S., Dixit, S., Laniado, M., Madaan, S., Collins, G., Pope, A., Welland, A., Nankivell, M., Wassersug, R., Parmar, M. K., Langley, R. E., & Abel, P. D. (2016). Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU International, 119(5), 667–675. [DOI:10.1111/bju.13687]
  • Graziottin, A., & Serafini, A. (2011). Medical Treatments for Sexual Problems in Women. In Mulhall, J. P., Incrocci, L., Goldstein, I., & Rosen, R. (Eds.). Cancer and Sexual Health (pp. 627–641). Totowa, New Jersey: Humana Press. [DOI:10.1007/978-1-60761-916-1_40]
  • Hawley, W. R., & Mosura, D. E. (2019). Effects of progesterone treatment during adulthood on consummatory and motivational aspects of sexual behavior in male rats. Behavioural Pharmacology, 30(7), 617–622. [DOI:10.1097/fbp.0000000000000490]
  • Holder, M. K., & Mong, J. A. (2017). The Role of Ovarian Hormones and the Medial Amygdala in Sexual Motivation. Current Sexual Health Reports, 9(4), 262–270. [DOI:10.1007/s11930-017-0131-4]
  • Javadivala, Z., Merghati-Khoei, E., Asghari Jafarabadi, M., Allahverdipour, H., Mirghafourvand, M., Nadrian, H., & Kouzekanani, K. (2018). Efficacy of pharmacological and non-pharmacological interventions on low sexual interest/arousal of peri- and post-menopausal women: a meta-analysis. Sexual and Relationship Therapy, 34(2), 242–270. [DOI:10.1080/14681994.2018.1446515]
  • Jones, B. C., Hahn, A. C., & DeBruine, L. M. (2019). Ovulation, Sex Hormones, and Women’s Mating Psychology. Trends in Cognitive Sciences, 23(1), 51–62. [DOI:10.1016/j.tics.2018.10.008]
  • King, S. R. (2012). Neurosteroids and the Nervous System. In King, S. R. Neurosteroids and the Nervous System (pp. 1–122). New York: Springer New York. [DOI:10.1007/978-1-4614-5559-2_1]
  • Kovalevsky, G. (2005). Female Sexual Dysfunction and Use of Hormone Therapy in Postmenopausal Women. Seminars in Reproductive Medicine, 23(2), 180–187. [DOI:10.1055/s-2005-869486]
  • Kristoffersen, K., & Lebech, P. E. (1975). May Hyperprogesteronaemia Cause Frigidity? Acta Obstetricia et Gynecologica Scandinavica, 54(S47), 42–42. [DOI:10.3109/00016347509158744]
  • Kronawitter, D., Gooren, L. J., Zollver, H., Oppelt, P. G., Beckmann, M. W., Dittrich, R., & Mueller, A. (2009). Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study. European Journal of Endocrinology, 161(2), 363–368. [DOI:10.1530/eje-09-0265]
  • Luttge, W. G. (1971). The role of gonadal hormones in the sexual behavior of the rhesus monkey and human: A literature survey. Archives of Sexual Behavior, 1(1), 61–88. [DOI:10.1007/bf01540937]
  • Michael, R. P., Saayman, G. S., & Zumpe, D. (1967). Inhibition of sexual receptivity by progesterone in rhesus monkeys. Journal of Endocrinology, 39(2), 309–310. [DOI:10.1677/joe.0.0390309]
  • Michael, R. P., & Zumpe, D. (1993). Medroxyprogesterone acetate decreases the sexual activity of male cynomolgus monkeys (Macaca fascicularis): An action on the brain? Physiology & Behavior, 53(4), 783–788. [DOI:10.1016/0031-9384(93)90189-m]
  • Modelska, K., & Milián, M. L. (2004). Treatment of female sexual dysfunction in postmenopausal women—What is the evidence? Reviews in Gynaecological Practice, 4(2), 121–132. [DOI:10.1016/j.rigp.2004.01.001]
  • Myers, L. S., Dixen, J., Morrissette, D., Carmichael, M., & Davidson, J. M. (1990). Effects of Estrogen, Androgen, and Progestin on Sexual Psychophysiology and Behavior in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 70(4), 1124–1131. [DOI:10.1210/jcem-70-4-1124]
  • Nadjafi-Triebsch, C. (2015). Progestogens in Non-gynecological Indications. In Carp, H. J. A. (Ed.). Progestogens in Obstetrics and Gynecology (pp. 191–202). Cham: Springer International Publishing. [DOI:10.1007/978-3-319-14385-9_14]
  • Nadler, R. D., Roth-Meyer, C., & Baulieu, E.-E. (1985). Behavioral and Endocrine Consequences of Long-Term Antiprogesterone (RU 486) Administration to Cynomolgus Monkeys: Preliminary Results. In Baulieu, E.-E., & Segal, S. J. (Eds.). The Antiprogestin Steroid RU 486 and Human Fertility Control (pp. 169–177). Boston: Springer US. [DOI:10.1007/978-1-4684-1242-0_14]
  • Nappi, R. E., Sommacal, A., Sances, G., Abbiati, I., Ferdeghini, F., Vercesi, C., Albani, F., & Polatti, F. (2004). Progesterone supplementation on mood and sexual well-being. Gynecological Endocrinology, 18(Suppl 1 [Abstracts of the 11th World Congress of Gynecological Endocrinology, Florence, Italy, February 26-29, 2004]), 133–134 (abstract no. S9). [Google Scholar] [PubMed] [URL] [PDF]
  • Neumann, F. (1978). The physiological action of progesterone and the pharmacological effects of progestogens – a short review. Postgraduate Medical Journal, 54(Suppl 2), 11–24. [Google Scholar] [PubMed] [PDF]
  • Pastor, Z., Holla, K., & Chmel, R. (2013). The influence of combined oral contraceptives on female sexual desire: A systematic review. The European Journal of Contraception & Reproductive Health Care, 18(1), 27–43. [DOI:10.3109/13625187.2012.728643]
  • Pazol, K., Wilson, M. E., & Wallen, K. (2004). Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques. The Journal of Clinical Endocrinology & Metabolism, 89(6), 2998–3006. [DOI:10.1210/jc.2003-032086]
  • Pazol, K., Northcutt, K. V., Wilson, M. E., & Wallen, K. (2006). Medroxyprogesterone acetate acutely facilitates and sequentially inhibits sexual behavior in female rats. Hormones and Behavior, 49(1), 105–113. [DOI:10.1016/j.yhbeh.2005.05.008]
  • Rastrelli, G., Corona, G., & Maggi, M. (2015). The role of prolactin in andrology: what is new? Reviews in Endocrine and Metabolic Disorders, 16(3), 233–248. [DOI:10.1007/s11154-015-9322-3]
  • Regan, P. C. (1999). Hormonal correlates and causes of sexual desire: A review. The Canadian Journal of Human Sexuality, 8(1), 1–16. [Google Scholar] [URL] [PDF 1] [PDF 2]
  • Regan, P. C., Lyle, J. L., Otto, A. L., & Joshi, A. (2003). Pregnancy and changes in female sexual desire: a review. Social Behavior and Personality, 31(6), 603–611. [DOI:10.2224/sbp.2003.31.6.603]
  • Roney, J. R., & Simmons, Z. L. (2013). Hormonal predictors of sexual motivation in natural menstrual cycles. Hormones and Behavior, 63(4), 636–645. [DOI:10.1016/j.yhbeh.2013.02.013]
  • Roney, J. R. (2014). An Evolutionary Functional Analysis of the Hormonal Predictors of Women’s Sexual Motivation. In Shackelford, T. K., & Hansen, R. D. (Eds.). The Evolution of Sexuality (pp. 99–121). Cham: Springer International Publishing. [DOI:10.1007/978-3-319-09384-0_6]
  • Roney, J. R., & Simmons, Z. L. (2016). Within-cycle fluctuations in progesterone negatively predict changes in both in-pair and extra-pair desire among partnered women. Hormones and Behavior, 81, 45–52. [DOI:10.1016/j.yhbeh.2016.03.008]
  • Roney, J. R. (2019). Evolutionary Perspectives on Hypoactive Sexual Desire Disorder in Women. Current Sexual Health Reports, 11(4), 243–250. [DOI:10.1007/s11930-019-00223-w]
  • Saadat, P., Boostanfar, R., Poysky, J., Munevar, C., Stanczyk, F., Buckwalter, G., & Roy, S. (2002). A randomized prospective study comparing the effects of micronized progesterone and medroxyprogesterone acetate on mood and libido. Fertility and Sterility, 77(Suppl 3 [Abstracts of the 50th Annual Meeting of the Pacific Coast Reproductive Society. April 17-21, 2002. Rancho Mirage, California, USA]), S21–S21 (abstract no. P-28). [Google Scholar] [PubMed] [DOI:10.1016/s0015-0282(02)03053-4]
  • Sandhu, K. S., Melman, A., & Mikhail, M. S. (2011). Impact of Hormones on Female Sexual Function and Dysfunction. Female Pelvic Medicine & Reconstructive Surgery, 17(1), 8–16. [DOI:10.1097/spv.0b013e318204491f]
  • Santoro, N., Worsley, R., Miller, K. K., Parish, S. J., & Davis, S. R. (2016). Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction. The Journal of Sexual Medicine, 13(3), 305–316. [DOI:10.1016/j.jsxm.2015.11.015]
  • Savolainen-Peltonen, H., Hautamäki, H., Tuomikoski, P., Ylikorkala, O., & Mikkola, T. S. (2014). Health-related quality of life in women with or without hot flashes. Menopause, 21(7), 732–739. [DOI:10.1097/gme.0000000000000120]
  • Schaffir, J. (2006). Hormonal Contraception and Sexual Desire: A Critical Review. Journal of Sex & Marital Therapy, 32(4), 305–314. [DOI:10.1080/00926230600666311]
  • Schmidt, P. J., Steinberg, E. M., Negro, P. P., Haq, N., Gibson, C., & Rubinow, D. R. (2008). Pharmacologically Induced Hypogonadism and Sexual Function in Healthy Young Women and Men. Neuropsychopharmacology, 34(3), 565–576. [DOI:10.1038/npp.2008.24]
  • Sherwin, B. B. (1991). The Impact of Different Doses of Estrogen and Progestin on Mood and Sexual Behavior in Postmenopausal Women. The Journal of Clinical Endocrinology & Metabolism, 72(2), 336–343. [DOI:10.1210/jcem-72-2-336]
  • Shirazi, T. N., Self, H., Dawood, K., Rosenfield, K. A., Penke, L., Carré, J. M., Ortiz, T., & Puts, D. A. (2019). Hormonal predictors of women’s sexual motivation. Evolution and Human Behavior, 40(3), 336–344. [DOI:10.1016/j.evolhumbehav.2019.02.002]
  • Wallen, K. (1984). Periovulatory changes in female sexual behavior and patterns of ovarian steroid secretion in group-living rhesus monkeys. Hormones and Behavior, 18(4), 431–450. [DOI:10.1016/0018-506x(84)90028-x]
  • Ward, I. L., Franck, J. E., & Crowley, W. R. (1977). Central progesterone induces female sexual behavior in estrogen-primed intact male rats. Journal of Comparative and Physiological Psychology, 91(6), 1417–1423. [DOI:10.1037/h0077419]
  • Waxman, J. H., Wass, J. A., Hendry, W. F., Whitfield, H. N., Bary, P., Besser, G. M., Malpas, J. S., & Oliver, R. T. (1983). Treatment of Advanced Prostatic Cancer with Buserelin, an Analogue of Gonadotrophin Releasing Hormone. British Journal of Urology, 55(6), 737–742. [DOI:10.1111/j.1464-410x.1983.tb03416.x]
  • Wibowo, E., Schellhammer, P., & Wassersug, R. J. (2011). Role of Estrogen in Normal Male Function: Clinical Implications for Patients With Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology, 185(1), 17–23. [DOI:10.1016/j.juro.2010.08.094]
  • Witt, D. M., Young, L. J., & Crews, D. (1995). Progesterone modulation of androgen-dependent sexual behavior in male rats. Physiology & Behavior, 57(2), 307–313. [DOI:10.1016/0031-9384(94)00247-3]
  • Worsley, R., Santoro, N., Miller, K. K., Parish, S. J., & Davis, S. R. (2016). Hormones and Female Sexual Dysfunction: Beyond Estrogens and Androgens—Findings From the Fourth International Consultation on Sexual Medicine. The Journal of Sexual Medicine, 13(3), 283–290. [DOI:10.1016/j.jsxm.2015.12.014]
  • Wren, B. G., Champion, S. M., Willetts, K., Manga, R. Z., & Eden, J. A. (2003). Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause, 10(1), 13–18. [DOI:10.1097/00042192-200310010-00004]
  • Zimmerman, Y., Eijkemans, M. J., Coelingh Bennink, H. J., Blankenstein, M. A., & Fauser, B. C. (2013). The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Human Reproduction Update, 20(1), 76–105. [DOI:10.1093/humupd/dmt038]
  • Zumpe, D., & Michael, R. P. (1988). Effects of medroxyprogesterone acetate on plasma testosterone and sexual behavior in male cynomolgus monkeys (Macaca fascicularis). Physiology & Behavior, 42(4), 343–349. [DOI:10.1016/0031-9384(88)90275-2]
  • Zumpe, D. (1991). Medroxyprogesterone acetate, aggression, and sexual behavior in male cynomolgus monkeys (Macaca fascicularis). Hormones and Behavior, 25(3), 394–409. [DOI:10.1016/0018-506x(91)90010-f]
  • Zumpe, D., Clancy, A. N., & Michael, R. P. (1997). Effects of Progesterone on the Sexual Behavior of Castrated, Testosterone-Treated Male Cynomolgus Monkeys (Macaca Fascicularis). Physiology & Behavior, 62(1), 61–67. [DOI:10.1016/s0031-9384(97)00135-2]
\ No newline at end of file diff --git a/transfemscience.org/articles/progestogens-transfem-excerpts/index.html b/transfemscience.org/articles/progestogens-transfem-excerpts/index.html index 703dc70b..7cad80c8 100644 --- a/transfemscience.org/articles/progestogens-transfem-excerpts/index.html +++ b/transfemscience.org/articles/progestogens-transfem-excerpts/index.html @@ -1 +1 @@ -Sources/Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy - Transfeminine Science Link

Sources/Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy

By Sam | First published April 18, 2020 | Last modified October 5, 2020

Oriel (2000)

Oriel, K. A. (2000). Clinical update: Medical care of transsexual patients. Journal of the Gay and Lesbian Medical Association, 4(4), 185–194. [DOI:10.1023/a:1026563806480]:

The use of progesterone to augment breast development is controversial in physicians treating MTF transsexuals. When deciding on a hormone regimen, prescribers should remember that it is estrogen that causes the serious side effects, so the lowest effective dose should be used.

[…] Progesterone is the third and optional component of the MTF regimen. Although some physicians working with transgendered patients do not prescribe progesterone, others argue feminization involves the actions of both estrogen and progesterone (31). Medroxyprogesterone is a weak antiandrogen, and testosterone suppression may be accomplished with lower doses of estrogen. Medroxyprogesterone is less androgenic than norethindrone and norgestrel. Progesterone is important for breast development (24). Unlike estrogen, progesterone does not carry the risk of thromboembolism, prolactinoma, and myocardial infarction. Although it has been noted that doses of 20–40 mg per day are required to suppress luteinizing hormone (20), medroxyprogesterone acetate may become androgenic at higher doses, so others (5) recommend 10 mg a day. Micronized progesterone (Prometrium) is advantageous because it has a more favorable side effect profile (anxiety and irritability) than medroxyprogesterone. It is also less androgenic when higher progesterone doses are needed, but is more costly.

Dittrich et al. (2005)

Dittrich, R., Binder, H., Cupisti, S., Hoffmann, I., Beckmann, M. W., & Mueller, A. (2005). Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Experimental and Clinical Endocrinology & Diabetes, 113(10), 586–592. [DOI:10.1055/s-2005-865900]:

Ethinyl oestradiol was no more effective in comparison with the oestradiol-17β valerate administered in the regimen studied here. Similar efficacy in terms of feminisation, e. g., increases in breast size, were achieved in the present study group compared to prior reported treatment regimes using cyproterone acetate and ethinyl oestradiol. The use of a progestin as part of the endocrine treatment regime of male-to-female transsexuals is still controversial; however, advantages in only a couple of patients with abnormal psychological irritability and mammary tenderness could be observed (Michel et al., 2001).

Gooren, Giltay, & Bunck (2008)

Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008). Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. The Journal of Clinical Endocrinology & Metabolism, 93(1), 19–25. [DOI:10.1210/jc.2007-1809]:

There is no evidence that progestagens add to the feminization process of M2F. In female reproductive endocrinology, progesterone prepares the uterus for conception and the breasts for lactation. Some patients strongly believe that progestagens are a necessary addition to estrogens in their feminization process. But this is not the case, and progestagens may have side effects, such as salt/water retention leading to elevated blood pressure or venous varicosis. In the large-scale study of postmenopausal hormone use in women, the combination of estrogens and progestagens appeared to be associated with a higher incidence of breast cancer (4) and cardiovascular disease.

Gooren (2011)

Gooren, L. J. (2011). Care of transsexual persons. New England Journal of Medicine, 364(13), 1251–1257. [DOI:10.1056/nejmcp1008161]:

Although progestins suppress androgen production, they have no role in the feminization of the body and may have harmful metabolic effects; consequently, progestins should be discontinued after orchiectomy.24 In postmenopausal women, progestins combined with estrogens increase the risk of breast cancer.25

Wierckx, Gooren, T’Sjoen (2014)

Wierckx, K., Gooren, L., & T’Sjoen, G. (2014). Clinical review: breast development in trans women receiving cross-sex hormones. The Journal of Sexual Medicine, 11(5), 1240–1247. [DOI:10.1111/jsm.12487]:

With regard to the hormonal impact on female breast development, the classic view is that estrogens induce proliferation, whereas progestins cause differentiation in female breast development [2,3]. It is widely assumed that progestins have no significant role in the formation of the volume of the breasts, the reason why it is not included in endocrine treatment of girls with Turner and juvenile trans women persons [1].

[…] Although there is undeniably a role of progesterone in breast development and lactation, it is uncertain whether the treatment of progestogens adds much to the volume of the breasts, the concern of trans women. […] In the medical profession and even more in the transsexual community, there has been an ongoing debate for many years on the potential benefit of adding progestogens to estrogen use in trans women’s hormonal treatment, especially concerning its role in the volume/size breast development and maintenance. Progestagen treatment is also often requested by trans women themselves as it is their perception that their treatment should closely mimic hormonal treatment of hypogonadal women requiring hormone treatment. However, for the latter group, addition of progestogens has a different relevance, specifically the modifying estrogen effects on the uterus potentially inducing cancerous development.

[…] Few studies have investigated the effects of cross-sex hormone treatment on breast volume. Meyer et al. [17] investigated breast growth in 52 trans women during cross-sex hormone treatment. Notably, 41 trans women received cross-sex hormone treatment with a median of 26.4 months before inclusion in the study. Different estrogen regimes (ethinyl estradiol [EE], conjugated estrogen, or both) were analyzed, and 15 trans women of their sample (28%) additionally received a progestational agent. No difference in breast size was observed between trans women who received progestogens compared with the others.

[…] The available evidence does not provide support for better effects on breast size of adding progestogens to cross-sex hormone administration in trans women as suggested by some authors [14,18,48–51]. However, it should be said that the quality and amount of available evidence are extremely poor and hamper any firm conclusion at this moment.

[…] Our knowledge concerning the natural history and effects of different cross-sex hormone therapies including progestogens on breast development in trans women is extremely sparse and based on low quality of evidence. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions.

Deutsch (2016)

Deutsch, M. B. (Ed.). (2016). Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition. Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California, San Francisco. [URL] [PDF]:

There have been no well-designed studies of the role of progestagens in feminizing hormone regimens. Many transgender women and providers alike report an anecdotal improved breast and/or areolar development, mood, or libido with the use of progestagens.[17,18] There is no evidence to suggest that using progestagens in the setting of transgender care are harmful. In reality some patients may respond favorably to progestagens while others may find negative effects on mood. While progestagens have some anti-androgen effect through central blockade of gonadotropins, there is also a theoretical risk of a direct androgenizing effect of progestagens. This class includes micronized bioidentical progesterone (Prometrium) as well as a number of synthetic progestins. The most commonly used synthetic progestin in the context of transgender care is the oral medroxyprogesterone acetate (Provera).

While concerns exist from the Women’s Health Initiative (WHI) regarding risks of cardiovascular disease and breast cancer in the setting of medroxyprogesterone use, these concerns likely do not apply in the context of transgender care for several reasons. First, the transgender women may be at lower risk of breast cancer than non-transgender women. Second, this arm of the WHI involved the use of conjugated equine estrogens in combination with medroxyprogesterone in a sample of menopausal women, some of whom were as long as 10 years post-menopausal at the time of hormone initiation. Third, while statistically significant, the clinical significance of the findings in the WHI was subtle at best. The study aimed to evaluate the role of menopausal hormone therapy in the prevention of chronic disease. The actual findings in the conjugated equine estrogen plus medroxyprogesterone group were an excess absolute risk per 10 000 person-years of 7 more cardiac events events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers, with no change in overall mortality.[19] As such this arm of the WHI was stopped early, and it was concluded that combined menopausal hormone therapy is not indicated for prevention of chronic disease.

In the setting of gender-affirming care, there are numerous differences to the findings of the WHI: populations tend to be younger, equine estrogens are not used, and the emphasis is on genderaffirming interventions which have numerous benefits on mental health and quality of life, rather than prevention. Considering these differences in demographics and goals of therapy, extremely modest increase in overall risk, and lack of difference in mortality, as well as more recent reassuring data with other forms of estrogen, the risks of using progestagens in transgender women are likely minimal or even absent (Grading: NT O M). Injected depomedroxyprogesterone acetate (Depo-Provera®) is less commonly used in transgender women. Other synthetic progestins may be used as necessitated by formulary limitations; some evidence suggests that norpregnane derived progestins (norethindrone, norgestrel) may have an increased risk of venous thromboembolism.[20]

Tangpricha & den Heijer (2017)

Tangpricha, V., & den Heijer, M. (2017). Oestrogen and anti-androgen therapy for transgender women. The Lancet Diabetes & Endocrinology, 5(4), 291–300. [DOI:10.1016/S2213-8587(16)30319-9]:

Some patients request progesterone for enhanced breast growth. However, there have not been any well designed studies to assess the eff ectiveness of progesterone to improve breast development. Results of studies of progesterone combined with oestrogen in postmenopausal cis-gender women—ie, women who are not transgender—suggest that progesterone combined with oestrogen might be associated with an increased risk of cardiovascular disease.21 In fact, in a population-based study of premenopausal cis-gender women, taking oral contraceptives including progesterone with or without oestrogen was associated with increased risk of thromboembolism.22

Hembree et al. (2017)

Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline [2nd Version]. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. [DOI:10.1210/jc.2017-01658] [PDF]:

In the future, we need more rigorous evaluations of the effectiveness and safety of endocrine and surgical protocols. Specifically, endocrine treatment protocols for GD/gender incongruence should include the careful assessment of the following: (1) the effects of prolonged delay of puberty in adolescents on bone health, gonadal function, and the brain (including effects on cognitive, emotional, social, and sexual development); (2) the effects of treatment in adults on sex hormone levels; (3) the requirement for and the effects of progestins and other agents used to suppress endogenous sex steroids during treatment; and (4) the risks and benefits of gender-affirming hormone treatment in older transgender people.

[…] Although the time course of breast development in transgender females has been studied (150), precise information about other changes induced by sex hormones is lacking (141). There is a great deal of variability among individuals, as evidenced during pubertal development. We all know that a major concern for transgender females is breast development. If we work with estrogens, the result will be often not what the transgender female expects. Alternatively, there are transgender females who report an anecdotal improved breast development, mood, or sexual desire with the use of progestogens. However, there have been no well-designed studies of the role of progestogens in feminizing hormone regimens, so the question is still open. Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in transgender females is extremely sparse and based on the low quality of evidence. Current evidence does not indicate that progestogens enhance breast development in transgender females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions (162).

Coxon & Seal (2018)

Coxon, J., & Seal, L. (2018). Hormone management of trans women. Trends in Urology & Men’s Health, 9(6), 10–14. [DOI:10.1002/tre.663]:

Progesterone is recommended by some gender clinics internationally, but rarely in the UK. Some trans women strongly believe that it should be added, to enhance breast development. A meta-analysis found no additional benefit for breast development when comparing progesterone plus oestrogen to oestrogen alone.17 We advise patients that oestrogen-only hormone therapy is the best and safest option, as progesterone is not produced during the breast development phase of physiological female puberty, and trans women do not have endometria to protect. At a cellular level, progesterone reverses oestrogen induced cell proliferation and, more importantly, evidence in cis women has shown that adding progesterone to oestrogen therapy is associated with increased risk of cardiovascular disease and breast cancer.18

Prior (2019)

Prior, J. C. (2019). Progesterone is important for transgender women’s therapy—applying evidence for the benefits of progesterone in ciswomen. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1181–1186. [DOI:10.1210/jc.2018-01777]:

Oral micronized progesterone, a fundamental ovarian steroid, molecularly identical to the natural hormone, should be added to E2 for transgender women based on physiology and emerging evidence of the importance of progesterone with E2 for ciswomen’s bone and likely cardiovascular health. Progesterone will probably prevent at least some of the negative cardiovascular system and bone health effects reported in transgender women on current long-term, E/E2-only, or E/E2 antiandrogen CHT. Progesterone will also aid antiandrogen effects through different pathways than spironolactone or cyproterone acetate and may promote feminine physiological breast maturation, while also aiding disturbed sleep and perhaps decreasing anxiety. It may also facilitate transgender women’s acceptance of physiological (rather than high) E2 doses ideally delivered transdermally. Evidence is mounting that ciswomen’s lifelong health is enhanced by sufficient P4 (normally ovulatory) within regular estradiol-sufficient monthly menstrual cycles. I believe it is time that we now follow current guidelines and provide transgender women with these P4 or progesterone benefits in their CHT.

Iwamoto et al. (2019)

Iwamoto, S. J., T’Sjoen, G., Safer, J. D., Davidge-Pitts, C. J., Wierman, M. E., Glodowski, M. B., & Rothman, M. S. (2019). Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen”. The Journal of Clinical Endocrinology & Metabolism, 104(8), 3127–3128. [DOI:10.1210/jc.2019-00249]:

We respect Dr. Jerilynn C. Prior’s many contributions to endocrinology and transgender (trans) health. Yet, we have multiple concerns about her Perspective(1) which is limited to her clinical experience, assumptions taken from in vitro and animal data, and selected data from cisgender (cis) women, whose female gender identity aligns with their natal sex.

[…] Prior asserts that P4 with estradiol (E2) will optimize breast maturation and size, but P4 causes ductal differentiation in puberty and has not been shown to enhance breast development in trans women(2). Prior argues that bone mineral density (BMD) improves with P4. However, selected studies from her meta-analysis were limited by significant heterogeneity of hormone dose, race and range of years after menopause(3). Although Prior states that low BMD is a major risk for trans women “on long-term” hormones, the major concerns are low baseline BMD before pharmacologic gender-affirming hormone therapy (GAHT) and monitoring after gonadectomy and cessation of GAHT(4). Recent ten-year GAHT data (without P4) showed gains in lumbar spine Z-scores of trans women(4).

We also object to Prior’s assumption that P4 will decrease breast cancer risk in trans women based on the French E3N self-administered questionnaire study in cis women. Randomized controlled trial (RCT) data from the Women’s Health Initiative (WHI) demonstrated increased invasive breast cancer during the intervention, postintervention and cumulative follow-up in the conjugated equine estrogen (CEE)+medroxyprogesterone (MPA) group compared to CEE alone(5).

Lastly, Prior’s statement of cardiovascular benefits with progestins conflicts with WHI data which revealed increased coronary heart disease in women ≥20 years past menopause onset and higher risk of stroke and blood clots in the CEE+MPA group during cumulative follow-up(5). Recent data raise concerns for higher risks of blood clots and stroke among trans women on GAHT compared to reference women and men(6).

[…] To conclude that oral micronized P4 will be positive for bone and cardiovascular health based on selected data in menopausal cis women is premature and potentially dangerous. Further, we know that clinical assumptions based on observational data, murine studies, cell models and personal experience can lead to risks to patients. Our transgender patients deserve the benefits of rigorous RCT data so we can provide evidence-based recommendations regarding the risks and benefits of GAHT.

Cheung et al. (2019)

Cheung, A. S., Wynne, K., Erasmus, J., Murray, S., & Zajac, J. D. (2019). Position statement on the hormonal management of adult transgender and gender diverse individuals. Medical Journal of Australia, 211(3), 127–133. [DOI:10.5694/mja2.50259]:

Despite anecdotal reports that progestins increase breast growth, no data support their use. Healthy postmenopausal women who received estradiol with progestins had increased risk of coronary heart disease compared with placebo34 (not reported with estradiol alone42). Progestins can also increase risk of thrombosis, bloating, nausea and weight gain and are not recommended.10 Cyproterone acetate, a commonly used anti-androgen agent, has progestogenic effects.

Iwamoto et al. (2019)

Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 2042018819871166. [DOI:10.1177/2042018819871166]:

Alternative anti-androgen therapies exist that have not yet been substantiated for routine use by supporting research. Progesterone is discussed in the breast development section, but we do not recommend its routine use in TW until more rigorous studies demonstrate potential benefits outweigh any risks.40

[…] The impact of various combinations of different oestrogens, anti-androgens and progestogens on breast development was previously reviewed by Wierckx and colleagues,67 who concluded that current evidence did not support or refute any enhancement of breast development with progestogens. Pubertal data in people assigned female at birth (AFAB) (e.g. girls with Turner syndrome) argue for delaying progesterone as it causes ductal differentiation and may interfere with optimal breast development.68 Due to unsatisfactory effects of GAHT alone on breast growth and development, 60–70% of all TW sought additional surgical breast augmentation.67 Articles on breast development in TW report inconclusive results, possibly due to differences in methodology and the lack of prospective RCTs. Prior69 recently published on the potential benefits of progesterone use on breast development (among other conclusions) in TW but the perspective was limited to clinical experience, assumptions taken from in vitro and animal data, and selected data from cis women.40 It would be worthwhile for future studies to use volume measurements for examining hormonally induced breast development in TW over a longer follow-up period in a large cohort, which may result in the identification of predictive markers for breast development.62 Additionally, rigorous prospective RCTs of oestrogen and oestrogen plus progesterone may provide more conclusive data to guide routine use of progesterone for breast development.

T’Sjoen et al. (2020)

T’Sjoen, G., Arcelus, J., De Vries, A. L., Fisher, A. D., Nieder, T. O., Özer, M., & Motmans, J. (2020). European Society for Sexual Medicine Position Statement “Assessment and Hormonal Management in Adolescent and Adult Trans People, with Attention for Sexual Function and Satisfaction”. The Journal of Sexual Medicine, 17(4), 570–584. [DOI:10.1016/j.jsxm.2020.01.012]:

To induce (more) feminine secondary sex characteristics and/or to reduce the masculine ones, estrogens and/or antiandrogens can be used. The debate on the use of progesterone is ongoing, caused by a lack of data.3 A wide range of estrogenic compounds exists, of which 17beta-estradiol (oral 2–6 mg/d or transdermal) represents the treatment of choice. Estrogen dosage should be adjusted to maintain serum estradiol at the level for premenopausal women (100–200 pg/mL), although timing of treatment intake may affect blood concentrations. The most commonly used antiandrogen drug in Europe is cyproterone acetate (oral 10–50 mg, once daily), a progestin with antiandrogenic properties. GnRHa are also effective in reducing testosterone levels with a low risk of adverse effects.3

Reisman (2020)

Reisman, T. (2020). Breast imaging in transgender individuals. In Legato, M. J. (Ed.). The Plasticity of Sex: The Molecular Biology and Clinical Features of Genomic Sex, Gender Identity and Sexual Behavior (pp. 187–205). London: Academic Press. [DOI:10.1016/B978-0-12-815968-2.00016-5]:

While the role of estrogen in breast growth has been most clearly established, other hormones have also been implicated in breast development. In his 1958 study, Lyon demonstrated in oophorectomized, adrenalectomized, and hypophysectomized rodents that estrogen, growth hormone, and corticosteroids are all required for ductal develoment.10 Progesterone does not appear to be important for either early pubertal duct development or breast growth. However, with increasing levels throughout pregnancy, progesterone is reported to mediate the lobular alveolar development facilitating lactation.

\ No newline at end of file +Sources/Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy - Transfeminine Science Link

Sources/Excerpts: Perspectives and Opinions of Clinicians and Researchers Concerning the Use of Progestogens in Transfeminine Hormone Therapy

By Sam | First published April 18, 2020 | Last modified October 5, 2020

Oriel (2000)

Oriel, K. A. (2000). Clinical update: Medical care of transsexual patients. Journal of the Gay and Lesbian Medical Association, 4(4), 185–194. [DOI:10.1023/a:1026563806480]:

The use of progesterone to augment breast development is controversial in physicians treating MTF transsexuals. When deciding on a hormone regimen, prescribers should remember that it is estrogen that causes the serious side effects, so the lowest effective dose should be used.

[…] Progesterone is the third and optional component of the MTF regimen. Although some physicians working with transgendered patients do not prescribe progesterone, others argue feminization involves the actions of both estrogen and progesterone (31). Medroxyprogesterone is a weak antiandrogen, and testosterone suppression may be accomplished with lower doses of estrogen. Medroxyprogesterone is less androgenic than norethindrone and norgestrel. Progesterone is important for breast development (24). Unlike estrogen, progesterone does not carry the risk of thromboembolism, prolactinoma, and myocardial infarction. Although it has been noted that doses of 20–40 mg per day are required to suppress luteinizing hormone (20), medroxyprogesterone acetate may become androgenic at higher doses, so others (5) recommend 10 mg a day. Micronized progesterone (Prometrium) is advantageous because it has a more favorable side effect profile (anxiety and irritability) than medroxyprogesterone. It is also less androgenic when higher progesterone doses are needed, but is more costly.

Dittrich et al. (2005)

Dittrich, R., Binder, H., Cupisti, S., Hoffmann, I., Beckmann, M. W., & Mueller, A. (2005). Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Experimental and Clinical Endocrinology & Diabetes, 113(10), 586–592. [DOI:10.1055/s-2005-865900]:

Ethinyl oestradiol was no more effective in comparison with the oestradiol-17β valerate administered in the regimen studied here. Similar efficacy in terms of feminisation, e. g., increases in breast size, were achieved in the present study group compared to prior reported treatment regimes using cyproterone acetate and ethinyl oestradiol. The use of a progestin as part of the endocrine treatment regime of male-to-female transsexuals is still controversial; however, advantages in only a couple of patients with abnormal psychological irritability and mammary tenderness could be observed (Michel et al., 2001).

Gooren, Giltay, & Bunck (2008)

Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008). Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. The Journal of Clinical Endocrinology & Metabolism, 93(1), 19–25. [DOI:10.1210/jc.2007-1809]:

There is no evidence that progestagens add to the feminization process of M2F. In female reproductive endocrinology, progesterone prepares the uterus for conception and the breasts for lactation. Some patients strongly believe that progestagens are a necessary addition to estrogens in their feminization process. But this is not the case, and progestagens may have side effects, such as salt/water retention leading to elevated blood pressure or venous varicosis. In the large-scale study of postmenopausal hormone use in women, the combination of estrogens and progestagens appeared to be associated with a higher incidence of breast cancer (4) and cardiovascular disease.

Gooren (2011)

Gooren, L. J. (2011). Care of transsexual persons. New England Journal of Medicine, 364(13), 1251–1257. [DOI:10.1056/nejmcp1008161]:

Although progestins suppress androgen production, they have no role in the feminization of the body and may have harmful metabolic effects; consequently, progestins should be discontinued after orchiectomy.24 In postmenopausal women, progestins combined with estrogens increase the risk of breast cancer.25

Wierckx, Gooren, T’Sjoen (2014)

Wierckx, K., Gooren, L., & T’Sjoen, G. (2014). Clinical review: breast development in trans women receiving cross-sex hormones. The Journal of Sexual Medicine, 11(5), 1240–1247. [DOI:10.1111/jsm.12487]:

With regard to the hormonal impact on female breast development, the classic view is that estrogens induce proliferation, whereas progestins cause differentiation in female breast development [2,3]. It is widely assumed that progestins have no significant role in the formation of the volume of the breasts, the reason why it is not included in endocrine treatment of girls with Turner and juvenile trans women persons [1].

[…] Although there is undeniably a role of progesterone in breast development and lactation, it is uncertain whether the treatment of progestogens adds much to the volume of the breasts, the concern of trans women. […] In the medical profession and even more in the transsexual community, there has been an ongoing debate for many years on the potential benefit of adding progestogens to estrogen use in trans women’s hormonal treatment, especially concerning its role in the volume/size breast development and maintenance. Progestagen treatment is also often requested by trans women themselves as it is their perception that their treatment should closely mimic hormonal treatment of hypogonadal women requiring hormone treatment. However, for the latter group, addition of progestogens has a different relevance, specifically the modifying estrogen effects on the uterus potentially inducing cancerous development.

[…] Few studies have investigated the effects of cross-sex hormone treatment on breast volume. Meyer et al. [17] investigated breast growth in 52 trans women during cross-sex hormone treatment. Notably, 41 trans women received cross-sex hormone treatment with a median of 26.4 months before inclusion in the study. Different estrogen regimes (ethinyl estradiol [EE], conjugated estrogen, or both) were analyzed, and 15 trans women of their sample (28%) additionally received a progestational agent. No difference in breast size was observed between trans women who received progestogens compared with the others.

[…] The available evidence does not provide support for better effects on breast size of adding progestogens to cross-sex hormone administration in trans women as suggested by some authors [14,18,48–51]. However, it should be said that the quality and amount of available evidence are extremely poor and hamper any firm conclusion at this moment.

[…] Our knowledge concerning the natural history and effects of different cross-sex hormone therapies including progestogens on breast development in trans women is extremely sparse and based on low quality of evidence. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions.

Deutsch (2016)

Deutsch, M. B. (Ed.). (2016). Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People, 2nd Edition. Center of Excellence for Transgender Health, Department of Family and Community Medicine, University of California, San Francisco. [URL] [PDF]:

There have been no well-designed studies of the role of progestagens in feminizing hormone regimens. Many transgender women and providers alike report an anecdotal improved breast and/or areolar development, mood, or libido with the use of progestagens.[17,18] There is no evidence to suggest that using progestagens in the setting of transgender care are harmful. In reality some patients may respond favorably to progestagens while others may find negative effects on mood. While progestagens have some anti-androgen effect through central blockade of gonadotropins, there is also a theoretical risk of a direct androgenizing effect of progestagens. This class includes micronized bioidentical progesterone (Prometrium) as well as a number of synthetic progestins. The most commonly used synthetic progestin in the context of transgender care is the oral medroxyprogesterone acetate (Provera).

While concerns exist from the Women’s Health Initiative (WHI) regarding risks of cardiovascular disease and breast cancer in the setting of medroxyprogesterone use, these concerns likely do not apply in the context of transgender care for several reasons. First, the transgender women may be at lower risk of breast cancer than non-transgender women. Second, this arm of the WHI involved the use of conjugated equine estrogens in combination with medroxyprogesterone in a sample of menopausal women, some of whom were as long as 10 years post-menopausal at the time of hormone initiation. Third, while statistically significant, the clinical significance of the findings in the WHI was subtle at best. The study aimed to evaluate the role of menopausal hormone therapy in the prevention of chronic disease. The actual findings in the conjugated equine estrogen plus medroxyprogesterone group were an excess absolute risk per 10 000 person-years of 7 more cardiac events events, 8 more strokes, 8 more pulmonary emboli, and 8 more invasive breast cancers, with no change in overall mortality.[19] As such this arm of the WHI was stopped early, and it was concluded that combined menopausal hormone therapy is not indicated for prevention of chronic disease.

In the setting of gender-affirming care, there are numerous differences to the findings of the WHI: populations tend to be younger, equine estrogens are not used, and the emphasis is on genderaffirming interventions which have numerous benefits on mental health and quality of life, rather than prevention. Considering these differences in demographics and goals of therapy, extremely modest increase in overall risk, and lack of difference in mortality, as well as more recent reassuring data with other forms of estrogen, the risks of using progestagens in transgender women are likely minimal or even absent (Grading: NT O M). Injected depomedroxyprogesterone acetate (Depo-Provera®) is less commonly used in transgender women. Other synthetic progestins may be used as necessitated by formulary limitations; some evidence suggests that norpregnane derived progestins (norethindrone, norgestrel) may have an increased risk of venous thromboembolism.[20]

Tangpricha & den Heijer (2017)

Tangpricha, V., & den Heijer, M. (2017). Oestrogen and anti-androgen therapy for transgender women. The Lancet Diabetes & Endocrinology, 5(4), 291–300. [DOI:10.1016/S2213-8587(16)30319-9]:

Some patients request progesterone for enhanced breast growth. However, there have not been any well designed studies to assess the eff ectiveness of progesterone to improve breast development. Results of studies of progesterone combined with oestrogen in postmenopausal cis-gender women—ie, women who are not transgender—suggest that progesterone combined with oestrogen might be associated with an increased risk of cardiovascular disease.21 In fact, in a population-based study of premenopausal cis-gender women, taking oral contraceptives including progesterone with or without oestrogen was associated with increased risk of thromboembolism.22

Hembree et al. (2017)

Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T’Sjoen, G. G. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline [2nd Version]. The Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. [DOI:10.1210/jc.2017-01658] [PDF]:

In the future, we need more rigorous evaluations of the effectiveness and safety of endocrine and surgical protocols. Specifically, endocrine treatment protocols for GD/gender incongruence should include the careful assessment of the following: (1) the effects of prolonged delay of puberty in adolescents on bone health, gonadal function, and the brain (including effects on cognitive, emotional, social, and sexual development); (2) the effects of treatment in adults on sex hormone levels; (3) the requirement for and the effects of progestins and other agents used to suppress endogenous sex steroids during treatment; and (4) the risks and benefits of gender-affirming hormone treatment in older transgender people.

[…] Although the time course of breast development in transgender females has been studied (150), precise information about other changes induced by sex hormones is lacking (141). There is a great deal of variability among individuals, as evidenced during pubertal development. We all know that a major concern for transgender females is breast development. If we work with estrogens, the result will be often not what the transgender female expects. Alternatively, there are transgender females who report an anecdotal improved breast development, mood, or sexual desire with the use of progestogens. However, there have been no well-designed studies of the role of progestogens in feminizing hormone regimens, so the question is still open. Our knowledge concerning the natural history and effects of different cross-sex hormone therapies on breast development in transgender females is extremely sparse and based on the low quality of evidence. Current evidence does not indicate that progestogens enhance breast development in transgender females, nor does evidence prove the absence of such an effect. This prevents us from drawing any firm conclusion at this moment and demonstrates the need for further research to clarify these important clinical questions (162).

Coxon & Seal (2018)

Coxon, J., & Seal, L. (2018). Hormone management of trans women. Trends in Urology & Men’s Health, 9(6), 10–14. [DOI:10.1002/tre.663]:

Progesterone is recommended by some gender clinics internationally, but rarely in the UK. Some trans women strongly believe that it should be added, to enhance breast development. A meta-analysis found no additional benefit for breast development when comparing progesterone plus oestrogen to oestrogen alone.17 We advise patients that oestrogen-only hormone therapy is the best and safest option, as progesterone is not produced during the breast development phase of physiological female puberty, and trans women do not have endometria to protect. At a cellular level, progesterone reverses oestrogen induced cell proliferation and, more importantly, evidence in cis women has shown that adding progesterone to oestrogen therapy is associated with increased risk of cardiovascular disease and breast cancer.18

Prior (2019)

Prior, J. C. (2019). Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen. The Journal of Clinical Endocrinology & Metabolism, 104(4), 1181–1186. [DOI:10.1210/jc.2018-01777]:

Oral micronized progesterone, a fundamental ovarian steroid, molecularly identical to the natural hormone, should be added to E2 for transgender women based on physiology and emerging evidence of the importance of progesterone with E2 for ciswomen’s bone and likely cardiovascular health. Progesterone will probably prevent at least some of the negative cardiovascular system and bone health effects reported in transgender women on current long-term, E/E2-only, or E/E2 antiandrogen CHT. Progesterone will also aid antiandrogen effects through different pathways than spironolactone or cyproterone acetate and may promote feminine physiological breast maturation, while also aiding disturbed sleep and perhaps decreasing anxiety. It may also facilitate transgender women’s acceptance of physiological (rather than high) E2 doses ideally delivered transdermally. Evidence is mounting that ciswomen’s lifelong health is enhanced by sufficient P4 (normally ovulatory) within regular estradiol-sufficient monthly menstrual cycles. I believe it is time that we now follow current guidelines and provide transgender women with these P4 or progesterone benefits in their CHT.

Iwamoto et al. (2019)

Iwamoto, S. J., T’Sjoen, G., Safer, J. D., Davidge-Pitts, C. J., Wierman, M. E., Glodowski, M. B., & Rothman, M. S. (2019). Letter to the Editor: “Progesterone Is Important for Transgender Women’s Therapy—Applying Evidence for the Benefits of Progesterone in Ciswomen”. The Journal of Clinical Endocrinology & Metabolism, 104(8), 3127–3128. [DOI:10.1210/jc.2019-00249]:

We respect Dr. Jerilynn C. Prior’s many contributions to endocrinology and transgender (trans) health. Yet, we have multiple concerns about her Perspective(1) which is limited to her clinical experience, assumptions taken from in vitro and animal data, and selected data from cisgender (cis) women, whose female gender identity aligns with their natal sex.

[…] Prior asserts that P4 with estradiol (E2) will optimize breast maturation and size, but P4 causes ductal differentiation in puberty and has not been shown to enhance breast development in trans women(2). Prior argues that bone mineral density (BMD) improves with P4. However, selected studies from her meta-analysis were limited by significant heterogeneity of hormone dose, race and range of years after menopause(3). Although Prior states that low BMD is a major risk for trans women “on long-term” hormones, the major concerns are low baseline BMD before pharmacologic gender-affirming hormone therapy (GAHT) and monitoring after gonadectomy and cessation of GAHT(4). Recent ten-year GAHT data (without P4) showed gains in lumbar spine Z-scores of trans women(4).

We also object to Prior’s assumption that P4 will decrease breast cancer risk in trans women based on the French E3N self-administered questionnaire study in cis women. Randomized controlled trial (RCT) data from the Women’s Health Initiative (WHI) demonstrated increased invasive breast cancer during the intervention, postintervention and cumulative follow-up in the conjugated equine estrogen (CEE)+medroxyprogesterone (MPA) group compared to CEE alone(5).

Lastly, Prior’s statement of cardiovascular benefits with progestins conflicts with WHI data which revealed increased coronary heart disease in women ≥20 years past menopause onset and higher risk of stroke and blood clots in the CEE+MPA group during cumulative follow-up(5). Recent data raise concerns for higher risks of blood clots and stroke among trans women on GAHT compared to reference women and men(6).

[…] To conclude that oral micronized P4 will be positive for bone and cardiovascular health based on selected data in menopausal cis women is premature and potentially dangerous. Further, we know that clinical assumptions based on observational data, murine studies, cell models and personal experience can lead to risks to patients. Our transgender patients deserve the benefits of rigorous RCT data so we can provide evidence-based recommendations regarding the risks and benefits of GAHT.

Cheung et al. (2019)

Cheung, A. S., Wynne, K., Erasmus, J., Murray, S., & Zajac, J. D. (2019). Position statement on the hormonal management of adult transgender and gender diverse individuals. Medical Journal of Australia, 211(3), 127–133. [DOI:10.5694/mja2.50259]:

Despite anecdotal reports that progestins increase breast growth, no data support their use. Healthy postmenopausal women who received estradiol with progestins had increased risk of coronary heart disease compared with placebo34 (not reported with estradiol alone42). Progestins can also increase risk of thrombosis, bloating, nausea and weight gain and are not recommended.10 Cyproterone acetate, a commonly used anti-androgen agent, has progestogenic effects.

Iwamoto et al. (2019)

Iwamoto, S. J., Defreyne, J., Rothman, M. S., Van Schuylenbergh, J., Van de Bruaene, L., Motmans, J., & T’Sjoen, G. (2019). Health considerations for transgender women and remaining unknowns: a narrative review. Therapeutic Advances in Endocrinology and Metabolism, 10, 2042018819871166. [DOI:10.1177/2042018819871166]:

Alternative anti-androgen therapies exist that have not yet been substantiated for routine use by supporting research. Progesterone is discussed in the breast development section, but we do not recommend its routine use in TW until more rigorous studies demonstrate potential benefits outweigh any risks.40

[…] The impact of various combinations of different oestrogens, anti-androgens and progestogens on breast development was previously reviewed by Wierckx and colleagues,67 who concluded that current evidence did not support or refute any enhancement of breast development with progestogens. Pubertal data in people assigned female at birth (AFAB) (e.g. girls with Turner syndrome) argue for delaying progesterone as it causes ductal differentiation and may interfere with optimal breast development.68 Due to unsatisfactory effects of GAHT alone on breast growth and development, 60–70% of all TW sought additional surgical breast augmentation.67 Articles on breast development in TW report inconclusive results, possibly due to differences in methodology and the lack of prospective RCTs. Prior69 recently published on the potential benefits of progesterone use on breast development (among other conclusions) in TW but the perspective was limited to clinical experience, assumptions taken from in vitro and animal data, and selected data from cis women.40 It would be worthwhile for future studies to use volume measurements for examining hormonally induced breast development in TW over a longer follow-up period in a large cohort, which may result in the identification of predictive markers for breast development.62 Additionally, rigorous prospective RCTs of oestrogen and oestrogen plus progesterone may provide more conclusive data to guide routine use of progesterone for breast development.

T’Sjoen et al. (2020)

T’Sjoen, G., Arcelus, J., De Vries, A. L., Fisher, A. D., Nieder, T. O., Özer, M., & Motmans, J. (2020). European Society for Sexual Medicine Position Statement “Assessment and Hormonal Management in Adolescent and Adult Trans People, with Attention for Sexual Function and Satisfaction”. The Journal of Sexual Medicine, 17(4), 570–584. [DOI:10.1016/j.jsxm.2020.01.012]:

To induce (more) feminine secondary sex characteristics and/or to reduce the masculine ones, estrogens and/or antiandrogens can be used. The debate on the use of progesterone is ongoing, caused by a lack of data.3 A wide range of estrogenic compounds exists, of which 17beta-estradiol (oral 2–6 mg/d or transdermal) represents the treatment of choice. Estrogen dosage should be adjusted to maintain serum estradiol at the level for premenopausal women (100–200 pg/mL), although timing of treatment intake may affect blood concentrations. The most commonly used antiandrogen drug in Europe is cyproterone acetate (oral 10–50 mg, once daily), a progestin with antiandrogenic properties. GnRHa are also effective in reducing testosterone levels with a low risk of adverse effects.3

Reisman (2020)

Reisman, T. (2020). Breast imaging in transgender individuals. In Legato, M. J. (Ed.). The Plasticity of Sex: The Molecular Biology and Clinical Features of Genomic Sex, Gender Identity and Sexual Behavior (pp. 187–205). London: Academic Press. [DOI:10.1016/B978-0-12-815968-2.00016-5]:

While the role of estrogen in breast growth has been most clearly established, other hormones have also been implicated in breast development. In his 1958 study, Lyon demonstrated in oophorectomized, adrenalectomized, and hypophysectomized rodents that estrogen, growth hormone, and corticosteroids are all required for ductal develoment.10 Progesterone does not appear to be important for either early pubertal duct development or breast growth. However, with increasing levels throughout pregnancy, progesterone is reported to mediate the lobular alveolar development facilitating lactation.

\ No newline at end of file diff --git a/transfemscience.org/feed-posts.xml b/transfemscience.org/feed-posts.xml index b4abe93e..2ed8b150 100644 --- a/transfemscience.org/feed-posts.xml +++ b/transfemscience.org/feed-posts.xml @@ -1 +1 @@ -Jekyll2024-03-21T19:23:45-07:00https://transfemscience.org/feed-posts.xmlTransfeminine ScienceTransfeminine Science is a site for information on hormone therapy for transfeminine people.Transfeminine Science \ No newline at end of file +Jekyll2024-03-29T02:48:24-07:00https://transfemscience.org/feed-posts.xmlTransfeminine ScienceTransfeminine Science is a site for information on hormone therapy for transfeminine people.Transfeminine Science \ No newline at end of file diff --git a/transfemscience.org/feed.xml b/transfemscience.org/feed.xml index 3b06e590..d656f363 100644 --- a/transfemscience.org/feed.xml +++ b/transfemscience.org/feed.xml @@ -1,4 +1,4 @@ -Jekyll2024-03-21T19:23:45-07:00https://transfemscience.org/feed.xmlTransfeminine Science | ArticlesTransfeminine Science is a site for information on hormone therapy for transfeminine people.Transfeminine SciencePuberty Blockers: A Review of GnRH Analogues in Transgender Youth2022-01-30T15:04:00-08:002022-01-31T00:00:00-08:00https://transfemscience.org/articles/puberty-blockersPuberty Blockers: A Review of GnRH Analogues in Transgender Youth
+Jekyll2024-03-29T02:48:24-07:00https://transfemscience.org/feed.xmlTransfeminine Science | ArticlesTransfeminine Science is a site for information on hormone therapy for transfeminine people.Transfeminine SciencePuberty Blockers: A Review of GnRH Analogues in Transgender Youth2022-01-30T15:04:00-08:002022-01-31T00:00:00-08:00https://transfemscience.org/articles/puberty-blockersPuberty Blockers: A Review of GnRH Analogues in Transgender Youth @@ -4488,13 +4488,13 @@ Using the term desistence in this way does not imply anything about the identity
  • Quaynor, S. D., Stradtman, E. W., Kim, H., Shen, Y., Chorich, L. P., Schreihofer, D. A., & Layman, L. C. (2013). Delayed Puberty and Estrogen Resistance in a Woman with Estrogen Receptor α Variant. New England Journal of Medicine, 369(2), 164–171. [DOI:10.1056/nejmoa1303611]
  • Rinaldi, S., Geay, A., Déchaud, H., Biessy, C., Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Shore, R. E., Riboli, E., Toniolo, P., & Kaaks, R. (2002). Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiology and Prevention Biomarkers, 11(10), 1065–1071. [Google Scholar] [PubMed] [URL]
  • Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3666–3672. [DOI:10.1210/jcem.84.10.6079]
    • -]]>    {"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}    Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy2020-07-01T18:39:00-07:002024-03-20T00:00:00-07:00https://transfemscience.org/articles/bica-adoptionBicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy +]]>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy2020-07-01T18:39:00-07:002024-03-23T00:00:00-07:00https://transfemscience.org/articles/bica-adoptionBicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy

    By Aly | First published July 1, 2020 - | Last modified March 20, 2024

    + | Last modified March 23, 2024

    Abstract / TL;DR

    @@ -4637,7 +4637,7 @@ Using the term desistence in this way does not imply anything about the identity
    • Angus, L. M., Nolan, B. J., Zajac, J. D., & Cheung, A. S. (November 2023). Bicalutamide as an anti-androgen in trans people: a cross-sectional study. AusPATH 2023 Symposium. [URL] [PDF] [Slides] [Trans Health Research Blog Post]
    • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
      • -
    • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (May 2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]): 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
      • +
    • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (May 2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]), 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
    • Gómez-Aguilar, F., Martínez-Sánchez, L., Arias-Constantí, V., Muñoz-Santanach, D., & Sarquella-Brugada, G. (2023). QT prolongation and Torsade de Pointes in a 13-year-old transgender adolescent in treatment with bicalutamide and tacrolimus. Clinical Toxicology, 61(Suppl 1 [43rd International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), 23–26 May 2023, Palma de Mallorca, Spain]), 81–82 (abstract no. 170). [DOI:10.1080/15563650.2023.2192024] [PDF] [Reactions Weekly]
    • Karakılıç Özturan, E., Öztürk, A. P., Baş, F., Erdoğdu, A. B., Kaptan, S., Kardelen Al, A. D., Poyrazoğlu, Ş., Yıldız, M., Direk, N., Yüksel, Ş., & Darendeliler, F. (2023). Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey. Journal of Clinical Research in Pediatric Endocrinology, 15(3), 276–284. [DOI:10.4274/jcrpe.galenos.2023.2023-1-13]
    • Vierregger, K., Tetzlaff, M., Zimmerman, B., Dunn, N., Finney, N., Lewis, K., Slomoff, R., & Strutner, S. (May 2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. National Transgender Health Summit (NTHS) 2023 Symposium. [Event Agenda PDF] [Symposium Session] [Symposium Abstracts/Program Book]
      • @@ -4662,7 +4662,7 @@ Using the term desistence in this way does not imply anything about the identity

      Of 229 results, 33 trials were found to be relevant and were included. Most of the trials were in men with prostate cancer, but a few were in women with cancer and boys with precocious puberty. Sam found that of a total of 7,703 evaluable participants, there were 2 instances of serious liver toxicity and 2 instances of serious lung toxicity with bicalutamide. This resulted in the same incidence rate of 0.026% (95% CI: 0.003% to 0.094%) or approximately 1 in 3,846 individuals for both liver toxicity and lung toxicity. Combining these toxicities resulted in a total incidence of serious liver or serious lung toxicity with bicalutamide of 0.052% (95% CI: 0.014% to 0.133%) or approximately 1 in 1,923 individuals. All of the observed toxicity events were rated as Grade 3 or 4. It should be noted that clinical trials of bicalutamide typically employ careful laboratory monitoring and assessment of clinical adverse events as well as prompt medication discontinuation upon unfavorable laboratory changes.

      -

      While the confidence intervals (CIs) in Sam’s analysis were wide and hence the estimates are very rough, they provide an idea of the potential real-world risk of serious toxicity with bicalutamide in transfeminine people based on high-quality clinical data. Notably, they do not suffer from the problem of under-reporting of adverse events that occurs with published case reports, pharmacovigilance databases, and certain types of observational studies. However, limitations of Sam’s analysis include (1) toxicity incidence rates for no-bicalutamide controls not being assessed and (2) most of the patients having cancer and being of older age, and hence the generalizability of the findings to healthy transfeminine people not being fully clear. In any case, I was surprised by how high the incidence rates were when I first saw her analysis, and I suspect that others may be as well.

      +

      While the confidence intervals (CIs) in Sam’s analysis were wide and hence the estimates are very rough, they provide an idea of the potential real-world risk of serious toxicity with bicalutamide in transfeminine people based on high-quality clinical data. Notably, they do not suffer from the problem of under-reporting of adverse events that occurs with published case reports, pharmacovigilance databases, and certain types of observational studies. However, limitations of Sam’s analysis include (1) toxicity incidence rates for non-bicalutamide-treated controls not being assessed and (2) most of the patients having cancer and being of older age, and hence the generalizability of the findings to healthy transfeminine people not being fully clear. In any case, I was surprised by how high the incidence rates were when I first saw her analysis, and I suspect that others may be as well.

      References

      @@ -4680,7 +4680,7 @@ Using the term desistence in this way does not imply anything about the identity
    • Ballentine, S., & Hollingsworth, H. (2023 April 13). Missouri to limit gender-affirming care for minors, adults. Associated Press. [URL]
    • Bambilla, A., Beal, C., & Vigil, P. (2023). Improving Access to Bicalutamide in Gender Affirming Medical Care. [Unpubished/pending publication] [QueerCME Blog Post]
    • Blackledge, G. R. P. (1996). Clinical progress with a new antiandrogen, Casodex™ (bicalutamide). European Urology, 29(Suppl 2), 96–104. [DOI:10.1159/000473847]
      • -
    • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]): 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
      • +
    • Burgener, K., DeBosch, B., Lewis, C., Wallendorf, M., & Herrick, C. (2023). Assessment of Liver Function and Toxicity in Transgender Female Adolescents Prescribed Bicalutamide. Hormone Research in Paediatrics, 96(Suppl 3 [Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting’ to Hormone Research in Paediatrics]), 377–378 (abstract no. 6232). [DOI:10.1159/000531602] [PDF]
    • Burgener, K., DeBosch, B., Wang, J., Lewis, C., & Herrick, C. J. (2024). Bicalutamide does not raise transaminases in comparison to alternative anti-androgen regimens among transfeminine adolescents and young adults: a retrospective cohort study. medRxiv, preprint. [DOI:10.1101/2024.02.21.24302999v1] [PDF]
    • Cocchetti, C., Ristori, J., Romani, A., Maggi, M., & Fisher, A. D. (2020). Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. Journal of Clinical Medicine, 9(6), 1609. [DOI:10.3390/jcm9061609]
    • Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., Hancock, A. B., Johnson, T. W., Karasic, D. H., Knudson, G. A., Leibowitz, S. F., Meyer-Bahlburg, H. F., Monstrey, S. J., Motmans, J., Nahata, L., … & Arcelus, J. (2022). [World Professional Association for Transgender Health (WPATH)] Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health, 23(Suppl 1), S1–S259. [DOI:10.1080/26895269.2022.2100644] [URL] [PDF]
      • @@ -4752,4 +4752,4 @@ Using the term desistence in this way does not imply anything about the identity
    • Vierregger, K. S. (2023). Bicalutamide Use as Antiandrogen in Trans Feminine Adults - A Safety Profile. USPATH 2023 Symposium. [Symposium Schedule]
    • Warus, J. (2023). Safety of Bicalutamide as Anti-Androgenic Therapy in Gender Affirming Care for Adolescents and Young Adults: A Retrospective Chart Review. USPATH 2023 Symposium. [Symposium Schedule]
    • Wilde, B., Diamond, J. B., Laborda, T. J., Frank, L., O’Gorman, M. A., & Kocolas, I. (2023). Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. Journal of Adolescent Health, 74(1), 202–204. [DOI:10.1016/j.jadohealth.2023.08.024]
      • -
    ]]>    {"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"}     \ No newline at end of file +]]>{"first_name"=>"Aly", "last_name"=>"W.", "author-link"=>"/about/#aly", "articles-link"=>"/articles-by-author/aly/"} \ No newline at end of file diff --git a/transfemscience.org/misc/index.html b/transfemscience.org/misc/index.html index 9b6d4aaf..bd5eba68 100644 --- a/transfemscience.org/misc/index.html +++ b/transfemscience.org/misc/index.html @@ -1 +1 @@ -Miscellaneous - Transfeminine Science Link

    Miscellaneous

    Tools

    Hormone Medication Simulation

    Injectable Dose, Volume, and Concentration Conversion

    Hormone Concentration Unit Conversion

    Free Hormone Calculation

    Dose Conversion by Route

    Publications

    Clinical Guidelines

    Selected Literature Reviews

    Academic Journals

    Large Cohort Studies

    Symposia Materials

    Literature

    Literature Access

    Wikipedia

    Communities

    Reddit

    Facebook

    Discord

    Other Sites

    DIY Hormone Therapy

    Transfeminine Science Translations

    \ No newline at end of file +Miscellaneous - Transfeminine Science Link

    Miscellaneous

    Tools

    Hormone Medication Simulation

    Injectable Dose, Volume, and Concentration Conversion

    Hormone Concentration Unit Conversion

    Free Hormone Calculation

    Dose Conversion by Route

    Publications

    Clinical Guidelines

    Selected Literature Reviews

    Academic Journals

    Large Cohort Studies

    Symposia Materials

    Literature

    Literature Access

    Wikipedia

    Communities

    Reddit

    Facebook

    Discord

    Other Sites

    DIY Hormone Therapy

    Transfeminine Science Translations

    \ No newline at end of file